# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 1 August 2002 (01.08.2002)

**PCT** 

# (10) International Publication Number WO 02/059377 A2

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number: PCT/US02/02242

(22) International Filing Date: 24 January 2002 (24.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US

- (71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225A Gateway Boulevard, South San Francisco, CA 94080-7019 (US).
- (72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

- (74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

/059377 A

**(54) Title:** METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.

# METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

#### CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

#### FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

15

## BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

5

10

15

20

25

30

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), none are currently approved for breast cancer therapy in the US.

5

10

15

20

25

30

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

#### SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

5

10

15

20

25

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

5

10

15

20

25

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

5

10

15

20

25

30

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

5

10

15

20

25

30

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer.

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

25

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

## DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

## **Definitions**

5

10

15

20

25

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

5

10

15

20

25

30

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

5

10

15

20

25

30

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

5

10

15

20

25

30

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (*see, e.g.*, the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

5

10

15

20

25

30

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3<sup>rd</sup> ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of  $\beta$ -sheet and  $\alpha$ -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

10

15

20

25

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and 5 linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T<sub>m</sub>) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T<sub>m</sub> for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

5

10

15

20

25

30

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include <sup>32</sup>P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

5

10

15

20

25

30

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

prognosis may be based at the genomic level, or at the level of RNA or protein expression.

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

5

10

15

20

25

30

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times

background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis *et al.* (1990) *PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc. N.Y.).

5

10

15

20

25

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, *et al.* 

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include *in vitro*, *in vivo*, and *ex vivo* activities.

5

10

15

20

25

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics *in vitro* or *in vivo*, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3<sup>rd</sup> ed. 1994).

5

10

15

20

25

30

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3<sup>rd</sup> ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain  $(V_L)$  and variable heavy chain  $(V_H)$  refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'<sub>2</sub>, a dimer of Fab which itself is a light chain joined to V<sub>H</sub>-C<sub>H</sub>1 by a disulfide bond. The F(ab)'<sub>2</sub>

may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'<sub>2</sub> dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (*see*, *e.g.*, Kohler & Milstein, *Nature* 256:495-497 (1975); Kozbor *et al.*, *Immunology Today* 4:72 (1983); Cole *et al.*, pp. 77-96 in *Monoclonal Antibodies and Cancer Therapy* (1985); Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies*, *A Laboratory Manual* (1988); and Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see*, *e.g.*, McCafferty *et al.*, *Nature* 348:552-554 (1990); Marks *et al.*, *Biotechnology* 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

# Identification of breast cancer-associated sequences

5

10

15

20

25

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

5

10

15

20

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are upregulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and treatment of

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (*see, e.g.*, Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

breast cancer is hereby expressly incorporated by reference.

5

10

15

20

25

# **Informatics**

5

10

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

5

10

15

20

25

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999); Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

5

10

15

20

25

30

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

# Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

5

10

15

20

25

30

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins *in situ*. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, *e.g.*, for blood, plasma, serum, or stool tests.

#### Use of breast cancer nucleic acids

5

10

15

20

25

30

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

10

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, *et al.*, *supra*. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

5

10

15

20

25

30

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

5

10

15

20

25

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

5

10

15

20

25

30

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (*see* 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip<sup>TM</sup> technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

# Expression of breast cancer proteins from nucleic acids

5

10

15

20

25

30

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

5

10

15

20

25

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, *supra*).

5

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Saccharomyces* cerevisiae and other yeasts, *E. coli, Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (*see*, *e.g.*, Fernandez & Hoeffler, *supra*). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez & Hoeffler, *supra*). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

5

10

15

20

25

30

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

# Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to

optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

5

10

15

20

25

30

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

5

10

15

20

25

Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, *CRC Crit. Rev. Biochem.*, pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

5

10

15

20

25

30

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field *et al., Mol. Cell. Biol.* 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan *et al., Molecular and Cellular Biology* 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (*Paborsky et al., Protein Engineering* 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (*Hopp et al., BioTechnology* 6:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al., Science* 255:192-194 (1992)); tubulin epitope peptide (Skinner *et al., J. Biol. Chem.* 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth *et al., Proc. Natl. Acad. Sci. USA* 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

### Antibodies to breast cancer proteins

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, *supra*; and Harlow & Lane, *supra*). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, *Nature* 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5

10

15

20

25

30

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

5

10

15

20

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, *J. Mol. Biol.* 227:381 (1991); Marks *et al.*, *J. Mol. Biol.* 222:581 (1991)). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, p. 77 (1985) and Boerner *et al.*, *J. Immunol.* 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all

5

10

15

20

25

30

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, *Bio/Technology* 10:779-783 (1992); Lonberg *et al.*, *Nature* 368:856-859 (1994); Morrison, *Nature* 368:812-13 (1994); Fishwild *et al.*, *Nature Biotechnology* 14:845-51 (1996); Neuberger, *Nature Biotechnology* 14:826 (1996); Lonberg & Huszar, *Intern. Rev. Immunol.* 13:65-93 (1995).

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

5

10

15

20

25

30

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

5

10

15

20

25

30

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a  $K_d$  of at least about 0.1 mM, more usually at least about 1  $\mu$ M, preferably at least about 0.1  $\mu$ M or better, and most preferably, 0.01  $\mu$ M or better. Selectivity of binding is also important.

# Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

5

10

15

20

25

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

5

10

15

20

25

30

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

5

10

15

20

25

30

In another preferred method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove nonspecific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein.

In a preferred embodiment, *in situ* hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

### Assays for therapeutic compounds

5

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, *et al.*, *Science* 279:84-8 (1998); Heid, *Genome Res* 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out inTable 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

5

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop *et al.*, *J. Med. Chem.* 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent No. 5,010,175, Furka, *Pept. Prot. Res.* 37:487-493 (1991), Houghton *et al.*, *Nature*, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Pätent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.,* 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

5

10

15

20

25

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, *e.g.*, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, *e.g.*, substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

5

10

15

20

25

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

30

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, *e.g.*, for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

5

10

15

20

25

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

5

10

15

20

25

Assays to identify compounds with modulating activity can be performed *in vitro*. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined *in vitro* by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or  $\beta$ -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

5

10

15

20

25

30

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon<sup>TM</sup>, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

5

10

15

20

25

30

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., <sup>125</sup>I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

5

10

15

20

25

30

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

5

10

15

20

25

30

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3<sup>rd</sup> ed., 1994), herein incorporated by reference. *See also*, the methods section of Garkavtsev *et al.* (1996), *supra*, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (<sup>3</sup>H)-thymidine at saturation density can be used to measure density limitation of growth. *See* Freshney (1994), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (<sup>3</sup>H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (<sup>3</sup>H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

#### Growth factor or serum dependence

5

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

#### Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), *supra*. Also, *see*, Unkless *et al.*, *J. Biol. Chem.* 249:4295-4305 (1974); Strickland & Beers, *J. Biol. Chem.* 251:5694-5702 (1976); Whur *et al.*, *Br. J. Cancer* 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

### Invasiveness into Matrigel

5

10

15

20

25

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with <sup>125</sup>I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

## Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (*see, e.g.*, Giovanella *et al.*, *J. Natl. Cancer Inst.* 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (*see, e.g.*, Bradley *et al.*, *Br. J. Cancer* 38:263 (1978); Selby *et al.*, *Br. J. Cancer* 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10<sup>6</sup> cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

## Polynucleotide modulators of breast cancer

5

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

## Ribozymes

5

10

15

20

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (*see, e.g.,* Castanotto *et al., Adv. in Pharmacology* 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel *et al.*, *Nucl. Acids Res.* 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (*see, e.g.*,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

# Methods of identifying variant breast cancer-associated sequences

5

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genetype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5

## Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, *etc.*) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., *Remington's Pharmaceutical Science* (15th ed., 1980) and Goodman & Gillman, *The Pharmacologial Basis of Therapeutics* (Hardman *et al.*,eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, *e.g.*, other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, *e.g.*, polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, *in vitro* or *in vivo*. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using *in vitro* (cell-free), *ex vivo* or *in vivo* (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

5

10

15

20

25

30

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

5

10

15

20

25

30

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff *et. al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (*see, e.g.*, U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

5

10

15

20

25

30

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

10

5

#### Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions

(i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

5

10

20

25

30

# Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

# Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

5

10

15

25

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing. They are next centrifuged at  $<8000\,$  rpm ( $<7500\,$ x g) for 5 minutes at  $4^{\circ}$ C.

The RNA wash is decanted. The pellet is carefully transferred to an

Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes.

Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H<sub>2</sub>0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A<sup>+</sup> mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

5

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H<sub>2</sub>0 at 1 ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

First Strand cDNA Synthesis

5

10

15

20

25

30

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNA1. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1 hour.

#### Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H<sub>2</sub>0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

## Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

## In vitro Transcription (IVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 1.5 ul T7 10xUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μl
Random Hexamers (1 μg/μl): 4 μl
H<sub>2</sub>O: μl
14 μl

5

10

20

Incubate the above 14  $\mu$ l mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl
50X dNTP mix: 0.6 μl
H<sub>2</sub>O: 2.4 μl
Cy3 or Cy5 dUTP (1mM): 3 μl
25 SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min.,  $42^{\circ}$ C. Then, 1  $\mu$ l SSII is added and incubated for another hour before being placed on ice.

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25  $\mu$ l each of 100mM dATP, dCTP, and dGTP; 10  $\mu$ l of 100mM dTTP to 15  $\mu$ l H<sub>2</sub>O. ]

RNA degradation is performed as follows. Add 86 µl H<sub>2</sub>O, 1.5 µl 1M NaOH/2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 µl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 µl buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

10

15

5

## Sample preparation

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H<sub>2</sub>0. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H<sub>2</sub>O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H<sub>2</sub>O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H<sub>2</sub>O. Dry slides and scan at appropriate PMT's and channels.

# TABLE 1: Figure 1 from BRCA 001 US

5 Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

15	ExAccn: UnigenelD: Unigene Title: R1:		Unigene gene title Ratio of normal breast tissue to tumor				
	Pkey	ExAccn	UnidenalD	UnigeneTitle 5	R1		
	ı ney	LANCOII	Onigeneib	omgonorius	•••		
20	100472	D90084	Hs.1023	pyruvate dehydrogenase (lipoamide) alpha	5		
	100499	T51986	Hs.283108	hemoglobin, gamma G	10		
	100545	M55405		gb:Homo sapiens mucin (MUC-3) mRNA, part	5		
		BE14201		Homo sapiens cDNA FLJ11572 fis, clone HE	10		
0.5		X52078		transcription factor 3 (E2A immunoglobul	5		
25		BE25903		Ewing sarcoma breakpoint region 1	5		
		X16841	Hs.167988	neural cell adhesion molecule 1	5		
		A03758		NM_000477*:Homo sapiens albumin (ALB), m	10		
		L27065		gb:Human neurofibromatosis 2 (NF2) mRNA,	5		
20		M60832		collagen, type VIII, alpha 2	5		
30		BE37972		fatty acid binding protein 4, adipocyte	10		
		AJ25056		transmembrane 4 superfamily member 2	5 5		
		M90424	Hs.2099 374 Hs.460	lipocalin 1 (protein migrating faster th activating transcription factor 3	10		
		NM_0016		FBJ murine osteosarcoma viral oncogene h	10		
35		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10		
55		M21305	1 10.4	gb:Human alpha satellite and satellite 3	10		
		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10		
		M27826		endogenous retroviral protease	10		
		AV65026		GRO2 oncogene	5		
40		M74447	Hs.502	transporter 2, ATP-binding cassette, sub	10		
		U22961		gb:Human mRNA clone with similarity to L	10		
		NM_0015	504 Hs.198252	G protein-coupled receptor 9	5		
		U48251	Hs.75871	protein kinase C binding protein 1	10		
	102515	U89337	Hs.169886	tenascin XB	10		
45	102571	U60115	Hs.239069	four and a half LIM domains 1	5		
	102800	AA31353	8	gb:EST185419 Colon carcinoma (HCC) cell	10		
	102857	NM_0067		retinol-binding protein 4, interstitial	10		
	102990	AA82928		serum amyloid A1	10		
<b>~</b> ^		X98085	Hs.54433	tenascin R (restrictin, janusin)	5		
50		AA08199		gb:zn26d06.r1 Stratagene neuroepithelium	10		
		AA12612		gb:zm78c07.r1 Stratagene neuroepithelium	5		
		AA13710		Homo sapiens, clone MGC:16638, mRNA, com	10		
		AA32621		hypothetical protein MGC1136	5		
		AB04103		kallikrein 11 (KLK11; TLSP; PRSS20; hipp	5		
55		R50727	Hs.336970		10 5		
		AA42212		gb:zv26h12.r1 Soares_NhHMPu_S1 Homo sapi	10		
		AL35395		hypothetical protein DKFZp434P0531 Homo sapiens clone 24734 mRNA sequence	10		
		F06638 AA42618	Hs.12440	gb:zw11e09.r1 Soares_NhHMPu_S1 Homo sapi	5		
60		N73185	Hs.94285	EST	10		
00		N91071	Hs.109650		10		
	104500	1101011	11- 570		-		

Unique Eos probeset identifier number

10

104511 N99542

104532 Al498763

Hs.572

orosomucoid 1

Hs.203013 hypothetical protein FLJ12748

Pkey:

5

	104536 104572			Homo sapiens cDNA FLJ14673 fis, clone NT phosphoinositide-3-kinase, class 2, beta	5 5
		AW969769	Hs.105201		5
		AA009764	Hs.190380		10
5		AA017245	Hs.32794		10
		AA019300		ESTs, Moderately similar to 154374 gene	10
		AI039243	Hs.278585	ESTs	5
		Al298208		ESTs	10
1.0		AA130390	Hs.25549	hypothetical protein FLJ20898	10
10		R61532	Hs.87016	hypothetical protein FLJ22938	5
		AW970043	HS.238039	hypothetical protein FLJ11090	5 10
		AA221036 AA421973	Un 160110	gb:zr03f12.r1 Stratagene NT2 neuronal pr ESTs, Weakly similar to T25731 hypotheti	5
		BE242857	Hs.27021	hypothetical protein FLJ11159	5
15		N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	10
		AL359624	Hs.11387	KIAA1453 protein	5
	106181	Al803651	Hs.191608	ESTs	10
	106194	AW976171	Hs.286194	hypothetical protein FLJ22233	5
20		A1085846	Hs.25522	KIAA1808 protein	10
20		AL042069		DKFZP434N061 protein	10
		AW235928	Hs.313182		10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10 5
		AA906434 AW054886	Hs.3776 Hs.25682	zinc finger protein 216 Homo saptens mRNA for KIAA1863 protein,	10
25		Al458623	113.23002	gb:tk04g09.x1 NCI_CGAP_Lu24 Homo sapiens	5
20		Al983730	Hs.26530	serum deprivation response (phosphatidyl	5
		Al347578		hypothetical protein MGC2605	5
	106954	AF128847	Hs.204038	indolethylamine N-methyltransferase	5
20		AJ223811	Hs.30127	hypothetical protein	5
30		A1446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	5
		AB006532	Hs.31442	RecQ protein-like 4 GS1999full	10 10
		Al005036 AF127026	Hs.5394	myosin IA	10
		AB020672		KIAA0865 protein	10
35		AI905985	Hs.111805		10
		U51704		ESTs, Moderately similar to ALU8_HUMAN A	5
	107423	W26652	Hs.6163	PTEN induced putative kinase 1	5
		W28516	Hs.19210	hypothetical protein MGC11308	10
40		AL042425		hypthetical protein PRO2389	10
40		A1092790	Hs.334703	hypothetical protein FLJ14529	5 10
		W38002 N53167	Hs.47623	Empirically selected from AFFX single pr ESTs	10
		W96141	Hs.220687		10
		AA017462	Hs.269244		10
45		BE621721	Hs.280792	hypothetical protein FLJ12387 similar to	10
	107864	AA025060	Hs.61246	ESTs	10
		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
		AA025836	Hs.191637		5 10
50		AL049176 AA043675	Hs.82223	chordin-like ESTs	10
50		AA093668	Hs.62633 Hs.28578	muscleblind (Drosophila)-like	5
		AA012881	Hs.72531		10
		AA059473	Hs.66783	EST	10
		AA677927	Hs.144269		5
55		AA070500		gb:zm70h03.s1 Stratagene neuroepithelium	5
		AA071193	11	gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
		NM_006770	Hs.67726	macrophage receptor with collagenous str	5 10
		AA075124		gb:zm86a01.s1 Stratagene ovarian cancer gb:zm97c09.s1 Stratagene colon HT29 (937	10
60	108441	AA079079 AA085383		gb:zn13g03.s1 Stratagene hNT neuron (937	10
00		AA074897		gb:zm85a05.r1 Stratagene ovarian cancer	10
		AA934589	Hs.49696	ESTs	5
	108662	AF117646		Cas-Br-M (murine) ectropic retroviral tr	5
	108706	AA121820	Hs.74569	KIAA0842 protein	10
65	108738	AA126583	Hs.158725		10
	108827	Al273692	Hs.110470		10 10
	109123	A1028376	Hs.73232	ESTs	10

	109389	AA101325	Hs.86154	hypothetical protein FLJ12457	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	5
		R40604	Hs.129539	ESTs, Weakly similar to MCAT_HUMAN MITOC	10
		Al094674	Hs.30524	ring finger protein 24	10
5		H46749	Hs.31540	ESTs	10
-		W22165	Hs.22586	ESTs	5
	110433	AW294162		UDP-N-acetyl-alpha-D-galactosamine:polyp	10
		H51276	Hs.13526	hypothetical protein FLJ12688	10
	110455	H52576		gb:yt85e08.r1 Soares_pineal_gland_N3HPG	5
10	110540	H72639	Hs.167608	ESTs	5
	110553	H60593	Hs.124990	ESTs	10
	110976	AL044174	Hs.159526	patched (Drosophila) homolog	10
	110987	AI753316	Hs.26034	ESTs	5
	111158	N66616	Hs.138629	H.sapiens mRNA for subtelomeric repeat s	5
15		Al798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		AJ224864	Hs.9688	leukocyte membrane antigen	5
		AA641636	Hs.37477	ESTs, Weakly similar to T46908 hypotheti	5
	111400	R00144	Hs.189771		10
20		Al168511		gb:ow90h09.s1 Soares_fetal_liver_spleen_	10
20		R16733	Hs.20499	ESTs	10
		R26065		gb:yh39d03.s1 Soares placenta Nb2HP Homo	5
		AA593731		ESTs, Moderately similar to ALU5_HUMAN A	10
		R42333	Hs.302292		10
25		AL117490	Hs.47225		10
25		NM_006668	Hs.25121	cytochrome P450, subfamily 46 (cholester	10
		R51889	Hs.24990	ESTs	5
		R31094	Hs.24378	ESTs	10
		R77302	11- 000000	gb:yi75h08.s1 Soares placenta Nb2HP Homo	10 5
30		BE618629	Hs.268809		5
30		T98628 Al057205	Hs.191290		5
		AA581428	Hs.14584 Hs.5021	EST	10
		T16837	Hs.4241	ESTs	5
		T51588	113.4241	gb:yb27e06.s1 Stratagene fetal spleen (9	10
35		T54659	He 301755	Homo sapiens cDNA FLJ11465 fis, clone HE	5
55		AA743563	Hs.10305	·	5
		AW207424	Hs.332594		10
		N92359		ESTs, Moderately similar to A48752 B-cel	10
		R16763	Hs.268679		5
40		AA913635		Homo sapiens cDNA FLJ20812 fis, clone AD	10
		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5
		Al791905	Hs.95549	hypothetical protein	10
	113790	Al244311	Hs.26912	ESTs	10
	113807	W07586	Hs.8045	ESTs	3
45	113958	W86195		gb:zh54e05.s1 Soares_fetal_liver_spleen_	· 10
	114211	Z39319	Hs.27347	EST	10
	114254	AB018263		tumor necrosis factor receptor superfami	5
		AA745978	Hs.28273	ESTs	5
~~		AA020736		gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50		AA034378	Hs.267319	endogenous retroviral protease	5
		AA065096		gb:zm50a02.s1 Stratagene fibroblast (937	5
		AA081507		gb:zn05b10.r1 Stratagene hNT neuron (937	5
		AA234826	Hs.87386	EST	5
<i></i>		AA234462	Hs.87350	ESTs	5
55		AK000725	Hs.50579	hypothetical protein FLJ20718	3
		AF173081		Vertebrate LIN7 homolog 1, Tax interacti	5 5
		AB020649	Hs.74569	KIAA0842 protein	10
		AA398841	Hs.39850	hypothetical protein FLJ20517 esophageal cancer related gene 4 protein	10
60		Al478427 AL133916	Hs.43125	hypothetical protein FLJ20093	10
UU		AA463902	Hs.13522	ESTs, Weakly similar to I38022 hypotheti	5
		AW968703	Hs.30085	hypothetical protein FLJ23186	5
		AW410377	Hs.41502	hypothetical protein FLJ21276	5
		AW194253	Hs.68607	ESTs	10
65		BE314852	Hs.168694	Homo sapiens clone 23763 unknown mRNA, p	5
J.J.		F10528	Hs.70001	ESTs, Moderately similar to JC6169 nucle	5
		AW801806		gb:IL5-UM0070-110400-062-g07 UM0070 Homo	5
				-	

	117151	A1803656	Hs.42373	ESTs	5
		N20468	110.72010	gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
		AI472863	Hs.43387	ESTs	5
		N34417	Hs.44584	<del></del>	3
5		N26627	Hs.82364	The state of the s	5
		N40551		Homo sapiens Ets-1 binding protein (E1B)	10
	117847	N49285	Hs.182391		10
		AW263476	Hs.44268	myelin gene expression factor 2	10
		BE222341	Hs.279472	ESTs	5
10		N53145		gb:yv55f09.s1 Soares fetal liver spleen	3
		AW955696	Hs.90960	ESTs	10
		A1078236	Hs.49688		5
		N70907	Hs.230619		10
15		AL122040		Homo sapiens mRNA; cDNA DKFZp434G1972 (f	3 5
13		AA993527 Al160570		hypothetical protein FLJ23403 pregnancy specific beta-1-glycoprotein 6	3
		AF142419	Hs.252097		5
		AA514422	Hs.221849		5
		AK002001		v-maf musculoaponeurotic fibrosarcoma (a	10
20		T77892	110.01000	gb:yd20f04.s1 Soares fetal liver spleen	5
		T81824	Hs.90949	EST	5
		W38051	***************************************	Empirically selected from AFFX single pr	10
		AL049798	Hs.80552	dermatopontin	3
	119800	AF086332	Hs.58314	ESTs	10
25	119817	AF088061	Hs.159690	ESTs	5
		AF086429	Hs.58429		5
		AW803308	Hs.62954	ferritin, heavy polypeptide 1	5
		U34249	Hs.337461	Human putative zinc finger protein (ZNFB	5
20		AL042725	11- 07400	gb:DKFZp434B1822_r1 434 (synonym: htes3)	10
30		AW136934	Hs.97162		5 5
		AA907743	Hs.142373		5
		AA401695 AA405763	Hs.97334	Homo sapiens cDNA FLJ20470 fis, clone KA	5
		AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35		AK000229	Hs.98017		10
55		AA447555	Hs.99116		10
		AA458945	Hs.95898		10
		AW135093	Hs.97282		5
	123601	AA609122	Hs.112645	Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5
40	123623	AI024595	Hs.97508	a disintegrin and metalloproteinase doma	5
		AA621529		gb:af47a02.s1 Soares_total_fetus_Nb2HF8_	10
		H62570		gb:yr44a01.r1 Soares fetal liver spleen	5
		H83465		gb:ys91a11.s1 Soares retina N2b5HR Homo	5
15		AK001527		hypothetical protein FLJ10665	5
45		NM_014312		cortic al thymocyte receptor (X. laevis	10
		T98199	Hs.48403	hypothetical protein FLJ10847 ESTs, Moderately similar to ALU8_HUMAN A	10 5
		BE299567 NM_002666	Hs.103253		10
		BE256206	Hs.17775	p75NTR-associated cell death executor; o	5
50		AA485421		ESTs, Weakly similar to ALU7_HUMAN ALU S	10
50		NM_002250	Hs.10082	potassium intermediate/small conductance	10
		R44214	Hs.101189		5
		C16161		hypothetical protein PRO2543	5
	128850	AA193106	Hs.180817	chromosome 11 open reading frame 23	10
55	128870	H39537	Hs.75309	eukaryotic translation elongation factor	10
		AW150717		STAT induced STAT inhibitor 3	10
		N62889		Homo sapiens cDNA FLJ12965 fis, clone NT	10
		AA443323		BPOZ protein	5
60		AA056483	Hs.301463 Hs.108665	Human Chromosome 16 BAC clone CIT987SK-A	5 10
60		NM_013403		zinedin SH3-domain protein 5 (ponsin)	5
	129140	AL117472 Al146494		ESTs, Weakly similar to IRX2_HUMAN IROQU	3
		U40714		tyrosyl-tRNA synthetase	5
		AA530892		dual specificity phosphatase 1	5
65		BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	10
00		AF110141		WAS protein family, member 2	10
		NM_003877	Hs.110776	STAT induced STAT inhibitor-2	5

		X06828		von Willebrand factor	5
		AW245805 W37944	Hs.110903 Hs.4007	claudin 5 (transmembrane protein deleted Sarcolemmal-associated protein	10 5
		BE061069		KIAA0467 protein	10
5		AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
	129554	BE222078	Hs.113069		10
		BE622468	Hs.11924		5
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	5 10
10		AK001676 AK000956	Hs.12457 Hs.13209	hypothetical protein FLJ10814 hypothetical protein FLJ10094	5
10		Al338993	Hs.134535		5
		AJ251760		guanine nucleotide binding protein (G pr	5
		NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
4.5	130014	NM_001158		amine oxidase, copper containing 2 (reti	5
15		M62402		insulin-like growth factor binding prote	10
		AA452006	Hs.333199		5 5
		W80711 D88435		Homo sapiens mRNA for KIAA1727 protein, cyclin G associated kinase	10
		Al241084		nonselective sodium potassium/proton exc	5
20		AA435746		gb:zt79e03.s1 Soares_testis_NHT Homo sap	5
	130400	V00517		hemoglobin, gamma G	10
		NM_001928		D component of complement (adipsin)	10
		X72308		small inducible cytokine A7 (monocyte ch	5
25		BE222978 AW390834	Hs.15760	MYG1 protein	10 5
23		BE270472	Hs.75874	pregnancy-associated plasma protein A HSPC015 protein	10
		AL110226	Hs.16441	DKFZP434H204 protein	10
•		Al652143		hypothetical protein FLJ13111	5
20		Al769067		ESTs, Weakly similar to T28770 hypotheti	3
30		AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10
		NM_006691	Hs.17917	extracellular link domain-containing 1 XPA binding protein 1; putative ATP(GTP)	10 5
		AA232075 AF263462	Hs.18259 Hs.18376	KIAA1319 protein	10
		N41322	Hs.18441	ESTs	5
35		M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
		AB040935	Hs.23954	cerebral cell adhesion molecule	10
		AA360419		inositol(myo)-1(or 4)-monophosphatase 1	10 10
40		X03350 AW939251	Hs.4 Hs.25647	alcohol dehydrogenase 1B (class I), beta v-fos FBJ murine osteosarcoma viral onco	10
40		AK000393	Hs.25817	BTB (POZ) domain containing 2	5
		AF110908		TNF receptor-associated factor 3	5
	131406	H83294		Wnt inhibitory factor-1	5
4.5		BE394648	Hs.27414	hypothetical protein	5
45		AW966881	Hs.41639	programmed cell death 2	10
		BE559681 AA829286	Hs.30736	KIAA0124 protein	5 10
		AA443966	Hs.31595	serum amyloid A1 ESTs	10
		H69342	Hs.26320	TRABID protein	10
50		AA021258	Hs.32753	ESTs	5
		BE244961		FE65-LIKE 2	5
	131828	AJ000263		keratin, hair, basic, 6 (monilethrix)	10
		AW294659	Hs.34054	Homo sapiens cDNA: FLJ22488 fis, clone H	5 5
55	131927	AJ003112 AK000010	Hs.34780 Hs.258798	doublecortex; lissencephaly, X-linked (d hypothetical protein FLJ20003	10
55	132115	H81604	Hs.178471		5
	132177	X80818	Hs.178078		5
	132296	AA467752	Hs.195161		5
<b>CO</b>	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
60	132477	S68874	Hs.170917		5 10
	1320/5	Al291496 NM_006283	Hs.5476 Hs.173159	Homo sapiens, clone IMAGE:3530123, mRNA, transforming, acidic coiled-coil contain	10
	132898	W28548	Hs.224829		10
	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
65	132953	BE175645	Hs.321264	LBP protein 32	5
	133116	BE563966	Hs.6529	ESTs, Weakly similar to I78885 serine/th	5
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10

		AF052138 AA668224	Hs.6580 Hs.6634	Homo sapiens cDNA: FLJ23227 fis, clone C Homo sapiens cDNA: FLJ22547 fis, clone H	5 5	
		AW956781		ESTs, Weakly similar to FXD2_HUMAN FORKH	5	
_		NM_002776	Hs.69423	kallikrein 10 (KLK10) (PRSSL1) (nes1)	5	
5		AA207059		gb:zq80h09.s1 Stratagene hNT neuron (937	5	
		AF017987	Hs.7306	secreted frizzled-related protein 1	5	
		H21497	Hs.7471	BBP-like protein 1	5 5	
	133702		Hs.75652	glutathione S-transferase M5	5 5	
10		H26904 N71725	Hs.75736	apolipoprotein D hemoglobin, alpha 2	10	
10		T85626	Hs.76239	hypothetical protein FLJ20608	5	
		AF072441	Hs.7840	calcineurin binding protein 1	10	
				ES1 (zebrafish) protein, human homolog o	10	
		Al372588	Hs.8022	TU3A protein	10	
15	134117	AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10	
	134177	BE243319	Hs.79672	KIAA0652 gene product	5	
	134308	AW905827	Hs.81454	ketohexokinase (fructokinase)	10	
		BE549343	Hs.82208	acyl-Coenzyme A dehydrogenase, very long	5	
20		AF207664	Hs.8230	a disintegrin-like and metalloprotease (	5	
20	134449		Hs.83450	laminin, alpha 3 (nicein (150kD), kalini	5	
		AI190413	Hs.8373	ESTs	10	
		M64936	Ua 250070	gb:Homo sapiens retinoic acid-inducible mitogen-activated protein kinase kinase	10 10	
		NM_002757 M26315	Hs.85258		10	
25		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	5	
		U73394		killer cell immunoglobulin-like receptor	5	
				dynein, axonemal, light polypeptide 4	5	
,		D10216	Hs.89394	POU domain, class 1, transcription facto	5	
	134758	NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10	
30	134786	T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10	
	134912		Hs.261457		5	
		NM_003394	Hs.91985	wingless-type MMTV integration site fami	10	
		H22570		hypothetical protein FLJ20093	5	
35		AA302517		KIAA1444 protein	5 10	
33		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10	
		AL036557 U76456	Hs.95910	putative lymphocyte G0/G1 switch gene tissue inhibitor of metalloproteinase 4	5	
		AB002361	Hs.96633	KIAA0363 protein	5	
		U83171	Hs.97203	small inducible cytokine subfamily A (Cy	5	
40		AA416829	Hs.191597		5	
-		AA905406	Hs.9905	ESTs, Weakly similar to unnamed protein	3	
	135417	X55019	Hs.99975	cholinergic receptor, nicotinic, delta p	10	
	101367	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5 .	
4.5		H39537	Hs.75309	eukaryotic translation elongation factor	5	
45				claudin 5 (transmembrane protein deleted	5	
		M62402		insulin-like growth factor binding prote	5 10	
		NM_006691	Hs.17917	extracellular link domain-containing 1	3	
		NM_003278 AF017987	Hs.65424 Hs.7306	tetranectin (plasminogen-binding protein secreted frizzled-related protein 1	5	
50		N71725		hemoglobin, alpha 2	5	
50		AF207664	Hs.8230	a disintegrin-like and metalloprotease (	5	
		X04430	Hs.93913	interleukin 6 (interferon, beta 2) -	10	
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5	
		AK001852	Hs.274151	ligatin	5	
55		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10	
		AW377752	Hs.83341	AXL receptor tyrosine kinase	5	
	427458	BE208364	Hs.29283	ESTs, Weakly similar to LKHU proteoglycan link	5	
		AA563892	Hs.306000		10	
60	449826	U85642	Hs.138506		5 200n	10
oo		RC_H15814_s YEL024w/RIP1		Human apM1 mRNA for GS3109 (novel adipose specific colla EST - YEL024w/RIP1	3	10
			-			

## TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

4	$\sim$
1	1)

5

Pkey:	Unique Eos probeset identifier number
	omquo Loo probocot racinano, mambor
CAT number	Gana cluster number

Accession:

Genbank accession numbers

15

	Pkey	CAT Number	Accessions
20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041 AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053
25			AA131489 AA071308 AA063317 AA070156 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895 AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929
30	124215 117058 110455 111168	1597154_1 1219924_1 46874_1 38585_1	H62570 H59063 AW801806 H90434 BE086530 H52576 AF085971 H52172 AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384
35			AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
40	111498 104340 103747 134496 Al684569 A	411008_1 46289_10 117944_1 46501_1	Al168511 Al022712 AA700366 R07371 R07324 AA426189 F15201 AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311
	A1084369 F	AA25/UTT	AI079277 AI241318 BE327710 AW975215 AW896268 AA884990 BE327514
45	103750 105239	118365_1 34624_1	AA126129 AA126033 AA082561  AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627  AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241  AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904  C16859
50	120379	34624_3	AL042725 BE063316 AW975610 AA457591 BE062092 AI655202 AA714296 AI267264 AI075321 AA223286 AA071122 AA227849 AA216700 AI696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868 AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
55	114624 106851 108392 100545 100654	111686_1 322947_1 113549_1 22955_11 tigr_HT2969	AA081507 AA070071 AA070840 AA084362 AI458623 AA639708 AA485409 R22065 AA485570 AA075124 AA075208 M55405 AW752552 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
60	100702 102208	tigr_HT3413 6735_9	L27065 U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195 AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101

N70806 A|141254 A|383191 A|401237 A|080709 A|093400 W84549 T90806 R00012 W01413 AA630557 A|378348 A|559265 AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404 AI133272 V00494 M12523 M12523 AI207526 AI133120 AI064802 AI174993 AI114729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AI110799 D17107 NM\_000477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 AI174710 5 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 AI174748 AI114663 AI133104 AI132999 AI133100 AI064925 AI064979 AI133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 10 N56507 T87485 AI133622 AA343370 T40075 T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 AI114589 R06691 AI110629 AF063503 AI140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 15 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 20 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 Al823482 Al114536 AA860651 AW242644 R07469 AW300438 Al133416 AW271670 Al991363 T78943 Al823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158 25 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 30 T28321 T55864 AA621529 genbank\_AA621529 123941 genbank\_N53145 118049 N53145 AA313538 U88895 U88902 102800 14782\_20 AA422123\_i\_atAA422123\_i 35 104106 111738 genbank\_R26065 R26065 T51588 113149 genbank\_T51588 113958 genbank\_W86195 W86195 genbank\_AA070500 genbank\_AA071193 108335 AA070500 40 AA071193 108351 AA079079 108441 genbank\_AA079079 genbank\_H83465 124276 H83465 entrez\_M21305 101447 M21305 genbank\_N20468 117226 N20468 45 AA207059,AA207241 133379 genbank\_AA207059 119366 genbank T77892 T77892 NOT\_FOUND\_entrez\_W38051 W38051 119528 112588 genbank\_R77302 R77302 114449 genbank\_AA020736 AA020736 50 114576 genbank\_AA065096 AA065096 W38002 s at W38002 s 107459 AA435746 130339 genbank\_AA435746

# TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

Pkey: ExAccn: UnigenelD: Unigene Title: R1: 10

15	Pkey	ExAccn	UnigenelD	Unigene Tittle	R1
		T51986	Hs.283108	hemoglobin, gamma G	10
	100549	BE142019	Hs.222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10
20		A03758		NM_000477*:Homo sapiens albumin (ALB), m	10
20		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
		NM_001674	Hs.460	activating transcription factor 3	10
		NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
25		M21305	110 70400	gb:Human alpha satellite and satellite 3	10
23		N98569 M27826	Hs.76422 Hs.267319	phospholipase A2, group IIA (platelets, endogenous retroviral protease	10 10
		M74447	Hs.502	transporter 2, ATP-binding cassette, sub-famil	10
		U22961	113.302	gb:Human mRNA clone with similarity to L	10
		U48251	Hs.75871	protein kinase C binding protein 1	10
30		AA313538	110.70071	gb:EST185419 Colon carcinoma (HCC) cell	10
20		NM 006744	Hs.76461	retinol-binding protein 4, interstitial	10
		AA829286	Hs.332053	serum amyloid A1	10
	103747	AA081995		gb:zn26d06.r1 Stratagene neuroepithelium	10
	103812	AA137107	Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10
35	104093	R50727	Hs.336970	ESTs	10
	104109	AL353957	Hs.284181	hypothetical protein DKFZp434P0531	10
		F06638	Hs.12440	Homo sapiens clone 24734 mRNA sequence	10
		N73185	Hs.94285	EST	10
40		N91071	Hs.109650	ESTs	10
40		Al498763	Hs.203013	hypothetical protein FLJ12748	10
		AA009764	Hs.190380	ESTs	10
		AA017245	Hs.32794	ESTs	10
		AA019300	Hs.125070	ESTs, Moderately similar to I54374 gene	10 10
45		Al298208 AA130390	Hs.28805 Hs.25549	ESTs hypothetical protein FLJ20898	10
40		AA221036	H5.20048	gb;zr03f12.r1 Stratagene NT2 neuronal pr	10
		N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	10
		Al803651	Hs.191608	ESTs	10
		AI085846	Hs.25522	KIAA1808 protein	10
50		AL042069	Hs.119021	DKFZP434N061 protein	10
• •		AW235928	Hs.313182	ESTs	10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10
	106782	AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
	107124	AB006532	Hs.31442	RecQ protein-like 4	10
55	107148	AI005036	Hs.334305	GS1999full	10
		AF127026	Hs.5394	myosin IA	10
		AB020672	Hs.175411	KIAA0865 protein	10
		AI905985	Hs.111805	ESTs	10
<b>CO</b>		W28516	Hs.19210	hypothetical protein MGC11308	10
60		AL042425	Hs.283976	hypthetical protein PRO2389	10
		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
		AA071193 F01449	Hs.26954	gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10 10
		AW294162	Hs.301062	Homo sapiens mRNA; cDNA DKFZp762G123 (fr UDP-N-acetyl-alpha-D-galactosamine:polyp	10
65		AL044174	Hs.159526	patched (Drosophila) homolog	5
05	110010	, 120-1717	. 10. 100020	paterior (Drocopring) nomolog	

	111160	A1798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		R16733	Hs.20499	ESTs	10
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
		AA034378	Hs.267319	endogenous retroviral protease	10
5		NM_002666	Hs.103253	perilipin	10
9		AA193106	Hs.180817	chromosome 11 open reading frame 23	5
		AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
		AF110141	Hs.288908	WAS protein family, member 2	10
		AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10		AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
10		BE222078	Hs.113069	ESTs	10
		M62402	Hs.274313	insulin-like growth factor binding prote	10
		D88435	Hs.153227	cyclin G associated kinase	10
		V00517	Hs.283108	hemoglobin, gamma G	10
15		NM_001928	Hs.155597	D component of complement (adipsin)	10
		BE270472	Hs.279900	HSPC015 protein	10
		AL110226	Hs.16441	DKFZP434H204 protein	10
		AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10
		NM_006691	Hs.17917	extracellular link domain-containing 1	10
20		AA046747	Hs.17917	extracellular link domain-containing 1	10
	130718	N70196	Hs.18376	KIAA1319 protein	10
	130798	M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
~ ~	131184	AB040935	Hs.23954	cerebral cell adhesion molecule	10
25	131282	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
		AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AW966881	Hs.41639	programmed cell death 2	10
		AA829286	Hs.332053	serum amyloid A1	10
20		H69342	Hs.26320	TRABID protein	10
30		AJ000263	Hs.278658	keratin, hair, basic, 6 (monilethrix)	10
		AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
		AI291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
		W28548	Hs.224829	ESTs	10
35		NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10 10
33		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
		AF017987	Hs.7306	secreted frizzled-related protein 1	10
		H26904 AF072441	Hs.75736 Hs.7840	apolipoprotein D calcineurin binding protein 1	10
		D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40		Al372588	Hs.8022	TU3A protein	5
70		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	5
		BE243319	Hs.79672	KIAA0652 gene product	10
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (	10
		M64936	110.0200	gb:Homo sapiens retinoic acid-inducible	10
45		NM_002757	Hs.250870	mitogen-activated protein kinase kinase	10
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
		NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10
50		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
	446674	AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10

## TABLE 2A

**Table 2A** shows the accession numbers for those pkeys lacking unigeneID's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	•	1 2
	Pkey:	Unique Eos probeset identifier number

5

15

CAT number: Gene cluster number
Accession: Genbank accession numbers

•		Pkey	CAT number	Accessions
2	0.0	111168		AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H69570
2	25	103747 134496	117944_1 46501_1	AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311 Al684569 AA257011 Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
3	0	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904
		100654	tigr_HT2969	C16859 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495
3	5	102208	6735_9	X51363 X51364 X51365 U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101 N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265
4	.0			AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404 Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496
4	-5			H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549
5	0			Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951
5	5			AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 Al114676 Al064778 AA035710 W52763 Al114786 T83564 AA341859 T81684 T55769 Al114710 T51776 AA343213 Al114714 T58102 Al110809 R28984 Al174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al055112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289
6	50			AA046980 Al823482 Al114536 AA660651 AW242644 R07469 AW300438 Al133416 AW271670 Al991363 T78943 Al823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158
				110

> T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

5 102800

108351

101447

# TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

4		

10	Pkey: ExAccn: UnigeneID: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor
----	---	--

I	2	

13	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	102208 102990	NM_006732 U22961 AA829286 AI798376		FBJ murine osteosarcoma viral oncogene h gb:Human mRNA clone with similarity to L serum amyloid A1 gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10.0 10.0 10.0 10.0
25	111803 130085 130840	AA593731 M62402 BE048821 AW966881 NM_003278		ESTs, Moderately similar to ALU5_HUMAN A insulin-like growth factor binding prote small inducible cytokine subfamily A (Cy programmed cell death 2 tetranectin (plasminogen-binding protein cholesteryl ester transfer protein, plas	10.0 10.0 10.0 10.0 10.0 10.0

### TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	

5

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15	Pkey	CAT number	Accessions
----	------	------------	------------

20	111168 38585_1	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659
		BE081531 H59570
25	1022086735_9	U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195
25		AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AI141254
		AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464
		AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 AI133272 V00494 M12523
20		M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799
30		D17107 NM_000477 AF190168 R50724 A1248416 A1207432 A1133684 A1133345 A1174710 A1133290 A1133304 A1174948
		AI207484 AI110717 AF074624 AI114515 AF063516 AI110642 AI114559 AI114498 AI114759 AI207568 AI064960 AI174753 AI114666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750
		T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999
		Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403
35		T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075
		T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 AI114589 R06691 AI110629
		AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749
		T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753
40		T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281
40		R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874
		AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676
		AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102
		AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364
45		AF075308 W86731 T82851 T48269 H54053 T73211 A1114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976
		R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354
		A1114720 A1433289 AA046980 A1823482 A1114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363
		T78943 A1823481 AA845518 AA719124 AA883464 T68850 T69115 A1935509 A1150977 T62890 T71374 T68294 A1174774
50	•	T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111
		AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811
	•	T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358
		T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290
55		AI312890 T67751 AI174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412
55		T64300 T28321 T55864

#### TABLE 4: Figure 4 from BRCA 001 US

5 Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title

Ratio of tumor to normal breast tissue

10

R1:

15 R1 ExAccn UnigeneID Unigene Title Pkey 2.3 100113 NM 001269Hs.84746 chromosome condensation 1 100114 X02308 Hs.82962 thymidylate synthetase 2.9 ectonucleotide pyrophosphatase/phosphodiesterase 1 100131 D12485 Hs.11951 1.9 20 100146 BE185499 Hs.2471 KIAA0020 gene product Hs.136348 osteoblast specific factor 2 (fasciclin I-like) (periostin) 7.5 100147 D13666 KIAA0101 gene product 100154 H60720 Hs.81892 gene predicted from cDNA with a complete coding sequence 1.6 100163 W44671 Hs.124 2.0 100220 AW015534 Hs.217493 annexin A2 25 Hs.112396 KIAA0077 protein 1.5 100265 D38521 100271 BE160081 Hs.256290 S100 calcium-binding protein A11 (calgizzarin) 13.5 5.1 100275 BE242802 Hs.154797 KIAA0090 protein KIAA0130 gene product 1.9 100323 D50920 Hs.23106 2.7 platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD) 100335 AW247529 Hs.6793 30 2.0 100364 NM\_004341Hs.154868 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 2.6 100372 NM\_014791Hs.184339 KIAA0175 gene product 3.2 100393 D84145 Hs.39913 novel RGD-containing protein 100400 AW954324 Hs.75790 phosphatidylinositol glycan, class C 1.5 KIAA0225 protein 2.0 100418 D86978 Hs.84790 2.9 35 heterogeneous nuclear ribonucleoprotein A/B 100482 M65028 Hs.81361 1.9 100518 NM\_004415Hs.74316 desmoplakin (DPI, DPII) 100666 L05424 Hs.169610 CD44 antigen (homing function and Indian blood group system) 5.7 Hs.169610 CD44 antigen (homing function and Indian blood group system) 9.0 100667 L05424 Hs.169610 CD44 antigen (homing function and Indian blood group system) 7.6 100668 L05424 40 53.2 100678 AW502935 Hs.740 PTK2 protein tyrosine kinase 2 100685 AA328229 Hs.184582 ribosomal protein L24 1.8 100690 AA383256 Hs.1657 estrogen receptor 1 1.6 100783 AF078847 Hs.191356 general transcription factor IIH, polypeptide 2 (44kD subunit) 5.9 1.7 100850 AA836472 Hs.297939 cathepsin B 45 100892 BE245294 Hs.180789 S164 protein 1.7 100945 AF002225 Hs.180686 ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome) solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 6.3 100969 AA157634 Hs.79172 11.4 100988 AK000405 Hs.76480 diaphorase (NADH/NADPH) (cytochrome b-5 reductase) 1.6 100999 H38765 Hs.80706 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase) 8.2 50 Hs.151738 101031 J05070 5.0 gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region. 101045 J05614 101077 N99692 Empirically selected from AFFX single probeset procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI)1.4 101093 L06419 Hs.75093 101161 NM\_006262Hs.37044 16.9 peripherin 2.0 55 101186 AA020956 Hs.179881 core-binding factor, beta subunit cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) 101216 AA284166 Hs.84113 1.8 101228 AA333387 Hs.82916 chaperonin containing TCP1, subunit 6A (zeta 1) 1.7 101247 AA132666 Hs.78802 glycogen synthase kinase 3 beta 1.9 protein kinase C, iota 1.5 101249 L18964 Hs.1904 101332 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 5.2 60 101332 J04088 Hs.156346 topoisomerase (DNA) II alpha (170kD) 3.4 COX17 (yeast) homolog, cytochrome c oxidase assembly protein 101352 Al494299 Hs.16297 6.3 proliferating cell nuclear antigen 4.2 101396 BE267931 Hs.78996 gb:Human Alu repeats in the region 5' to the small nuclear rib 101445 M21259 1.9 101470 NM\_000546Hs.1846 tumor protein p53 (Li-Fraumeni syndrome) 65

	404470	NIM 000000Us 750	DAG and available politicator (CTDaga politicating protein) 1	2.5
		NM_002890Hs.758	RAS p21 protein activator (GTPase activating protein) 1 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide l	5.5
		M24486 Hs.76768	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoi	
		J04977 Hs.84981		1.6
5		NM_012151Hs.83363	proteasome (prosome, macropain) 26S subunit, ATPase, 3 coagulation factor VIII-associated (intronic transcript)	5.7
5		AF064853 Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
		AF064853 Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	5.6
		BE391804 Hs.62661	guanylate binding protein 1, interferon-inducible, 67kD	2.4
			protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10			cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
10		M80244 Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+system), member 5	5.0
			carboxypeptidase B1 (tissue)	14.4
		AA306495 Hs.1869	phosphoglucomutase 1	5.2
		AW409747 Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15			S100 calcium-binding protein A7 (psoriasin 1)	8.9
13			peroxisomal membrane protein 3 (35kD, Zellweger syndrome)	3.2
			nuclear autoantigenic sperm protein (histone-binding)	1.6
			glycoprotein hormones, alpha polypeptide	31.3
		AF182645 Hs.8024	IK cytokine, down-regulator of HLA II	1.8
20		U41514 Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-	
20		Al904232 Hs.75323	prohibitin	8.4
		BE245149 Hs.82643	protein tyrosine kinase 9	1.3
		BE250127 Hs.82906	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	2.0
		T35901 Hs.75117	interleukin enhancer binding factor 2, 45kD	1.6
25		T35901 Hs.75117	interleukin enhancer binding factor 2, 4 3kD	1.3
25		BE258602 Hs.182366		1.4
		NM_001809Hs.1594	centromere protein A (17kD)	1.8
			death associated protein 3	4.6
		AW950852 Hs.74598	polymerase (DNA directed), delta 2, regulatory subunit (50kD)	4.3
30		AA829978 Hs.301613		6.7
50		U24389 Hs.65436	•	4.3
			iysosomal heterochromatin-like protein 1	1.9
			karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	4.4
		AA306342 Hs.69171	protein kinase C-like 2	2.7
35		BE298063 Hs.77254	chromobox homolog 1 (Drosophila HP1 beta)	1.5
55		BE378432 Hs.95577	cyclin-dependent kinase 4	2.3
		U37519 Hs.87539		2.0
			baculoviral IAP repeat-containing 2	3.2
			hepatocyte nuclear factor 3, alpha	2.0
40				6.2
40			PTK7 protein tyrosine kinase 7	1.5
			deoxyguanosine kinase	6.9
		U48705 Hs.75562 NM_001359Hs.81548	discoidin domain receptor family, member 1 2,4-dienoyl CoA reductase 1, mitochondrial	1.8
			amyloid beta precursor protein-binding protein 1, 59kD	1.5
45			origin recognition complex, subunit 3 (yeast homolog)-like	3.3
43		AL080116 Hs.74420		2.1
		Al188137 Hs.75193 AF217197 Hs.74562	COP9 homolog siah binding protein 1; FBP interacting repressor; pyrimidine tract binding splicing	3.2
			solute carrier family 1 (neutral amino acid transporter), member 5	2.8
		AF040253 Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50		U59423 Hs.79067		2.3
50			RAB31, member RAS oncogene family	5.3
		1160808 He 150081	CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1	2.1
	102000	U60808 Hs.152981	enhancer of zeste (Drosophila) homolog 2	1.6
	102301		tubulin-specific chaperone e	2.1
55	102002	001232 H3.32073	COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
55			extracellular matrix protein 1	5.8
		AL037672 Hs.81071		1.3
			zinc finger protein 184 (Kruppel-like)	1.8
			karyopherin (importin) beta 2	2.3
60		BE262989 Hs.12045	putative protein	4.3
60	102687	NM_007019Hs.93002	ubiquitin carrier protein E2-C	6.0
	102689		hydroxyacyl-Coenzyme A dehydrogenase, type II	4.2
		BE540274 Hs.239	forkhead box M1  RBCA1 associated PING domain 1	4.2 1.9
		AU077058 Hs.54089	BRCA1 associated RING domain 1	2.3
65	102/05	T97490 Hs.50002	small inducible cytokine subfamily A (Cys-Cys), member 19	2.3 1.2
65	102/50	AB014460 Hs.66196	nth (E.coli endonuclease III)-like 1	6.4
	102801	BE252241 Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinase high-mobility group (nonhistone chromosomal) protein 17-like 3	1.6
	102812	U90549 Hs.236774	riign-moniity group (noninstane amomosomai) protein 17-like 3	1.0

	40000=	DE044500 11 0450	1 1 1 1 TOD4 10 (Incla)	E 0
		BE244588 Hs.6456	chaperonin containing TCP1, subunit 2 (beta)	5.6
		AA262170 Hs.80917	adaptor-related protein complex 3, sigma 1 subunit	2.0
			5 WW domain-containing protein 1	1.3
_	102868	X02419 Hs.77274	plasminogen activator, urokinase	4.4
5	102925	BE440142 Hs.2943	signal recognition particle 19kD	1.9
	102935	BE561850 Hs.80506	small nuclear ribonucleoprotein polypeptide A'	2.4
	102968	AU076611 Hs 15467	2 methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cycl	ohydrolase2.7
	102983	BE387202 Hs 11863	non-metastatic cells 1, protein (NM23A) expressed in	3.1
		U95742 Hs.2707	G1 to S phase transition 1	5.2
10	102303	113.27 U	O multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
10				2.5
			3 CDC28 protein kinase 1	
			4 matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
		AU077231 Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatosis 1)	3.1
	103089	D31152 Hs.17972	ollagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	2.4
15	103177	BE244377 Hs.48876	farnesyl-diphosphate farnesyltransferase 1	3.5
	103178	AA205475 Hs.27586	5 ribosomal protein S18	9.9
		NM_001777Hs.82685		1.3
		X69636 Hs.33473	1 Homo sapiens, clone IMAGE:3448306, mRNA, partial cds	2.0
		NM_006825Hs.74368		1.6
20		AA401039 Hs.2903	protein phosphatase 4 (formerly X), catalytic subunit	2.5
20				2.2
		NM_004766Hs.75724	coatomer protein complex, subunit beta 2 (beta prime)	6.3
		NM_004939Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1	
		X72755 Hs.77367	monokine induced by gamma interferon	8.8
		BE275607 Hs.1708	chaperonin containing TCP1, subunit 3 (gamma)	3.0
25	103232	X75962 Hs.12978	tumor necrosis factor receptor superfamily, member 4	1.8
		Al369285 Hs.75189	death-associated protein	5.6
	103297	NM 001545Hs.9078	immature colon carcinoma transcript 1	1.9
		Al803447 Hs.77496	the state of the s	2.5
		X89059	gb:H.sapiens mRNA for unknown protein expressed in macrophage	1.6
30			3 coated vesicle membrane protein	1.8
50		X94453 Hs.11436	5 pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)	2.3
			ability and the deligation areas over 1 f 2	4.0
		X94563	gb:H.sapiens dbi/acbp gene exon 1 & 2.	1.3
		BE564090 Hs.20716		
2.5			1 myeloid/lymphoid or mixed-lineage leukemia 3	5.6
35	103505	AL031224 Hs.33102	transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	5.1
			2 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)	9.7
	103588	NM_006218Hs.85701	phosphoinositide-3-kinase, catalytic, alpha polypeptide	2.0
	103613	NM_000346Hs.2316	SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	1.3
	103621	BE379766 Hs.15067	5 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	2.0
40			2 membrane component, chromosome 11, surface marker 1	2.3
			1 growth factor receptor-bound protein 2	1.3
		AL135301 Hs.8768	hypothetical protein FLJ10849	1.8
			9 Homo sapiens mRNA; cDNA DKFZp586l2022 (from clone DKFZp586l2022)	1.3
			2 hypothetical 43.2 Kd protein	7.5
45			Homo sapiens BTB domain protein (BDPL) mRNA, partial cds	1.2
43			gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar	1.5
	103/9/	AA080912	gp:zn04003.11 Stratagene hivi heuron (937253) nomo sapiens cova cione 3 similar	1.5
		AI042582 Hs.18127		
	103855		7 hypothetical protein FLJ10330	1.5
	103886	AK001278 Hs.10573	7 hypothetical protein FLJ10416 similar to constitutive photomorphogenic protein 1	6.5
50	104052	NM_002407Hs.97644	mammaglobin 2	2.9
	104079	AA251242 Hs.10323	8 ESTs	1.4
	104174	AA478984 Hs.6451	PRO0659 protein	5.6
		AB002343 Hs.98938		1.6
	104275	Al751970 Hs.10106	7 GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55	104325	BE379766 Hs.15067	5 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
		AA324597 Hs.21851		1.6
	104070	R83113 Hs.1432	protein kinase C substrate 80K-H	5.2
	104420	AB037762 Hs.44268		1,2
	104402	ALANDES No. 20204	3 hypothetical protein FLJ12748	2.1
60				1.2
60	104563	ALT17403 FIS.30010	9 DKFZP434F1735 protein	
		Al239923 Hs.30098	ESTs	1.3
			9 olfactory receptor, family 2, subfamily I, member 6	2.3
	104804	Al858702 Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	1.3
	104806	AB023175 Hs.22982	KIAA0958 protein	2.3
65	104827	AW052006 Hs.8551	PRP4/STK/WD splicing factor	10.9
	104846	Al250789 Hs.32478	ESTs	5.6
	104854	AA041276 Hs.15472	9 3-phosphoinositide dependent protein kinase-1	12.3

	104867	AA278898		hypothetical protein similar to small G proteins, especially RAP-2A	2.0
		T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (from clone DKFZp564O2364)	1.3
		AW015318		EST's	17.7
_	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5	104916	AW958157	Hs.155489	NS1-associated protein 1	1.7
		AA026880		prolactin receptor	1.4
		AF043467		neurexophilin 2	2.2
		NM_015310		KIAA0942 protein	5.0
1.0		Y12059		bromodomain-containing 4	1.4
10		AL136877		SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.4
		AL136877		SMC4 (structural maintenance of chromoso	2.3
			Hs.19322		
		AA937934			1.3
. ~				mitochondrial GTP binding protein	3.5
15		BE379584		dolichyl-diphosphooligosaccharide-protein glycosyltransferase	5.5
		AF098158		chromosome 20 open reading frame 1	3.3
		AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2
		AA127818		gb:zl12a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:501674 3'	6.8
20		AA907305		ESTs	2.5
20		AB037716		KIAA1295 protein	2.2
				speckle-type POZ protein	3.8
		AA151342		CGI-147 protein	9.5
		AA147884		Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716	5.6
0.5		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
25		Z78407	Hs.27023	vesicle transport-related protein	2.2
		BE387350		KIAA1160 protein	1.6
		AW975433		ESTs	6.3
				nudix (nucleoside diphosphate linked moiety X)-type motif 5	2.1
20				mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A	2.7
30				hypothetical protein NUF2R	1.9
				S164 protein	1.7
		AA191512		Homo sapiens cDNA FLJ11309 fis, clone PLACE1010076	4.8
		AA071276		KIAA0859 protein	1.9
25		AA263143		RAD51-interacting protein	2.8 1.9
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	8.0
		AA700122		sentrin-specific protease	1.8
				KIAA0779 protein	8.2
		NM_016019		CGI-68 protein	5.0
40				hypothetical protein FLJ21918	2.5
40		AW887701		hypothetical protein FLJ20628	2.2
				hypothetical protein FLJ10326	2.3
				membrane protein CH1 interleukin enhancer binding factor 3, 90kD	5.4
				Npw38-binding protein NpwBP	1.6
45		AF198620			1.6
40		AA252395	115.05040	gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685026 3', mRNA sequence	
			He 226318	CCR4-NOT transcription complex, subunit 7	1.6
				hypothetical protein FLJ20364	1.3
		AB023179		KIAA0962 protein	3.4
50		AA262640			9.3
50				hypothetical protein FLJ14299	1.4
		AA579535		hypothetical protein FLJ20452	10.9
	105597	AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9
	105608	AI808201	Hs 287863	hypothetical protein FLJ12475	1.7
55				fetal Alzheimer antigen	1.4
55		AK000892		glucocorticoid modulatory element binding protein 1	1.7
				casein kinase 1, gamma 2	5.5
				hypothetical protein FLJ20059	9.4
		AW499988	Hs.27801	zinc finger protein 278	2.0
60		R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	1.7
30		BE246502		sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short	2.6
		AW151952		hypothetical protein FLJ20739	1.5
	105759		Hs.15159	chemokine-like factor, alternatively spliced	1.3
	105771	Al267720		synovial sarcoma, translocated to X chromosome	1.6
65	105820	AA741336	Hs.152108	transcriptional unit N143	2.2
				E3 ubiquitin ligase SMURF2	1.3
	105856	A1262106	Hs 12653	FSTs	2.4

	105858	AF151066	Hs.281428	· Ab	2.9
		AK001708	Hs.32271	hypothetical protein FLJ10846	1.4
	105930	AF016371	Hs.9880		5.2
		AW194426	Hs.20726	ESTs	1.7
5		AW081202	Hs.12284		2.8
	106017	AA477956	Hs.26268	ESTs	1.4
		AL157441	Hs.17834		1.4
	106078	AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	1.6
	106094	AA533491		hypothetical protein FLJ14681	8.6
10	106140	AB006624	Hs.14912		1.6
	106271	AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, clone MGC:13155, mRNA, complete cd	s 10.8
				KIAA1321 protein	1.3
		Y10043	Hs.19114	high-mobility group (nonhistone chromosomal) protein 4	3.6
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15		AK001404			5.7
		AW390282		transmembrane 7 superfamily member 2	6.3
		AB040916		KIAA1483 protein	6.5
		AW748420			2.2
		AF119256		zinc finger protein 278	2.7
20				Homo sapiens cDNA: FLJ23038 fis, clone LNG02039	2.3
		AA454036		ESTs	1.6
		AA243837			1.6
		AK000933		Homo sapiens cDNA FLJ10071 fis, clone HEMBA1001702	2.4
		AA458882		fibulin 1	7.9
25		NM_003595			7.7
23		AL049951	He 22370		1.8
	106660	AV657117	He 184164	ESTs, Moderately similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	1.3
	100003	RE61/1902	He 18/1352	hypothetical protein FLJ12549	4.5
	100713	A A 600257	He 220480		1.3
30		BE388094			1.6
20				LOIG	5.7
		AW959893	HS.283733		16.2
				hypothotioar protonin Educated Chilman to a me a mitoriana protonin =	1.5
		BE564871		Contain, E. Harra Protein, C (CE CO.)	2.2
35	100840	AB037744		TAIL OF TOPO PROCESS	1.3
33				nypoutous. Proton	16.8
		N49809		Tronto daptorioj diono ina remiser to tray in a daj parameter	1.5
		W79171	Hs.9567		2.2
				adilotipati testo sin i==	3.3
40					6.8
40		AK000511		hypothotoch protein art ap to the terminate tary	6.6
		BE156256		Hypothotical protein	4.8
		AL043152		The Mozoo gono product	6.0
		AW631480		2010	1.3
1 =					1.8
45		AF264750			
		AW385224			1.7
		AK000733			2.5
		AK000512		Hypothotical protein r Eczeree	1.7
<b>#</b> 0		AV661958		Citor protein	4.6
50		AV661958		Citati pictori	3.3
	107146	AK001455	Hs.5198	20111 of the control	2.0
	107151	AW378065	Hs.8687		6.3
	107155	AW391927	Hs.7946		33.5
		BE122762	Hs.25338		5.2
55		W15477	Hs.64639	Suprime harman Samuran Francisco	6.1
	107221	AW888411	Hs.81915		17.4
	107243	BE219716	Hs.34727		7.4
	107248	AW263124	Hs.315111		1.8
	107263	D60341	Hs.21198		6.6
60	107265	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.5
		N95657	Hs.6820		2.5
		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	1.7
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2
		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (from clone DKFZp586I0324)	2.0
65	107354	NM 00629	9Hs.96448	zinc finger protein 193	5.0
	107392	AW299900	Hs.267632	TATA element modulatory factor 1	1.2
	107481	AA307703	Hs.279766	kinesin family member 4Å	1.6

					3.0	
	107554	AA001386	Hs.59844		1.3	
	107681	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.2	
_	107772	AA018587	Hs.303055	Loto, trodity diffici to the i_frenit it the open times to the interest in the	2.1	
5		AW732573	Hs.47584	bottopiditi tottago gatoa etteritiot aetal ea recenteri eserenti et mente.	8.4	
	107901		Hs.335952	Notatili 42	2.5	
	107901		Hs.335952	1101.0011.00	1.6	
					2.2	
	107974	AW956103	Hs.61712		6.7	
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	1.5	
		AA054224		20.0	1.3	
				1 Box only protein o	7.1	
			Hs.161623	2010	2.5	
	108496	AA083069	Hs.339659		3.5	
15	108607	BE300380	Hs.69476	Tronce despitation and the feet	3.4	
			Hs.182685		1.6	
		AW022410		40.0	1.7	
		BE546947		11011100 0071 0 70	9.8	
••		AB029000		Title tree protein	7.2	
20				nypourodour protonii i zazoo i o	1.3	
		AI089575		progressione membrane amaning proteins	2.7	
				Bit Zi co ico ico pictom	1.8	
		AL121500	Hs.178904	2010	1.5	
~~	108872	H06720	Hs.111680	Ondooding diplica	2.1	
25		Al801235		20.0	5.3	
	108894	AK001431	Hs.5105		4.0	
	108955	AA149754	Hs.195155	110110 daplotto ditalio della tratioporto yeteni (12 / 27/27 / 1/2	5.6	
				Homes now (expressed in the sensy i	1.6	
20				in positional protein in the record	6.2	
30		AB028987		To action proton	1.7 1.4	
		AA156542	Hs./212/			5.3
		AA157811	11. 70545	gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu repe	2.9	5.5
		AA164293		mo. c	1.6	
35		AW608930		Type a to to to to to	3.2	
33				njpoulousur protour i za rerez	1.7	
				Hypothetical protein i abbanco.	2.6	
	109139	AJ 132392			2.9	
		BE566742	HS.73023		2.0	
40					5.3	
40		NM_016603	Hs.189998	potential tradical protein death of and mine protein	5.7	
	109220	A11077291	He 170285		5.3	
		N99673	Hs.3585	(idoloopoint 2 i iii )	1.4	
	100270	A A 375752	He 82719		2.9	
45	100273	AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	
73			Hs.115099	and the free Abel and an action	2.9	
	109391	A1 096858	Hs 184245		1.5	
		H83603	Hs.40408		2.2	
		N30531	Hs.42215		3.0	
50		Al160029			1.9	
•			Hs.189915		1.8	
					3.7	
		NM_015310		KIAA0942 protein	3.2	
	109478	AW074143	Hs.87134		2.0	
55		L40027	Hs.118890		2.1	
		F02614			1.4	
		R71264	Hs.16798		1.3	
		H11938	Hs.21907	histone acetyltransferase	2.0	
	110056	AA503041	Hs.279009	matrix Gla protein	2.5	
60	110085	AA603840	Hs.29956	KIAA0460 protein	1.7	
		T07353	Hs.7948	ESTs	2.9	
	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7	
	110154	NM_01452	1Hs.17667	SH3-domain binding protein 4	4.2	
	110240	Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOCHROME P450 4A11 PRECURSOR [H.sapiens]	4.2	
65	110242	N41744		CGI-30 protein	1.3	
	110259	H28428	Hs.32406		2.2	
	440040	DEGEROOR	Un 44006	hypothesical protein El 112080	21	

	110330	Al288666	Hs.16621	DKFZP434I116 protein	6.2
		H55748		gb:yq94a01.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:203400 3'	6.1
		H55915		hypothetical protein FLJ11016	6.1
5		H57330 AK001160	Hs,37430	EST by mothetical protein EL 140008	6.3 1.3
5		T97586	Hs.18090	hypothetical protein FLJ10298 ESTs	1.8
		AB007902		KIAA0442 protein	1.6
		AW190338		hypothetical protein MGC11256	7.6
		AL138077		hypothetical protein FLJ12707	2.5
10		BE044245		hypothetical protein MGC2963	9.3
		AK000322		hypothetical protein FLJ20315	5.5
		BE000831		Homo sapiens cDNA FLJ11812 fis, clone HEMBA1006364	2.1
		A1089660		dpy-30-like protein FK506 binding protein precursor	1.5 6.6
15		T25829 AA767373	Hs.24048	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	
13		R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens]	3.4
		N31598	Hs.12727	hypothetical protein FLJ21610	1.7
		Al740792			1.7
		BE612992		hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase	4.7
20	110856	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3' similar to contains element	2.3
		BE384447		hypothetical protein MGC13186	3.5
		AL117430		DKFZP434D156 protein	2.2
		BE092285 H04360		hypothetical protein FLJ13187	2.6 · 1.9
25		NM_005864	Hs.24283	ESTs, Moderately similar to reduced expression in cancer [H.sapiens] signal transduction protein (SH3 containing)	6.7
23		AK002180		DKFZP564O123 protein	2.0
		AK001980		ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2	1.3
		AW613287			1) 1.8
• •		N63823		ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30		AB037807		hypothetical protein	2.1
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170	2.3
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	3.7 7.5
		AL050166 AK000136		Homo sapiens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122) asporin (LRR class 1)	7.5 7.1
35				Homo sapiens cDNA FLJ20738 fis, clone HEP08257	6.7
55				Homo sapiens cDNA FLJ20738 fis, clone HE	3.3
				ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens]	3.6
		AW139408	Hs.152940	ESTs	1.5
40				KIAA1361 protein	2.6
40				KIAA1866 protein	4.6
				hypothetical protein FLJ22087	7.9 6.9
		AA778711		eukaryotic translation initiation factor 1A KIAA1265 protein	5.0
			Hs.34504	ESTs ESTS	3.8
45		T99755	Hs.334728		1.2
•				LIS1-interacting protein NUDE1, rat homolog	5.1
	111352	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
			Hs.94631	brefeldin A-inhibited guanine nucleotide-exchange protein 1	2.8
50				HSCARG protein	2.2
50				oxidation resistance 1 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)	2.1
				Homo sapiens, clone IMAGE:3659680, mRNA, partial cds	5.1 8.4
	111452	R02354	Hs.15999	ESTs	2.7
			Hs.227978		6.5
55		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	1.4
		R10720	Hs.20670	EST	1.6
		R52656	Hs.21691	ESTs	1.6
		AB037834		Homo sapiens mRNA for KIAA1413 protein, partial cds	2.4
60		BE298665 AW083791		Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)	10.6
00		NM_015310		suppressor of potassium transport defect 3 KIAA0942 protein	6.6 5.1
	112134		Hs.7413	ESTs; calsyntenin-2	2.8
		AB029000	Hs.70823	KIAA1077 protein	14.6
	112388	R46071	Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA, partial cds	9.0
65		NM_016248	3Hs.232076	A kinase (PRKA) anchor protein 11	1.4
		AW007287		Homo sapiens cDNA: FLJ21086 fis, clone CAS03272	1.4
	112506	A1742756	HS.200/9	ESTs	3.2

	112513	R68425	Hs.13809		2.0	
	112752	AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	
	112884	AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein, partial cds	6.6	
_	112923	T10258	Hs.5037	EST	1.5	
5	112936	AW970826	Hs.6185	KIAA1557 protein	3.2	
	112958	R61388	Hs.6724		6.0	
	112966	Z44718	Hs.102548	glucocorticoid receptor DNA binding factor 1	6.4	
		AK000272			1.2	
		AA737033			5.6	
10		BE276112			2.0	
		Al571940			1.9	
		AW965190			2.4	
			Hs.270862		1.3	
		T57317	113.270002	gb:yb51a03.s1 Stratagene fetal spleen (937205) Homo sapiens cDNA clone IMAGE:74668 3',	1.7	
15		T63857		gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence	2.8	
1.5			Ha 11440	DKFZP564O123 protein	1.3	
			Hs.11774		3.2	
			Hs.179808	) (1 )	1.2	
					5.9	
20		AI467908			2.0	
20		H59588	Hs.15233		3.6	
			Hs.142442		1.3	
			MS.1881/3			
		T97307			4.4	
25			Hs.184411		1.3	
25		AW499665		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member		
					13.4	
		AL359588		77	1.7	
					1.3	
20		W44735	Hs.9286		3.3	
30		BE207480			3.1	
		H13325	Hs.332795		3.2	
		AW378212			2.3	
		T26483	Hs.6059		11.3	
25		W57902	Hs.90744	h	2.7	
35		AL079314		,	6.1	
		AW959486			6.6	
		AW953484		7,	1.9	
		W87544	Hs.268828		1.2	
40				******* ** <b>!</b> ***** == **** *** *** *** *** *** *** *	5.4	
40				·//	9.4	
		AB029551		· · · · · · · · · · · · · · · · · · ·	1.8	
				fucose-1-phosphate guanylyltransferase	1.5	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	
4.5				Homo sapiens, Similar to zinc finger protein 136 (clone pHZ-20), clone MGC:10647, mRNA, complete the complete sapiens and the complete sapiens are complete sapiens.		2.3
45		AL117518		KIAA0978 protein	1.4	
				KIAA0306 protein	15.8	
				fatty acid desaturase 2	1.9	
	114309	AA332453	Hs.20824	CGI-85 protein	2.4	
50	114392	AA249590	Hs.100/48	==,,	1.8	
50			HS.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (from clone DKFZp434B0425)	1.2	
		H37908			5.5	
	114463	AL120247	Hs.40109	KIAA0872 protein	5.2	
	114464	AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial		
	114471	AA028074	Hs.104613	RP42 homolog	1.8	
55	114480	BE066778	Hs.1516/8	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-Ti		
				hypothetical protein FLJ13346	1.9	
	114698	AA476966	HS.11085/		3.5	
	114730	Al373544	Hs.331328	intermediate filament protein syncoilin	3.8	
<b>C</b> O				minichromosome maintenance deficient (S. cerevisiae) 4	1.6	
60	114774	AV656017	Hs.184325	CGI-76 protein	3.1	
	114798	AA159181	Hs.54900	serologically defined colon cancer antigen 1	3.5	
	114860	AL157545	Hs.42179		4.3	
		AA236177			7.1	(t =
65	114896	BE539101	HS.5324	hypothetical protein	1.3	4 -
65	114911	AA236672	Un 400747	gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:723771 3', mRNA se		1.5
	114930	AA23/022	Hs.188717	EOIS EOTo	2.0	
	114938	AA242834	<b>#5.5058</b>	E018	2.9	

	114965	A1733881	Hs.72472	BMP-R1B	2.3
		AF102546		dachshund (Drosophila) homolog	1.3
		AA252360		toll-like receptor 9	1.6
				Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5				LIM protein (similar to rat protein kina	1.5
			Hs.5324	hypothetical protein	1.5
	115121		Hs.88155		2.8
			Hs.186572		2.5
		AW365434		hypothetical protein FLJ10116	1.5
10		BE251328		hypothetical protein FLJ10881	1.3
				ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4
	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
	115285	AW972872	Hs.293736	ESTs	2.4
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	6.2
15	115400	Al215069	Hs.89113	ESTs	6.6
	115468	AA314349	Hs.48499	tumor antigen SLP-8p	7.4
	115471	AK001376	Hs.59346	hypothetical protein FLJ10514	1.4
	115479	AW301608		ESTs, Moderately similar to I54374 gene NF2 protein [H.sapiens]	4.0
	115496	AW247593	Hs.71819	eukaryotic translation initiation factor 4E binding protein 1	16.3
20		Y14443	Hs.88219	zinc finger protein 200	5.0
					2.5
			Hs.61082		6.1
				HSPC039 protein	2.9
0.5				7-60 protein	5.3
25		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	4.7
	115652	BE093589	Hs.38178	hypothetical protein FLJ23468	10.6
				Homo sapiens, clone MGC:16063, mRNA, complete cds	12.7 2.0
		Al138785	Hs.40507	ESTs	3.0
20		AA953006		ESTs	1.7
30		AA625132		hypothetical protein FLJ21615	6.8
		AF231023		cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	1.7
		BE395161		proteasome (prosome, macropain) subunit, beta type, 2	2.6
		Al950339		ESTS	2.1
35		NM_01543		DKFZP434B168 protein	2.1
33		AI732742		ESTs ESTs	1.3
		Al675217	Hs.42761	hypothetical protein MGC5370	4.4
		AW062629		KIAA0867 protein	7.2
		N55669		mitochondrial ribosomal protein L13	1.2
40		AI867451		hypothetical protein FLJ20739	5.5
10		AB037753		KIAA1332 protein	9.8
		BE275469		Down syndrome critical region gene 5	1.4
		AL359053		Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
		AA770688		H2A histone family, member L	1.8
45		BE243834		CGI-04 protein	1.4
		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0684 [H.sapiens]	1.2
		AW821113		ESTs	2.1
		AV660717		DKFZP586N0819 protein	1.7
				baculoviral IAP repeat-containing 6	1.7
50	116262	Al936442	Hs.59838	hypothetical protein FLJ10808	1.7
	116298	AI955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133	1.9
		AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DICE1	4.9
	116325	Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631	1.4
	116336	AL133033	Hs.4084	KIAA1025 protein	1.9
55	116339	AK000290	Hs.44033	dipeptidyl peptidase 8	1.5
	116350	AA497129	Hs.184771		1.9
		Al149586	Hs.38125	interferon-induced protein 75, 52kD	1.9
	116365	N50174	Hs.46765	ESTs	6.1
<i></i>	116368	N90466	Hs.71109	KIAA1229 protein	1.6
60	116417	AW499664	HS.12484	Human clone 23826 mRNA sequence	7.4
	116436	AA161411	HS.58668	chromosome 21 open reading frame 57	2.1
	116462	AF218313	Hs.236828		1.5 2.1
	1164/0	AI272141		SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4	1.2
65	1164/0	Al272141 AA312572	Hs.83484	phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.5
65	1160/0	AK001043	He 02022	integrin-linked kinase-associated serine/threonine phosphatase 2C	2.7
		X89984	He 211562	B-cell CLL/lymphoma 7A	2.3
	110040	/\UJJUT	10,211000	o oon oeen mignomu (/)	2.0

	116700	Al800202	Hs.317589	hypothetical protein MGC10765	1.4	
				hypothetical protein FLJ14566	3.4	
				ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.9	
		AW068115		biglycan	8.3	
5	116926	H73608	Hs.290830	EŠTs	1.7	
	117034	U72209		YY1-associated factor 2	3.4	
	117132	Al393666	Hs.42315	p10-binding protein	5.2	
		N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264803 3', mRNA se	equence.	5.5
		N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HEMBB1001208	1.5	
10				Homo sapiens cDNA FLJ10590 fis, clone NT2RP2004392, weakly similar to MNN4 PROTEIN	2.0	
			Hs.42502	ESTs	2.0	
			Hs.90336	ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J	2.1	
		AF150275		ESTs	2.7	
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic acid transporters), member 6	1.4	
15		AF123050		diubiquitin	3.4	
		N34895	Hs.44648	· · · · · · · · · · · · · · · · · · ·	3.4	
		BE294925			3.0	
		AA121673			1.9	
				chromosome 11 open reading frame 24	1.8	
20				butyrate-induced transcript 1	5.7	
20				hypothetical protein MGC5370	5.9	
	117011	AL 137370	He 47125	hypothetical protein FLJ13912	1.7	
	117933			hypothetical protein FLJ20048	1.7	
				KIAA1785 protein	5.4	
25				EST EST	5.2	
23		N54321	Hs.47790		2.6	
		AA453902			2.5	
				cytochrome c oxidase subunit VIc	4.1	1
		AL157545		bromodomain and PHD finger containing, 3	1.2	
30				rapa-2 (rapa gene)	1.5	
30		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HEMBA1006595	7.4	
		AI949952		ESTS	2.5	
			Hs.293287		1.2	
				ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	2.1	
35			HS.50187	KIAA1287 protein	5.2	
33		AA199686		gb:zq75g09.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:647488 5'		
		N92293	HS.206832	ESTs, Moderately similar to ALUS_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	1.4	
				ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	3.0	
				bladder cancer overexpressed protein	4.8	
40		W24781		KIAA1710 protein	1.7	
40		AW453069		activity-dependent neuroprotective protein	2.2	
		AW453069		activity-dependent neuroprotective prote	1.6	
		BE539706		ESIS	1.4	
		N57568	Hs.48028	EST	25.1	
. ~	119298	NM_00124	1Hs.155478	cyclin T2	1.6	
45				ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	1.3	
		T65004	Hs.163561		8.4	
				nucleolar protein NOP5/NOP58	6.7	
			Hs.170042		2.4	
		AI796730	Hs.55513	ESTs	2.1	
50		W37933		Empirically selected from AFFX single probeset	1.9	
				Homo sapiens mRNA; cDNA DKFZp667I103 (from clone DKFZp667I103)	3.7	
	119602	AW675298	Hs.233694	hypothetical protein FLJ11350	3.0	
	119676	AA243837	Hs.57787	ESTs	1.4	
	119682	W61019	Hs.57811	ESTs	1.2	
55		AB032977	Hs.6298	KIAA1151 protein	1.8	
	119780	NM_01662	5Hs.191381	hypothetical protein	3.1	
	119789	BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum corneum tryptic enzyme)	9.2	
		AJ223810		ESTs, Weakly similar to IEFS_HUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP	3.6	
		AA130970			2.5	
60	119863	AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT2RP3003157	2.7	
<b>J J</b>	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danios syndrome type IV, autosomal dominant)	2.6	
		AA703129		ESTS	2.7	
		W57554		lymphoid nuclear protein (LAF-4) mRNA	1.2	
		H26735		Homo sapiens clone PP1498 unknown mRNA	45.7	
65			Hs 173250	uncharacterized bone marrow protein BM033	1.2	
JJ				fibroblast growth factor 12B	38.9	
		AW131940			9.6	
	120200			4010		

	4000=4			1. OR OR A MOLOGAD DIGITION AND ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION AND ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINISTRATION ADMINI	4 C
	120274	AA177051			4.6
	120280	AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 3', mRNA sequence	2.0
			Hs 2998831	hypothetical protein FLJ23399	1.8
				ESTs, Weakly similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	15.2
_					
5		AA195517			5.5
	120325	AA195651	Hs.104106	ESTs	6.4
	120327	AK000292	Hs 278732	hypothetical protein FLJ20285	16.1
					2.9
		N85785		eukaryotic translation elongation factor 1 alpha 1	
	120342	AW450669	Hs.45068	hypothetical protein DKFZp434I143	5.7
10	120345	AA210722	Hs.104158	ESTs	4.5
		AW969481			16.8
					5.0
		R06859		ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	
	120356	AF000545	Hs.296433	putative purinergic receptor	28.1
	120371	AA219305	Hs.104196	EST	12.4
15		AA228026			4.0
13					9.7
				FSH primary response (LRPR1, rat) homolog 1	
	120386	AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6
	120388	AA232874	Hs.104245	ESTs	3.1
	120389	AW967985	Hs 325572	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	21.7
20	420200	A A 42 400C	110.020072	culton settle translation initiation feater AE	12.5
20		AA134006			
	120404	AB023230	Hs.96427	KIAA1013 protein	7.2
	120418	AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F1323)	11.4
		AA236453		Homo sapiens cDNA: FLJ22822 fis, clone KAIA3968	1.9
			113,10010		19.4
~ ~		Al950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	
25		AA251973			5.4
	120484	AA253170	Hs.96473	EST	10.4
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:682387 3', mRNA sequen	ce. 3.9
			U- OCEAE		9.4
		BE047718			
	120520	AA258601	Hs.161731	EST	2.4
30	120535	BE350244	Hs.96547	ESTs	2.5
				Homo sapiens, clone IMAGE:3613029, mRNA, partial cds	5.2
	120001	AA213100	113.111707	TOTE SUPERIOR CONTRACTOR AND	14.4
				ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	
				ZNF135-like protein	10.2
	120590	AW372799	Hs.125790	leucine-rich repeat-containing 2	2.1
35				N-acetylglucosamine-phosphate mutase	7.5
55					2.5
		AW965339			
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52.0
	120639	AA286942		gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:701505 3' similar to contains	Alu2.4
			Un 440200	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	5.0
40					
40	120653	AW063659	Hs.191649	ESIS	2.2
	120668	AW969638	Hs.112318	6.2 kd protein	2.2
		BE536739			1.9
			113.100000	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	
		AA976503			40.0
	120696	Al821539	Hs.97249	ESTS	2.5
45	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT2RP2000027	5.9
		AA292747		ESTs	2.9
					7.0
		Al191410			
		Al608909	Hs.193985		7.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848 protein	6.8
50		AA346495	11010000	gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat,	4.4
<i>5</i> 0			11. 404000		
	120938	AA386260	Hs.104632	ES1	4.4
	120977	AA398155	Hs.97600	ESTS	4.4
	120984	BE262951	Hs 99052	ESTs	5.6
	100007	V1340006	U- 07502	ESTS	1.2
	120900	Al219896	MS.97592	E015	
55	121011	AA398360	Hs.97608	ESI	3.1
	121026	Al439713	Hs.165295	ESTs	3.5
•	121021	A A 308721	He 1867/19	ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
	121133	AA363307	HS.9/U32	E015	3.7
	121176	AL121523	Hs.97774	ESIS	1.7
60	121223	Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.saplens]	2.9
- 0		AA403008			1.9
	121340	AW956981	HS.9/910	Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
	121408	AA406137	Hs.98019	EST	6.0
		AA410190		ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	7.4
65	101150	V V V U G V 3 U	He 105362	Homo sapiens, clone MGC:18257, mRNA, complete cds	6.9
	121400	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	110.100002	ECTA	
	121452	AW971063	HS.292002	EOIS	1.8
	121455	H58306	Hs.15165	retinoic acid induced 14	10.5

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
	121496	AA442224	Hs.97900	ESTs	14.4
	121505	AA494172	Hs.194417	ESTs	13.1
	121508	AA402515	Hs.97887	ESTs	28.0
5	121513	AA416653	Hs.181510	ESTs	6.2
	121514	AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:727563 3', mRNA sequence	e. 2.6
			Hs.98142	EST	7.4
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:730150 3' similar to contain	s2.8
			Hs.98096	EST	3.5
10 '		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	6.1
		AD001528	Hs 89718	spermine synthase	3.9
			Hs.98247		2.2
			Hs.126065		4.2
	121655	AA410531	He 179072	Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023)	7.8
15				Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	2.0
15			Hs.110286		4.7
		U55184		hypothetical protein FLJ11585	12.7
					8.1
				Homo sapiens cDNA FLJ11953 fis, clone HEMBB1000883	1.8
20			Hs.98325		4.0
20			Hs.180744		7.1
			Hs.97514		19.5
				hypothetical protein NUF2R	7.9
				KIAA1196 protein	
25			Hs.161008		1.7
25				hypothetical protein FLJ22501	6.6
			Hs.98376		10.5
			Hs.98434		5.8
			Hs.218289		3.8
20				ESTs, Highly similar to KIAA1048 protein [H.sapiens]	5.0
30				serine/threonine kinase 23	2.7 2.3
		AA446628		cartilage linking protein 1	
			Hs.293044		2.9
			Hs.98459	ESIS	5.0
25		AA427950	11- 000 105	gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3'	7.2
35				ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	2.5 2.3
			Hs.98611		2.3 3.4
				hypothetical protein FLJ14904	11.4
				Homo sapiens, clone IMAGE:2822295, mRNA, partial cds	
40		AA210863		nemo-like kinase	3.8 6.4
40			Hs.98668		2.2
				Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	
			Hs.98706	ESTS	6.5
		W92142		ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
15		AI453076		ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	9.1
45			Hs.98750		13.1
			Hs.104921		1.5
		AA398838	11. 00040	gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence	3.3
		AA435936		EST HOT bladford for the 7hands!	5.6 5.1
50		AA329550		HCF-binding transcription factor Zhangfei	
50	122257	AA436819	HS.98899	ESTS	5.6
	122302	AA441801	Hs.104947	ESIS	5.8
	122341	AW601969	HS.99010	hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1	2.0
	122356	AA443794	Hs.98390	EOIS FOT-	7.3
<i></i>	122369	AA443985	Hs.303222	ESIS	12.2
55	1223/1	AA868555	Hs.178222	EOIS	5.0
	122372	AA446008	Hs.336677	EST humathatian mustain DVF7-700V0045	7.6
				hypothetical protein DKFZp762K2015	2.5
	122405	AA4465/2	Hs.303223	EOT	2.8
60	122412	AA446869	Hs.119316		7.3
60	122415	AA446918	115.33U00	EST  FSTs Maderataly similar to similar to KIA 40766 [L] capienes	1.9
	122418	AA446966	HS.99090	ESTs, Moderately similar to similar to KIAA0766 [H.sapiens]	6.8
	122440	AW505139	ris.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
		AA447603		EST	1.8
<i>C</i> =	122448	AA447626	Hs.99127	E01 FOT-	3.5
65			Hs.104980	EDTS Markly similar to 042500 004040 6 protein. Cooperhabilitie classes IC alexand	1.5
		AW418788		ESTs, Weakly similar to S43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
	122464	AA448108	Hs.99152	EOI	4.8

	122490	AA448349	Hs.238151		6.1	
	122492	AA448417	Hs.104990	ESTs	5.4	
	122502	AA204969	Hs.234863		1.3	
	122510	AA449232	Hs.99195	ESTs	11.2	
5	122530	AW959741	Hs.40368	adaptor-related protein complex 1, sigma 2 subunit	10.1	
	122547	AA779725	Hs.164589	ESTs	2.5	
	122555	AA194055	Hs.293858	ESTs	1.9	
		AA452578	Hs 262907	FSTs	9.5	
	122572	AA452601	Hs.99287		11.0	
10	122586	AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516	3.4	
	122587	AB040893	Hs.6968	KIAA1460 protein	2.0	
		AI028173	Hs.99329	ESTs	1.7	
		AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	
		AA411925	Hs.301960	ESTs	4.6	
15		AA453518		ESTs	61.5	
		AA453630			10.7	
		AA453638			107.3	
				serine/threonine kinase 33	121.4	
	122618	AA453641	11011 10100	gb:zx48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	31.1	
20	122610	ΔΔ453987	Hs 144802	FSTs	5.6	
20	122717	ΔΔ456850	He 178358	ESTs	8.5	
	122762	A1376875	He 105119	ESTs	10.4	
	122702	V/V/3U/E3U	He 00500	ESTE	81.8	
	122023	A A A 61 A Q 2	He 005/15	Home saniers cDNA FL 110658 fis clone NT2RP2006052	3.6	
25	122034	AA401432	He 200006	Figure Supports General Editions in Group IVI 214 2555552	4.5	
23	122000	AA400001	He 203565		2.7	
	122001	AA401303	Un 22/200	ESTs	75.3	
	122000	AA400004	Ha 0625	NIMA (nover in mitoric gang a) related kinase 6	7.7	
	122004	AA000233	115.3023	Nilva (iteva in micolo gene a)-related kinase o	5.8	
30	122000	A1929374	HS./ 000/	SIC-like-duapter	1.3	
30	122001	AA335721	H\$.119394	EOIS	4.1	
	122800	BE039000	HS.203703	ED18	5.3	
	122868	AF005216	HS.110041	Janus Kinase z (a protein tyrosine Kinase)	9.9	
	122870	AVV5/6312	HS.318/22	HOMO Sapiens CDNA: FLJ21700 ils, dione GOLF7175	5.3	
25	122872	AW081394	HS.97103	ESTS ESTS Janus kinase 2 (a protein tyrosine kinase) Homo sapiens cDNA: FLJ21766 fis, clone COLF7179 ESTS ESTS ESTS ESTS EST ESTS ESTS ESTS	13.9	
35	122879	AA769410	HS.128654	ESIS .	11.5	
	122907	AA4/00/4	HS.169896	ESIS	1.7	
	122916	AA470140	HS.229170	ES1	5.0	
	122981	AA478951	Hs.105629	ESIS	15.4	
40	123013	AW968324	Hs.1/384	ES18	2.8	
40	123016	AW338067	Hs.323231	Homo sapiens CDNA FLJ11946 fis, clone HEMBB1000709	8.7	
	123034	AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.8	
	123072	Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein [H.sapiens]		
	123082	AA485360	Hs.105661	2010	3.9	
					3.8	
45		AA486256		201	7.4	
			Hs.265848	myomegalin	2.8	
	123131	T52027	Hs.271795	ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.4	
	123132	AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434	15.6	
	123136	AW451999	Hs.194024	ESTs	5.1	
50	123149	Al734179	Hs.105676	ESTs	23.8	
	123152	AW601773	Hs.270259	ESTs	5.2	
	123258	AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 [H.s	apiens]	9.3
	123315	AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755827 3' similar to	14.1	
		AA504757	Hs.105738	ESTs	6.9	
55	123394	AA731404	Hs.105510	ESTs	3.6	
	123433	AW450922	Hs.112478	ESTs	3.7	
	123466	AA599042	Hs.112503	EST	7.4	
	123470	AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene similar	to 3.5	
	123471	AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	
60	123475	BE439553	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA, partial cds	1.7	
	123482	N95059	Hs.55098	ESTs	1.6	
	123486	BE019072	Hs.334802	Homo sapiens cDNA FL.114680 fis. clone NT2RP2004242, weakly similar to	2.4	
	123508	AW380388	Hs.155546	KIAA1080 protein: Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	2.2	
	123615	AA609170	. 101 1000 10	gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	7.8	
65	123610	AA602964		gb:no97c02 s1 NCL CGAP_Pr2 Homo saniens cDNA clone, mRNA sequence	2.8	
55		AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similar to contain	s Alu.	1.7
			Hs.105187	kinesin protein 9 gene	5.7	

	123735	NM_01324	1Hs.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
				Huntingtin interacting protein E	30.6	
_			Hs.261915	EST, Weakly similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	2.1	
5		AA620586		gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951320 3'	2.7	
				metastasis-associated 1-like 1	6.2	
				choline dehydrogenase .	4.4	
		L42542		ralA binding protein 1	7.0	
1.0		Al147155			8.1	
10				HIV-1 rev binding protein 2	3.7	
				topoisomerase-related function protein 4-2	1.2	
	124178	BE463721	Hs.97101	putative G protein-coupled receptor	3.1	
				ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens]	5.7	
4.5		AA640891			3.1	
15		D87454	Hs.192966	KIAA0265 protein	3.5	
		A1267847		gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
		AA317338		COBW-like protein	2.8	
			Hs.279780	NY-REN-18 antigen	7.1	
00		N34059		gb:yv28h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3' similar to contains Al		
20				ribosomal protein L17	2.9	
				Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
		R10084	Hs.113319	kinesin heavy chain member 2	2.6	
		N53935		gb:yv59d09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3', mRNA sequence	7.9	
~ ~		H79433	Hs.268997		7.8	
25		AA669097			3.3	
		N71076		ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens]	4.5	
				FLVCR protein	3.2	
	124634	AI765123	Hs.143671	Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371	5.8	
20				hypothetical protein	9.3	
30				sorting nexin 17	3.5	
		N92593	Hs.313054		6.1	
		AW297702			8.3	
		R48170	Hs.78436	EDURATION OF THE PROPERTY OF T	5.6	
25		AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
35			Hs.191148		5.7	
		R22952	Hs.268685		11.3	
				Homo sapiens mRNA for KIAA1771 protein, partial cds	9.0	
		AW368528			8.1	
40		R41772	Hs.100878		4.9	
40		R41933		ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	2.8	
		R43543		Homo sapiens cDNA: FLJ22726 fis, clone HSI15005	5.1 4.2	
				Homo sapiens EST from clone 35214, full insert	4.2 14.2	
				hypothetical protein FLJ22604	7.9	
45	124012	R47948	Hs.188732	Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
73		AA501669			2.3	
		AW975868			2.7	
		R63652	Hs.137190		2.3	
			Hs.101477		23.9	
50				bromodomain-containing 1	2.0	
50				GDP-mannose pyrophosphorylase A	4.4	
				hypothetical protein FLJ22242	2.7	
		H37941	Hs.101883	,	5.7	
		AW296713			32.4	
55		AI076343		ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	22.8	
		R99978		ESTs, Moderately similar to B34087 hypothetical protein [H.sapiens]	6.1	
		Al078645	Hs.431	murine leukemia viral (bmi-1) oncogene homolog	1.9	
	124980		Hs.98681		4.5	
	125002			ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60	125047		Hs.279793	• •	5.0	
-	125051		Hs.100588		135.3	
	125056		Hs.100592		5.4	
	. — -	A1472068		KIAA1856 protein	5.6	
	125113			ESTs, Weakly similar to ALUF_HUMAN !!!! ALU CLASS F WARNING ENTRY !!! [H.sapiens]	1.8	
65	125115	T97341	0	qb:ye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' simil		9.6
J J		Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end of		1.5
		14/28150		Empirically selected from AFEX single probeset	17	•••

	125161	W44657	Hs.144232	EST	10.7
	125249	AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	1.3
				timeless (Drosophila) homolog	9.4
	125279	AW401809	Hs.4779	KIAA1150 protein	1.5
5	125280	AI123705	Hs.106932	ESTs	8.0
	125298	AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone HEP01068	1.5
		AW292171		scaffold attachment factor B	5.9
	125827	NM_003403	3Hs.97496	YY1 transcription factor	1.2
	125891	U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.4
10	126005	AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (survivin)	14.3
	126202	AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.4
	126695	AA643322	Hs.172028	a disintegrin and metalloproteinase domain 10	9.1
	127050	AW411066	Hs.274351	CGI-89 protein	17.0
	127274	AW966158	Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947	12.8
15	128355	AW293012	Hs.161623	ESTs	7.3
	128493	D87466	Hs.240112	KIAA0276 protein	3.1
		D87466		KIAA0276 protein	1.3
				putative nucleolar RNA helicase	9.4
	128527	AA504583		transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	1.5
20	128528	R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens]	2.8
	128595	U31875	Hs.272499	short-chain alcohol dehydrogenase family member	12.1
	128599	NM_015366	3Hs.102336	Rho GTPase activating protein 8	2.3
	128604	A1879099	Hs.102397	GIOT-3 for gonadotropin inducible transcription repressor-3	1.3
				zinc finger protein	7.1
25	128625	AB037841	Hs.102652	hypothetical protein ASH1	1.3
				DKFZP434A043 protein	3.2
				CGI-47 protein	2.0
	128656	AA458542	Hs.10326	coatomer protein complex, subunit epsilon	1.4
	128656	AA458542	Hs.10326	coatomer protein complex, subunit epsilo	1.3
30	128658	BE397354	Hs.324830	diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2	2.4
				Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete co	ds _/.
		W27939		hypothetical protein MGC5576	7.7
			Hs.225977	nuclear receptor coactivator 3	3.8
0.5		Y15221		small inducible cytokine subfamily B (Cys-X-Cys), member 11	1.6
35		T85231		tubulin, beta 5	7.6
	128717	AK001564	Hs.104222	hypothetical protein FLJ10702	5.5
1	128733	BE147740	Hs.104558	ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens]	2.7
				RP42 homolog	2.8
40				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40				actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
				PDZ-binding kinase; T-cell originated protein kinase	2.8
				thymidine kinase 1, soluble	5.3
		N71826		small nuclear ribonucleoprotein polypeptide F	53.9
4.5				stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45				RD RNA-binding protein	2.6
				nuclear prelamin A recognition factor	2.2
	128830	BE281170	Hs.106357	valosin-containing protein	5.9
				Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6 2.2
50				hypothetical protein FLJ13855	1.9
50				hypothetical protein FLJ13855	3.0
				chromosome 22 open reading frame 3	2.2
				chromosome 22 open reading frame 3	
			HS.100778	ATPase, Ca++ transporting, type 2C, member 1	1.5 13.3
<i>5                                    </i>	128891	F34856		Homo sapiens, clone MGC:16362, mRNA, complete cds	4.7
55	128906	R57988	Hs.10706	epithelial protein lost in neoplasm beta	1.4
				programmed cell death 5 Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.9
	128925	R67419	Hs.21851	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	7.2
	128940	Y13153		a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12)	2.4
60	128949	AA009647	113.000U	hypothetical protein DKFZp434N035	1.3
60				hypothetical protein DKF2p434N035 hypothetical protein FLJ11200	10.9
	128909	Al580127 AW150697			1.4
	128905	AW150697 Al375672	He 165020	FQTe	1.3
	120970	MI3/30/2	He 284222	NICE-5 protein	14.0
65	1209/5	AM074047	113.204233 He 201/2/	Homo sapiens cDNA FLJ14028 fis, clone HEMBA 1003838	1.6
UJ		AI816224	He 1077/7	DKFZP566C243 protein	1.9
	120000	A1950087	110.101141	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	2.9
	123013	11000001		Security and Control of the second section of the second o	

	120021	A1 044675	He 173091	KIAA0530 protein	3.8
				KIAA0530 protein KIAA0530 protein	2.5
				ubiquitin-conjugating enzyme E2L 3	3.4
	120002	AM/206806	He 326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens]	5.0
5		Al351010			2.1
-		AA744610			17.1
				thrombospondin 2	2.7
				WW Domain-Containing Gene	20.9
				zinc finger protein 22 (KOX 15)	3.0
10				ATP-binding cassette, sub-family C (CFTR/MRP), member 5	5.8
		W93048	Hs.250723	hypothetical protein MGC2747	5.9
		AA356620	Hs.108947	KIAA0050 gene product	6.3
	129172	AW162916	Hs.241576	hypothetical protein PRO2577	1.8
	129192	AA286914	Hs.183299	ESTs	2.1
15	129194	AA150797	Hs.109276	latexin protein	3.2
	129198	N57532	Hs.109315	KIAA1415 protein	5.8
	129207	Al934365	Hs.109439	osteoglycin (osteoinductive factor, mimecan)	8.0
		U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9
	129229	AF013758	Hs.109643	polyadenylate binding protein-interacting protein 1	3.2
20		AA252468		DKFZp434J1813 protein	2.6
	129255	Al961727	Hs.109804	H1 histone family, member X	7.3
				ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens]	9.6
		Al051967			1.2
05		AA287239		Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102	5.1
25	129340	H75334		F-box only protein 9	4.6
		BE614192	Hs.279869	melanoma-associated antigen recognised by cytotoxic T lymphocytes	7.6 6.7
	129362	U30246	Hs.110736	solute carrier family 12 (sodium/potassium/chloride transporters), member 2	8.6
				Homo sapiens clone 23785 mRNA sequence	1.4
20				SAR1 protein	2.0
30	129372	NM_016039	HS.110803	CGI-99 protein	7.4
				pituitary tumor-transforming 1 interacting protein	5.0
		Al267700			2.5
		AI267700			10.2
35				hypothetical protein FLJ20647	8.0
33				ADP-ribosylation factor-like 7 Lsm3 protein	3.2
		AA188185			6.7
		AA188185			3.6
				hypothetical protein AL110115	7.1
40	120515	AF255303	He 112227	membrane-associated nucleic acid binding protein	2.5
-10	129527	AA769221	Hs 270847	delta-tubulin	3.2
		W01296	Hs.11360		7.5
		AA317841		hypothetical protein MGC2752	6.8
		Al923097			2.0
45		F08282		progestin induced protein	1.6
		H14718	Hs.11506	i vita di managaran	6.8
				postmeiotic segregation increased 2-like 9	1.4
	129591	N57423	Hs.179898	HSPC055 protein	7.3
	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombin conversion accelerator)	9.0
50	129596	AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	1.6
	129628	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	2.2
	129628		Hs.1174	cyclin-dependent kinase inhibitor 2A (me	1.4
		AK000398		hypothetical protein FLJ20391	3.8
		AD000092		calreticulin	3.3
55			6Hs.172180	KIAA0440 protein	13.4
	129680	U03749		gb:Human chromogranin A (CHGA) gene, promoter an	14.1
	129689	AW748482	Hs.77873	B7 homolog 3	2.6
		A1304966		ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	7.4 2.0
<b>CO</b>	129720	AA156214	HS.12152	APMCF1 protein	1.7
60			5HS.211539	eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	
		H15474		fatty acid desaturase 1	8.3 1.8
	129//8	AK001676	HS. 1245/	hypothetical protein FLJ10814	5.4
	129//9	AA394090	HS. 12400	Homo sapiens clone 23870 mRNA sequence	1.7
65	129800	AF052112	115.1204U	lysosomal KIAA0931 protein	1.2
65		BE565817		hypothetical protein FLJ21657	3.1
		NM_006590		SnRNP assembly defective 1 homolog	1.8
	123040	.117_000031		on the accountry adjudged a montalog	

	129861	AL049999	Hs.85963	DKFZP564M182 protein	2.2
	129864	Al393237	Hs.129914		1.7
	129869	Al222069	Hs.13015	hypothetical protein similar to mouse Dnajl1	2.7
			Hs.13386	gamma-tubulin complex protein 2	4.5
5	129945	BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8
	129953	AA412195	Hs.13740	ESTs	2.5
	129972	AW753185	Hs.180628	dynamin 1-like	1.8
	129983	U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3
	129989				4.0
10	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6
	130081	184   Al393237   18-12991   18-12991   18-12991   18-12996   18-12906   18-13018   18-	4.0		
	130082	S73265	Hs.1473	gastrin-releasing peptide	1.8
	130097	AL046962	Hs.14845	forkhead box O3A	2.8
	130100	AL135561	Hs.14891	hypothetical protein FLJ21047	2.3
15	130111	X53002	Hs.149846	integrin, beta 5	2.3
	130112	AA916785	Hs.180610	splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)	3.0
	130112	AA916785	Hs.180610		2.1
	130128	L76937	Hs.150477		1.8
	130135	AA311426	Hs.21635		6.1
20	130211	NM_003358	3Hs.23703	ESTs, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.sapiens]	1.6
					1.3
	130236	R85367	Hs.51957	splicing factor, arginine/serine-rich 2, interacting protein	2.0
	130241	AL035588	Hs.153203	MyoD family inhibitor	3.2
	130242	X79201	Hs.153221	synovial sarcoma, translocated to X chromosome	5.4
25	130249				4.8
	130263	NM_002497	'Hs.153704	NIMA (never in mitosis gene a)-related kinase 2	1.4
	130287	AA479005	Hs.154036	tumor suppressing subtransferable candidate 3	2.6
	130310	AB011121	Hs.154248	amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3	6.3
	130353	Z19084	Hs.172210	MUF1 protein	6.2
30	130356	AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4
	130357	AJ224442	Hs.155020	putative methyltransferase	3.4
	130359	NM_013449	Hs.277401	bromodomain adjacent to zinc finger domain, 2A	8.5
	130367	AL135301	Hs.8768	hypothetical protein FLJ10849	1.4
	130372	Al077464	Hs.5011	RNA binding motif protein 9	3.3
35	130393	N89487	Hs.155291	KIAA0005 gene product	1.8
	130399	AW374106	Hs.155356	hypothetical protein MGC2840 similar to a putative glucosyltransferase	3.4
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	2.3
	130409	NM_001197	7Hs.155419	BCL2-interacting killer (apoptosis-inducing)	2.7
4.0	130419	AF037448	Hs.155489	NS1-associated protein 1	1.8
40	130441	U63630	Hs.155637	protein kinase, DNA-activated, catalytic polypeptide	2.3
	130448	BE513202	Hs.15589	PPAR binding protein	3.9
	130455				33.6
					4.6
4 ~					2.7
45					5.0
				<b>3</b>	4.3
					1.6
					16.1
<b>~</b> ^					6.1
50					5.3
					2.1
					7.8
					1.5
					14.4
55					4.7
					7.9
					3.3
					1.2
<b>~</b>					5.6
60				· · · · · · · · · · · · · · · · · · ·	1.4
					1.5
					1.3
					12.1
c =					2.4
65		AA383439		Spir-1 protein	15.9
		BE246961		Homo sapiens ubiquitin protein ligase (UBE3B) mRNA, partial cds	13.9
	130674	AL048842	HS. 194019	auracun	1.5

	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4
	130692	AA652501	Hs.13561	hypothetical protein MGC4692	5.0
	130693	R68537	Hs.17962	ESTs	2.0
_	130712	AJ271881		bromodomain-containing 7	1.8
5	130714	Al348274	Hs.18212	DNA segment on chromosome X (unique) 9879 expressed sequence	2.0
	130730	AB007920	Hs.18586	KIAA0451 gene product	3.7
	130744	H59696	Hs.18747	POP7 (processing of precursor, S. cerevisiae) homolog	3.1
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	1.4
		AL036067		protein x 0001	5.7
10				ATP-binding cassette, sub-family A (ABC1), member 1	5.1
	130789	AK000355	Hs.8899	sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
	130815	AB018298		SEC24 (S. cerevisiae) related gene family, member D	1.5
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15.7
				Homo sapiens cDNA FLJ20848 fis, clone ADKA01732	2.8
15	130843	AA447492			1.5
		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.4
				putative DNA/chromatin binding motif	1.7
		NM_016578		HBV pX associated protein-8	1.9
20		NM_003416		zinc finger protein 7 (KOX 4, clone HF.16)	1.4
20		BE514434		kinesin-like 2	2.1
		AL120837		high-glucose-regulated protein 8	2.4
				sphingosine-1-phosphate lyase 1	1.7
		BE409769		DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
25		N79110	Hs.21276		2.3
25		BE382657		signal transducer and activator of transcription 1, 91kD	5.4
		N39842	Hs.301444		2.2
		BE398091		desmoplakin (DPI, DPII)	1.8
		T97401	Hs.21929	ESTs	1.6 1.6
20		AV658308		thyroid hormone receptor interactor 3	1.2
30		Al879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP), gamma	1.6
		Al826288		hypothetical protein MGC2628	7.4
		AA321649		small inducible cytokine subfamily B (Cys-X-Cys), member 10	3.0
		AA321649		small inducible cytokine subfamily B (Cy ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	1.7
35		H23230	Hs.22481		5.1
33		AA194422		myosin VI	2.5
		AA194422 N53344		myosin VI ESTs	7. <b>1</b>
			Hs.22607	dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (	2.0
		AA749230 AA749230		dolichyl-phosphate (UDP-N-acetylglucosam	1.9
40				COX15 (yeast) homolog, cytochrome c oxidase assembly protein	7.0
40		NM_00654		nuclear receptor coactivator 2	1.9
		BE280074		cyclin B1	5.8
		AW138839		ESTs	2.0
		AA885699			7.0
45		H62087	Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	7.5
73		N47468	Hs.59757		2.9
		D89053		fatty-acid-Coenzyme A ligase, long-chain 3	3.5
				spectrin SH3 domain binding protein 1	2.8
		AL080080		thioredoxin domain-containing	2.8
50				fatty acid amide hydrolase	5.6
-		AA251716			5.7
		X80038		Homo sapiens clone F19374 APO E-C2 gene cluster	1.3
				CGI-76 protein	5.0
				splicing factor (CC1.3)	1.8
55	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131375	AW293165	Hs.143134	ESTs	5.4
	131390	BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3
	131410	BE259110	Hs.279836	HSPC166 protein	2.2
60	131412	NM_01224	7Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4
	131458	BE297567	Hs.27047	hypothetical protein FLJ20392	1.7
	131475	AA992841	Hs.27263	KIAA1458 protein	2.0
	131501	AV661958	Hs.8207	GK001 protein	2.6
65	131501	AV661958	Hs.8207	GK001 protein	1.6
	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone COL02535	2.0
	131528	AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6

	131533	BE268278	He 28303	hypothetical protein MGC2592	7.4
					2.2
		AW966881		programmed cell death 2	
		AL355715		programmed cell death 9 (PDCD9)	2.1
_	131562	NM_003512		H2A histone family, member L	1.7
5	131564	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405	5.1
	131564		Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	1.8
				nucleoporin 50kD	5.0
		BE393822	Un 20645	Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.8
			H5.28040	Tiomo appleio michan, cona Dia 2protoco (nom cione Dia 2protoco), paradi cos	1.3
10	131622			Homo sapiens cDNA FLJ11436 fis, clone HEMBA1001213	
10		AB037791		hypothetical protein FLJ10980	2.2
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	1.9
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
		AW960597		ESTs	1.3
		Al218918		KIAA0854 protein	2.8
15				uracil-DNA glycosylase 2	2.8
13	131669		Hs.3041		5.6
		BE559681		KIAA0124 protein	
	131714	AA642831	Hs.31016	putative DNA binding protein	2.9
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransferase	3.4
	131737	AK001641	Hs.31323	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	3.8
20		X76732	Hs.3164	nucleobindin 2	2.9
20		X76732	Hs.3164	nucleobindin 2	2.8
					3.4
		AI878932		topoisomerase (DNA) I	
				KIAA0948 protein	25.5
	131774	BE267158	Hs.169474	DKFZP586J0119 protein	5.5
25	131787	D87077	Hs.196275	KIAA0240 protein	2.4
				Homo sapiens cDNA FLJ14656 fis, clone NT2RP2002439	7.9
		BE501849		high-mobility group 20B	1.4
					4.1
		X86098		adenovirus 5 E1A binding protein	
••		U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease	4.2
30	131824	U28838	Hs.32935	TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
	131850	Al251317	Hs.33184	ESTs -	5.1
		AA083764	Hs 6101	hypothetical protein MGC3178	5.8
		BE502341		ESTs	13.7
		BE502341		ESTs	2.4
35			H5.3402	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member	
22	131887	W17064	HS.332848	5W/5NF felated, matrix associated, actin dependent regulator of chromatin, sublamily e, member	0.2
				Homo sapiens, clone MGC:15961, mRNA, complete cds	8.7
	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	2.0
	131904	AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone KAT11914	5.5
		AA179298		stomatin-like 2	11.3
40				degenerative spermatocyte (homolog Drosophila; lipid desaturase)	1.7
<b>T</b> U				ESTs .	5.2
	131910	AA025976	MS.34309		2.7
				anaphase promoting complex subunit 11 (yeast APC11 homolog)	
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HEMBA1001711	5.3
	131941	BE252983	Hs.35086	ubiquitin specific protease 1	2.3
45	131950	AA355113	Hs.35380	x 001 protein	1.5
				hypothetical protein FLJ20039	2.3
		W79283	Hs.35962	ESTs	1.4
					3.5
				hypothetical protein MDS025	
<b>~</b> ^		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	6.5
50	131985	AA503020	Hs.36563	hypothetical protein FLJ22418	2.4
	131991	AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
	132019	H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, partial cds	3.2
	122031	AF193844		COP9 complex subunit 7a	5.8
	102001	BE266155	Ha 2022	clathrin-associated protein AP47	1.5
					3.7
55		NM_00226		karyopherin alpha 3 (importin alpha 4)	
		BE171921		ESTs	1.4
	132105	AV646076	Hs.39959	ESTs	5.8
		AW960474		ESTs	1.7
		AA857025		kinesin-like 1	3.3
60	132180	NM_00446	NHs Δ18	fibroblast activation protein, alpha	14.7
UU	102100	AA206153	Un 4200		5.5
				mitochondrial ribosomal protein L37	
		R42432	Hs.4212	ESTs .	4.4
				synaptosomal-associated protein, 29kD	2.2
		BE206939		E2F transcription factor 6	2.2
65		AV658411		KIAA1681 protein	7.8
55		AB018324		KIAA0781 protein	1.5
	133323	AI566004	Hs 141260	Homo sapiens cDNA: FLJ21550 fis, clone COL06258	1.3
	IJEEJE	, 1100000T	110.171200	i formo dapidito (IDIA), i Eur 1000 noi diono doctoreo	

	420000	4 4 0 0 4 0 0 0	11- 40000	to an alter the element in El 140000	5.7
		AA301228			4.2
		AA227710		DKFZP586L151 protein	2.1
				hypothetical protein FLJ13089	1.5
5		N36110	HS.305971	solute carrier family 2 (facilitated glucose transporter), member 10	10.0
5		AB023191		KIAA0974 protein	1.9
		NM_015986		cytokine receptor-like molecule 9	9.2
		AW405882 N37065		hypothetical protein FLJ12116	2.0
			Hs.44856	heterogeneous nuclear ribonucleoprotein D-like	6.5
10				· · · · · · · · · · · · · · · · · · ·	3.8
10		AW572805		ESTS  cored LIDB galactosocial acontrigulactosomino alpha P hota 1.3 galactosyltransferase	1,5
		AF155582		core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase	12.5
		A1279892		sorting nexin 14 HSPCO34 protein	28.3
		AA312135			1.9
15		AL135094		hypothetical protein FLJ14495	1.9
13		AA100012		hypothetical protein FLJ12085	6.1
				mitochondrial ribosomal protein S14	1.7
		AB011084			8.6
		AW169847		KIAA1634 protein	5.2
20		Al224456		H.sapiens polyA site DNA	1.4
20		X16660		RAB4, member RAS oncogene family	6.1
		AW885606		ESTs	3.3
		T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.0
		AA306105		SEC22, vesicle trafficking protein (S. cerevisiae)-like 1	2.0
25		AA454132		mitochondrial ribosomal protein L16	2.9
25		BE388673		hypothetical protein MGC10433	
		BE568452		protein regulator of cytokinesis 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevisiae, homolog of	1.7
		AW631437		TH1 drosophila homolog	7.1
20		AK001484		CGI-45 protein	2.2
30		AA345547		hypothetical protein FLJ13287	. 2.2
		H12751	Hs.5327	PRO1914 protein	6.8
				hypothetical protein PRO1855	14.0
		A1796870		DNA segment on chromosome X (unique) 9928 expressed sequence	11.4
25		U51127	Hs.54434	hypothetical protein MGC1715	1.9
35		AB018319		KIAA0776 protein	2.6
				collagen, type VIII, alpha 2	2.0
		F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645	1.5
		NM_004600		Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
40		Al142265			2.4
40				hypothetical protein MGC4840	12.4
		AA010233		glutamyl-prolyl-tRNA synthetase	14.6
	-	AA125985			2.7
		Y10275	Hs.56407		3.0
4.5				KIAA0493 protein	2.3
45				GDP dissociation inhibitor 2	1.8
		Al026701	Hs.5716	KIAA0310 gene product	3.7
				mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)	1.8
	132810	AB007944	Hs.5737	KIAA0475 gene product	5.9
<b>~</b> 0	132813	BE313625	Hs.57435	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	8.7
50		AI815189	Hs.57475	sex comb on midleg homolog 1	6.4
				tousled-like kinase 2	3.6
		AJ251595	Hs.169610	CD44 antigen (homing function and Indian blood group system)	2.8
	132833	U78525	Hs.57783	eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)	14.6
			4Hs.279771	Homo sapiens clone PP1596 unknown mRNA	1.6
55		F12200	Hs.5811	chromosome 21 open reading frame 59	2.5
	132851	U09716	Hs.287912	lectin, mannose-binding, 1	1.4
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	4.2
				ESTs, Moderately similar to AF116721 89 PRO2168 [H.sapiens]	2.8
		AW007683		KIAA1266 protein	2.0
60		NM_004850		Rho-associated, coiled-coil containing protein kinase 2	1.6
		BE267143		U2(RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol)	1.4
		AW503667		ring finger protein 15	5.4
	132902	Al936442	Hs.59838	hypothetical protein FLJ10808	6.1
<i></i>	132912	AW732760		Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1
65	132913	W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921	2.8
	132940	T79136		Homo sapiens mRNA for KIAA1724 protein, partial cds	6.1
	132941	Al817165	Hs.6120	hypothetical protein FLJ13222	10.3

	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
	132952	A1658580	Hs.61426	Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial cds	2.2
	132962	AA576635	Hs.6153	CGI-48 protein	4.9
	132972	AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575	2.7
5	132973	AA035446	Hs.323277	ESTs	5.3
132962 AA576635 Hs.6153 CGI-48 protein 132972 AA034356 Hs.289624 Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575 132987 AA035446 Hs.323277 132987 AA036346 Hs.323277 132989 AA040696 Hs.62016 ESTs 132989 AA112748 Hs.279905 clone HQ0310 PRO0310p1 133015 AJ002744 Hs.246315 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylg 133015 AJ002744 Hs.246315 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylg 133015 AJ065016 Hs.6390 Homo sapiens clone FLB3344 PRO0845 mRNA, complete or 133022 AW500374 Hs.84691 Hs.64301 Protein with polyglutamine repeat; calcium (ca2+) homeostati 133140 AR08174 Hs.65228 ESTs 133141 AF198620 Hs.65648 RNA binding motif protein 8A 133145 PH34227 Hs.65928 Homo sapiens, clone IMAGE:2961368, mRNA, partial cds 133152 211695 Hs.324473 hypothetical protein MGC2745 133175 AW936532 Hs.66666 ESTs, Weakly similar to 51950 protein MP4 - n 133177 X97795 Hs.666718 RAD54 (S.cerevisiae)-like 133226 AW936549 Hs.268281 Hs.68031 133226 AW936569 Hs.296287 Homo sapiens, slimilar to bromodomain-containing 4, clone 133226 AW94569 Hs.296287 Homo sapiens, slimilar to bromodomain-containing 4, clone 133226 AW94569 Hs.296287 Homo sapiens, slimilar to bromodomain-containing 4, clone 133226 AW95649 Hs.296287 Homo sapiens, slimilar to bromodomain-containing 4, clone 133226 AW95649 Hs.296287 Homo sapiens, slimilar to bromodomain-containing 4, clone 133226 AW95647 Hs.293302 Hs.65631 133237 AL390127 Hs.27104 133336 Al02670 Hs.70725 133337 AL390127 Hs.27147 133380 AR001485 Hs.71816 133360 AW96490 Hs.74280 133370 AF245505 Hs.71217 133394 AA001851 Hs.71870 133394 AM308127 Hs.237225 133327 AL390127 Hs.7104 133339 AB50332 Hs.75810 133394 AM308127 Hs.237225 133327 AL390127 Hs.7300 133395 AM36880 Hs.75817 133399 AM96380 Hs.75830 13399 AW9648018 Hs.758	RNA binding motif protein 3	3.2			
10 15 20 25 30 35 40 45					1.3
	132994	AA112748	Hs.279905		3.0
	133012	AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	10.3
10	133015	AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T	7) 2.1
132862 AR56859 Hs. 61426	1.3				
12982 Al656896 Hs.61425 CGL48 protein nesenchymal stem cell protein DSC96 mRNA, partial cds (12972 AA03485 hs.288624 Homo sapiens cDNA FLJ11392 fis, done HEMBA1000675 (12974 AA03485 hs.288624 Homo sapiens cDNA FLJ11392 fis, done HEMBA1000675 (12974 AA03625 hs.288624 Homo sapiens cDNA FLJ11392 fis, done HEMBA1000675 (12974 AA03625 hs.2976 EST3 (12984 AA11274) hs.278905 (one H00310 PR.0031091 (12984 AA11274) hs.278905 (one MAGE:2981308, mRNA, partial cds (12984 AA11274) hs.278905 (one mage:2984 AA11274) hs.278905 (one mage:2984 AA11274) hs.278905 (one mage:2984 AA11274) hs.278905 (one mage:29	6.0				
				PRO0149 protein	5.3
					4.9
15				KIAA0483 protein	3.5
	133110	AA808177	Hs.65228		13.1
			Hs.65648		1.3
					2.2
••					1.3
20	133174	AA431620	Hs.324178	hypothetical protein MGC2745	17.1
					1.8
					4.9
					3.1
~~	133208	AI801777	Hs.6774	ESTS	4.4
25					1.7
					6.0
					1.5
					1.4
20	133266	AI160873	Hs.69233	zinc finger protein	5.6
30	133268	AW956781	Hs.293937	ESTS, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9 4.7
					5.0
					2.7
			HS./U/25	gamma-aminobutync acid (GABA) A receptor, pi	9.3
25					4.4
33					1.8
					5.5
				v-akt munne tnymoma virai oncogene nomolog i	2.7
				non-metastatic cells 5, protein expressed in (nucleoside-dipriospriate kinase)	1.7
40					1.8
40					1.7
					1.3
					16.1
					12.2
15					10.4
43	100407	NIM DOOTS	115.7570 DUG 27/1282	protein kingen interferen inducible double stranded RNA denendent	1.2
				protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
					11.1
					2.8
50				proteasome (prosome macronain) 26S subunit non-ATPase, 2	2.9
50				damage_specific DNA hinding protein 1 (127kD)	2.5
					1.5
				mitogen-activated protein kinase-activated protein kinase 2	2.1
	133582	RE301579		Fas-activated serine/threopine kinase	1.3
55	133594	AW160781	Hs 172589		2.2
<i>J J</i>				transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
					5.7
					25.5
					15.8
60	133631	NM 00040	1Hs.75334		3.3
50					1.6
133012 AAB4743 Hs.62711 Homo sappiens, clone IMAGE:3351256, mRNA 133016 AN002744 Hs.4281315 UPA-Necept-lajha-D-agalacksamine-polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-133016 AV39988 Hs.6289 133052 AW500374 Hs.64056 133069 BE427441 Hs.64056 133069 BE427441 Hs.64056 133069 BE427441 Hs.64056 133079 AK001628 Hs.64091 133174 AAB08177 Hs.65548 133143 AF198260 Hs.65648 133152 Z11695 Hs.322473 133164 AA431620 Hs.24278 133175 AW55632 Hs.66668 133177 X97795 Hs.65678 133175 AW55632 Hs.66666 133177 X97795 Hs.66718 AF1844 133240 AK001469 Hs.242789 kg.66669 13326 AW586469 Hs.282874 13328 AW586469 Hs.282837 13328 AW586741 Hs.7823300 Homospalens, clone IMAGE:354662, mRNA, partial cds inclinate and process of the proces	4.1				
				•	1.5
	133722	AW969976	Hs.279009	matrix Gla protein	6.3
65	133751	AW402048	. Hs.334787	Homo sapiens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
			Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.7
	133760	BE271766			1.8

			Hs.75929	cadherin 11, type 2, OB-cadherin (osteoblast)	1.5
				decorin	3.5
					6.8
-					2.6
3					1.4
10 15 20 25					8.0
					13.5 2.2
					1.8
10					2.0
133780   AA657660   Hs.76152   decorén	2.8				
					6.7
					2.5
					3.0
15					1.4
13					5.4
			115.323540 SHe 211602	SMC1 (structural maintenance of chromosomes 1, yeast), like 1	4.9
					3.7
					12.1
20					9.7
20					3.1
		A1 040328	Hs 78202	SWI/SNE related matrix associated actin dependent regulator of chromatin	1.3
					9.7
					2.4
25					2.5
					1.3
					4.2
					2.2
					5.0
30	134200				3.2
					2.5
	134208	NM_000288	3Hs.79993	peroxisomal biogenesis factor 7	2.1
	134219	NM_000402	2Hs.80206	glucose-6-phosphate dehydrogenase	9.1
				Homo sapiens, clone IMAGE:3535294, mRNA, partial cds	2.8
35	134275	Al878910	Hs.3688	cisplatin resistance-associated overexpressed protein	1.8
35 134234 BE300078 Hs.80449 Homo sapiens, clone IMAGE:3535294, mRNA, partial cds 134275 Al878910 Hs.3688 cisplatin resistance-associated overexpressed protein immunoglobulin superfamily, member 3 134301 AW502505 Hs.81360 Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HS	immunoglobulin superfamily, member 3	2.0			
					2.5
					2.8
40					10.4
40					1.9
					2.6
					2.3
				interleukin 6 signal transducer (gp130, oncostatin M receptor)	13.0
15					8.8
43					1.5
				hypothetical protein MGC3222	8.1
					4.1 1.7
50					2.6
50					1.3
					3.2
					1.9
	134471	A11077196	Hs 82985		10.3
55					2.4
55	134446	AA112036			1.2
					1.6
				CDC28 protein kinase 2	2.1
	134480	NM 005000			5.3
60	134485	X82153			2.5
- <b>-</b>	134498	AW246273			2.1
	134513	AA425473	Hs.84429	KIAA0971 protein	3.8
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	2.4
	134520	BE091005	Hs.74861	activated RNA polymerase II transcription cofactor 4	6.7
65	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.3
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor for tRNAs)	5.5
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	5.8

	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.2
		AF035119		deleted in liver cancer 1	2.0
	134632	X78520	Hs.174139	chloride channel 3	2.3
		AK001741	Hs.8739	hypothetical protein FLJ10879	1.4
5	134664	AA256106	Hs.87507	ESTs	72.9
	134666	BE391929	Hs.8752	transmembrane protein 4	8.5
	134687	U62317	Hs.88251	arylsulfatase A	6.0
	134692	NM_003474	Hs.8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha)	4.3
10		BE161887		anaphase-promoting complex subunit 10	2.3 6.7
10		Y14768	Hs.890	lysosomal	2.3
		AA852985		chromobox homolog 5 (Drosophila HP1 alpha)	2.9
				F-box only protein 6	6.6
				ring finger protein 22 CD2 antigen (p50), sheep red blood cell receptor	2.3
15		AW630803	He 80/07	lamin B1	6.2
10				integral membrane protein 1	1.9
		AD001528		spermine synthase	1.8
		AW451370		adaptor-related protein complex 1, gamma 2 subunit	1.4
		Al701162		hypothetical protein MGC11138	1.4
20		BE268326		5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	5.6
		D26488		KIAA0007 protein	2.8
		AI879195	Hs.90606	15 kDa selenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fis, clone NT2RP3002255	1.7
<b>~</b> -		AW885909		PRO1073 protein	2.1
25		AW401361		protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	1.3 2.1
				phosphoserine aminotransferase	2.1
		R50333		Leman coiled-coil protein	2.3 1.6
				KIAA1414 protein	3.9
30		NM_000408		glycerol-3-phosphate dehydrogenase 2 (mitochondrial) hypothetical protein FLJ12619	6.2
30		AW503733		KIAA1488 protein	2.0
		AB036063		p53-inducible ribonucleotide reductase small subunit 2 homolog	1.3
		AF027219		zinc finger protein 202	7.1
				zinc finger protein 36 (KOX 18)	3.2
35		Al093155			2.5
				px19-like protein	1.4
		AA477514		translin-associated factor X	5.0
		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATIVE C10 PROTEIN [H.sapiens]	6.1
		T78802	Hs.96560		4.6
40		BE463721		putative G protein-coupled receptor	5.6
	135245	Al028767	Hs.262603	ESTs	3.5
				ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2 2.6
		A1088775		geranylgeranyl diphosphate synthase 1	5.3
15		AA448460			9.1
45		AA150320		protein kinase Njmu-R1	2.4
		Al090838 Al743770	Hs.98368	ESTs ESTs, Weakly similar to KIAA0822 protein [H.sapiens]	13.3
		A1652069		ribosome binding protein 1 (dog 180kD homolog)	2.6
				cell division cycle 2-like 1 (PITSLRE proteins)	8.3
50				Homo sapiens cDNA FLJ10174 fis, clone HEMBA1003959	1.5
-		U05237		fetal Alzheimer antigen	4.9
		X78592	Hs.99915	androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar	2.0
	134975	R50333	Hs.92186	Leman coiled-coil protein	2.6
	. 135011	AB037835	Hs.92991	KIAA1414 protein	1.4
55	135022	NM_00040	8Hs.93201	glycerol-3-phosphate dehydrogenase 2 (mi	1.6
				hypothetical protein FLJ12619	1.4
	135077	AW503733	Hs.9414	KIAA1488 protein	1.8
		AB036063		p53-inducible ribonucleotide reductase s	2.5
<b>C</b> O		AF027219		zinc finger protein 202	1.5
60				zinc finger protein 36 (KOX 18)	2.1 4.4
		Al093155	Hs.95420	JM27 protein	4.4 14.9
				px19-like protein translin-associated factor X	1.3
	135199	AA477514 N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7
65	13520/	T78802	Hs.96560	hypothetical protein FLJ11656	6.1
0,5	135243	BE463721		putative G protein-coupled receptor	2.7
		ΔΙΩ28767			12.2

	135257	AW291023 H	ls.97255	ESTs, Weakly similar to A46010 X-linked	7.6
				geranylgeranyl diphosphate synthase 1	1.8
		AA448460 H			4.1
_		AA150320 F		protein kinase Njmu-R1	1.2 4.8
5				2010	5.8
				ESTs, Weakly similar to KIAA0822 protein ribosome binding protein 1 (dog 180kD ho	12.3
				cell division cycle 2-like 1 (PITSLRE pr	5.7
				Homo sapiens cDNA FLJ10174 fis, clone HE	7.9
10	135389	U05237 F	ls.99872	fetal Alzheimer antigen	1.9
				androgen receptor (dihydrotestosterone r	13.9
				the tree opposite there.	5.3 2.2
				HER2 receptor tyrosine kinase (c-erb-b2,	1.4
15				HSPC070 protein MSTP033 protein	5.2
13				Homo sapiens clone IMAGE:32553, mRNA seq	2.3
		AA808229 F			2.8
				ZW10 interactor	2.0
••				rab3 GTPase-activating protein, non-cata	5.5
20				Golgi apparatus protein 1	1.4 1.3
				nucleosome assembly protein 1-like 1	2.9
				PRO1912 protein hypothetical protein	1.6
				RP42 homolog	1.8
25	407827	BE278431 H	Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.6
				SRY (sex determining region Y)-box 22	6.1
		A1580090 H	Hs.48295	RNA helicase family	5.6
				ESTs, Weakly similar to T32527 hypotheti	2.6
20				hypothetical protein, expressed in osteo	2.4 1.5
30		Al267592 H AW304454 H		SFRS protein kinase 1	4.2
		AA381133 H		UBX domain-containing 1 high-mobility group (nonhistone chromoso	23.6
				TATA box binding protein (TBP)-associate	5.8
				cathepsin K (pycnodysostosis)	1.3
35		NM_0069101		retinoblastoma-binding protein 6	1.6
			Hs.96264	alpha thalassemia/mental retardation syn	2.3
			Hs.1334	v-myb avian myeloblastosis viral oncogen	1.6 3.5
				MCT-1 protein	4.9
40				retinoic acid repressible protein histone deacetylase 3	3.1
40				peptidylprolyl isomerase C (cyclophilin	1.9
		AA302744 h			2.4
	422055	NM_014320H	Hs.111029	putative heme-binding protein	4.1
	423750	AF165883 H	Hs.298229	prefoldin 2	7.0
45				paternally expressed 10 (PEG10; KIAA105	4.9
	425182	AF041259 H	Hs.155040	zinc finger protein 217	3.4 2.1
	425284	AF155568 F	HS.155489	NS1-associated protein 1 DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	7.5
	420372	A\A/183765 I	MS. 109001	GW128 protein	1.7
50	420043	AW500533 1	Hs 11482	splicing factor, arginine/serine-rich 11	2.4
50		AB001636		DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	3.8
		AK001333		Homo sapiens hepatocellular carcinoma-as	5.6
	441560	F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	2.0
	445580	AF167572	Hs.12912	skb1 (S. pombe) homolog	7.5
55				hypothetical protein MGC4485	2.2 2.8
		Al017574 H		cysteine-rich protein 1 (intestinal) ESTs, Weakly similar to S16506 hypotheti	1.7
		BE620592 I		density-regulated protein	5.9
		W68520 I	Hs.331328	intermediate filament protein syncoilin	5.6
60	450701	H39960 I	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	1.4
	450703	AA011202 I	Hs.184771	nuclear factor I/C (CCAAT-binding transc	4.7
	452461	N78223	Hs.108106	transcription factor	2.9
				Homo sapiens cDNA FLJ20845 fis, clone AD	12.1
65		AF077036 I		DKFZP586G1722 protein	4.7 1.3
65	453658	BE541906 I	™° 1088∪J	Homo sapiens, clone MGC:2492, mRNA, comp N-ethylmaleimide-sensitive factor	3.2
		U50360	113.100072	gb:Human calcium, calmodulin-dependent p	6.2
	102401	JJ0500		Denterment constant contracting as between	-

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	7	7.9
			Hs.78793	protein kinase C, zeta	2	2.0
	104331			cdk inhibitor p21 binding protein	Ę	5.3
				hypothetical protein FLJ10697	2	2,0
5	115008	AK001827	Hs.87889	helicase-moi	Ę	5.7
	119075	M10905	Hs.287820	fibronectin 1	1	1.3
	119615	AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	2	2.9
	125006	BE065136	Hs.145696	splicing factor (CC1.3)	1	1.7
	127609	X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture	2	2.4
10	129209	R62676	Hs.17820	Rho-associated, coiled-coil containing p	Ę	5.2
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg		4.5
	130182	BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo		11.0
	130365	W56119	Hs.155103	eukaryotic translation initiation factor	3	3.3
	131135	NM_016569	9Hs.267182	TBX3-iso protein		1.3
15	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		3.2
	131881	AW361018	Hs.3383	upstream regulatory element binding prot		14.3
	132726	N52298	Hs.55608	hypothetical protein MGC955		3.0
	135193	X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.7
	409487	H19886		gb:yn57a05.r1 Soares adult brain N2b5H		2.3
20	416040	AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone HE	7	7.4

#### TABLE 4A

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

Accession: Gene cluster number
Gene cluster number
Gene cluster number

15				
13	Pkey	CAT number	r Accessions	
	123615	3068615	AA609170	
20		371681_1	AA602964 AA609200	
20		16505	M21259	
		656394_1 1642364 1	Al267847 N27351 N34059 N46979	
		1657509 1	N53935 N53950	
		3128128	U50360	
25		110522	X89059	
	110856	19346_14 .	AA992380 N33063 N21418 H79958 R21911 H79957	
			103797 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA	113892
			AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974	305
30		160212_1	AA190577 AA181657 T63857 AW971220 AA493469 T63699	
30		328626_1 44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW	V967671
	120412	44313_2	AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 B	
			AJ219788 AA884444 N92578 F13493 AA927794 AJ560251 AW874068 AL134043 AW235363 AA663345 AW008282	
			AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW15032	
35			AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW6299	
			BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293	
			AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032	
			F00531 H83488 W37181 W78802 R66056 A1002839 R67840 AA300207 AW959581 T63226 F04005	1100 1200
40	129019	44573_2	AJ950087 N70208 R97040 N36809 AJ308119 AW967677 N35320 AJ251473 H59397 AW971573 R97278 W01059 AW	<i>V</i> 967671
			AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 B	E328517
			Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282	AA488964
			AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW15032	9 A1053832
45			Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW6295 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA	
43			AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293	
			AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032	
,			F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005	
	120695	9683_3	AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603	3 AW052210
50			AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468	
		275673_1	AA398838 AA435847 AA416568 AA442889 AA417233 AA442223	
		283769_1 305217_1	AA410008 AA442009 AA417233 AA442223 AA453641 AA454061	
		150431 1	AA157811 AA836869	
55		genbank_AA6		
	123811	genbank_AA6		
		genbank_T97		
			D_entrez_W38150 W38150	
60		382979_1 genbank_AA1	AA199686 N73861 177051 AA177051	
UU		genbank_T57		
		genbank_AA2		
		genbank_AA2		

		genbank_AA34		AA346495
		genbank_T973		T97307
	129680	23162_1		L_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122
_				55958 Al684005 D53170 AA854091 Al025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441
5				Al969102 AA405741 Al091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 Al148432
				A782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
				/32275 Al584185 C05724 AA789023 Al686818 D54392 Al022485 AA431410 AA854232 W39212 W15214 AA894441
			A1803081 A	1167381 AW245389 AA319430 AA335156 Al042646 AA327030 AA725170 T27943 AA889304 AA976699 Al687001
			A1621107 A	I865540 AA772107 C06286 AA319661 AA405992
10	101045	entrez_J05614	J05614	
	117247	genbank	N21032	
	110501	genbank	H55748	
	103392	entrez_X94563	3X94563	
	105032	genbank	AA127818	
15	119513	NOT_FOUND_	_entrez	W37933
	105445	genbank	AA252395	
	121514	genbank	AA412112	
	121558	genbank	AA412497	
	121911	genbank	AA427950	
20	123315	714071_1	AA496369	<b>\A496646</b>
	114911	genbank	AA236672	
		1134778_1	H19886 AV	/402806 T10231

# TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

10

Pkey:	Unique E	os probe	eset ide	ntifier	nur	nbei	ſ

Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue

ExAccn:
UnigenelD:
Unigene Title:
R1:

15	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
13	100114	X02308	Hs.82962	thymidylate synthetase	2.9
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
		H60720	Hs.81892	KIAA0101 gene product	9.2
		AW247529		platelet-activating factor acetylhydrola	2.7
20		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7
20		L05424	Hs.169610	CD44 antigen (homing function and Indian	9
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.6
		AW502935		PTK2 protein tyrosine kinase 2	53.2
		AK000405		ubiquitin-like 4	11.4
25		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.2
23		J05614	113.101700	gb:Human proliferating cell nuclear anti	5
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4
		A1494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	6.3
		NM_01215		coagulation factor VIII-associated (intr	5.7
30		AF064853		guanine nucleotide binding protein (	5.6
-		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4
		AA586894		S100 calcium-binding protein A7 (psorias	8.9
		NM 00031		peroxisomal membrane protein 3 (35kD, Ze	3.2
		AJ904232	Hs.75323	prohibitin	8.4
35		BE258602	Hs.182366	heat shock protein 75	1.4
	102165	BE313280	Hs.159627	death associated protein 3	4.6
	102198	AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.3
	102217	AA829978	Hs.301613	JTV1 gene	6.7
	102220	U24389	Hs.65436	lysosomal	4.3
40	102302	AA306342	Hs.69171	protein kinase C-like 2	2.7
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2
	102374	U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
	102455	U48705	Hs.75562	discoidin domain receptor family, member	6.9
'		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
45	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
		NM_007019		ubiquitin carrier protein E2-C	4.3
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6
		AU077058		BRCA1 associated RING domain 1	1.9
		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3
50		BE252241		pyridoxal (pyridoxine, vitamin B6) kinas	6.4
		BE244588		chaperonin containing TCP1, subunit 2 (b	5.6
		NM_00594		matrix metalloproteinase 11 (MMP11; stro	4.5
		AU077231		cyclin D1 (PRAD1: parathyroid adenomatos	3.1
~ ~		AA205475		ribosomal protein S18	9.9
55		X72755	Hs.77367	monokine induced by gamma interferon	8.8
		AI369285	Hs.75189	death-associated protein	5.6
		Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7
		BE270465		protein kinase C, zeta	7.9
60			Hs.105737	hypothetical protein FLJ10416 similar to	6.5 6.3
60	104325		Hs.150675	polymerase (RNA) II (DNA directed) polyp	10.9
		AW052006		PRP4/STK/WD splicing factor ESTs	5.6
		A1250789	Hs.32478	3-phosphoinositide dependent protein kin	12.3
		AA041276	Hs.154729	hypothetical protein similar to small G	2
	104867	AA278898	Hs.225979	nyponetical protein similar to small G	4

	104896	AW015318	Hs.23165	ESTs	17.7
		AW408164		transcription factor 19 (SC1)	5
		AW958157		NS1-associated protein 1	1.7
5		AA026880		prolactin receptor	1.4 1.4
)		Y12059 Al199268	Hs.278675 Hs.19322	bromodomain-containing 4 Homo sapiens, Similar to RIKEN cDNA 2010	7.2
		AF098158		chromosome 20 open reading frame 1	3.3
		AA907305		ESTs	2.5
	105079	AA151342	Hs.12677	CGI-147 protein	9.5
10		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2
		AF167570		interleukin enhancer binding factor 3, 9	5.4
		AA262640		unknown	9.3 1.4
		BE616694 AA985190		hypothetical protein FLJ14299 hypothetical protein FLJ20059	9.4
15		AW151952		hypothetical protein FLJ20739	1.5
~~		AF151066		hypothetical protein	2.9
	105930	AF016371	Hs.9880	peptidyl prolyl isomerase H (cyclophilin	5.2
		AA533491		hypothetical protein FLJ14681	6.8
20		AK001404		cyclin B2	5.7 6.3
20		AW390282 AA458882		transmembrane 7 superfamily member 2 fibulin 1	7.9
		NM_003598		tyrosylprotein sulfotransferase 2	7.7
		BE614802		hypothetical protein FLJ12549	4.5
	106829	AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2
25		AB037744		KIAA1323 protein	2.2
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA	, 16.8 6.6
		BE156256 AF264750		hypothetical protein myeloid/lymphoid or mixed-lineage leukem	1.8
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1
30		AW732573		potassium voltage-gated channel, delayed	8.4
		L42612	Hs.335952	keratin 6B	2.5
		BE153855		lg superfamily receptor LNIR	2.2
		AW956103		pyruvate dehydrogenase kinase, isoenzyme	6.7
35		AF129535 BE546947		F-box only protein 5 homeo box C10	7.1 9.8
33		AB029000		KIAA1077 protein	7.2
		AK001431		hypothetical protein FLJ10569	4
		AA156542		ESTs	1.4
40		AA164293		ESTs	2.9
40		AA375752		Homo sapiens mRNA; cDNA DKFZp586F182	2 (f 2.9 3.2
		NM_015310 Al668594	Hs.176588	KIAA0942 protein ESTs, Weakly similar to CP4Y_HUMAN CYTO	
		Al288666	Hs.16621	DKFZP4341116 protein	6.2
		H55748	110110021	gb:yg94a01.s1 Soares fetal liver spleen	6.1
45		AW190338	Hs.28029	hypothetical protein MGC11256	7.6
		BE044245	Hs.30011	hypothetical protein MGC2963	9.3
		AA992380	411a 04507	gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3 6.7
		NM_005864 N63823	Hs.269115	signal transduction protein (SH3 contain ESTs, Moderately similar to Z195_HUMAN Z	
50		AK000136		asporin (LRR class 1)	7.1
-		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
	111285	AA778711	Hs.4310	eukarvotic translation initiation factor	6.9
		W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA	N, 8.4
<i>E E</i>	111937		Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016	14.6
55	112244	AB029000 AA737033	Hs.70823 Hs.7155	KIAA1077 protein ESTs, Moderately similar to 2115357A TYK	5.6
		BE266947	Hs.10590	zinc finger protein 313	13.4
	113791		Hs.135578	chitobiase, di-N-acetyl-	1.3
	113811	BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1
60	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3
	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7 6.1
	1138/0	AL079314 AW953484	Hs.16537 Hs.3849	hypothetical protein, similar to (U06944 hypothetical protein FLJ22041 similar to	1.9
	114275	AW515443	Hs.306117	KIAA0306 protein	15.8
65	114895	AA236177	Hs.76591	KIAA0887 protein	7.1
	114965	AI733881	Hs.72472	BMP-R1B	2.3
	115061	AI751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8

	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
		BE545072		hypothetical protein FLJ10461	6.2
		BE093589		hypothetical protein FLJ23468	10.6
		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.8
5		AI867451	Hs.46679	hypothetical protein FLJ20739	5.5
	115968	AB037753	Hs.62767	KIAA1332 protein	9.8
	116011	AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN	2.4
		AW499664		Human clone 23826 mRNA sequence	7.4
10		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1
10		AK001043	Hs.92033	integrin-linked kinase-associated serine	2.7
		Al393666	Hs.42315	p10-binding protein	5.2
			Hs.260622	butyrate-induced transcript 1 ESTs	5.7 7.4
		A1949952	Hs.49397	fibronectin 1	7.4 5.7
15		M10905 BE539706	Hs.287820 Hs.285363	ESTs	1.4
13	119349		Hs.163561	ESTs	8.4
		AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7
		BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum com	9.2
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7
20		AA131376	Hs.326401	fibroblast growth factor 12B	38.9
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
	120325	AA195651	Hs.104106	ESTs	6.4
		AK000292	Hs.278732	hypothetical protein FLJ20285	16.1
0.5		AW969481		hypothetical protein	16.8
25		AF000545	Hs.296433	putative purinergic receptor	28.1
		AA219305	Hs.104196	EST	12.4
		AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7 32.6
		AW969665		hypothetical protein DKFZp434D0127 ESTs, Moderately similar to ALU7_HUMAN A	
30		AW967985 AA134006		eukaryotic translation initiation factor	12.5
50		AW966893		Homo sapiens mRNA; cDNA DKFZp586F132	
		Al950087	110.20010	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi	
		AA253170	Hs.96473	EST	10.4
		AA280679		ESTs, Weakly similar to ALU1_HUMAN ALU	3 14.4
35		BE244830	Hs.284228	ZNF135-like protein	10.2
	120596	AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.5
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52
•		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapie	
40		AW449855		Homo sapiens cDNA FLJ12727 fis, clone NT	5.9
40		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
		A1608909	Hs.193985	ESTs	7.8
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	4.4
		AA346495 BE262951	Hs.99052	gb:EST52657 Fetal heart II Homo sapiens ESTs	5.6
45		AA398721	Hs.186749	ESTs, Highly similar to I37550 mismatch	5.4
73		AA406137	Hs.98019	EST	6
		AA494172	Hs.194417	ESTs	13.1
		AA402515	Hs.97887	ESTs	28
		AA416653	Hs.181510	ESTs	6.2
50		AA412477	Hs.98142	EST	7.4
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sap	
		AA421537		Homo sapiens mRNA; cDNA DKFZp434B102	3 (f 7.8
		AA398784		ESTs	7.1
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5
55		AB033022	Hs.158654	KIAA1196 protein	7.9 5.8
	121832	AW340797 AA425691		ESTs ESTs, Highly similar to KIAA1048 protein	5.0
	121009	AA426376	Hs.191606 Hs.98459	ESTs. Highly similar to KIAA 1040 protein	5
	121002	AA427950	115.50435	gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.2
60	121011	AA430211	Hs.98668	EST	6.4
00	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU	
	122356	AA443794	Hs.98390	ESTs	7.3
	122371	AA868555	Hs.178222	ESTs	5
65	122372	AA446008	Hs.336677	EST	7.6
		AW418788		ESTs, Weakly similar to S43569 R01H10.6	9.7
	122490	AA448349	Hs.238151	EST	6.1

	122492	AA448417	Hs.104990	ESTs	5.4
	122510	AA449232	Hs.99195	ESTs	11.2
		AW959741		adaptor-related protein complex 1, sigma	10.1
5		AA452601		EST	11
3		AA453518		ESTs	61.5 10.7
		AA453630 AA453638		EST ESTs	107.3
		AA453641	113, 1010/3	gb:zx48e06.s1 Soares_testis_NHT Homo sap	
		AA453987	Hs.144802	ESTs	5.6
10		AA456859		ESTs	8.5
		AW204530		ESTs	81.8
	122838	AA460584	Hs.334386	ESTs	75.3
		Al929374	Hs.75367	Src-like-adapter	5.8
1 ~		AF005216		Janus kinase 2 (a protein tyrosine kinas	5.3
15		AA470074		ESTs	11.5
		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	
			Hs.44054	ninein (GSK3B interacting protein) ESTs	8.7 5.1
		AW451999 AW601773		ESTs	5.2
20		AA731404		ESTs	3.6
20		AA599042		EST	7.4
		BE019072		Homo sapiens cDNA FLJ14680 fis, clone NT	2.4
		AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	7.8
	123735	NM_013241	1Hs.95231	FH1/FH2 domain-containing protein	10
25		AA609955		Huntingtin interacting protein E	30.6
		AI147155	Hs.270016	ESTs	8.1
		Al267847	11- 400040	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
		AA532519		Human DNA sequence from clone 989H11 on ESTs	7.8 8.3
30		AW297702 AA381661		ESTS, Weakly similar to M3K9_HUMAN MITO	
50		R22952	Hs.268685	ESTs	11.3
		AA374756		Homo sapiens mRNA for KIAA1771 protein,	9
		AW368528		ESTs	8.1
	124788	R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1
35	124811	R46068	Hs.288912	hypothetical protein FLJ22604	14.2
		R47948	Hs.188732	ESTs	7.9
		AA418160			
		R65763	Hs.101477	EST ESTs	23.9 32.4
40		AW296713 Al076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
40		R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1
		T79956	Hs.100588	EST	135.3
		T81310	Hs.100592	ESTs	5.4
		A1472068	Hs.286236	KIAA1856 protein	5.6
45	125115	T97341		gb:ye57e05.s1 Soares fetal liver spleen	9.6
		Al123705	Hs.106932	ESTs	8
		AW966158		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
		R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s Homo sapiens, Similar to RIKEN cDNA 1700	2.8
50		AA975486	Hs.103441 Hs.103834	hypothetical protein MGC5576	7.7
50		W27939 BE302796		thymidine kinase 1, soluble	5.3
		N71826	Hs.105465	small nuclear ribonucleoprotein polypept	-53.9
	128797			stem cell growth factor; lymphocyte secr	13.3
	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	3
55	128891	F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, cor	
	128946	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	7.2
		BE560779		NICE-5 protein	14
		Al816224	Hs.107747	DKFZP566C243 protein	1.9
60		Al950087 AW296806	De 336334	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi ESTs, Highly similar to T46422 hypotheti	en 2.9 5
00		AA744610		palladin	17.1
	120000	AA463189	Hs.288906	WW Domain-Containing Gene	20.9
		N57532	Hs.109315	KIAA1415 protein	5.8
	129347	BE614192		melanoma-associated antigen recognised b	7.6
65	129362	U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7
	129372	NM_01603		CGI-99 protein	2
	129404	Al267700	Hs.317584	ESTs	5

	129482	AA188185	Hs.289043	spindlin	6.7
	129559	W01296	Hs.11360	hypothetical protein FLJ14784	7.5
	129587	H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8
_		AK000398		hypothetical protein FLJ20391	3.8
5		AD000092	Hs.16488	caireticulin	3.3
		U03749		gb:Human chromogranin A (CHGA) gene, pro	
		AW748482		B7 homolog 3	2.6
		Al304966	Hs.12035	ESTs, Weakly similar to 138022 hypotheti	7.4
10		AA156214		APMCF1 protein	2
10		AA301116		nucleolar phosphoprotein Nopp34	1.6
		AL046962	Hs.14845	forkhead box O3A	2.8
		AA311426		tubulin, gamma 1	6.1
		NM_003358		ESTs, Moderately similar to CEGT_HUMAN C	
15		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4
15		NM_013449		bromodomain adjacent to zinc finger doma	8.5
		W56119	Hs.155103	eukaryotic translation initiation factor	11 3.9
		BE513202		PPAR binding protein	33.6
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	2.7
20		AL121438 BE208491	Hs.183706 Hs.295112	adducin 1 (alpha)	16.1
20		L32137	Hs.1584	KIAA0618 gene product cartilage oligomeric matrix protein (pse	6.1
		U64675	Hs.179825	RAN binding protein 2-like 1	7.8
		AF062649		pituitary tumor-transforming 1	14.4
		AI907018	Hs.15977	Empirically selected from AFFX single pr	4.7
25		AA383092		replication protein A3 (14kD)	7.9
			Hs.16178	apoptosis antagonizing transcription fac	1.2
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
		BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9
		R68537	Hs.17962	ESTs	2
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.1
	130757	AL036067	Hs.18925	protein x 0001	5.7
	130880	BE514434	Hs.20830	kinesin-like 2	2.1
	130944	BE382657	Hs.21486	signal transducer and activator of trans	5.4
	131046	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4
35		AA194422		myosin VI	5.1
		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7
		NM_016569		TBX3-iso protein	3.3
		BE280074		cyclin B1	5.8
40		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40		AL080080	Hs.24766	thioredoxin domain-containing Homo sapiens clone F19374 APO E-C2 gene	2.8
		X80038	Hs.339713		5
		AL389951 AW410601	Hs.271623	nucleoporin 50kD HSPC182 protein	2.9
		AA642831		putative DNA binding protein	2.9
45		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4
72		X76732	Hs.3164	nucleobindin 2	2.9
		AW966127			7.9
		BE502341	Hs.3402	ESTs	13.7
		AA099014		Homo sapiens, clone MGC:15961, mRNA, cor	
50		AA179298	Hs.3439	stomatin-like 2	11.3
		BE252983		ubiquitin specific protease 1	2.3
	131971	BE567100	Hs.154938	hypothetical protein MDS025	3.5
	132180	NM_004460	)Hs.418	fibroblast activation protein, alpha	14.7
		NM_004782		synaptosomal-associated protein, 29kD	7.8
55		AA227710	Hs.43658	DKFZP586L151 protein	10
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2
		AB023191		KIAA0974 protein	2
		AW067708		heterogeneous nuclear ribonucleoprotein	12.5
<b>C</b> C		AW572805		ESTs	28.3
60		AA312135		HSPCO34 protein	6.1
		AA100012		hypothetical protein FLJ12085	8.6
		AW169847		KIAA1634 protein	6.1
		AA454132		mitochondrial ribosomal protein L16	7.1
65		AW631437		TH1 drosophila homolog	14
65		A1796870 NM_00460	Hs.54277	DNA segment on chromosome X (unique) 992	
		N52298	)Hs.55608	Sjogren syndrome antigen A2 (60kD, ribon hypothetical protein MGC955	3.7 14.3
	104140	1102230		TOP CONCINCE DIVICE IN INCIDENCE	17.0

13274 AA01023 Hs.295901 132798 Al028701 Hs.57783 132810 AB007934 Hs.57783 132821 V75825 Hs.57783 132824 NM_016154 Hs.27971 Hs.57787 132851 U09716 Hs.57873 132824 NM_016154 Hs.279712 U09716 Hs.297912 U09716 Hs.297917 U09716 U0971		132731	Al189075	Hs.301872	hypothetical protein MGC4840	5.9
132788 AIDS701   Hs.5716   132810 AB007944   Hs.5737   132831 U78525   Hs.57783   132842   Wh.O.16154Hs.279771   132861 U09716   Hs.287912   132891   BE287143   Hs.582911   132891   BE287143   Hs.582911   132891   BE287143   Hs.582911   132891   AB01456   Hs.6120   132972   AN043656   Hs.288924   132990   AA040896   Hs.62016   133994   AA112748   Hs.279905   133016   A439688   Hs.6289   Hs.62016   133016   A439688   Hs.6289   Hs.62016   133018   A801777   Hs.6774   Hs.6774   Hs.273301   133266   A160873   Hs.62933   133286   A1660873   Hs.289371   A13326   A8054678   Hs.289372   A805468   Hs.289382   A8054688   Hs.289382   A8054681   Hs.78737   A805468   A8054681   Hs.78737   A805468   Hs.289382   A8054681   Hs.78738   A8054681   Hs.289382   A8054681   Hs.78221   A805468   Hs.289381   A8054681   Hs.289381   A8064681   Hs.289381   A8064681   Hs.289381   A8064681   Hs.28684   A8054681   Hs.28684   Hs.28684   A8054681   Hs.28684   Hs.28684   A8054681   Hs.28686   A8054681   Hs.28686   A8054681   Hs.286864   Hs.286864   Hs.286864   Hs.286864						
132810 AB007944 Hs.5737   132842 NM. 016154Hs.279771   132841 BE257143 Hs.57273   132841 BE257143 Hs.59271   132891 BE257143 Hs.59271   132994 AN0406956 Hs.62016   132994 AA112748 Hs.279305   133016 A819588 Hs.62894   133208 A801777 Hs.6774   13326 A8107777 Hs.6774   13326 A8107777 Hs.6774   13326 A8107777 Hs.6774   133286 A8168737 Hs.289982   133286 A8168737 Hs.289982   133288 AW956781 Hs.289982   133286 A8168737 Hs.289982   133285 MF6477 Hs.289082   133390 A81850382 Hs.728601   133390 A81850382 Hs.728601   133391 AW1033864 Hs.727   133264 A8167421 Hs.75373   133264 A8167421 Hs.75373   133263 A8107377 Hs.6774   133274 A8153293   133285 A8168781 Hs.289372   133285 A8168781 Hs.289372   133285 A8168781 Hs.289372   133285 A8168781 Hs.278360   133391 A81933384 Hs.727   133540 A81037159 Hs.74619   133791 Ms.4338 Hs.727   133760 BE271766 Hs.181357   133784 BE622734 Hs.778278   133865 A8011578 Hs.778279   133881 U30672 Hs.778279   133885 W20992 Hs.76787   133885 W20992 Hs.76787   133881 U30672 Hs.77897   133881 U30672 Hs.77897   133899 A8124113 Hs.78281   13424 BE300075 Hs.8099		132773	AA459713	Hs.295901		14.6
13283   U78525   Hs.57783   eukaryotic franslation initiation factor   6.1	_	132798	Al026701	Hs.5716		
132842 NM	5					
132851   U09716						
132891   E5287143   Hs. 59271						
132941 ABI37165						
132972 AA034365   Hs. 28924   Hs. 279905   Hs. 28076   Hs. 279905   Hs. 28076   Hs. 279905   Hs. 28076   Hs. 279905   Hs. 28076   Hs. 28	10					
132994 AA1040956   Hs.2016   ESTs   1.3	10				Homo sapiens cDNA FL J11392 fis. clone HE	
132994 AA1127/48   Hs.279905   Hs.686718   Hs.68291   Hs.686718   Hs.68291   Hs.68714   Hs.273330   Hs.6867421   Hs.273330   Hs.69233   Hs.69233   Hs.69233   Hs.69233   Hs.69233   Hs.72660   Hs.239391   Hs.72660   Hs.239391   Hs.72660   Hs.72690   Hs.73691   Hs.239391   Hs.72690   Hs.73691   Hs.239391   Hs.73690   Hs.73691   Hs.239391   Hs.73690   Hs.73691   Hs.239391   Hs.73690   Hs.74619   Hs.75691   Hs.239391   Hs.75737   Hs.289082   Hs.75737   Hs.289082   Hs.75737   Hs.289082   Hs.75737   Hs.289082   Hs.76731   Hs.75737   Hs.289082   Hs.76731   Hs.76738   Hs.76738   Hs.76272   Hs.76738   Hs.76738   Hs.76272   Hs.76738   Hs.76738   Hs.76272   Hs.76738   Hs.76738   Hs.76738   Hs.76738   Hs.76272   Hs.76738   Hs.7						
133016 Al439688						17.1
133208   Al801777   Hs. 6774   Hs. 27330   Homo sapiens, clone   IMAGE:3544662, mRNA,						4.4
133264 Ali5677421   Hs.273330   Hs.69203   133268 AW956781   Hs.293937   Hs.293937   Hs.293937   Hs.239393   Als650382   Hs.72696   Hs.72697	15	133177	X97795	Hs.66718	RAD54 (S.cerevisiae)-like	
133266 Al160873						
133265   W76477   Hs.293937   Hs.293937   Ts.2650   Ts						•
133285 M76477					zinc finger protein	
133391 AW103364 Hs.7260   phosphatidylserine receptor   5.7   133594 AV1037159 Hs.74619   proteasome (prosome, macropain) 26S subu 1.7   nibin, beta A (activin A, activin AB a   25.5   proteasome (prosome, macropain) 26S subu 1.7   nibin, beta A (activin A, activin AB a   25.5   proteasome (prosome, macropain) 26S subu 1.7   nibin, beta A (activin A, activin AB a   25.5   nibin, beta A (activin A, activin AB activin AB activin AB   25.5   nibin, beta A (activin A, activin AB activin AB   25.5   nibin, beta A (activin Abeta   25.5   nibin, beta A (activin A, activin AB activin AB   25.5   nibin, beta A (activin Abeta   25.5   nibin, beta A (activin Abeta   25.5   nibin, beta A (activin Abeta   25.5   nibin, beta Alexa   25.5   nibin, beta Alexa   40.46   6.7   13.5	20					
133991 AW103364 Hs.7277	20					
133540 AL037159 Hs.74619						
25 133594 AW160781 Hs.172589 133621 NM_004893Hs.75288 133720 L27841 Hs.75737 133760 BE271766 Hs.181357 133760 BE271767 Hs.301064 133791 M34338 Hs.76244 133791 M34338 Hs.76244 133879 AL133921 Hs.76272 133820 D50525 Hs.699 133880 W29092 Hs.7678 133880 W29092 Hs.7678 133881 W30872 Hs.77204 133894 D86326 Hs.252948 13394 D86326 Hs.77204 133994 D86326 Hs.77897 133989 AL040328 Hs.77897 133989 AL040328 Hs.78202 133997 Al824113 Hs.78281 134234 BE300078 Hs.80449 40 134348 AW291946 Hs.82065 134379 AW362124 Hs.323193 134405 AW067903 Hs.82772 134421 AU077196 Hs.82395 45 134491 AW303083 Hs.82945 134516 AK001571 Hs.273357 134529 AW411479 Hs.848 134516 AK001571 Hs.273357 134529 AW311479 Hs.848 13476 AM650803 Hs.89497 13489 D26488 Hs.99315 134971 AL097346 Hs.89037 135245 Al028767 Hs.262633 135247 Al25269 Hs.98378 135245 Al028767 Hs.262633 135257 AW291023 Hs.97255 135307 Al743770 Hs.98368 135321 Al652069 Hs.98364 40 X78892 Hs.99315 302276 AW057736 Hs.323910 317781 NM_007057Hs.42650 321114 AA902256 Hs.78297 65 322556 BE041451 Hs.17507 420802 U22376 Hs.1334 Probe probe in Veryol avian myeloblastosis viral oncogen 2.3						
133621 NM_004893Hs.75258						
133760   BE271766   Hs. 181357   Iaminin receptor 1 (67kD, ribosomal prot	25					13.5
133794   BE622743   Hs.301064   133797   M34338   Hs.76242   retinoblastoma-binding protein 2   1.3   33852   D50525   Hs.699   Hs.7678   cellular retinoic acid-binding protein 1   4.2   discs, large (Drosophila) homolog 5   5   centromere protein F (350/400kD, mitosin 9.1   33854   M33959   Ms.789   Hs.77204   discs, large (Drosophila) homolog 5   5   centromere protein F (350/400kD, mitosin 9.1   33895   Ms.789   Hs.77897   Ms.24213   Hs.78291   Hs.78291   Ms.78291		133720	L27841	Hs.75737	pericentriolar material 1	
33791 M34338						
133797 AL133921 Hs.76272						
133822 D50525 Hs.699 peptidylprolyl isomerase B (cyclophilin 9.7 cellular retinolo acid-binding protein 1 4.2 discs, large (Drosophila) homolog 5 5 centromere protein F (350/400kD, mitosin 9.1 vesicle docking protein p115 1.8 13395 X81789 Hs.77897 splicing factor 3a, subunit 3, 60kD 10.4 133997 Al824113 Hs.78281 134224 BE300078 Hs.80449 Hs.80449 Hs.80491946 Hs.82065 134379 AW362124 Hs.323193 134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 134504 AW067903 Hs.82785 134529 AW411479 Hs.848 134751 AW630803 Hs.89497 134790 BE002798 Hs.287850 134860 AD001528 Hs.89718 134859 D26488 Hs.90315 134971 Al097346 Hs.286049 135181 BE250865 Hs.279529 T35207 N26427 Hs.9634 135327 AW291023 Hs.98265 135307 Al743770 Hs.98368 Hs.90315 135400 X78592 Hs.99915 302276 AW057736 Hs.323910 317781 NM_007057Hs.42650 321114 AA902256 Hs.78979 420802 U22376 Hs.1334	20					
133850   W29092	30					
133865   AB011155   Hs. 170290   AB01155   AB01155   Hs. 1702007   Hs. 1702007   AB01155   Hs. 1702007   AB01155   Hs. 1702007   Hs. 1702007   AB01155   Hs. 1702007   Hs. 17020007						
13381   U30872   Hs.77204   centromere protein F (350/400kD, mitosin   9.1						
133924						
133959	35					
133989   AL040328   Hs.78202   133997   Al824113   Hs.78281   Hs.78281   Hs.80449   Homo sapiens, clone IMAGE:3535294, mRNA, 10.3   134376   X06560   Hs.82396   2',5'-oligoadenylate synthetase 1 (40-46   5.5   134379   AW362124   Hs.323193   Hypothetical protein MGC3222   5.8   134405   AW067903   Hs.82772   collagen, type VI, alpha 1   72.9   Collagen, type VI, alpha 1   Collagen, ty					splicing factor 3a, subunit 3, 60kD	10.4
40 134348 AW291946 Hs.80449 Homo sapiens, clone IMAGE:3535294, mRNA, 10.3 interleukin 6 signal transducer (gp130, 6.7 134376 X06560 Hs.82396 2',5'-oligoadenylate synthetase 1 (40-46 5.5 hypothetical protein MGC3222 5.8 hypothetical protein MGC3222 5.8 collagen, type XI, alpha 1 72.9 134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.7 134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 hypothetical protein FLJ10709 1.4 FK506-binding protein 4 (59kD) 2.8 lamin B1 6.1 134790 BE002798 Hs.287850 integral membrane protein 1 1.2 spermine synthase 2.6 hypothetical protein MGC11138 9.1 134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 135181 BE250865 Hs.279529 px19-like protein 135245 Al028767 Hs.262603 135257 AW291023 Hs.97255 135207 AI743770 Hs.98368 ESTs, Weakly similar to C10_HUMAN PUTATI 1.7 ESTs, Weakly similar to KIAA0822 protein 5.8 135302 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.7 androgen receptor (dihydrotestosterone r 13.9 322556 BE041451 Hs.177507 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
134348 AW291946 Hs.82065 134376 X06560 Hs.82396 134377 AW362124 Hs.323193 134405 AW067903 Hs.82772 134421 AU077196 Hs.82985 134421 AU077196 Hs.82985 134516 AK001571 Hs.273357 134529 AW411479 Hs.848 134751 AW630803 Hs.89497 134790 BE002798 Hs.287850 134860 AD001528 Hs.89718 134859 D26488 Hs.90315 134859 D26488 Hs.90315 134971 Al097346 Hs.286049 135181 BE250865 Hs.279529 135207 N26427 Hs.9634 135207 AV291023 Hs.97255 135307 AI743770 Hs.98368 135321 Al652069 Hs.98614 60 135354 AA456454 Hs.183418 13507 X78592 Hs.99915 302276 AW057736 Hs.323910 317781 NM_007057Hs.42650 321144 AA902256 Hs.78979 65 322556 BE044451 Hs.177507 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2,55-oligoadenylate synthetaes 1 (40-46 5.5 hypothetical protein MGC3222 5.8 hypothetical protein MGC3222 5.8 hypothetical protein FLJ10709 1.4 hypothetical protein GC11138 1.2 hypothetical protein MGC11138 1.3 hypothetical protein MGC11138 1.3 hypothetical protein MGC11138 1.3 hypothetical protein MGC1		133997	A1824113	Hs.78281	regulator of G-protein signalling 12	
134376 X06560 Hs.82396 134379 AW362124 Hs.323193 hypothetical protein MGC3222 5.8 134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 134421 AU077196 Hs.82985 collagen, type XI, alpha 2 6.7 134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 Hs.287850 Hs.287850 AJ701162 Hs.90207 hypothetical protein MGC11138 9.1 134850 AD001528 Hs.89718 spermine synthase 2.6 134850 AJ701162 Hs.90207 hypothetical protein MGC11138 9.1 134850 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 px19-llke protein 21.2 135245 Al028767 Hs.262603 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 AN291023 Hs.97255 ESTs, Weakly similar to KIAA0822 protein 5.8 135307 AI743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135327 AW291023 Hs.99915 302276 AW057736 Hs.323910 302276 AW057736 Hs.323910 302276 AW057736 Hs.323910 302276 AW057736 Hs.323910 302276 BE041451 Hs.177507 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3	40					
134379 AW362124 Hs.323193 hypothetical protein MGC3222 5.8 134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.7 134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 lamin B1 6.1 134790 BE002798 Hs.287850 spermine synthase 2.6 134806 AD001528 Hs.89718 spermine synthase 2.6 134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 134851 BE250865 Hs.29529 hypothetical protein MGC11138 9.1 134851 BE250865 Hs.29529 FXIAA0007 protein MGC11138 9.1 135181 BE250865 Hs.279529 phosphoserine aminotransferase 2 px19-like protein 13.3 13527 AW291023 Hs.97255 ESTs, Weakly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135307 AI743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135324 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 132255 BE041451 Hs.177507 hypothetical protein 2.9 135257 AV291023 Hs.99915 androgen receptor (dihydrotestosterone r 13.9 135255 BE041451 Hs.177507 hypothetical protein 1 5.5 132256 BE041451 Hs.1734 v-myb avian myeloblastosis viral oncogen 2.3	40					
134405 AW067903 Hs.82772 collagen, type XI, alpha 1 72.9 134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.7 134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 lamin B1 6.1 134790 BE002798 Hs.287850 134806 AD001528 Hs.89718 spermine synthase 2.6 134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 135181 BE250865 Hs.279529 px19-like protein 13.3 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 317781 NM_00705748.42650 322556 BE044t451 Hs.177507 yhpothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3						
134421 AU077196 Hs.82985 collagen, type V, alpha 2 6.7  134480 NM_005000Hs.83916 Empirically selected from AFFX single pr 6.2 134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 FK506-binding protein 4 (59kD) 2.8 134790 BE002798 Hs.287850 integral membrane protein 1 1.2 134806 AD001528 Hs.89718 spermine synthase 2.6 134850 Al701162 Hs.90207 hypothetical protein MGC11138 9.1 134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 hypothetical protein MGC11138 9.1 135181 BE250865 Hs.279529 hypothetical protein MGC11138 9.1 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.262603 ESTs Weakly similar to C10_HUMAN PUTATI 1.7 135257 AW291023 Hs.97255 ESTs, Weakly similar to KIAA0822 protein 5.8 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 137781 NM_007057Hs.42650 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 132256 BE041451 Hs.177507 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3						
134480 NM_005000Hs.83916						
134516 AK001571 Hs.273357 hypothetical protein FLJ10709 1.4 134529 AW411479 Hs.848 FK506-binding protein 4 (59kD) 2.8 134751 AW630803 Hs.89497 Hs.287850 integral membrane protein 1 1.2 134806 AD001528 Hs.89718 spermine synthase 2.6 134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 135181 BE250865 Hs.279529 px19-like protein  14.9 135245 Al028767 Hs.9634 ESTs, Weakly similar to C10_HUMAN PUTATI 1.7 135245 AW291023 Hs.97255 ESTs, Weakly similar to C10_HUMAN PUTATI 1.7 135257 AW291023 Hs.97255 ESTs, Weakly similar to KIAA0822 protein 7.6 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 135354 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.7 135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9) 302276 AW057736 Hs.323910 AM007057Hs.42650 32114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 132255 BE041451 Hs.177507 hypothetical protein v-myb avian myeloblastosis viral oncogen 2.3	45				Empirically selected from AFFX single pr	
134529 AW411479 Hs.848						1.4
134790 BE002798 Hs.287850 integral membrane protein 1 1.2 spermine synthase 2.6 hypothetical protein MGC11138 9.1 hypothetical protein MGC1113		134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	
50         134806         AD001528         Hs.89718         spermine synthase         2.6           134859         Al701162         Hs.90207         hypothetical protein MGC11138         9.1           134859         D26488         Hs.90315         KIAA0007 protein         13.3           134971         Al097346         Hs.286049         phosphoserine aminotransferase         2           135181         BE250865         Hs.279529         px19-like protein         14.9           55         135207         N26427         Hs.9634         ESTs, Highly similar to C10_HUMAN PUTATI 1.7           135245         Al028767         Hs.262603         ESTs, Weakly similar to A46010 X-linked         7.6           135307         Al743770         Hs.98368         ESTs, Weakly similar to KIAA0822 protein         5.8           135321         Al652069         Hs.98614         ribosome binding protein 1 (dog 180kD ho         12.3           60         135354         AA456454         Hs.183418         cell division cycle 2-like 1 (PITSLRE pr         5.7           135400         X78592         Hs.99915         androgen receptor (dihydrotestosterone r         13.9           302276         AW057736         Hs.323910         ERR2 receptor tyrosine kinase (c         5.3						
134859 Al701162 Hs.90207 hypothetical protein MGC11138 9.1 134871 Al097346 Hs.286049 phosphoserine aminotransferase 2 135181 BE250865 Hs.279529 px19-like protein 44.9 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.262603 ESTs 12.2 135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.6 135307 Al743770 Hs.98368 ESTs, Weakly similar to KIAA0822 protein 5.8 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 135340 X78592 Hs.99915 alozofe AW057736 Hs.323910 Hs.323910 AW057736 Hs.323910 AW057736 Hs.323910 AW057736 Hs.323910 AW057736 Hs.329310 AW05256 Hs.78979 Golgi apparatus protein 1 5.5 132556 BE041451 Hs.177507 hypothetical protein WGC11138 9.1 KIAA0007 protein MGC11138 9.1 Hs.286049 phosphoserine aminotransferase 2 px19-like protein 1.4.9 ESTs, Weakly similar to A46010 X-linked 7.6 ESTs, Weakly similar to KIAA0822 protein 5.8 ribosome binding protein 1 (dog 180kD ho 12.3 cell division cycle 2-like 1 (PITSLRE pr 5.7 androgen receptor (dihydrotestosterone r 13.9 HER2 receptor tyrosine kinase (c 5.3 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 hypothetical protein 9.1						
134859 D26488 Hs.90315 KIAA0007 protein 13.3 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 135181 BE250865 Hs.279529 px19-like protein 14.9 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.262603 ESTs, Weakly similar to A46010 X-linked 7.6 135257 AW291023 Hs.97255 ESTs, Weakly similar to KIAA0822 protein 7.6 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 13534 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 5.7 androgen receptor (dihydrotestosterone r 13.9 1302276 AW057736 Hs.99915 AVM_007057Hs.42650 ZW10 interactor 2.8 132156 BE041451 Hs.177507 hypothetical protein 2.9 1302276 AW02376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3	50					- · ·
134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 px19-like protein 14.9 14.9 14.9 155 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.262603 Hs.97255 135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.6 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 135340 X78592 Hs.99915 302276 AW057736 Hs.323910 302776 AW057736 Hs.323910 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321144 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3						
135181 BE250865 Hs.279529 px19-like protein 14.9 135207 N26427 Hs.9634 ESTs, Highly similar to C10_HUMAN PUTATI 1.7 135245 Al028767 Hs.262603 ESTs, Weakly similar to A46010 X-linked 7.6 135257 AW291023 Hs.97255 ESTs, Weakly similar to KIAA0822 protein 5.8 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 13534 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 3.7 135400 X78592 Hs.99915 a02276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 1317781 NM_007057Hs.42650 ZW10 interactor 2.8 1321514 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 1322556 BE041451 Hs.177507 hypothetical protein 2.9 14.9 14.9 14.9 15.7 15.7 15.8 15.8 15.8 15.8 15.8 15.8 15.8 15.8						
55       135207       N26427       Hs.9634       ESTs, Highly similar to C10_HUMAN PUTATI 1.7         135245       Al028767       Hs.262603       ESTs       12.2         135257       AW291023       Hs.97255       ESTs, Weakly similar to A46010 X-linked       7.6         135307       Al743770       Hs.98368       ESTs, Weakly similar to KIAA0822 protein       5.8         135321       Al652069       Hs.98614       ribosome binding protein 1 (dog 180kD ho       12.3         60       135354       AA456454       Hs.183418       cell division cycle 2-like 1 (PITSLRE pr       5.7         135400       X78592       Hs.99915       androgen receptor (dihydrotestosterone r       13.9         302276       AW057736       Hs.323910       HER2 receptor tyrosine kinase (c       5.3         317781       NM_007057Hs.42650       ZW10 interactor       2.8         321114       AA902256       Hs.78979       Golgi apparatus protein 1       5.5         65       322556       BE041451       Hs.1334       v-myb avian myeloblastosis viral oncogen       2.3						
135245 Al028767 Hs.262603 ESTs 12.2 135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.6 135307 Al743770 Hs.98368 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 13540 X78592 Hs.99915 cell division cycle 2-like 1 (PITSLRE pr 5.7 135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9) 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3) 317781 NM_070757Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgl apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3	55				ESTs. Highly similar to C10 HUMAN PUTATI	
135257 AW291023 Hs.97255 ESTs, Weakly similar to A46010 X-linked 7.6 135307 AI743770 Hs.98368 135321 AI652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 13540 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 3217781 NM_070577Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgl apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3					ESTs	
135307 Al743770 Hs.98368 Hs.98361 ribosome binding protein 1 (dog 180kD ho 12.3 135321 Al652069 Hs.98614 ribosome binding protein 1 (dog 180kD ho 12.3 13534 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 13.9 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 13.9 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		135257	AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	
60 135354 AA456454 Hs.183418 cell division cycle 2-like 1 (PITSLRE pr 135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 13.9 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		135307	A1743770			
135400 X78592 Hs.99915 androgen receptor (dihydrotestosterone r 33.9 302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3						
302276 AW057736 Hs.323910 HER2 receptor tyrosine kinase (c 5.3 317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3	60					
317781 NM_007057Hs.42650 ZW10 interactor 2.8 321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		135400	X78592			
321114 AA902256 Hs.78979 Golgi apparatus protein 1 5.5 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		3022/6	WANDOLUE	7He 12650		
65 322556 BE041451 Hs.177507 hypothetical protein 2.9 420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3		201111	ΔΔQΩ2256	Hs 78979		
420802 U22376 Hs.1334 v-myb avian myeloblastosis viral oncogen 2.3	65	322556	BE041451			
	0.5	420802	U22376			
		424001	W67883			7

	425182	AF041259	. Hs.155040	zinc finger protein 217	2.3
	446999	AA151520	Hs.334822	hypothetical protein MGC4485	7.5
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	AF077036	Hs.31989	DKEZP586G1722 protein	12.1

### TABLE 5A

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	Unique Eos probeset identifier number
	CAT number:	Gene cluster number
	Accession:	Genhank accession numbers

5

15	Pkey	CAT number	Accessions
20	123615 124385 110856 120472	3068615 656394_1 19346_14 44573_2	AA609170 Al267847 N27351 AA992380 N33063 N21418 H79958 R21911 H79957 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586
25	٠		AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW7050512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586
35			AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226
40	122618 125115	305217_1 genbank_T973	
45	120809 129680	genbank_AA3 23162_1	U03749 NM_001275 J03483 J03915 Al214509 AW245744 AL046455 AA318960 Al741505 AA843875 Al829382 Al560122 Al858999 D55958 Al684005 D53170 AA854091 Al025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 Al969102 AA405741 Al091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 Al148432 Al038109 AA782478 AA910064 Al220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
50			AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214 AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992
55	101045 110501 121558 121911	entrez_J05614 genbank_H55 genbank_AA4 genbank_AA4	748 H55748 12497 AA412497

# TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

Pkey: ExAccn:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number

UnigenelD: 10

Unigene Title: R1:

Unigene number
Unigene gene title
Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9
	102455	U48705	Hs.75562	discoidin domain receptor family, member	6.9
20		X72755	Hs.77367	monokine induced by gamma interferon	8.8
		BE246502		sema domain, immunoglobulin domain (lg),	2.6
		AW151952		hypothetical protein FLJ20739	1.5
		AW503807		histone acetyltransferase	1.8
25		A1668594		ESTs, Weakly similar to CP4Y_HUMAN CYTOC	
25				coat protein gamma-cop	3.2 45.7
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA fibroblast growth factor 12B	38.9
				ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
				M-phase phosphoprotein homolog	52
30		AA976503	110.170010	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8
50		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA402515		ESTs	28
	122607	AA453518	Hs.98023	ESTs	61.5
	122616	AA453638	Hs.161873	ESTs	107.3
35	122618	AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
	122829	AW204530	Hs.99500	ESTs	81.8
		AA460584			75.3
			Hs.234961	Huntingtin interacting protein E	30.6
40		Al267847	11 404477	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
40		R65763	Hs.101477		23.9
		AI076343		ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8 135.3
		T79956 N71826	Hs.100588	small nuclear ribonucleoprotein polypept	53.9
				WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
43		AW748482		B7 homolog 3	2.6
				KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1
		AA321649		small inducible cytokine subfamily B (Cy	7.4
50		AW410601		HSPC182 protein	2.9
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.7
ι	132180	NM_004460	)Hs.418	fibroblast activation protein, alpha	14.7
		AW572805		ESTs	28.3
~ ~		AA112748			17.1
55		AJ439688	Hs.6289	hypothetical protein FLJ20886	4.4
		Al160873	Hs.69233	zinc finger protein	16.1
		AW103364		inhibin, beta A (activin A, activin AB a	25.5 1.2
		A1690916 NM 000402	Hs.178137	transducer of ERBB2, 1 glucose-6-phosphate dehydrogenase	1.9
60		AW067903		collagen, type XI, alpha 1	72.9
00		AW411479		FK506-binding protein 4 (59kD)	2.8
		R50333	Hs.92186	Leman coiled-coil protein	2.6
		BE250865		· · · · · · · · · · · · · · · · · · ·	14.9
		BE041451			2.9

### TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

ľ	1	١	
		,	

5

Unique Eos probeset identifier number

Pkey: CAT number: Gene cluster number

Genbank accession numbers Accession:

15			
15	Pkey	CAT number	Accessions
	124385 120695	656394_1 9683 3	Al267847 N27351 AA976503 Al917802 AA953664 AA404613 AA428771 BE280542 AW194691 Al927301 Al740458 Al796100 Al935603
20	120095	9003_3	AM052210 AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468
	122618	305217_1	AA453641 AA454061

## TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	Diam	Makana Tananahasak Mandiffan mumban
10	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigeneID:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal breast tissue
15	ORF struct info:	Structural characterization of open reading frame for the sequence

	R1:			ormal breast tissue				
15	5 ORF struct info:		io: Structural characterization of open reading frame for the sequence of the gene					
				11-1	R1	ORF struct info		
	Pkey	ExAccn	UnigenelD	UnigeneTitle	Kı	ORF SHUCK IIIIO		
	100113	NM_001269	Hs.84746	chromosome condensation 1	2.3	TM		
20		X02308	Hs.82962	thymidylate synthetase	2.9	other		
20		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	1.9	other		
		BE185499	Hs.2471	KIAA0020 gene product	1.9	TM		
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.6	other		
		H60720	Hs.81892	KIAA0101 gene product	9.2	other		
25		W44671	Hs.124	gene predicted from cDNA with a complete	1.6	other		
25		AW015534	Hs.217493	annexin A2	2	other		
				KIAA0077 protein	1.5	other		
		D38521	Hs.112396		13.5	other		
		BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	5.1	other		
20		BE242802	Hs.154797	KIAA0090 protein	1.9	TM		
30		D50920	Hs.23106	KIAA0130 gene product	2.7	other		
		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.1	other		
		NM_004341		carbamoyl-phosphate synthetase 2, aspart	2.6			
		NM_014791		KIAA0175 gene product		other		
25		D84145	Hs.39913	novel RGD-containing protein	3.2	other		
35		AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5 2	other		
		D86978	Hs.84790	KIAA0225 protein		other		
		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein	2.9	other		
		NM_004415		desmoplakin (DPI, DPII)	1.9	other		
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	other ?		
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	9			
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.7 53.2	other other		
		AW502935	Hs.740	PTK2 protein tyrosine kinase 2				
		AF078847	Hs.191356	general transcription factor IIH, polype	6	other		
15		BE245294	Hs.180789	S164 protein	1.7	?		
45		AF002225	Hs.180686	ubiquitin protein ligase E3A (human papi	1.5	other		
		AA157634	Hs.79172	solute carrier family 25 (mitochondrial	6.3	other		
		AK000405	Hs.76480	ubiquitin-like 4	11.4	?		
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5	1.6	other		
<b>~</b> 0		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.4	other		
50		J05614		gb:Human proliferating cell nuclear anti	5	?		
		N99692	Hs.75227	Empirically selected from AFFX single pr	2.6	other		
		L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dio	1.4	?		
		AA020956	Hs.179881	core-binding factor, beta subunit	2	TM		
	101216	AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	1.8	other		
55	101228	AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (	1.7	TM		
	101247	AA132666	Hs.78802	glycogen synthase kinase 3 beta	1.9	other		
	101249	L18964	Hs.1904	protein kinase C, iota	1.5	other		
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5.3	other		
		AI494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	4.2	other		
60	101396	BE267931	Hs.78996	proliferating cell nuclear antigen	1.9	TM		
		M21259		gb:Human Alu repeats in the region 5' to	1.6	TM		
		NM_000546		tumor protein p53 (Li-Fraumeni syndrome)	2.5	other		
	101478	NM_002890	0 Hs.758	RAS p21 protein activator (GTPase activa	5.5	other		

	404400		11 70700		0.4	albar
		M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-di	2.1	other
		J04977	Hs.84981	X-ray repair complementing defective rep	1.6	other
	101573	AW248421	Hs.250758	proteasome (prosome, macropain) 26S subu	5.7	other
_	101580	NM_012151	Hs.83363	coagulation factor VIII-associated (intr	1.8	other
5	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6	?
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-	2.4	other
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), reg	1.3	other
	101734	M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	2.1	?
		M80244	Hs.184601	solute carrier family 7 (cationic amino	5	TM
10		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS,
10		AA306495	Hs.1869	phosphoglucomutase 1	5.2	other
		AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H	8.6	other
					8.9	SS,TM
		AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias		
1.5		NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15		AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
		AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
	101920	AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8	other
	101973	U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.4	other
	102009	BE245149	Hs.82643	protein tyrosine kinase 9	1.3	other
20	102036	BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi	2	?
	102083	T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.6	other
	102107	BE258602	Hs.182366	heat shock protein 75	1.4	other
		NM_001809	Hs.1594	centromere protein A (17kD)	1.8	other
		BE313280	Hs.159627	death associated protein 3	4.6	?
25		AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.4	?
2,5		AA829978	Hs.301613	JTV1 gene	6.7	other
		U24389	Hs.65436	lysosomal	4.4	TM
				•	1.9	TM
		AW163390	Hs.278554	heterochromatin-like protein 1	4.4	other
20		AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, impor		
30		AA306342	Hs.69171	protein kinase C-like 2	2.7	?
		BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
		BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	TM
	102349	AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2	other
35	102369	U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2	other
	102374	U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	other
	102391	AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
		U48705	Hs.75562	discoidin domain receptor family, member	7	other
		NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondri	1.8	SS,
40		U50939	Hs.61828	amyloid beta precursor protein-binding p	1.5	?
10		AL080116	Hs.74420	origin recognition complex, subunit 3 (y	3.3	other
		AI188137	Hs.75193	COP9 homolog	2.1	other
				siah binding protein 1; FBP interacting	3.2	other
		AF217197	Hs.74562		2.8	?
15		BE250944	Hs.183556	solute carrier family 1 (neutral amino a		?
45		AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	<u>-</u> '
		U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	other
		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	2.1	other
	102581	AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6	?
50	102582	U61232	Hs.32675	tubulin-specific chaperone e	2.1	other
	102617	AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	1.8	other
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	other
		NM_002270	Hs.168075	karyopherin (importin) beta 2	1.8	TM
55		BE262989	Hs.12045	putative protein	2.3	other
55		NM_007019	Hs.93002	ubiquitin carrier protein E2-C	4.4	?
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	?
				forkhead box M1	4.2	other
		BE540274	Hs.239	BRCA1 associated RING domain 1	1.9	other
<b>C</b> O		AU077058	Hs.54089			
60		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	SS,TM
		AB014460	Hs.66196	nth (E.coli endonuclease III)-like 1	1.2	TM
		BE252241	Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinas	6.5	other
		U90549	Hs.236774	high-mobility group (nonhistone chromoso	1.6	other
	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	TM
65	102844	AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
	102868	X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
	102925	BE440142	Hs.2943	signal recognition particle 19kD	1.9	other

						•
		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	2.4	?
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2	?
5	103023	AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
-		AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
		NM_005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5	other
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos	3.1	other
		D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	2.4	other
10			Hs.48876	farnesyl-diphosphate farnesyltransferase	3.5	other
10		BE244377			9.9	?
		AA205475	Hs.275865	ribosomal protein S18	1.3	other
		NM_001777	Hs.82685	CD47 antigen (Rh-related antigen, integr		
		X69636	Hs.334731	Homo sapiens, clone IMAGE:3448306, mRNA,	2	other
1 ~		NM_006825	Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15	103191	AA401039	Hs.2903	protein phosphatase 4 (formerly X), cata	2.5	other
	103193	NM_004766	Hs.75724	coatomer protein complex, subunit beta 2	2.2	TM
	103194	NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8	TM
	103223	BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20		X75962	Hs.129780	tumor necrosis factor receptor superfami	1.8	other
		A1369285	Hs.75189	death-associated protein	5.6	TM
		NM_001545	Hs.9078	immature colon carcinoma transcript 1	1.9	?
			Hs.77496	small nuclear ribonucleoprotein polypept	2.5	other
		AI803447	HS.11430		1.6	other
25		X89059	11- 000070	gb:H.sapiens mRNA for unknown protein ex	1.8	other
25		AL036166	Hs.323378	coated vesicle membrane protein		other
		X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	
		X94563		gb:H.sapiens dbi/acbp gene exon 1 & 2.	4	TM
	103430	BE564090	Hs.20716	translocase of inner mitochondrial membr	1.3	other
	103491	AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7	?
30	103505	AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.1	other
	103547	Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7	?
	103588	NM 006218	Hs.85701	phosphoinositide-3-kinase, catalytic, al	2	other
	103613	NM_000346	Hs.2316	SRY (sex determining region Y)-box 9 (ca	1.3	?
		BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	2	other
35		AA609685	Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
55		AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
		Al015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (f	1.3	other
			Hs.169992	hypothetical 43.2 Kd protein	7.6	?
		AA094752		Homo sapiens BTB domain protein (BDPL) m	1.3	SS,TM
40		H26531	Hs.7367		1.6	other
40		AA080912	11 404074	gb:zn04d03.r1 Stratagene hNT neuron (937		
		Al042582	Hs.181271	CGI-120 protein	1.6	other
		W02363	Hs.302267	hypothetical protein FLJ10330	1.6	other
	103886	AK001278	Hs.105737	hypothetical protein FLJ10416 similar to	6.6	TM
	104052	NM_002407	Hs.97644	mammaglobin 2	2.9	other
45	104079	AA251242	Hs.103238	ESTs	1.4	other
	104174	AA478984	Hs.6451	PRO0659 protein	5.6	TM
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6	other
	104275	Al751970	Hs.101067	GCN5 (general control of amino-acid synt	5.4	other
		BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	other
50		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.6	other
50		R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
		AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
		Al239923	Hs.30098	ESTs	1.4	other
				olfactory receptor, family 2, subfamily	2.4	other
<i>55</i>		AI694413	Hs.332649	ESTs, Weakly similar to N-WASP [H.sapien	1.4	other
55		AI858702	Hs.31803			
		AB023175	Hs.22982	KIAA0958 protein	2.4	other
		AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9	other
		Al250789	Hs.32478	ESTs	5.7	other
		AA041276	Hs.154729	3-phosphoinositide dependent protein kin	12.3	?
60	104867	AA278898	Hs.225979	hypothetical protein similar to small G	2.1	other
	104871	T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (f	1.4	other
		AW015318	Hs.23165	ESTs	17.7	other
		AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
		AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65		AA026880	Hs.25252	prolactin receptor	1.5	other
05		AF043467	Hs.32893	neurexophilin 2	2.3	other
		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
	104313	141N_0 100 10	110.0100	(W. O. 100 12 protein		

					4	
	104974	Y12059	Hs.278675	bromodomain-containing 4	1.5	other
	104975	AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.4	other
	104978	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	7.3	other
	104979	AA937934	Hs,321062	ESTs	1.3	other
5		Al499930	Hs.334885	mitochondrial GTP binding protein	3.6	?
Ū		BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
				chromosome 20 open reading frame 1	3.4	other
		AF098158	Hs.9329	Chromosome 20 open reading name i		
		Al050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
	105041	AB037716	Hs.26204	KIAA1295 protein	2.2	other
10	105045	BE242899	Hs.129951	speckle-type POZ protein	3.9	?
	105079	AA151342	Hs.12677	CGI-147 protein	9.5	TM
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	5.7	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
		Z78407		vesicle transport-related protein	2.2	other
15			Hs.27023		1.6	other
15		BE387350	Hs.33122	KIAA1160 protein		
		AW975433	Hs.36288	ESTs	6.4	?
	105127	AA045648	Hs.301957	nudix (nucleoside diphosphate linked moi	2.2	other
	105141	AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
	105158	AW976357	Hs.234545	hypothetical protein NUF2R	2	other
20		BE245294	Hs.180789	S164 protein	1.7	other
20		AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
					2	TM
		AA071276	Hs.19469	KIAA0859 protein		?
		AA263143	Hs.24596	RAD51-interacting protein	2.9	
~ ~		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.9	TM
25	105302	AA700122	Hs.3355	sentrin-specific protease	8.2	?
	105331	AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
	105359	NM_016015	Hs.8054	CGI-68 protein	8.4	other
		BE264645	Hs.282093	hypothetical protein FLJ21918	5.1	other
		AW887701	Hs.32356	hypothetical protein FLJ20628	2.6	other
30					2.2	TM
30		BE242803	Hs.262823	hypothetical protein FLJ10326		
		AW592146	Hs.108636	membrane protein CH1	2.3	SS,TM
	105393	AF167570	Hs.256583	interleukin enhancer binding factor 3, 9	5.5	SS,
	105399	BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6	other
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	1.6	other
35		AA252395		gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens	5.1	?
		BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6	other
		AA113449	Hs.32471	hypothetical protein FLJ20364	1.3	other
					3.5	other
		AB023179	Hs.9059	KIAA0962 protein		other
4.0		AA262640	Hs.27445	unknown	9.3	
40		BE616694	Hs.288042	hypothetical protein FLJ14299	1.4	other
	105596	AA579535	Hs.18490	hypothetical protein FLJ20452	10.9	TM
	105597	AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
	105608	Al808201	Hs.287863	hypothetical protein FLJ12475	1.7	?
		AA280072	Hs.99872	fetal Alzheimer antigen	1.4	other
45		AK000892	Hs.4069	glucocorticoid modulatory element bindin	1.7	TM
73				casein kinase 1, gamma 2	5.6	other
		AW302245	Hs.181390		9.4	other
		AA985190	Hs.246875	hypothetical protein FLJ20059		
		AW499988	Hs.27801	zinc finger protein 278	2	TM
	105708	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.7	other
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	?
		Al123118	Hs.15159	chemokine-like factor, alternatively spl	1.3	other
		AI267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
		AA741336	Hs.152108	transcriptional unit N143	2.2	other
55				E3 ubiquitin ligase SMURF2	1.3	other
55		AA478756	Hs.194477	•		
		Al262106	Hs.12653	ESTs	2.4	other
		AF151066	Hs.281428	hypothetical protein	2.9	other
	105875	AK001708	Hs.32271	hypothetical protein FLJ10846	1.4	other
		AF016371	Hs.9880	peptidyl prolyl isomerase H (cyclophilin	5.3	other
60		AW194426	Hs.20726	ESTs	1.7	other
00		AW081202	Hs.12284	Homo sapiens, clone IMAGE:2989556, mRNA,	2.8	other
		AA477956	Hs.26268	ESTs	1.4	other
				downstream neighbor of SON	1.4	other
		AL157441	Hs.17834		1.6	?
<i>(</i> =		AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN A		
65		AA533491	Hs.23317	hypothetical protein FLJ14681	6.9	other
		AB006624	Hs.14912	KIAA0286 protein	1.6	other
	106271	AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430	. 10.8	?

	106288	AB037742	Hs.24336	KIAA1321 protein	1.3	other
		Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen	5.5	SS,
		AK001404	Hs.194698	cyclin B2	5.8	other
5		AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
_		AB040916	Hs.24106	KIAA1483 protein	6.6	other
	106389	AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
	106457	AF119256	Hs.27801	zinc finger protein 278	2.7	other
	106470	D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone L	2.3	other
10	106586	AA243837	Hs.57787	ESTs	1.6	other
	106589	AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
	106610	AA458882	Hs.79732	fibulin 1	8	SS,
	106624	NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8	other
1.7		AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (f	1.8	other
15		AV657117	Hs.184164	ESTs, Moderately similar to S65657 alpha	1.3	TM
		BE614802	Hs.184352	hypothetical protein FLJ12549	4.6	other
		AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	1.3	other
		BE388094	Hs.21857	ESTs	1.6	SS,
20		AF174487	Hs.293753	Bcl-2-related ovarian killer protein-lik	5.7	other
20		AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
		BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5	other
		AB037744	Hs.34892	KIAA1323 protein	2.2	other
		AF151031	Hs.300631	hypothetical protein	1.3	other
25		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA,	16.8	other
25		W79171	Hs.9567	GL002 protein	1.5 2.2	TM other
		AA861271	Hs.222024	transcription factor BMAL2	3.4	other
		AK001838 AK000511	Hs.296323	serum/glucocorticoid regulated kinase hypothetical protein DKFZp434L1435 simil	6.8	?
		BE156256	Hs.6294 Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS,
50		AA146872	Hs.300700	hypothetical protein FLJ20727	1.3	other
		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	1.8	other
		AW385224	Hs.35198	ectonucleotide pyrophosphatase/phosphodi	1.7	other
		AK000733	Hs.23900	GTPase activating protein	2.5	other
35		AK000733	Hs.69388	hypothetical protein FLJ20505	1.7	other
<i>- - - - - - - - - -</i>		AV661958	Hs.8207	GK001 protein	4.7	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	2	other
		AW378065	Hs.8687	ESTs	6.4	TM
		AW391927	Hs.7946	KIAA1288 protein	33.5	other
40	107174	BE122762	Hs.25338	ESTs	5.2	?
	107197	W15477	Hs.64639	glioma pathogenesis-related protein	6.1	other
	107221	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (	17.4	other
	107243	BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc	7.4	?
	107248	AW263124	Hs.315111	nuclear receptor co-repressor/HDAC3 comp	1.8	other
45		D60341	Hs.21198	translocase of outer mitochondrial membr	6.7	other
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5	other
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2	TM
		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586l0324 (f	2	TM
~^		NM_006299	Hs.96448	zinc finger protein 193	5	?
50		AW299900	Hs.267632	TATA element modulatory factor 1	1.2	other
		AA307703	Hs.279766	kinesin family member 4A	1.6	other
		BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3 1.4	TM other
		AA001386	Hs.59844	ESTs Moderately similar to ALU7, HUMAN A	2.3	SS,TM
55		BE379594 AA018587	Hs.49136 Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.2	?
33			Hs.47584	potassium voltage-gated channel, delayed	8.4	TM
		AW732573 L42612	Hs.335952	keratin 6B	2.5	other
		BE153855	Hs.61460	lg superfamily receptor LNIR	2.3	other
		AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme	6.8	other
60		AL121031	Hs.159971	SWI/SNF related, matrix associated, acti	1.6	other
		AA054224	Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
		N31256	Hs.161623	ESTs	2.6	other
		AA083069	Hs.339659	ESTs	3.6	other
65	108607	BE300380	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	3.5	other
	108621	AA101809	Hs.182685	ESTs	1.7	other
		AW022410	Hs.69507	ESTs	1.8	SS,TM

	108647	BE546947	Hs.44276	homeo box C10	9.8	other
		AB029000	Hs.70823	KIAA1077 protein	7.3	other
		AI089575	Hs.9071	progesterone membrane binding protein	2.8	?
		AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5	108859	AL121500	Hs.178904	ESTs	1.6	TM
		H06720	Hs.111680	endosulfine alpha	2.2	other
		AI801235	Hs.48480	ESTs	5.4	other
		AK001431	Hs.5105	hypothetical protein FLJ10569	4.1	TM
10		AA149754	Hs.195155	Homo sapiens amino acid transport system	5.7 1.7	? other
10		AA151708 AA152178	Hs.171980 Hs.23467	homeo box (expressed in ES cells) 1 hypothetical protein FLJ10633	6.3	other
		AB028987	Hs.72134	KIAA1064 protein	1.7	other
		AA156542	Hs.72127	ESTs	1.5	other
		AA157811	110.72121	gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15		AA164293	Hs.72545	ESTs	3	other
		AW608930	Hs.52184	hypothetical protein FLJ20618	1.6	SS,
	109112	AW419196	Hs.257924	hypothetical protein FLJ13782	3.3	TM
	109124	AK000684	Hs.183887	hypothetical protein FLJ22104	1.7	other
••		AJ132592	Hs.59757	zinc finger protein 281	2.7	other
20		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3	TM
		BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
		NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-li	5.4	other
		AW958181	Hs.189998	ESTs	5.8 5.3	other other
25		AU077281 N99673	Hs.170285 Hs.3585	nucleoporin 214kD (CAIN) ESTs, Weakly similar to AF126743 1 DNAJ	1.4	other
23		AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other
		AA213506	Hs.115099	EST	3	?
		AL096858	Hs.184245	KIAA0929 protein Msx2 interacting nuclea	1.5	other
30		H83603	Hs.40408	homeo box C9	2.2	SS,
		N30531	Hs.42215	protein phosphatase 1, regulatory subuni	3.1	TM
		Al160029	Hs.61438	ESTs	2	?
		AA232103	Hs.189915	ESTs	1.8	other
25		AB032969	Hs.173042	KIAA1143 protein	3.8	other
35		NM_015310	Hs.6763	KIAA0942 protein	3.3	other
		AW074143	Hs.87134	ESTs	2 2.1	TM other
		L40027 F02614	Hs.118890 Hs.27319	glycogen synthase kinase 3 alpha ESTs	1.4	other
		R71264	Hs.16798	ESTs	1.3	other
40		H11938	Hs.21907	histone acetyltransferase	2	other
.0		AA503041	Hs.279009	matrix Gla protein	2.5	other
		AA603840	Hs.29956	KIAA0460 protein	1.7	other
	110110	T07353	Hs.7948	ESTs	2.9	other
. =	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU S	1.7	SS,
45	110154	NM_014521	Hs.17667	SH3-domain binding protein 4	4.3	other
		A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.3	?
		N41744	Hs.19978	CGI-30 protein	1.3	other
		H28428	Hs.32406	ESTs, Weakly similar to I38022 hypotheti	2.2 2.1	other other
50		BE256986	Hs.11896	hypothetical protein FLJ12089 gb:yq94a01.s1 Soares fetal liver spleen	6.1	?
50		H55748 H55915	Hs.210859	hypothetical protein FLJ11016	6.1	тM
		H57330	Hs.37430	EST	6.4	other
		AK001160	Hs.5999	hypothetical protein FLJ10298	1.3	?
		T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
		AW190338	Hs.28029	hypothetical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
		BE044245	Hs.30011	hypothetical protein MGC2963	9.3	?
<b>60</b>		AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60		BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, clone HE	2.1	TM TM
		A1089660	Hs.323401 Hs.24048	dpy-30-like protein FK506 binding protein precursor	1.5 6.7	TM
	110000	T25829 AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
		R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	3.4	other
65		N31598	Hs.12727	hypothetical protein FLJ21610	1.7	TM
		Al740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	1.7	other
		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other

	110056	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3	other
		BE384447	Hs.16034	hypothetical protein MGC13186	3.5	?
		AL117430	Hs.6880	DKFZP434D156 protein	2.2	?
		BE092285	Hs.29724	hypothetical protein FLJ13187	2.6	SS,
5		H04360	Hs.24283	ESTs, Moderately similar to reduced expr	1.9	TM
•		NM_005864	Hs.24587	signal transduction protein (SH3 contain	6.7	other
		AK002180	Hs.11449	DKFZP564O123 protein	2	other
		AK001980	Hs.24284	ADP-ribosyltransferase (NAD+; poly(ADP-r	1.3	other
		AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	?
10		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
	111132	AB037807	Hs.83293	hypothetical protein	2.1	TM
	111164	N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
	111172	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7	other
	111174	AL050166	Hs.26295	Homo sapiens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15		AK000136	Hs.10760	asporin (LRR class 1)	7.1	other
		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.8	other
		N67603	Hs.272130	ESTs, Weakly similar to S65824 reverse t	3.6	SS,
		AW139408	Hs.152940	ESTs	1.5	other
20		AB037782	Hs.15119	KIAA1361 protein	2.6	other
20		AA852773	Hs.334838	KIAA1866 protein	4.7 7.9	other ?
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9	other
		AA778711 AB033091	Hs.4310 Hs.74313	eukaryotic translation initiation factor KIAA1265 protein	5	other
		Al523913	Hs.34504	ESTs	3.8	other
25		T99755	Hs.334728	ESTs	1.2	TM
20		AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
		Al478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	2.8	?
		N94606	Hs.288969	HSCARG protein	2.2	other
30		AK000987	Hs.169111	oxidation resistance 1	2.1	other
	111452	R02354	Hs.15999	ESTs	2.7	TM
	111486	Al051194	Hs.227978	EST	6.6	other
	111549	W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN Z	1.4	other
	111585	R10720	Hs.20670	EST	1.6	?
35		R52656	Hs.21691	ESTs	1.6	other
		AB037834	Hs.18685	Homo sapiens mRNA for KIAA1413 protein,	2.4	other
		BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr	10.6	other
		AW083791	Hs.21263	suppressor of potassium transport defect	6.6	TM
40		NM_015310	Hs.6763	KIAA0942 protein	5.1 2.8	other other
40		R41823	Hs.7413 Hs.70823	ESTs; calsyntenin-2 KIAA1077 protein	2.6 14.6	other
		AB029000 R46071	Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA,	9	other
		NM_016248	Hs.232076	A kinase (PRKA) anchor protein 11	1.4	other
		AW007287	Hs.28538	Homo sapiens cDNA: FLJ21086 fis, clone C	1.4	TM
45		AI742756	Hs.26079	ESTs	3.2	other
		R68425	Hs.13809	hypothetical protein FLJ10648	2	TM
		AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	other
	112884	AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein,	6.6	other
	112923	T10258	Hs.5037	EST	1.5	?
50	112936	AW970826	Hs.6185	KIAA1557 protein	3.2	other
		R61388	Hs.6724	ESTs	6.1	other
		Z44718	Hs.102548	glucocorticoid receptor DNA binding fact	6.5	other
		AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	other
<i></i>		AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6 2	other other
55		BE276112	Hs.7165	zinc finger protein 259	1.9	other
		A1571940	Hs.7549 Hs.7560	ESTs Homo sapiens mRNA for KIAA1729 protein,	2.4	TM
		AW965190 T40707	Hs.270862	ESTs	1.3	SS,
		T57317	113.210002	gb:yb51a03.s1 Stratagene fetal spleen (9	1.7	other
60		T63857		gb:yc16e01.s1 Stratagene lung (937210) H	2.8	other
00		AK002180	Hs.11449	DKFZP564O123 protein	1.3	other
		AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isome	3.2	other
		AA688021	Hs.179808	ESTs	1.2	other
		Al467908	Hs.8882	ESTs	6	other
65	113547	H59588	Hs.15233	ESTs	2	SS,
		AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MA	1.3	SS,
	113702	T97307		gb:ye53h05.s1 Soares fetal liver spleen	4.4	other

	440770 411140000		OUNDATE A LA L	4.0	-11	
	113759 AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	
	113777 BE266947	Hs.10590	zinc finger protein 313	13.4	other	
	113783 AL359588	Hs.7041	hypothetical protein DKFZp762B226	1.7	other	
_	113791 Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5	113808 W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	3.3	other	
	113811 BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
	113817 H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
	113826 AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
4.0	113834 T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10	113868 W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7	other	
	113870 AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1	other	
	113885 AW959486	Hs.21732	ESTs	6.6	other	
	113923 AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9	?	
	113989 W87544	Hs.268828	ESTs	1.2	other	
15	114022 Al539519	Hs.120969	Homo sapiens cDNA FLJ11562 fis, clone HE	5.4	other	
	114030 Al825386	Hs.164478	hypothetical protein FLJ21939 similar to	9.4	other	
	114060 AB029551	Hs.7910	RING1 and YY1 binding protein	1.8	other	
	114196 AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	1.5	other	
	114226 AB028968	Hs.7989	KIAA1045 protein	1.8	other	
20	114253 BE149866	Hs.14831	Homo sapiens, Similar to zinc finger pro	2.3	other	
	114262 AL117518	Hs.3686	KIAA0978 protein	1.4	TM	
	114275 AW515443.c	omp	Hs.306117	KIAA0:	306 protein 15.8 ·	other
	114292 Al815395	Hs.184641	fatty acid desaturase 2	1.9	TM	
	114309 AA332453	Hs.20824	CGI-85 protein	2.4	other	
25	114392 AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r	1.9	other	
	114407 BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (f	1.3	TM	
	114455 H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU S	5.6	other	
	114463 AL120247	Hs.40109	KIAA0872 protein	5.3	TM	
	114464 AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110	1.3	other	
30	114471 AA028074	Hs.104613	RP42 homolog	1.9	?	
	114480 BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	13.4	other	
	114671 AA766268	Hs.266273	hypothetical protein FLJ13346	2	other	
	114698 AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.6	other	
	114730 Al373544	Hs.331328	intermediate filament protein syncoilin	3.9	other	
35	114767 Al859865	Hs.154443	minichromosome maintenance deficient (S.	1.7	other	
	114774 AV656017	Hs.184325	CGI-76 protein	3.2	other	
	114798 AA159181	Hs.54900	serologically defined colon cancer antig	3.6	other	
	114860 AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.4	other	
	114895 AA236177	Hs.76591	KIAA0887 protein	7.2	other	
40	114896 BE539101	Hs.5324	hypothetical protein	1.3	other	
	114911 AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT H	1.5	other	
	114930 AA237022	Hs.188717	ESTs	2	SS,	
	114938 AA242834	Hs.58384	ESTs	2.9	other	
	114965 Al733881	Hs.72472	BMP-R1B	2.3	?	
45	115023 AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3	other	
	115038 AA252360	Hs.87968	toll-like receptor 9	1.6	other	
	115061 Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8	other	
	115117 Al670847	Hs.5324	hypothetical protein	1.5	other	
	115206 AW183695	Hs.186572	ESTs	2.5	other	
50	115221 AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	other	
	115239 BE251328	Hs.73291	hypothetical protein FLJ10881	1.3	TM	
	115242 Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
	115278 AK002163	Hs.301724	hypothetical protein FLJ11301	1.5	other	
	115285 AW972872	Hs.293736	ESTs	2.4	other	
55	115291 BE545072	Hs.122579	hypothetical protein FLJ10461	6.3	SS,	
	115400 Al215069	Hs.89113	ESTs	6.7	?	
	115468 AA314349	Hs.48499	tumor antigen SLP-8p	7.5	?	
	115471 AK001376	Hs.59346	hypothetical protein FLJ10514	1.4	TM	
	115479 AW301608	Hs.278188	ESTs, Moderately similar to I54374 gene	4.1	TM	
60	115496 AW247593	Hs.71819	eukaryotic translation initiation factor	16.3	other	
	115500 Y14443	Hs.88219	zinc finger protein 200	5	other	
	115553 AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5	other	
	115581 Al540842	Hs.61082	ESTs	6.2	other	
	115587 BE081342	Hs.283037	HSPC039 protein	2.9	other	
65	115590 AA399477	Hs.67896	7-60 protein	5.3	TM	
	115646 N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.8	?	
	115652 BE093589	Hs.38178	hypothetical protein FLJ23468	10.6	other	

	445000 4104000	11 000011	11 1 1 1400 40000 PM	40.7	T1.4
	115655 AL048269	Hs.288544	Homo sapiens, clone MGC:16063, mRNA, com	12.7	TM
	115663 Al138785	Hs.40507	ESTs	2	other
	115676 AA953006	Hs.88143	ESTs	3.1	other
	115690 AA625132	Hs.44159	hypothetical protein FLJ21615	1.7	TM
5	115693 AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.9	other
•	115715 BE395161	Hs.1390	proteasome (prosome, macropain) subunit,	1.7	other
	115734 AI950339	Hs.40782	ESTs	2.7	TM
					other
	115811 NM_015434	Hs.48604	DKFZP434B168 protein	2.1	
10	115823 Al732742	Hs.87440	ESTs	2.1	other
10	115837 Al675217	Hs.42761	ESTs	1.3	other
	115844 Al373062	Hs.332938	hypothetical protein MGC5370	4.4	other
	115866 AW062629	Hs.52081	KIAA0867 protein	7.3	other
	115875 N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2	other
	115941 Al867451	Hs.46679	hypothetical protein FLJ20739	5.5	other
15			•••	9.8	other
13	115968 AB037753	Hs.62767	KIAA1332 protein		4
	116003 BE275469	Hs.66493	Down syndrome critical region gene 5	1.4	other
	116011 AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN	2.4	other
	116108 AA770688	Hs.28777	H2A histone family, member L	1.8	other
	116134 BE243834	Hs.50441	CGI-04 protein	1.4	other
20	116189 N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
20	116195 AW821113	Hs.72402	ESTs	2.1	other
				1.7	other
	116238 AV660717	Hs.47144	DKFZP586N0819 protein		
	116246 AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7	other
	116262 Al936442	Hs.59838	hypothetical protein FLJ10808	1.8	?
25	116298 Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	1.9	other
	116318 AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
	116325 Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4	SS,
	116336 AL133033	Hs.4084	KIAA1025 protein	1.9	?
				1.5	other
20	116339 AK000290	Hs.44033	dipeptidyl peptidase 8		?
30	116350 AA497129	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.9	
	116358 Al149586	Hs.38125	interferon-induced protein 75, 52kD	1.9	?
	116365 N50174	Hs.46765	ESTs	6.1	other
	116368 N90466	Hs.71109	KIAA1229 protein	1.6	?
	116417 AW499664	Hs.12484	Human clone 23826 mRNA sequence	7.4	other
35	116436 AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1	other
55			putative helicase RUVBL	1.5	TM
	116462 AF218313	Hs.236828		2.1	TM
	116470 Al272141	Hs.83484	SRY (sex determining region Y)-box 4		
	116575 AA312572	Hs.6241	phosphoinositide-3-kinase, regulatory su	1.5	other
	116637 AK001043	Hs.92033	integrin-linked kinase-associated serine	2.7	other
40	116640 X89984	Hs.211563	B-cell CLL/lymphoma 7A	2.3	other
	116700 Al800202	Hs.317589	hypothetical protein MGC10765	1.4	other
	116705 AW074819	Hs.12313	hypothetical protein FLJ14566	3.4	other
	116732 AW152225	Hs.165909	ESTs, Weakly similar to I38022 hypotheti	2.9	other
		Hs.290830	ESTs	1.7	TM
15	116926 H73608			3.4	TM
45	117034 U72209	Hs.180324	YY1-associated factor 2		
	117132 Al393666	Hs.42315	p10-binding protein	5,2	?
	117247 N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Ho	5.5	TM
	117276 N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
	117284 AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT	2	other
50	117367 Al041793	Hs.42502	ESTs	2	other
30	117368 Al878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.1	?
				2.7	TM
	117382 AF150275	Hs.40173	ESTs		
	117412 N32536	Hs.42645	solute carrier family 16 (monocarboxylic	1.4	other
	117557 AF123050	Hs.44532	diubiquitin	3.4	TM
55	117588 N34895	Hs.44648	ESTs	3.4	?
	117745 BE294925	Hs.46680	. CGI-12 protein	3	SS,
	117754 AA121673	Hs.59757	zinc finger protein 281	1.9	other
	117879 N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	other
		Hs.332938	hypothetical protein MGC5370	6	?
60	117904 BE540675			1.7	other
60	117911 AL137379	Hs.47125	hypothetical protein FLJ13912		
	117933 Y10518	Hs.116470	hypothetical protein FLJ20048	1.7	other
	117983 AL110246	Hs.47367	KIAA1785 protein	5.4	other
	118078 N54321	Hs.47790	EST	5.2	other
	118301 AA453902	Hs.293264	ESTs	2.6	other
65	118429 AA243332	Hs.74649	cytochrome c oxidase subunit VIc	2.5	TM
	118472 AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1	other
	118488 AJ277275	Hs.50102	rapa-2 (rapa gene)	1.2	other
	110700 70411410		/1.mpm 30110)		

		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	1.5	other
		Al949952	Hs.49397	ESTs	7.4	?
		A1458020	Hs.293287	ESTS	2.5 1.2	other
5		AA332845 AB033113	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z KIAA1287 protein	2.1	TM TM
5		AA199686	Hs.50187	gb:zq75g09.r1 Stratagene hNT neuron (937	5.2	other
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	1.4	other
		Al668709	Hs.240722	ESTs, Moderately similar to ALU8_HUMAN A	3.6	other
		AF148713	Hs.125830	bladder cancer overexpressed protein	4.9	?
10		W24781	Hs.293798	KIAA1710 protein	1.7	TM
		AW453069	Hs.3657	activity-dependent neuroprotective prote	2.2	other
	119265	BE539706	Hs.285363	ESTs	1.4	?
	119279	N57568	Hs.48028	EST	25.1	other
	119298	NM_001241	Hs.155478	cyclin T2	1.6	?
15	119338	A1417240	Hs.320836	ESTs, Weakly similar to A47582 B-cell gr	1.3	other
		AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7	TM
		AI624342	Hs.170042	ESTs	2.4	other
		AI796730	Hs.55513	ESTs	2.1	other
20		W37933	11-04004	Empirically selected from AFFX single pr	1.9	other TM
20		AK000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp667I103 (fr	3.7 3	other
		AW675298	Hs.233694	hypothetical protein FLJ11350	1.4	other
		AA243837 W61019	Hs.57787 Hs.57811	ESTs ESTs	1.2	?
		AB032977	Hs.6298	KIAA1151 protein	1.8	TM
25		NM_016625	Hs.191381	hypothetical protein	3.1	other
23		BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum com	9.2	other
•		AJ223810	Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	TM
		AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	?
		AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT	2.7	TM
30		AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	2.6	other
	119966	AA703129	Hs.58963	ESTs	2.7	other
	120132	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
	120206	H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7	other
2.5		A1924294	Hs.173259	uncharacterized bone marrow protein BM03	1.2	other
35		AW131940	Hs.104030	ESTs	9.6	other
		AA177051		gb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens	4.7	other
		AA190577	11- 000000	gb:zp52g02.s1 Stratagene HeLa cell s3 93	2.1	other
		AW995911	Hs.299883	hypothetical protein FLJ23399	1.9 15.2	TM other
40		AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	5.6	?
40		AA195517 AA195651	Hs.191643 Hs.104106	ESTs ESTs	6.5	other
		AK000292	Hs.278732	hypothetical protein FLJ20285	16.1	other
		N85785	Hs.181165	eukaryotic translation elongation factor	3	other
		AW450669	Hs.45068	hypothetical protein DKFZp434I143	5.8	other
45		AA210722	Hs.104158	ESTs	4.6	SS,TM
		AW969481	Hs.55189	hypothetical protein	16.8	other
	120352	R06859	Hs.193172	ESTs, Weakly similar to 138022 hypotheti	5.1	other
	120356	AF000545	Hs.296433	putative purinergic receptor	28.1	TM
	120371	AA219305	Hs.104196	EST	12.4	?
50		AA228026	Hs.38774	ESTs	4.1	TM
		AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7	TM
		AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6	other
		AA232874	Hs.104245	ESTs ESTs, Moderately similar to ALU7_HUMAN A	3.2 21.7	other other
55		AW967985	Hs.325572	eukaryotic translation initiation factor	12.5	other
55		AA134006 AB023230	Hs.79306 Hs.96427	KIAA1013 protein	7.3	other
		AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (f	11.4	other
		AA236453	Hs.18978	Homo sapiens cDNA: FLJ22822 fis, clone K	1.9	other
		AI950087	110.10010	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	19.4	other
60		AA251973	Hs.269988	ESTs	5.5	?
00		AA253170	Hs.96473	EST	10.4	?
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapi	4	?
		BE047718	Hs.96545	ĔSTs	9.4	other
	120520	AA258601	Hs.161731	EST	2.4	other
65	120535	BE350244	Hs.96547	ESTs	2.5	?
		AA279160	Hs.111407	Homo sapiens, clone IMAGE:3613029, mRNA,	5.3	other
	120570	AA280679	Hs.271445	ESTs, Weakly similar to ALU1_HUMAN ALU S	14.4	?

		D=0.1.1000	11 001000	Thursday III	40.0	•
		BE244830	Hs.284228	ZNF135-like protein	10.2	?
		AW372799	Hs.125790	leucine-rich repeat-containing 2	2.2	?
		AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.6	other
_		AW965339	Hs.111471	ESTs	2.5	other
5		AW407987	Hs.173518	M-phase phosphoprotein homolog	52	other
		AA286942		gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens	2.4	other
		AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
		AW063659	Hs.191649	ESTs	2.2	other
10		AW969638	Hs.112318	6.2 kd protein	2.2	TM
10		BE536739	Hs.109909	ESTs	1.9	TM
		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
	120696	Al821539	Hs.97249	ESTs	2.5	other
	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
	120718	AA292747	Hs.97296	ESTs	2.9	other
15	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
	120774	AI608909	Hs.193985	ESTs	7.9	other
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7	TM
	120809	AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.5	other
	120938	AA386260	Hs.104632	EST	4.5	?
20	120977	AA398155	Hs.97600	ESTs	4.5	other
		BE262951	Hs.99052	ESTs	5.6	other
		Al219896	Hs.97592	ESTs	1.3	other
		AA398360	Hs.97608	EST	3.2	other
		Al439713	Hs.165295	ESTs	3.6	other
25		AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.5	other
		AA363307	Hs.97032	ESTs	3.8	other
		AL121523	Hs.97774	ESTs	1.7	TM
		Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.	2.9	other
		AA403008	Hs.301927	c6.1A	1.9	other
30		AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PL	3.5	other
50		AA406137	Hs.98019	EST	6.1	?
		AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.5	other
		AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, com	7.1	other
		AW971063	Hs.292882	ESTs	1.8	other
35		H58306	Hs.15165	retinoic acid induced 14	10.5	other
55		W07404	Hs.144502	hypothetical protein FLJ22055	3.5	TM
		AA442224	Hs.97900	ESTs	14.4	other
		AA494172	Hs.194417	ESTs	13.1	other
		AA402515	Hs.97887	ESTs	28	other
40				ESTs	6.3	other
40		AA416653	Hs.181510	gb:zt69b02.s1 Soares_testis_NHT Homo sap	2.7	SS,
		AA412112	Un 00142	EST	7.5	?
		AA412477	Hs.98142	gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.8	other
		AA412497	Un 00000	EST	3.5	?
45		AA411970 AA416568	Hs.98096	qb:zu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
43			U- 00740		4	other
		AD001528	Hs.89718	spermine synthase	2.2	other
		AA626010	Hs.98247	ESTS	4.3	TM
		AA416931	Hs.126065	ESTs	7.9	
50		AA421537	Hs.178072	Homo sapiens mRNA; cDNA DKFZp434B1023 (f		other
50		AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	2 4.7	other ?
		AV660305	Hs.110286	ESTs .		
		U55184	Hs.154145	hypothetical protein FLJ11585	12.7	other
		AA419225	Hs.98269	Homo sapiens cDNA FLJ11953 fis, clone HE	8.3	?
<i></i>		Al949597	Hs.98325	ESTs	1.8	TM
55		AA421041	Hs.180744	ESTs	4.1	TM
		AA398784	Hs.97514	ESTs	7.1	SS,
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5	other
	121773	AB033022	Hs.158654	KIAA1196 protein	8	other
<b>C</b> C		AA421773	Hs.161008	ESTs	1.7	other
60	121776	AA292579	Hs.125133	hypothetical protein FLJ22501	6.7	other
	121786	AI810774	Hs.98376	ESTs	10.5	other
		AW340797	Hs.98434	ESTs	5.9	other
	121836	AA328348	Hs.218289	ESTs	3.9	other
~~	121839	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	. 5	other
65	121842	AF027406	Hs.104865	serine/threonine kinase 23	2.7	?
	121847	AA446628	Hs.2799	cartilage linking protein 1	2.3	other
	121871	AW972668	Hs.293044	ESTs	2.9	TM

	10				_	
		AA426376	Hs.98459	ESTs	5 .	. other
		AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
		AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
_		AA428647	Hs.98611	EST	2.3	other ·
5		AA298760	Hs.180191	hypothetical protein FLJ14904	3.4	other
		Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA,	11.4	other
	121995	AA210863	Hs.3532	nemo-like kinase	3.8	?
	121999	AA430211	Hs.98668	EST	6.5	other
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone A	2.2	other
10	122013	AA431085	Hs.98706	ESTs ·	6.6	other
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU S	13.1	other
	122050	Al453076	Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
	122060	AA431738	Hs.98750	EST	13.1	?
	122114	AW161023	Hs.104921	ESTs	1.5	other
15	122188	AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sap	3.4	other
	122204	AA435936	Hs.98842	EST	5.6	other
	122246	AA329550	Hs.29417	HCF-binding transcription factor Zhangfe	5.2	other
	122257	AA436819	Hs.98899	ESTs	5.6	other
		AA441801	Hs.104947	ESTs	5.8	other
20		AW601969	Hs.99010	hypothetical protein FLJ22263 similar to	2	other
		AA443794	Hs.98390	ESTs	7.4	SS,TM
		AA443985	Hs.303222	ESTs	12.2	?
		AA868555	Hs.178222	ESTs	5	?
		AA446008	Hs.336677	EST	7.8	?
25		AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5	?
		AA446572	Hs.303223	EST	2.8	TM
		AA446869	Hs.119316	ESTs	7.4	other
		AA446918	Hs.99088	EST	1.9	other
		AA446966	Hs.99090	ESTs, Moderately similar to similar to K	6.9	?
30		AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
50		AA447603	Hs.99123	EST	1.8	TM
		AA447626	Hs.99127	EST	3.5	other
		Al266159	Hs.104980	ESTs	1.5	other
		AW418788	Hs.99148	ESTs, Weakly similar to S43569 R01H10.6	9.7	other
35		AA448158	Hs.99152	EST	4.9	other
55		AA448349	Hs.238151	EST	6.2	?
		AA448417	Hs.104990	ESTs	5.5	other
		AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
		AA449232	Hs.99195	ESTs	11.2	?
40		AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1	other
-10		AA779725	Hs.164589	ESTs	2.5	SS,
		AA194055	Hs.293858	ESTs	1.9	other
		AA452578	Hs.262907	ESTs	9.5	other
		AA452601	Hs.99287	EST	11	?
45		AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PL	3.4	other
-13		AB040893	Hs.6968	KIAA1460 protein	2	other
		Al028173	Hs.99329	ESTs	1.7	?
		AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	?
		AA411925	Hs.301960	ESTs	4.7	other
50		AA453518	Hs.98023	ESTs	61.5	other
50		AA453630	Hs.99339	EST	10.7	?
		AA453638	Hs.161873	ESTs	107.3	?
	122617	Al681535	Hs.148135	serine/threonine kinase 33	121.4	other
		AA453641	110.110100	gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
55	122672	AA453987	Hs.144802	ESTs	5.6	other
55		AA456859	Hs.178358	ESTs	8.5	SS,
	122717	Al376875	Hs.105119	ESTs	10.4	other
	122702	AW204530	Hs.99500	ESTs	81.8	?
	122023	AA461492	Hs.99545	Homo sapiens cDNA FLJ10658 fis, clone NT	3.7	?
60		AA460581	Hs.290996	ESTs	4.6	other
UU	122000	AA461509	Hs.293565	ESTs, Weakly similar to putative p150 [H	2.7	TM
	122037	AA460584	Hs.334386	ESTs	75.3	other
	122000	AA600235	Hs.9625	NIMA (never in mitosis gene a)-related k	7.8	other
		Al929374	Hs.75367	Src-like-adapter	5.8	other
65	122000	AA335721	Hs.119394	ESTs	1.3	other
05	122001	BE539656	Hs.283705	ESTs	4.2	other
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3	other
	122000	000210		amina minas a la biarria. Arania imina		

						•
		AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone C	9.9	?
	122872	AW081394	Hs.97103	ESTs	5.3	other
	122879	AA769410	Hs.128654	ESTs	13.9	other
	122907	AA470074	Hs.169896	ESTs	11.5	other
5		AA470140	Hs.229170	EST	1.7	TM
•		AA478951	Hs.105629	ESTs	5	other
		AW968324	Hs.17384	ESTs	15.4	other
					2.8	other
		AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	8.7	other
10		AL359571	Hs.44054	ninein (GSK3B interacting protein)		
10		Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein	8.8	other
	123082	AA485360	Hs.105661	ESTs	4	?
	123088	Al343652	Hs.105667	ESTs	3.8	other
	123110	AA486256	Hs.193510	EST	7.4	other
	123114	BE304942	Hs.265848	myomegalin	2.8	?
15		T52027	Hs.271795	ESTs. Weakly similar to 138022 hypotheti	2.4	other
		AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6	TM
		AW451999	Hs.194024	ESTs	5.2	other
				ESTs	23.8	TM
		A1734179	Hs.105676			other
20		AW601773	Hs.270259	ESTs	5.2	
20		AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL	9.3	?
	123315	AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
	123369	AA504757	Hs.105738	ESTs	7	other
	123394	AA731404	Hs.105510	ESTs	3.7	other
	123433	AW450922	Hs.112478	ESTs	3.8	other
25		AA599042	Hs.112503	EST	7.4	other
		AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other
		AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	?
			Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	1.7	other
		BE439553			1.6	other
20		N95059	Hs.55098	ESTS		
30		BE019072	Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
	123508	AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamm	2.2	TM
	123615	AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	7.9	other
	123619	AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo saplens	2.8	other
	123658	AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sap	1.7	?
35		Al269609	Hs.105187	kinesin protein 9 gene	5.7	?
55		NM_013241	Hs.95231	FH1/FH2 domain-containing protein	10	other
		AA609891	Hs.112777	EST	5.2	other
			Hs.234961	Huntingtin interacting protein E	30.6	TM
		AA609955			2.1	other
40		AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-a		
40		AA620586		gb:ae60g05.s1 Stratagene lung carcinoma	2.7	other
		AB012922	Hs.173043	metastasis-associated 1-like 1	6.3	?
		AJ272267	Hs.146178	choline dehydrogenase	4.4	other
	124001	L42542	Hs.75447	ralA binding protein 1	7.1	?
	124006	AI147155	Hs.270016	ESTs	8.3	SS,
45	124070	AI950314	Hs.154762	HIV-1 rev binding protein 2	3.8	other
	124074	H05635	Hs.294030	topoisomerase-related function protein 4	1.2	SS,
		BE463721	Hs.97101	putative G protein-coupled receptor	3.2	?
		AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC0	5.7	other
	. —	AA640891	Hs.102406	ESTs	3.1	TM
50		D87454	Hs.192966	KIAA0265 protein	3.5	other
50			113.132300	gb:ag49a10.x1 Stanley Frontal NB pool 2	57.1	?
		AI267847	11- 7505			
	124390	AA317338	Hs.7535	COBW-like protein	2.8	other
		AF155099	Hs.279780 ·	NY-REN-18 antigen	7.1	other
		N34059		gb:yv28h09.s1 Soares fetal liver spleen	3.3	other
55	124428	H13540	Hs.82202	ribosomal protein L17	2.9	other
	124440	AA532519	Hs.129043	Human DNA sequence from clone 989H11 on	7.9	other
		R10084	Hs.113319	kinesin heavy chain member 2	2.6	TM
	124482	N53935		gb:yv59d09.s1 Soares fetal liver spleen	7.9	TM
		H79433	Hs.268997	ESTs	7.8	other
60	12/15/15	AA669097	Hs.109370	ESTs	3.3	other
00		N71076	Hs.102800	ESTs, Weakly similar to neuronal thread	4.6	?
					3.2	other
	124031	NM_014053	Hs.270594	FLVCR protein	5.8	other
	124634	A1765123	Hs.143671	Homo sapiens cDNA FLJ13533 fis, clone PL		
<i>~</i>		AA160474	Hs.75798	hypothetical protein	9.3	other
65		AW968856	Hs.278569	sorting nexin 17	3.5	other
	124649	N92593	Hs.313054	ESTs	6.1	TM
	124661	R48170	Hs.78436	EphB1	5.6	other

	124602 44204664	Un 110979	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	TM
	124683 AA381661	Hs.119878	ESTs	5.7	other
	124712 R09166	Hs.191148		11.3	?
	124735 R22952	Hs.268685	ESTs		
_	124761 AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9	other
5	124768 AW368528	Hs.100855	ESTs	8.3	other
	124775 R41772	Hs.100878	ESTs	4.9	other
	124777 R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.8	other
	124788 R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1	other
	124809 AL355722	Hs.106875	Homo sapiens EST from clone 35214, full	4.2	other
10	124811 R46068	Hs.288912	hypothetical protein FLJ22604	14.2	other
	124812 R47948	Hs.188732	ESTs	7.9	other
	124822 AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6	other
	124825 AA501669	Hs.336693	ESTs	2.3	SS,TM
	124833 AW975868	Hs.294100	ESTs	2.7	SS.TM
15	124857 R63652	Hs.137190	ESTs	2.3	other
13	124860 R65763	Hs.101477	EST	23.9	?
			bromodomain-containing 1	2	other
	124863 Al382555	Hs.127950		4.4	SS,
	124876 AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	2.7	other
20	124878 BE397530	Hs.288057	hypothetical protein FLJ22242		
20	124902 H37941	Hs.101883	ESTs	5.7	other
	124903 AW296713	Hs.221441	ESTs	32.4	other
	124930 Al076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8	other
	124942 R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1	other
	124958 AI078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	1.9	other
25	124980 T40841	Hs.98681	ESTs	4.5	?
	125002 T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
	125047 T79815	Hs.279793	ESTs	5	?
	125051 T79956	Hs.100588	EST	135.3	?
	125056 T81310	Hs.100592	ESTs	5.4	other
30	125101 Al472068	Hs.286236	KIAA1856 protein	5.6	other
50	125113 T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN !!!!	1.8	other
	125115 T97341	110.002210	gb:ye57e05.s1 Soares fetal liver spleen	9.6	?
	125125 Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14	1.5	TM
		113.240707	Empirically selected from AFFX single pr	1.7	?
35	125147 W38150	Un 144222	EST	10.7	?
33	125161 W44657	Hs.144232		1.3	other
	125249 AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN !	9.4	other
	125255 AF098162	Hs.118631	timeless (Drosophila) homolog	1.5	
	125279 AW401809	Hs.4779	KIAA1150 protein		?
40	125280 Al123705	Hs.106932	ESTs	8.1	?
40	125298 AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone H	1.5	other
	125660 AW292171	Hs.23978	scaffold attachment factor B	5.9	other
	125827 NM_003403	Hs.97496	YY1 transcription factor	1.2	?
	125891 U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.5	?
	126005 AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (sur	14.3	?
45	126202 AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.5	SS,
	126695 AA643322	Hs.172028	a disintegrin and metalloproteinase doma	9.1	SS,TM
	127050 AW411066	Hs.274351	CGI-89 protein	17	other
	127274 AW966158	Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
	128355 AW293012	Hs.161623	ESTs	7.4	SS,
50	128493 D87466	Hs.240112	KIAA0276 protein	3.1	TM
50	128522 BE173977	Hs.10098	putative nucleolar RNA helicase	9.4	other
	128527 AA504583	Hs.101047	transcription factor 3 (E2A immunoglobul	1.5	other
	128528 R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
			short-chain alcohol dehydrogenase family	12.1	TM
E E	128595 U31875	Hs.272499	Rho GTPase activating protein 8	2.4	?
55	128599 NM_015366	Hs.102336	GIOT-3 for gonadotropin inducible transc	1.3	other
	128604 Al879099	Hs.102397		7.2	other
	128608 BE267994	Hs.102419	zinc finger protein		
	128625 AB037841	Hs.102652	hypothetical protein ASH1	1.3	other
	128629 AL096748	Hs.102708	DKFZP434A043 protein	3.2	other
60	128639 AW582962	Hs.102897	CGI-47 protein	2	TM
	128656 AA458542	Hs.10326	coatomer protein complex, subunit epsilo	1.4	other
	128658 BE397354	Hs.324830	diptheria toxin resistance protein requi	2.5	other
	128670 AA975486	Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691 W27939	Hs.103834	hypothetical protein MGC5576	7.8	?
65	128696 BE081143	Hs.225977	nuclear receptor coactivator 3	3.8	other
	128700 Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714 T85231	Hs.179661	tubulin, beta 5	7.8	other

	100717	AVODATEA	Un 404000	hunothelical protein El 110702	5.5	other
		AK001564	Hs.104222	hypothetical protein FLJ10702	5.5	
		BE147740	Hs.104558	ESTs, Moderately similar to 138022 hypot	2.7	TM
		AF292100	Hs.104613	RP42 homolog	2.8	TM
_		AA307211	Hs.251531	proteasome (prosome, macropain) subunit,	4.5	?
5		Al470163	Hs.323342	actin related protein 2/3 complex, subun	2.2	other
	128747	AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
	128772	BE302796	Hs.105097	thymidine kinase 1, soluble	5.4	other
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9	TM
	128797	NM_002975	Hs.105927	stem cell growth factor; lymphocyte secr	13.3	other
10		AW630942	Hs.106061	RD RNA-binding protein	2.6	other
		AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
		BE281170	Hs.106357	valosin-containing protein	6	other
		AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	1.6	SS,
		BE159181	Hs.168232	hypothetical protein FLJ13855	2.3	other
15		AF189723		ATPase, Ca++ transporting, type 2C, memb	1.5	?
IJ			Hs.106778		4.8	other
	_	R57988	Hs.10706	epithelial protein lost in neoplasm beta		other
		AA622037	Hs.166468	programmed cell death 5	1.4	
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.9	other
20		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	7.3	?
20		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	2.5	other
	128959	Al580127	Hs.107381	hypothetical protein FLJ11200	1.3	other
	128965	AW150697	Hs.107418	ESTs	1.4	?
	128970	Al375672	Hs.165028	ESTs	1.3	other
	128975	BE560779	Hs.284233	NICE-5 protein	14	other
25		AW271217	Hs.281434	Homo sapiens cDNA FLJ14028 fis, clone HE	1.6	TM
		Al816224	Hs.107747	DKFZP566C243 protein	1.9	other
		AI950087		gb:wg05c02.x1 NCI_CGAP_Kid12 Homo sapien	2.9	other
		AL044675	Hs.173081	KIAA0530 protein	3.8	other
		R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4	other
30		AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti	5	other
50					2.1	other
	_	Al351010	Hs.102267	lysosomal	17.1	other
		AA744610	Hs.194431	palladin		
		L12350	Hs.108623	thrombospondin 2	2.7	other
25		AA463189	Hs.288906	WW Domain-Containing Gene	20.9	TM
35		BE243933	Hs.108642	zinc finger protein 22 (KOX 15)	3	other
		AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR	5.8	TM
	129136	W93048	Hs.250723	hypothetical protein MGC2747	6	other
	129149	AA356620	Hs.108947	KIAA0050 gene product	6.4	TM
	129172	AW162916	Hs.241576	hypothetical protein PRO2577	1.8	TM
40	129192	AA286914	Hs.183299	ESTs	2.1	?
	129194	AA150797	Hs.109276	latexin protein	3.3	SS,TM
	129198	N57532	Hs.109315	KIAA1415 protein	5.9	other
		A1934365	Hs.109439	osteoglycin (osteoinductive factor, mime	8.1	other
		U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9	other
45		AF013758	Hs.109643	polyadenylate binding protein-interactin	3.3	?
		AA252468	Hs.1098	DKFZp434J1813 protein	2.6	SS,TM
		AI961727	Hs.109804	H1 histone family, member X	7.4	other
		W26392	Hs.110080	ESTs, Weakly similar to S13495 pregnancy	9.6	other
		AI051967		ESTs	1.2	other
50			Hs.110122	Homo sapiens cDNA FLJ11311 fis, clone PL	5.2	other
50		AA287239	Hs.5518		4.7	SS,
		H75334	Hs.11050	F-box only protein 9		
		BE614192	Hs.279869	melanoma-associated antigen recognised b	7.7	TM
		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7	TM
	129366	BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6	SS,
55		AI686379	Hs.110796	SAR1 protein	1.4	TM
	129372	NM_016039	Hs.110803	CGI-99 protein	2	other
	129403	AF149785	Hs.111126	pituitary tumor-transforming 1 interacti	7.5	other
	129404	A1267700	Hs.317584	ESTs	5.1	other
	129423	AA204686	Hs.234149	hypothetical protein FLJ20647	10.2	other
60		AA188185	Hs.289043	spindlin	6.8	other
0.0		AW843633	Hs.306163	hypothetical protein AL110115	7.1	SS,
	129515	AF255303	Hs.112227	membrane-associated nucleic acid binding	2.5	other
	129527	AA769221	Hs.270847	delta-tubulin	3.2	other
		W01296	Hs.11360	hypothetical protein FLJ14784	7.5	other
65	120560	AA317841	Hs.7845	hypothetical protein MGC2752	6.8	other
05	120570	Al923097	Hs.11441	chromosome 1 open reading frame 8	2.1	other
	120010	F08282	Hs.278428	progestin induced protein	1.6	other
	129010	1 00202	13.210420	programmingood protom		Guioi

	400					
		H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
	129588	BE408300	Hs.301862	postmeiotic segregation increased 2-like	1.4	TM
	129591	N57423	Hs.179898	HSPC055 protein	7.4	other
	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5		AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
•		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	2.2	other
					3.3	other
		AD000092	Hs.16488	calreticulin	13.4	
		NM_015556	Hs.172180	KIAA0440 protein		other
10		U03749		gb:Human chromogranin A (CHGA) gene, pro	14.1	?
10	129689	AW748482	Hs.77873	B7 homolog 3	2.6	other
	129702	Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	7.5	TM
	129720	AA156214	Hs.12152	APMCF1 protein	2	other
		NM_001415	Hs.211539	eukaryotic translation initiation factor	1.7	TM
		AK001676	Hs.12457	hypothetical protein FLJ10814	1.8	other
15		AA394090		Homo sapiens clone 23870 mRNA sequence	5.5	TM
13			Hs.12460	•	1.7	?
		AF052112	Hs.12540	lysosomal		-
		AB023148	Hs.173373	KIAA0931 protein	1.2	other
	129815	BE565817	Hs.26498	hypothetical protein FLJ21657	3.1	other
	129840	NM_006590	Hs.12820	SnRNP assembly defective 1 homolog	1.8	other
20	129861	AL049999	Hs.85963	DKFZP564M182 protein	2.3	other
		AI393237	Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
		Al222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	ΤM
		BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8	other
					2.5	
25		AA412195	Hs.13740	ESTs	-	other
25		AW753185	Hs.180628	dynamin 1-like	1.8	?
	129983	U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3	other
	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6	other
	130081	AA287325	Hs.14713	ESTs	4.1	other
		S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30		AL046962	Hs.14845	forkhead box O3A	2.8	other
50		AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
					2.3	other
		X53002	Hs.149846	integrin, beta 5		
		AA916785	Hs.180610	splicing factor proline/glutamine rich (	3	other
	130128	L76937	Hs.150477	Werner syndrome	1.8	other
35	130135	AA311426	Hs.21635	tubulin, gamma 1	6.1	other
	130211	NM_003358	Hs.23703	ESTs, Moderately similar to CEGT_HUMAN C	1.6	other
		D80001	Hs.152629	KIAA0179 protein	1.3	other
		R85367	Hs.51957	splicing factor, arginine/serine-rich 2,	2	other
		AL035588	Hs.153203	MyoD family inhibitor	3.2	other
40				synovial sarcoma, translocated to X chro	5.4	?
40		X79201	Hs.153221			
		D81983	Hs.322852	GAS2-related on chromosome 22	4.9	other
	130263	NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	1.4	other
	130287	AA479005	Hs.154036	tumor suppressing subtransferable candid	2.6	other
	130310	AB011121	Hs.154248	amyotrophic lateral sclerosis 2 (juvenil	6.3	other
45	130353	Z19084	Hs.172210	MUF1 protein	6.2	other
		AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4	other
		AJ224442	Hs.155020	putative methyltransferase	3.5	TM
		NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	8.5	other
				hypothetical protein FLJ10849	1.4	other
50		AL135301	Hs.8768			?
50		AI077464	Hs.5011	RNA binding motif protein 9	3.3	
	130393	N89487	Hs.155291	KIAA0005 gene product	1.8	other
		AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	2.3	other
	130409	NM_001197	Hs.155419	BCL2-interacting killer (apoptosis-induc	2.7	TM
55	130419	AF037448	Hs.155489	NS1-associated protein 1	1.8	other
55	130///1	U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
		BE513202	Hs.15589	PPAR binding protein	4	TM
				N-acetyltransferase 1 (arylamine N-acety	33.6	?
		D90041	Hs.155956			
		BE245851	Hs.180779	H2B histone family, member B	5	other
60	130487	U49844	Hs.77613	ataxia telangiectasia and Rad3 related	4.4	other
	130498	L38951	Hs.180446	karyopherin (importin) beta 1	1.6	SS,TM
	130503	BE208491	Hs.295112	KIAA0618 gene product	16.1	other
	130511	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1	other
		AW876523	Hs.15929	hypothetical protein FLJ12910	2.1	other
65		AA321238	Hs.4310	eukaryotic translation initiation factor	1.5	other
05	130544	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4	?
	130555	Al907018		Empirically selected from AFFX single pr	4.8	other
	120220	AISO/ UTO	Hs.15977	Embinosity selected from Vi 1 V strikle bi	7.0	outer

	120507	A A 202000	1 to 4000	raplication protain A2 (14(D)	8	other
		AA383092	Hs.1608	replication protein A3 (14kD)	3.4	
		AA232119	Hs.16085	putative G-protein coupled receptor		other
		AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2	other
_		AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4	other
5		AA609738	Hs.16525	ESTs	1.5	TM
	130614	AI354355	Hs.16697	down-regulator of transcription 1, TBP-b	1.3	other
	130617	M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1	TM
	130618	AA383439	Hs.16758	Spir-1 protein	15.9	other
	130667	BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9	other
10		AL048842	Hs.194019	attractin	1.5	other
		AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other
		AA652501	Hs.13561	hypothetical protein MGC4692	5	other
		R68537	Hs.17962	ESTs	2	other
		AJ271881	Hs.279762	bromodomain-containing 7	1.8	TM
15				DNA segment on chromosome X (unique) 987	2	TM
13		AI348274	Hs.18212		3.8	?
		AB007920	Hs.18586	KIAA0451 gene product		?
		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.2	
		AF052105	Hs.18879	chromosome 12 open reading frame	1.4	other
••		AL036067	Hs.18925	protein x 0001	5.7	other
20	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
	130789	AK000355	Hs.8899	sirtuin (silent mating type information	1.6	other
	130836	J05068	Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS,
	130841	AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, clone AD	2.8	other
	130843	AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 prote	1.5	other
25		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.5	other
		AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7	other
		NM_016578	Hs.20509	HBV pX associated protein-8	1.9	other
		NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
		BE514434	Hs.20830	kinesin-like 2	2.1	TM
30		AL120837	Hs.20993	high-glucose-regulated protein 8	2.5	other
50				sphingosine-1-phosphate lyase 1	1.7	other
		AB033078	Hs.186613		1.8	other
		BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe		
		N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture	2.3	TM
25		BE382657	Hs.21486	signal transducer and activator of trans	5.4	other
35		N39842	Hs.301444	KIAA1673	2.2	SS,
	130993	T97401	Hs.21929	ESTs	1.6	other
	131005	AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6	?
	131028	A1879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP),	1.2	other
	131042	Al826288	Hs.171637	hypothetical protein MGC2628	1.6	other
40	131046	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4	?
	131060	AA194422	Hs.22564	myosin VI	5.1	other
		N53344	Hs.22607	ESTs	7.1	other
		AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	2.1	TM
		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7.1	other
45		NM_006540	Hs.29131	nuclear receptor coactivator 2	1.9	?
1.5		BE280074	Hs.23960	cyclin B1	5.8	?
		AW138839	Hs.24210	ESTs	2	other
		AA885699	Hs.24332	CGI-26 protein	7.1	TM
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.6	?
50				zinc finger protein 281	2.9	other
20		N47468	Hs.59757	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
		D89053	Hs.268012			
	131243	AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	?
		AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM
		AL043100	Hs.326190	fatty acid amide hydrolase	5.6	other
55		AA251716	Hs.25227	ESTs	5.8	other
	131283	X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3	other
	131305	AV656017	Hs.184325	CGI-76 protein	5	?
	131320	AA505691	Hs.145696	splicing factor (CC1.3)	1.8	TM
	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
60		AW293165	Hs.143134	ESTs	5.4	other
00		BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3	other
		BE259110	Hs.279836	HSPC166 protein	2.2	other
		NM_012247	Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human		2
		AL046302	Hs.26750	hypothetical protein FLJ21908	1.4	other
65		BE297567	Hs.27047	hypothetical protein FLJ20392	1.7	other
05	121/175	AA992841	Hs.27263	KIAA1458 protein	2	other
		AV661958	Hs.8207	GK001 protein	2.6	other
	191901	WA00 1900	110.0201	Oraco i protoni	2.0	54101

	404544	4.4700450	11. 07005	1)		- 11
		AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fls, clone C	2	other
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
	131532	BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
	131543	AW966881	Hs.41639	programmed cell death 2	2.2	other
5	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
		NM 003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5	other
10		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10		R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3	other
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	2.2	TM
	131643	AW410601	Hs.30026	HSPC182 protein	3	other
	131653	AW960597	Hs.30164	ESTs	1.3	other
		Al218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracii-DNA glycosylase 2	2.8	other
13		BE559681	Hs.30736	KIAA0124 protein	5.6	?
						?
		AA642831	Hs.31016	putative DNA binding protein	2.9	
		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
• •	131737	AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20	131763	A1878932	Hs.317	topoisomerase (DNA) I	3.4	other
	131772	AA382590	Hs.170980	KIAA0948 protein	25.5	other
	131787	D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8	TM
		BE501849	Hs.32317	high-mobility group 20B	1.5	other
25						
23		X86098	Hs.301449	adenovirus 5 E1A binding protein	4.2	other
		U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
	131824	U28838	Hs.32935	TATA box binding protein (TBP)-associate	3.5	other
	131850	Al251317	Hs.33184	ESTs	5.2	TM
	131878	AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30	131885	BE502341	Hs.3402	ESTs	13.7	other
•		AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
					11.3	other
•		AA179298	Hs.3439	stomatin-like 2		
25		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTs	5.2	TM
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	other
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
	131941	BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
	131950	AA355113	Hs.35380	x 001 protein	1.5	?
40		AK000046	Hs.267448	hypothetical protein FLJ20039	2.3	other
		W79283	Hs.35962	ESTs	1.4	other
		BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
						TM
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	
4 ~		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
	132019	H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, p	3.3	TM
	132062	BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
	132084	NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
		BE171921	Hs.3991	ESTs	1.5	other
50		AV646076	Hs.39959	ESTs	5.8	TM
50		AW960474	Hs.40289	ESTs	1.7	other
					3.4	other
		AA857025	Hs.8878	kinesin-like 1		
		NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
		R42432	Hs.4212	ESTs	2.2	other
55	132207	BE206939	Hs.42287	E2F transcription factor 6	1.5	other
	132235	AV658411	Hs.42656	KIAA1681 protein	5.7	other
	132252	A1566004	Hs.141269	Homo sapiens cDNA: FLJ21550 fis, clone C	2.1	other
		AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
		AA227710	Hs.43658	DKFZP586L151 protein	10	other
60				hypothetical protein FLJ13089	2	other
60		AA653507	Hs.285711		9.2	other
		N36110	Hs.305971	solute carrier family 2 (facilitated glu		
		AB023191	Hs.44131	KIAA0974 protein	2	other
	132298	NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
		AW405882	Hs.44205	cortistatin	3.8	other
65	132325	N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
	132370	AW572805	Hs.46645	ESTs	28.3	?
		AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other
			-	÷ •		

	400070		11 40004		0	2
		Al279892	Hs.46801	sorting nexin 14	2	?
		AA312135	Hs.46967	HSPCO34 protein	6.1	?
	132393	AL135094	Hs.47334	hypothetical protein FLJ14495	1.7	other
_	132450	AA100012	Hs.48827	hypothetical protein FLJ12085	8.6	other
5	132452	AW973521	Hs.247324	mitochondrial ribosomal protein S14	5.3	other
	132456	AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.5	other
	132470	AI224456	Hs.4934	H.sapiens polyA site DNA	2	other
	132484		Hs.119007	RAB4, member RAS oncogene family	2,9	SS,
		AW885606	Hs.5064	ESTs	2.2	other
10		AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	1.7	other
10					7.2	TM
		AA454132	Hs.5080	mitochondrial ribosomal protein L16		
		BE388673	Hs.5086	hypothetical protein MGC10433	2.2	SS,
	132543	BE568452	Hs.5101	protein regulator of cytokinesis 1	2.2	other
	132574	AW631437	Hs.5184	TH1 drosophila homolog	14	?
15	132596	AK001484	Hs.5298	CGI-45 protein	1.9	other
	132611	AA345547	Hs.53263	hypothetical protein FLJ13287	2.6	TM
	132612		Hs.5327	PRO1914 protein	2	other
		BE262677	Hs.283558	hypothetical protein PRO1855	3.1	other
		Al796870	Hs.54277	DNA segment on chromosome X (unique) 992	12.4	TM
20					2.8	SS,
20		AB018319	Hs.5460	KIAA0776 protein	3	other
		AW191962	Hs.249239	collagen, type VIII, alpha 2		
		F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	1.8	other
	132718	NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7	other
	132724	AI142265	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	TM
25	132731	Al189075	Hs.301872	hypothetical protein MGC4840	5.9	other
	132744	AA010233	Hs.55921	glutamyl-prolyl-tRNA synthetase	8.7	other
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6	other
		Y10275	Hs.56407	phosphoserine phosphatase	2.8	TM
		AA459713	Hs.295901	KIAA0493 protein	14.6	other
30				GDP dissociation inhibitor 2	1.7	other
30		AI142133	Hs.56845		2.5	other
		AI026701	Hs.5716	KIAA0310 gene product		
		U07418	Hs.57301	mutL (E. coli) homolog 1 (colon cancer,	1.4	other
	132810	AB007944	Hs.5737	KIAA0475 gene product	4.3	SS,
	132813	BE313625	Hs.57435	solute carrier family 11 (proton-coupled	2.8	other
35	132815	AI815189	Hs.57475	sex comb on midleg homolog 1	1.6	other
		N27852	Hs.57553	tousled-like kinase 2	1.4	other
		AJ251595	Hs.169610	CD44 antigen (homing function and Indian	5.4	other
		U78525	Hs.57783	eukaryotic translation initiation factor	6.1	?
			Hs.279771	Homo sapiens clone PP1596 unknown mRNA	7.2	other
40		NM_016154			2.9	other
40		F12200	Hs.5811	chromosome 21 open reading frame 59		other
		U09716	Hs.287912	lectin, mannose-binding, 1	6.1	
		AW963217	Hs.203961	ESTs, Moderately similar to AF116721 89	1.8	other
	132873	AW007683	Hs.58598	KIAA1266 protein	2.2	other
	132875	NM_004850	Hs.58617	Rho-associated, coiled-coil containing p	5	TM
45	132891	BE267143	Hs.59271	U2(RNU2) small nuclear RNA auxillary fac	2.7	?
	132897	AW503667	Hs.59545	ring finger protein 15	5.4	?
		Al936442	Hs.59838	hypothetical protein FLJ10808	3.2	other
		AW732760	Hs.167578	Homo sapiens cDNA FLJ11095 fis, clone PL	1.4	other
		W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3	other
50		T79136		Homo sapiens mRNA for KIAA1724 protein,	10.3	other
50			Hs.127243		2.1	SS,
		AA554458	Hs.197751	KIAA0666 protein		other
		AI658580	Hs.61426	Homo sapiens mesenchymal stem cell prote	1.3	
		AA576635	Hs.6153	CGI-48 protein	4.9	other
	132972	AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.6	TM
55	132973	AA035446	Hs.323277	ESTs	13.1	other
	132977	AA093322	Hs.301404	RNA binding motif protein 3	1.3	other
	132980	AA040696	Hs,62016	ESTs	2.3	?
		AA112748	Hs.279905	clone HQ0310 PRO0310p1	17.1	other
		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	1.9	other
60		AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	5	TM
UU				PRO0149 protein	6.1	other
		AW500374	Hs.64056		1.5	TM
		BE247441	Hs.6430	protein with polyglutamine repeat; calci		other
		AK001628	Hs.64691	KIAA0483 protein	1.4	
		AA808177	Hs.65228	ESTs	5.6	other
65		AF198620	Hs.65648	RNA binding motif protein 8A	1.9	other
		H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA,	4.8	?
	133152	Z11695	Hs.324473	mitogen-activated protein kinase 1	5	other

	133174	AA431620	Hs.324178	hypothetical protein MGC2745	2.7	other		
	133175	AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	9.3	other		
	133177	X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM		
		Al801777	Hs.6774	ESTs	5.5	TM		
5		AW954569	Hs.296287	Homo sapiens, Similar to bromodomain-con	2.7	other		
5					1.7	?		
		Al492924	Hs.6831	golgi phosphoprotein 1				
		AI567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other		
		AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2	other		
	133291	BE297855	Hs.69855	NRAS-related gene	1.2	other		
10	133314	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	1.7	TM		
		T79526	Hs.179516	integral type I protein	11.1	?		
		AL390127	Hs.7104	Kruppel-like factor 13	2.9	other		
					2.5	?		
		BE257758	Hs.71475	acid cluster protein 33				
		AI016521	Hs.71816	v-akt murine thymoma viral oncogene homo	1.5	other		
15		AA292811	Hs.72050	non-metastatic cells 5, protein expresse	2.1	other		
	133367	AF231919	Hs.18759	KIAA0539 gene product	1.3	other		
	133370	AF245505	Hs.72157	DKFZP564I1922 protein	2.2	other		
		Al950382	Hs.72660	phosphatidylserine receptor	5.7	TM		
		AW103364	Hs.727	inhibin, beta A (activin A, activin AB a	25.5	other		
20					3.3	other		
20		AA305127	Hs.237225	hypothetical protein HT023				
	133437	AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other		
	133452	NM_002759	Hs.274382	protein kinase, interferon-inducible dou	4.1	other		
	133453	Al659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other		
		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM		
25		W45623	Hs.74571	ADP-ribosylation factor 1	4	?		
20					1.8	?		
		AU077073	Hs.108327	damage-specific DNA binding protein 1 (1		· .		
		AU077050	Hs.75066	translin	1.5	other		
	133579	X75346	Hs.75074	mitogen-activated protein kinase-activat	3.5	TM		
	133582	BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM		
30	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	TM		
-		AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other		
		NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1	other		
					13.5	other		
		NM_004893	Hs.75258	H2A histone family, member Y				
0.5		NM_002047	Hs.75280	glycyl-tRNA synthetase	2.2	other		
35	133631	NM_000401	Hs.75334	exostoses (multiple) 2	1.8	other		
	133649	U25849	Hs.75393	acid phosphatase 1, soluble	2	other	′	
	133690	AV661185	Hs.75574	mitochondrial ribosomal protein L19	2.8	other		
		L27841	Hs.75737	pericentriolar material 1	6.8	other		
		AW969976	Hs.279009	matrix Gla protein	2.5	other		
40						sapiens, Similar to likely ortholog	3.1	TM
40		AW402048.cd		Hs.334787			J. I	1141
		T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.4	?		
	133760	BE271766	Hs.181357	laminin receptor 1 (67kD, ribosomal prot	5.4	other		
	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	5	other		
		AA557660	Hs.76152	decorin	3.8	other		
45		AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1	?		
75		D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7	?		
				putative human HLA class II associated p	2.4	other		
		AW797468	Hs.285013	·				
	133845	AA147026	Hs.76704	ESTs	2.5	other		
50	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5	other		
		AB011155		discs, large (Drosophila) nomolog 5 KIAA0097 gene product		other ?		
•	133867	AB011155 AW340125	Hs.76989	KIAA0097 gene product	5			
	133867 133868	AB011155 AW340125 AB012193	Hs.76989 Hs.183874	KIAA0097 gene product cullin 4A	5 2.5 2.1	? other		
	133867 133868 133922	AB011155 AW340125 AB012193 U30825	Hs.76989 Hs.183874 Hs.77608	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9	5 2.5 2.1 2.8	? other TM		
	133867 133868 133922 133924	AB011155 AW340125 AB012193 U30825 D86326	Hs.76989 Hs.183874 Hs.77608 Hs.325948	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115	5 2.5 2.1 2.8 1.8	? other TM SS,		
	133867 133868 133922 133924 133929	AB011155 AW340125 AB012193 U30825 D86326 NM_006306	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso	5 2.5 2.1 2.8 1.8 2	? other TM SS, ?		
55	133867 133868 133922 133924 133929	AB011155 AW340125 AB012193 U30825 D86326	Hs.76989 Hs.183874 Hs.77608 Hs.325948	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase	5 2.5 2.1 2.8 1.8 2 2.6	? other TM SS, ? other		
	133867 133868 133922 133924 133929 133936	AB011155 AW340125 AB012193 U30825 D86326 NM_006306	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2	5 2.5 2.1 2.8 1.8 2	? other TM SS, ? other other		
	133867 133868 133922 133924 133936 133941	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2	5 2.5 2.1 2.8 1.8 2 2.6	? other TM SS, ? other		
	133867 133868 133922 133924 133936 133941 133959	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4	? other TM SS, ? other other		
	133867 133868 133922 133924 133929 133936 133941 133959 133976	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 Al908165	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9	? other TM SS, ? other other other other		
55	133867 133868 133922 133924 133929 133936 133941 133959 133976	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6	? other TM SS, ? other other other other SS,		
	133867 133868 133922 133924 133929 133936 133941 133959 133976 133989	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.777897 Hs.169946 Hs.78202 Hs.78281	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13	? other TM SS, ? other other other other other SS, other		
55	133867 133868 133922 133924 133936 133941 133959 133976 133989 133997	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8	? other TM SS, ? other		
55	133867 133868 133922 133924 133936 133941 133959 133976 133989 133997 134010 134015	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5	? other TM SS, ? other other other other other other sS, other other SS,		
55	133867 133868 133922 133924 133936 133941 133959 133976 133989 133997 134010 134015	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3	? other TM SS, ? other other other other other sS, other other sS, other SS, other		
55	133867 133868 133922 133924 133936 133941 133959 133969 133989 134010 134015 134070	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5	? other TM SS, ? other other other other other other sS, other other SS,		
55 60	133867 133868 133922 133924 133936 133941 133959 133976 133989 134010 134010 134010	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764 NM_003590 U41060	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.7770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.78946 Hs.79136	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3	? other TM SS, ? other other other other other sS, other other sS, other SS, other		
55	133867 133868 133922 133924 133936 133941 133959 133976 133989 133997 134010 134015 134010	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764 NM_003590 U41060 NM_014742	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.79136 Hs.79305	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3 LIV-1 protein, estrogen regulated KIAA0255 gene product	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3 2.7 4.2	? other TM SS, ? other other other other sS, other		
55 60	133867 133868 133922 133924 133929 133936 133941 133959 133997 134010 134015 134070 134112 134134	AB011155 AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764 NM_003590 U41060	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.7770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.78946 Hs.79136	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3	5 2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3 2.7	? other TM SS, ? other other other other sS, other		

	134206	AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
		NM_000402	Hs.80206	glucose-6-phosphate dehydrogenase	1.9	other
		BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA,	10.3	SS,
_		A1878910	Hs.3688	cisplatin resistance-associated overexpr	2.5	other
5	134292	Al906291	Hs.81234	immunoglobulin superfamily, member 3	1.3	TM
		AW502505	Hs.81360	Homo sapiens cDNA: FLJ21927 fis, clone H	1.6	TM
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	2.1	TM
		AB029023	Hs.179946	KIAA1100 protein	5.3 2.5	? TM
10		AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (vers RAD21 (S. pombe) homolog	3.9	?
10		N92036 NM_004922	Hs.81848 Hs.81964	SEC24 (S. cerevisiae) related gene famil	2.4	TM
		AW291946	Hs.82065	interleukin 6 signal transducer (gp130,	6.8	TM
		AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	2.3	TM
	134376		Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5	other
15		AW362124	Hs.323193	hypothetical protein MGC3222	5.9	TM
	134384	AI589941	Hs.8254	Homo sapiens, Similar to tumor different	2.2	other
	134391	AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	2.1	other
		AA456539	Hs.8262	lysosomal	2.3	other
20		AW067903	Hs.82772	collagen, type XI, alpha 1	72.9	other other
20		BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium bindin protein tyrosine phosphatase type IVA, m	4.4 2.3	other
		A1750762	Hs.82911 Hs.82985	collagen, type V, alpha 2	6.8	?
	134424	AU077196	Hs.83023	peroxisomal biogenesis factor 11B	2.4	other
		AA112036	Hs.83419	KIAA0252 protein	2.9	other
25		M58603	Hs.83428	nuclear factor of kappa light polypeptid	6.7	other
		X54942	Hs.83758	CDC28 protein kinase 2	2.4	other
		NM_005000	Hs.83916	Empirically selected from AFFX single pr	6.3	?
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	1.9	other
•		AW246273	Hs.84131	threonyl-tRNA synthetase	1.8	other
30		AA425473	Hs.84429	KIAA0971 protein	1.4	other
		AK001571	Hs.273357	hypothetical protein FLJ10709	1.4	other other
		BE091005	Hs.74861	activated RNA polymerase II transcriptio	5.6 2.8	?
		AW411479 BE244323	Hs.848 Hs.85951	FK506-binding protein 4 (59kD) exportin, tRNA (nuclear export receptor	1.7	other
35		AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.7	TM
55		AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.1	other
		AF035119	Hs.8700	deleted in liver cancer 1	1.3	other
		X78520	Hs.174139	chloride channel 3	2.1	?
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	2.3	other
40	134666	BE391929	Hs.8752	transmembrane protein 4	. 4	other
		U62317	Hs.88251	arylsulfatase A	6.2	other
		NM_003474	Hs.8850	a disintegrin and metalloproteinase doma	2	other
		BE161887	Hs.88799	anaphase-promoting complex subunit 10	1.3	SS, ?
45		Y14768	Hs.890 Hc.80232	lysosomal chromobox homolog 5 (Drosophila HP1 alph	7.2 3.2	other
43		AA852985 AF129536	Hs.89232 Hs.284226	F-box only protein 6	2.5	other
		X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell	5	other
		AW630803	Hs.89497	lamin B1	6.1	other
		BE002798	Hs.287850	integral membrane protein 1	5.6	TM
50		AW451370	Hs.8991	adaptor-related protein complex 1, gamma	5.3	other
	134850	Al701162	Hs.90207	hypothetical protein MGC11138	9.1	other
		BE268326	Hs.90280	5-aminoimidazole-4-carboxamide ribonucle	2.4	other
		Al879195	Hs.90606	15 kDa selenoprotein	2.7	other
		AW885909	Hs.6975	PRO1073 protein	1.5	other other
55		AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), cat phosphoserine aminotransferase	4.9 2	other
		A1097346	Hs.286049 Hs.92186	Leman coiled-coil protein	2.6	TM
		R50333 AB037835	Hs.92991	KIAA1414 protein	1.4	?
	135011	NM_000408	Hs.93201	glycerol-3-phosphate dehydrogenase 2 (mi	1.6	?
60	135022	AW301984	Hs.173685	hypothetical protein FLJ12619	1.4	other
00		AW503733	Hs.9414	KIAA1488 protein	1.8	other
		AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5	other
		AF027219	Hs.9443	zinc finger protein 202	1.5	TM
		AA081258	Hs.132390	zinc finger protein 36 (KOX 18)	2.1	other
65		Al093155	Hs.95420	JM27 protein	4.4	?
		BE250865	Hs.279529	px19-like protein	14.9	? other
	135199	AA477514	Hs.96247	translin-associated factor X	1.3	oulei

	135207	N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
		T78802	Hs.96560	hypothetical protein FLJ11656	6.2	other
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
_	135245	Al028767	Hs.262603	ESTs	12.2	TM
5		AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.7	TM
		Al088775	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	other
		AA448460	Hs.112017	GE36 gene	4.2	SS,
		AA150320	Hs.9800	protein kinase Njmu-R1	1.2 4.9	other other
10		A1090838	Hs.98006 Hs.98368	ESTs ESTs, Weakly similar to KIAA0822 protein	5.9	?
10		A1743770 A1652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3	TM
		AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
		AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
		U05237	Hs.99872	fetal Alzheimer antigen	1.9	other
15	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9	TM
	302256	AA857131	Hs.171595	HIV TAT specific factor 1	1.6	other
	302276	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
	303135	AW592789	Hs.279474	HSPC070 protein	2.2	TM
20		AK000714	Hs.109441	MSTP033 protein	1.4	SS,
20		R43191	Hs.101248	Homo sapiens clone IMAGE:32553, mRNA seq	5.2	other
		AA808229	Hs.167771	ESTs	2.3 2.9	? ?
		NM_007057	Hs.42650	ZW10 interactor rab3 GTPase-activating protein, non-cata	2.9	r other
		A1268997	Hs.197289 Hs.78979	Golgi apparatus protein 1	5.6	SS,
25		AA902256 N24236	Hs.179662	nucleosome assembly protein 1-like 1	1.4	?
23		AF118083	Hs.29494	PRO1912 protein	1.3	other
		BE041451	Hs.177507	hypothetical protein	2.9	SS,
		AF292100	Hs.104613	RP42 homolog	1.6	other
		BE278431	Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.8	other
30	408196	AL034548	Hs.43627	SRY (sex determining region Y)-box 22	1.6	other
	408813	A1580090	Hs.48295	RNA helicase family	6.2	other
		R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti	5.7	other
		H19886		gb:yn57a05.r1 Soares adult brain N2b5HB5	2.7	other
25		AB000115	Hs.75470	hypothetical protein, expressed in osteo	2.6	?
35		Al267592	Hs.75761	SFRS protein kinase 1	2.4	TM
		AW304454	Hs.77495	UBX domain-containing 1	2.4 2.3	other other
		AW819158 AA381133	Hs.289044 Hs.80684	Homo sapiens cDNA FLJ12048 fis, clone high-mobility group (nonhistone chromoso	4.2	TM
		R57256	Hs.82037	TATA box binding protein (TBP)-associate	23.6	other
40		S79895	Hs.83942	cathepsin K (pycnodysostosis)	5.8	other
		NM_006910	Hs.85273	retinoblastoma-binding protein 6	1.3	other
		U72937	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3	?
	421225	AA463798	Hs.102696	MCT-1 protein	1.6	?
45	421642	AF172066	Hs.106346	retinoic acid repressible protein	3.5	other
		AW891965	Hs.279789	histone deacetylase 3	5	other
		AI252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin	3.1	TM
		AA302744	Hs.104518	ESTs	1.9 2.4	TM other
50		NM_014320	Hs.111029 Hs.298229	putative heme-binding protein prefoldin 2	4.2	?
50		AF165883 W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1	?
		AF041259	Hs.155040	zinc finger protein 217	2.3	other
		AF155568	Hs.155489	NS1-associated protein 1	3.5	other
		BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.9	?
55		AW183765	Hs.182238	GW128 protein	7.6	?
	428477	AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	1.7	other
	437562	AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.4	other
		AK001333	Hs.6216	Homo sapiens hepatocellular carcinoma-as	3.8	other
<b>CO</b>		F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	other
60		AF167572	Hs.12912	skb1 (S. pombe) homolog	2 7.6	TM other
		AA151520	Hs.334822 Hs.17409	hypothetical protein MGC4485 cysteine-rich protein 1 (intestinal)	2.2	other
		A1017574 BE620592	Hs.71190	ESTs, Weakly similar to S16506 hypotheti	2.9	other
		NM_003677	Hs.22393	density-regulated protein	1.8	other
65		W68520	Hs.331328	intermediate filament protein syncoilin	5.9	other
00		H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.7	other
	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.4	other

					•
	452461 N78223	Hs.108106	transcription factor	4.8	?
	452511 BE408178	Hs.285165	Homo sapiens cDNA FLJ20845 fis, clone AD	2.9	other
	453157 AF077036	Hs.31989	DKFZP586G1722 protein	12.1	SS,TM
_	453658 BE541906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other TM
5	100685 AA328229	Hs.184582	ribosomal protein L24	1.8 1.6	other
	100690 AA383256	Hs.1657	estrogen receptor 1	1.3	other
	100833 AF135168	Hs.108802	N-ethylmaleimide-sensitive factor	1.7	?
	100850 AA836472	Hs.297939	cathepsin B	16.9	other
10	101161 NM_006262	2 Hs.37044	peripherin gb:Human calcium, calmodulin-dependent p	3.2	other
10	102481 U50360 102831 AA262170	Hs.80917	adaptor-related protein complex 3, sigma	2	?
	103549 BE270465	Hs.78793	protein kinase C, zeta	8	other
1	103749 BE270403	Hs.8768	hypothetical protein FLJ10849	1.8	other
	104331 AB040450	Hs.279862	cdk inhibitor p21 binding protein	2	?
15	104531 AB040430	Hs.203013	hypothetical protein FLJ12748	2.1	other
13	104563 AL117403	Hs.306189	DKFZP434F1735 protein	1.2	other
	105032 AA127818	113.000100	gb:zl12a02.s1 Soares_pregnant_uterus_NbH	7	?
	105039 AA907305	Hs.36475	ESTs	2.6	?
	106531 AA454036	Hs.8832	ESTs	1.6	other
20	106977 AL043152	Hs.50421	KIAA0203 gene product	4.9	other
	107298 N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
	108717 AA122393	Hs.70811	hypothetical protein FLJ20516	1.3	other
	110018 AW579842		hypothetical protein FLJ10697	5.3	TM
	110330 Al288666	Hs.16621	DKFZP434I116 protein	6.3	other
25	111391 NM_00389	6 Hs.225939	sialyltransferase 9 (CMP-NeuAc:lactosylc	5.1	SS,
	111392 W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA,	8.4	other
	113554 AW503990	Hs.142442	HP1-BP74	3.7	TM
	113722 AV653556	Hs.184411	albumin	1.3	other
	115008 AK001827	Hs.87889	helicase-moi	2_	other
30	115062 AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5	other
	115121 Al634549	Hs.88155	ESTs	2.8	other
	117881 AF161470	Hs.260622	butyrate-induced transcript 1	5.8	TM
	119075 M10905	Hs.287820	fibronectin 1	5.7	other other
25	119615 AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	1.3 38.9	other
35	120253 AA131376	Hs.326401	fibroblast growth factor 12B	2.9	?
	125006 BE065136	Hs.145696	splicing factor (CC1.3) collagen, type IV, alpha 3 (Goodpasture	1.8	other
	127609 X80031 128868 AA419008	Hs.530 Hs.106730	chromosome 22 open reading frame 3	3	other
	128891 F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, com	13.3	other
40	128959 AI580127	Hs.107381	hypothetical protein FLJ11200	10.9	other
40	129209 R62676	Hs.17820	Rho-associated, coiled-coil containing p	2.4	other
	129449 Al096988	Hs.111554	ADP-ribosylation factor-like 7	8.2	TM
	129453 AW974265		Lsm3 protein	3.3	?
	129629 AK000398		hypothetical protein FLJ20391	3.9	other
45	129917 M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	5.3	TM
	129922 AF042379	Hs.13386	gamma-tubulin complex protein 2	4.6	other
	129989 AB015856		activating transcription factor 6	4	SS,
	130182 BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	4.6	other
	130365 W56119	Hs.155103	eukaryotic translation initiation factor	11	other
50	130471 AL121438	Hs.183706	adducin 1 (alpha)	2.7	other
	130542 U64675	Hs.179825	RAN binding protein 2-like 1	7.9	other
	130586 AB007891		KIAA0431 protein	5.6	TM
	130768 AF258627		ATP-binding cassette, sub-family A (ABC1	5.2	other
	130992 BE398091		desmoplakin (DPI, DPII)	1.8	TM ?
55	131047 H23230	Hs.22481	ESTs, Moderately similar to A46010 X-lin	1.7 3.3	τ'n
	131135 NM_01656	69 Hs.267182	TBX3-lso protein Nijmegen breakage syndrome 1 (nibrin)	2.6	other
	131339 AF058696		nucleobindin 2	2.9	TM
	131760 X76732	Hs.3164	DKFZP586J0119 protein	5.6	other
60	131774 BE267158 131853 Al681917	Hs.169474 Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
60	131881 AW361018		upstream regulatory element binding prot	3.2	TM
	131887 W17064	Hs.332848	SWI/SNF related, matrix associated, acti	3.2	other
	132031 AF193844		COP9 complex subunit 7a	5.9	?
	132192 AA206153	Hs.4209	mitochondrial ribosomal protein L37	2.2	TM
65	132203 NM_00478	32 Hs.194714	synaptosomal-associated protein, 29kD	7.9	?
00	132240 AB018324	Hs.42676	KIAA0781 protein	4.3	other
	132348 AW06770	8 Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5	other

	132571	T78736 AW674699	Hs.50758 Hs.5169	SMC4 (structural maintenance of chromoso suppressor of G2 allele of SKP1, S. cere	7.4 6.9	? other	
		N52298	Hs.55608	hypothetical protein MGC955	14.3	?	
5		BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
3		AI439688	Hs.6289 Hs.6390	hypothetical protein FLJ20886 Homo sapiens clone FLB3344 PRO0845 mRNA,	4.4 1.8	other SS,TM	
		Al065016 Al275243	Hs.180201	hypothetical protein FLJ20671	1.8	other	
		AK001489	Hs.242894	ADP-ribosylation factor-like 1	1.8	other	
	133266	Al160873	Hs.69233	zinc finger protein	16.1	other	
10		M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
		BE313555	Hs.7252	KIAA1224 protein	1.5	?	
		AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
		BE622743	Hs.301064	arfaptin 1	12.1	other	
15		M34338	Hs.76244	spermidine synthase	9.7	other	
15		W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2 2.2	SS, other	
		U86782	Hs.178761 Hs.77204	26S proteasome-associated pad1 homolog centromere protein F (350/400kD, mitosin	9.1	other	
		U30872 NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
		AA334551	Hs.82767	sperm specific antigen 2	1.4	other	
20		AF045239	Hs.321576	ring finger protein 22	1.4	other	
		AD001528	Hs.89718	spermine synthase	2.6	other	
		D26488	Hs.90315	KIAA0007 protein	13.3	other	
		X95525	Hs.96103	TATA box binding protein (TBP)-associate	3.1	other	
		AA243007		ESTs	1.6	?	
25		T70541		ESTs	2.5	SS,	
		X57766		Human stromelysin-3 mRNA	4.5	other	
		S66431		Homo sapiens clone 23592 mRNA sequence	3.1	other	
		AA453483		ESTS	4.6	TM	
30		R63925		ESTs	1.4 1.9	other other	
30		AA173417 AA280588		ESTs ESTs	2.2	other	
		AA504223		ESTs Highly similar to CHROMOSOME	2.4	other	
		AA609996		ESTs Highly similar to Surf-4 protein [M.musculus]	5.5	?	
		F02907	•	ESTs	2.3	TM	
35		AA480103		ESTs Weakly similar to !!!! ALU SUBFAMILY J	2.8	TM	
		AA024664		Human NADH:ubiquinone oxidoreductase subunit	6.2	other	
		AA251776		ESTs	2.3	other	
		AA399047		ESTs	2.4	other	
40		N34059		EST - RC_N34059	3.3	other	714
40		U95367		Human GABA-A receptor pi subunit mRNA complet	e cas 3.3	1.7 other	TM
		AA490899	•	ESTs ESTs	2.9	?	
		T54762 Z41963		Homo sapiens HP protein (HP) mRNA complete cds		?	
		AA521186		ESTs	1.6	TM	
45		AA400195		ESTs	1.3	other	
		AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLAS	Ε	2.5	other
		AA099589		Homo sapiens mRNA for GDP dissociation inhibitor		1.6	TM
		W85712		ESTs Weakly similar to PROCOLLAGEN ALPHA 2(		2.6	TM
<b>~</b> 0		W45728		ESTs Highly similar to HETEROGENEOUS	3.7	other	- 11
50		U61232		Human tubulin-folding cofactor E mRNA complete c		2.1	other
		AA425154		ESTs ESTs Weakly similar to ZK1058.4 [C.elegans]	5.3 2.6	other SS,TM	
. '		T39176 AA496000		ESTs Weakly Similar to 2K 1056.4 [C.elegans]	1.9	SS, TW	
		W38150		EST - RC_W38150	1.7	?	
55		T96595		EST - RC_T96595	1.8	TM	
55		AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	?
		R46025		ESTs	2.8	SS,	
		AA233177		ESTs	2	other	
<b>CO</b>		AA338760		ESTs	1.3	?	
60		AA412106		ESTs	6.2	other	
		L47276		EST - L47276	3.4	other	a#- a-
		D82307		ESTs Weakly similar to TH1 protein [D.melanogaste ESTs	erj 1.5	11.4 other	other
		AA293568 R37778		ESTs	2.4	other	
65		AA250843		Interferon regulatory factor 5	14.6	?	
0.5		W49521		Human prolyl 4-hydroxylase alpha (II) subunit	6.5	?	
		D80000		Human mRNA for KIAA0178 gene partial cds	2	other	

	R99978	ESTs Weakly similar to line-1 protein ORF2 [H.sap		6.1	?
	AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRe		?	
	Z38501	ESTs Weakly similar to PROBABLE E5	1.4	other	
_	U37547	Human IAP homolog B (MIHB) mRNA complete co		other	
5	AA479961	ESTs	1.7	other	
	X57579	Inhibin beta A (activin A activin AB alpha polypeption	de)	15.8	?
	AA449071	ESTs	1.3	TM	
	N51855	ESTs Moderately similar to NAD(+) ADP-	1.3	other	
	AA421213	ESTs Weakly similar to F28F8.3 [C.elegans]	3.2	other	
10	AA355201	ESTs	1.2	SS,TM	
	N78717	H.sapiens mRNA for translin	1.5	?	
	N73808	ESTs	5	?	
	U86782	Human 26S proteasome-associated pad1	2.2	other	
	AA234817	ESTs	1.3	other	
15	D13666	Homo sapiens mRNA for osteoblast specific	7.5	SS,	
~ ~	AA236177	ESTs	7.1	?	
	U50648	Protein kinase interferon-inducible double	4.1	?	
	M28211	Homo sapiens GTP-binding protein (RAB4)	2,9	other	
	AA446949	ESTs	2.2	other	
20	W03007	ESTs	1.2	other	
	W61011	ESTs	1.2	other	
	W87544	ESTs	1.2	other	
	X02751	Neuroblastoma RAS viral (v-ras) oncogene homolo		?	
	Z14077	YY1 transcription factor	1.2	other	
25	Z38839	ESTs	1.2	?	
	AA410894	ESTs	1.7	other	
	AA504499	ESTs Highly similar to probable chloride channel 3		1.3	other
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Lo 10 1 lightly diffinal to probable diffoliate official of	I. work		0.101

### TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey CAT number

Accession

102481 31281\_-28

U50360 AA127818

105032 genbank\_AA127818 409487 1134778\_1

H19886 AW402806 T10231

## TABLE 8: Figure 8 from BRCA 001-1 US

Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue. Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10	Pkey:	Unio	jue Eos probe	set identifier number				
	ExAccn: Unigene		Exemplar Accession number, Genbank accession number Unigene number					
	Unigene		Unigene gene title					
15	normal body tissue							
	R2:		Ratio of tumor to normal breast tissue					
	Pkey	ExAccn -	UnigenelD	Unigene Title	R1	R2		
20	100075	AF152333	Hs.284160	protocadherin gamma subfamily B, 4	1	3.8		
		AV652249		polymerase (DNA directed), beta	1.7	5.3		
		D38500		postmeiotic segregation increased 2-like	0.8	4.8		
		BE160081		S100 calcium-binding protein A11 (calgiz	3.2	2.3		
25		Al907114	Hs.71465	squalene epoxidase	3.3	1.4		
25		X51501	Hs.99949	prolactin-induced protein	11.9 3.8	0.4 1.2		
		AA019521 X77343	Hs.301946	•	3.6 9.4	9.4		
	100599			transcription factor AP-2 alpha (activat fibronectin 1	3.4	7.8		
		AA383256	Hs.1657	estrogen receptor 1	4.4	4.4		
30		U01351	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9		
50		K01160	110.70112	NM_002122:Homo sapiens major histocomp	-	4		
		AA382524	Hs.250959		0.8	4.1		
	101148	NM_002923	Hs.78944	regulator of G-protein signalling 2, 24k	1.2	12		
	101161	NM_006262	Hs.37044	peripherin	3.1	1.1		
35		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	4.4	0.6		
		Al186220	Hs.83164	collagen, type XV, alpha 1	3.1	3.4		
		AW468397	Hs.100000	S100 calcium-binding protein A8 (calgran	0.9	4.2		
		M21305	11 100010	gb:Human alpha satellite and satellite 3	29.9	0.3		
40		AA310162		cytochrome c	0.8 1	4.9 5.9		
40		M33552	Hs.56729	lysosomal	2.8	5.9 4		
		BE561617 M55998	HS. 119192	H2A histone family, member Z	3.1	1.7		
		NM_002291	Hs.82124	gb:Human alpha-1 collagen type I gene, 3 laminin, beta 1	1.5	4.1		
		AA350659	Hs.83347	angio-associated, migratory cell protein	3.1	1.4		
45		AF112213		putative Rab5-interacting protein	1.3	6.9		
		AL036335	Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9		
		AA334592	Hs.79914	lumican	2.2	3.8		
	102304	AF015224	Hs.46452	mammaglobin 1	4.2	0.7		
	102345	NM_003480	Hs.300946	Microfibril-associated glycoprotein-2	1.1	4.2		
50		NM_001394	Hs.2359	dual specificity phosphatase 4	4.5	0.5		
		U96759		von Hippel-Lindau binding protein 1	1.4	4.2		
		Al379954	Hs.79025	KIAA0096 protein	0.9	3.9		
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	1.5	10.9		
<i>E E</i>		R50032		collagen, type VI, alpha 2	2.2 5.6	6.2		
55		AW293542	Hs.75309	eukaryotic translation elongation factor cadherin 3, type 1, P-cadherin (placenta	3.7	5.7 0.5		
		X63629 X69089	Hs.2877 Hs.79227	myomesin (M-protein) 2 (165kD)	1.3	4		
		D38616	Hs.54941	phosphorylase kinase, alpha 2 (liver)	1.3	3.8		
		X83492	Hs.82359	tumor necrosis factor receptor superfami	0.8	4.6		
60		BE536700	Hs.4888	seryl-tRNA synthetase	0.9	8		
		T34708	Hs.272927		1.1	5.1		
		Y00815	Hs.75216	protein tyrosine phosphatase, receptor t	3.7	1.2		
	103546	Z14244	Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4		

		NM_000088 AA084874	Hs.172928	collagen, type I, alpha 1 gb:zn13e04.r1 Stratagene hNT neuron (937	3.2 0.9	3 10	
	103774		Hs.92918	hypothetical protein	1.9	15.9	
_	103821	AA095971		Homo sapiens cDNA: FLJ22463 fis, clone H	1.2	3.9	
5		BE439604		ATPase, H+ transporting, lysosomal (vacu	1.4	3.9	
		AW130242		hypothetical protein FKSG44	1.6	4.1	
		AK001913		hypothetical protein	1.5	4.3	
		AF183810		opposite strand to trichorhinophalangeal	7	7	
10		AB040927		KIAA1494 protein	2 0.7	4.6 4.5	
10		AB002347 AW583693		KIAA0349 protein N-terminal acetyltransferase complex ard	3.3	3.3	
		AW365522		hypothetical protein PRO2219	2.3	4.2	
		AW804296	Hs.9950	Sec61 gamma	3.1	7	
		AF283775		x 001 protein	4	1.3	
15	104432			prolactin-induced protein	3.8	0.6	
	104464	AW966728	Hs.54642	methionine adenosyltransferase II, beta	0.8	6.7	
		AK001731		Homo sapiens mRNA; cDNA DKFZp586H092		1.7	4.8
		W94824		RIKEN cDNA 2010100012 gene	2	7.5	
20		AW630488		protease, serine, 23	1.9	7.4	
20		AF123303		hypothetical protein	1.1	6.3	
		R82252		protein kinase (cAMP-dependent, catalyti hypothetical protein	1.2 1.4	4 3.9	
		AW270555 AA960961		zinc finger protein 83 (HPF1)	1.5	4.2	
		AA305351	Hs 274369	uncharacterized hypothalamus protein HAR	1.1	4.1	
25		Al279065		ribosomal protein S6	1.3	4.6	
		AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
		W70164	Hs.20107	ESTs	0.8	4.2	
	104861	AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RE	LEASE	1.7	5.1
	104873	W03831	Hs.20597	host cell factor homolog	0.8	5.4	
30		W44626	Hs.30627		0.7	6.8	
		AW955089		Novel human gene mapping to chomosome 2:		1 3.9	
		BE298808		DKFZP434N093 protein	3.3	3.3	
		AW076098		desmoplakin (DPI, DPII)	1.2	3.7 5.5	
35		AB029020 Al392640		KIAA1097 protein amino acid transporter system A1	1.1 3.2	1.4	
33		BE613061	Hs 337772	Homo sapiens, Similar to RIKEN cDNA 0610		11.4	
		N39760	Hs.8859	Homo sapiens, Similar to RIKEN cDNA 5830	1.5	7.2	
		BE410438	Hs.9006	VAMP (vesicle-associated membrane protei	1.1	3.5	
		AF146277		CD2-associated protein	1.2	10	
40		AA313825		AD036 protein	3.6	8.3	
	105182	BE407961	Hs.18271	golgi phosphoprotein 3	1.7	6.8	
		AI554929		ATPase, H+ transporting, lysosomal (vacu	1.1	3.7	
		BE243327		chromosome 22 open reading frame 5	1.5	4	4.4
15		Al015709		Homo sapiens mRNA; cDNA DKFZp586l2022		1.5	14
45		W20027	Hs.23439	stress-associated endoplasmic reticulum	4.3 1.5	2.9 5	
		W03516 AA252372		KIAA1033 protein	1.2	3.6	
		AL137257		Homo sapiens cDNA: FLJ23015 fis, clone L	1.7	15.8	
		Al805717		CGI-43 protein	2	4.8	
		AL037715		microfibrillar-associated protein 3	1.3	3.9	
		AB040884	Hs.109694	KIAA1451 protein	2.7	11.4	
		AB024334	Hs.25001	tyrosine 3-monooxygenase/tryptophan 5-mo	1.3	6.1	
		BE504200	Hs.30127	hypothetical protein	1.7	4.5	
<i></i>		AA788946	Hs.16869	ESTs, Moderately similar to CA1C RAT COL		24.6	
55		BE614149	Hs.20814	CGI-27 protein	1.8 1.9	3.6 6.6	
		A1559444 AA329449	Hs.293960	twisted gastrulation	1.5	4.3	
		AI827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9	
60 1		BE392914	Hs.30503	Homo sapiens cDNA FLJ11344 fis, clone PL	1.7	4	
		AW028485		hypothetical protein MGC14156	1.7	7.4	
		AL137728	Hs.12258	Homo sapiens mRNA; cDNA DKFZp434B092		1.2	3.8
		AB033075	Hs.10669	development and differentiation enhancin	1.3	4.6	
		AB030656	Hs.17377	coronin, actin-binding protein, 1C	1.1	5.9	
65		A1690586	Hs.29403	hypothetical protein FLJ22060	2	4.6	
		AI240665	Hs.8895	ESTS	4.1	1.2	
		NM_001329	Hs.171391 Hs.5957	C-terminal binding protein 2 Homo sapiens clone 24416 mRNA sequence	2.6 1 <i>t</i>	7 10.7	
	100010	T74445	10.0001	Tiomo sapiens cione 244 to minim sequence	17		

	106083	H62087	Hs.31659	thyroid hormone receptor-associated prot	1.5	3.6	
		AA425414	Hs.33287	nuclear factor I/B	5.4	1.2	
		BE613206		calpastatin	1.8	4	
		BE568205	Hs.28827	mitogen-activated protein kinase kinase	5.1	6.1	
5	106538	AK000274		HDCMA18P protein	1.2	5.9	
	106568	AW051564	Hs.28285	patched related protein translocated in	1.8	5.4	
	106574	BE044325	Hs.227280	U6 snRNA-associated Sm-like protein	2.3	11.2	
	106613	N88604	Hs.30212	thyroid receptor interacting protein 15	1.2	3.6	
4.0	106617	H09548	Hs.5367	ESTs, Weakly similar to 138022 hypotheti	0.9	4.4	
10	106619	AA459480	Hs.23956	hypothetical protein FLJ20502	1.3	3.6	
		BE387614	Hs.25797	splicing factor 3b, subunit 4, 49kD	1.6	7.3	
		AA741038	Hs.6670	ESTs	1.7	6.1	
		AA206079	Hs.6693	hypothetical protein FLJ20420	1	5.4	
1.5		AA487416		Homo sapiens cDNA: FLJ23111 fis, clone L	1.6	5.4	
15		BE185536		molecule possessing ankyrin repeats indu	3.3	1.2	
		BE503373		hypothetical protein FLJ13576	1.4	6.3	
		T85594		hypothetical protein FLJ10120	3.3	1.8	
		AF216751	Hs.26813	CDA14	3	3	
20		BE391904	Hs.12482	glyceronephosphate O-acyltransferase	1.7	7.6	
20		BE147611	Hs.6354	stromal cell derived factor receptor 1	1.2	4.3	
		AI289507		hypothetical protein FLJ23399	1.8	6.5	
		BE172058	Hs.82689	tumor rejection antigen (gp96) 1	1.2 1.4	6.9 3.5	
		BE267795	Hs.22595	hypothetical protein FLJ10637	2.6	4.3	
25		AA186629 AA011510	Hs.80120 Hs.60512	UDP-N-acetyl-alpha-D-galactosamine:polyp ESTs	1.8	4.5	
23		AA011310 AA027229	Hs.61329	ESTs, Weakly similar to T16370 hypotheti	1.3	3.5	
		AF109219		phosphatidylinositol glycan, class N	1.6	3.5	
		AW368993		Homo sapiens clone CDABP0086 mRNA seq		1.8	8.1
		AA291440	Hs.73149	paired box gene 8	1.1	3.5	•.,
30		AA093668	Hs.28578	muscleblind (Drosophila)-like	0.7	5.6	
50		Al283611		ESTs, Weakly similar to HMG1_HUMAN HIG		1.2	5.6
		AW068579	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564A072		3.1	6.9
		Al879238		collapsin response mediator protein-5; C	1.5	4.6	
		AA333660	Hs.71331	hypothetical protein MGC5350	1.5	4	
35		AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU	S	6.3	4.7
		AA074374	Hs.67639	ESTs	1.3	3.8	
	108399	AF086070	Hs.237519	EST	1	3.6	
	108469	AA079487		gb:zm97f08.s1 Stratagene colon HT29 (937	1.5	3.6	
	108470	AA079500		gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	4.3	
40	108564	M23114	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	2	4.9	
	108641	AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1	3.5	
	108668	AA058522	Hs.185751	ESTs	1.2	3.6	
		AA036725	Hs.61847	ESTs	1.4	3.6	
4 ~		AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456		glucocorticoid receptor DNA binding fact	1.2	4	
		BE276891		retinoic acid induced 3	1.3	3.6	
		AA152312	Hs.72047	ESTs	1.1	4.1	
		AI732585	Hs.22394	hypothetical protein FLJ10893	1.2	3.5	
50		AA167512	11- 004007	gb:zp10f12.s1 Stratagene fetal retina 93	1.3	5	
50		BE220601		hypothetical protein FLJ13033	4	6.1	7.4
		BE179030	Hs.64239	Human DNA sequence from clone RP5-1174		1.7 7.7	7.4
		AA878923		hypothetical protein FLJ21016 hypothetical protein FLJ11838	3.8 1.9	4	
		AA366263 AA173942	Hs.72531	Homo sapiens mRNA; cDNA DKFZp564H191		3.7	1.3
55		BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	4.6	7.4	1.0
33		AW151660	Hs.31444	ESTs	1.2	3.5	
		AW001579	Hs.9645	Homo sapiens mRNA for KIAA1741 protein,	3.7	3.3	
		NM_014899	Hs 188006	KIAA0878 protein	2.8	3.7	
60		N21207	Hs.182999		1.6	3.5	
		BE242691	Hs.14947	ESTs	3.1	1.2	
		AI753230	Hs.323562	hypothetical protein DKFZp564K142	1.9	7.5	
		Al681293	Hs.12186	hypothetical protein FLJ22558	2	4	
		AK001566	Hs.23618	hypothetical protein FLJ10704	1.1	3.8	
		BE301871	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	1	8.2	
65		BE314949	Hs.87128	hypothetical protein FLJ23309	3.3	6.1	
		R27975		ESTs, Moderately similar to S65657 alpha	1.2	5.4	
	111900	AF131784	Hs.25318	Homo sapiens clone 25194 mRNA sequence	3.2	0.8	

	111951	NM_014906 NM_014927	Hs.100527	KIAA1072 protein KIAA0902 protein Phosphatidylglycerophosphate Synthase	1 1 1.4	5.4 3.8 3.5	
	112193	AW137198	Hs.138238		1.5	3.6	
5		NM_003655	Hs.5637	ESTs	4.6	2	
•		AW500106	Hs.23643	serine/threonine protein kinase MASK	3.3	10.5	
		Z42387	Hs.83883	transmembrane, prostate androgen induced	3.2	3	
	112984	T16971		ESTs, Weakly similar to A43932 mucin 2 p	3.7	10.8	
	113056	AF019226	Hs.8036	glioblastoma overexpressed	4.5	3.7	
10	113449	AW160683		hypothetical protein	1.2	4.4	
		AF143321	Hs.15572	hypothetical protein IMAGE 109914	0.9	3.6	
		AL042936		holocytochrome c synthase (cytochrome c	1.1	3.5	
		AK001898	Hs.16740	hypothetical protein FLJ11036	1.2	3.9	
15		AI075407		ESTs, Moderately similar to 154374 gene	1.7	5.3	
15		NM_014214	Hs.5753	inositol(myo)-1(or 4)-monophosphatase 2	0.8 1.7	6.1 6.2	
		W30681	Hs.5297	Homo sapiens cDNA: FLJ22130 fis, clone H DKFZP564A2416 protein	1.7	4.6	
		AW243158 BE255499	Hs.3496	hypothetical protein MGC15749	1.5	4	
		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	3.8	1	
20		AA345519	Hs.9641	complement component 1, q subcomponent,	1.2	4.7	
		Al342493	Hs.24192	Homo sapiens cDNA FLJ20767 fis, clone CO		4.3	
		BE179882		glutathione peroxidase 3 (plasma)	1.1	4.3	
		N58309	Hs.19575	CGI-11 protein	1.6	9.2	
		AA075488		gb:zm88d01.s1 Stratagene ovarian cancer	1.6	3.7	
25	114760	Al929382	Hs.252692	hypothetical protein FLJ20343	1.4	4	
	114781	T10446	Hs.95388	ESTs	1	4.3	
	114795	AB037858		hypothetical protein FLJ10337	1.6	9.2	
		AV660012		hypothetical protein FLJ10788	1.4	5.2	
20		A1683069	Hs.175319	ESTs	3.7	1	
30		BE541042	Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	3.2	4.2	
		N36110		solute carrier family 2 (facilitated glu	1.5	3.9 5.9	
		AW582256	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	1.3 1.7	6.6	
		AW410233 AB037836	He 100315	YME1 (S.cerevisiae)-like 1 KIAA1415 protein	1.7	9.1	
35		BE383668	Hs.42484	hypothetical protein FLJ10618	0.9	4.3	
55		BE395293	Hs.94491	hypothetical protein FLJ20297	1.6	5.5	
		AI129767		guanine nucleotide binding protein (G pr	3.2	2.4	
		Z24854	Hs.42299	ESTs	0.8	4.7	
		Al371223	Hs.288671	Homo sapiens cDNA FLJ11997 fis, clone HE	2.4	3.9	
40	116429	AF191018		putative nucleotide binding protein, est	5.5	5.5	
	116461	AA313607	Hs.58633		5	1.3	
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	8.7	4.5	
		D21262	Hs.75337	nucleolar and coiled-body phosphprotein	3.2	6.9	
15		AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (	3.2	3	
45		AI557212	Hs.17132		3.1	8.3	
		H25836		ESTs, Moderately similar to unknown [H.s	3.2 7	4.5 5.5	
		N25929		ADP-ribosylation factor-like 5 PTPRF interacting protein, binding prote	1.2	6.2	
		N20066 M18217		Homo sapiens cDNA: FLJ21409 fis, clone C	4.5	2.4	
50		Al383467	Hs.44597	ESTs	1.4	4.2	
50		U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.3	0.5	
		AF161470		butyrate-induced transcript 1	2.1	5.7	
		BE327311	Hs.47166	HT021	3.6	7.7	
		N66845		gb:za46c11.s1 Soares fetal liver spleen	4.2	0.5	
55		AL353944	Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J111	2 (f	3.5	3.3
	118505	N67343		gb:yz50b07.s1 Morton Fetal Cochlea Homo	2.1	3.8	
,		AF142419	Hs.15020	homolog of mouse quaking QKI (KH domain	3.7	1.5	
		BE048061	Hs.37054	ephrin-A3	3	1.1	
<b>CO</b>		BE218319	Hs.5807	GTPase Rab14	1.1	5.6	
60		BE041667	Hs.314544		1.4	4.3	
		A1905687	Hs.2533	EST DVEZDESCEDO240 protoin	3.2 4.3	1 0.7	
		AL050097	Hs.272531	•	4.3 3.5	1.9	
	119943	BE565849 AA235207	Hs.14158	copine III hypothetical protein DKFZp762F2011	1.5	3.7	
65		AW968080		Homo sapiens clone 24630 mRNA sequence		1.4	
00		AF150208	Hs.108327	damage-specific DNA binding protein 1 (1	1.6	6.8	
	120867	AA350781	Hs.96967	ESTs	1.1	3.6	
	5007						

	121368	BE262956	Hs.178292		1.5	4.1	
	121603	AA416785			2.2	5.5	
		AA243499			3.4	3.2	-
-		AF169797			3.9	3.9	
5		AB032948			1.4	7.1	
		AI718702			1.4 1.2	3.7 4.9	
		AF121856 AF161426			2.4	3.6	
		AA421581	Hs.178443		0.9	5.2	
10		W28673			1.3	5.1	
•		AA608657			2.1	5.2	
		AA608751		gb:ae56h07.s1 Stratagene lung carcinoma	2.1	9.3	
	123768	AI932318	Hs.188762	ESTs, Moderately similar to H2BL_HUMAN H		3.6	
4 =	123961	AL050184			1.1	3.5	
15		AF084555	Hs.7351		1.4	3.8	
		BE563957	Hs.74861		1.9	11.2	
		AB037860			1.5	4.4	
		BE387335			14.8 1.2	11.5 6.2	
20		AW195237 BE300094	Hs.7734		2.5	12.7	
20		AU077333			1	4.1	
		BE613340			1.5	8.4	
		AK001552			1.8	10.2	
		D87454			1.1	4.8	
25	124432	N39016	Hs.268869	ESTs, Weakly similar to ALUC_HUMAN !!!!	1.3	4.1	
		N48000			2.7	4.3	
		D54120			2.1	5.7	
		AI393320	Hs.104573	<del></del>	1	4.1	
20		H66409	Hs.108275		1.4	4	
30		AL036596			0.7 1.1	3.5	
		AA749315 H60193	Hs.77171		1.4	3.6	
		AI680737	Hs 289068	Homo sapiens cDNA FLJ11918 fis, clone HE		9.9	
		BE270465			0.7	4	
35		AW408586	Hs.91052	ESTs, Moderately similar to ALU5_HUMAN A		3.6	
		BE410405	Hs.76288		1.3	3.9	
	124792	R44357	Hs.48712	hypothetical protein FLJ20736	1.8	4.2	
		R56485		3-70	1	3.6	
40		AF068846			3.2	3.4	
40		AI903210		and annotation to the state of	1	4.4	
		AL023513		, , ,	0.9	5.2 3.5	
		T52700	Hs.110044 Hs.187775		0.9 1.2	5	
		AA610577 BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152		1.5	3.7
45		T83731	Hs.3343		0.9	6	· · ·
		AA973971	110.0010	gb:oq02h08.s1 NCI_CGAP_Lu5 Homo sapien:		1 3.7	
		T91518			3.2	2.5	
	125103	AA570056	Hs.122730	ESTs, Moderately similar to KIAA1215 pro	5.3	6.6	
<b>~</b> ^	125154	W38419		•	0.9	6.1	
50		AA837043	Hs.143669		1.1	4.3	
		AK000669		TRF2-interacting telomeric RAP1 protein	1.1	4.1 3.8	
		AL020996	Hs.8518	selenoprotein N ESTs, Weakly similar to 2004399A chromos	1.1 1	3.6	
		R40815 W67577	Hs.12396 Hs.84298		1.2	7.8	
55		H05635		topoisomerase-related function protein 4	1	4.9	
55		AW884980		triple functional domain (PTPRF interact	1.3	4.8	
		BE612888		myosin regulatory light chain	1.1	16.1	
		W27235	Hs.64311	a disintegrin and metalloproteinase doma	1.4	5.3	
	125824	Z45258	Hs.286013	short coiled-coil protein	2.4	8.7	
60		AW630088	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264		1.8	4.6
	125970	AW504721		high density lipoprotein binding protein	1.9	3.8	
		AW160399	Hs.30376	hypothetical protein	1.4	4.1	
		BE384361			2 1.3	3.7 4.1	
65		AA057593 AA340277	Hs.334762 Hs.10248	hypothetical protein FLJ14735 Homo sapiens cDNA FLJ20167 fis, clone CO		5	
U.J		AI243596	Hs.94830	ESTs, Moderately similar to T03094 A-kin	4.3	0.9	
		J04182	Hs.150101		1.5	4.7	

	400450	V00704	11- 007000	Channe attend	4.0	4.2	
	128453			fibronectin 1	1.2	4.3	
	128460			ESTs, Highly similar to LDHH_HUMAN L-LAC		44.4	
	128491			hypothetical protein DKFZp434N1429	0.6	13.1	
~	128495	NM_005904		MAD (mothers against decapentaplegic, Dr	1.3	4	
5	128546	NM_003478	Hs.101299		1	5.1	
	128574	Al185977		ubiquitin specific protease 18	0.8	4	
	128611	NM_014721	Hs.102471	KIAA0680 gene product	1.3	3.7	
	128652	AA432202	Hs.103147	hypothetical protein FLJ21347	1.4	3.9	
	128653	D87432	Hs.10315	solute carrier family 7 (cationic amino	1.2	3.6	
10		Al246669			0.8	4.1	
		BE246444		hypothetical protein FLJ20396	3	1.6	
		AK001564		hypothetical protein FLJ10702	2.8	4.8	
		AA476220		CD81 antigen (target of antiproliferativ	1.1	10.6	
		AF026692		secreted frizzled-related protein 4	1	3.8	
15					5.3	5.3	
15		AA194554		ATPase, H+ transporting, lysosomal (vacu			
		A1638184		Homo sapiens clone 23836 mRNA sequence		5.3	
		Al917602	Hs.106440		1	4.5	
		AA768242		hypothetical protein	0.8	3.6	
20	128889			•	4.6	3.7	
20	128890	Al222020	Hs.182364	CocoaCrisp	3	1.5	
	128915	AK000140	Hs.107139	hypothetical protein	0.2	3.9	
	128920	AA622037	Hs.166468	programmed cell death 5	2.5	15.2	
	128926	AF155096	Hs.107213	hypothetical protein FLJ20585	4	4	
	128930	AA298958	Hs.10724	MDS023 protein	1.2	4.5	
25		AW247536		hypothetical protein	1.4	5	
		AW953622		RAB31, member RAS oncogene family	2.3	5.6	
		AB020716		KIAA0909 protein	0.9	3.9	
		AW271217		Homo sapiens cDNA FLJ14028 fis, clone HE		3.6	
		AA258924	He 10758	NM_002495*:Homo sapiens NADH dehydroge	na	0.8	3.8
30		AI770025		hypothetical protein FLJ22059	1.2	5.7	0.0
50				Homo sapiens cDNA FLJ14368 fis, clone HE		9.9	
	129009						
		AA371156		DKFZP564M112 protein	2.4	3.8	
		Al634522		KIAA1268 protein	1.2	3.8	
25		AW504486		sterol regulatory element binding transc	1.2	5.5	
35	129113	BE543205		DKFZP586A0522 protein	0.5	3.7	
		AB002450		CGI-109 protein	1	5.2	
	129126	AW881089		Homo sapiens mRNA; cDNA DKFZp566M094	7 (f	1.5	7
	129151	N23018	Hs.171391	C-terminal binding protein 2	2.1	9.7	
	129230	AA335362	Hs.109646	Empirically selected from AFFX single pr	0.9	8.6	
40	129234	M18916		glucosidase, beta; acid (includes glucos	1.1	3.5	
	129238	BE542214	Hs.109697		1.1	12.8	
		W57656		ubiquitin-like 5	3.2	5.1	
		A1878857		hematological and neurological expressed	1.9	5.7	
		BE169531		TAK1-binding protein 2; KIAA0733 protein	1.2	6.6	
45	129247			CGI-131 protein	1.5	3.5	
73				Empirically selected from multiple AFFX	1.5	5.4	
		AA344367		poly(A)-binding protein, cytoplasmic 1-I			
		AA250970			1.3	4.1	
		AF077200	HS.2/9813	hypothetical protein	1.6	3.9	
50		AA357185		ras homolog gene family, member H	1.8	4.2	
50		AB007896	Hs.110	putative L-type neutral amino acid trans	1.1	6.1	
		AA318224	Hs.296141		2.5	4.8	
	129300	W94197		ribosomal protein L26 homolog	1.6	5.1	
	129318	AF189062	Hs.285976	tumor metastasis-suppressor	1.8	6.5	
	129352	AW511656	Hs.170177	Meis1 (mouse) homolog	0.9	4	
55	129362	U30246	Hs.110736	solute carrier family 12 (sodium/potassi	1.4	9.2	
		BE278964		CGI-111 protein	1	4.8	
		AA318271		hypothetical protein	1	4.1	
		AA016188		hypothetical protein	1.8	10.7	
		Al498631		ferritin, light polypeptide	1.1	4.8	
60		W92931		heat shock factor binding protein 1	1.8	9.3	
00		AL050260	He 222817	DKFZP547E1010 protein	1.0	5	
			11- 202772	ECUD region gone 1		4.2	
		NM_004477		FSHD region gene 1	1.1		
		AA449789		connective tissue growth factor	1.9	6.8	
~		Al631811		STRIN protein	1.1	9.7	
65		AA769221		delta-tubulin	1.1	4.3	
		R18087		cisplatin resistance related protein CRR	1	4.2	
	129579	AW517695	Hs.286218	junctional adhesion molecule 1	2.3	3.5	
				400			

	400000	411/000044	11 100051			
		AW968941		hypothetical protein DKFZp566I133	2.4	4.4
		AA209534		tetraspan NET-6 protein	3.2	13
		D79338		CCR4-NOT transcription complex, subunit	1.6	4.6
_	129621	AL110212	Hs.301005	purine-rich element binding protein B	1.1	5.7
5		AB020335	Hs.181300	sel-1 (suppressor of lin-12, C.elegans)-	0.9	4.3
	129663	AI207406	Hs.11866	translocase of inner mitochondrial membr	1.9	4.8
•	129679	AW889132	Hs.11916	ribokinase	0.9	4.1
	129688	U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
	129691	M26939	Hs.119571		4.7	3.7
10		U46386	Hs.12102	sorting nexin 3	1.2	3.6
- •		AL050272	Hs.12305	DKFZP566B183 protein	1	8.9
		BE397454		Homo sapiens clone 24707 mRNA sequence		3.6
		BE218319	Hs.5807	GTPase Rab14	2.9	5.1
		M62839	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3	5.1
15		AF052112			1.6	
15			Hs.12540	lysosomal		8.8
		AL080084		CGI-100 protein	0.9	5.3
		AW410233		YME1 (S.cerevisiae)-like 1	1.8	9.9
		NM_014840		KIAA0537 gene product	0.9	3.6
20		AA626937		hypothetical protein MGC2594	1.4	9.5
20		Z43161		30 kDa protein	1.1	6.3
		AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	2	5.1
	129976	X14008	Hs.234734	lysosomal	0.9	4.9
	129982	Z14221		gb:H.sapiens germline transcript of lg h	1.2	3.6
25	130007	R15917	Hs.142570	Homo sapiens clone 24629 mRNA sequence	4.3	1.3
	130060	BE277024		RNA binding motif protein, X chromosome	1.6	3.8
		X57815.comp		Empirically selected from AFFX single pr	1.2	8.2
		M93143	Hs 262869	plasminogen-like	1.4	7.9
		H97878		zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838	hypothetical protein FLJ10773	0.2	4.6
50		W61005	Hs.14896		1.	4.1
				DHHC1 protein		
		AA916785		splicing factor proline/glutamine rich (	1.2	5.3
		T47294		X-box binding protein 1	3.8	0.8
25		NM_005095		zinc finger protein 262	1	4.2
35		BE094848	Hs.15113	homogentisate 1,2-dioxygenase (homogenti	0.5	4
		R42678		KIAA0564 protein	1	3.7
		M23115	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	0.4	4.4
	130213	BE278370	Hs.15265	heterogeneous nuclear ribonucleoprotein	1.7	7.5
	130215	BE301883	Hs.152707	glioblastoma amplified sequence	1	5.6
40	130232	U29463		gb:Human cytochrome b561 gen	1.2	4.2
	130252	U92014	Hs.153527	Homo sapiens pTM5 mariner-like transposo	1.3	3.6
		W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
		AB040914		KIAA1481 protein	2.9	7.5
		AW067800		stanniocalcin 2	3.2	0.2
45		AW842182		small inducible cytokine A5 (RANTES)	1.4	10.6
73		AW163518			1.7	11.7
				huntingtin interacting protein 2		
		AA852868		KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3
50		AW362955	Hs.15641	Homo sapiens cDNA FLJ14415 fis, clone HE		7.6
50		R44163	Hs.12457	hypothetical protein FLJ10814	0.9	4.1
		AB007915	Hs.158286	KIAA0446 gene product	1	3.8
	130546	Al598022	Hs.193989	TAR DNA binding protein	1.3	4.7
	130568	AA232119	Hs.16085	putative G-protein coupled receptor	1.2	9.4
	130606	Al652143	Hs.288382	hypothetical protein FLJ13111	1	4.1
55	130612	BE242873	Hs.16677	WD repeat domain 15	1.1	3.6
		AL049963		up-regulated by BCG-CWS	0.6	3.8
		AL045128		glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
		AL042896	Hs.1697	ATPase, H+ transporting, lysosomal (vacu	0.9	3.9
		AW073971		ESTs, Weakly similar to KIAA1204 protein	0.9	6.9
60				ESTs, Moderately similar to 154374 gene		3.9
00		AI557212	Hs.17132		2.6	
		AF158555		glutaminase	1.2	13.8
		AI861791	Hs.278479		1.3	4
		Al831962	Hs.17409	cysteine-rich protein 1 (intestinal)	2.5	4
65		AL117508		KIAA0737 gene product	1.3	6.2
65		AI928985	Hs.17680	hypothetical protein MGC1314 similar to	1.4	3.9
		R68537	Hs.17962	ESTS	3.2	0.8
	130694	NM_014827	Hs.17969	KIAA0663 gene product	1.1	4.8

	130696	AA325308	Hs.18016	Homo sapiens mRNA; cDNA DKFZp586H032	4 (f	1.8
		Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
	130707	AW190925	Hs.203559		1.2	4.1
_		Al932971	Hs.18593	Homo sapiens cDNA: FLJ21449 fis, clone C	1.4	6.9
5		AF072813	Hs.252831	reticulon 3	1.2	11.2
		AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
		NM_001761	Hs.1973	cyclin F	1.3	4.1
		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.2 1	5.9 3.8
10		AB037750 AW195747	Hs.21061 Hs.21122	KIAA1329 protein hypothetical protein FLJ11830 similar to	1.3	7.9
10		BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe		3.7
		BE390905	Hs.21198	translocase of outer mitochondrial membr	1.9	4
		H96115	Hs.21293	UDP-N-acteylglucosamine pyrophosphorylas		10.3
		AB023182		KIAA0965 protein	1.5	6.8
15		AA393071		leucine aminopeptidase	1.4	5.5
	130975	AA099923	Hs.283728	PEST-containing nuclear protein	1.3	3.8
		BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
		D87436	Hs.166318	• • • • • • • • • • • • • • • • • • • •	1.6	3.5
20		AA194422	Hs.22564	myosin VI	4.5	5
20		AL137682	Hs.22937	I-kappa-B-interacting Ras-like protein 2	2	3.7
		BE387561	Hs.22981	DKFZP586M1523 protein		4.5
		W27770	Hs.75354	ESTs, Weakly similar to T31475 hypotheti GCN1 (general control of amino-acid synt	0.9 2.1	3.5 4.5
		BE620886 BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25		AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
		AW953575		p53-induced protein PIGPC1	4.5	13.5
		X77753	Hs.23582	tumor-associated calcium signal transduc	3.4	0.4
		Al472209	Hs.323117		8.0	4.9
	131164	AW013807	Hs.182265	keratin 19	3.3	2.4
30	131181	H25094	Hs.293663	ESTs, Moderately similar to I38022 hypot	0.6	4
		AW864222	Hs.24083	KIAA0997 protein	1.4	3.8
		AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341	transcriptional co-activator with PDZ-bi	0.7	4.7
35		Al815486		Homo sapiens cDNA FLJ20738 fis, clone HE		8.2
33		D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7 1.3	3.5 5.4
		AW956868 AU077158	Hs.24608 Hs.24930	DKFZP564D177 protein tubulin-specific chaperone a	1.6	4.8
		AU077002	Hs.24950	regulator of G-protein signalling 5	1.4	4.4
		Al750575		nuclear factor I/A	3.3	2.2
40		AW293399		nuclear receptor co-repressor 1	1.6	3.9
		NM_006052	Hs.26146	Down syndrome critical region gene 3	1	11.1
	131388	NM_014810	Hs.92200	KIAA0480 gene product	5	2
		Al452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
4.5		AW960146		hypothetical protein FLJ12888	1	3.5
45		BE270734	Hs.2795	lactate dehydrogenase A	2	6.5
		AB040927		KIAA1494 protein	1.5	10.7
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.3 1.3	4.7 4.9
		AF157326 T47364		TBP-interacting protein interferon, alpha-inducible protein 27	1.5	8
50		AA936296		DKFZP586G011 protein	1.8	3.5
50		C18825	Hs.29191	epithelial membrane protein 2	1.3	8.2
		D83032		nuclear protein	2.8	3.9
		BE514605	Hs.289092	Homo sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
	131670	H03514	Hs.10130	ESTs	1.3	4.8
55	131697	C19034	Hs.288613	Homo sapiens cDNA FLJ14175 fis, clone NT	3.2	9.7
		AF103798	Hs.30819	hypothetical protein	1.3	5.2
		AW160865	Hs.30888	cytochrome c oxidase subunit VIIa polype	1.3	7.8
		AF017986	Hs.31386	secreted frizzled-related protein 2	10.6	14.7
60		AI805664	Hs.31731	peroxiredoxin 5	1.1	3.6
60	131781 131791	AF077036	Hs.31989	DKFZP586G1722 protein	1.6	3.7 3.5
		Al681917	Hs.3321	gb:H.sapiens VII-5 gene for immunoglobul ESTs, Highly similar to IRX1_HUMAN IROQU	1.1	3.5 1.2
		NM_014874	Hs.3363	KIAA0214 gene product	0.6	4.2
		NM_004642	Hs.3436	deleted in oral cancer (mouse, homolog)	2.4	4.9
65		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	2.4	6
		AA772603	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	1.7	9.2
		BE252983	Hs.35086	ubiquitin specific protease 1	0.5	5.2

	131947	Al123939	Hs.182997	ESTs	0.7	4.1
	131961	AA129782	Hs.3576	Homo sapiens mRNA full length insert cDN	0.9	4.8
	131964	AW381148	Hs.198365	2,3-bisphosphoglycerate mutase	1.1	6.1
_	131974	AF208856	Hs.268122	hypothetical protein	1.3	3.9
5	131983	AF119665	Hs.184011	pyrophosphatase (inorganic)	3.3	6.9
	131997	AF229181	Hs.136644	CS box-containing WD protein	0.9	5.2
	132006	AW162336	Hs.3709	low molecular mass ubiquinone-binding pr	1.2	3.6
	132063	BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosulfate sy	3.2	1.8
	132065	BE379335	Hs.211594		1.2	3.6
10	132071	AF217798	Hs.3850	LIS1-interacting protein NUDEL; endoolig	0.7	5.2
	132079	AI701457	Hs.38694	ESTs	2	5.3
	132094	NM_016045	Hs.3945	CGI-107 protein	1.2	4.3
	132116	AW960474	Hs.40289	ESTs	3.1	3.1
	132164	Al752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3.7
15	132181	AW961231	Hs.16773	Homo sapiens clone TCCCIA00427 mRNA se	equ	1.2
	132208	AL031709	Hs.241575	hypothetical protein CAB56184	1.4	4.2
	132258	AA306325	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
	132303	BE177330	Hs.325093	Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
	132316	U28831	Hs.44566	KIAA1641 protein	5.9	1.6
20	132358	NM_003542	Hs.46423	H4 histone family, member G	5.8	1.5
	132384	AA312135	Hs.46967	HSPCO34 protein	2.1	9.3
	132397	AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	4.6
	132413	AW361383	Hs.260116	metalloprotease 1 (pitrilysin family)	2	4.9
	132442	AW970859	Hs.313503		1.2	5
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2	3.9
	132540	BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
	132554	AF065391	Hs.194718	zinc finger protein 265	1.2	4
		AV660538		60S ribosomal protein L30 isolog	3	1.7
20		AF029750		TAP binding protein (tapasin)	1.8	4.7
30		AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
		AA353044	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	4.2	2
		Al264357	Hs.55405	hypothetical protein MGC16212	1.1	5.3
25		AK000868	Hs.5570	hypothetical protein FLJ10006	1.4	5.2
35		BE222975	Hs.56205	insulin induced gene 1	1.1	5.8
		F07424	Hs.279840	zinc finger protein 222	1.3	3.7
		AB020713	Hs.56966	KIAA0906 protein	2.3	6.3
		AW975748	Hs.5724	sclerostin	0.7	7.7
40		BE268048		RAB10, member RAS oncogene family	1.8	6.2
40		D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 fis, clone C	1	3.8
		AW118826	Hs.6093	Homo sapiens cDNA: FLJ22783 fis, clone K	0.7	5.4
		BE263252	Hs.6101	hypothetical protein MGC3178	1.6	4.1
45		Al248173		hypothetical protein MGC12936	1	4.2
45		BE539199	Hs.62112	zinc finger protein 207	1.5	4.4
		X77343 Y00062	HS.334334	transcription factor AP-2 alpha (activat	13.9	0.8
		AW499985		protein tyrosine phosphatase, receptor t	0.6	4.6 11.1
		NM_006379	Hs.42915	ARP2 (actin-related protein 2, yeast) ho sema domain, immunoglobulin domain (lg),	1.5 3.5	1
50		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA		
50		AW502761	Hs.30909	KIAA0430 gene product	0.9	4.5 5.5
		H12028			4	
		Al654133	Hs.6396 Hs.30212	jumping translocation breakpoint thyroid receptor interacting protein 15	1.7 0.6	5.3 4.9
		AK000708		hypothetical protein FLJ20701	1.2	3.5
55		AF089816	Hs.6454	chromosome 19 open reading frame 3	1.2	17.5
55		AA808177	Hs.65228	ESTs	0.9	5.1
		AV655783	Hs.661	Empirically selected from AFFX single pr	1.1	4.5
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	1.5	4.8
		AF231981		homolog of yeast long chain polyunsatura	5.5	5.9
60		AA464362	Hs.6748	hypothetical protein PP1665	1.2	3.7
50		AB037773	Hs.6762	hypothetical protein	1.6	8.6
		W32474		RAP2A, member of RAS oncogene family	2.4	4.8
		AL137480	Hs.6834	KIAA1014 protein	1	4.2
		AW796524	Hs.68644	Homo sapiens microsomal signal peptidase	1.3	3.9
65		BE617892	Hs.6895	actin related protein 2/3 complex, subun	1.4	5.4
	133271	Z48633		H.sapiens mRNA for retrotransposon	3.1	0.7
	133273	N27672	Hs.69469		2.5	6.5

	133287	AW797437	Hs.69771	B-factor, properdin	1.3	4	
			Hs.69855	NRAS-related gene	1.4	5	
			Hs.699	peptidylprolyl isomerase B (cyclophilin	2.2	6.8	
~			Hs.69997	zinc finger protein 238	1.5	4.3	
5			Hs.70333	hypothetical protein MGC10753	1.4	6.3	
				apolipoprotein A-II	0.2	3.6	
			Hs.71475		0.6 1,2	5 4.2	
			Hs.72157	and the second s	3.7	5.8	
10				KIAA0447 gene product	1.4	5.1	
10				hexokinase 2	0.9	6.3	
			Hs.73287	KIAA1235 protein	1.2	3.7	
	133442	AL137663	Hs.7378	Homo sapiens mRNA; cDNA DKFZp434G227	(fr	0.7	4.8
	133448	M27749	Hs.288168	immunoglobulin lambda-like polypeptide 1	1.1	4.3	
15			Hs.7381	voltage-dependent anion channel 3	0.7	4.2	
			Hs.74284	hypothetical protein MGC2714	3.1	5.9	
			Hs.74316	desmoplakin (DPI, DPII)	4.3	11.5	
			Hs.74346	hypothetical protein MGC14353	1.8	19.7	
20			Hs.74579	KIAA0263 gene product Empirically selected from AFFX single pr	1.2 1.4	5.4 3.9	
20			Hs.225936		0.8	4.9	
	133589				2	10.8	
			Hs.75111		2.1	4.5	
				wee1+ (S. pombe) homolog	3.3	1.1	
25	133617		Hs.75249	ADP-ribosylation factor-like 6 interacti	2.3	5.6	
	133651	Al301740	Hs.173381	dihydropyrimidinase-like 2	0.8	13.5	
				popeye protein 3	1	9.1	
			Hs.75438	quinoid dihydropteridine reductase	0.5	5.8	
20	133668			mitogen-activated protein kinase 6	1.1	6.9	
30				zinc finger protein 146	1.8 1.5	3.8	
			Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo heterogeneous nuclear ribonucleoprotein	2	11.1 3.9	
			Hs.75667	synaptophysin	0.6	3.5	
			Hs.75824	KIAA0174 gene product	1.2	7.2	
35			Hs.75847	CREBBP/EP300 inhibitory protein 1	1.5	5	
			Hs.75873	zyxin	1.2	4.8	
			Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	4.1	
	133776			ADP-ribosyltransferase (NAD+; poly (ADP-	2.1	3.8	
40				DKFZP564B167 protein	1.9	12.6	
40			Hs.76293	thymosin, beta 10	2.6	6.6	
			Hs.76297	G protein-coupled receptor kinase 6	1	4.9	
			Hs.76325	step II splicing factor SLU7	0.5 1.5	3.8	
			Hs.7644 Hs.76550	H1 histone family, member 2 Homo sapiens mRNA; cDNA DKFZp564B1264		4.5 3.7	5.6
45			Hs.76688	carboxylesterase 1 (monocyte/macrophage	0.3	4.4	5.0
			Hs.76704	ESTs	5.5	2.9	
			Hs.76930	synuclein, alpha (non A4 component of am	0.6	4.8	
	133887		Hs.77271	protein kinase, cAMP-dependent, catalyti	1	10.2	
	133892	AW859528	Hs.301497	arginyltransferase 1	0.9	4.8	
50			Hs.7753	calumenin	2.8	10.5	
			Hs.77542	ESTs	1.8	5.6	
			Hs.7756	proteasome (prosome, macropain) 26S subu	1.5	6.6	
	133947		Hs.77810		1.5	3.8	
55	133987			v-Ki-ras2 Kirsten rat sarcoma 2 viral on von Hippel-Lindau syndrome	0.9 2.3	4.3 4.3	
55			Hs.78202	SWI/SNF related, matrix associated, acti	3.3	3.4	
	133990		Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C1210		1.3	5.7
				hypothetical protein hCLA-iso	1	6.5	•.,
			Hs.78683	ubiquitin specific protease 7 (herpes vi	1.7	3.6	
60	134042	AI027881	Hs.7869	lysosomal	1	7.5	
			Hs.78825	matrin 3	1.2	4	
			Hs.79069	cyclin G2	2.7	4.8	
			Hs.79086	·	3.3	2.1	
65	134207	443U39		KIAA0009 gene product	1.3 1.7	3.5	
65	134210		Hs.80019 Hs.80205	programmed cell death 6 pim-2 oncogene	0.8	6.9 5.3	
			Hs.80919	synaptophysin-like protein	1.4	11.4	
	107210			of the section of the section			

	40.40		11 00000		0.0	۰.
		NM_004369	Hs.80988	collagen, type VI, alpha 3	2.6	3.5
		NM_000712	Hs.81029	biliverdin reductase A	1.8	5.8
		Al022650	Hs.8117	erbb2-interacting protein ERBIN	1.1	3.6
~		R00603	Hs.8128	phosphatidylserine decarboxylase	1.1	5.9
5		NM_001430	Hs.8136	endothelial PAS domain protein 1	0.5	4.8
		AL037800	Hs.8148	selenoprotein T	1.7	7.9
		D50683	Hs.82028	transforming growth factor, beta recepto	0.8	7.6
		X76534	Hs.82226	glycoprotein (transmembrane) nmb	2.2	3.6
1.0		N22687	Hs.8236	ESTs	1.9	3.6
10		AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.5	8.3
		BE512856	Hs.109051	SH3 domain binding glutamic acid-rich pr	1.1	3.6
		A1750762	Hs.82911	protein tyrosine phosphatase type IVA, m	1.9	4.6
	134417	NM_006416	Hs.82921	solute carrier family 35 (CMP-sialic aci	1.2	7.5
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.6	8.7
15	134439	Z23024	Hs.138860	Rho GTPase activating protein 1	2	3.9
	134454	NM_013230	Hs.286124	CD24 antigen (small cell lung carcinoma	3.5	1.1
	134494	D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
	134501	W84869	Hs.211568	eukaryotic translation initiation factor	1.2	5.7
	134505	AW960673	Hs.177530	ATP synthase, H+ transporting, mitochond	1.3	3.9
20	134520	BE091005	Hs.74861	activated RNA polymerase II transcriptio	1.8	4.3
	134528	M23161	Hs.84775	Human transposon-like element mRNA	8.0	5.6
	134545	AI902899	Hs.85155	butyrate response factor 1 (EGF-response	1.4	5
	134553	AI203545	Hs.296169		8.0	3.9
	134573	NM_016142	Hs.279617	steroid dehydrogenase homolog	1.3	5.7
25		AB033017	Hs.8594	KIAA1191 protein	0.9	3.7
		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4	6.8
		AW936928	Hs.85963	DKFZP564M182 protein	2.2	4.3
		AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.6	3.6
		AF078859	Hs.86347	hypothetical protein	2.1	3.5
30		AF265208	Hs.123090	SWI/SNF related, matrix associated, acti	1.7	4.2
20		AK000606	Hs.8868	golgi SNAP receptor complex member 1	4.4	0.9
		D17530	Hs.89434	drebrin 1	3.1	1.6
		T51986	Hs.283108		0.5	4.6
		AA428520	Hs.90061	progesterone binding protein	1.3	3.7
35		J03464	Hs.179573	collagen, type I, alpha 2	8.7	17.3
55		AA587775	Hs.66295	multi-PDZ-domain-containing protein	1.7	4
		AB020689	Hs.90419	KIAA0882 protein	3.4	0.9
		Al803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
		AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40		R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
		AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1	4.3
		BE560779		NICE-5 protein	1.4	10.4
		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	1.6	4.1
45		AB037835	Hs.92991	KIAA1414 protein	1.2	5.6
15		AW301984		hypothetical protein FLJ12619	1.7	7.6
		AL034344		forkhead box C1	3.2	0.6
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.2	4.1
		AK001887		protein kinase, AMP-activated, gamma 2 n	1.3	4.8
50		AK000967	Hs.93872	KIAA1682 protein	2	3.7
50		AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
		AB017363		frizzled (Drosophila) homolog 1	2.4	4.8
		T97257		ESTs, Moderately similar to I38022 hypot	1.4	5.8
		AA132813	Hs.69559	KIAA1096 protein	1.8	8.5
55 r		BE563088	Hs.9552	binder of Arl Two	1.2	6.8
55 ,		AB028956	Hs.12144	KIAA1033 protein	3.1	1.4
		BE250865	Hs.279529	px19-like protein	1.3	7.5
		AA534009	Hs.183487	interferon stimulated gene (20kD)	1.3	3.8
	135333	AL038812	Hs.96800	ESTs, Moderately similar to ALU7_HUMAN A		3.9
60	125280	AW372569	Hs.9788	hypothetical protein MGC10924 similar to	0.9	8.4
00	135203	AA331901		hypothetical protein FLJ10097	1	3.8
	135250	T83882	Hs.97927	ESTs	1.2	3.5
	1353/0	AA114212	Hs.9930	serine (or cysteine) proteinase inhibito	2.6	8.9
	125257	Al565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	2.5	5.4
65	13530F	M16029	Hs.287270		0.4	7.9
05	135300	W79431	Hs.326249		1.5	4.5
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	1.8
	100400	A 0002	. 13.033 13	androgen receptor (diriyarotestestestestes t		

5	302892 302963 303131 303150 310125 312662	AA887146 AA147979 AA233808	Hs.42346 Hs.151945 Hs.103180 Hs.8217 Hs.285005 Hs.286241	Homo sapiens cDNA FLJ12843 fis, clone NT calcineurin-binding protein calsarcin-1 mitochondrial ribosomal protein L43 DC2 protein stromal antigen 2 mitochondrial import receptor Tom22 protein kinase, cAMP-dependent, regulato	3.3 0.9 3 6.2 1.2	3.6 1.6 4.2 17.3 4 6.6 3.5			
10	320591 406779 410691	AA054761 AA412048 AW239226	Hs.169149 Hs.279574 Hs.65450	junctional adhesion molecule 1 karyopherin alpha 1 (importin alpha 5) CGI-39 protein; cell death-regulatory pr reticulon 4	1.3 1.2	4.7 5.6 3.5 13.9			
15	415738 420186 422055	BE539367 NM_015925 NM_014320	Hs.95697 Hs.111029	hypothetical protein FLJ21776 ESTs, Weakly similar to AF220049 1 uncha liver-specific bHLH-Zip transcription fa putative heme-binding protein	2 1.3 1.5 2	5.1 3.9 6.2 11.3			
20	426218 427397 427466	AF119043 Al929685 AA523543	Hs.168005 Hs.177656 Hs.7678	ESTs, Moderately similar to 138022 hypot Homo sapiens cDNA FLJ13372 fis, clone PL calmodulin 1 (phosphorylase kinase, delt cellular retinoic acid-binding protein 1	1.3 1.1	3.6 2.8 4.7 3.7			
20	427723 428673 430219	Al355260 AW601325 X99209	Hs.279789 Hs.324278 Hs.235887	26S proteasome-associated pad1 homolog histone deacetylase 3 Homo sapiens mRNA; cDNA DKFZp566M063 HMT1 (hnRNP methyltransferase, S. cerevi	1.8	2.5 22 1.1 8.8	5.2		
25	432866 433423	R23553 BE395875 BE407127 AB001636		hypothetical protein mitochondrial carrier homolog 2 heat shock 70kD protein 1A DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.1 1.5 1.3 1.6	5.6 6.1 7.6 6.5			
30	437754 440252	R60366	Hs.286218 Hs.5822 Hs.6101 Hs.7857	junctional adhesion molecule 1 Homo sapiens cDNA: FLJ22120 fis, clone H hypothetical protein MGC3178 erythrocyte membrane protein band	1.3 2 1.1 0.5	3.5 5.7 6.2 3.7	×.		
35	449404 449964	BE281316 H51066 AW001741 N73222		hypothetical protein FLJ14495 leptin receptor gene-related protein hypothetical protein FLJ10706 matrix Gla protein	2.5 1.1 1.4 4	4.9 3.6 3.5 11.2			
		Al634651 RC_H15847_s RC_W84712	Hs.30250	v-maf musculoaponeurotic fibrosarcoma (a peptidylprolyl isomerase B (cyclophilin B) calumenin lysozyme (renal amyloidosis)	0.8 1.8 3.5 0.9	5.6 4.8 4.6 4.5			
40		X14008_ma1_ RC_H86543_f H07011 RC_AA164586	i_s	ESTs ESTs; Weakly similar to SAS [H.sapiens]	1.8 1.8 ESTs	6.6 3.9 6.2	0.8		
45		RC_AA070485 RC_H98714_s RC_AA406145 AA458584		Homo sapiens clone 23967 ESTs SRY (sex determining region Y)-box 4	3.4 1.6 ESTs 3.4	2.6 3.5 4.6 0.4	3		
50		AA031548 X02761 RC_AA487193 R25326	<b>i</b>	cell division cycle 42 (GTP-binding protein; 25 fibronectin 1 secreted frizzled-related protein 4 Homo saplens mRNA for putative vacuolar	kD) 3.6 4.7 0.9	3.1 15.2 4 5	3.9		
		RC_AA393805 RC_AA449333 RC_AA287681 RC_AA490864	_s	ESTs; Weakly similar to (defline not ESTs  ESTs; Highly similar to heat shock factor	1.1 2.9 ESTs 1.4	8.4 4.6 1.3 5	4		
55		RC_C14243_f R21443 RC_AA251902		ESTs; Highly similar to heat shock factor ESTs Homo sapiens lysophospholipase (LPL1) small inducible cytokine A5 (RANTES)	1.7 1.6 2.2 0.9	5 3.7 3.8 9.9			
60		M21121_s C00038_s Y00503 RC_R27006_f		ESTs keratin 19 ESTs	2.8 3.1 1.6	4.8 1.1 3.7			
65		RC_AA416886 RC_AA460450 RC_AA488433 RC_AA278400 U28831 RC_AA199588	Lf	ESTs; Weakly similar to predicted using fibroblast growth factor receptor 2 (bacteria-ESTs; Weakly similar to deduced amino acid Human protein immuno-reactive with anti-PTHomo saplens actin-related protein Arp3 (ARF	Homo sapie 14.4	3.1 3.7 4 ens HRIHFB211 0.6 1.8	5 mRNA; partial cds	1.5	3.6

AF006082	Homo sapiens actin-related protein Arp2 (Al	RP2)	1.6	10.9
RC_H90899	desmoplakin (DPI; DPII)	5.4	5.5	
RC_W95070 ·	desmoplakin (DPI; DPII)	5	2.6	
RC_T90946_f	Human mRNA for KIAA263 gene; complete	cds	1.1	3.9
D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
AA313414_s	ESTs; Weakly similar to cDNA EST EMBL:1	1157	1.5	5.3
RC_H73484_s	ESTs; Weakly similar to similar to Yeast	1.3	6.3	
AFFX-HUMISGF3A/M97	935_3		2.3	13.5
AFFX-HUMRGE/M10098	3_5	1.1	7.9	
AFFX-M27830_5			0.5	7.4
AFFX-M27830_5			0.6	5.4
RC_AA063431_f		ESTs	0.8	4.1
RC_T63769_f	ferritin; light polypeptide	1.1	3.7	
	RC_H90899 RC_W95070 RC_T90946_f D87258 AA313414_s RC_H73484_s AFFX-HUMISGF3A/M97 AFFX-HUMRGE/M10098 AFFX-M27830_5 AFFX-M27830_5 RC_AA063431_f	RC_H90899 desmoplakin (DPI; DPII) RC_W95070 desmoplakin (DPI; DPII) RC_T90946_f Human mRNA for KIAA263 gene; complete D87258 protease; serine; 11 (IGF binding) AA313414_s ESTs; Weakly similar to cDNA EST EMBL:1 RC_H73484_s ESTs; Weakly similar to similar to Yeast AFFX-HUMISGF3A/M97935_3 AFFX-HUMRGE/M10098_5 AFFX-M27830_5 AFFX-M27830_5 RC_AA063431_f	RC_H90899       desmoplakin (DPI; DPII)       5.4         RC_W95070       desmoplakin (DPI; DPII)       5         RC_T90946_f       Human mRNA for KIAA263 gene; complete cds         D87258       protease; serine; 11 (IGF binding)       2.4         AA313414_s       ESTs; Weakly similar to cDNA EST EMBL:T1157         RC_H73484_s       ESTs; Weakly similar to similar to Yeast       1.3         AFFX-HUMISGF3A/M97935_3       1.1         AFFX-HUMRGE/M10098_5       1.1         AFFX-M27830_5       1.1         AFFX-M27830_5       RC_AA063431_f	RC_H90899       desmoplakin (DPI; DPII)       5.4       5.5         RC_W95070       desmoplakin (DPI; DPII)       5       2.6         RC_T90946_f       Human mRNA for KIAA263 gene; complete cds       1.1         D87258       protease; serine; 11 (IGF binding)       2.4       3.5         AA313414_s       ESTs; Weakly similar to cDNA EST EMBL:T1157       1.5         RC_H73484_s       ESTs; Weakly similar to similar to Yeast       1.3       6.3         AFFX-HUMISGF3A/M97935_3       2.3         AFFX-HUMRGE/M10098_5       1.1       7.9         AFFX-M27830_5       0.5         AFFX-M27830_5       0.6         RC_AA063431_f       ESTs       0.8

### TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

35

40

45

50

60

### Pkev CAT number Accessions

Pkey	CA1 number	Accessions
		AA079487 AA128547 AA128291 AA079587 AA079600 AA973971 T88817 AA253263
114636	109698_1	AA075488 AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519 AA074510 AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335
		AA078829 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296
123526	genbank_AA6	08657 AA608657
123533	genbank_AA6	08751 AA608751
125154	genbank_W38	419 W38419
118475	genbank_N668	845 N66845
118505	genbank_N673	343 N67343
101046	entrez_K01160	0K01160
129982	221_267	Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
		AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X6
		Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278
	108469 125076 114636 123526 123533 125090 125154 118475 118505 101046	108469 116761_1 125076 190299_1 114636 109698_1 123526 genbank_AA6 123533 genbank_AA6 125090 genbank_T91! 125154 genbank_W38 118475 genbank_N66 118505 genbank_N67 101046 entrez_K0116 129982 221_267

(62107 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM\_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 Al857980 AW368899 Al905833 AW406586 AA482084 Al872299 AA715266 AW404328 Al831674 Al709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113

55 108470 genbank\_AA079500 AA079500 101447 entrez\_M21305 M21305 124447 genbank\_N48000 N48000 101624 entrez\_M55998 M55998

131791 221\_260

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043 H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 Al735017 T47421 R48719 H27570 H44599 Al45958 H42347 H41938 H24993 AA345888 H22339 Al538691 AJ012264 AA664201 Al880450 AA327310 Al991250 AI833028 AW001210 AI956075 H30467 AA326915 H41943 AI749266 AI744441 AA327377 AW512326 AI735170 H01634 5 Al587047 Al571623 AA327486 AA327103 AA327195 AA326973 T28143 R56485 R37248 R59992 124842 217726\_1 AA084874 f 103758 AA084874\_f\_at X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 130064 221\_264 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 10 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063764 15 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500 AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z74694 AF194588 AF194601 U09901 U09911 U09992 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 20 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599 AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF093581 AF103620 AW405934 Al445389 AW383753 AA360256 AF099676 H21654 H39501 Al820828 H53689 W26785 AW384496 AW407708 AA541663 AA911602 AI821461 AA588300 AA327050 H42717 AI951280 AA421322 AI923193 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 25 130232 18831\_2 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 T88946 F10106 AA232161 AA243117 AA158937 AA100864

AA167512

109097 genbank\_AA167512

# TABLE 9: Figure 9 from BRCA 001-2 US

Table 9 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

	Pkey:	Unique Eos probeset identifier number
10	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

15	Pkey	ExAccn	UnigenelD	UnigeneTitle
	100690	AA383256		estrogen receptor 1
		BE314524		putative transmembrane protein
20			Hs.82128	5T4 oncofetal trophoblast glycoprotein
20		AF183810	Hs.26102	opposite strand to trichorhinophalangeal syndrome I
	105038	AW503733		KIAA1488 protein
	105500	AW602166	Hs.222399	CEGP1 protein
	105990	Al690586	Hs.29403	hypothetical protein FLJ22060
	106155	AA425414	Hs.33287	nuclear factor I/B
25	106373	AW503807	Hs.21907	histone acetyltransferase
	106414	BE568205	Hs.28827	mitogen-activated protein kinase kinase kinase 2
	110009	BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal
	111900	AF131784	Hs.25318	Homo sapiens clone 25194 mRNA sequence
	114540	Al904232	Hs.75323	prohibitin
30	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone COL03924
	119771	Al905687	Hs.2533	EST
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypothetical protein YGL050w
35	131148	AW953575	Hs.303125	p53-induced protein PIGPC1
	132371	AA235448	Hs.46677	PRO2000 protein
	134169	Al690916	Hs.178137	transducer of ERBB2, 1
		AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112
		AL133619	Hs.29383	Homo sapiens mRNA; cDNA DKFZp434
				•

# TABLE 10: Figure 10 from BRCA 001-3 PCT

Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal body tissue
	R2:	Ratio of 90th percentile tumor to body
15	R3:	Ratio of 75th percentile body to tumor
	R4:	Ratio of tumor to normal breast tissue

20	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
	100082	AA130080	Hs.4295	proteasome (prosome, macropain) 26S subu	4.2	152	36	12.2
		AA380887	Hs.5085	dolichyl-phosphate mannosyltransferase p	9.8	123	13	5
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
25		H60720	Hs.81892	KIAA0101 gene product	4.1	320	78	10.6
		D14661	Hs.119	Wilms' tumour 1-associating protein	4.7	119	26	3
		AL037228		D123 gene product	5.1	106	21	9.2
		BE242284	Hs.172199	adenylate cyclase 7	4.7	47	1	4.3
		D26361	Hs.3104	KIAA0042 gene product	4.7	47	4	0.7
30		AW972300		bone marrow stromal cell antigen 2	3.8	350	93	1.9
50		D29677	Hs.3085	KIAA0054 gene product; Helicase	4.1	64	16	3
		NM 01515		KIAA0071 protein	3.4	77	23	5.9
		NM_00620		platelet-derived growth factor receptor-	4.5	45	4	4
		D38491	Hs.322478	KIAA0117 protein	5.9	59	1	2.6
35		D42084	Hs.82007	KIAA0094 protein	3.5	96	28	1.3
50		BE247550		growth factor receptor-bound protein 7	3.1	306	98	1.5
		AA331881		peroxiredoxin 3	12.8	128	1	11.7
		AW247529		platelet-activating factor acetylhydrola	4.2	187	44	5.4
		AI878927	Hs.79284	mesoderm specific transcript (mouse) hom	4.5	129	29	3.1
40		D80004	Hs.75909	KIAA0182 protein	3.5	78	23	4.8
-10		D86957	Hs.80712	KIAA0202 protein	10.2	102	1	4.8
		D86961	Hs.79299	lipoma HMGIC fusion partner-like 2	4	40	1	3.8
		NM_01473		KIAA0215 gene product	3.2	32	2	2.9
		D86978	Hs.84790	KIAA0225 protein	3.6	36	7	3.2
45		AA013051		topoisomerase (DNA) II binding protein	5.6	76	14	2
10		AA347720		KIAA0264 protein	3.5	35	9	3.1
		AF234887	Hs.57652	cadherin, EGF LAG seven-pass G-type rece	5.5	145	27	2.2
		D87470	Hs.75400	KIAA0280 protein	3.4	34	1	1.2
		X51501	Hs.99949	prolactin-induced protein	22.7	760	34	1.4
50		AA019521		lysosomal	14.4	144	9	4.7
50		NM_00503		plastin 3 (T isoform)	4.1	259	63	1.9
	100661		Hs.132748	Homo sapiens ribosomal protein L39 mRNA,	3.3	116	36	2.2
		L05424	Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
		L05424	Hs.169610	CD44 antigen (homing function and Indian	3	594	201	2.3
55			Hs.144630	nuclear receptor subfamily 2, group F, m	5	82	17	0.9
55		J05581	Hs.89603	mucin 1, transmembrane	3.5	37	11	2.8
		AF078847	Hs.191356	general transcription factor IIH, polype	9.7	97	10	7.2
	100821		7,0.70.700	gb:Homo sapiens (clone 104) retinoblasto	3.3	33	1	0.8
	100864		Hs.74861	activated RNA polymerase II transcriptio	3.7	477	130	3.1
60		X80821	Hs.27973	KIAA0874 protein	6.3	63	4	5.7
00		BE245294	Hs.180789	S164 protein	4.7	47	1	4.2
		BE297139		replication protein A2 (32kD)	3.8	115	30	7.1
		K01160		NM_002122:Homo sapiens major histocompat	3.9	390	100	11.1
			Hs.250502	carbonic anhydrase VIII	3.9	39	8	3.6
	101010		5.200002					

	101084	AW409934	He 75528	nucleolar GTPase	4.1	53	13	4
		AW862258		neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_00162		aryl hydrocarbon receptor	11.3	113	8	3.9
		L20320	Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9
5		AU077288		ADP-ribosylation factor-like 1	4	110	28	10.7
		BE545277		Ts translation elongation factor, mitoch	4.2	50	12	4.4
		BE535511		transmembrane trafficking protein	6.6	135	21	13.1
		BE267931		proliferating cell nuclear antigen	6.4	249	39	22.4
10		M21305	113.70000	gb:Human alpha satellite and satellite 3	6.5	878	135	0.8
10		NM_000424	1Hs 195850	keratin 5 (epidermolysis bullosa simplex	4.8	622	130	0.7
		NM_000546		tumor protein p53 (Li-Fraumeni syndrome)	5.1	97	19	9.3
		NM_002890		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		AA053486		interferon-induced protein with tetratri	11.2	112	8	5.9
15		X16896	Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
10		BE391804		guanylate binding protein 1, interferon-	3.6	36	1	2.6
		M55998	113.02001	gb:Human alpha-1 collagen type I gene, 3	3.1	2898	923	2.2
		AA436989	He 121017	H2A histone family, member A	6.9	103	15	8.4
		M63256	Hs.75124	cerebellar degeneration-related protein	6.4	64	2	4.9
20		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
20		S70114	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	3.6	824	227	1.4
		M83822	Hs.62354	cell division cycle 4-like	9	144	16	13
		M84605	Hs.957	putative opioid receptor, neuromedin K (	3.3	36	11	2.4
25		AW024390		pre-B-cell leukemia transcription factor	5.4	180	34	15.9
43		M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
		AA446644		GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
		AL049610		transcription elongation factor A (SII)-	7.3	73	1	5.3
		AL049010 AL036287		calponin 3, acidic	3.8	399	105	3.3
30		BE245149		protein tyrosine kinase 9	4.6	148	32	11.3
50		U11313	Hs.75760	sterol carrier protein 2	9.5	95	4	8.8
		NM 001809		centromere protein A (17kD)	4.2	42	7	3.4
		NM_006456		sialyltransferase	9.3	93	4	3
		NM_004419		dual specificity phosphatase 5	5.4	137	26	2.5
35		AA450274		CDC16 (cell division cycle 16, S. cerevi	4.6	151	33	2.0
55		BE313280		death associated protein 3	9.3	93	5	8
		AL036335		secreted phosphoprotein 1 (osteopontin,	45.7	457	1	39.7
		BE314524		putative transmembrane protein	3.9	442	114	1.3
		NM_006769		LIM domain only 4	4.9	49	1	3.6
40		U27185	Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	i	1.3
40		NM_001546		inhibitor of DNA binding 4, dominant neg	3.8	163	43	0.5
		AA306342		protein kinase C-like 2	4.5	45	1	3.6
		AF015224		mammaglobin 1	8.5	2058	243	1.4
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
45		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
73		AW602154		E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330		selenophosphate synthetase 2	3.3	111	34	7.5
		NM_001394		dual specificity phosphatase 4	20.2	202	5	1.3
		NM_003937		kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50		U63830	Hs.146847	TRAF family member-associated NFKB activ	8.2	82	i	6.8
50		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
		AL037672		extracellular matrix protein 1	10.2	628	62	17.2
		U67319	Hs.9216	caspase 7, apoptosis-related cysteine pr	5	66	13	5.3
		NM_002270		karyopherin (importin) beta 2	6.1	126	21	2.4
55		U71207	Hs.29279	eyes absent (Drosophila) homolog 2	4.5	45	1	2.8
55		U79293	Hs.159264	Human clone 23948 mRNA sequence	4.1	41	i	2.4
		U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58	1.6
		U90304	Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6
		BE242035	Hs.151461	embryonic ectoderm development	3.5	35	1	2.7
60				carboxypeptidase D	5.6	56	1	5.3
UU		D85390	Hs.5057	clones 23667 and 23775 zinc finger prote	4.2	42	7	3.7
		BE262386	Hs.7137	signal recognition particle receptor ('d	3.2	58	18	5
		Al815559	Hs.75730	keratin 15 .	5.2 5.8	753	131	0.4
		NM_00227		keratin 18	3.1	815	266	1.7
65		BE512730		activating transcription factor 2	3.1	32	4	2.6
05		AL119505		methylene tetrahydrofolate dehydrogenase	5.7	251	44	6.6
		AU076611		trefoil factor 1 (pS2)	5.7 5.6	1346	239	5.4
	103003	Al910275	Hs.1406	troiotriactor i (poz)	5.0	10-70	200	U. <del>T</del>

		AW500470			5.8	218	38	13
		NM_002343		lactotransferrin	3.7	1421	388	1.9
	103036	M13509	Hs.83169		3.1	94	30	5.8
-		AA926960	Hs.334883		3.5	332	94	3.1
5	103119	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	4.8	312	65	30.9
	103134	X65724	Hs.2839	Norrie disease (pseudoglioma)	5.2	331	64	1.5
	103134	X65724	Hs.2839	Norrie disease (pseudoglioma)	4.9	49	5	3.8
	103171	AW583058	Hs.234726	serine (or cysteine) proteinase inhibito	3.3	1497	458	2.1
	103206	X72755	Hs.77367	monokine induced by gamma interferon	3.5	796	228	3.2
10	103208	AW411340		retinoblastoma-binding protein 7	5.6	191	34	3.5
	103226	X75042	Hs.44313	v-rel avian reticuloendotheliosis viral	4.1	53	13	4.9
		AA206186		monocyte to macrophage differentiation-a	3.4	34	8	2.3
	103346		Hs.5464	thyroid hormone receptor coactivating pr	3.9	43	11	1
	103352		Hs.78853		9.3	93	8	8.2
15		NM 005982			9.7	97	1	9.3
		AL036166		coated vesicle membrane protein	6.3	98	16	9.1
	103370		Hs.114366	pyrroline-5-carboxylate synthetase (glut	4.3	77	18	7.2
		AW175781		M-phase phosphoprotein 6	4.9	153	31	2.4
			Hs.180139	SMT3 (suppressor of mif two 3, yeast) ho	4.9	261	53	3.7
20				protein tyrosine phosphatase, receptor t	3.5	564	162	1.7
20	103471		Hs.75216		3.9	49	13	2.5
		AW408009		alkylglycerone phosphate synthase	7.5	136	18	3.4
		AL133415		vimentin				
		BE270266		5T4 oncofetal trophoblast glycoprotein	7.9	79 745	2	6.9
25		BE409838		cadherin 1, type 1, E-cadherin (epitheli	3.3	745	229	1.8
25		AW403814		BCL2-associated athanogene	3.2	41	13	2.8
		NM_000346		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
		380000_MM		collagen, type I, alpha 1	3.8	1612	429	3.1
	103666	NM_003528	3Hs.2178	H2B histone family, member Q	3.2	32	5	2.8
	103988	AA314389	Hs.42500	ADP-ribosylation factor-like 5	3.2	32	9	2.7
30	103990	AB033112	Hs.42179	bromodomain and PHD finger containing, 3	4.9	49	1	4.2
	104052	NM_002407	'Hs.97644	mammaglobin 2	7.2	498	69	9.3
	104115	AF183810	Hs.26102	opposite strand to trichorhinophalangeal	29	290	1	26.8
	104129	H63349	Hs.98806	hypothetical protein	3.7	37	7	2.1
	104146	AW880614	Hs.146381	RNA binding motif protein, X chromosome	5.2	52	1	4.3
35	104147	BE081342	Hs.283037	HSPC039 protein	8	84	11	6.3
		AB012113		small inducible cytokine subfamily A (Cy	5.8	58	1	3.2
		AB002367		doublecortin and CaM kinase-like 1	6.4	64	8	3
		AW583693		N-terminal acetyltransferase complex ard	4.7	229	49	7.9
		AI337300	Hs.284123	hypothetical protein MGC4604	3.2	32	7	2.4
40		AA129551		Homo sapiens cDNA: FLJ21409 fis, clone C	5.3	144	27	13.1
	104432		Hs.99949	prolactin-induced protein	6.9	1494	218	1.3
		R56678	Hs.88959	hypothetical protein MGC4816	7.7	77	8	6.9
		AA040620		hypothetical protein AF140225	3.7	37	5	2.5
		AW373062		nuclear receptor subfamily 1, group I, m	6.1	493	81	0.7
45		H47610	113.00020	gb:yp75f03.s1 Soares fetal liver spleen	3.8	38	4	1.2
73		AF123303	Uc 2/712	hypothetical protein	4.8	231	49	7.3
			Hs.30977	ESTs, Weakly similar to B34087 hypotheti	3.4	154	46	3
		H00820		protein kinase (cAMP-dependent, catalyti	5	468	94	4.7
		R82252	Hs.106106	Homo sapiens mRNA; cDNA DKFZp564D016 (fr		82	22	3.1
50		BE298665			14.9	149	1	6.4
30		Al239923	Hs.30098	ESTs			26	3.2
		BE244072	HS.20815	macrophage erythroblast attacher	6.3	165		
		AA027317			3.8	40	11	3.8
		AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	7.7	77	1	5.1
,		AI139058	Hs.125790	leucine-rich repeat-containing 2	7	70	1	6.5
55	104846	AI250789	Hs.32478	ESTs	4.7	201	43	4.5
	104896	AW015318	Hs.23165	ESTs	7.4	74	1	6
	104919	AA026880	Hs.25252	prolactin receptor	3.9	280	72	3.3
	104926	BE298808	Hs.33363	DKFZP434N093 protein	4.2	135	32	4
	104943	AF072873	Hs.114218	frizzled (Drosophila) homolog 6	16.2	162	1	4.2
60	104968	AI249502	Hs.29669	ESTs	3.8	38	1	2.4
		Al392640	Hs.18272	amino acid transporter system A1	3.2	522	165	1.9
		AA121686		ESTs	3.2	32	4	2.9
		Al122691	Hs.13268	ESTs	3.7	157	43	3.6
		AW503733		KIAA1488 protein	5.5	55	1	5.2
65		AB037716		KIAA1295 protein	10.3	103 -	1	3.9
		AA148710		lumican	6.6	66	1	5.4
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.1	31	1	2.5

	105091	AA148859	Hs.179909	hypothetical protein FLJ22995	3.2	32	1	3
	105143	Al368836	Hs.24808	ESTs, Weakly similar to 138022 hypotheti	7.3	73	1	3.8
		AA307279		methyl-CpG binding domain protein 4	4.2	90	22	2.8
		AL133033		KIAA1025 protein	6	60	6	4.6
5							2	3.2
5		AW612147		Homo sapiens C1orf19 mRNA, partial cds	3.8	38		
		AA313825		AD036 protein	9.3	436	47	5.8
	105195	AA975096	Hs.19522	hypothetical protein PRO2849	5.7	57	8	5.3
	105200	AA328102	Hs.24641	cytoskeleton associated protein 2	4.5	45	1	3.6
	105248	AW952479	Hs.22826	tropomodulin 3 (ubiquitous)	4.3	43	1	3.9
10		AB039670		ALEX1 protein	8	80	6	7.3
10		AW997484		KIAA0456 protein	3.9	39	6	3.2
		AA894638		ESTs	3.5	35	7	2.7
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	4.5	45	10	0.5
		AK000796		hypothetical protein	3.8	93	25	7.5
15	105329	AA234561	Hs.22862	ESTs	2.8	131	47	3.9
	105344	AF151073	Hs.8645	hypothetical protein	3.9	79	20	6.5
		AW994032		hypothetical protein FLJ10849	5.1	181	36	15.8
		AW500718		Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3,3
								5.6
20		AF198620		RNA binding motif protein 8A	6.2	62	6	
20		W20027	Hs.23439	ESTs	3.3	206	63	2.2
	105483	AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fis, clone L	3.2	466	146	8.4
	105496	AL117441	Hs.301997	hypothetical protein FLJ13033	16.6	166	8	12.7
	105500	AW602166	Hs.222399	CEGP1 protein	25.4	508	20	3
		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (f		117	13	10.6
25		AB037829		regulator of nonsense transcripts 2; DKF	3.2	32	6	1.5
23								
		AK001269		hypothetical protein FLJ10407	8.3	83	3	1.8
		AB040884		KIAA1451 protein	3.5	73	21	1.6
	105564	BE616694	Hs.288042	hypothetical protein FLJ14299	5.8	336	58	2
	105610	AA280072	Hs.99872	fetal Alzheimer antigen	3.2	32	1	1
30	105616	R35343	Hs.24968	Human DNA sequence from clone RP1-233G16	4.8	79	17	5.2
		AA281279	Hs 23317	hypothetical protein FLJ14681	4	75	19	1.7
		AA001021		thyroid hormone receptor interactor 8	4.5	45	1	3.7
							i	0.1
		AW294631		ESTs	3.6	36		
2.5		Al609530	Hs.279789	histone deacetylase 3	6.4	64	8	6
35	105687	NM_014517	7Hs.28423	upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
	105691	A1680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
	105730	AW377314	Hs.5364	DKFZP564I052 protein	6.9	69	1	4.4
		AA834664		nuclear receptor coactivator 2	3.4	34	1	3.1
		BE246502		sema domain, immunoglobulin domain (lg),	3	30	10	0.9
40							1	4.4
40			Hs.15159	chemokine-like factor, alternatively spl	5.4	54		
		H57111	Hs.221132	ESTs	5.3	67	13	5.3
	105774	AW369278	Hs.23412	hypothetical protein FLJ20160	4.9	49	1	4.5
	105784	W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
	105795	AA878183	Hs.17448	Homo sapiens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45		AF206019		REV1 (yeast homolog)- like	4	40	3	3.2
		AA788946		ESTs, Moderately similar to CA1C RAT COL	4.7	747	158	5.7
								4.6
		A1559444	Hs.293960	ESTs	3.9	371	94	
		AW802282		pyruvate dehydrogenase phosphatase	3.6	68	19	6
	105840	AA601518	Hs.22209	secreted modular calcium-binding protein	4.8	134	28	3.2
50	105851	Al827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
•	105864	A1640775	Hs.28332	Homo sapiens cDNA: FLJ21560 fis, clone C	4.3	43	1	3.7
		AW021691		GCN5 (general control of amino-acid synt	3.6	36	7	3.1
		AK001708		hypothetical protein FLJ10846	3.4	34	8	2.9
							13	1.3
F F		AK001735		UDP-glucose:glycoprotein glucosyltransfe	3.6	45		
55		N25986	Hs.22380	ESTs	3.4	34	1	1.5
	106012	A1240665	Hs.8895	ESTs	21.2	212	6	17.4
	106020	AA043039	Hs.7870	hypothetical protein	3.9	47	12	4.4
	106024	AL122072	Hs.103804	heterogeneous nuclear ribonucleoprotein	4.4	174	40	1.6
		AW952005		hypothetical protein FLJ12903	4.7	47	1	4
60		AA382267		ESTs	3.4	49	15	4.4
00			113, 10000					1.2
		AA417034	11- 000074	gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	
		BE614474		F-box only protein 22	3.4	116	35	2.2
		NM_001329	9Hs.171391	C-terminal binding protein 2	3.6	444	125	4.6
	106070	T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.6	365	103	6.9
65	106095	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	26.3	356	14	1
		AW379378		protein tyrosine phosphatase, receptor t	3.2	267	83	2.3
		AA576953		hypothetical protein FLJ13352	3.8	38	1	3.3
	100120	, 4-101 0000	110,22012	11/postosion protoni i Ed 1000Z	5.0	50	•	5.5

	100155		11 00007	and the second second	0.0	400	40	4.0
		AA425414		nuclear factor I/B	9.9	483	49	1.8
		W37943	Hs.34892	KIAA1323 protein	6.7	94	14	8
	106198	AI244563	Hs.325531	Homo sapiens clone 015h12 My015 protein	3.3	95	29	4.4
_	106236	AB040896	Hs.21104	KIAA1463 protein	3.8	83	22	7.5
5	106286	AI765107	Hs.274422	hypothetical protein FLJ20550	3.3	97	30	6.4
	106290	AW961393	Hs.16364	hypothetical protein FLJ10955	4.5	116	26	4.5
		R98185	Hs.17240	ESTs	7	70	3	1.3
		AB007866		KIAA0406 gene product	3.2	37	12	2.6
		AW977397		ESTs	3.8	38	1	1.9
10						255	16	6.6
10		AA447453		Homo sapiens mRNA; cDNA DKFZp586M0723 (i				
		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone C	4.9	337	70	2.7
	106394	Z42993	Hs.25320	Homo sapiens clone 25142 mRNA sequence	3.1	72	23	5
	106432	AK000310	Hs.17138	hypothetical protein FLJ20303	3.1	165	54	1.6
	106459	AA789081	Hs.4029	glioma-amplified sequence-41	3.1	31	1	2.6
15	106503	AB033042	Hs.29679	cofactor required for Sp1 transcriptiona	5.5	147	27	4.4
		Al205785	Hs.30348	ESTs	4.4	222	51	1.8
		NM_014892		KIAA1116 protein	7.4	74	3	1.7
		AA243837		ESTs	15.2	152	1	12.6
					3.8	263	69	3.9
20		AK000933		Homo sapiens cDNA FLJ10071 fis, clone HE				
20		AA452379		ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
		R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
		AW188205	Hs.12311	Homo sapiens clone 23570 mRNA sequence	5.3	166	32	14.9
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (f	5.4	75	14	8.0
	106683	BE296396	Hs.14512	DIPB protein	3.6	210	58	4.7
25	106698	N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
		N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
		AA600357		TIA1 cytotoxic granule-associated RNA-bi	4.3	101	24	1.6
		NM_007118		triple functional domain (PTPRF interact	4.6	46	1	4.
					3.5	58	17	1.6
20		AL044182		KIAA0753 gene product				
30		AB037744		KIAA1323 protein	5.4	192	36	4.4
		BE185536		molecule possessing ankyrin repeats indu	3.3	696	214	1.8
	106882	AA149537	Hs.26994	hypothetical protein FLJ20477	3.8	38	1	1.6
	106893	AA835868	Hs.25253	mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
	106895	AK001826	Hs.25245	hypothetical protein FLJ11269	3.6	36	1	1.2
35	106897	AF039023	Hs.167496	RAN binding protein 6	4.5	45	1	3.8
		AA134329		Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3
		Al868648	Hs.22315	ESTs	3.5	180	52	2.3
		AF216751		CDA14	5.5	130	24	12.5
		AA280722		ESTs, Weakly similar to I38022 hypotheti	3.2	266	83	1.8
40					5.1	298	59	4.4
40		AL157479	HS.23/40	KIAA1598 protein				
		AA598820		gb:ae36h12.s1 Gessler Wilms tumor Homo s	3.3	228	69	2.8
		AV650537		succinate-CoA ligase, GDP-forming, beta	3.1	55	18	3.8
	107056	AW401864	Hs.18720	programmed cell death 8 (apoptosis-induc	3.1	75	24	2.2
	107071	AW385224	Hs.35198	ectonucleotide pyrophosphatase/phosphodi	3.1	367	119	2.3
45	107080	AL122043	Hs.19221	hypothetical protein DKFZp566G1424	3.9	98	25	8.6
	107102	AB037765	Hs.30652	KIAA1344 protein	6.3	63	1	5.4
	107109	AA249096	Hs.32793	ESTs	4.6	71	16	3.6
		AV661958		GK001 protein	2.5	392	155	4.3
		AW378065		ESTs	15.6	156	7	10.8
50		AL080235		DKFZP586E1621 protein	4.8	48	8	3.1
50		BE172058		tumor rejection antigen (gp96) 1	3.4	251	74	23.7
					3.6	36	6	0.5
		Al290284		ESTs			_	4
		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	
		AA186629		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	199	44	19.2
55		BE277457	Hs.30661	hypothetical protein MGC4606	12.5	156	13	2.9
	107316	T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (f	3.2	110	35	9.6
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	2.6
	107485	AL042613		S-adenosylmethionine decarboxylase 1	5.8	151	26	11.4
		A1498986	Hs.60090	Homo sapiens cDNA FLJ13595 fis, clone PL	3.2	32	5	2.1
60		A1580492	Hs.42743	hypothetical protein	4.4	73	17	6.2
00				ubiquitin-like 3	3.5	282	80	3.7
		AA149707				85	15	7.8
		AW732573		potassium voltage-gated channel, delayed	5.7			1.0
		AW372451		CGI-79 protein	3.5	35	1	
~~		AA054949		ESTs	4.3	43	10	2.7
65		AA025782		ESTs	3.1	31	9	2.2
		AF087999		ESTs	4.7	47	4	4.3
	107922	BE153855	Hs.61460	Ig superfamily receptor LNIR	9	90	1	5.5

	107994	AA036811	Hs.48469	LIM domains containing 1	4.5	45	1	3.8
		AL121031		SWI/SNF related, matrix associated, acti	6.5	65	2	6
		AJ404672		hypothetical protein FLJ23571	7.4	74	8	6
		BE548479		hypothetical protein FLJ10773	3.4	34	1	2.3
5	108339	AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	1	17
	108467	A1478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
	108539	AA084677	Hs.54558	hypothetical protein FLJ22222	5.7	57	1	4.9
	108634	AW022410	Hs.69507	ESTs	3.2	32	5	1.7
	108647	BE546947	Hs.44276	homeo box C10	8.7	247	29	5.7
10		AB029000		KIAA1077 protein	3.7	625	168	3.8
		AF133123		general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo sapiens clone 24674 mRNA sequence	3.4	34	1	2.8
			Hs.49376	hypothetical protein FLJ20644	3.5	35	1	3.2
1.5		AW295647		hypothetical protein MGC5350	5.3	53	1	2.8
15		AL117452		DKFZP586G1517 protein	4.8	96	20	6.5
		AK001468		anillin (Drosophila Scraps homolog), act	5.4	54	1	4
		BE276891		retinoic acid induced 3	3.1	529	170	4.1
			Hs.173648	ESTs, Weakly similar to Zinc-finger prot	3.3	33	5	1.7
20		NM_007240		dual specificity phosphatase 12	3.4	34	1	2.6
20		BE062109		chloride channel, calcium activated, fam	3.1	31	8	2
		AW608930		hypothetical protein FLJ20618	3.4	71	21	2.4
		AW419196		hypothetical protein FLJ13782	4.1	334	82	3.4
		AK000684		hypothetical protein FLJ22104	3.3	33	1	2.9
25		H89083	Hs.181915	ESTs	4	40	7	1.1
23		BE220601		hypothetical protein FLJ13033	3.8	233 199	62 23	3.8
		AA219691		RAB6 interacting, kinesin-like (rabkines	8.8	32	1	16.1 2.2
		AA179962		Home conions of NA: EL 121254 fis close C	3.2 3.2	32	10	2.2
		AW976516 Al381800	Hs.300684	Homo sapiens cDNA: FLJ21354 fis, clone C	4.9	121	25	10.4
30		AA375752		calcitonin gene-related peptide-receptor Homo sapiens mRNA; cDNA DKFZp586F1822 (f		114	39	9.9
50		AW975746		KIAA1702 protein	7.1	71	1	6.5
		AL096858		KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
		R98881	Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
		BE543313		hypothetical protein FLJ10520	4.2	56	14	2.2
35		U80736	Hs.110826	trinucleotide repeat containing 9	12.3	123	1	11.3
50		AA878923		hypothetical protein FLJ21016	3.2	286	91	5.7
		Al631874	Hs.155140	casein kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
		AA989362		ESTs	5.9	59	10	4.2
		F10024	Hs.268740	ESTs	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (i	5.9	208	36	1.8
	109799	AW965076	Hs.180378	hypothetical protein 669	5	50	5	4.1
	109883	R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
	109912	AW390822	Hs.301528	L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
		Al084066	Hs.20072	myosin regulatory light chain interactin	4.1	41	7	1.7
45		AA001266		ESTs	4.2	58	14	0.8
		Al796320	Hs.10299	Homo sapiens cDNA FLJ13545 fis, clone PL	3.2	136	43	3.6
		BE075297		ESTs, Weakly similar to A43932 mucin 2 p	6.3	693	110	7.2
		A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC		913	199	2.9
50		AK000768		hypothetical protein FLJ20761	3.8	38	7	2.8
50		Al610702	Hs.28212	ESTs, Weakly similar to TRHY_HUMAN TRICH		78 27	12	3
		H11236	Hs.31034	peroxisomal biogenesis factor 11A	3.7	37	1	2.1
		AF075089	Hs.36823	ESTs	3.6	36	10 1	2.5 1.8
		H61560 AA071276	He 104co	gb:yr22g03.s1 Soares fetal liver spleen	3.3 3.5	33 35	8	1.9
55		AB007902		KIAA0859 protein	3.6	282	79	1.7
55		H97678	Hs.31319	KIAA0442 protein ESTs	4.4	103	24	3.8
		NM_014899		KIAA0878 protein	3.3	138	42	3.6
		BE000831		Homo sapiens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
		N22414	113.20007	gb;yw39a07.s1 Weizmann Olfactory Epithel	5.4	54	i	3.7
60			Hs.12244	hypothetical protein FLJ20097	4.7	47	4	4.2
00		AI089660	Hs.323401	dpy-30-like protein	5	50	i	4.3
		AL157503	Hs.27552	Homo sapiens mRNA; cDNA DKFZp586N2424 (i		31	i	2.7
		AF153330		solute carrier family 19 (thiamine trans	8.4	84	<u>i</u>	5.3
		AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65		BE612992		hypothetical protein FLJ10607 similar to	7.9	79	1	6.2
		AW963705		molecule possessing ankyrin repeats indu	3.9	353	90	1.2
	110908	Al433165	Hs.9856	ESTs	3.1	31	1	1.3

	110915	BE092285	Hs.29724	hypothetical protein FLJ13187	20.9	209	1	19.5
		BE242691	Hs.14947	ESTs	3.4	115	34	2.4
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.5	35	9	3.2
_		H44186	Hs.15456	PDZ domain containing 1	4.3	43	1	2
5		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	5.4	54	1	4.3
		AB037807		hypothetical protein	7.2	72 77	10	6.1
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5
		AK000136		asporin (LRR class 1)	25.1 3.9	288 146	12 37	6.7 9.8
10			Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.3	63	1	5.8
10		AK002055 AB037782		hypothetical protein FLJ11193 KIAA1361 protein	3.7	119	33	6.7
		AA852773		KIAA1866 protein	3.6	402	112	4.9
		AW389845		ESTs	4.3	43	1	1
		AA902656		NIF3 (Ngg1 interacting factor 3, S.pombe	3.3	33	i	1.1
15		AA345644		PAN2 protein	4.8	61	13	5.6
		AW263155		hypothetical protein FLJ10540	4.3	43	5	2.2
		W20090	Hs.6616	ESTs	4.1	41	1	2.6
	111357	BE314949	Hs.87128	hypothetical protein FLJ23309	3.8	425	111	4
	111378	AW160993	Hs.326292	hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20	111389	AK000987	Hs.169111	oxidation resistance 1	3.4	314	91	2.4
	111540	U82670	Hs.9786	zinc finger protein 275	3.5	35	1	2.1
	111806	BE071382	Hs.279008	hypothetical protein FLJ20170	3.5	105	30	9.6
		AW502285		hypothetical protein FLJ12879	3.2	37	12	3.5
0.5		BE383234		Homo sapiens, clone MGC:15393, mRNA, com		62	2	5.9
25		AF027208		prominin (mouse)-like 1	8.1	328	41	1.7
		R40576	Hs.21590	hypothetical protein DKFZp564O0523	4.2	125	30	7.4
4		NM_015310	)Hs.6763	KIAA0942 protein	6.5	65	10	1.5
		R44538	LIa 7449	gb:yg29c02.s1 Soares infant brain 1NIB H	3.3 6.1	33	10 31	2.3 6.6
30		R41823	Hs.7413	ESTs; calsyntenin-2 ESTs	3.5	185 507	145	3.3
50		NM_003658 Al432672	Hs.288539	hypothetical protein FLJ22191	3.5	40	12	2.5
		AB029000		KIAA1077 protein	5.7	567	100	6.7
		R51818	113.7 0020	gb:yg77h12.s1 Soares infant brain 1NIB H	4	70	18	6.8
		R53734	Hs.25978	ESTs, Weakly similar to 2109260A B cell	3.7	37	1	3
35		AW972635		hypothetical protein FLJ12671	4.3	45	11	4.4
50		AA863360		ESTs, Weakly similar to fatty acid omega	2.8	751	270	1.3
		AK000914		hypothetical protein FLJ10052	3.5	41	12	3.7
		AW969785		Homo sapiens cDNA FLJ11321 fis, clone PL	4.2	42	6	3.6
	112513	R68425	Hs.13809	hypothetical protein FLJ10648	4.7	54	12	4.5
40	112571	AA412205	Hs.140996	ESTs	4.8	48	2	3.4
	112971	Z42387	Hs.83883	transmembrane, prostate androgen induced	4.5	390	87	5.3
				ESTs	3.2	99	31	3.1
		Al571940	Hs.7549	ESTs	9.6	124	13	9
15		N39342	Hs.103042	microtubule-associated protein 1B	9.1	91	6	8.3
45		AA283057		hypothetical protein FLJ14281	6.5	65	6	4.8
		T66847	Hs.194040	ESTs, Weakly similar to 138022 hypotheti	3.5	35 35	1	1.4
		AW449560		inner mitochondrial membrane peptidase 2	3.5 7.6	76	4	3.3 4.2
		A1791905	Hs.95549 Hs.296083	hypothetical protein ESTs, Moderately similar to 154374 gene	3.1	453	148	7
50		Al075407 Al869372	Hs.17207	Homo sapiens cDNA FLJ11922 fis, clone HE	3.6	36	4	2.6
50		T97307	113.17207	gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		AL359588	Hs.7041	hypothetical protein DKFZp762B226	4.6	46	4	4.3
		A1269096	Hs.135578	chitobiase, di-N-acetyl-	3.6	36	1	1.2
		T62849	Hs.11090	membrane-spanning 4-domains, subfamily A	3.3	744	227	2.5
55		BE247683	Hs.14611	dual specificity phosphatase 11 (RNA/RNP	3.3	180	54	2.1
	113808	W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	5.1	51	5	4.5
	113847	NM_005032	2Hs.4114	plastin 3 (T isoform)	3.2	238	75	2.1
		AA457211		bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
		AW002834	Hs.24095	ESTs	6.1	110	18	10.2
60		W76027	Hs.23920	hypothetical protein FLJ11105	4	48	12	4
		AW953484		hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	4.3	819	191	1.2
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fr		123	12	7
65		A1825386	Hs.164478	hypothetical protein FLJ21939 similar to	4.4	44 45	6	2.3
65	114051	AB026436	Hs.177534	dual specificity phosphatase 10	4.5	45 35	4	2.6
		AF116653		Homo sapiens PRO0823 mRNA, complete cds	3.5 3.1	35 31	6 5	3.2 1.5
	114082	AK001612	113.20302	Homo sapiens cDNA FLJ10750 fis, clone NT	J. 1	J1	J	1.0

	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
	114162	AF155661		pyruvate dehydrogenase phosphatase	3.8	73	19	1.8
_	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4	104	24	5.1
5		AL049466		ESTs	5.7	57	1	4.9
		AL137667		Homo sapiens mRNA; cDNA DKFZp434B231 (fr		33	1	2.4
	114251			ESTs	4.2	46	11	1.4
		AF100143		fibroblast growth factor 13	4.5	45	2	3
10		AF183810		trichorhinophalangeal syndrome I	4.4 4.7	44 770	166	ა 5.8
10		AW970128 Al521936	Hs.107149	anterior gradient 2 (Xenepus laevis) hom novel protein similar to archaeal, yeast	5.2	52	3	2.3
			Hs.154443	minichromosome maintenance deficient (S.	4.6	196	43	10
		AF212848		ets homologous factor	13.7	137	1	8.9
		AV656017		CGI-76 protein	3.3	168	51	7.3
15		AA159181		serologically defined colon cancer antig	7.4	137	19	1.8
	114821	AI648602		ESTs	4.7	57	12	4.7
	114860	AL157545		bromodomain and PHD finger containing, 3	9.1	91	1	7.6
	114918	BE165762	Hs.23518	hypothetical protein from BCRA2 region	10.1	111	11	10.2
20		BE092696		ESTs	6.4	67	11	5
20		Al733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
		AW162998		KIAA1376 protein	9.4	94	8	7.3
		AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens		115	1 9	6.9
		AA329340		mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	1	1.1 4.2
25		AW265668	Hs.41271	hypothetical protein FLJ12428 Homo sapiens mRNA full length insert cDN	5.1 4.5	51 290	65	3.7
23		AI751438 NM_014158		HSPC067 protein	4.8	48	1	4.4
			Hs.191533	ESTs	3.2	49	16	4.2
		AK000219		hypothetical protein FLJ20212	3.3	33	1	3
		AW183695		ESTs	5.8	58	1	5
30		AW365434		hypothetical protein FLJ10116	5.5	343	62	2.5
	115262	AI422867	Hs.88594	ESTs	11.2	112	1	10.3
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	4.5	96	21	7.8
		AK001468		anillin (Drosophila Scraps homolog), act	5.9	59	1	4.2
25		NM_012317		leucine zipper, down-regulated in cancer	9.8	98	1	8.8
35		AA081395		Homo sapiens cDNA FLJ10366 fis, clone NT	4.6	46	2	1.8
		Al088691	Hs.208414	Homo sapiens mRNA; cDNA DKFZp564D0472 (f	3.2	44 372	7 115	1.1 2.1
		N36110		solute carrier family 2 (facilitated glu Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
		AW992356 W87707	Hs.82065	interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
40		AW992405	4	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
.0		AW899053		F-box only protein 8	3.1	58	19	2.5
		AW582256		anterior gradient 2 (Xenepus laevis) hom	5.7	368	65	28.5
		AW338063		zinc-finger protein ZBRK1	3.9	39	8	2.2
	115825	R50956	Hs.159993	gycosyltransferase	4.2	79	19	1.9
45	115839	BE300266	Hs.28935	transducin-like enhancer of split 1, hom	5.8	58	1	4.4
		Al373062		hypothetical protein MGC5370	6.2	62	1	5.4
		AA291377		ESTs	3.2	40	13	0.7
		Al745379		ESTs	8.4	101	12	8.7
50		AW673312		hypothetical protein FLJ20331	3.6	36	1	2
30		Al198719 AL133916	Hs.176376	ESTs hypothetical protein FLJ20093	5.1 3.4	51 34	8	1
		AF126743		DNAJ domain-containing	3.5	35	8	3.3
		AF189011		putative ribonuclease III	4.5	45	9	3.4
		AW861622		Homo sapiens cDNA FLJ14934 fis, clone PL	5.2	52	4	3.9
55		AW976438		RBP1-like protein	3.8	38	7	2.1
	116238	AV660717	Hs.47144	DKFZP586N0819 protein	5.1	198	39	17.9
	116250	N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	13.3	133	8	3.2
			Hs.88201	ESTs, Weakly similar to A Chain A, Cryst	3.3	106	33	9.8
		Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	4.8	179	38	2.8
60		AL133033	Hs.4084	KIAA1025 protein	3.2	173	55	3
		AL133623	Hs.82501	similar to mouse Xm1 / Dhm2 protein	3.7	37	1	1.8
		N50174	Hs.46765	ESTs hypothetical protein DKFZp761C169	3.9 5.6	39 106	10	0.6 9
			Hs.71252 He 270023	putative nucleotide binding protein, est	5.6 3.6	106 256	19 72	3.7
65		Al654450	Hs.279923 Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr		119	39	2
0.5		AA313607	Hs.58633	Homo sapiens cDNA: FLJ22145 fis, clone H	5.5	315	58	3.1
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6
			<del>-</del> ·	• • •				

	116507	AI418366	Hs.68501	ESTs	3.1	31	4	1.9
		AW888411		leukemia-associated phosphoprotein p18 (	3.3	931	279	5.6
		F01601	Hs.241567	RNA binding motif, single stranded inter	3.6	36	1	1.9
		Al768015	Hs.92127	ESTs	4.5	96	22	6.9
5	116680	AW902848	Hs.273829	ESTs	4.2	42	1	2.7
		F10577	Hs.306088	v-crk avian sarcoma virus CT10 oncogene	7.1	71	9	6.9
		AA741307		hypothetical protein FLJ20073	4.3	190	44	5.4
		H25836	Hs.301527	ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
10		AW362955		Homo sapiens cDNA FLJ14415 fis, clone HE	4.9	108	22	9
10		AW161357		microtubule-associated protein tau	4.6 6.9	163 69	35 10	7.3 2.4
		H64938	Hs.337434	ESTs, Weakly similar to A46010 X-linked	4.8	48	1	2.5
		AW085208 H91164	Hs.335797	ESTs ESTs	3.3	33	i	2.3
		H95785	Hs.167652	ESTs, Highly similar to 1819485A CENP-E	3.1	38	13	1.7
15		AW901347		hypothetical protein FLJ23342	4.8	48	1	0.9
		N25929	Hs.42500	ADP-ribosylation factor-like 5	3.1	295	96	27.9
		W03011	Hs.306881	MSTP043 protein	3.6	41	12	2.8
		M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	4.4
	117367	Al041793	Hs.42502	ESTs	3.5	72	21	1.3
20	117412	N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
		N30205	Hs.93740	ESTs, Weakly similar to 138022 hypotheti	3.2	35	11	0.7
		AW341639		hypothetical protein FLJ22059	5	50	1	4.7
		U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.5	211 1	47	5
25			Hs.136102	KIAA0853 protein	4.6	46	1	3.8
25		N49967	Hs.46624	HSPC043 protein	3.1 4.9	31 49	1	2.7 4.4
		A1521436	Hs.38891	ESTS	4.9 5	50	2	3.1
		AA374756 Al813865	Hs.164478	Homo sapiens mRNA for KIAA1771 protein, hypothetical protein FLJ21939 similar to	3.6	89	25	0.9
		AF091434	Hs.43080	platelet derived growth factor C	3.2	378	117	2.8
30		AL157545		bromodomain and PHD finger containing, 3	14.5	145	1	2.4
20		N66845	113.72110	gb:za46c11.s1 Soares fetal liver spleen	3.1	199	64	1
		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	6	60	5	3.7
		Al949952	Hs.49397	ESTs	3.3	81	25	1.5
	118828	N79496	Hs.50824	EST, Moderately similar to I54374 gene N	3.4	740	217	2.8
35	118836	AW134482	Hs.173001	hypothetical protein FLJ13964	4.3	162	38	12.1
	118854	T58283	Hs.10450	Homo sapiens cDNA: FLJ22063 fis, clone H	3.4	118	35	2.3
		Al824009	Hs.44577	ESTs	3.5	35	1	2.9
		Al191811	Hs.54629	ESTs	8.4	84	10	0.8
40		AW292577		ESTs	7.3	73	3	5.4
40		N29309	Hs.39288	ESTS	5	50	5	4.7
			7Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7 3.3	37 36	6 11	0.5 0.6
		N98488 R39261	Hs.90790	gb:zb82h01.s1 Soares_senescent_fibroblas Homo sapiens cDNA: FLJ22930 fis, clone K	3.3	167	51	2.6
		R45175	Hs.117183	ESTs	5.3	53	6	2.3
45		H09334	Hs.92482	ESTs	3.7	37	4	3
10		Al061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
			1Hs.155478	cyclin T2	4	40	4	1.2
	119307	BE048061	Hs.37054	ephrin-A3	3.3	571	171	2
	119367	T78324	Hs.250895	ribosomal protein L34	3.4	34	3	2.4
50	119427	AW474547	Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
		AL079310		high-mobility group protein 2-like 1	8.1	94	12	6.5
	119586	AF088033	Hs.159225	ESTs	3.3	33	8	0.9
		NM_01612		NY-REN-58 antigen	3.3	33	10	0.5
<i>5                                    </i>		AA243837		ESTS	5.4	54	1	4.1
55		AA918317		B-cell CLL/lymphoma 11B (zinc finger pro	4.6	46 2073	7 595	0.8 2.1
		Al905687		EST	3.5 4.4	44	1	3.1
			5Hs.191381 Hs.121281	hypothetical protein prion protein 2 (dublet)	3.4	34	i	2.5
		AL133390 AJ223810		ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	36	i	2.9
60		AW245741		ESTs, Weakly similar to A35659 krueppel-	5.2	52	6	1.8
00		A1057404	Hs.58698	ESTs	3.7	37	4	1.9
			Hs.272531	DKFZP586B0319 protein	6.9	162	24	2.6
		BE565849		copine III	3.7	590	159	3.8
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	319	47	2.1
65	120150	BE005771	Hs.153746	hypothetical protein FLJ22490	5.3	53	5	0.9
			Hs.108787	phosphatidylinositol glycan, class N	3.2	106	34	3.3
	120260	AK000061	Hs.101590	hypothetical protein	3.4	34	1	1.7

	4000					404	00	4.0
		AW995911	Hs.299883	hypothetical protein FLJ23399	4.2	124	30	1.8
		R06859	Hs.193172	ESTs, Weakly similar to I38022 hypotheti	7.5	112	15	2.5
	120378	AA223249	Hs.285728	abl-interactor 12 (SH3-containing protei	3.3	33	10	2.8
		AW966893		Homo sapiens mRNA; cDNA DKFZp586F1323 (f	4.8	48	1	0.5
5		AA251973		ESTs	3.4	34	4	0.1
5				Homo sapiens clone 24630 mRNA sequence	3.9	161	42	2
		AW968080		·				
		AA261852		ESTs	6.8	68	1	0.2
		AA284447		ESTs	3.2	32	5	0.6
	120562	BE244580	Hs.302267	hypothetical protein FLJ10330	8.5	127	15	1.6
10	120571	AB037744	Hs.34892	KIAA1323 protein	3.7	37	1	0.5
		H39599	Hs.294008	ESTs	3.6	36	8	0.2
		AA703226		Homo sapiens mRNA; cDNA DKFZp586B211 (fr		101	18	1.6
				leucine zipper protein FKSG14	5.4	54	10	2.5
		AA687322						
1 ~		AI952639	Hs.98267	ESTs	3.2	32	8	3
15		AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	5.3	58	11	3.3
	120821	Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
	120822	AA347422	Hs.238040	EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
		AL135556		ESTs	3.5	37	11	0.1
		AA481003		ESTs	3.1	31	1	0.4
20							i	2.7
20		AA398155		ESTs	7.9	79		
		AI972375	Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
	121125	AL042981	Hs.251278	KIAA1201 protein	3.7	37	10	1
	121176	AL121523	Hs.97774	ESTs	7	70	1	0.9
	121202	AA970946	Hs.97794	ESTs	3.9	39	1	0.2
25		AA406293		ESTs	3.4	34	1	8.0
23		AF044197		B-cell attracting chemokine 1 (CXCL13;	3.5	35	1	2.6
				hypothetical protein FLJ20275	10.3	103	i	9.3
		AK000282						
		Al002968	Hs.235402	ESTs, Weakly similar to T26525 hypotheti	3.5	143	41	2.6
	121553	AA412488	Hs.48820	TATA box binding protein (TBP)-associate	4.6	46	3	0.8
30	121556	AA412494	Hs.98152	EST	4.2	77	19	1,.4
	121581	AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	8.0
		Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (f	3.4	34	10	0.7
		AA243499		hypothetical protein FLJ10134	2.9	214	74	3.7
					3.9	39	1	0.2
25		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT				
35		AA425887		hypothetical protein FLJ14303	4.4	48	11	0.9
	121873	AV650929	Hs.145696	splicing factor (CC1.3)	3.6	150	42	3.2
	121913	A1249368	Hs.98558	ESTs; protease inhibitor 15 (PI15)	2.7	864	321	0.6
	121916	AW117207	Hs.98523	ESTs	3.5	35	3	2.3
		Al810721	Hs.95424	ESTs	4.9	49	7	3.7
40		AW794215		KIAA1085 protein	3.2	88	28	1.2
40				adaptor protein containing pH domain, PT	12.6	126	7	7.5
		AF169797						
		AA436475		membrane-associated nucleic acid binding	4.1	43	11	1.6
		AI298368	Hs.150926	fucose-1-phosphate guanylyltransferase	3.1	31	1	1
	122383	AA446189	Hs.99051	ESTs	3.3	53	16	4
45	122507	BE567620	Hs.99210	ESTs	3.2	291	91	4
	122524	AA449453	Hs.192915	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.1	31	6	8.0
		AW651706		hypothetical protein FLJ14007	3.5	35	1	3
		AA454149		EST	3.2	32	10	3.1
					3.2	36	11	2.5
50		AW366286		splicing factor (CC1.3)				
50		AA335721		ESTs	5.6	108	20	1.8
		AA749382		ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
	122946	A1718702	Hs.308026	major histocompatibility complex, class	3.7	162	44	12.4
	122963	AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
			Hs.194215	ESTs, Weakly similar to I38022 hypotheti	4.7	59	13	4.7
55		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	3.3	207	63	3.5
55		AL135185		niban protein	3.8	207	55	5.5
					9.9	351	36	
		A1073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior				13.9
			Hs.105273	ESTs	4.1	72	18	1.5
	123284	AA488988	Hs.293796	ESTs	3.7	41	11	1.6
60	123442	AA299652	Hs.111496	Homo sapiens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564D036 (fr	3.4	34	1	2.6
			Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	9.7	102	11	6
			Hs.112110	mitochondrial ribosomal protein L42	4.2	42	7	2.9
	400500	AMOTERE	He 2024E6		3.9	39	1	3.2
65	123503	ANALOGO!	Hs.293156	ESTs, Weakly similar to I78885 serine/th				
65			Hs.173933	nuclear factor I/A	4.3	43	1	3.5
	123518	AL035414	MS.21068	hypothetical protein	5.8	58	1	4.9
	123523	AA608588		gb:ae54e06.s1 Stratagene lung carcinoma	3.1	927	295	2.1

	123527	AF150208	Hs 108327	damage-specific DNA binding protein 1 (1	5	121	25	5.9
		AA608955		ESTs	6.8	68	10	6.1
		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
_	123673	BE550112		ESTs, Weakly similar to T2D3_HUMAN TRANS	3.9	39	5	3.7
5		AA706910		ESTs	3.9	60	16	4.8
		AA425769		Alg5, S. cerevisiae, homolog of	3.4	80	24	3.8
		AW082862		hypothetical protein FLJ23189	4.5	45	2	3.6
		Al147155	Hs.270016	ESTs	5.8	321	55	17
10		BE387335		ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
10		H88296	Hs.5123	inorganic pyrophosphatase	3.1 3.2	41 32	14 1	2.7 1.5
	124292		Hs.13366	Homo sapiens cDNA: FLJ23567 fis, clone L	10.5	105	1	9.9
		AA249027 NM_005402		ribosomal protein S6 v-ral simian leukemia viral oncogene hom	12.8	141	11	12.2
		AF283776		Homo sapiens mRNA; cDNA DKFZp586C1723 (f		31	1	1.8
15		Al821780	Hs.179864	ESTs	3.3	33	1	1.7
		R01073		gb:ye84c03.s1 Soares fetal liver spleen	4.2	42	7	3
	124777	R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.4	210	63	3.3
	124940	AF068846	Hs,103804	heterogeneous nuclear ribonucleoprotein	6.5	162	25	14.7
	125079	T90298	Hs.271396	ESTs	3.1	31	6	2.4
20	125091			gb:ye20f05.s1 Stratagene lung (937210) H	3.4	985	286	2.8
		AA570056		ESTs, Moderately similar to KIAA1215 pro	3.6	224	63	4
		AB037742	Hs.24336	KIAA1321 protein	6.3	63	6	5
		W38240		Empirically selected from AFFX single pr	3.6	38	11	2.6
25		W93048	Hs.250723	hypothetical protein MGC2747	3.1	31	1	2.8
25		AA782536		N-myristoyltransferase 2	3.2 13.1	37 131	12 1	3.6 5.1
	125279	AW401809		KIAA1150 protein ESTs	7.7	81	11	7.6
		AA173319	Hs.102720	hypothetical protein MGC12217	14.3	143	9	13.1
		W72949	Hs.77495	UBX domain-containing 1	3.3	34	11	3.2
30		AL038165		translocase of outer mitochondrial membr	8.2	124	15	11.5
50		AA421691		UDP-glucose ceramide glucosyltransferase	3.7	224	61	21
		AA287921		ESTs	6.7	67	1	6
	125621		Hs.278544	acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
	125628	AA418069	Hs.241493	natural killer-tumor recognition sequenc	5.5	63	12	1
35 ·	125660	AW292171	Hs.23978	scaffold attachment factor B	4.3	68	16	2.8
	125698	AF078847	Hs.191356	general transcription factor llH, polype	4.8	48	5	4.1
		Al858032		ribophorin II	6.8	223	33	2.8
		AA143045		v-kit Hardy-Zuckerman 4 feline sarcoma v	8.3	87	11	0.4
40		NM_003403		YY1 transcription factor	11.3	124 306	11 4	9.7 26.5
40		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (f	4.9	68	14	1.4
	126349	AW090198	Hs.13531	hypothetical protein FLJ10971 KIAA1150 protein	6.4	74	12	6.6
		W78968	Hs.181307	H3 histone, family 3A	5	264	53	3.4
		AA316181		six transmembrane epithelial antigen of	3.8	38	1	2.7
45		AW518478		ESTs	3.6	36	6	2.9
		AA643322		a disintegrin and metalloproteinase doma	3.1	31	1	2.5
		AA036755		syntaxin 16	4.4	76	18	1
	126801	AW663887	Hs.7337	hypothetical protein FLJ10936	3.8	38	1	3
	126813	AW163483	Hs.48320	double ring-finger protein, Dorfin	6.7	155	23	1.4
50		AL043489		mitochondrial carrier homolog 2	8.8	110	13	10.5
		AA129640		ESTs	3.6	36	10	1.9
	126971	T26989	Hs.283664	aspartate beta-hydroxylase	5.5	79	15	4.4
		AA625690		ESTs	3.1	33 35	11 1	2.3 3.1
55		AA936428		ESTs ESTs	3.5 4.8	106	22	1
55		AA412108 D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	7.5	75	1	6.5
		A1926047	Hs.162859	ESTs	3.8	38	7	3.4
		AA703684		ESTs, Moderately similar to ALU5_HUMAN A	3.3	33	9	0.9
		AF175265		vacuolar protein sorting 35 (yeast homol	4.3	152	35	12.5
60	127774	AA313639	Hs.119488	cystein-rich hydrophobic domain 2	5.4	73	14	6.8
	127999	AW978827	Hs.69851	nucleolar protein family A, member 1 (H/	5.2	81	16	1.1
	128218	AA186733		stromal cell protein	3.9	220	57	2.5
	128305	AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3
<i></i>			Hs.100261	Homo sapiens mRNA; cDNA DKFZp564B222 (fr		46	8	3.9
65	128482	A1694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
	128501	AL133572	HS.199009	protein containing CXXC domain 2	3.8	38 73	1	0.9
	128517	AW994403	1100001	hypothetical protein FLJ14600	5.6	10	13	6.1

	128530	Al932995	Hs.183475	Homo sapiens clone 25061 mRNA sequence	4.2	104	25	7.8
	128579			Homo sapiens cDNA FLJ14232 fis, clone NT	3.1	172	55	3.1
	128595			short-chain alcohol dehydrogenase family	3.3	105	32	3
5		N48373		activated leucocyte cell adhesion molecu	7.3	106	15	5
5	128653	D87432 AA307211		solute carrier family 7 (cationic amino	3.1 3.6	31 130	1 36	2.2 3.5
		NM_004131		proteasome (prosome, macropain) subunit, granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
		AF026692		secreted frizzied-related protein 4	17.4	409	24	7.8
		AB011125		KIAA0553 protein	3.1	34	11	2.7
10		NM_014720		Ste20-related serine/threonine kinase	3.6	36	5	1.5
		AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	3.3	288	87	7.9
	128906			epithelial protein lost in neoplasm beta	11.3	113	8	2.5
		R67419		Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
1.5		AA009647		a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15		AA115333		ESTs	8.2	82	1	7.4
	129075	BE250162		dihydrofolate reductase	5 3.2	50 814	1 257	3.3 2.4
		N23018		thrombospondin 2 C-terminal binding protein 2	4.4	44	1	3.8
				chromosome 14 open reading frame 2	14.2	142	6	9.4
20		AF013758		polyadenylate binding protein-interactin	7.1	71	1	6.2
_ •		BE169531		TAK1-binding protein 2; KIAA0733 protein	5	64	13	6.3
		AF220050		uncharacterized hematopoietic stem/proge	5.2	75	15	6.4
	129278	NM_015344	lHs.11000	leptin receptor overlapping transcript-l	3.7	39	11	3.2
0.5		NM_014918		KIAA0990 protein	9.5	95	1	8.5
25		AL049538		ras association (RalGDS/AF-6) domain con	7.6	92	12	1.4
		BE220806			7.1	150	21	14.5
		BE219987		phosphatidylinositol glycan, class F	3.9 3.6	54 36	14 1	5.1 2.7
	129457	NM_005754		aspartylglucosaminidase Ras-GTPase-activating protein SH3-domain	4	40	4	3.2
30		AW964541			4.6	199	44	2.3
20	129598				4.2	42	1	3.8
		M26939		collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
	129698	BE242144	Hs.12013	ATP-binding cassette, sub-family E (OABP	4.8	48	8	3.8
2.7		NM_001415		eukaryotic translation initiation factor	5.8	171	30	2.9
35		BE165866		nuclear receptor subfamily 1, group I, m	4.5	45	1	2.4
		R42216		Homo sapiens clone 24538 mRNA sequence	5.3	53	9	3.6
		R39246		Homo sapiens cDNA FLJ13495 fis, clone PL	3.1 11.4	31 114	2 1	2.5 10
		AB028945 Al222069	Hs.13015	cortactin SH3 domain-binding protein hypothetical protein similar to mouse Dn	4.7	556	119	4.5
40	129965		Hs.13854	ESTs	3.1	31	3	3
.0		NM_000399		early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2
		BE061916		chromosome 8 open reading frame 2	6.7	67	1	5.7
	130057	AF027153	Hs.324787	solute carrier family 5 (inositol transp	1	1	1	1
		AK001635		hypothetical protein FLJ10773	14.6	219	15	7.6
45	130115			X-box binding protein 1	3.1	1336	434	1.4
		AW977534		calcium/calmodulin-dependent serine prot	5.3	53	9	3.2
	130173	AB040914		TAR (HIV) RNA-binding protein 1 KIAA1481 protein	4.2 13.2	46 331	11 25	1.1 12.4
		AF127577		nuclear receptor interacting protein 1	3.3	354	108	4
50		AL135301		hypothetical protein FLJ10849	8.1	81	9	5.5
		AW067800		stanniocalcin 2	72.2	722	1	1.9
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	6.5	65	4	5.3
	130417	AW163518	Hs.155485	huntingtin interacting protein 2	3.5	79	23	2.5
ــ بــ		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55	130455			N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
		W19744		Homo sapiens cDNA FLJ20653 fis, clone KA	3.9	39	1	1.9
		AW876523 AA383092		hypothetical protein FLJ12910 replication protein A3 (14kD)	3.9 4.4	39 44	1	2.6 4.1
		AA383256		estrogen receptor 1	32.2	322	1	4.7
60		Al354355	Hs.16697	down-regulator of transcription 1, TBP-b	5.2	251	48	21
00		M90516		glutamine-fructose-6-phosphate transamin	10	100	1	7.6
		Al963376			3.9	39	1	3.4
	130625	AF176012	Hs.260720	J domain containing protein 1	10.5	105	1	9
		AL161961	Hs.17767	KIAA1554 protein	6.8	129	19	12.1
65		R62676	Hs.17820	Rho-associated, coiled-coil containing p	4.1	41	1	3.6
		R68537 AJ271881	Hs.17962 Hs.279762	ESTs bromodomain-containing 7	9.2 17.5	234 175	26 2	16.8 12.8
	130/12	MZ1 1001	113.213/02	biomodomain-containing /		113	-	12.0
				<b></b> .				

	400700	DE0.47070	11: 40440	<b>5</b> 4	0.4	0.4	2	0.0
		BE247676		E-1 enzyme	8.1	81	3	2.8
		AF052105		chromosome 12 open reading frame	4.9	49	1	4.3
		AA197226		hypothetical protein MGC11321	3.6	100	28	6.6
~		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
5		AF080158		inhibitor of kappa light polypeptide gen	10.5	121	12	1.6
		AL044315		Homo sapiens mRNA for KIAA1750 protein,	6	202	34	3.7
		NM_00352		H2B histone family, member Q	7.1	100	14	7.5
		NM_01244		single-stranded-DNA-binding protein	3.2	87	27	1.7
1.0		BE613269	Hs.21893	hypothetical protein DKFZp761N0624	3.5	124	35	6.5
10	130993	T97401	Hs.21929	ESTs	4.5	45	1	2.5
	131076	AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	3.2	210	66	3.8
	131085	BE207357	Hs.3454	KIAA1821 protein	3.8	42	11	0.6
	131126	NM_01615	6Hs.181326	KIAA1073 protein	6.7	67	6	1.9
	131129	BE541042	Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	5.8	115	20	2.5
15	131148	AW953575	Hs.303125	p53-induced protein PIGPC1	3.8	585	153	3.7
	131164	AW013807	Hs.182265	keratin 19	5.2	1320	256	3.2
	131176	AA465113	Hs.23853	ESTs, Weakly similar to A34615 profilagg	3.8	38	1	3.3
	131200	BE540516	Hs.293732	hypothetical protein MGC3195	4.8	48	1	4.1
	131216	A1815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.1	343	56	16.4
20		AL080080	Hs.24766	thioredoxin domain-containing	8	100	13	2.9
		AI038989	Hs.332633	Bardet-Biedl syndrome 2	4	95	24	1.1
		AW206008		Homo sapiens cDNA: FLJ21778 fis, clone H	4.6	239	53	3.5
		NM_00315		stanniocalcin 1	3.5	402	114	2.1
			Hs.173933	nuclear factor I/A	3.3	775	233	2.4
25		AW293165		ESTs	3.8	38	1	3
		AK001123		hypothetical protein FLJ10261	3.9	116	30	0.5
		NM_01481		KIAA0480 gene product	7.6	76	1	5
		AA992841		KIAA1458 protein	5.1	113	22	6.1
		Al452601	Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169	20	4.6
30		AV661958		GK001 protein	3.1	197	63	18.7
50		N22120	Hs.75277	hypothetical protein FLJ13910	5.9	59	1	4.4
		AL355715		programmed cell death 9 (PDCD9)	5.1	51	i	3.9
		AA093668		muscleblind (Drosophila)-like	3.8	79	21	6.9
		NM_00351		H2A histone family, member L	4	350	88	3
35		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7	381	81	6.4
55		AA306477		hypothetical protein FLJ10687	4.6	46	7	3.8
					3.2	82	26	6.6
		NM_00210		granzyme K (serine protease, granzyme 3;	6.7	93	14	8.4
		BE297635 AB012124		heat shock 70kD protein 9B (mortalin-2)	3.8	53 51	14	1.7
40				transcription factor-like 5 (basic helix	7.2	72	4	5.7
40		AW963776		SAR1 protein	2.1	1561	757	1.7
		AF017986		secreted frizzled-related protein 2	11.7	117	1	10.1
		AA961420		ESTs	4.8	48	1	4.6
		AB014548		KIAA0648 protein	3.2	207	64	5.5
45		D87077 X86098	Hs.196275	KIAA0240 protein	3.4	115	34	9.1
45			Hs.301449	adenovirus 5 E1A binding protein	5.8	91	16	1.4
		W00712	Hs.32990	DKFZP566F084 protein	4.9	632	129	1.7
		A1681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	6.8			5.6
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	4	68 140	1 35	1.8
50		AW361018		upstream regulatory element binding prot				4.5
50		BE502341		ESTS	5.7 5.5	57 90	1 17	2.9
		AF078866		Homo sapiens cDNA: FLJ22993 fis, clone K				
		T15803	Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6	95	17	9.1
		BE252983		ubiquitin specific protease 1	7.4	103	14	6.5
55		NM_00291		replication factor C (activator 1) 4 (37	3.7	37	1	3.4
55		AK000010		hypothetical protein FLJ20003	3.5	35	1	2.5
		W79283	Hs.35962	ESTs	5.5	168	31	4.4
	1319//	U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
		AA503020		hypothetical protein FLJ22418	40.2	402	1	4
60		Al878910	Hs.3688	cisplatin resistance-associated overexpr	7.3	73	1	1.2
60	132064	AA121098	HS.3838	serum-inducible kinase	22.6	226	10	0.9
	132094	NM_01604	5HS.3945	CGI-107 protein	3.1	227	73	16.8
		AW190902		cysteine knot superfamily 1, BMP antagon	3.5	73	21	6.3
		AW960474		ESTS	3.6	141	39	12.6
<i>C</i> =	132143	D52059	Hs.7972	KIAA0871 protein	4.9	49	1	4.1
65	132160	W26406	Hs.295923	seven in absentia (Drosophila) homolog 1	4.4	53	12	2.1
	132164	AI752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	5	225	45	9.1
	132180	NM_00446	UHS.418	fibroblast activation protein, alpha	10.7	433	41	7.2

	132197	Al699482	Hs.42151	ESTs	3.4	58	17	4
		AI078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	4.2	42	ï	2.2
		NM_01598		cytokine receptor-like molecule 9	3.4	34	2	3
		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
5		N37065	Hs.44856	hypothetical protein FLJ12116	5.5	323	59	10.5
-		NM_00354		H4 histone family, member G	3.3	979	298	2.2
	132384	AA312135	Hs.46967	HSPCO34 protein	3.6	36	1	3.1
		W32624	Hs.278626	Arg/Abl-interacting protein ArgBP2	5.9	186	32	3.7
	132393	AL135094	Hs.47334	hypothetical protein FLJ14495	4.2	159	38	7.1
10	132407	BE613126	Hs.47783	B aggressive lymphoma gene	4.6	46	1	4.3
	132425	N87549	Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
	132440	AB020699	Hs.112751	KIAA0892 protein	3.3	33	4	2.9
	132465	AW169847	Hs.49169	KIAA1634 protein	8.3	145	18	3.7
	132522	AB023164	Hs.5070	KIAA0947 protein	4.6	46	1	4.4
15	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
		AA306105		SEC22, vesicle trafficking protein (S. c	4.9	49	1	4.4
		BE568452		protein regulator of cytokinesis 1	11.8	201	17	19.1
		Al929659	Hs.237825	signal recognition particle 72kD	3.8	38	1	3
00		AW803564		Homo sapiens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20		AW606927		hypothetical protein DKFZp586F1122 simil	6.1	61	2	5.9
		BE262677		hypothetical protein PRO1855	3.4	193	58	12.3
		AF037335		carbonic anhydrase XII	14.2	390	28	22.5
		AL050025		hypothetical protein FLJ20151	3.3	909	274	3.2
25		AU076916		guanine monphosphate synthetase	5	50	1	4.1
23		AB018319		KIAA0776 protein	4.2	171 65	41	12.6
		AA025480		ESTs, Weakly similar to T33468 hypotheti	6.5 3.7	65 37	1 1	5.6 2.2
		AW242243	Hs.57419	peroxisomal farmesylated protein	3. <i>1</i> 7	115	17	5.4
		U25435 AL120050		CCCTC-binding factor (zinc finger protei	3.3	61	19	5.1
30		NM_00144		Homo sapiens cDNA: FLJ23005 fis, clone L glypican 4	4.8	48	1	3.6
50		BE077155		hypothetical protein DKFZp761B1514	12.6	126	8	9.9
		Al936442		hypothetical protein FLJ10808	11	187	17	10.4
		BE613337		geminin	3.3	106	33	2.6
		AL047045		Homo sapiens clone 122482 unknown mRNA	3.5	110	32	2.1
35		AF234532		myosin X	4.1	62	15	4.9
		AA093322		RNA binding motif protein 3	22.1	221	9	17.8
		X77343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AA112748	Hs.279905	clone HQ0310 PRO0310p1	3	380	127	5.5
	133011	NM_00637	9Hs.171921	sema domain, immunoglobulin domain (lg),	7.3	271	37	2.3
40	133015	AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4
	133070	U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.6	36	1	3.1
	133091	AK001628	Hs.64691	KIAA0483 protein	5.2	117	23	5
	133192	AA218564	Hs.67052	vacuolar protein sorting 26 (yeast homol	3.1	359	118	2.5
		Al275243	Hs.180201	hypothetical protein FLJ20671	5.1	58	12	5.7
45		AF231981		homolog of yeast long chain polyunsatura	3	816	275	3.9
		W32474	Hs.301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
		AK001489		ADP-ribosylation factor-like 1	8.1	81	1	4.6
		Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
50		BE297855		NRAS-related gene	3.3	33	1	2.9
50		AJ001388		zinc finger protein 238	7.9	234 46	30 5	18.9 3.5
		AI499220	Hs.71573	hypothetical protein FLJ10074	4.6 5	110	22	9.7
		AK001519 AF245505		CGI-74 protein DKFZP564I1922 protein	3.2	725	227	3.2
		AF017987		secreted frizzled-related protein 1	4.1	374	91	1.1
55		AB033061	Hs.73287	KIAA1235 protein	4.3	43	1	3.9
55		Al929357	Hs.323966	Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
		W01556	Hs.238797	ESTs, Moderately similar to 138022 hypot	3.5	35	7	2.1
		AW998046		arginine-glutamic acid dipeptide (RE) re	3.6	39	11	0.4
		NM_00441		desmoplakin (DPI, DPII)	4.1	640	158	3
60		NM_00016		gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
•		W25797	Hs.177486	amyloid beta (A4) precursor protein (pro	3.2	226	71	2.8
		AU077050		translin	3.4	178	53	8.8
		D21262	Hs.75337	nucleolar and coiled-body phosphprotein	4.7	47	1	4
		AW246428		ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
65		NM_00692		splicing factor, arginine/serine-rich 5	3.6	36	1	0.4
		Al352558	Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	3.4	234	68	10.7
	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8

		M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	560	174	2.6
		AA557660		decorin	5.4	144	27	13.3
		BE622743 NM_002462		arfaptin 1 myxovirus (influenza) resistance 1, homo	4.7 3.3	47 380	1 114	4.1 4.9
5		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (		304	46	7.8
J		AA147026		ESTs	6.2	600	97	4.1
•		AU076964		calumenin	3.3	889	267	5
		AA355986		transcription factor 8 (represses interl	3.7	91	25	2.6
1.0		R48316	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C1216 (	f 3.4	91	27	8.5
10		AA535244		RAB2, member RAS oncogene family	7.8	78	1	5.6
		NM_005025		serine (or cysteine) proteinase inhibito	5.9	59	1	3.3
		AF091622		KIAA0244 protein	5.8 6.4	58 100	1 16	4.9 4.4
		U51166 R51273	Hs.173824 Hs.79029	thymine-DNA glycosylase ESTs	5.1	51	9	3.8
15		NM_004354		cyclin G2	5	50	1	3.2
10		BE513171		mitochondrial ribosomal protein L3	4.8	246	51	3.9
		U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134125	NM_014781	1Hs.50421	KIAA0203 gene product	4.6	69	15	5.8
•	134246	D28459	Hs.80612	ubiquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20		C05768	Hs.8078	Homo sapiens clone FBD3 Cri-du-chat crit	3.4	34	5	2.6
		X76040	Hs.278614	protease, serine, 15	3.6	36	1	2.8
		R45621	Hs.81057	hypothetical protein MGC2718	6.7	67	9	5.7 12
		Al022650 BE538082	Hs.8117	erbb2-interacting protein ERBIN ESTs, Moderately similar to A46010 X-lin	4.5 5.2	137 52	31 1	4.9
25		AW903838		chondroitin sulfate proteoglycan 2 (vers	8.6	568	66	22.4
20		AW959281		ESTs	4.8	53	11	3.7
		AW291946		interleukin 6 signal transducer (gp130,	7.1	71	4	6.4
		NM_001982		v-erb-b2 avian erythroblastic leukemia v	3	68	23	2.8
• •		AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	4.4	44	1	4.1
30		N22687	Hs.8236	ESTs	13.3	445	34	6
		AU077143		minichromosome maintenance deficient (S.	4.5	45	2	3.4
		AA456539		lysosomal	6 4.1	60	5 73	5.9
		Al916662 AW067903		kinectin 1 (kinesin receptor) collagen, type XI, alpha 1	4.1 4.6	301 1216	73 267	6.1 4.4
35		Al750762	Hs.82911	protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
55		NM_006416		solute carrier family 35 (CMP-sialic aci	4.9	49	3	3.8
		W95642	Hs.82961	trefoil factor 3 (intestinal)	3.2	1872	592	3.3
		AU077196		collagen, type V, alpha 2	6.3	1075	171	3.8
4.0	134436	U29344	Hs.83190	fatty acid synthase	3.3	710	217	2
40		X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
		AF061739		protein associated with PRK1	4.8	153	32	4.3
		D63477	Hs.84087	KIAA0143 protein	3.1 3.3	147 33	48 1	12.7 2
		BE091005 M14156	Hs.85112	activated RNA polymerase II transcriptio insulin-like growth factor 1 (somatomedi	4.2	42	5	2.6
45		U66615	Hs.172280	SWI/SNF related, matrix associated, acti	3.9	39	1	2.5
		AW903849		HUEL (C4orf1)-interacting protein	3.7	41	11	0.6
		NM_002884		RAP1A, member of RAS oncogene family	5.2	52	1	3
	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	4.9	49	1	3.7
<b>50</b>		AW299723		bone morphogenetic protein receptor, typ	5.2	52	5	3.5
50		AK001741		hypothetical protein FLJ10879	6.4	64	1	5.1
	134636	Al750878 AF271212	Hs.87409	thrombospondin 1 disrupter of silencing 10	12.6 5.4	126 81	1 15	10.8 2.6
		AK000606		golgi SNAP receptor complex member 1	3.4	179	52	1.5
		X04011	Hs.88974	cytochrome b-245, beta polypeptide (chro	3.2	143	45	13.9
55		AF129536	Hs.284226	F-box only protein 6	7	70	6	6
		BE281128	Hs.9030	TONDU	3.1	31	1	2.3
	134880	A1879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
		X87241	Hs.166994	FAT tumor suppressor (Drosophila) homolo	3.2	153	48	4.7
60		AL137491	Hs.125511	Homo sapiens mRNA; cDNA DKFZp434P1530 (		452	114	2
60		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	5.1	150	30	7.2 9.9
		AW968058 H58818	Hs.187579	nudix (nucleoside diphosphate linked moi hydroxysteroid (17-beta) dehydrogenase 7	8.2 11.5	114 115	14 1	10
		AL034344	Hs.284186	forkhead box C1	5.4	259	48	1.4
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	3.3	1296	394	2.2
65			Hs.93872	KIAA1682 protein	3.8	240	64	3.2
		W55956	Hs.94030	Homo sapiens mRNA; cDNA DKFZp586E1624 (		101	13	7.9
	135098	AW274526	Hs.277721	ovarian carcinoma antigen CA125	3.3	33	1	2.6

	135117	W52493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
-	`135144	NM_01625	5Hs.95260	Autosomal Highly Conserved Protein	7.4	74	5	2.4	
	135154	AK001835	Hs.267812	sorting nexin 4	6.6	69	11	6.3	
	135155	Al207958	Hs.166556	Homo sapiens, Similar to TEA domain fami	6.1	61	1	5.1	
5	135172	AB028956	Hs.12144	KIAA1033 protein	3.4	88	26	1.4	
	135242	AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	3.4	169	50	9.1	
	135269	NM_00340	3Hs.97496	YY1 transcription factor	3.4	475	142	2.5	
	135356	BE312948	Hs.18104	hypothetical protein FLJ11274	3.1	31	10	1.7	
10	135357	A1565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	135397	L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	1	2.4	
	-135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
	•	AI471525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast glycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotransfera	as	3.1	31	1	2.6
		Al267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide	В	7.8	137	18	11.9
		AA044840	Hs.241676	stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMIL'	1	4.7	151	32	9.3
		AA873285	Hs.137947	ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
. *		AA305536		"EST176522 Colon carcinoma (Caco-2) cell line	li	3.6	121	34	11.8
~ ~		Al369384		arylsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs.242396	ESTs: Moderately similar to !!!! ALU SUBFAMILY	/1	3.4	107	32	9.9

### TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

-		•
1	•	1
	1	,

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accession
20	123619	371681_1	AA602964 AA609200
20	104602		H47610 R86920
	121581	283769_1	AA416568 AA442889 AA417233 AA442223
	123523		
	100821		M26460 U09116
	125091	genbank_T91518	T91518
.25	125150	NOT_FOUND_entrea	z_W38240 W38240
	118475	genbank_N66845	N66845
	104787	genbank_AA027317	AA027317
	106055	genbank_AA417034	AA417034
	113702	genbank_T97307	T97307
30	101046	entrez_K01160	K01160
	101447	entrez_M21305	M21305
	101624	entrez_M55998	M55998
	124677	genbank_R01073	R01073
	110581	genbank_H61560	H61560
35	119023	genbank_N98488	N98488
	110775	genbank_N22414	N22414
	112092	genbank R44538	R44538
	112253	genbank_R51818	R51818
	107014	-	AA598820
40	114988	• . –	

# TABLE 11: Figure 11 from BRCA 001-3 PCT

Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10 15	Pkey: ExAccn: UnigenelD: Unigene Title: R1: R2: R3: R4:	Exemplar Acce Unigene numbe Unigene gene i Ratio of tumor i Ratio of 90th pe Ratio of 75th pe				
20	Pkey ExA	ccn Unigenel	O Unigene Title	R1	R2 R3	R4
25		666 Hs.13634 501 Hs.99949 124 Hs.1696	8 osteoblast specific factor 2 (fasciclin	13.2 15.7 22.7 8.5 15.3 9.6	244 19 1030 66 760 34 85 1 153 1 96 1	9.9 5 1.4 3.2 14.1 8.5
30	101724 L116 101754 S70 101888 AL0 102165 BE3 102304 AF0	590 Hs.620 114 Hs.23948 49610 Hs.9524 13280 Hs.1596 15224 Hs.4645	bullous pemphigoid antigen 1 (230/240kD) 9 TIA1 cytotoxic granule-associated RNA-bi transcription elongation factor A (SII)- 7 death associated protein 3 mammaglobin 1	9.4 8.9 7.3 9.3 8.5	94 1 89 5 73 1 93 5 2058 243	0.3 8 5.3 8 1.4
35	102567 U63 102823 D85 103557 AL13	.001394Hs.2359 830 Hs.14684	dual specificity phosphatase 4 7 TRAF family member-associated NFKB activ carboxypeptidase D	6.4 20.2 8.2 5.6 7.5 7.3	428 67 202 5 82 1 56 1 136 18 73 1	2.3 1.3 6.8 5.3 3.4 5.2
40	104667 Al23 104804 Al85 104807 Al13 104896 AW	8702 Hs.31803 9058 Hs.12579 915318 Hs.2316	ESTs ESTs, Weakly similar to N-WASP [H.sapien leucine-rich repeat-containing 2 ESTs	29 14.9 7.7 7 7.4 16.2	290 1 149 1 77 1 70 1 74 1 162 1	26.8 6.4 5.1 6.5 6 4.2
45	105038 AW5 105329 AA2 105500 AW6 105516 AK0	503733 Hs.9414 34561 Hs.2286	9 CEGP1 protein	5.5 2.8 25.4 8.3 6.9	55 1 131 47 508 20 83 3 69 1	5.2 3.9 3 1.8 4.4
50	106012 Al24 106095 AF1 106155 AA4 107102 AB0		ESTs E74-like factor 5 (ets domain transcript nuclear factor I/B	21.2 26.3 9.9 6.3 2.5	212 6 356 14 483 49 63 1 392 155	17.4 1 1.8 5.4 4.3
55	107151 AW3 107922 BE1 108339 AW1 109112 AW4	378065 Hs.8687 53855 Hs.61460 151340 Hs.5161 119196 Hs.2579	ESTs Ig superfamily receptor LNIR ESTs, Weakly similar to ALU7_HUMAN ALU S 4 hypothetical protein FLJ13782	15.6 9 18.7 4.1	156 7 90 1 187 1 334 82	10.8 5.5 17 3.4
60	109415 U80 109912 AW3 110009 BE0	736 Hs.1108 990822 Hs.3015 75297 Hs.6614 92285 Hs.2972	<ul> <li>KIAA1702 protein</li> <li>trinucleotide repeat containing 9</li> <li>L-kynurenine/alpha-aminoadipate aminotra ESTs, Weakly similar to A43932 mucin 2 p hypothetical protein FLJ13187</li> <li>Homo sapiens cDNA FLJ13289 fis, clone OV</li> </ul>	7.1 12.3 14.2 6.3 20.9 7.7	71 1 123 1 142 1 693 110 209 1 77 1	6.5 11.3 9.5 7.2 19.5 5

	111179	AK000136	He 10760	asporin (LRR class 1)	25.1	288	12	6.7
				hypothetical protein FLJ11193	6.3	63	1	5.8
				KIAA1866 protein	3.6	402	112	4.9
		BE314949	Hs.87128	hypothetical protein FLJ23309	3.8	425	111	4
5		AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
_		Al571940	Hs.7549	ESTs	9.6	124	13	9
		T97307	. 10.7 0 10	gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
10		AF212848		ets homologous factor	13.7	137	1	8.9
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		AI733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
		AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo saplens		115	1	6.9
			Hs.186572		5.8	58	1	5
15	115719	AW992405	Hs.59622	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
		Al373062		hypothetical protein MGC5370	6.2 ·	62	1	5.4
		AI272141	Hs.83484	SRY (sex determining region Y)-box 4	1.8	1047	596	1.6
		H25836		ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	4.4
20	117412	N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
	118472	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
	119271	Al061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
	119771	Al905687	Hs.2533	EST	3.5	2073	595	2.1
	120562	BE244580	Hs.302267	hypothetical protein FLJ10330	8.5	127	15	1.6
25	121463	AK000282	Hs.239681	hypothetical protein FLJ20275	10.3	103	1	9.3
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134	2.9	214	74	3.7
	122963	AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
	123137	AI073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
••	123619	AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
30					3.9	60	16	4.8
		Al147155	Hs.270016		5.8	321	55	17
		BE387335		ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
		AA249027		ribosomal protein S6	10.5	105	1	9.9
25		AW401809		KIAA1150 protein	13.1	131	1	5.1
35			Hs.164950		6.7	67	1	6
		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	30.6	306	4	26.5
		Al954968		matrix Gla protein	7.5	75	1	6.5
		A1694143		programmed cell death 4	7.2	72	1	5.8
40				secreted frizzled-related protein 4	17.4	409	24	7.8
40		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392 82	56	3.6
			Hs.107968		8.2 7.1	71	1	7.4 6.2
				polyadenylate binding protein-interactin	9.5	95	1	8.5
				KIAA0990 protein Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
45		AB028945		cortactin SH3 domain-binding protein	11.4	114	1	10
73			Hs.125849		6.7	67	i	5.7
				solute carrier family 5 (inositol transp	1	1	i	1
		AK001635		hypothetical protein FLJ10773	14.6	219	15	7.6
				KIAA1481 protein	13.2	331	25	12.4
50				stanniocalcin 2	72.2	722	1	1.9
				hypothetical protein MGC3017	6.5	65	4	5.3
		U63630		protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
		D90041		N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
		AA383256	Hs.1657	estrogen receptor 1	32.2	322	1	4.7
55	130617	M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
	130712	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8
	131148	AW953575	Hs.303125	p53-induced protein PIGPC1	3.8	585	153	3.7
		NM_014810	)Hs.92200	KIAA0480 gene product	7.6	76	1	5
	131564	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7	381	81	6.4
60			Hs.31433	ESTs	11.7	117	1	10.1
	131877		Hs.156346	topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
		AA503020	Hs.36563	hypothetical protein FLJ22418	40.2	402	1	4
		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
~~		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
65				ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
	132990			transcription factor AP-2 alpha (activat	12.7	311	25	2.4
	133015	AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4

	133199	AF231981	Hs.250175	homolog of yeast long chain polyunsatura	3	816	275	3.9
	133240	AK001489	Hs.242894	ADP-ribosylation factor-like 1	8.1	81	1	4.6
	133271	Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
_	133640	AW246428	Hs.75355	ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1
10	134880	AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1
	128305	AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3

#### TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey CAT number Accession

123619 371681\_1 AA602964 AA609200 113702 genbank\_T97307 T97307 114988 genbank\_AA251089 AA251089

# TABLE 12: Figure 12 from BRCA 001-3 PCT

5 **Table 12** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	UnigenelD: Unigene Title:		Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title					•
	R1: R2:		Ratio of tumor to normal body tissue Ratio of 90th percentile tumor to body					
15	R3:							
10	R4:							
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100131	D12485	Hs.11951	phosphodiesterase I (PC-1)	13.2	244	19	9.9
	105500	AW602166	6 Hs.222399	ESTs	25.4	508	20	3
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	114124	W57554	Hs.125019	ESTs	24.2	242	10	5.6
	119771	AI905687	Hs.2533	ESTs	3.5	2073	595	2.1
25	121723	AA243499	Hs.104800	ESTs	2.9	214	74	3.7
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	131148	AW953575	5 Hs.303125	ESTs	3.8	585	153	3.7
	131985	AA503020	Hs.36563	ESTs	40.2	402	1	4
	133100	ΔF231081	He 250175	Homo saniens clone 23904 mRNA sequence	3	816	275	3.9

### TABLE 13: Table 1 from BRCA 001-5 US

5 Table 13 depicts a preferred group of genes upregulated in breast cancer cells.

10	Pkey: ExAccn; UnigenelD:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number
	Unigono Titlo:	Unicana gana titla .

Unigene Title: Unigene gene title Ratio of tumor to normal body tissue

	KI.	IX.	allo of lufflor to	normal body ussue	
15					
13	Pkey	ExAccn	UniGene ID	Unigene Title	R1
				<b>-</b>	
	100038	M97935		control	16.7
• •	100039	M97935		control	6.3
20		M97935		control	8.3
	100041	M97935		control	14.8
	100082	AB003103	Hs.4295	proteasome (prosome; macropain) 26S sub	7.5
			Hs.111783	Lsm1 protein	4.9
~ ~		AF006084		actin related protein 2/3 complex; subunit	4.7
25	100103	AF007875	Hs.5085	dolichyl-phosphate mannosyltransferase p	13.4
		D00596	Hs.82962	thymidylate synthetase	15.9
		D10495	Hs.155342	protein kinase C; delta	4.6
		D10523	Hs.168669	oxoglutarate dehydrogenase (lipoamide)	7.5
• •		D11094	Hs.61153	proteasome (prosome; macropain) 26S sub	4.4
30		D12485	Hs.11951	phosphodiesterase I/nucleotide pyrophosp	8.7
		D13627	Hs.15071	chaperonin containing TCP1; subunit 8 (t	9.5
		D13643	Hs.75616	Human mRNA for KIAA0018 gene; comp	6
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin I-like	8.5
2.5		D14657	Hs.81892	KIAA0101 gene product	10.5
35		D14812	Hs.173714	MORF-related gene X	4.6
		D14878	Hs.82043	D123 gene product	7.9
		D21090	Hs.178658	RAD23 (S. cerevisiae) homolog B	5.6
		D25538	Hs.172199	adenylate cyclase 7	9.9
40		D26308	Hs.76289	biliverdin reductase B (flavin reductase (N	4.9
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit	14.2
		D26599	Hs.1390	proteasome (prosome; macropain) subunit	11.3
		D28137	Hs.118110	bone marrow stromal cell antigen 2	5.7
		D28915	Hs.82316	interferon-induced; hepatitis C-associated	5.7
15		D31888	Hs.78398	KIAA0071 protein	7.4
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e	5.6
		D49396	Hs.75454	antioxidant protein 1	12.9
		D50525	Hs.699	hypothetical protein	8.4
		D63391	Hs.6793	platelet-activating factor acetylhydrolase;	6.8
50		D63487	Hs.82563	KIAA0153 protein	4.4
50		D78129	Hs.71465	Homo sapiens mRNA for squalene epoxid	12.6 4.6
		D78514 D79987	Hs.78563 Hs.153479	ubiquitin-conjugating enzyme E2G 1 (hom	4.6 6.5
				extra spindle poles; S. cerevisiae; homolo	8.4
		D79997 D80004	Hs.184339	KIAA0175 gene product KIAA0182 protein	4.5
55		D82060	Hs.75909 Hs.278721	Ke4 gene; mouse; human homolog of	4.5 8.1
55		D83777	Hs.75137	KIAA0193 gene product	10.7
		D84145	Hs.39913	novel RGD-containing protein	7.2
		D84557	Hs.155462	minichromosome maintenance deficient (m	7.2
		D86425	Hs.82733	nidogen 2	5.4
60		D86479	Hs.118397	AE-binding protein 1	4.3
50		D86957	Hs.80712	KIAA0202 protein	11.9
		D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp	9.7
		D87464	Hs.10037	KIAA0274 gene product	6.4
		D87465	Hs.74583	KIAA0275 gene product	10
65		D87469	Hs.57652	EGF-like-domain; multiple 2	6.2
33	100-1-10	201 .00		015	0.12

	100467	D89052	Hs.7476	ATPase; H+ transporting; lysosomal (vacu	7.5
	100468	D89289	Hs.118722	fucosyltransferase 8 (alpha (1;6) fucosyltr	5
		HT1112	Hs.10842	Ras-Like Protein Tc4	16.9
~		HT1400	Hs.79137	Carboxyl Methyltransferase, Aspartate, A	5.6
5		HT2710	Hs.114599	Collagen, Type Viii, Alpha 1	7.5
		HT3018	Hs.132748	Ribosomal Protein L39 Homolog	4.4 4.6
		HT3127 HT3938	Hs.169610 Hs.169610	Epican, Alt. Splice 11 Epican, Alt. Splice 12	4.4
		HT3742	Hs.287820	Fibronectin, Alt. Splice 1	9
10		HT26388	Hs.89603	Mucin 1, Epithelial, Alt. Splice 9	4.7
		HT4018	Hs.191356	Basic Transcription Factor, 44 Kda Subun	13.7
	100829	HT4343	Hs.278544	Cytosolic Acetoacetyl-Coenzyme A Thio	10.6
	100830	HT4344	Hs.4756	Rad2	5.5
1 ~		HT4392	Hs.183418	Protein Kinase Pitslre, Alpha, Alt. Splice	4.1
15		HT417	Hs.297939	Cathepsin B	4
		HT4582	Hs.75113	Transcription Factor Ilia	4.9
		HT5158	Hs.5398	Guanosine 5'-Monophosphate Synthase	8.7 7.2
	100914	HT511	Hs.324178 Hs.73946	Ras Inhibitor Inf Endothelial Cell Growth Factor 1	5.9
20		HT884	Hs.180686	Oncogene E6-Ap, Papillomavirus	4.6
20		J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin	30.1
		J03589	Hs.76480	ubiquitin-like 4	8.3
		J03909	Hs.14623	interferon; gamma-inducible protein 30	6.9
		J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom	4.3
25		J04430	Hs.1211	acid phosphatase 5; tartrate resistant	5.9
		J04599	Hs.821	biglycan	5.1
		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B;	37.2 6.1
		J05249 K02405	Hs.79411 Hs.73931	replication protein A2 (32kD) Human MHC class II HLA-DQ-beta mRN	4.3
30		K03515	Hs.180532	glucose phosphate isomerase	4.3
50		L06132	Hs.149155	voltage-dependent anion channel 1	7.4
		L06797	Hs.89414	chemokine (C-X-C motif); receptor 4 (fus	4.6
		L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPY	18.3
	101143	L12723	Hs.90093	heat shock 70kD protein 4	17.4
35		L13800	Hs.9884	Homo sapiens liver expressed protein gen	7.6
		L19779	Hs.795	H2A histone family; member O	10.9
		L25876	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	7.4 14.6
		L29008 L33801	Hs.878 Hs.78802	sorbitol dehydrogenase glycogen synthase kinase 3 beta	7.5
40		L38810	Hs.79387	proteasome (prosome; macropain) 26S sub	4.4
		L42572	Hs.78504	inner membrane protein; mitochondrial (m	5.8
		L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topo	18.9
	101348	L77213	Hs.30954	phosphomevalonate kinase	7.5
4.5		L77701	Hs.16297	COX17 (yeast) homolog; cytochrome c ox	9.3
45		M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.1
		M15796	Hs.78996	proliferating cell nuclear antigen	8.6 4.5
		M16342 M20902	Hs.182447 Hs.268571	heterogeneous nuclear ribonucleoprotein C apolipoprotein C-I	6.1
		M22538	Hs.51299	NADH dehydrogenase (ubiquinone) flavo	8.7
50		M22877	Hs.169248	Human somatic cytochrome c (HCS) gene	4.2
• •		M22960	Hs.118126 '	protective protein for beta-galactosidase (	6.5
	101478	M23379	Hs.758	RAS p21 protein activator (GTPase activa	14
		M24594	Hs.20315	interferon-induced protein 56	9.2
		M30818	Hs.926	myxovirus (influenza) resistance 2; homol	5.1
55		M30938	Hs.84981	X-ray repair complementing defective rep	4.7
		M31169	110 00044	Human propionyl-CoA carboxylase beta-s hypoxanthine phosphoribosyltransferase 1	5.5 8.5
		M31642 M34677	Hs.82314 Hs.83363	DNA segment on chromosome X (unique)	4.5
		M37583	Hs.119192	H2A histone family; member Z	5.7
60		M60750	Hs.2178	H2B histone family; member A	5.8
		M60752	Hs.121017	H2A histone family; member A	13.5
	101667	M60858	Hs.79110	nucleolin	4
		M63256	Hs.75124	cerebellar degeneration-related protein (62	7.6
		M64929	Hs.179574	protein phosphatase 2 (formerly 2A); regu	4.2
65		M77142	Hs.239489	TIA1 cytotoxic granule-associated RNA-b	4.5
	101758	M77836	Hs.79217	pyrroline-5-carboxylate reductase 1 carboxypeptidase B1 (tissue)	5.7 21.7
	101767	M81057	Hs.180884	camayhahnasa n i (nsana)	21.7
				21.	

	404770 1404004	11- 70000	Among siniting along attention for story A (OII), d	4.6
	101770 M81601	Hs.78869	transcription elongation factor A (SII); 1	4.6
	101791 M83822	Hs.62354	cell division cycle 4-like	9.7 5.5
	101803 M86546 101809 M86849	Hs.155691 Hs.323733	pre-B-cell leukemia transcription factor 1 Homo sapiens connexin 26 (GJB2) mRNA	22.5
5	101839 M93036	Hs.692	membrane component; chromosomal 4; su	4
5	101851 M94250	Hs.82045	midkine (neurite growth-promoting factor	7.6
	101888 M99701	Hs.95243	transcription elongation factor A (SII)-like	11.4
	101973 S82597	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	4.6
	101991 U00968	Hs.166	Human SREBP-1 mRNA; complete cds	4.1
10	102009 U02680	Hs.82643	protein tyrosine kinase 9	4.4
	102025 U03911	Hs.78934	mutS (E. coli) homolog 2 (colon cancer; n	4
	102047 U07158	Hs.83734	syntaxin 4A (placental)	6.1
	102051 U07550	Hs.1197	heat shock 10kD protein 1 (chaperonin 10	4.4
	102083 U10323	Hs.75117	interleukin enhancer binding factor 2; 45k	10.4
15	102095 U11313	Hs.75760	sterol carrier protein 2	9.5
	102130 U15009	Hs.1575	small nuclear ribonucleoprotein D3 polyp	6.6
	102133 U15173	Hs.155596	BCL2/adenovirus E1B 19kD-interacting p	4.3
	102148 U16954	Hs.75823	ALL1-fused gene from chromosome 1q	6.9
•	102179 U19713	Hs.76364	allograft inflammatory factor 1	4.8
20	102180 U19718	Hs.83551	microfibrillar-associated protein 2	7.2
	102193 U20758	Hs.313	secreted phosphoprotein 1 (osteopontin; b	7.2
	102198 U21090	Hs.74598	polymerase (DNA directed); delta 2; regu	4.3
	102202 U21931	Hs.574	fructose-bisphosphatase 1	4.5
25	102209 U22970	Hs.265827	interferon; alpha-inducible protein (clone	9.9
25	102211 U23070	Hs.78776	putative transmembrane protein	4.9
	102220 U24389	Hs.65436	lysyl oxidase-like 1	8.5
	102224 U24704	Hs.148495	proteasome (prosome; macropain) 26S sub	5.4 7.7
	102234 U26312	Hs.278554 Hs.74122	chromobox homolog 3 (Drosophila HP1 g	7.7 5.4
30	102250 U28014		caspase 4; apoptosis-related cysteine prot	6.3
50	102260 U28386 102261 U28488	Hs.159557 Hs.155935	karyopherin alpha 2 (RAG cohort 1; impo complement component 3a receptor 1	5.7
	102273 U30888	Hs.75981	ubiquitin specific protease 14 (tRNA-guan	6.1
	102273 U30808 102298 U32849	Hs.54483	N-myc (and STAT) interactor	4.1
	102302 U33052	Hs.69171	protein kinase C-like 2	4.3
35	102305 U33286	Hs.90073	chromosome segregation 1 (yeast homolo	5.4
22	102320 U34683	Hs.82327	glutathione synthetase	4.1
	102330 U35451	Hs.77254	chromobox homolog 1 (Drosophila HP1 b	4
	102348 U37519	Hs.87539	aldehyde dehydrogenase 8	9.4
	102361 U39400	Hs.75859	chromosome 11 open reading frame 4	5.2
40	102362 U39412	Hs.75932	N-ethylmaleimide-sensitive factor attachm	9.3
	102369 U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	7.7
	102395 U41767	Hs.92208	a disintegrin and metalloproteinase domai	10.4
	102409 U43286	Hs.118725	selenophosphate synthetase 2	6.2
. ~	102418 U43923	Hs.79058	suppressor of Ty (S.cerevisiae) 4 homolog	4.1
45	102425 U44772	Hs.3873	palmitoyl-protein thioesterase (ceroid-lipo	4.8
	102457 U48807	Hs.2359	dual specificity phosphatase 4	6.3
	102465 U49352	Hs.81548	2;4-dienoyi CoA reductase 1; mitochondri	9.4
	102495 U51240	Hs.79356	Lysosomal-associated multispanning mem	6.5
50	102534 U56833	Hs.198307	von Hippel-Lindau binding protein 1	8.6
30	102546 U57877	Hs.3577	succinate dehydrogenase complex; subuni	4.3 6.3
	102549 U58046	Hs.198899 Hs.264428	eukaryotic translation initiation factor 3; s	5
	102557 U58766 102562 U59309	Hs.75653	tissue specific transplantation antigen P35 fumarate hydratase	6
	102568 U59877	Hs.223025	RAB31; member RAS oncogene family	9.1
55	102580 U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatid	7.9
55	102581 U61145	Hs.77256	enhancer of zeste (Drosophila) homolog 2	7.6
	102590 U62136	Hs.79300	Homo sapiens enterocyte differentiation a	7
	102591 U62325	Hs.324125	amyloid beta (A4) precursor protein-bindi	4
	102592 U62389	Hs.11223	Human putative cytosolic NADP-depende	5
60	102617 U65928	Hs.198767	Jun activation domain binding protein	6.1
	102618 U65932	Hs.81071	extracellular matrix protein 1	23.2
	102638 U67319	Hs.9216	caspase 7; apoptosis-related cysteine prot	8.9
	102663 U70322	Hs.168075	karyopherin (importin) beta 2	7.1
	102666 U70660	Hs.279910	ATX1 (antioxidant protein 1; yeast) homo	4.7
65	102679 U72661	Hs.11342	ninjurin 1; nerve injury-induced protein-1	4.7
	102687 U73379	Hs.93002	ubiquitin carrier protein E2-C	7.7
	102704 U76638	Hs.54089	BRCA1 associated RING domain 1	5.6

	100705 1177400	Ua 50000	amall indusible autaking authomily A /Cu	11.8
	102705 U77180	Hs.50002	small inducible cytokine subfamily A (Cy	15
	102721 U79241	Hs.118666	Human clone 23759 mRNA; partial cds	5
	102729 U79254 102739 U79282	Hs.181311	asparaginyl-tRNA synthetase Human clone 23801 mRNA sequence	6
5	102742 U79293	Hs.155572 Hs.159264	Human clone 23948 mRNA sequence	13.1
3	102742 079293 102761 U82130	Hs.118910	tumor susceptibility gene 101	7
	102788 U86602	Hs.74407	nucleolar protein p40	4.1
	102790 U87269	Hs.154196	E4F transcription factor 1	7.1
	102730 007203 102801 U89606	Hs.38041	pyridoxal (pyridoxine; vitamin B6) kinase	4.7
10	102808 U90426	Hs.179606	nuclear RNA helicase; DECD variant of D	7.5
10	102817 U90904	Hs.83724	Human clone 23773 mRNA sequence	15.2
	102823 U90914	Hs.5057	carboxypeptidase D	6.6
	102827 U91327	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
	102838 U94592	Hs.80658	Human uncoupling protein homolog (UCP	6.1
15	102841 U95006	Hs.37616	Human D9 splice variant B mRNA; comp	4.2
~~	102844 U96113	Hs.324275	Homo sapiens Nedd-4-like ubiquitin-prot	6.8
	102868 X02419	Hs.77274	plasminogen activator; urokinase	4
	102907 X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
	102919 X12447		aldolase A; fructose-bisphosphate	9.9
20	102929 X13238	Hs.74649	cytochrome c oxidase subunit Vic	5.4
	102973 X16663	Hs.14601	hematopoietic cell-specific Lyn substrate	4.8
	102983 X17620	Hs.118638	non-metastatic cells 1; protein (NM23A)	4.6
	102985 X17644	Hs.2707	G1 to S phase transition 1	20.6
	103003 X52003	Hs.1406	trefoil factor 1 (breast cancer; estrogen-ind	10.7
25	103018 X53296	Hs.81134	interleukin 1 receptor antagonist	5.8
	103023 X53793	Hs.117950	multifunctional polypeptide similar to SA	4
	103036 X54925	Hs.83169	matrix metalloproteinase 1 (interstitial col	7.3
	103060 X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin	17.8
	103073 X59417	Hs.74077	proteasome (prosome; macropain) subunit	5.6
30	103075 X59543	Hs.2934	ribonucleotide reductase M1 polypeptide	4.2
	103080 X59798	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomat	6.7
	103094 X60787	Hs.296281	interleukin enhancer binding factor 1	5.7
	103105 X61970	Hs.76913	proteasome (prosome; macropain) subunit	5.8
~ -	103121 X63679	Hs.4147	translocating chain-associating membrane	4.2
35	103149 X66363	Hs.171834	PCTAIRE protein kinase 1	12
	103180 X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mit	18.9
	103182 X69819	Hs.99995	intercellular adhesion molecule 3	10.7
	103188 X70040	Hs.2942	macrophage stimulating 1 receptor (c-met	4.1
40	103191 X70218	Hs.2903	protein phosphatase 4 (formerly X); cataly	10.7
40	103193 X70476	Hs.75724	coatomer protein complex; subunit beta 2	8.2
	103194 X70649	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box pol	13.7
	103195 X70940	Hs.2642	eukaryotic translation elongation factor 1	13.4
	103206 X72755	Hs.77367	monokine induced by gamma interferon	15.1 5.3
45	103207 X72790	Un 21214	Human endogenous retrovirus mRNA for	12.3
45	103208 X72841 103216 X74262	Hs.31314 Hs.16003	retinoblastoma-binding protein 7 retinoblastoma-binding protein 4	4.1
	103216 X74202 103226 X75042	Hs.44313	v-rel avian reticuloendotheliosis viral onco	6.9
	103230 X75861	Hs.74637	testis enhanced gene transcript	7.9
	103262 X78565	Hs.289114	hexabrachion (tenascin C; cytotactin)	5
50	103278 X79882	Hs.80680	lung resistance-related protein	5.7
2.0	103276 X73682 103297 X81788	Hs.9078	immature colon carcinoma transcript 1	4.6
	103302 X82103	Hs.3059	coatomer protein complex; subunit beta	4.5
	103316 X83301	Hs.324728	SMA5	7.1
	103330 X85373	Hs.77496	small nuclear ribonucleoprotein polypepti	4
55	103349 X89059	1101111100	serine/threonine kinase 9	4.7
	103352 X89398	Hs.78853	uracil-DNA glycosylase	5.3
	103364 X90872	Hs.279929	SULT1C sulfotransferase	4
	103374 X91788	Hs.84974	chloride channel; nucleotide-sensitive; 1A	4.2
	103380 X92396	Hs.24167	synaptobrevin-like 1	13.6
60	103395 X94754	Hs.279946	methionine-tRNA synthetase	14.2
	103402 X95404	Hs.180370	cofilin 1 (non-muscle)	4.6
	103410 X96506	Hs.295362	DR1-associated protein 1 (negative cofact	8.3
	103420 X97065	Hs.173497	Sec23 (S. cerevisiae) homolog B	4.9
	103421 X97074	Hs.119591	adaptor-related protein complex 2; sigma	5
65	103427 X97303	Hs.250655	H.sapiens mRNA for Ptg-12 protein	7
	103430 X97544	Hs.20716	translocase of inner mitochondrial membr	4.5
	103438 X98263	Hs.152720	M-phase phosphoprotein 6	4.5

	400404	V0000F	Un 70470	innulin like manuah fantan O manantan	4.2
		Y00285	Hs.76473	insulin-like growth factor 2 receptor	
		Y00796	Hs.174103	integrin; alpha L (antigen CD11A (p180);	4.5
		Y08991	Hs.83050	phosphatidylinositol 3-kinase-associated p	4.1
_		Y09912	Hs.33102	transcription factor AP-2 beta (activating	4.5
5		Z14982	Hs.180062	proteasome (prosome; macropain) subunit	4.3
		Z15115	Hs.75248	topoisomerase (DNA) II beta (180kD)	4
	103565	Z22548	Hs.146354	thioredoxin-dependent peroxide reductase	7.6
	103587	Z29083	Hs.82128	5T4 oncofetal trophoblast glycoprotein	14.6
	103621	Z47727	Hs.150675	polymerase (RNA) II (DNA directed) pol	6.3
10		Z48042	Hs.278672	membrane component; chromosome 11; s	4.4
		Z74615	Hs.172928	collagen; type I; alpha 1	5.9
		Z93784		Homo sapiens DNA sequence from PAC	4.4
			Hs.278554	chromobox homolog 3 (Drosophila HP1 g	4.9
		AA092898		ESTs; Weakly similar to R07G3.8 [C.eleg	6.1
15			Hs.198793	KIAA0750 gene product	23.3
13		AA172215		ESTs; Moderately similar to TRANSCRIP	4
			Hs.105737	ESTs; Weakly similar to gene 9306 protei	4.9
					7.8
		AA236843		ESTs; Weakly similar to unknown [S.cere	4.8
20			Hs.239189	ESTs	5.3
20		AA393432		hypothetical protein	
		AA428090		ESTS	28.7
		AA442669		zv68f6.r1 Soares_total_fetus_Nb2HF8_9w	5.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	6.9
0.5		AA476564		ESTs; Weakly similar to finger protein HZ	5.2
25			Hs.283740	ESTs	7.8
			Hs.114309	ESTs	5.1
		AA486946		Homo sapiens mRNA; cDNA DKFZp564	4.3
		AB000221		small inducible cytokine subfamily A (Cy	12.3
	104234	AB002357	Hs.168212	kinesin family member 3B	6.2
30	104271	C01687	Hs.7381	ATP synthase; H+ transporting; mitochon	4.2
	104278	C02582	Hs.109253	ESTs; Highly similar to N-terminal acetyl	4.5
	104307	D52818	Hs.111680	endosulfine alpha	4.7
	104309	D55869	Hs.284123	Homo sapiens mRNA full length insert cD	4.2
		H19378	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
35		L44497	Hs.7351	ESTs	4.9
		M19169	Hs.123114	cystatin SN	11.6
		N33807	Hs.324275	protease; serine; 15	5.6
		R56678	Hs.88959	Human DNA sequence from clone 967N2	6.3
		R81003	Hs.325820	serine protease; umbilical endothelium	13.6
40		AA004274		ESTs	6.3
40			Hs.106106	ESTs	10.1
		AA007145		Homo sapiens mRNA; cDNA DKFZp564	4.3
		AA007143		ESTs	16.6
			Hs.301553	ESTs; Moderately similar to !!!! ALU SU	4.6
45		AA009596 AA025534		ESTs	4.8
40		AA025554 AA027163			8.1
				ESTs	10.9
			Hs.301871	ESTs; Moderately similar to cAMP induc	5.5
		AA031357		ESTs; Weakly similar to N-WASP [H.sap	10.4
50		AA032147		ESTs	
50		AA039469		ESTs; Weakly similar to KIAA0299 [H.s	4.6
			Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	4.3
			Hs.225979	Human gene from PACs 37M17 and 305B	4.5
		AA053021		SCO (cytochrome oxidase deficient; yeast	4.7
~ ~		AA055809		ESTs; Weakly similar to phosphoprotein [	8.8
55		AA057193		ESTs	5.5
		AA057839		ESTs	4.2
•		AA058846		DKFZP434N093 protein	7
	104938	AA064627	Hs.318725	ESTs; Highly similar to CGI-72 protein [H	7.1
	104943	AA065217	Hs.114218	ESTs .	5.7
60	104957	AA074919	Hs.10026	ESTs; Weakly similar to ORF YJL063c [S	4.7
	104961	AA076672	Hs.33905	ESTs	5.5
	104968	AA084602	Hs.29669	ESTs	4.3
	104975	AA086071	Hs.50758	chromosome-associated polypeptide C	8.3
	104977	AA088228	Hs.18272	ESTs	6.2
65	104978	AA088458	Hs.19322	ESTs	6.7
		AA101723		ESTs	9.2
			Hs.182704	ESTs; Moderately similar to alternatively	6.9

	405040 44440000	H= 0000	ah un managana 200 ay an manding france 4	10.7
	105012 AA116036		chromosome 20 open reading frame 1	10.7
	105019 AA121879		proteasome (prosome; macropain) subunit	5.7 4.4
	105029 AA126855		ESTs	6.3
5	105033 AA127964		TP53 target gene 1	6.5
9	105035 AA128486 105039 AA130349		ESTs ESTs	4
	105062 AA134968		ESTs	4.3
	105076 AA142858		ESTs	6.4
	105076 AA142036		ESTs	9.2
10	105091 AA148859		ESTs; Weakly similar to !!!! ALU SUBFA	5.7
10	105093 AA149051		ESTs	6.3
	105107 AA152302		DKFZP566G223 protein	6.2
	105127 AA158132		ESTs; Weakly similar to contains similari	5.7
	105132 AA159501		HBV associated factor	4.2
15	105143 AA165333		ESTs	4.7
	105154 AA171736		methyl-CpG binding domain protein 4	9
	105162 AA176690		KIAA1025 protein	9.1
	105186 AA191512		Homo sapiens mRNA; cDNA DKFZp564	19.3
	105209 AA205072		KIAA0980 protein	7.4
20	105223 AA211388		ESTs	5.1
	105252 AA227428		ESTs; Weakly similar to KIAA0512 prote	11.1
	105253 AA227448		KIAA0456 protein	6.4
	105261 AA227871	Hs.6361	MEK partner 1	9.1
	105263 AA227926	Hs.6682	ESTs	6.7
25	105274 AA228122	Hs.281866	ATPase; H+ transporting; lysosomal (vacu	5.3
	105297 AA233451	Hs.183858	transcriptional intermediary factor 1	8.7
	105309 AA233790	Hs.4104	ESTs; Weakly similar to cDNA EST yk38	7.4
	105312 AA233854	Hs.23348	S-phase kinase-associated protein 2 (p45)	5.8
	105342 AA235286		ESTs	4.5
30	105376 AA236559	Hs.8768	ESTs; Weakly similar to !!!! ALU SUBFA	5.8
	105386 AA236950		ESTs	5.5
	105397 AA242868	Hs.7395	ESTs; Weakly similar to house-keeping p	7.7
	105399 AA243007		ESTs; Highly similar to SH3 domain-bind	5.6
0.5	105400 AA243052		RNA binding motif protein 8	5.8
35	105404 AA243303		ESTs	9.1
	105409 AA243562		ESTs	4.4
	105436 AA252172		ESTs; Moderately similar to cAMP induc	5.1
	105483 AA255874		ESTs	4.9 6
40	105493 AA256268		ESTS	5.2
40	105495 AA256317		Homo sapiens mRNA; cDNA DKFZp586	8.7
	105496 AA256323		DKFZP434N126 protein CGI-96 protein	9.5
	105500 AA256485 105507 AA256678		ESTs; Moderately similar to CCR4-associ	4.1
	105538 AA258860		ring finger protein (C3H2C3 type) 6	4.1
45	105536 AA256060 105544 AA261954		ESTs	8
73	105546 AA262032		ESTs; Weakly similar to 62D9.a [D.melan	8.1
	105549 AA262417		ESTs	4.6
	105551 AA262477		ribonuclease HI; large subunit	9.1
	105560 AA262783		ESTs	4.5
50	105565 AA278302		ESTs; Weakly similar to partial CDS [C.e	4.2
	105566 AA278323		Homo sapiens clone 24606 mRNA sequen	11.9
	105575 AA278717	Hs.12772	ESTs	5.9
	105584 AA279012	Hs.3454	ESTs; Weakly similar to KIAA0665 prote	4.4
	105596 AA279418		ESTs	4
55	105604 AA279787	Hs.15467	ESTs; Moderately similar to putative pho	5.6
	105610 AA279991	Hs.99872	ESTs; Weakly similar to trithorax homolo	5.3
	105621 AA280865	Hs.6375	Homo sapiens mRNA; cDNA DKFZp564	4.8
	105627 AA281245	Hs.23317	ESTs	7.5
	105638 AA281599	Hs.247817	Homo sapiens mRNA for for histone H2B	5.9
60	105645 AA282138		ESTs	6.4
	105650 AA282347		ESTs; Highly similar to HSPC003 [H.sap	11.3
	105666 AA283930		ESTs	4.7
	105674 AA284755		CDW52 antigen (CAMPATH-1 antigen)	8
~~	105687 AA286809		ESTs	7.1
65	105700 AA287643		ESTs; Weakly similar to hypothetical pro	4.9
	105705 AA290767		Homo sapiens mRNA; cDNA DKFZp434	8
	105709 AA291268	ms.20/01	DKFZP586L0724 protein	6.8

	405704	A A 000744	11- 00404	FOT-	
		AA292711		ESTS	6.4
			Hs.110857	ESTs	7
		AA348014		ESTs	7.1
_		AA350771		ESTs	13.4
5		AA358038		SH3-binding domain glutamic acid-rich p	4.3
		AA393803		ESTs; Moderately similar to COLLAGEN	5.3
	105808	AA393808	Hs.286131	KIAA0438 gene product	4.1
	105812	AA394126	Hs.20814	ESTs; Highly similar to CGI-27 protein [H	14.6
	105813	AA394140	Hs.18585	ESTs	4.9
10	105819	AA397920	Hs.28783	Homo sapiens mRNA; cDNA DKFZp564	4.9
	105870	AA399623	Hs.101067	ESTs	4.8
	105874	AA400074	Hs.171118	ESTs	4
	105896	AA400999	Hs.7838	Human ring zinc-finger protein (ZNF127-	4.8
		AA404248		ESTs	5.2
15			Hs.263727	ESTs; Weakly similar to bisphosphate 3'-	4
		AA406105		adaptor-related protein complex 1; gamma	8.3
		AA406321		KIAA0895 protein	4.6
		AA410336		ESTs; Weakly similar to PROBABLE AT	4.5
		AA410510		ESTs	4.9
20		AA410972		ESTs	5.8
20		AA411462		ESTs; Weakly similar to veli 1 [H.sapiens	6.9
					5
		AA411819 AA412473		KIAA0898 protein	
				ESTs	6.6
25			Hs.169895	ubiquitin-conjugating enzyme E2L 6	4.6
25			Hs.289074	ESTs	4.5
		AA417558		ESTs	12.3
		AA417761		Homo sapiens clone 24416 mRNA sequen	5
		AA421104		ESTs	15.4
• •		AA424006		ESTs; Moderately similar to H5AR [M.m	6.4
30		AA425304		ESTs	5.1
	106157	AA425367	Hs.34892	ESTs	11.1
	106166	AA425872	Hs.19561	NADH dehydrogenase (ubiquinone) 1 alp	19.3
		AA428024		ESTs	4.7
	106210	AA428239	Hs.10338	ESTs	5.7
35		AA428582		ESTs; Moderately similar to metargidin p	7.7
		AA429951		ESTs	8
		AA430074		ESTs; Weakly similar to Ylr218cp [S.cere	4.4
		AA431462		ESTs	4.9
		AA435536		ESTs	8.8
40		AA435591		signal sequence receptor; gamma (transloc	8.7
10		AA436244		ESTs	4.5
		AA436568		ESTs	4
		AA436705		KIAA0766 gene product	4.4
		AA441798		ESTs; Moderately similar to pIL2 hypoth	23.7
45		AA442253		ESTs	4.7
77.7		AA442763			
				cyclin B2	6.1
		AA443923		ESTs	6.8
		AA446949		ESTs	4.7
50		AA447223		Homo sapiens clone 25142 mRNA sequen	4.4
30		AA448282		ESTs; Weakly similar to F55C12.5 [C.ele	4.5
		AA449741		glioma-amplified sequence-41	4.8
		AA449912		ESTs; Highly similar to CGI-77 protein [H	5.2
		AA450047		ESTs	6.8
~ ~		AA450351		ESTs	12.4
55		AA452108		transcription factor AP-2 alpha (activating	4.5
	106503	AA452411	Hs.29679	ESTs; Highly similar to mediator [H.sapie	5.1
	106507	AA452584	Hs.267819	protein phosphatase 1; regulatory (inhibito	4.9
	106533	AA453786	Hs.145998	ESTs	8.3
	106568	AA455970	Hs.28285	patched related protein translocated in ren	7.6
60	106586	AA456598	Hs.57787	ESTs	8.2
		AA456646		ESTs	4.8
		AA457730		Homo sapiens clone 23851 mRNA sequen	4.4
		AA458904		ESTs; Weakly similar to torsinA [H.sapie	7
		AA458934		ESTs	4.5
65		AA459657		Homo sapiens clone 23570 mRNA sequen	6.5
		AA459961		ESTs	5.5
		AA460239		ESTs	4.4
	,55517			2010	7,7

	106664	AA460969	Hs.7510	mitogen-activated protein kinase kinase ki	8.4
		AA463745		ESTs; Weakly similar to PROBABLE AT	5.3
			Hs.236844	ESTs	5.6
5		AA465339		ESTs	10.1
3		AA476473 AA477263	Hs.171957	triple functional domain (PTPRF interacti ESTs	10.4 4.2
			Hs.306117	interleukin 13 receptor; alpha 1	6.9
			Hs.227913	API5-like 1	5.1
		AA482014		centrin; EF-hand protein; 3 (CDC31 yeast	5.1
10			Hs.238707	ESTs	4.8
		AA482548		ESTs	10.3
			Hs.285123	ESTs; Weakly similar to similar to oxyste	6.2
		AA487228		ESTs Homo sapiens mRNA; cDNA DKFZp586	4.5 7.9
15		AA488872 AA489101		oxysterol binding protein	6.4
13		AA489665		ESTs	4.6
			Hs.250747	SUMO-1 activating enzyme subunit 1	4.2
		AA490885		ESTs	12.3
			Hs.296323	ESTs	6.2
20		AA496204		ESTs	4
		AA496347		retinoblastoma-binding protein 7	4.8
		AA496788 AA504631		KIAA0532 protein ESTs; Weakly similar to hypothetical 43.2	4 4.4
		AA504631		Human DNA sequence from clone 167A1	5.4
25		AA521121		bromodomain adjacent to zinc finger dom	4.1
		AA521157		ESTs	5.7
	106998	AA598461	Hs.195464	insulin-like growth factor binding protein	18.7
		AA598710		ESTs	6.2
20		AA599214		ESTs	4.1
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta glyceronephosphate O-acyltransferase	5.3 4.8
		AA600134 AA600147		ESTs; Weakly similar to NADH-cytochro	5.8
		AA600310		programmed cell death 8 (apoptosis-induc	4.9
		AA609210		ESTs	8.4
35		AA609723		ESTs	8
		AA609943		ESTs	9.5
		AA620553		flap structure-specific endonuclease 1	4.9
		AA620598		ESTs	5.3 4
40		AA620795	Hs.170088	ESTs ESTs	6.7
<del>-1</del> 0		AA621169		ESTs	19
		AA621340		ESTs; Weakly similar to ORF YKR081c [	8.1
		AA621714		ESTs	8.5
		D51095	Hs.35861	DKFZP586E1621 protein	7.2
45		D59971	Hs.25925	ESTs	7.9
		T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	5.6
		T40327 T81665	Hs.30661 Hs.278422	lung resistance-related protein DKFZP586G1122 protein	8.4 7.5
		U85625	Hs.8297	ribonuclease 6 precursor	4.7
50		U85773	Hs.154695	phosphomannomutase 2	4.8
		W58247	Hs.279766	Homo sapiens kinesin superfamily motor	6.3
	107531	Y13936	Hs.17883	protein phosphatase 1G (formerly 2C); ma	8.3
		AA024835		potassium voltage-gated channel; delayed	7.3
<i>E E</i>		AA026030		ESTs; Weakly similar to CALPAIN 2; LA	7.3
55		AA026894 AA041341		ESTs	4.9 5.4
			Hs.159971	ESTs ESTs	8.4
		AA046424		ESTs: Weakly similar to HYPOTHETICA	6.6
		AA058686		ESTs	7.7
60	108255	AA063157	Hs.172608	ESTs	4
		AA071514		ESTs	4
		AA100694		Human DNA sequence from BAC 15E1 o	5.5
		AA112396		ESTs; Moderately similar to HOMEOBO	14.3
65		AA115562 AA120785	Hs.274417	Homo sapiens mRNA; cDNA DKFZp564 ESTs	5.2 5.6
05		AA121315		KIAA1077 protein	10.5
		AA126422	0.7 0020	zn84f1.s1 Stratagene lung carcinoma 9372	4.4

	400==4		11 74040	FOT ALL LAND COULD OF OUR	4.0
		AA128125		ESTs; Moderately similar to CELL GROW	4.6
		AA131584		DKFZP564O0463 protein	5.5
			Hs.111680	ESTs	7.2
_		AA134958		ESTs	11.3
5		AA135894		retinoic acid induced 3	8.9
	109008	AA156360	Hs.87128	ESTs	14.7
	109010	AA156460	Hs.44229	dual specificity phosphatase 12	4.9
	109011	AA156542	Hs.72127	ESTs	4.6
	109042	AA159525	Hs.71779	Homo sapiens DNA from chromosome 19	7.2
10	109086	AA166695	Hs.270737	tumor necrosis factor (ligand) superfamily	4
	109090	AA167006	Hs.70499	ESTs	5.9
		AA167708		ESTs	4.2
			Hs.257924	ESTs	4
			Hs.301997	DKFZP434N126 protein	4
15		AA179845		RAB6 interacting; kinesin-like (rabkinesin	13.6
10			Hs.283707	ESTs	11.8
			Hs.192789	ESTs; Weakly similar to !!!! ALU SUBFA	5.4
		AA195255		ESTs	6.7
				ESTs; Weakly similar to alternatively spli	4.9
20		AA195515			5.4
20		AA196332		ESTs	5.5
		AA206800		ESTs; Moderately similar to zinc finger p	
			Hs.110826	trinucleotide repeat containing 9	20.1
			Hs.295232	ESTs	4.7
0.5		AA232904		ESTs	6.8
25			Hs.289069	ESTs; Weakly similar to WD40 protein C	10.6
		AA233892		ESTs; Weakly similar to !!!! ALU SUBFA	8
		AA234087		ESTs; Weakly similar to ORF2: function	8.2
	109572	F02027	Hs.171937	ESTs	4.8
	109632		Hs.235873	ESTs; Weakly similar to K11C4.2 [C.eleg	5.2
30	109644	F04477	Hs.291531	ESTs; Moderately similar to GLYCERAL	6.6
	109703	F09684	Hs.24792	ESTs; Weakly similar to ORF YOR283w	7.1
	109726	F10009	Hs.9196	ESTs	5
	109747	F10161	Hs.22969	ESTs	4.7
	109799		Hs.180378	Homo sapiens clone 669 unknown mRNA	4.5
35	109814		Hs.153106	Homo sapiens clone 23728 mRNA sequen	8.7
		H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H25577	Hs.176588	ESTs; Weakly similar to CYTOCHROME	6.2
		H29285	Hs.32468	ESTs	4.5
		H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7
40		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	19.5
40		H95079	Hs.15617	ESTs; Weakly similar to IIII ALU SUBFA	6.2
		H98714	Hs.24131	ESTs	30.2
				ESTs	5.8
		N22262	Hs.131705		8.2
45		N23174	Hs.22891	solute carrier family 7 (cationic amino aci	6.7
43		N24716	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	5.9
		N25262	Hs.27931	ESTs	
		N26101	Hs.323401	Human ring zinc-finger protein (ZNF127-	4
		N29454	Hs.27552	ESTs; Weakly similar to putative p150 [H	4.3
50		N30856	Hs.30246	solute carrier family 19 (thiamine transpo	12.8
50		N31952	Hs.167531	Homo sapiens mRNA full length insert cD	10.1
	110854		Hs.27931	ESTs	4.7
	110856	N33063		ESTs; Weakly similar to S164 [H.sapiens	4.2
	110860	N33438	Hs.170065	ESTs	12.5
	110897	N39148	Hs.6880	DKFZP434D156 protein	4
55	110915	N46252	Hs.29724	ESTs	23.2
	110935	N48787	Hs.305979	protease inhibitor 1 (anti-elastase); alpha-	4.8
	110970	N51374	Hs.96870	Homo sapiens mRNA full length insert cD	5.4
		N53375	Hs.166146	Homer; neuronal immediate early gene; 3	4.7
		N53388	Hs.7222	ESTs	13.3
60		N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7
		N59543	Hs.15456	PDZ domain containing 1	8.3
		N62522	Hs.20450	ESTs	14.3
		N63823	Hs.269115	ESTs	7.9
		N64378	Hs.83293	ESTs; Highly similar to unknown function	4.4
65		N64683	Hs.290943	ESTs	6
	444464	N66857	Hs.14808	ESTs; Weakly similar to !!!! ALU CLASS	4.1
			Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	5.5
	1111/2	N67102	113,21001	Homo supicina minara, opiara pini zpodo	5.5

	111178 N67227	Hs.24633	ESTs	5.7
	111179 N67239	Hs.10760	ESTs	37
	111181 N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro	5.6
	111184 N67437	Hs.243901	Homo sapiens mRNA; cDNA DKFZp564	8.7
5	111221 N68869	Hs.15119	ESTs	7.3
3	111221 N68921	Hs.297939	ESTs; Weakly similar to neogenin [H.sap	9
	111229 N69113	Hs.110855	ESTs	8.9
	111241 N69514	Hs.288880	ESTs; Weakly similar to CGI-82 protein [	6.9
	111268 N70481	Hs.26118	Homo sapiens clone 24766 mRNA sequen	4.5
10	111295 N73275	Hs.21275	ESTs; Weakly similar to ubiquitin-conjug	5.6
	111299 N73808	Hs.24936	ESTs	8.5
	111336 N79565	Hs.29894	ESTs	6.7
	111357 N91023	Hs.87128	ESTs	15
	111370 N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide-e	5.2
15	111806 R33468	Hs.279008	ESTs	10
,	111825 R35885	Hs.286148	stromal antigen 1	4.5
	111836 R36228	Hs.25119	ESTs	7.2
	111890 R38678	Hs.12365	ESTs	17.3
	111923 R39995	Hs.25925	Homo sapiens clone 23860 mRNA sequen	7.3
20	111942 R40576	Hs.21590	ESTs	9.2
	111987 R42036	Hs.6763	KIAA0942 protein	10.6
	112101 R44793	Hs.296341	adenylyl cyclase-associated protein 2	5.3
	112134 R46025	Hs.7413	ESTs	17.4
	112197 R49482	Hs.5637	ESTs	4.4
25	112244 R51309	Hs.70823	KIAA1077 protein	11
	112253 R51818		Homo sapiens mRNA; cDNA DKFZp566	9.3
	112305 R54822	Hs.26244	ESTs	4.4
	112449 R63802	Hs.124186	ring finger protein 2	6.3
20	112483 R66534	Hs.285885	ESTs	4.9
30	112519 R68631	Hs.11861	ESTs	14.3
	112610 R79392	Hs.23643	ESTs	5.2
	112693 R88741	Hs.91065	ESTs; Moderately similar to proliferation	4.6
	112751 R93507	Hs.8207	ESTs	5.6
25	112801 R97486	Hs.157160	protein kinase; DNA-activated; catalytic p	8.7
35	112869 T03313	Hs.4747	dyskeratosis congenita 1; dyskerin	5.9
	112871 T03352	Hs.12285	ESTs	5.8 4.1
	112908 T10065	Hs.3530	TLS-associated serine-arginine protein glucocorticoid receptor DNA binding fact	5.7
	112966 T17119 112971 T17185	Hs.102548 Hs.83883	ESTs	6.4
40	112971 177165 112995 T23528	Hs.7155	ESTs; Weakly similar to TYKi protein [M	9.1
70	113047 T25867	Hs.7549	ESTs	5.4
	113077 T23607	Hs.6986	ESTs; Weakly similar to !!!! ALU SUBFA	5.7
	113117 T47819	Hs.159153	ESTs	5.8
	113206 T58044	Hs.241471	ESTs; Moderately similar to !!!! ALU SU	6.4
45	113248 T63857	110.21117	yc16e1.s1 Stratagene lung (#93721) Homo	4.6
	113260 T64896	Hs.287420	ESTs	6.9
	113277 T65797	Hs.11774	protein (peptidyl-prolyl cis/trans isomeras	5.6
	113278 T65802	Hs.11135	yc11h10.s1 Stratagene lung (#937210) Ho	4.5
	113440 T86121	Hs.191445	ESTs	6.4
50	113523 T90037	Hs.95549	ESTs	6.4
	113604 T92735	Hs.296083	ESTs	8.7
	113702 T97307		ESTs; Moderately similar to !!!! ALU SU	9.5
	113783 W19222	Hs.7041	ESTs; Weakly similar to !!!! ALU SUBFA	5.2
	113794 W37382	Hs.11090	ESTs	11.9
55	113808 W44735	Hs.9286	ESTs	16.7
	113811 W44928	Hs.6994	ESTs	4
	113822 W47350	Hs.17466	retinoic acid receptor responder (tazaroten	4.8
	113823 W47388	Hs.55099	rab6 GTPase activating protein (GAP and	4
<i>c</i> o	113836 W56792	Hs.12040	ESTs; Weakly similar to KIAA0881 prote	4.1
60	113857 W65477	Hs.5297	Homo sapiens mRNA; cDNA DKFZp564	4.3
	113886 W72471	Hs.23920	ESTs	4.6
	113895 W73738	Hs.12921	ESTs	7.1
	113923 W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p	6.8
C F	113931 W81205	Hs.3496	ESTS	6.1
65	113950 W85765	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434	14 15
	113970 W86748	Hs.8109 Hs.177534	ESTs dual specificity phosphatase 10	15 5.4
	114051 W94942	113.177304	addi opedinolly priospriatase to	5.4

					4.0
		W96222	Hs.34192	ESTs	4.8
		Z38266	Hs.288649	Homo sapiens PAC clone DJ0777O23 fro	5.1
		Z38347	Hs.118338	ESTs, Weakly similar to similar to S. cere	6.2
~		Z38435	Hs.184108	ribosomal protein L21	4.6
5		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 prote	22
		Z38763	Hs.15740	amyloid beta (A4) precursor protein-bindi	8.8
		Z38814	Hs.27196	ESTs	4
		Z38909	Hs.22265	ESTs	7.2
4.0		Z39062	Hs.23740	ESTs	5.3
10		Z39211	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4
	114208	Z39301	Hs.7859	ESTs	5.1
	114250	Z39897	Hs.13297	ESTs	7.2
	114251	Z39898	Hs.21948	ESTs	14.7
	114292	Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
15	114297	Z40758	Hs.173091	DKFZP434K151 protein	8.9
	114334	Z41342	Hs.22941	ESTs	13.7
	114460	AA024604	Hs.26102	ESTs .	10.1
	114471	AA028074	Hs.104613	ESTs	5.7
			Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	7.3
20			Hs.106469	suppressor of var1 (S.cerevisiae) 3-like 1	4.3
			Hs.293380	ESTs	11.7
			Hs.292833	ESTs	7.3
			Hs.107149	ESTs; Weakly similar to PTB-ASSOCIAT	6.1
		AA113303		transmembrane 4 superfamily member (te	4.3
25			Hs.110857	ESTs; Highly similar to putative DNA-dir	7.1
20			Hs.154443	minichromosome maintenance deficient (S	5.3
			Hs.109929	ESTs	4.2
			Hs.269956	ESTs	4.8
		AA161161		multiple inositol polyphosphate phosphata	7.1
30		AA165313		ESTs	4.4
50		AA235035		ESTs; Moderately similar to ubiquitin spe	5
			Hs.196437	ESTs; Weakly similar to R26660_1; parti	16.9
		AA236359		ESTs	5.1
		AA243012		ESTs	8.5
35				ESTs	35.1
55		AA250737			5.7
		AA252627		homeo box B5	6.2
		AA252863		ESTS	13
		AA253217		ESTS	28.2
40			Hs.198269	NADH dehydrogenase (ubiquinone) 1 alp	8.8
40		AA256486		ESTs Weakly similar to supported by CE	
			Hs.279938	ESTs; Weakly similar to supported by GE	4.1
			Hs.284216	ESTs	8.3 5.1
			Hs.186572	ESTs	4.6
45		AA278650		ESTs; Weakly similar to similar to the bet	
43			Hs.283732	ESTs	8.3
		AA278961		ESTs	10.1 9.5
		AA279071		splicing factor 3b; subunit 1; 155kD	
			Hs.293736	ESTS	5.8
50			Hs.122579	ESTs	5.1
30		AA281793		ESTS	5
	44-1-		Hs.193063	ESTs	6.1
		AA283198		ESIS	4.9
			Hs.193090	ESTs	5.8
55		AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
55		AA292537		Human DNA sequence from clone 620E1	6.8
		AA331393		ESTs FOR A LINE OF THE PROPERTY OF THE PROPERT	5.8
		AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	8.7
60		AA400247		ESTs	4
60		AA400948		ESTs; Weakly similar to zinc finger prote	8.4
			Hs.305971	ESTS	5.3
		AA405098		ESTs	16.1
		AA405620		ESTs; Weakly similar to weak similarity t	4.7
C =			Hs.183056	Human DNA sequence from clone 34B21	5.1
65		AA406546		Homo sapiens mRNA; cDNA DKFZp564	20.5
		AA417102	HS.90960	ESTS	4.8
	115763	AA421560		ESTs	7

	115764	AA421562	Hs.91011	anterior gradient 2 (Xenepus laevis) homo	41.6
	115835	AA428576	Hs.41371	ESTs	4.2
		AA430124		ESTs	11.9
_		AA433943		ESTs; Weakly similar to Weak similarity	33.5
5		AA435839		KIAA0887 protein	7.2
	115922	AA441911	Hs.71869	ESTs; Weakly similar to KIAA0926 prote	5.1
	115941	AA443602	Hs.46679	ESTs	4.8
		AA443793		ESTs	8.3
		AA443798		poly(A)-specific ribonuclease (deadenylat	13.5
10					
10			Hs.301048	cofilin 1 (non-muscle)	7.5
		AA446887		ESTs	8.8
	115984	AA447687	Hs.91109	ESTs	13.1
	116009	AA449448	Hs.44238	ESTs	5.5
	116024	AA451748	Hs.83883	Human DNA sequence from clone 718J7	7.5
15		AA452112		thioredoxin-like	12.7
10		AA453656		ESTs	7.2
			Hs.176376	ESTs	11.8
		AA457566		ESTs	4.5
	116121	AA459254	Hs.48855	ESTs	4.5
20	116127	AA459703	Hs.279884	v-myc avian myelocytomatosis viral onco	4.3
	116129	AA459956	Hs.49163	ESTs; Highly similar to putative ribonucle	7.6
		AA460649		ESTs	4.8
			Hs.108646	ESTs	6.8
25		AA478397		ESTs	4.9
25		AA478415		ESTs	4
	116238	AA479362	Hs.47144	DKFZP586N0819 protein	4.6
	116246	AA479961	Hs.250646	ESTs; Highly similar to ubiquitin-conjuga	4
	116249	AA480886	Hs.86693	ESTs	18.5
		AA480975		ESTs	10.8
30		AA481146		ESTs; Weakly similar to OXYSTEROL-B	9.1
50				ESTs; Weakly similar to lysophospholipa	8.4
		AA481256			
			Hs.272239	Homo sapiens mRNA; cDNA DKFZp586	7.2
		AA482595		ESTs; Weakly similar to F25B5.3 [C.eleg	11.1
	116282	AA486550	Hs.204501	ESTs; Weakly similar to Wiskott-Aldrich	6.2
35	116298	AA489046	Hs.94109	ESTs	4.9
	116300	AA489194	Hs.159471	ESTs; Weakly similar to snRNP protein B	4.6
		AA490959		Homo sapiens mRNA; cDNA DKFZp564	5.8
		AA491457		ESTs	4.3
		AA496127		ESTs	8.4
40					
40		AA504116		Homo sapiens mRNA; cDNA DKFZp434	5.3
		AA504806		Homo sapiens clone 23620 mRNA sequen	5.2
	116415	AA609204	Hs.27973	KIAA0874 protein	6.6
	116443	AA620313	Hs.190488	ESTs; Weakly similar to KERATIN; TYP	4.5
	116470	C13992	Hs.83484	ESTs	4.5
45		C14088		glyceraldehyde-3-phosphate dehydrogena	5.6
		D51272	Hs.75337	nucleolar phosphoprotein p130	4.1
		D51276	Hs.81915	leukemia-associated phosphoprotein p18	5.8
		F02028	Hs.81907	ESTs	4.9
		F03069	Hs.15395	ESTs; Weakly similar to ARGINYL-TRN	6.1
50	116674	F04816	Hs.92127	ESTs	10.6
	116680	F08813	Hs.273829	LINE retrotransposable element 1	4.2
	116700	F09983	Hs.317589	ESTs	13
		F13665	Hs.65641	ESTs	8.5
		F13681	Hs.53913	ESTs	
55					5.6
55		F13779	Hs.165909	ESTs	11.6
		F13789	Hs.93796	DKFZP586D2223 protein	5.4
	116760	H11054	Hs.155342	protein kinase C; delta	4.3
	116780	H22566	Hs.30098	ESTs	5.7
		H25836	Hs.301527	tumor necrosis factor (ligand) superfamily	8.8
60		H28581	Hs.15641	ESTs	8.6
00		H29532	Hs.101174	microtubule-associated protein tau	22.2
		H47357		ESTs; Moderately similar to weak similar	
			Hs.109701		6.7
		H68116	Hs.168732	ESTs	6.5
<i></i>		H72948	Hs.821	biglycan	20.7
65		N20083	Hs.42792	ESTs	4.4
	117232	N20579	Hs.61153	ESTs	7.4
	117284	N22162	Hs.183779	ESTs; Weakly similar to cDNA EST vk33	4.1
				,,	

	117344	N24046	Hs.210706	ESTs	7.4
		N24954	Hs.42502	ESTs	10.5
		N26175	Hs.93405	ESTs	5.8
	117394	N26257	Hs.39871	KIAA0727 protein	8.4
5	117412	N26722	Hs.42645	ESTs	18.1
	117498	N31726	Hs.44268	ESTs; Highly similar to myelin gene expr	5.8
	117557	N33920	Hs.44532	diubiquitin	12.3
	117634	N36421	Hs.13323	ESTs; Weakly similar to SODIUM- AND	4.4
4.0	117639	N36923	Hs.44833	ESTs	6
10		N47469	Hs.59757	ESTs	7.6
		N49408	Hs.136102	KIAA0853 protein	5.9
		N50050	Hs.303025	ESTs; Weakly similar to keratin; 67K typ	7.9
		N51056	Hs.38891	ESTs	7.9
1.5		N51394	Hs.75478	KIAA0956 protein	5
15		N52000	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586	7
		N57773	Hs.93560	ESTs; Weakly similar to trg [R.norvegicu	4.8
		N62195	Hs.77910	3-hydroxy-3-methylglutaryl-Coenzyme A	13.4
		N62339	Hs.166254	heat shock 90kD protein 1; alpha	5.4 4.2
20		N62827	Hs.48645	EST	7.2
20		N63604	Hs.47166 Hs.48938	ESTs ESTs	6
		N64168 N66158	Hs.74649	ESTS	4.1
		N66769	Hs.291033	ESTs	5.4
		N66818	Hs.42179	ESTs	10.8
25		N66845	115.42115	ESTs; Weakly similar to !!!! ALU CLASS	4.5
20		N67149	Hs.50115	ESTS	5.3
		N67889	Hs.49397	ESTs	10.4
		N68010	Hs.49427	ESTs	7.9
		N69222	, 10. 10 12.	ESTs	9.2
30		N71781	Hs.50081	Homo sapiens mRNA full length insert cD	9.8
		N72113	Hs.50187	ESTs	4.3
	118901	N90719	Hs.94445	ESTs	8.1
	118952	N92966		ESTs; Highly similar to CGI-90 protein [H	12.5
	118976	N93629	Hs.93391	ESTs	5
35	118986	N94362	Hs.125830	ESTs	7.3
	118989	N94439	Hs.45105	ESTs	8.2
	119027	N99256	Hs.114611	ESTs	5
		R05316	Hs.5472	ESTs	4
40		R36451	Hs.287820	fibronectin 1	6
40		T15916	Hs.102950	ESTs; Highly similar to coat protein gamm	4.1
		T16387	Hs.65328	ESTs	12.1
		T23820	Hs.155478	cyclin T2	5.6
		T25725	11- 440000	ESTs	14.3
45		T62571	Hs.146388	microtubule-associated protein 7	4 5.3
43		W35390	Hs.55533 Hs.92260	ESTs	5.6
		W42451 W46286	Hs.233694	high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele	6.5
		W47620	Hs.56009	2'-5'oligoadenylate synthetase 3	8.1
		W60473	Hs.57787	ESTs	5.5
50		W69134	Hs.57987	ESTs	4.6
50		W69747	Hs.94806	KIAA1062 protein	4
		W73788	Hs.43213	ESTs	4
		W80702	Hs.58461	ESTs	4.8
		W80852	Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4.2
55		W81129	Hs.44865	Homo sapiens mRNA; cDNA DKFZp586	4.8
	119899	W84767	Hs.58698	ESTs	5.9
	119940	W86779	Hs.272531	DKFZP586B0319 protein	9
	119943	W86835	Hs.14158	copine III	4.8
	119970	W87812	Hs.93581	Homo sapiens mRNA; cDNA DKFZp586	4
60		Z38656	Hs.75887	coatomer protein complex; subunit alpha	4.2
		Z39549	Hs.153746	ESTs	11
		Z40805	Hs.91668	ESTs	8.2
		Z41815	Hs.65946	ESTs	15.6
65		AA169752		ESTs; Weakly similar to Similarity to Yea	4.2
65			Hs.221040	KIAA1038 protein	6.8
	120325	AA195651	Hs.104106	ESTs .	15.2
	120352	MMZ 1 1400	Hs.193172	1019	6.8

	120420	* * * * * * * * * * * * * * * * * * * *	U- 470004	MAAAAAA matain	E 6
			Hs.173694	KIAA1097 protein	5.6 5.6
			Hs.192905	ESTS	4.5
			Hs.104413	ESTs ESTs	4.9
5		AA280738	Hs.192843	ESTS	4.5
5			Hs.238205	ESTS	6.7
			Hs.292913	ESTs	8.3
			Hs.102506	eukaryotic translation initiation factor 2 al	4.6
		AA292655		ESTs	10.6
10			Hs.100747	ESTs	5.4
10		AA358015	113.100141	EST	7.1
			Hs.301872	ESTs; Moderately similar to !!!! ALU SU	4.6
			Hs.301444	ESTs	8.2
			Hs.104650	ESTs; Highly similar to similar to mago n	8.6
15			Hs.129206	casein kinase 1; gamma 3	10.5
		AA398155		ESTs	10.9
		AA398936		EST	7.4
		AA401753		lung cancer candidate	5.3
			Hs.301927	T-cell receptor; alpha (V;D;J;C)	13.5
20			Hs.239681	ESTs; Weakly similar to KIAA0554 prote	8.9
			Hs.174104	ESTs	22.6
			Hs.104800	ESTs; Weakly similar to Mouse 19.5 mRN	8
			Hs.234545	ESTs	5.6
		AA434411		ESTs	5.3
25	122522	AA449444	Hs.98969	ESTs	4
	122655	AA454756	Hs.97837	ESTs	4
	122704	AA456326	Hs.99445	ESTs	6.2
	122782	AA459894	Hs.99472	ESTs	5.3
	122856	AA463740	Hs.75367	Src-like-adapter	13.1
30	122882	AA465381	Hs.108812	ESTs; Weakly similar to B0041.5 [C.eleg	5.5
	122928	AA476578	Hs.101840	ESTs	6.3
	122974	AA478625	Hs.194215	ESTs	6
	122997	AA479295	Hs.106290	Kelch motif containing protein	12.5
	123016	AA480103	Hs.323231	ESTs; Weakly similar to alternatively spli	4.4
35	123107	AA486071	Hs.104207	ESTs	8.3
	123111	AA486273	Hs.191721	ESTs	4.2
			Hs.129928	ESTs; Moderately similar to KIAA0454 p	5.2
			Hs.194024	ESTs	4.2
40			Hs.100686	ESTs; Weakly similar to secreted cement	14.6
40		AA488892		ESTs; Weakly similar to Gag-Pol polypro	4.5
		AA489020		ESTs	5.2
			Hs.187585	ESTs	4
			Hs.223014	protease; serine; 15	7.3
15			Hs.111496	ESTs	5.9
45			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564	4.1
			Hs.112110	ESTs	4
			Hs.293156	ESTs Weekly similar to IIII ALLI SUDEA	12.8 7.9
		AA608751		ESTs; Weakly similar to !!!! ALU SUBFA	23.1
50		AA609200	Hs.158549	ESTs ESTs	6.6
50			Hs.278672		4.7
			Hs.112264	membrane component; chromosome 11; s ESTs	4
			Hs.287733	methylmalonate-semialdehyde dehydroge	7.6
		D57317	Hs.74861	activated RNA polymerase II transcription	4.4
55		D60302	Hs.270016	ESTs	20.6
33		D80240	Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
		F02859	Hs.13974	ESTs -	4.7
		F10523	Hs.74519	primase; polypeptide 2A (58kD)	4.7
		F13673	Hs.283713	ESTs	7.7
60		H66710	Hs.133525	ESTs	5.5
•		H93575	Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	11.4
		H94877	Hs.215766	GTP-binding protein	13.7
		H94892	Hs.288757	v-ral simian leukemia viral oncogene hom	14
		N21359	Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65		N21626	Hs.102406	ESTs	7.2
		N22401		yw37g07.s1 Morton Fetal Cochlea Homo	5.2
		N29325	Hs.7535	ESTs; Highly similar to COBW-like place	7.9

	12//20	NIA0400	Hs.11090	ESTs	9.5
		N40188 N48000	HS.11090	Homo sapiens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
		N63172	Hs.146409	cell division cycle 42 (GTP-binding prote	5.6
5		N74604	Hs.11090	ESTs	12.8
		N79515	Hs.306117	interleukin 13 receptor; alpha 1	6.4
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.3
		R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
		R01073	110.101010	ESTs; Weakly similar to !!!! ALU CLASS	5.4
10		R12405	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586	6.6
10		R40923	Hs.106604	ESTs	4.9
		R41933		ESTs	7.2
		R44357	Hs.48712	ESTs; Weakly similar to cDNA EST EMB	8.6
		R63652	Hs.137190	ESTs	4.9
15		R88992	Hs.180612	ESTs	4.7
	124955	T10598	Hs.324841	ESTs; Weakly similar to !!!! ALU SUBFA	4.4
	124958	T11134	Hs.431	murine leukemia viral (bmi-1) oncogene h	12.6
	125038	T78089	Hs.270134	ESTs	4.1
	125092	T92544	Hs.137548	CD84 antigen (leukocyte antigen)	14.8
20	125132	W15495	Hs.129781	chromosome 21 open reading frame 5	6.7
	125144	W37999	Hs.24336	ESTs	4.8
	125154	W38419		ESTs	5.3
	125243	W86423	Hs.105413	ESTs	6.6
	125279	W93640	Hs.4779	ESTs; Moderately similar to similar to AD	5.8
25	125299	Z39436	Hs.102720	ESTs	12.2
	125303	Z39821	Hs.288193	ESTs	10.2
		Z39833	Hs.124940	GTP-binding protein	6.8
		AA151216		tyrosine 3-monooxygenase/tryptophan 5-m	8
20			Hs.288967	ESTs	5.4
30			Hs.267812	sorting nexin 4	4.1
		AA507383		cytochrome c oxidase subunit VIc	11.5
		Al432621	Hs.82685	CD47 antigen (Rh-related antigen; integri	4
			Hs.191356	general transcription factor IIH; polypepti	9.4
25		Al283493		ribophorin II	6.2 25.9
35		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	4.1
		AA434562		ESTs	16.4
		N90960	Hs.265398	ESTs; Weakly similar to transformation-r tumor necrosis factor receptor superfamily	9.5
		N99638 Al066486	Hs.124084	similar to S. cerevisiae RER1	5.6
40		U46278	Hs.40500 Hs.122489	ESTs	7.5
40		W40262	Hs.146310	ESTs; Weakly similar to putative p150 [H	4.1
		W78968	Hs.181307	H3 histone; family 3A	4.5
		AA205862		ESTs	5.2
		T72569	Hs.125359	Thy-1 cell surface antigen	4.4
45		Al334393		ESTs	4.6
		Al203334	Hs.160628	ESTs	11.7
			Hs.279607	ESTs	4
		A1052047	Hs.26102	ESTs	7
		R31652	Hs.821	biglycan	5.6
50			Hs.179729	collagen; type X; alpha 1 (Schmid metaph	14.3
			Hs.204214	ESTS	4.5
	127663	W07286	Hs.10340	ESTs; Weakly similar to weak similarity t	5.1
			Hs.264190	ESTs; Highly similar to MEM3 [M.muscu	17.3
	127814	AA761755	· Hs.136713	ESTs; Weakly similar to V4-1 [H.sapiens	4.1
55	127997	Al281549	Hs.311054	ESTs	5.5
	128092	AA904617	Hs.166229	ESTs	5.8
		H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
	128466	D59653	Hs.241471	EST	7.4
		U83908	Hs.296251	programmed cell death 4	5.8
60			Hs.100861	ESTs; Weakly similar to p60 katanin [H.s	8.3
			Hs.183475	Homo sapiens clone 25061 mRNA sequen	6.6
			Hs.101448	metastasis associated 1	5.2
		AA412048		keratin 8	5.1
CF		U31875	Hs.152677	short-chain alcohol dehydrogenase family	27.1
65		L38608	Hs.10247	activated leucocyte cell adhesion molecule	13.2 6.7
			Hs.102708	DKFZP434A043 protein	4.5
	120049	AA 142003	Hs.103106	Homo sapiens mRNA for G7b protein (G	7.5

	128651	AA446990	Hs.103135	ESTs	6.1
		R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
		AA458542		coatomer protein complex; subunit epsilon	14.3
5		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566	24.5 7.3
5		M64174 N49308	Hs.50651 Hs.104938	Janus kinase 1 (a protein tyrosine kinase) ESTs; Weakly similar to alpha 1(XVIII) c	9.2
		X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
		W93562	Hs.105749	KIAA0553 protein	4.6
	128835	W15528	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586	4
10		AA455658		basement membrane-induced gene	6.9
		AA400271		Homo sapiens mRNA for putative Ca2+-t	4.5
		AA252023		ESTs; Weakly similar to HRIHFB2157 [H	6.4 6.4
		D61676 AA410325	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586 ESTs	0.4 7
15		N29353	Hs.107318	kynurenine 3-monooxygenase (kynurenin	5.2
10		AA485655		proteasome (prosome; macropain) subunit	13.1
		F10290	Hs.185807	Homo sapiens clone 24758 mRNA sequen	5.8
	129005	AA460049	Hs.13323	ESTs; Weakly similar to SODIUM- AND	12.6
20		AA131421		ESTs	9.8
20		H13108	Hs.107968	ESTs (CAMPATILA - Campa	13.9
		X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7 4.7
		AA129465 L12350	Hs.108623	ESTs thrombospondin 2	4.4
		AA234530		N-ethylmaleimide-sensitive factor	20.7
25		AA131252		ESTs	5.9
		AA282183		ESTs	5.8
	129180	R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6
		X89109	Hs.109606	coronin; actin-binding protein; 1A	12
20		AA211941		polyadenylate binding protein-interacting	7.9
30		W24360 AA435665	Hs.237868	interleukin 7 receptor ESTs; Moderately similar to HN1 [M.mus	5.3 8.4
		H88033	Hs.109700	KIAA0733 protein	7.8
		AA151574		pilin-like transcription factor	6.4
		AA090695		ESTs	6.2
35	129270	Z35227	Hs.109918	ras homolog gene family; member H	5.4
		AA026318		glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosomal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7 6
40		AA037467 AA167268		ESTs Human ras inhibitor mRNA; 3' end	9.3
-10		H18027	Hs.184697	plexin C1	18.2
		W92984	Hs.288224	ESTs	5.9
	129388	AA151621	Hs.110964	ESTs	4.1
4.5		T80814	Hs.11101	discs; large (Drosophila) homolog 3 (neur	10.9
45		AA172056		ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4 8
		AA412087 AA421213		EST; Highly similar to protein inhibitor o Lsm3 protein	5.5
		C00225	Hs.306163	ESTs; Weakly similar to fos39554_1 [H.s	5.5
50		AA298786		ESTs	6.8
		R21443	Hs.166254	heat shock 90kD protein 1; alpha	5
		AA278243		ESTs	6.8
		AA447410		ESTs; Weakly similar to !!!! ALU SUBFA	5.1
55		AA258308		Homo sapiens mRNA; cDNA DKFZp564	5.3
33		U26727 R50008	Hs.1174 Hs.11806	cyclin-dependent kinase inhibitor 2A (mel 7-dehydrocholesterol reductase	8.2 4.3
		AA442768		translocase of inner mitochondrial membr	4.4
		M88458	Hs.118778	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4
	129691	X06700	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos	6
60		AA454618		associated molecule with the SH3 domain	6.4
		AA252436		lysophospholipase I	7.7
		AA452161		YME1 (S.cerevisiae)-like 1	5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
65		AA102520 AA043021		ESTs; Weakly similar to heat shock prote UDP-Gal:betaGlcNAc beta 1;4- galactosy	5 6.6
05		M87789	113,13223	immunoglobulin gamma 3 (Gm marker)	4
		AA450045	Hs.140452	cargo selection protein (mannose 6 phosp	5.8
				•	

	130020	AA236412	He 236510	ESTs; Moderately similar to PFT27 [M.m	5.6
		M90696	Hs.181301	cathepsin S	5.4
		AA195260		ESTs; Moderately similar to !!!! ALU SU	7.4
		AA055896		collagen; type V; alpha 1	7.6
5		T24055	Hs.91379	ribosomal protein L26	4
		X14850	Hs.147097	H2A histone family; member X	12.1
			Hs.197955	KIAA0704 protein	5
		AA234717		ESTs	7.8
10		M36803	Hs.1504	hemopexin	7.2
10		M61764	Hs.21635	tubulin; gamma 1	5.6
		D43947	Hs.151469 Hs.151761	calcium/calmodulin-dependent serine pro KIAA0100 gene product	7.5 6.4
		AA620556		peroxisomal D3;D2-enoyl-CoA isomerase	6.4
		D50840	Hs.23703	UDP-glucose ceramide glucosyltransferas	4.5
15		X14046	Hs.153053	CD37 antigen	9.1
		S75295	Hs.169149	karyopherin alpha 1 (importin alpha 5)	8.6
	130280	L13738	Hs.153937	activated p21cdc42Hs kinase	5
		AA620323		ubiquitin-activating enzyme E1C (homolo	6.1
20		D86967	Hs.154332	KIAA0212 gene product	10
20		AA135673		KIAA0391 gene product	6.1
		X84373	Hs.155017	nuclear receptor interacting protein 1	10.6
		Z38501	Hs.8768 Hs.155188	ESTs; Weakly similar to !!!! ALU SUBFA	8.3 7.1
		T47333 X66364	Hs.166071	TATA box binding protein (TBP)-associa cyclin-dependent kinase 5	5.6
25		D13630	Hs.155291	KIAA0005 gene product	4.1
		AA449417		Homo sapiens mRNA for putative glucosy	4.6
		N29888	Hs.155410	ESTs	7
	130414	M21121	Hs.241392	small inducible cytokine A5 (RANTES)	4.1
• •		U58522	Hs.155485	huntingtin-interacting protein 2	7.9
30		D21260	Hs.178710	clathrin; heavy polypeptide-like 2	4
		U35835	Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetyl	26.4 4.8
		L38951	Hs.180446 Hs.158286	karyopherin (importin) beta 1 Homo sapiens mRNA for KIAA0446 prot	6.1
35		L32137	Hs.1584	cartilage oligomeric matrix protein (pseud	8.3
55			Hs.252587	pituitary tumor-transforming 1	7.5
		H96654	Hs.15984	ESTs; Weakly similar to gene pp21 protei	5.6
		AA232535		ESTs; Highly similar to CGI-13 protein [H	4
4.0	130583	W24957	Hs.293907	ESTs; Moderately similar to similar to C.e	13.3
40		H66211	Hs.16331	ESTs	10.1
		X03635	Hs.1657	estrogen receptor 1	39.9
		AA132007		ESTs ESTs	5.1 5.9
		AA477739 AA235247		ESTs; Weakly similar to cytochrome P45	4.1
45		F03969	Hs.260720	matrix metalloproteinase 2 (gelatinase A;	8.3
10		L23808	Hs.1695	matrix metalloproteinase 12 (macrophage	10.3
		M60346	Hs.1697	ATPase; H+ transporting; lysosomal (vacu	7
	130635	M87503	Hs.1706	interferon-stimulated transcription factor	5.5
		D59711	Hs.17132	ESTs	7.2
50		H17861	Hs.17767	ESTs	13.5
	130681	D82808	Hs.17820	Rho-associated; coiled-coil containing pro	6
	130693	AA487202		ESTs	6.1 4.3
		N63295	Hs.18103 Hs.201673	ESTs cornichon-like	4.5
55			Hs.279762	adenylate cyclase 7	5.1
		X92896	Hs.18212	DNA segment on chromosome X (unique)	8.4
		T98227	Hs.171952	occludin	5.7
		AA203527	Hs.18747	POP7 (processing of precursor; S. cerevis	6.2
<b>CO</b>		AA471293		ESTs	8.2
60		AA435633		Homo sapiens clone 23965 mRNA sequen	8.3
	130796	R39390	Hs.19525	ESTs	4.5 7.7
		AA223386	Hs.19574 Hs.143323	ESTs; Weakly similar to katanin p80 subu putative DNA/chromatin binding motif	7.7 4.3
		AA423439 AA287327		ceroid-lipofuscinosis; neuronal 2; late infa	9.8
65		M58028	Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a	4.3
		D14678	Hs.20830	kinesin-like 2	4.5
		D31891	Hs.20991	SET domain; bifurcated; 1	4

	40000=	4 4 0 5 0 4 0 0	11. 400000	TOT	0.7
		AA056489		ESTs	8.7
	_	W03592	Hs.21198	translocase of outer mitochondrial membr	20.9
		AA291710		collagen; type IV; alpha 3 (Goodpasture a	9
_		AA074596		bromodomain adjacent to zinc finger dom	5.3
5		M97935	Hs.21486	signal transducer and activator of transcrip	18.8
		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Weakly similar to cAMP inducible	8.5
		N48963	Hs.21992	KIAA0689 protein	7.2
10		AA435748		ESTs; Weakly similar to phosphatidic acid	5.2
10		X02530	Hs.2248	small inducible cytokine subfamily B (Cy	10.1
	131091	T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
	131153	H11760	Hs.23606	ESTs	7.3
	131185	M25753	Hs.23960	cyclin B1	6.2
	131200	AA609427	Hs.293732	ESTs; Moderately similar to !!!! ALU SU	4.3
15	131206	AA044078	Hs.24210	ESTs	5.5
	131210	AA430047	Hs.95549	ESTs	7.1
		AA429472		DKFZP434P106 protein	5.6
		D38076	Hs.24763	RAN binding protein 1	5.5
		AA620599		DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stanniocalcin	8.9
		AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2
		H84658	Hs.279836	ESTs	12.1
25		AA608962		calcyclin binding protein	18.1
23		Z39053	Hs.27263	ESTs	7.5
		AA121127			5.5
				H3 histone; family 3A	5.1
		X02152	Hs.2795	lactate dehydrogenase A	
20		N39152	Hs.301804	ESTs	4.3
30		D60856	Hs.28309	UDP-glucose dehydrogenase	8.4
		N33236	Hs.28555	ESTs; Weakly similar to B0511.8 [C.eleg	5.6
		D30946	Hs.28707	signal sequence receptor; gamma (transloc	8.7
		U90551	Hs.28777	H2A histone family; member L	18.8
25		AA491465		ESTs	11.8
35		AA235385		ESTs; Moderately similar to alternatively	4.7
		M15182	Hs.183868	glucuronidase; beta	5.2
		U52100	Hs.29191	epithelial membrane protein 2	4.4
		D14533	Hs.192803	xeroderma pigmentosum; complementatio	4.6
40		AA136126		mitogen-activated protein kinase-activated	4.3
40		AA136660	Hs.30579	ESTs	9.4
	131684	U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
	131687	L11066	Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.2
	131689	AA599653	Hs.30696	transcription factor-like 5 (basic helix-loo	8.3
	131693	W60913	Hs.110796	ESTs; Weakly similar to cDNA EST yk45	9
45	131710	AA233225	Hs.30985	MRS1 protein	5.2
	131716	D49738	Hs.31053	cytoskeleton-associated protein 1	6.6
	131742	D31352	Hs.31433	ESTs	11
	131762	H46831	Hs.107767	ESTs; Moderately similar to CaM-KII inh	4.9
	131781	AA460450		DKFZP586G1722 protein	9.2
50	131795	N32724	Hs.32317	Sox-like transcriptional factor	4.5
		L76517	Hs.3260	presenilin 1 (Alzheimer disease 3)	5.4
		AA437226		interleukin 10 receptor; alpha	4
		AA091932		dynamin-like protein	6.7
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5
55		AA044095		ESTs	11.1
		AA158258		heterogeneous nuclear protein similar to r	5.6
		AA248470		ESTs; Weakly similar to RING finger pro	4.5
		AA205460		ESTs	14.3
		D62657	Hs.35086	ubiquitin-specific protease 1	6.2
60		W90146	Hs.35962	ESTs	6.3
50		D86960	Hs.3610	KIAA0205 gene product	4.2
		R70167	Hs.154938	ESTs	4.3
				Homo sapiens mRNA; cDNA DKFZp586	4.6
		AA410424 F09788	Hs.268122 Hs.3622	procollagen-proline; 2-oxoglutarate 4-diox	6.4
65		AA479515		Human DNA sequence from clone 703H1	12
05				Homo sapiens clone 23714 mRNA sequen	10
		D82399	Hs.136644	Homo sapiens vav 3 oncogene (VAV3) m	4.7
	132017	W67251	Hs.267659	Trumo sapiens vav o uncogene (vAvo) ili	4./

	132021		Hs.306079	chaperonin containing TCP1; subunit 5 (e	5.2
	132065	D82226	Hs.211594	proteasome (prosome; macropain) 26S sub	8.5
	132085	D44466	Hs.3887	proteasome (prosome; macropain) 26S sub	13.5
_	132089	AA131971	Hs.39122	ESTs	4.8
5		AA599801		ESTs	6.2
	132143	AA257056	Hs.7972	KIAA0871 protein	14.6
	132149	T10822	Hs.324743	ESTs	5.3
	132153	N90141	Hs.41066	ESTs; Moderately similar to ELONGATI	9.2
	132160	AA281770	Hs.295923	seven in absentia (Drosophila) homolog 1	5.5
10	132164	U84573	Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy	8.1
	132180	AA405569	Hs.418	fibroblast activation protein; alpha; sepras	15.4
	132183	L19183	Hs.199695	hypothetical protein	12.2
	132225	AA128980		ESTs	5.6
	132227	AA412620	Hs.4248	ESTs	6.7
15	132235	F09058	Hs.42656	ESTs	6.2
	132256	AA608856	Hs.431	murine leukemia viral (bmi-1) oncogene h	6
	132298		Hs.7120	Homo sapiens cytokine receptor related p	5.6
		AA285290	Hs.44499	small EDRK-rich factor 2	6.8
	132325	N37065	Hs.44856	ESTs	4.7
20		AA479933		Human DNA sequence from clone 167A1	4.2
		R70914	Hs.281434	heat shock 70kD protein 1	9.1
		W85888	Hs.47334	ESTs; Moderately similar to !!!! ALU SU	4
	132406		Hs.4774	ESTs	15
		AA431459		ESTs	8
25			Hs.260116	KIAA1104 protein	4
		AA426218		ESTs	5.3
		AA047896		ESTs	15.4
			Hs.238126	ESTs; Highly similar to CGI-49 protein [H	9
	132492		Hs.4990	KIAA1089 protein	8.5
30		AA283006		chromosome-associated polypeptide C	4.3
-		AA488987		synaptogyrin 2	9.8
		AA417152		protein regulator of cytokinesis 1	10.1
	132580		Hs.283738	casein kinase 1; alpha 1	5.9
		AA412452		DKFZP434N024 protein	4.2
35		AA199588		ARP3 (actin-related protein 3; yeast) hom	4.2
55			Hs.283558	isocitrate dehydrogenase 2 (NADP+); mit	5.2
		AA171913		carbonic anhydrase XII	10.1
			Hs.279916	adaptor-related protein complex 1; gamma	4.8
	132640		Hs.5437	Tax1 (human T-cell leukemia virus type I	5.7
40		AA453614		KIAA0776 protein	4.4
		M60830	Hs.5509	ecotropic viral integration site 2B	15.6
		N47109	Hs.5521	ESTs	7
		AA417962		geranylgeranyl diphosphate synthase 1	5.6
		W42674	Hs.264636	ESTs; Moderately similar to neuronal thre	4.9
45			Hs.292812	ESTs; Weakly similar to C43H8.1 [C.eleg	7.9
	132744		Hs.55921	glutamyl-prolyl-tRNA synthetase	4.1
		H99152	Hs.57079	ESTs	8
		AA331777		mutL (E. coli) homolog 1 (colon cancer; n	8
	132811		Hs.57419	transcriptional repressor	4
50		AB004884		tousled-like kinase 2	6.5
-	132840		Hs.5807	Homo sapiens clone 23675 mRNA sequen	5.6
		D62588	Hs.5813	ESTs	12.4
	132847		Hs.58189	eukaryotic translation initiation factor 3; s	7
		W79865	Hs.58367	glypican 4	6.2
55	132869		Hs.203961	ESTs	6.5
		AA425776		ESTs	5.6
			Hs.177537	ESTs	7.2
		D82422	Hs.5944	ESTs	7.5
	132900		Hs.5978	LIM domain only 7	4.4
60		AA235404		Homo sapiens clone 25186 mRNA sequen	9.1
	132904		Hs.59889	3-hydroxy-3-methylglutaryl-Coenzyme A	10.7
			Hs.234896	ESTs; Highly similar to geminin [H.sapie	10.2
		AA496037		ESTs	4.7
		AA252605		KIAA0616 protein	7.1
65		AB002305		KIAA0307 gene product	8.3
	132951		Hs.61418	microfibrillar-associated protein 1	4.3
		AA234791		Human gene from PAC 753P9; chromoso	13.2
	,02007				

	132959	AA028103	Hs.61472	ESTs; Weakly similar to unknown [S.cere	18.9
		N77151	Hs.61638	myosin X	5.8
	132984	H80409	Hs.62112	zinc finger protein 207	4.3
		AA458761		transcription factor AP-2 alpha (activating	4.2
5			Hs.279905	solute carrier family 2 (facilitated glucose	26.4
		Y00062	Hs.170121	protein tyrosine phosphatase; receptor typ	4.4
		AF006082		ARP2 (actin-related protein 2; yeast) hom	4.7 6.6
		C21400 AA047036	Hs.278605 Hs.246315	KIAA0970 protein ESTs	7.9
10		W81298	Hs.6289	growth factor receptor-bound protein 2	5.2
10		X62055	Hs.63489	protein tyrosine phosphatase; non-recepto	4
		S67325	Hs.63788	propionyl Coenzyme A carboxylase; beta	5.2
		AA071387		jumping translocation breakpoint	5
		R33663	Hs.64056	ESTs	5.4
15		N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		AA122147		K(AA0483 protein	5
			Hs.285996	ESTs	5.6
		AA156049		ESTs	4.1
20		D16469	Hs.6551	ATPase; H+ transporting; lysosomal (vacu	6.2 5.1
20		R37367 Y10659	Hs.6727 Hs.285115	Ras-GTPase activating protein SH3 doma interleukin 13 receptor; alpha 1	6.2
		Z41415	Hs.6823	ESTs; Weakly similar to intrinsic factor-B	8.3
		N90029	Hs.6831	Homo sapiens clone 1400 unknown prote	4.7
			Hs.179882	Homo sapiens clone 24655 mRNA sequen	5.5
25		D31161	Hs.242894	ESTs	9
	133257	AF006086	Hs.6895	actin related protein 2/3 complex; subunit	7.7
		W72187	Hs.69192	ESTs; Weakly similar to cDNA EST yk37	6.7
		AA488886		ESTs	4.2
20		AA421079		ESTs; Weakly similar to Sox-like transcri	4.9
30		AA410507		ESTs	4.3 9.3
		L15702 R79723	Hs.69771 Hs.69997	B-factor; properdin	30.4
		AA600057		zinc finger protein 238 KIAA0905 protein	10.4
			Hs.152316	ESTs	8.5
35		H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
		AA156897		DKFZP564I1922 protein	5
	133391	X57579	Hs.727	inhibin; beta A (activin A; activin AB alp	13.9
		AA491296		ESTs	4.3
40		N79516	Hs.73287	ESTs; Weakly similar to eyelid [D.melano	4.5
40		AA255438		Homo sapiens mRNA; cDNA DKFZp566	8
		T23983	Hs.323966	ESTs	5 8.7
		AA094989 X03068	Hs.73931	voltage-dependent anion channel 3 major histocompatibility complex; class fl	5. <i>1</i>
		X78710	Hs.211581	metal-regulatory transcription factor 1	5.3
45		AA316868		ESTs; Weakly similar to 140G11.h [D.me	6.8
		X52947	Hs.74471	gap junction protein; alpha 1; 43kD (conn	5.7
	133551	D63480	Hs.278634	KIAA0146 protein	4.8
		AA313977		transcription elongation factor B (SIII); po	9.5
50		W94333	Hs.279915	translocase of inner mitochondrial membr	5
50		F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
		L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5 4.2
		D13315 AA148318	Hs.75207	glyoxalase I KIAA0069 protein	4.5
		U09587	Hs.75280	glycyl-tRNA synthetase	10
55		D21262	Hs.75337	nucleolar phosphoprotein p130	4.5
		U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15.2
		D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
	133644	D89077	Hs.75367	Src-like-adapter	6.4
<b>CO</b>		AA479139		acid phosphatase 1; soluble	4.8
60		AA287383		ESTS	4.2
		AA458946		ESTs	4.3 8.3
		K01396 N21648	Hs.297681 Hs.75659	protease inhibitor 1 (anti-elastase); alpha- MpV17 transgene; murine homolog; glom	6.3 4.6
		Y00282	Hs.75722	ribophorin II	7.5
65		L27841	Hs.75737	pericentriolar material 1	9.4
		U49278	Hs.75875	ubiquitin-conjugating enzyme E2 variant	4.5
		D21255	Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4
				•	

		W73693	Hs.76038	isopentenyl-diphosphate delta isomerase	7.9
		Z23090	Hs.76067	heat shock 27kD protein 1	4.1
	133776	J03473	Hs.177766	ADP-ribosyltransferase (NAD+; poly (AD	13
_	133784	AA214305	Hs.301064	ESTs	5.2
5	133814	M33882	Hs.76391	myxovirus (influenza) resistance 1; homol	11.7
	133829	AA453783	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	9.4
	133834	AA147510	Hs.288660	serine protease; umbilical endothelium	4.8
	133839	M59815	Hs.170250	complement component 4A	6.7
	133842	U73477	Hs.285013	putative human HLA class II associated p	7.1
10	133845	T68510	Hs.76704	ESTs	6.3
	133859	U86782	Hs.178761	26S proteasome-associated pad1 homolog	13.7
	133867	D43948	Hs.76989	KIAA0097 gene product	4.1
		U58090	Hs.183874	cullin 4A	4
		AA454597	Hs.182793	ESTs	4.7
15		X01060	Hs.77356	transferrin receptor (p90; CD71)	8.3
~~		N32811	Hs.77542	ESTs	5
		W72783	Hs.58382	ESTs; Weakly similar to C13F10.5 [C.ele	4.5
		AA045870		Homo sapiens mRNA; cDNA DKFZp564	6.3
			Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20		L34587	Hs.184693	transcription elongation factor B (SIII); po	6.3
20		D00760	Hs.250811	proteasome (prosome; macropain) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2
		M28213	Hs.78305	RAB2; member RAS oncogene family	5.2
		J03077	Hs.78575	prosaposin (variant Gaucher disease and v	4.6
25		Z81326		protease inhibitor 12 (neuroserpin)	6.5
23			Hs.78589	, , , ,	11.9
		S82470 D28473	Hs.78768	BB1	5.2
			Hs.172801	isoleucine-tRNA synthetase	7.3
		D87685	Hs.78893	KIAA0244 protein	4.7
20		H98621	Hs.78946	cullin 3	7
30		U51166	Hs.173824	thymine-DNA glycosylase	
		M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	4.5
		X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	4.4
2.5		U32519	Hs.220689	Ras-GTPase-activating protein SH3-doma	6.6
35			Hs.181634	Human Chromosome 16 BAC clone CIT9	8.6
		M63138	Hs.79572	cathepsin D (lysosomal aspartyl protease)	9.3
		U88871	Hs.79993	peroxisomal biogenesis factor 7	6.3
		L28010	Hs.808	heterogeneous nuclear ribonucleoprotein F	4.3
4.0		AA430008		ESTs	6.9
40		AA313414		Homo sapiens clone 24856 mRNA sequen	7.4
		U16306	Hs.81800	chondroitin sulfate proteoglycan 2 (versic	6.1
		D38551	Hs.81848	RAD21 (S. pombe) homolog	8.6
			Hs.111222	ESTs; Weakly similar to CGI-128 protein	6.1
	134351	R82074	Hs.82109	syndecan 1	4.4
45	134357	L43575	Hs.82171	Human clone 191B7 placenta expressed m	6.6
	134363	M37033	Hs.82212	CD53 antigen	5.3
	134367	X54199	Hs.82285	phosphoribosylglycinamide formyltransfe	4.8
		D62633	Hs.8236	ESTs	15.2
	134375	AA412720	Hs.82389	ESTs; Highly similar to CGI-118 protein	7.2
50	134376	X02874	Hs.82396	2';5'-oligoadenylate synthetase 1	6.4
	134381	U56637	Hs.184270	capping protein (actin filament) muscle Z-	4
	134388	·M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
		L09717	Hs.8262	lysosomal-associated membrane protein 2	6.9
		H99801	Hs.82689	tumor rejection antigen (gp96) 1	4.5
55		AA243746		kinectin 1 (kinesin receptor)	11.2
		J04177	Hs.82772	collagen; type XI; alpha 1	15.3
		AA329274	Hs.82911	protein tyrosine phosphatase type IVA; m	4.1
		D87969	Hs.82921	solute carrier family 35 (CMP-sialic acid t	4.2
		L08044	Hs.82961	trefoil factor 3 (intestinal)	5.9
60		AA122386		collagen; type V; alpha 2	5.8
00		W96151	Hs.83006	ESTs; Highly similar to CGI-139 protein	4.4
		AA449984	Hs.246857	ESTs; Highly similar to proteine kinase JN	7
		T25732	Hs.83419	KIAA0252 protein	4.6
		X70683	Hs.83484	SRY (sex determining region Y)-box 4	5.1
65		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		R38185	Hs.83954	Homo sapiens unknown mRNA	5
		D63477	Hs.84087	KIAA0143 protein	16.1
	,51.00			•	

		M63180	Hs.84131	threonyl-tRNA synthetase	6.1
		U45328	Hs.84285	ubiquitin-conjugating enzyme E2I (homol	4.6
		H24460	Hs.848	FK506-binding protein 4 (59kD)	6.2
_		U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5		AA234966		CGG triplet repeat binding protein 1	4.7
		R68884	Hs.86347	ESTs; Weakly similar to predicted using G	5.8
		X74496	Hs.86978	prolyl endopeptidase	4.5
		W23625	Hs.8739	ESTs; Weakly similar to ORF YGR200c [	13.7
1.0		AA454070		ESTs	5.8
10		AA250745		protein kinase; cAMP-dependent; catalyti	8.9
	134711	X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
	134714	U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
		W47183	Hs.284226	ESTs; Weakly similar to neural F box pro	8.1
	134776	J05582	Hs.89603	mucin 1; transmembrane	6.2
15	134806	Z49099	Hs.89718	spermine synthase	4.2
	134810	M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
	134840	U51477	Hs.89981	diacylglycerol kinase; zeta (104kD)	4.1
	134843	H60595	Hs.90061	progesterone binding protein	4.7
	134853	D82348	Hs.90280	5-aminoimidazole-4-carboxamide ribonuc	10.2
20	134866	U84011	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotr	12.1
	134868	Z39762	Hs.90419	KIAA0882 protein	6
	134885	N27670	Hs.9071	progesterone membrane binding protein	5
	134982	N46086	Hs.92308	ESTs	4.1
	134989	AA236324	Hs.92381	Homo sapiens mRNA; chromosome 1 spe	16.8
25	134992	H05625	Hs.5831	ESTs	4
	134993	AA282343	Hs.301005	purine-rich element binding protein B	4.4
	135010	D59675	Hs.92927	ESTs	7
	135015	U54999	Hs.278338	LGN protein	4.8
	135029	AA224180		ESTs; Moderately similar to 17-beta-hydr	13.6
30		AA243497	Hs.173685	Human DNA sequence from clone 30M3	4
		U77948	Hs.278589	general transcription factor II; i	8
		AA598449		Homo sapiens clone 24483 unknown mRN	5.4
		L08069	Hs.94	heat shock protein; DNAJ-like 2	9.3
		AA495950		ESTs	6.7
35		W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	10.2
		AA044842		Homo sapiens mRNA; cDNA DKFZp586	6.6
		AA126433		sorting nexin 4	7.4
		D31157	Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
		AA454930		ESTs	19.5
40		AA215333		putative G protein-coupled receptor	8.8
. •		H20989	Hs.198281	pyruvate kinase; muscle	12.4
		D83174	Hs.9930	collagen-binding protein 2 (colligen 2)	5.5
		AA480109		TYRO protein tyrosine kinase binding pro	5.4
		U05237	Hs.99872	fetal Alzheimer antigen	7.8
45		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
. •		L10333	Hs.99947	reticulon 1	5.3
		M97935		AFFX control: STAT1	8.3
		M97935		AFFX control: STAT1	7
		M97935		AFFX control: STAT1	14
50		Al199738	Hs.208275	ESTs; Weakly similar to !!!! ALU CLASS	9,1
		AI694585	Hs.270464	ESTs; Weakly similar to !!!! ALU CLASS	7.4
		AW079607		ESTs; Weakly similar to ZnT-3 [H.sapien	30.1
		AW015860		ESTs	11.9
		AA699328		ESTs	5.5
55		Al492179	Hs.166244	ESTs; Weakly similar to cDNA EST yk40	11
		AW293224		ESTs	11
		T79326	Hs.298262	ESTs; Weakly similar to dJ88J8.1 [H.sapi	8.8
		N85789	Hs.150186	ESTs; Weakly similar to PTERIN-4-ALP	6
		Al682905	Hs.270431	ESTs; Weakly similar to !!!! ALU SUBFA	4.7
60		AA373124		ESTs; Weakly similar to C17G10.1 [C.ele	8
30		AA526313		ESTs Veakly similar to C 17G to . 1 [C.ele	4.2
	301782		Hs.143046	EST cluster (not in UniGene) with exon h	18
		AA312082		GDNF family receptor alpha 1	20.7
		NM 004694		EST cluster (not in UniGene) with exon h	11.6
65		AF013956		chromobox homolog 4 (Drosophila Pc cla	9.2
		NM_001992		EST cluster (not in UniGene) with exon h	4.3
	302032		Hs.222399	ESTs; Weakly similar to protein-tyrosine	7.8
	302001	1100000	1 10.22233	LOTS, Freakly Similar to protein-tyrosine	7.0

	302145	NM_00361	3He 151407	EST cluster (not in UniGene) with exon h	15.1
			Hs.6557	zinc finger protein 161	25.8
		NM_00444	3Hs.323910	EST cluster (not in UniGene) with exon h	21.6
_	302290	AL117607	Hs.175563	Homo sapiens mRNA; cDNA DKFZp564	41.4
5		NM_00427		EST cluster (not in UniGene) with exon h	8.9
		AB023141		KIAA0924 protein	5.4
		AL117406		Homo sapiens mRNA; cDNA DKFZp434	8.9
		AB021227		matrix metalloproteinase 24 (membrane-in	5.2 5.3
10		AF129530 AF022726		EST cluster (not in UniGene) with exon h EST cluster (not in UniGene) with exon h	9.9
10		AL049650		multiple UniGene matches	4.3
		L36149	Hs.248116	chemokine (C motif) XC receptor 1	4.9
		AA463798		ESTs; Weakly similar to C11D2.4 [C.eleg	5.3
	302656	AW293005	Hs.70704	ESTs	8.4
15	302792	AA343696	Hs.46821	ESTs; Weakly similar to putative [H.sapie	4.5
		X04588	Hs.85844	EST cluster (not in UniGene) with exon h	6.8
		U66049	Hs.82171	EST cluster (not in UniGene) with exon h	8.4
		N58545	Hs.42346	histone deacetylase 3	22.8
20		AW263124		EST cluster (not in UniGene) with exon h	6.8
20		N46406 AA478876	Hs.84700	EST cluster (not in UniGene) with exon h pallid (mouse) homolog; pallidin	8.9 10.1
		AF140242		EST cluster (not in UniGene) with exon h	24.4
		AW081061		actin-like 6	6.3
		Al929819	Hs.4055	ESTs	17.7
25		U09759	Hs.246857	mitogen-activated protein kinase 9	11.4
	303387	AA908797	Hs.180799	ESTs	15.8
		Al815990	Hs.293515	ESTs	7.2
		AA488528	11 -04000	EST cluster (not in UniGene) with exon h	5.3
30		T07216	Hs.301226	EST cluster (not in UniGene) with exon h	16.2
30		AA397546 Al953377	Hs.28444	ESTs ESTs: Weakly similar to predicted using G	8.9 12
		AW299459		ESTs; Weakly similar to predicted using G EST cluster (not in UniGene) with exon h	4.2
		AA436942		ESTs	8.4
		AW502498		ESTs; Weakly similar to zinc finger prote	5.2
35		Al424014	Hs.18995	ESTs; Moderately similar to KIAA0456 p	28.4
	303792	C75094	Hs.199839	ESTs; Highly similar to NG22 [H.sapiens	4.4
		Al337304	Hs.126268	ESTs; Weakly similar to similar to PDZ d	8.1
		AW475081	Hs.172928	collagen; type I; alpha 1	7.5
40		AA421948		EST singleton (not in UniGene) with exon	6.5
40		AA456426 AA505702		EST EST singleton (not in UniGene) with exon	5.4 9.8
		AA503702 AA507875		EST singleton (not in UniGene) with exon	7.5
		AA533185		EST singleton (not in UniGene) with exon	7
		AA630582	Hs.169476	glyceraldehyde-3-phosphate dehydrogena	12.4
45		AA653159		EST singleton (not in UniGene) with exon	8.7
	305415	AA725116	Hs.78465	EST singleton (not in UniGene) with exon	5.3
		AA738110		EST singleton (not in UniGene) with exon	4.1
		AA872838		keratin 8	7.7
50		AA876109		EST singleton (not in UniGene) with exon	6.3
30		AA884479 AA889992	He 2186	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	5.6 13.2
	306004	AA894560	Hs 283370	EST singleton (not in UniGene) with exon	4.4
		AA906161		EST singleton (not in UniGene) with exon	4.6
		AA970548		EST singleton (not in UniGene) with exon	7.6
55	306505	AA987722	Hs.172928	EST singleton (not in UniGene) with exon	19.7
		AA995761		EST singleton (not in UniGene) with exon	5.5
		Al184111	Hs.76067	heat shock 27kD protein 1	7.7
		Al185516	Hs.172928	collagen; type I; alpha 1	8.8
60		A1190870	Hs.276417	EST singleton (not in UniGene) with exon	4.1
60		Al280859 Al281603	Hs.62954	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	6 10 B
		Al351739	Hs.172928 Hs.276726	EST singleton (not in UniGene) with exon	10.8 4.7
		Al472733	Hs.270208	ESTs	4.2
		Al581398	Hs.172928	collagen; type I; alpha 1	5.4
65		AI687580	Hs.169476	EST singleton (not in UniGene) with exon	10.1
		Al738593	Hs.101774	EST singleton (not in UniGene) with exon	15.1
	308677	Al761173		EST singleton (not in UniGene) with exon	4.6

	308974	Al829848 Al872290	Hs.182937 Hs.300697	peptidylprolyl isomerase A (cyclophilin A immunoglobulin gamma 3 (Gm marker)	5.9 4.5
		AI873242		EST singleton (not in UniGene) with exon	7.6
5		Al880172 Al951118		EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	6.6 24.3
9		Al952723	Hs.90207	EST singleton (not in UniGene) with exon	6.1
		AI955915	110.00201	major histocompatibility complex; class I;	5.6
		Al969897		EST singleton (not in UniGene) with exon	6.2
1.0	309279	Al990102		EST singleton (not in UniGene) with exon	7.9
10		AW170035		EST	64.5
		AW191929		EST	5.3
		AW192764 AW194230		collagen; type l; alpha 1 EST	6.9 11.4
		AW 194230 AW 238461		ribosomal protein; large; P0	4.3
15		AW241170		Homo sapiens clone 24703 beta-tubulin m	11.9
		Al335004	Hs.148558	ESTs	4.2
	310094	AW450967	Hs.235240	ESTs	5.7
		AW080778		ESTs	4.8
20		AW022192		ESTs	39.1
20		Al281848	Hs.194691	ESTs	4.9
		AW205632		ESTs	7
		T47784	Hs.188955	ESTs ESTs	4.1 11.2
		Al587332 Al821294	Hs.209115 Hs.118599	ESTS	24.1
25		T57896	Hs.191095	EST cluster (not in UniGene)	5.7
		AI758660	Hs.206132	ESTs	15.7
		AI828254	Hs.271019	ESTs	6.4
	311774	AA700870		ESTs	6.2
	311785	AI056769	Hs.133512	ESTs	5
30			Hs.189679	ESTs	5.9
		AA216387		EST cluster (not in UniGene)	5.5
		N51511	Hs.188449	ESTs	5.2
		A1435650	Hs.128778	ESTs	4.3 14.7
35		AA588275 T89855	Hs.195648	ESTs EST cluster (not in UniGene)	9.8
55		AA759250		cytochrome b-561	27.1
		T92251	Hs.198882	ESTs	4.2
		Al222168	Hs.191168	ESTs	6.1
	312226	AI796815	Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40		AW451893	Hs.151124	ESTs	18.4
		Al080505	Hs.134529	ESTs	11.9
		AA582039		Homo sapiens mRNA; chromosome 1 spe	4
		R46180	Hs.153485	ESTs	13.6
45		AW139117 AW451347		ESTs ESTs	4.1 4.6
73		Al417526	Hs.7753	ESTs	15.3
		AA033609		ESTs	12.5
		Al498371	Hs.183526	ESTs	14.6
	312638	AW439195	Hs.256880	ESTs	5.3
50		R99834	Hs.250383	ESTs	8.4
		H63791		EST cluster (not in UniGene)	4.3
		AA699325		ESTs	8.3
		AW292286		ESTs	7.1
55		AA846353 AA828713		ESTs EST cluster (not in UniGene)	5.9 4.1
55		AA088446		ESTs	7.3
		AI422367		ESTs	6.1
		AA732534		ESTs	4.2
		AA720887		EST cluster (not in UniGene)	18.1
60		N59284	Hs.288010	ESTs	17
	313197	Al738851	Hs.222487	ESTs	12.9
		N74924	Hs.182099	ESTs	7.1
		AW068358		ESTS	13.7
65		AW449211		ESTS	27.9
05		AW292127 AA741151		ESTs ESTs	9.8 8.2
		AA741151 AW081702		ESTs	6.9
	0 10400	AVV001/02	119.00011	2010	5.5

	313590	AA804410	Hs.291677	EST cluster (not in UniGene)	5.3
		AI953261		ESTs	7.6
		U69201	Hs.13684	ESTs; Weakly similar to choline kinase is	12.5
		AW450376		ESTs	5.5
5		AW271022		ESTs	4.3
_		AA535580		ESTs	7.7
			Hs.163443	ESTs	27.1
		A1858884		ESTs	5.7
		Al310151	Hs.173524	ESTs	4.3
10		AA648744		ESTs	14.5
		AA228366		ESTs	9.5
		AA205569		ESTs	5.4
		AA535840		ESTs; Weakly similar to alternatively spli	5.3
			Hs.130816	ESTs	13.2
15		AA347951		ESTs	6.2
10		AA602917		ESTs	18.1
		AI934422		ESTs :	4.2
		AA358265		ESTs	6.1
		AA833655		ESTs	27.8
20		AI204418		ESTs	9.5
20			Hs.190721	ESTs	22.5
		AA436432		EST cluster (not in UniGene)	13.3
		AW207206		ESTs	21.4
		AW026761		ESTs	4.4
25		A1149880		ESTs	4.4
23		A1476797		cell division cycle 2; G1 to S and G2 to M	18.4
				ESTs	10.2
		AW008061 Al689617		ESTS	5.3
		Al538613	Hs.200934 Hs.298241	ESTs	20.7
30		AA531082		ESTs	5
50		AA532807		ESTs	6.1
		A1493046		ESTs	12
		AA534953		ESTs	8.3
					6.1
35		AW205863		ESTs; Weakly similar to gene MAC25 pr	12.7
33		AW292425		EST ESTs	7.6
		AI968598		ESTS	13.9
		AW452948			4.4
		AA744550		ESTs ESTs	5.1
40		AI221325		ESTs	
40		AA557351		ESTs; Moderately similar to MULTIFUN	4.7
		A1025842		ESTs	11.9
		AA972756		ESTs	28.8
		AA876905		ESTs	16.1 25.7
45		AW194364		ESTs; Weakly similar to FIG-1 PROTEIN	12.3
43		AA604799		ESTs; Moderately similar to !!!! ALU SU	4.6
		AA643602		ESTs; Highly similar to serine protease [H ESTs	4.8
		AW291563		ESTs; Weakly similar to alternatively spli	4.4
		Al801565 AW273261			5
50				ESTs ESTs	7.6
50		AA872000		ESTS	4.9
		AA828850			5.2
		AA665612		ESTs ESTs; Moderately similar to !!!! ALU SU	4.8
		AA628539			4.4
55		Al791138	Hs.116768	ESTs .	22.4
55		A1200852	Hs.127780	ESTs .	5.9
		AA737415		ESTs	8.8
		AA837085			15
		AA648983		ESTs ESTs	6.3
60		AI521489	Hs.3053		
60	3156/6	AW002565	HS.124000	ESTs	9.2
		AA814309		ESTs	8.1
		AI831760	Hs.155111	ESTs	13.4
		AA812168		ESTs	5.4
65		AA744875		ESTs	4.4
65	315978	AA830893		ESTs	10.4
		A1015862	Hs.131793	ESTs	5 147
	316042	AW297979	HS. 170098	ESTs	14.7

	040400		11 404000		
		AA830808		ESTs	4
		Al908272	Hs.293102	EST cluster (not in UniGene)	32.6
		AA741300		ESTs	4.8
_		AA757900	Hs.270823	ESTs	4.8
5	316480	Al749921	Hs.205377	ESTs	12.9
	316564	Al743571	Hs.168799	ESTs; Weakly similar to !!!! ALU SUBFA	8.1
	316714	AA809792	Hs.123307	ESTs	5
		A1440266		ESTs	4.2
		AA828116		ESTs	5.2
10			Hs.134604	ESTs	13.3
10		AW138241			
				ESTs	6.2
		AW014875		ESTs	5.3
		AA856749		ESTs	7.2
	317008	AW051597	Hs.143707	ESTs	4.1
15	317028	AA962623	Hs.189144	ESTs; Weakly similar to RENAL SODIU	4.2
	317067	Al805392	Hs.325335	ESTs	4.5
		Al732892		ESTs	6.4
		AA490718		EST cluster (not in UniGene)	4.4
		Al922374	Uc 1595/0	ESTs	5.9
20					4.6
20		AW139077		ESTs	
		AW294909		ESTs	5.2
		Al798630		ESTs	4.3
	317836	AA983913	Hs.128929	ESTs	12.4
	317881	Al827248	Hs.224398	ESTs	12.1
25	317902	AI828602	Hs.211265	ESTs	8.8
		A1565071	Hs.159983	ESTs	12.6
		AW294522		ESTs	5.6
			Hs.133469	ESTs	4
		AW296888		ESTs	5.2
20					
30			Hs.248942	ESTs	4.7
		AW167087		ESTs	15.7
			Hs.150521	ESTs	5.9
	318186	AW016773	Hs.3709	ESTs	5.3
	318481	Al291584	Hs.145921	ESTs; Weakly similar to HYPOTHETICA	7.6
35	318566	Al335361	Hs.226376	ESTs	5.8
		AW247252		nucleoside phosphorylase	11.1
			Hs.294014	ESTs	16.3
		AW192139		H3 histone; family 3A	4
					21.3
40		NM_00254		EST cluster (not in UniGene)	
40		Al793124		ESTs	35
		AA317274		ESTs	11.7
	319163	F15257	Hs.27	glycine dehydrogenase (decarboxylating;	7
	319478	R06841	Hs.270307	EST cluster (not in UniGene)	8.9
	319545	R83716	Hs.14355	ESTs	8.2
45		NM 00273		EST cluster (not in UniGene)	25.4
		AA460775		ESTs	7
		AA179304		ESTs; Moderately similar to !!!! ALU SU	8.7
		W22152	Hs.282929		5.6
				EST cluster (not in UniGene)	
50		AA307665		ESTs	4.9
50		H06350	Hs.135056	ESTs	9.2
		AA632632		EST cluster (not in UniGene)	4.6
	320074	AA321166	Hs.278233	EST cluster (not in UniGene)	16.7
	320092	AF022799	Hs.113292	calpain 9 (nCL-4)	5.4
	320107	AA836461	Hs.291712	EST cluster (not in UniGene)	5.3
55	320133	D63271		EST cluster (not in UniGene)	5.5
• •		AA984373	Hs gnzgn	EST cluster (not in UniGene)	15
		T99949	Hs.303428	EST cluster (not in UniGene)	6.7
				DEME-6 protein	24.3
		AL039402	Hs.125783		
60		U90449	Hs.152717	nucleoside diphosphate kinase type 6 (inh	10
60		Al884396	Hs.24131	ESTs	5.4
		R31386	Hs.191791	EST cluster (not in UniGene)	4.9
	320521	N31464	Hs.24743	ESTs	9.5
	320661	AA864846	Hs,115175	EST cluster (not in UniGene)	6.6
	320691	R61576	Hs.313951	hypothetical protein	5.9
65		R63161	Hs.118249	EST cluster (not in UniGene)	4
		U96044	Hs.181125	EST cluster (not in UniGene)	15.3
		AL050145		Homo sapiens mRNA; cDNA DKFZp586	7.2
	525550				

	004040 44707044 11-404004	FOT alvator (a at la UniO and)	C 4
	321012 AA737314 Hs.194324	EST cluster (not in UniGene)	6.1
	321050 AW393497	EST cluster (not in UniGene)	5
	321051 AF134149 Hs.240395	EST cluster (not in UniGene)	11.4
5	321171 Al769410 Hs.221461	ESTs	7.7
5	321192 AA295304 Hs.297939	ESTs; Weakly similar to neogenin [H.sap	5.5 16.9
	321354 AA078493	EST cluster (not in UniGene) ESTs; Weakly similar to !!!! ALU SUBFA	4.2
	321387 H68014 Hs.141278 321412 AW366305 Hs.22891		6.3
		EST cluster (not in UniGene)	9
10	321489 AW392474 Hs.172759	ESTs; Moderately similar to !!!! ALU SU	11.3
10	321539 N98619 Hs.42915	ARP2 (actin-related protein 2; yeast) hom	10.4
	321593 H84762 Hs.253197	ESTs	19.9
	321666 D28390 Hs.272897	EST cluster (not in UniGene)	5.6
	321891 AW157424 Hs.165954	ESTs ESTs; Weakly similar to !!!! ALU SUBFA	
15	321910 H67065 Hs.271530	ESTs; Weakly similar to !!!! ALU CLASS	5.4 6.5
13	321953 AW068268 Hs.292833		10.2
	321978 N77342 Hs.21851	EST cluster (not in UniGene) ESTs	9.8
	322017 AA310039 Hs.9192		27.8
	322026 AA233527 Hs.283675	low density lipoprotein receptor (familial	40.2
20	322035 AL137517 Hs.306201	EST cluster (not in UniGene)	5.7
20	322171 AF085968 Hs.48474	EST cluster (not in UniGene)	3.7 7.7
	322175 AF085975	EST cluster (not in UniGene)	
	322236 AL134970 Hs.104222	follistatin-like 1	14.4
	322303 W07459 Hs.157601	EST cluster (not in UniGene)	13.4
25	322735 AA086123 Hs.297856	EST cluster (not in UniGene)	7.6 4.4
23	322777 AA679082 Hs.269947	ESTs	
	322818 AW043782 Hs.293616	ESTs	21
	322882 AW248508 Hs.279727	DiGeorge syndrome critical region gene 2	15.3
	322975 C16391	EST cluster (not in UniGene)	21.3 11.7
30	322991 C18965 Hs.159473	ESTs	
30	323011 AA580288	EST cluster (not in UniGene)	8.9
	323091 AW014094 Hs.210761	ESTs	10.8
	323107 Al301107 Hs.150790	ESTs	6.5
	323136 AL120351 Hs.30177	EST cluster (not in UniGene)	5.5
25	323168 AL120862 Hs.124165	ESTs	17.9
35	323195 Al064982 Hs.117950	multifunctional polypeptide similar to SA	5.8
	323201 AL049370 Hs.13350	Homo sapiens mRNA; cDNA DKFZp586	11.6
	323203 AA203135 Hs.130186	ESTs	6.4
	323243 W44372 Hs.110771	EST cluster (not in UniGene)	7.3 15.8
40	323244 T70731 Hs.193620	EST cluster (not in UniGene)	4.8
40	323328 AA228078 Hs.255096	EST cluster (not in UniGene)	20.2
	323332 Al829520 Hs.227513	ESTs	8.8
	323333 AA228883 Hs.208558	EST cluster (not in UniGene) ESTs; Weakly similar to !!!! ALU SUBFA	5
	323570 AL038623 Hs.208752 323604 Al751438 Hs.41271		6.5
45		ESTs; Weakly similar to !!!! ALU SUBFA	7.1
43	323685 AA344205 Hs.289088 323753 AA327102 Hs.70266	EST cluster (not in UniGene) EST cluster (not in UniGene)	6.1
	323817 AA410943		16.8
		EST cluster (not in UniGene) ESTs; Weakly similar to wacław [D.melan	10.1
			6.4
50	323930 AA570698 Hs.8173	ESTs	8
50	323997 AA844907 Hs.274454	EST cluster (not in UniGene)	6.3
	324047 AA378201 Hs.271340	EST cluster (not in UniGene)	50.1
	324261 AL044891 Hs.269350	EST cluster (not in UniGene) ESTs; Weakly similar to !!!! ALU SUBFA	5.7
	324302 AA543008 Hs.292471		9.5
55	324338 AL138357 Hs.145078 324344 AW502000 Hs.46677	ESTs EST cluster (not in UniGene)	9.5 4.4
55			
	324432 AA464510 Hs.152812	EST cluster (not in UniGene) ESTs; Weakly similar to !!!! ALU CLASS	16.7
	324495 AW501411 Hs.122489		5.5
	324497 AW152624 Hs.136340	ESTS	5.4
60	324598 AA502659 Hs.163986	ESTs	8.8
60	324603 AW016378 Hs.292934	ESTs	23.1
	324620 AA448021 Hs.94109	EST cluster (not in UniGene)	21.2
	324727 Al610425 Hs.19597	ESTs	5
	324774 Al031771 Hs.132586	ESTs	5
65	324783 AA640770 Hs.200994	EST cluster (not in UniGene)	4.1
65	324824 Al826999 Hs.224624	ESTs	6.3
	324826 AA704806 Hs.143842	ESTs	11.7
	324902 D31323 Hs.271492	ESTs	4.8

	324961 AA613792	EST cluster (	not in UniGene)	13.3
	324987 T06882 Hs.17	72634 ESTs	·	19.6
			not in UniGene)	24.5
5	325146 Al064690 Hs.17 325622	71176 ESTs CH.14_hs gi[	5867000	4.6 5.2
5	326213	CH.17_hs gil		8.1
	326474	CH.19_hs gi		12.7
	326816	CH.20_hs gi		9.4
10	326817	CH.20_hs gip		11.7
10	327110 327196	CH.21_hs gi  CH.01_hs gi		14.7 5.1
	327283	CH.01_hs gi		4.3
	327313	CH.01_hs gi	5867501	4.8
1.5	327450	CH.02_hs gil		4.1
15	328059	CH.06_hs gil		6.2 5.4
	328304 328492	CH.07_hs gi  CH.07_hs gi		7
	328857	CH.07_hs gil		5.2
••	329367	CH.X_hs gi 5		7.6
20	329373	CH.X_hs gil6		12
	329655 329899	CH.14_p2 gi  CH.15_p2 gi		4 4
	329960	CH.15_p2 gi		7.6
	330084	CH.19_p2 gi		4
25	330384 M23263	androgen red	eptor (dihydrotestosterone re	5.8
	330385 AA449749		similar to secreted apoptosi	10.2
	330387 H14624 330388 X03363		similar to secreted apoptosi or tyrosine kinase (c-erbB-2;	4.4 17.7
		8221 c-myc binding		10.1
30	330460 TIGR:HT544	Hs.73946	, , , , , , , , , , , , , , , , , , , ,	Endothelial Cell Growth Factor 1 5.5
	330486 M13755 Hs.83		nulated protein; 15 kDa	67
		37868 interleukin 7 i		6 13.1
		9222 galactosidase 27729 FK506-bindin	g protein 2 (13kD)	29
35			dase B1 (tissue)	38.5
	330541 U22970 Hs.26	65827 multiple UniG	ene matches	7.4
			450; 51 (lanosterol 14-alpha	15
			3-dioxygenase	11 6.5
40		99867 hepatocyte ne 6460 transporter pr	uclear factor 3; alpha otein	7.7
.0		3393 cystatin E/M		4
		21403 Sec23 (S. cei	revisiae) homolog A	10.5
	330711 AA164687 Hs.17		pha-1;3-)-glycoprotein beta-1	24.3
45	330814 AA015730 Hs.26 330850 AA075298 Hs.33		similar to transformation-r	44.1 4.4
73	330874 AA127474 Hs.19		similar to !!!! ALU SUBFA	8.1
	330884 AA133457 Hs.16	02548 ESTs	, •••••••	5.2
	330912 AA195936 Hs.83	2719 general trans	cription factor IIA; 1 (37kD a	5
50	330924 AA232136 Hs.18		s mRNA; cDNA DKFZp434	9.1 7.6
50	330997 H55762 Hs.93 331014 H98597 Hs.30	302 ESTs 0340 ESTs		13.5
	331024 N32919 Hs.2			9.1
	331046 N66563 Hs.19	91358 ESTs		10.5
55	331135 R61398 Hs.4		- tollest- OVECOUDONE	7.4
55		29873 ESTs; Weakl 7385 ESTs	similar to CYTOCHROME	41.9 4.7
		73904 ESTs		4.1
	331230 W69807 Hs.16		protein; similar to (U06944)	4.9
	331306 AA252079 Hs.63	3931 dachshund (E	Prosophila) homolog	15.1
60	331327 AA281076 Hs.10			4.8
	331337 AA287662 Hs.50 331341 AA303125 Hs.23		y similar to !!!! ALU SUBFA	7.6 13
	331344 AA357927 Hs.1		, carman to an rade occi ri	12.4
	331362 AA417956 Hs.46	0782 ESTs		6.5
65	331363 AA421562 Hs.9		ent 2 (Xenepus laevis) homo	28.2
	331376 AA443802 Hs.4 331384 AA456001 Hs.9	•	y similar to cDNA EST yk47	15.1 7.9
	ווייייניא אייייניני האא אייייניני			

	224470	NOCCOO	U= 40000	FCT-	7
		N26608	Hs.40639	ESTS	7 19.8
		N49967	Hs.46624	ESTS	6.5
		N51517 W85712	Hs.47282 Hs.119571	ESTs	13.8
5		W88502	Hs.182258	collagen; type III; alpha 1 (Ehlers-Danios ESTs	9.9
		AA284372		ESTs	5.6
		AA284840		ESTs	5.8
		AA292721		ESTs; Weakly similar to unknown [H.sap	7.4
		AA312861		ESTs	7.8
10		AA411144		ESTs	15.2
	331890	AA432166	Hs.3577	succinate dehydrogenase complex; subuni	24.3
	331952	AA454756	Hs.97837	ESTs	5
		AA487910		ESTs; Weakly similar to !!!! ALU CLASS	10.5
1.5		AA490831		ESTs	11.4
15		AA504779		ESTs	13.6
		AA598594		ESTS	9.1 8.8
		AA608794 AA620669		ESTs EST	9
		N22508	Hs.139315	ESTs	7.1
20		N33213	Hs.100425	ESTs	12.2
		N57927	Hs.120777	ESTs; Weakly similar to RNA POLYME	15.6
	332247	N58172	Hs.109370	ESTs	16.9
		N70088	Hs.138467	ESTs	4
2.7		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.2
25		T96130	Hs.137551	ESTs	7.7
		W15495	Hs.129781	chromosome 21 open reading frame 5	14.1 4.4
		W60326 W93640	Hs.288684 Hs.4779	ESTs ESTs; Moderately similar to similar to AD	4.4 16.9
		AA489630		KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
50		AA018182		delodinase; lodothyronine; type II	5.8
		AA281753		inositol 1;4;5-triphosphate receptor; type	19
	332532	N63192	Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
	332565	AA234896	Hs.25272	E1A binding protein p300	12.3
35		R41791	Hs.36566	LIM domain kinase 1	11.1
		AA417152		protein regulator of cytokinesis 1	18.2
		AA262768		KIAA1067 protein	15.2 4.7
	332702	H93968	Hs.75725 Hs.76293	transgelin 2 thymosin; beta 10	5.5
40		AA479968		arylsulfatase A	9.8
	332927	701110000	110.00201	CH22_FGENES.38_1	17.7
	332929			CH22_FGENES.38_3	4.7
	332930			CH22_FGENES.38_4	7.4
	332955			CH22_FGENES.48_12	5.4
45	332958			CH22_FGENES.48_15	17.8
	332961			CH22_FGENES.48_18	10.6
	332983			CH22_FGENES.54_5	4.3
	333009			CH22_FGENES.61_1 CH22_FGENES.61_2	5.2 8.1
50	333010 333013			CH22_FGENES.61_5	8.5
50	333108			CH22_FGENES.79_14	5.6
	333139			CH22_FGENES.83_16	6.3
	333254			CH22_FGENES.118_2	6.8
	333305			CH22_FGENES.137_2	11.4
55	333343			CH22_FGENES.139_12	5.1
	333388			CH22_FGENES.144_3	12.7
	333456			CH22_FGENES.157_5	4.2
	333459			CH22_FGENES.157_8 CH22_FGENES.173_2	7.6 8.2
60	333517 333585			CH22_FGENES.175_2 CH22_FGENES.203_4	5
	333679			CH22_FGENES.247_6	4.3
	333743			CH22_FGENES.264_1	13.4
	333758			CH22_FGENES.268_1	4
	333767			CH22_FGENES.271_6	5.6
65	333768			CH22_FGENES.271_7	12.2
	333769			CH22_FGENES.271_8	48.3
	333795			CH22_FGENES.275_1	6.1

	222706	CHOO ECENER OFF 2	6.8
	333796 333903	CH22_FGENES.275_3 CH22_FGENES.292_14	4.4
	333892 333004		6.5
	333904	CH22_FGENES.294_2	
5	333905	CH22_FGENES.294_3	9.3
)	333921 333069	CH22_FGENES.296_12	9.6 15.0
	333968	CH22_FGENES.307_4	15.9 7.1
	334102	CH22_FGENES.327_60	
	334222	CH22_FGENES.360_3	6.7
10	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1
	334360	CH22_FGENES.378_5	6.1
	334784	CH22_FGENES.432_9	4.8
1.5	334789	CH22_FGENES.432_14	5.1
15	334794	CH22_FGENES.434_2	7
	334889	CH22_FGENES.452_3	12.4
	335004	CH22_FGENES.472_8	7.9
	335115	CH22_FGENES.496_2	18.8
20	335287	CH22_FGENES.526_11	4.5
20	335342	CH22_FGENES.536_1	5.3
	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	7
	335498	CH22_FGENES.571_7	12.2
	335544	CH22_FGENES.576_5	8.4
25	335610	CH22_FGENES.583_4	12.9
	335653	CH22_FGENES.590_4	6.7
	335682	CH22_FGENES.595_2	12.1
	335687	CH22_FGENES.596_2	13.9
	335755	CH22_FGENES.604_4	11.5
30	335782	CH22_FGENES.609_4	17.9
	335791	CH22_FGENES.611_7	27.3
	335809	CH22 FGENES.617_6	19.2
	335822	CH22_FGENES.619_7	19.1
	335823	CH22_FGENES.619_8	4.5
35	335824	CH22_FGENES.619_11	40.2
	335825	CH22_FGENES.619_12	34.3
	335895	CH22_FGENES.635_3	10.2
	335917	CH22_FGENES.636_13	6
	335920	CH22_FGENES.636_16	8.8
40	336035	CH22_FGENES.678_6	5.9
70		CH22_FGENES.679_4	5.8
•	336042	CH22_FGENES.691_2	11.6
	336093 336006		7.6
	336096	CH22_FGENES.691_5	6.3
15	336150	CH22_FGENES.706_6	0.3 10.5
45	336152	CH22_FGENES.706_9	
	336416	CH22_FGENES.823_38	5
	336444	CH22_FGENES.827_10	4.8
	336449	CH22_FGENES.829_6	13.6
<b>50</b>	336471	CH22_FGENES.829_30	6.9
50	336512	CH22_FGENES.834_7	21.4
	336558	CH22_FGENES.842_3	8.2
	336560	CH22_FGENES.842_5	9
	336676	CH22_FGENES.43-4	9.4
	336959	CH22_FGENES.367-13	19
55	337968	CH22_EM:AC005500.GENSCAN.103-2	13.4
	338008	CH22_EM:AC005500.GENSCAN.127-9	15.2
	338057	CH22_EM:AC005500.GENSCAN.160-1	13.9
	338410	CH22_EM:AC005500.GENSCAN.341-6	8
	338451	CH22_EM:AC005500.GENSCAN.359-3	11.6
60	338588	CH22 EM:AC005500.GENSCAN.432-1	10.3
	338665	CH22_EM:AC005500.GENSCAN.464-2	4.8
	338689	CH22_EM:AC005500.GENSCAN.475-3	6.7
	338832	CH22 DJ246D7.GENSCAN.6-9	4.8
	338980	CH22 DA59H18.GENSCAN.2-4	5.1
65	339352	CH22 BA354I12.GENSCAN.29-7	6.9
05	339373	CH22_BA232E17.GENSCAN.1-29	4.3
	555010	0.122_5.12022 11.002.1001.11.1 E0	

## TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Unique Eos probeset identifier number

Pkey: CAT number: Gene cluster number Accession: Genbank accession numbers

15

13			
	Pkey	CAT number	Accession
20	103207 103349 110856	371681_1 306354 110522 19346_14 328626_1	AA602964 AA609200 X72790 X89059 AA992380 N33063 N21418 H79958 R21911 H79957 T63857 AW971220 AA493469 T63699
25		44573_2	Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970
30	400500	aanhank AAG	BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 08751 AA608751
35	116480 132225 125154 118475	genbank_AA6 genbank_C14 genbank_AA1 genbank_W38 genbank_N66	088 C14088 28980 AA128980 419 W38419
40	102919	25180_2	AA323294 W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367 AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385 AA054395 H30840 AW498825 AA086141 AI557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257
45			AW176086 AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 C04921 AA345696 R89640 AA085425 AA481708 AA313637 AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854 AA192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 AI366131 H14328 AA197161 AA379497 AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921
50			AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789 AW362775 AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553 R87925 AA292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW372969 AA337549 AA327342 H93855 AI074079 F29118 AA852940 F35696 AA345963
<b>55</b>			AA079578 AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 AI909845 AW374374 AW374382 AW374401 AW374373 AW374370 AI909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 AI525039 H13744 R31007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149 AA806213 AA481936 C04941 AW375299 M21190 AA410818 AA250940 AI354547 AA317422 AA250903 AI865497 AA890603
60			AA366197 AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393 AW376830 AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811 H44129 N84794 F01135 AA477852 AA293062 AW361595 H27194 AI831650 H43253 H24797 AI564680 AA380090 W20057 AI921586 AI192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00946

C03986 Al318091 Al860172 AA582179 Al633388 AA557193 R68075 F24105 AW518239 W56622 Al625219 Al925243 AW468046 Al921828 AA339164 Al144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 Al680458 AA159956 AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 Al630871 Al633128 AW514329 AA010455 AA563928 Al571596 Al128394 W73707 Al423575 AA583809 AA657988 Al950837 AA169782 AA600009 Al885540 AA771884 AI978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 AI905695 AA480115 AA574051 5 Al889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 Al038538 AA411329 AA781570 Al833176 AA935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 Al460085 AA193244 Al538037 AA515572 AA758587 Al149311 AA508610 AA206409 AA534004 AA994600 AA827543 Al916349 AW245129 AW517804 D25663 AA781985 AA284536 Al819422 H16040 H27531 AA456564 AA845555 Al423596 AA012908 AA889439 AA716311 AA968868 10 AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 Al342442 Al003519 Al002503 Al347597 AJ040946 AA197162 AA987883 AA292865 AW001944 AJ640711 AW244044 AA456784 F30588 AA290829 H24754 AJ978683 AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204 AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA4777746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 Al569314 AA961665 Al922050 Al759000 AA555236 AA514432 15 AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 Al361315 AA284988 F36340 Al361322 F26969 AA991922 AA021267 F26973 Al361314 F35891 Al918509 AA250964 AA190992 AA577139 AA865535 AA134324 AW192842 Al224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007 Al830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921 T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259 20 AA179789 AA088908 H43704 AA194320 F35950 Al880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390 AI302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301 Al025737 AA101239 AA088887 Al214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715 F37529 Al811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245 AA331222 F25634 F21996 W28215 F21911 R65793 Al192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 25 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411 H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455 F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 F24835 F34672 F26474 AI926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297 Al937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863 30 F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566 F34230 F33258 F20860 F17998 Al695701 118600 genbank\_N69222 N69222 118952 genbank\_N92966 N92966 120873 genbank\_AA358015 113702 genbank\_T97307 AA358015 35 T97307 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165 129982 221\_267 AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 40 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 45 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 50 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068661 AF068664 55 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM\_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 Al857980 AW368899 Al905833 AW406586 AA482084 Al872299 AA715266 AW404328 Al831674 Al709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 60 115763 genbank\_AA421560 AA421560 genbank\_N22401 124357 N22401 108733 504187\_1 AA121022 AA126422 101544 entrez\_M31169 M31169 124447 genbank\_N48000 N48000 124677 genbank R01073 R01073 65 124777 genbank\_R41933 R41933 119302 genbank\_T25725 T25725

```
103680 entrez_Z93784Z93784
          135029 H58818_at
          112253 genbank_R51818
                                            R51818
         Pkey
                  CAT number Accession
         322175 46877_1
  5
                                 AF085975 H53458 H53459
          323011 139750_1
                                AA580288 AA315655 AA133031 AA377748
         322975 1510563_1
317210 211994_1
                                C16391 C16413
                                AW881145 AA490718 M85637 AA304575 T06067 AA331991
          323817 233566_1
                                 AA410943 AW948953 AA334202 AA332882
10
          309583 1046029 -2
                                AW170035
          324961 376239 1
                                 AA613792 AW182329 T05304 AW858385
          303502 325188_1
                                BE174240 AA488528 AL042253
         320133 447553_1
                                BE151746 BE336853 D63271 T94955 AA774994
         311935 174129_1
                                AA216387 T63548 AA228676
15
         321050 502195_1
                                C05928 AW393497
         319977 345248_1
                                AA534222 AA632632 T81234
                                AW962299 AA310349 AW962294 H63791 H63751
         312772 4380 7
         321354 116028 -2
                                AA078493
         336512 CH22_3941FG_834_7_LINK_DJ
336558 CH22_3992FG_842_3_LINK_DJ
20
         336560 CH22_3994FG_842_5_LINK_DJ
         329367 c_x_hs
         329373 c_x_hs
         336676 CH22_4154FG_43_4_
25
         338008 CH22_6490FG__LINK_EM:AC00
         338057 CH22_6558FG__LINK_EM:AC00
         329655 c14_p2
336959 CH22_4764FG_367_13_
         329899 c15_p2
30
         329960 c16_p2
         338410 CH22_7067FG__LINK_EM:AC00
338451 CH22_7124FG__LINK_EM:AC00
         338588 CH22_7331FG__LINK_EM:AC00
338665 CH22_7438FG__LINK_EM:AC00
338689 CH22_7464FG__LINK_EM:AC00
35
         308677 Al761173
         338832 CH22_7678FG__LINK_DJ246D7
         338980 CH22_7859FG__LINK_DA59H18
         333009 CH22_233FG_61_1_LINK_EM:A
40
         333010 CH22_234FG_61_2_LINK_EM:A
         333013 CH22_237FG_61_5_LINK_EM:A
         308981 Al873242
         308995 Al880172
         333108 CH22_336FG_79_14_LINK_EM:
45
         333139 CH22_368FG_83_16_LINK_EM:
         333254 CH22_495FG_118_2_LINK_EM:
         333305 CH22_550FG_137_2_LINK_EM:
         333343 CH22_589FG_139_12_LINK_EM
         333388 CH22 634FG 144 3 LINK EM:
         326213 c17_hs
333456 CH22_706FG_157_5_LINK_EM:
50
         333459 CH22_709FG_157_8_LINK_EM:
         333517 CH22_773FG_173_2_LINK_EM:
333585 CH22_846FG_203_4_LINK_EM:
333679 CH22_941FG_247_6_LINK_EM:
55
         326474 c19_hs
         333743 CH22_1009FG_264_1_LINK_EM
333758 CH22_1024FG_268_1_LINK_EM
333767 CH22_1034FG_271_6_LINK_EM
60
         333768 CH22_1035FG_271_7_LINK_EM
         333769 CH22_1036FG_271_8_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
333796 CH22_1065FG_275_3_LINK_EM
          335004 CH22_2326FG_472_8_LINK_EM
65
         333892 CH22_1163FG_292_14_LINK_E
         335115 CH22_2447FG_496_2_LINK_EM
```

333904 CH22\_1176FG\_294\_2\_LINK\_EM

	333905 333921 333968	CH22_1177FG_294_3_LINK_EM CH22_1194FG_296_12_LINK_E CH22_1245FG_307_4_LINK_EM
5	328059 335287 326816 326817	c_6_hs CH22_2629FG_526_11_LINK_E c20_hs c20_hs
10	335342 335491 335495 335498	CH22_2689FG_536_1_LINK_EM CH22_2843FG_570_23_LINK_E CH22_2847FG_570_28_LINK_E CH22_2850FG_571_7_LINK_EM
	328304 305453 335544	c_7_hs AA738110 CH22_2899FG_576_5_LINK_EM
15	335610 335653 335682	CH22_2969FG_583_4_LINK_EM CH22_3013FG_590_4_LINK_EM CH22_3043FG_595_2_LINK_EM
20	335687 328492 335755 335782	CH22_3048FG_596_2_LINK_EM c_7_hs CH22_3122FG_604_4_LINK_EM CH22_3151FG_609_4_LINK_EM
	335791 335809 335822	CH22_3160FG_611_7_LINK_EM CH22_3181FG_617_6_LINK_EM CH22_3195FG_619_7_LINK_EM
25	335823 335824 335825	CH22_3196FG_619_8_LINK_EM CH22_3197FG_619_11_LINK_E CH22_3198FG_619_12_LINK_E
30	335895 335917 335920 305898	CH22_3272FG_635_3_LINK_EM CH22_3294FG_636_13_LINK_E CH22_3297FG_636_16_LINK_E AA872838
	305913 305950 328857	AA876109 AA884479 c_7_hs
35	330084 337968 309177	c19_p2 CH22_6419FGLINK_EM:AC00 Al951118
40	309198 309226 339352 309279	Al955915 Al969897 CH22_8317FG'LINK_BA354I1 Al990102
	339373 325622 334102	CH22_8348FGLINK_BA232E1 c14_hs CH22_1380FG_327_60_LINK_E
45	332927 332929 332930	CH22_148FG_38_1_LINK_C20H CH22_150FG_38_3_LINK_C20H CH22_151FG_38_4_LINK_C20H
50	332955 332958 332961 332983	CH22_179FG_48_12_LINK_EM: CH22_182FG_48_15_LINK_EM: CH22_185FG_48_18_LINK_EM: CH22_207FG_54_5_LINK_EM:A
	334222	CH22_1506FG_360_3_LINK_EM CH22_1507FG_360_4_LINK_EM
55	327110 334343 334360	c21_hs CH22_1636FG_375_25_LINK_E CH22_1654FG_378_5_LINK_EM
60	327196 327283 327313 304465	c_1_hs c_1_hs c_1_hs AA421948
	304507 327450 304591	AA456426 c_2_hs
65	304659	AA507875 AA533185 CH22_2096FG_432_9_LINK_EM

```
334789 CH22_2101FG_432_14_LINK_E
334794 CH22_2106FG_434_2_LINK_EM
336035 CH22_3420FG_678_6_LINK_DJ
336042 CH22_3427FG_679_4_LINK_DJ
336093 CH22_3481FG_691_2_LINK_DJ
336096 CH22_3481FG_691_5_LINK_DJ
334889 CH22_2206FG_452_3_LINK_EM
336150 CH22_3540FG_706_6_LINK_DA
336152 CH22_3543FG_706_9_LINK_DA
336416 CH22_3833FG_823_38_LINK_B
336444 CH22_3834FG_827_10_LINK_D
336449 CH22_3870FG_829_6_LINK_DJ
336441 CH22_3894FG_829_30_LINK_D
```

## TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402;489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15				
	Pkey	Ref	Strand	Nt_position
	332955	Dunham, I. et.al.	Plus	2508896-2508992
	332958	Dunham, I. et.al.	Plus	2516164-2516310
20	332961	Dunham, I. et.al.	Plus	2521424-2521555
	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et.al.	Plus	2521424-2521555
	333305	Dunham, I. et.al.	Plus	4630388-4630645
~ -	333388	Dunham, I. et.al.	Plus	4913749-4913805
25	333517	Dunham, I. et.al.	Plus	5570729-5570925
	333585	Dunham, I. et.al.	Plus	6234778-6234894
	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
20	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333795	Dunham, I. et.al.	Plus	7807688-7807795
	333796	Dunham, I. et.al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
25	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334102	Dunham, I. et.al.	Plus	9995140-9996373
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	334343	Dunham, I. et.al.	Plus	13655828-13656307
40	334794	Dunham, I. et.al.	Plus	16374312-16374458
40	334889	Dunham, I. et.al.	Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et.al.	Plus	24140688-24140872
45	335498	Dunham, I. et.al.	Plus	24172082-24172161
43	335653	Dunham, i. et.al.	Plus	25329710-25329802
	335687	Dunham, I. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et.al.	Plus	26364087-26364196
50	335823	Dunham, I. et.al.	Plus	26365925-26366004
50	335824 335825	Dunham, I. et.al.	Plus Plus	26376860-26376942
		Dunham, I. et.al. Dunham, I. et.al.	Plus	26378175-26378268
	336035	•		29016748-29017410
	336093 336096	Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	29556922-29557002
55	336444	Dunham, I. et.al.	Plus	29578878-29579047 34190585-34190718
55	336959	Dunham, I. et.al.	Plus	
	338008	Dunham, I. et.al.	Plus	13233040-13233126
	338057	Dunham, I. et.al.	Plus	7697068-7697236 8526397-8526522
	338410	Dunham, I. et.al.	Plus	19292807-19292916
60	338588	Dunham, I. et.al.	Plus	22896767-22896920
UU	338665	Dunham, I. et.al.	Plus	24472654-24472853
	338832	Dunham, I. et.al.	Plus	27775128-27775290
	338980	Dunham, I. et.al.	Plus	29896789-29896874
	339352	Dunham, I. et.al.	Plus	33544784-33545121
	300002			33311101203010121

	332929	Dunham, I. et.al.	Minus	2020758-2020664
	332930	Dunham, I. et.al.	Minus	2022565-2022497
	332983	Dunham, I. et.al.	Minus	2631933-2631797
	333009	Dunham, I. et.al.	Minus	2766043-2765856
5	333010	Dunham, I. et.al.	Minus	2766207-2766119
•	333013	Dunham, I. et.al.	Minus	2772278-2772039
	333108	Dunham, I. et.al.	Minus	3240494-3240389
	333343	Dunham, I. et.al.	Minus	4692886-4692753
	333456	Dunham, I. et.al.	Minus	2631933-2631797
10			Minus	5144548-5144344
10	333459 333743	Dunham, I. et.al.	Minus	7573218-7573060
	333758	Dunham, I. et.al.	Minus	7666413-7666091
		Dunham, I. et.al.		
	333904	Dunham, I. et.al.	Minus	8217374-8217261
15	333905	Dunham, I. et.al.	Minus	8217796-8217670
13	334222	Dunham, I. et.al.	Minus	12732417-12732289
	334223	Dunham, I. et.al.	Minus	12734365-12734269
	334360	Dunham, I. et.al.	Minus	13728850-13728751
	334784	Dunham, I. et.al.	Minus	16294548-16294360
20	334789	Dunham, I. et.al.	Minus	16306095-16305996
20	335004	Dunham, I. et.al.	Minus	20581911-20581794
	335115	Dunham, I. et.al.	Minus	21388250-21388146
	335342	Dunham, I. et.al.	Minus	22597448-22597284
	335544	Dunham, I. et.al.	Minus	24650505-24650403
0.5	335610	Dunham, I. et.al.	Minus	25068943-25068841
25	335682	Dunham, I. et.al.	Minus	25421215-25421093
	335755	Dunham, I. et.al.	Minus	25763806-25763747
	335782	Dunham, I. et.al.	Minus	25908578-25908440
	335791	Dunham, l. et.al.	Minus	25948563-25948411
	335895	Dunham, I. et.al.	Minus	26975307-26975239
30	335917	Dunham, I. et.al.	Minus	27028481-27028377
	335920	Dunham, I. et.al.	Minus	27034927-27034811
	336042	Dunham, I. et.al.	Minus	29041694-29041500
	336150	Dunham, I. et.al.	Minus	30150423-30150256
	336152	Dunham, I. et.al.	Minus	30156053-30155870
35	336416	Dunham, I. et.al.	Minus	34047408-34047311
	336449	Dunham, I. et.al.	Minus	34204707-34204577
	336471	Dunham, I. et.al.	Minus	34215091-34214978
	336512	Dunham, I. et.al.	Minus	34278373-34278275
	336558	Dunham, I. et.al.	Minus	34375825-34375698
40	336560	Dunham, I. et.al.	Minus	34376814-34376596
	336676	Dunham, I. et.al.	Minus	2022565-2022497
	337968	Dunham, I. et.al.	Minus	7095797-7095680
	338451	Dunham, I. et.al.	Minus	20174286-20174193
	338689	Dunham, I. et.al.	Minus	24893073-24892972
45	339373	Dunham, I. et.al.	Minus	33860127-33860047
	325622	5867000	Plus	69994-70075
	329655	6448516	Minus	35565-35843
	329899	6563505	Minus	111058-111783
	329960	5091594	Minus	1031-1162
50	326213	5867224	Minus	60751-60927
50	326474	5867405	Plus	16995-18101
	330084	6015302	Minus	57019-59337
	326816	6552458	Plus	198354-198436
	326817	6552458	Plus	199909-200001
55		6117842	Plus	94608-94785
55	327110 327196	5867446		180921-181333
			Plus	
	327283	5867478	Minus	567-962
	327313	5867501	Minus	89734-89838
60	327450	5867766	Minus	47928-48076
60	328059	6117819	Plus	37052-37204
	328492	5868455	Minus	46094-46241
	328304	6004478	Minus	3884-3952
	328857	6381927	Minus	80557-81051
15	329367	5868842	Minus	87201-87587
65	329373	6682537	Minus	38950-39301

# TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast 5 cancer cells.

Pkey: ExAccn: UnigeneID: Unigene Title: Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number 10 Unigene gene title Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100038	M97935		AFFX control: STAT1	16.7
	100114	D00596	Hs.82962	thymidylate synthetase	15.9
• •	100975	J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin)	30.1
20		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B; 9	37.2
		L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPYY	18.3
		L12723	Hs.90093	heat shock 70kD protein 4	17:4
		L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topois	18.9
0.5		M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.1
25		M86849	Hs.323733	Homo sapiens connexin 26 (GJB2) mRNA	22.5
		U65932	Hs.81071	extracellular matrix protein 1	23.2
		U79241	Hs.118666	Human clone 23759 mRNA; partial cds	15
		U90904	Hs.83724	Human clone 23773 mRNA sequence	15.2
20		X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
30		X17644	Hs.2707	G1 to S phase transition 1	20.6
		X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin 3	17.8
		X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mito	18.9
		X72755	Hs.77367	monokine induced by gamma interferon	15.1
35			Hs.198793	KIAA0750 gene product	23.3
33		AA428090		ESTs	28.7
		AA007234		ESTS	16.6 19.3
		AA191512 AA421104		Homo sapiens mRNA; cDNA DKFZp564G	15.4
		AA621169		ESTs ESTs	19.4
40			Hs.110826	trinucleotide repeat containing 9	20.1
40		H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CON	19.5
		H98714	Hs.24131	ESTs	30.2
		N46252	Hs.29724	ESTs	23.2
45		N67239	Hs.10760	ESTs	37
		N91023	Hs.87128	ESTs	15
		R46025	Hs.7413	ESTs	17.4
		W86748	Hs.8109	ESTs	15
	114124	Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 protein	22
50	114292	Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
	114901	AA236276	Hs.196437	ESTs; Weakly similar to R26660_1; partial	16.9
	114965	AA250737	Hs.72472	ESTs	35.1
		AA405098		ESTs	16.1
	115875	AA433943		ESTs; Weakly similar to Weak similarity t	33.5
55		H29532	Hs.101174	microtubule-associated protein tau	22.2
		H72948	Hs.821	biglycan	20.7
		N26722	Hs.42645	ESTs	18.1
		Z41815	Hs.65946	ESTs	15.6
<b>CO</b>			Hs.104106	ESTs	15.2
60			Hs.174104	ESTs	22.6
		AA609200	11- 070040	ESTs	23.1
		D60302	Hs.270016	ESTs	20.6
		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B	25.9
	120100	N90960	Hs.265398	ESTs; Weakly similar to transformation-rel	16.4

	127677	AA916752	Hs.264190	ESTs; Highly similar to MEM3 [M.muscul	17.3
		U31875	Hs.152677	short-chain alcohol dehydrogenase family m	27.1
		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566L	24.5
5		AA234530		N-ethylmaleimide-sensitive factor	20.7
3		H18027 X17059	Hs.184697	plexin C1	18.2 26.4
		X03635	Hs.155956 Hs.1657	N-acetyltransferase 1 (arylamine N-acetylt estrogen receptor 1	39.9
		W03592	Hs.21198	translocase of outer mitochondrial membra	20.9
		M97935	Hs.21486	signal transducer and activator of transcript	18.8
10	131472	AA608962	Hs.27258	calcyclin binding protein	18.1
		U90551	Hs.28777	H2A histone family; member L	18.8
		AA405569		fibroblast activation protein; alpha; seprase	15.4
		F09979	Hs.4774	ESTs	15 15.4
15		AA047896 AA505133		ESTs solute carrier family 2 (facilitated glucose t	26.4
13		R79723	Hs.69997	zinc finger protein 238	30.4
		U24166	Hs.234279	microtubule-associated protein; RP/EB fam	15.2
		D62633	Hs.8236	ESTs	15.2
	134405	J04177	Hs.82772	collagen; type XI; alpha 1	15.3
20		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		D63477	Hs.84087	KIAA0143 protein	16.1
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; memb	35.7
		AA454930		ESTs	19.5 20.7
25		AA312082 NM_00444		GDNF family receptor alpha 1 EST cluster (not in UniGene) with exon hit	21.6
23		AL117607		Homo sapiens mRNA; cDNA DKFZp564N	41.4
		AI951118	113.17 0000	EST singleton (not in UniGene) with exon	24.3
		AW170035		EST	64.5
		AW022192		ESTs	39.1
30	311166	Al821294	Hs.118599	ESTs	24.1
		AA759250		cytochrome b-561	27.1
		Al969390		ESTs	27.1
	-	AA833655		ESTs	27.8
35		A1873274		ESTs ESTs	22.5 21.4
55		AW207206 Al476797		cell division cycle 2; G1 to S and G2 to M	18.4
		AA972756		ESTs	28.8
		Al908272		EST cluster (not in UniGene)	32.6
		AW167087		ESTs	15.7
40		A1285898	Hs.294014	ESTs	16.3
		NM_00254		EST cluster (not in UniGene)	21.3
			Hs.144479	ESTs	35
		NM_00273		EST cluster (not in UniGene)	25.4 16.7
45		AA321166 AL039402		EST cluster (not in UniGene) DEME-6 protein	24.3
73		U96044	Hs.181125	EST cluster (not in UniGene)	15.3
		AW043782		ESTs	21
	322882	AW248508	Hs.279727	DiGeorge syndrome critical region gene 2	15.3
<b>~</b> 0	324261	AL044891	Hs.269350	EST cluster (not in UniGene)	50.1
50		AA464510		EST cluster (not in UniGene)	16.7
		AW016378		ESTs	23.1
		AA448021		EST cluster (not in UniGene) EST cluster (not in UniGene)	21.2 24.5
		T06997 X03363	Hs.121028	HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
55		M13755	Hs.833	interferon-stimulated protein; 15 kDa	67
		AA015730		ESTs: Weakly similar to transformation-rel	44.1
		R72427	Hs.129873	ESTs; Weakly similar to CYTOCHROME	41.9
		AA252079		dachshund (Drosophila) homolog	15.1
60		AA432166		succinate dehydrogenase complex; subunit	24.3
60		AA281753		inositol 1;4;5-triphosphate receptor; type 3	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHANO	15.3
		AA262768	HS.243901	KIAA1067 protein CH22_FGENES.48_15	15.2 17.8
	332958 333769			CH22_FGENES.440_15 CH22_FGENES.271_8	48.3
65	333968			CH22_FGENES.307_4	15.9
	334223			CH22_FGENES.360_4	33.5
	334264			CH22_FGENES.367_15	18.5

 335791
 CH22\_FGENES.611\_7
 27.3

 336512
 CH22\_FGENES.834\_7
 21.4

 338008
 CH22\_EM:AC005500.GENSCAN.127-9
 15.2

#### TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15

	Pkey	CAT number	Accession
20	336512	10460292 CH22_3941FG_ CH22_6490FG_	
25	333968 335791	CH22_1245FG_ CH22_3160FG_	.271_8_LINK_EM .307_4_LINK_EM .611_7_LINK_EM
23	332958 334223 334264	CH22_1551FG_	360_4_LINK_EM

### TABLE 14B

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Ref: Sequence source entitled "T  Strand: Indicates DNA s  Nt_position: Indicates nucleo			corresponding to an Eos probeset e. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication he DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. trand from which exons were predicted. tide positions of predicted exons.			
	Pkey	Ref	Strand	Nt_position			
20	333769 333968	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	2516164-2516310 7696625-7696707 8681004-8681241 13234447-13234544			
25	334223 335791	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Minus Minus	7697068-7697236 12734365-12734269 25948563-25948411 34278373-34278275			

# TABLE 15: Table 3 from BRCA 001-5 US

# Table 15 shows genes downregulated in breast cancer cells.

5

10

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

Pkey: ExAccn: UnigeneID: Unigene Title: R1:

15	Pkey	ExAccn	UniGene II	OUnigene Title	R1
	100115	D00632	Hs.172153	glutathione peroxidase 3 (plasma)	1.7
	100499	TIGR:HT1428		Globin, Beta	1.5
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	100815	TIGR:HT4268	Hs.9739	L-Glycerol-3-Phosphate:Nad+ Oxidoreduct	1.7
20	101125	L10373	Hs.82749	transmembrane 4 superfamily member 2	1.5
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha po	2.9
	101397	M15856	Hs.180878	lipoprotein lipase	1.6
	101883	M98399	Hs.75613	CD36 antigen (collagen type I receptor; thr	1.6
	102227	U25138	Hs.93841	potassium large conductance calcium-activ	1.6
25	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
	103211	X73079	Hs.288579	polymeric immunoglobulin receptor	1.8
	103496	Y09267	Hs.132821	flavin containing monooxygenase 2	1.5
	103562	Z21966	Hs.2815	POU domain; class 6; transcription factor 1	1.8
	104672	AA007629		glycerol-3-phosphate dehydrogenase 1 (sol	2.4
30	105083	AA146619	Hs.18791	ESTs; Weakly similar to CALCIUM-BIND	1.7
		AA164519	Hs.15248	ESTs	1.5
		AA417915	Hs.25930	ESTs	1.5
		AA487576	Hs.26530	serum deprivation response (phosphatidyls	1.6
2 ~		AA609645	Hs.211568	•	2.7
35		AA004901	Hs.261164		1.6
		AA037388	Hs.82223	Human DNA sequence from clone 141H5 o	1.7
		AA099820	Hs.49696	ESTs	2.4
		N64265	Hs.19515	yz44h12.s1 Morton Fetal Cochlea Homo sa	1.7 1.6
40		R36447	Hs.24453	ESTS	1.0
40		R70255	Un 201022	ESTS	1.5
		R97970 T40652	Hs.281022	DKFZP434C171 protein	1.9
		AA418033	Hs.283559		1.6
		AA443800	Hs.43125	ESTs	2
45		AA446661	Hs.173233		2.2
75		N20300	Hs.218707		1.7
		N32174	Hs.44317	SRY (sex-determining region Y)-box 10	1.7
		R15436	Hs.77889	Friedreich ataxia region gene X123	1.7
		R71792		ESTs; Weakly similar to cell death activato	2.8
50		T71021 .	Hs.285681		1.9
		W73386	Hs.249129	,	3
		AA365784	Hs.97044	ESTs	1.6
		AA405747	Hs.97984	ESTs; Weakly similar to WASP-family pro	1.8
	121750	AA421184	Hs.97549	ESTs	1.5
55	122127	AA434447	Hs.106771	ESTs	2.5
	122348	AA443695	Hs.293410	ESTs	2.1
	122485	AÀ448300	Hs.160318	phospholemman	1.5
		AA598841	Hs.167382		1.8
60		AA600135		ESTs; Moderately similar to !!!! ALU SUB	1.5
60		W94688	Hs.103253	· · · · · · · · · · · · · · · · · · ·	1.7
		D81972	11. 400040	HUM427D08B Human fetal brain (TFujiw	1.8
		R72515	Hs.160318	F	1.6
		AA309765	Hs.116017		1.5
	127357	AA452788	Hs.75432	zx39g11.r1 Soares_total_fetus_Nb2HF8_9	1.7

		AA634405 AA972780	Hs.122608	ESTs ESTs; Weakly similar to !!!! ALU SUBFA	1.5 1.5
		AI092391	Hs.134886		1.5
_		N44757	Hs.20340	ESTs	1.6
5	128870	R71403	Hs.75309	eukaryotic translation elongation factor 2	1.7
		AA459944		DKFZP586P1422 protein	1.5
	129285		Hs.11006	ESTs	2.1
		N93465		ESTs; Highly similar to CGI-38 protein [H	1.5 1.7
10		M62402 M25079		insulin-like growth factor binding protein 6 hemoglobin; beta	1.7
10		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
		AA131466	Hs.23767	ESTs	1.9
		M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma p	2.2
	131304	AA295848	Hs.25475	aquaporin 7	1.7
15		D49487		leptin (murine obesity homolog)	2.5
		AA045503	Hs.56874	ESTs; Weakly similar to Homo sapiens p2	1.6
	132931		Hs.6090	deleted in bladder cancer chromosome regi	1.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2 1.5
20		U95367 X74295	Hs.70725 Hs.74369	gamma-aminobutyric acid (GABA) A recep integrin; alpha 7	1.7
20		S95936	Hs.284176		2.3
		N56898	Hs.75652	glutathione S-transferase M5	1.9
		N79674	Hs.8022	TU3A protein	4.6
~ =	134699	U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25		L10955	Hs.89485	carbonic anhydrase IV	1.6
		M72885	Hs.95910	Human G0S2 protein gene; complete cds	1.9
		AW027556	Hs.156286 Hs.257891		1.7 1.5
		AI369956 AA514805	Hs.293055		1.8
30		AI807692	Hs.129129		1.6
		AA923549	Hs.224121		2.1
	302910	N77976	Hs.251577	hemoglobin; alpha 1	1.8
		V00505	Hs.36977	hemoglobin; delta	1.6
25		T04868	Hs.46780	EST cluster (not in UniGene) with exon hit	1.7
35		U94362	Hs.58589	glycogenin 2	1.5
		H91086 AA516384		EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	1.5 1.5
		AA550994		EST singleton (not in UniGene) with exon	1.7
		AA782347	Hs.272572	EST singleton (not in UniGene) with exon	1.5
40		AA923457		EST singleton (not in UniGene) with exon	1.5
	307206	Al192534		EST singleton (not in UniGene) with exon	1.6
		AI222691		EST singleton (not in UniGene) with exon	1.5
		Al452732		EST singleton (not in UniGene) with exon	1.9
45		A1612774	Hs.79372 Hs.255504	retinoid X receptor; beta	1.5 1.5
43		AW296073 AI720978		ESTs; Moderately similar to alternatively s	1.8
		AW241947	Hs.232478		1.6
		AW238092	Hs.254759		2.1
	312082	T79860	Hs.118180	ESTs	1.9
50	312575	H25237	Hs.306814	ESTs	2.3
	313076	N49684	Hs.143040		1.8
		W32480	Hs.157099		2.2
		AW328672 AI754634	Hs.132760 Hs.131987		1.9 1.7
55		AA759098	Hs.192007		1.8
55		AA680055	Hs.264885		1.5
		AA948612	Hs.130414		1.6
	316586	A1205077	Hs.294085	ESTs	1.7
<i></i> 0		AA837079	Hs.24647	ESTs	1.5
60		A1480204	Hs.177131		1.5
		A1650625	Hs.300756 Hs.129621		1.6 1.5
	310400	AW206520 W26902	Hs.154085		1.7
	320757	H22654	Hs.6382	EST cluster (not in UniGene)	1.5
65	321594	AA021402	Hs.11067	ESTs	1.7
	322102	H45589		EST cluster (not in UniGene)	1.5
	322814	A1824495	Hs.211038	ESIS	2.2

	322929	Al365585	Hs.146246	ESTs	2.3
	323831	AA335715	Hs.200299	ESTs	1.7
	324044	AL045752	Hs.22350	ESTs	1.8
_	324675	AW014734	Hs.157969	ESTs	2.2
5	325272			CH.11_hs gij5866902	1.5
	325558			CH.12_hs gij6056302	1.6
	325656			CH.14_hs gij6056305	1.6
	326120			CH.17_hs gi 5867194	1.5
	326139			CH.17_hs gij5867203	1.5
10	326855			CH.20_hs gij6552460	1.5
	327438			CH.02_hs gij6004454	1.6
	329733			CH.14_p2 gi 6065783	1.6
	330931	F01443	Hs.284256		4.6
	331591	N71677	Hs.42146	ESTs	1.9
15	332159	AA621393	Hs.112984	EST	1.5
	332364	W94688	Hs.103253	perilipin	2.1
	332502	H21819	Hs.14896	Homo sapiens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
	336336			CH22_FGENES.814_8	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EM:AC005500.GENSCAN.110-1	2
	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354l12.GENSCAN.34-2	1.5

#### TABLE 15A

**Table 15A** shows the accession numbers for those pkeys lacking unigeneID's for Table 15. For each probeset, we have listed the gene cluster number from which the oligonucleotides 5 were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

```
Pkey:
                 Unique Eos probeset identifier number
CAT number:
                 Gene cluster number
                 Genbank accession numbers
Accession:
```

15

#### Pkey CAT number Accession

336336 CH22\_3746FG\_814\_8\_LINK\_BA

```
126300 250375 2
                            D81972 BE003132
20
        112538 504579_1
                            AA908813 R70255
        123505 genbank_AA600135
                                       AA600135
        104672 6735_7
                            AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263
                            Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375
                            H45809 F33447 AA774528 AA007629 H42537 C01077 F32386
25
        322102 46708_1
                            H45589 H19807 AF075038 H19808 H42437
        336865 CH22 4590FG 305 1
        338192 CH22_6755FG__LINK_EM:AC00
        329733 c14_p2
        326120 c17_hs
30
        326139 c17_hs
        326855 c20 hs
        335352 CH22_2699FG_539_5_LINK_EM
        335639 CH22_2999FG_584_19_LINK_E
        307206 Al192534
35
        307377 Al222691
337494 CH22_5727FG_799_12_
        337764 CH22_6115FG__LINK_EM:AC00
337983 CH22_6438FG__LINK_EM:AC00
        339366 CH22_8336FG__LINK_BA354I1
40
        325272 c11_hs
        325558 c12_hs
        325656 c14_hs
        334175 CH22_1455FG_349_10_LINK_E
        304182 H91086
45
        334347 CH22_1640FG_375_31_LINK_E
        327438 c_2_hs
        304622 AA516384
        334737 CH22_2049FG_424_12_LINK_E
        304682 AA550994
50
        336244 CH22_3642FG_746_2_LINK_DA
        306193 AA923457
```

### TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
	334347	Dunham, I. et.al.	Plus	13663814-13663926
• •	334737	Dunham, I. et.al.	Plus	15998517-15998685
20	335639	Dunham, I. et.al.	Plus	25173591-25173696
	337494	Dunham, I. et.al.	Plus	33339024-33339148
	334175	Dunham, l. et.al.	Minus	11668659-11668597
	335352	Dunham, I. et.al.	Minus	22681512-22681384
~ -	336244	Dunham, l. et.al.	Minus	31402729-31402583
25	336336	Dunham, I. et.al.	Minus	33797209-33797076
	336865	Dunham, I. et.al.	Minus	8622405-8622289
	337764	Dunham, I. et.al.	Minus	4035640-4035446
	337983	Dunham, I. et.al.	Minus	7275495-7275271
• •	338192	Dunham, I. et.al.	Minus	13248453-13248277
30	339366	Dunham, I. et.al.	Minus	33647431-33647293
	325272	5866902	Minus	13247-13312
	325558	6056302	Plus	70930-71030
	325656	6056305	Minus	78190-78707
~ ~	329733	6065783	Plus	163237-163450
35	326120	5867194	Plus	36116-36276
	326139	5867203	Minus	218901-218960
	326855	6552460	Minus	111390-111463
	327438	6004454	Minus	199569-199692

# TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in 5 breast cancer cells.

Pkey: ExAccn: UnigeneID: Unigene Title:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

10

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha	2.9
20	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
20			U- 044500	glycerol-3-phosphate dehydrogenase 1	2.4
	107099	AA609645	Hs.211568	eukaryotic translation initiation factor 4 gam	2.7
	108604	AA099820	Hs.49696	ESTs	2.4
		AA443800	Hs.43125	ESTs	2
25		AA446661	Hs.173233	ESTs	2.2
23	119175 119798	R71792 W73386	Hs.301002	ESTs; Weakly similar to cell death activator ESTs	2.8 3
			Hs.249129	ESTs	3 2.5
	122127 122348	AA434447 AA443695	Hs.106771 Hs.293410	ESTS	2.5
	122346	T62068	Hs.11006	ESTs	2.1
30	131267	AA211776	Hs.2504		3.8
50		M12272	Hs.4	myomesin 1 (skelemin) (185kD)	2.2
	131810	D49487	Hs.194236	alcohol dehydrogenase 3 (class I); gamma leptin (murine obesity homolog)	2.5
	133120	X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2.3
	133601	S95936	Hs.284176	transferrin	2.3
35	134111	N79674	Hs.8022	TU3A protein	4.6
55		AA923549	Hs.224121	ESTs	2.1
		AW238092	Hs.254759	ESTs	2.1
	312575	H25237	Hs.306814	ESTs	2.3
		W32480	Hs.157099	ESTs	2.2
40	322814	Al824495	Hs.211038	ESTs	2.2
	322929	Al365585	Hs.146246	ESTs	2.3
		AW014734	Hs.157969	ESTs	2.2
	330931	F01443	Hs.284256	ESTs	4.6
	332364	W94688	Hs.103253	perilipin	2.1
45	337983			CH22 EM:AC005500.GENSCAN.110-1	2

#### TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

Accessi

15

20

Pkey CAT number Accession

104672 6735\_7

AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263 Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

## TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1:	Ratio of tumor to normal breast tissue

	Pkey	ExAccn	UnigenelD	Unigene Title	R1
20	100227	AV654694	Hs.82316	interferon-induced, hepatitis C-associat	3
	100405	AW291587	Hs.82733	nidogen 2	3.2
		AI962060		AE-binding protein 1	3.6
	100420	D86983		Melanoma associated gene	3.2
	100911	X83300	Hs.289103	SMA4	5.2
25	100960	J00124	Hs.117729	keratin 14 (epidermolysis bullosa simple	4.3
	101011	BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3
	101183	AA442324	Hs.795	H2A histone family, member O	3.2
	101194	L20971	Hs.188	phosphodiesterase 4B, cAMP-specific (dun	3
	101329	U66042 `	Hs.82171	Homo sapiens clone 191B7 placenta expres	4.1
30	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		R07566	Hs.73817	small inducible cytokine A3 (homologous	3.9
		M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
0.5		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4
35		NM_003528	Hs.2178	H2B histone family, member Q	5.6
		BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6
		M81057		carboxypeptidase B1 (tissue)	12
		M89907		SWI/SNF related, matrix associated, acti	3.2
40		BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1
40		M97815		cellular retinoic acid-binding protein 2	6.5
		NM_002038		interferon, alpha-inducible protein (clo	3
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	3
		NM_001504		G protein-coupled receptor 9	3.7
15		NM_005824		37 kDa leucine-rich repeat (LRR) protein	3.7
45		NM_005651		tryptophan 2,3-dioxygenase	5.2
		AL043202	Hs.90073	chromosome segregation 1 (yeast homolog)	3.5
		U39840		hepatocyte nuclear factor 3, alpha	3.9
		U62325		amyloid beta (A4) precursor protein-bind	4 3.5
50		H16646 AA363025		hypothetical protein PP591 Human clone 23801 mRNA sequence	3.5 3.2
50		AF080229	HS. 100072	qb:Human endogenous retrovirus K clone 1	3.2
		NM_002318	Hs.83354	lysyl oxidase-like 2	3.2
		M73779		retinoic acid receptor, alpha	3.3
		X52509		tyrosine aminotransferase	12.4
55		T81656		ribosomal protein S3	4.5
55		X63578		parvalbumin	3
		X72790	113.200 110	gb:Human endogenous retrovirus mRNA for	5.9
		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.9
		AI751601	Hs.8375	TNF receptor-associated factor 4	3.3
60		X85134	Hs.72984	retinoblastoma-binding protein 5	3.1
<b>~ ~</b>		X90872	Hs.279929	gp25L2 protein	3
		NM_007069	Hs.37189	similar to rat HREV107	3.4
		AA496425	Hs.9629	papillary renal cell carcinoma (transloc	3.2
				• • •	

	103498	Y09306	Hs.30148	homeodomain-interacting protein kinase 3	3.4
		BE616547	Hs.2785	keratin 17	3.7
		L02911		Activin A receptor, type I (ACVR1) (ALK	3.2
5		BE336654	Hs.70937	H3 histone family, member A	4.5
5		Al571835 AW779318	Hs.55468 Hs.88417	ESTs ESTs	4 3.8
		AW021102	Hs.21509	ESTS	4.3
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
		AA461618	Hs.31704	ESTs, Weakly similar to KIAA0227 [H.sapi	3.6
10	104173	AA084273	Hs.76561	ESTs, Weakly similar to S47072 finger pr	4
		AF173296		DC6 protein	3
		AB040927		KIAA1494 protein	3.2
		AI559444 AI929700	Hs.293960	endosulfine alpha	4.3 3.1
15		H20816		Homo sapiens mRNA; cDNA DKFZp586i1420 (f	3.2
10		AV650851	Hs.96900	hypothetical protein; KIAA1830 protein	4.4
	104658	AA360954	Hs.27268	Homo sapiens cDNA: FLJ21933 fis, clone H	3.2
		AA015879	Hs.33536	ESTs	3.2
20		T49951	Hs.9029	DKFZP434G032 protein	4.5
20		AA035613	Hs.141883		6.9 11.1
		AW294092 T79340	Hs.21594 Hs.22575	hypothetical protein MGC15754  B-cell CLL/lymphoma 6, member B (zinc fi	3.5
•		BE298684	Hs.26802	protein kinase domains containing protei	6.5
		H78517	Hs.33905	ESTs	3.6
25		AW503733	Hs.9414	KIAA1488 protein	4.5
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.8
		AA148982	Hs.29068	ESTs	3
		AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G0321 (f	4.8 8.2
30		AW134924 AA814807	Hs.190325 Hs.7395	hypothetical protein FLJ23182	3.1
50		AW505076		DiGeorge syndrome critical region gene 8	4.2
		AA252033		hypothetical protein DKFZp434K1421	4.4
	105552	AA256750	Hs.28802	centaurin-alpha 2 protein	3.2
25		AA279439		hypothetical protein FLJ10504	3.5
35		W16741	Hs.25635	HSPC003 protein	3.7
		Al299139 Al133161	Hs.17517	ESTs CGI-101 protein	5.5 3.5
		AW973653	Hs.20104	hypothetical protein FLJ00052	3.3
		AA195191	Hs.5111	hypothetical protein FLJ20729	3.2
40		AA131657	Hs.23830	ESTs	3.3
		AL117474	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3.2
		W28948	Hs.10762	ESTs	3.3
		N39842	Hs.301444		4.1
45		BE397649 BE383668	Hs.94109 Hs.42484	Homo sapiens cDNA FLJ13634 fis, clone PL hypothetical protein FLJ10618	3.1 3.2
73		AA351978	Hs.4943	hepatocellular carcinoma associated prot	7.8
		AL134708	Hs.145998		3
	106614	AA648459	Hs.335951	hypothetical protein AF301222	3.8
<b>60</b>		AW958037	Hs.286	ribosomal protein L4	3.3
50		AW499914	Hs.7579	hypothetical protein FLJ10402	3
		BE613328	Hs.21938	hypothetical protein FLJ12492	4.2 3.4
		AA485055 AI311928	HS. 100213	sperm associated antigen 6 gb:qo89h04.x1 NCI_CGAP_Kid5 Homo sapiens	3.4 4.4
		AW192535	Hs.19479	ESTs	3.6
55		AW472981		hypothetical protein MGC2771	4.1
	106942	AA995351	Hs.31314	retinoblastoma-binding protein 7	3.6
		AF216751	Hs.26813	CDA14	5.3
		AW963419		stanniocalcin 2	3.4
60		N32849 AW263124	Hs.31844	hypothetical protein FLJ12586	3.1 5.9
oo		BE379594	Hs.315111 Hs.49136	nuclear receptor co-repressor/HDAC3 comp ESTs, Moderately similar to ALU7_HUMAN A	3.9
		AW961576	Hs.60178	ESTs	4.6
		Al955040		ESTs, Weakly similar to transformation-r	3
	107890	AA025386	Hs.61311	ESTs, Weakly similar to S10590 cysteine	3.1
65		T40064	Hs.71968	Homo sapiens mRNA; cDNA DKFZp564F053 (fr	4.8
		A1263307		H2B histone family, member L	3.3
	108217	AA058686	Hs.62588	ESTs	3.8

		T82427		Homo sapiens cDNA: FLJ20869 fis, clone A	3 3.3
		AB033073 AA121022	Hs.43857	similar to glucosamine-6-sulfatases gb:zn84f10.r1 Stratagene lung carcinoma	3.9
		AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
5		AA011449	Hs.271627		3.6
	108912	AA136674	Hs.118681	EST	3.9
		AF186114		tumor necrosis factor (ligand) superfami	3.7
		AK000684		hypothetical protein FLJ22104	3.1
10		A1970536	Hs.16603	hypothetical protein FLJ13163	3.7 4.5
10		N23235 AA196443	Hs.30567 Hs.86043	ESTs, Weakly similar to B34087 hypotheti Homo sapiens cDNA FLJ13558 fis, clone PL	3.7
		AW504732	Hs.21275	hypothetical protein FLJ11011	4.6
		AA232255		ESTs, Moderately similar to A46010 X-lin	6.4
		AA234087		ESTs, Weakly similar to S72482 hypotheti	4.8
15		R45584	Hs.23025	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.3
		AA325138		hypothetical protein FLJ22672	3
		AW973964	Hs.291531	ESTs, Highly similar to 1203217A dehydro	3
		F09609 F06838	Hs.14763	gb:HSC33H092 normalized infant brain cDN ESTs	3.2 3.2
20		R43646	Hs.12422	ESTs	3.8
		AW818436	Hs.23590	solute carrier family 16 (monocarboxylic	3.3
		AK001680	Hs.30488	DKFZP434F091 protein	3.6
	110024	AW973152	Hs.31050	ESTs	4.2
0.5		AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	5.1
25		H89355		adrenergic, alpha-2A-, receptor	5.3 3.7
		Al239832 BE092285	Hs.15617 Hs.29724	ESTs, Weakly similar to ALU4_HUMAN ALU S hypothetical protein FLJ13187	3.7
		N64683	Hs.290943		4
		N66563	Hs.191358		3.1
30		AI767435	Hs.29822	ESTs	4.5
	111336	A1457338	Hs.29894	ESTs	5.4
		R07856	Hs.16355	ESTs	3.2
		R08440	Un 00000	gb:yf19f09.s1 Soares fetal liver spleen	3.1 3.2
35		AA602004 R35252	Hs.23260 Hs.24944	ESTs ESTs, Weakly similar to 2109260A B cell	3.3
55		R38239		ESTs, Weakly similar to putative p150 [H	3.1
		AA421081	Hs.12388	ESTs	3.4
		AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	3.3
40		AW379029		ESTs, Weakly similar to unnamed protein	4.4
40		BE246743		hypothetical protein FLJ22635	7.3
		AB033064		KIAA1238 protein	3.2 4.4
		H24334 R54797	Hs.26125	ESTs gb:yg87b07.s1 Soares infant brain 1NIB H	3.4
		R66067	Hs.28664	ESTs	8.2
45		Al791493		ESTs, Weakly similar to A36036 cytochrom	5.5
		R82040		gb:yj06b06.s1 Soares placenta Nb2HP Homo	3.9
	112637	R82331	Hs.164599		5.4
		AW844878	Hs.19769	hypothetical protein MGC4174	3.2
50		A1418466	Hs.33665	ESTs choline/ethanolaminephosphotransferase	4.7 3.7
50		AA082465 AB032977	Hs.6298	KIAA1151 protein	3.1
		AA828380	Hs.126733		3.4
		AW813731		ESTs, Moderately similar to S65657 alpha	3.4
		BE613410	Hs.31575	SEC63, endoplasmic reticulum translocon	3.2
55		T57773	Hs.10263	ESTs	3.5
		BE262470	Hs.241471	RNB6	6.2
		T79925		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7 3
		U54727 T91451	Hs.191445 Hs.86538	ESTS	3.4
60		AW367788	Hs.323954		3.1
00		Al702609	Hs.15713	hypothetical protein MGC2776	3.1
		NM_004585	Hs.17466	retinoic acid receptor responder (tazaro	3.9
		Al912410	Hs.27475	Homo sapiens cDNA FLJ12749 fis, clone NT	3
65		W81598		gb:zd88g02.s1 Soares_fetal_heart_NbHH19W	4.6
65		W84768	Hs.8109	gb:zh53d03.s1 Soares_fetal_liver_spleen_ hypothetical protein FLJ21080	3.1 6.9
		W27249 AA378776	Hs.288649		4.3
	1 1-7000			-What are brotont the court	

		AW470411		neurotrimin	4.1
		AW780192	Hs.267596		3.4
		AW163267		suppressor of var1 (S.cerevisiae) 3-like	3.1
_		Al979168	Hs.82226	glycoprotein (transmembrane) nmb	4.8
5		Al733881	Hs.72472	BMP-R1B	10.1
		AA769266	Hs.193657		3.6
		AI634549	Hs.88155	ESTs	3.2
		AW968073		ESTs, Highly similar to A55713 inositol	4.2 3
10		AA749209	Hs.43728	hypothetical protein hypothetical protein MGC4126	3.6
10		BE149845 AA814100	Hs.86693	ESTs	3.9
		N46436	Hs.109221		3.4
		AA281636	Hs.334827		4.8
		AA405620	Hs.55158	ESTs, Weakly similar to T29520 hypotheti	3.5
15		AA953006	Hs.88143	ESTs	9.3
13		AW293849	Hs.58279	ESTs, Weakly similar to ALU7_HUMAN ALU S	3.4
		AA417812	Hs.38775	ESTs	4
		Al126772	Hs.40479	ESTs	3.1
		AW970529	Hs.86434	hypothetical protein FLJ21816	3.6
20		AA521410	Hs.41371	ESTs	3.1
		NM_014937	Hs.52463	KIAA0966 protein	3
		AK001500	Hs.165186	hypothetical protein FLJ13852	3.2
		AA354549	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3
	115948	AL042465	Hs.43445	poly(A)-specific ribonuclease (deadenyla	3.1
25		AB041035	Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (	6.7
		AL042355	Hs.70202	WD repeat domain 10	3.6
		AW450737		CGI-09 protein	3.1
		AA464976	Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.3
20		AI219083	Hs.42532	ESTs, Moderately similar to ALU8_HUMAN A	3.2
30		AF265555		baculoviral IAP repeat-containing 6	3.6
		AW962196		LBP protein 32 SRY (sex determining region Y)-box 4	4.1 4.1
		AI272141 AK001114	Hs.83484		8.6
		AA649530	Hs.53913	hypothetical protein FLJ10252 gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens	3.2
35		H88256	Hs.50456	ESTs, Moderately similar to ZN75_HUMAN Z	3.5
55		AI569804	Hs.42792	ESTs, Weakly similar to 178885 serine/th	3.1
		AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	3.2
		H84455	Hs.40639	ESTs	4.7
		AB040959	Hs.93836	DKFZP434N014 protein	3
40		AW968941		hypothetical protein DKFZp566l133	3.3
	118363	AI183838	Hs.48938	hypothetical protein FLJ21802	4.3
	118416	N66028	Hs.49105	FKBP-associated protein	3.1
	118470	AW970584	Hs.291033		3.4
	118502	AL157488	Hs.50150	Homo sapiens mRNA; cDNA DKFZp564B182 (fr	5.2
45		AK000465	Hs.50081	KIAA1199 protein	3.4
		N92293		ESTs, Moderately similar to ALU8_HUMAN A	3.3
		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19.7
		R95872		chemokine binding protein 2	3.7
50		R16833	Hs.53106	ESTs, Moderately similar to ALU1_HUMAN A	4.1
50		M10905		fibronectin 1	3.2 3.3
		W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	
		AF041853	Hs.43670	kinesin family member 3A ESTs	3.1 5
		Al970797 AL037824	Hs.64859	ras homolog gene family, member I	3.8
55		AU37624 AW449064	He 110571	collagen, type III, alpha 1 (Ehlers-Dani	3.1
		W94472	Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	8.4
		AA825686	Hs.321176	ESTs, Weakly similar to S65824 reverse t	3.6
		AA196300	Hs.21145	hypothetical protein RG083M05.2	3.2
		AA225084	,	gb:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens	3.6
60		AA357172		ESTs, Moderately similar to ALU1_HUMAN A	5.8
		AA365515		hypothetical protein MGC4840	3
		AA398118	Hs.97579	ESTs, Weakly similar to A46010 X-linked	3.7
	121054	AW976570	Hs.97387	ESTs	5.3
		AA320134		Homo sapiens mRNA for KIAA1657 protein,	4
65		AA398936	Hs.97697	EST	3.5
		AA399371	Hs.189095	similar to SALL1 (sal (Drosophila)-like	6.3
	121337	AW885727	Hs.301570	E518	4.7

	121351	AW206227	Hs.287727	hypothetical protein FLJ23132	5
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
	121643	AA640987	Hs.193767	ESTs	5.6
_		NM_015902	Hs.278428	progestin induced protein	3.4
5		AK000492	Hs.98806	hypothetical protein	4.1
		AA443311	Hs.98998	ESTs	3_
		AA446965	Hs.112092		4.7
		Al767879	Hs.99214	ESTS	3.8
10		AW973253	Hs.292689		3
10		AA323296 AA526911	Hs.97837 Hs.82772	Homo sapiens mRNA; cDNA DKFZp547J047 (fr collagen, type XI, alpha 1	5.6 3.2
		AW205931	Hs.99598	hypothetical protein MGC5338	8.6
		AA487809		catenin (cadherin-associated protein), d	3
		AA228776	Hs.191721	· · · · · · · · · · · · · · · · · · ·	6.9
15		AA371307	Hs.125056		3.6
		AA491253		Empirically selected from AFFX single pr	7
		BE149685	Hs.17767		3.1
		T66087		Homo sapiens unknown mRNA sequence	3.4
	123485	Al308876		hypothetical protein DKFZp761D112	3.1
20	123645	AI675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	3.8
		AA580082	Hs.112264		4.7
		AA352723	Hs.241471		3.8
		H69125	Hs.133525		4.1
25		N22401	400045	gb:yw37g07.s1 Morton Fetal Cochlea Homo	4.1
25		N22508		Homo sapiens cDNA: FLJ21479 fis, clone C	3.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1 3.5
		N34151 R41396		interferon induced transmembrane protein hypothetical protein FLJ23045	4.3
		BE065136		splicing factor (CC1.3)	6
30		T78906		ESTs, Moderately similar to ALU1_HUMAN A	8.1
50		W60326		Homo sapiens cDNA FLJ11750 fis, clone HE	4.7
		AW970536	Hs.105413	•	3.1
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.3
		AL359573		GTP-binding protein	3
35	125330	AW880562	Hs.114574	ESTs	3
	125331	Al422996	Hs.161378		3.2
		Al924630	Hs.4943	hepatocellular carcinoma associated prot	3.2
		N99638		gb:za39g11.r1 Soares fetal liver spleen	4
40		AW975814		Homo sapiens clone IMAGE:713177, mRNA se	4
40		AA648886	Hs.151999		3.8 3
		AW450979 AW771958	Un 175/27	gb:UI-H-BI3-ala-a-12-0-UI.s1 NCI_CGAP_Su	3.6
		AA961459	Hs.125644	ESTs, Moderately similar to PC4259 ferri	4.1
		AW068311		Homo sapiens mRNA full length insert cDN	3.3
45		AA650274	Hs.41296		4.6
		NM_003616		survival of motor neuron protein interac	3.9
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	3.1
	128955	AA775076		Homo sapiens, Similar to PRO0478 protein	3.9
		D56365	Hs.63525	poly(rC)-binding protein 2	3.3
50		AA357185		ras homolog gene family, member H	3.1
		AF182277		cytochrome P450, subfamily IIB (phenobar	3.9
		AA172106		Rag C protein	6.2
		AA209534		tetraspan NET-6 protein	3.4 3
55		AK000398 X56411	Hs.11747 Hs.1219	hypothetical protein FLJ20391 alcohol dehydrogenase 4 (class II), pi p	3.2
33		Al754813		collagen, type V, alpha 1	5.4
		X03363		v-erb-b2 avian erythroblastic leukemia v	4.4
		Al347487		class I cytokine receptor	4.6
		NM_003450		zinc finger protein 174	5.6
60		A1582291	Hs.16846	ESTs, Weakly similar to O4HUD1 debrisoqu	3
	130703	R77776	Hs.18103	ESTs	3.8
		AA809875	Hs.25933	ESTs .	4.2
		AB014544	Hs.21572	KIAA0644 gene product	4.7
<i>C</i> =		Al399653	Hs.22917	ESTs	4.3
65		H09048	Hs.23606	ESTs	3.8
		R71802	Hs.24853	ESTs	3.5
	1313/2	AW293399	пs. 144904	nuclear receptor co-repressor 1	3.6

	131507	A1826268	Hs.27769	ESTs, Weakly similar to MCAT_HUMAN MITOC	3.2
		Al695549		glucuronidase, beta	3.1
	131739	AF017986	Hs.31386	secreted frizzled-related protein 2	3.2
_	131795	BE501849	Hs.32317	high-mobility group 20B	3.2
5		D86960	Hs.3610	KIAA0205 gene product	3.6
		NM_002314	Hs.36566	LIM domain kinase 1	3.2
		AA400091	Hs.39421	ESTs	3.2
		AA426202	Hs.40403	Cbp/p300-interacting transactivator, wit	3 3.2
10		D76435 AA192669	Hs.41154 Hs.45032	Zic family member 1 (odd-paired Drosophi ESTs	3.5
10		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	9.2
		AV660345		CGI-49 protein	8.2
		BE568452	Hs.5101	protein regulator of cytokinesis 1	3.4
		AA326108	Hs.33829	bHLH protein DEC2	3.2
15			Hs.5521	ESTs	4.8
	132725	NM_006276	Hs.184167	splicing factor, arginine/serine-rich 7	3.6
		W73311		SAC2 (suppressor of actin mutations 2, y	3.2
		T48195	Hs.58189	eukaryotic translation initiation factor	3.5
20		Y00272		cell division cycle 2, G1 to S and G2 to	4.4 4.8
20		AL120659 Al128606	Hs.6111 Hs.6557	aryl-hydrocarbon receptor nuclear transl	3.3
		AW952412	Hs.65874	zinc finger protein 161 ESTs, Weakly similar to A40348 Elav/Sex-	3.5
		AW162840	Hs.6641	kinesin family member 5C	4.5
		AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25		AA085191	Hs.6949	hypothetical protein MGC11275	3
	133275	Z93241	Hs.239934	CGI-96 protein	4.5
	133287	AW797437	Hs.69771	B-factor, properdin	4.1
		BE618768	Hs.7232	acetyl-Coenzyme A carboxylase alpha	5.1
20		AW675064	Hs.73875	fumarylacetoacetate hydrolase (fumarylac	3
30		AW162919 BE274552		RAB2, member RAS oncogene family-like protein inhibitor of activated STAT3	3.4 3.9
		Al908165	Hs.76578	GATA-binding protein 3 (T-cell receptor	6.2
		BE391929	Hs.8752	transmembrane protein 4	3.1
		Al433797	Hs.8889	serine hydroxymethyltransferase 1 (solub	3
35		D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
-	134776	J05582	Hs.89603	mucin 1, transmembrane	4
	135230	AF064804	Hs.96757	suppressor of Ty (S.cerevisiae) 3 homolo	3.2
		R61253	Hs.98265	KIAA1877 protein	3.3
40		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	4.8
40		L10333	Hs.99947	reticulon 1	3.8 3.8
		Al199738 AW614220	Hs.189402	ESTs, Weakly similar to ALUA_HUMAN !!!!	4.2
		AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
		AW591433		Transmembrane protease, serine 3	4.9
45		Z45270		hypothetical protein FLJ22672	3.4
	300973	AA572949	Hs.207566		3.5
		R10799	Hs.191990		3.8
		AA887801		G protein-coupled receptor	13.9
50		Al091631		two pore potassium channel KT3.3	4.4
50		AA312082 U79745		GDNF family receptor alpha 1 solute carrier family 16 (monocarboxylic	5.7 8.6
		T97905	П5. 1 14324	gb:ye54c10.r1 Soares fetal liver spleen	3.9
		AB020711	Hs 278346	KIAA0904 protein	7.7
		BE542706		CEGP1 protein	7.3
55		AW749321	Hs.6786	ESTs	3.3
	302099	AL049670	Hs.137576	ribosomal protein L34 pseudogene 1	4.2
		NM_003613		cartilage intermediate layer protein, nu	7.9
		AL049987		Homo sapiens mRNA; cDNA DKFZp564F112 (fr	5.6
<b>CO</b>		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	5.4
60		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (f ATP-binding cassette transporter MRP8	34.1 6.7
		AL117406 AL109712		Homo sapiens mRNA full length insert cDN	4
		Al678059		synaptonemal complex protein 2	4.3
		AJ224172		lipophilin B (uteroglobin family member)	13.8
65		AW192334	Hs.38218 .	ESTs	9.6
	302830	A1038997	Hs.132921		5
	302857	AF282265	Hs.44836	inner centromere protein antigens (135kD	3.4

	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
	302970	W05608	Hs.312679	ESTs. Weakly similar to A49019 dynein he	5.1
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
		AL121460			4.1
5			DS.272073	hypothetical protein FLJ20508	
5		AW006352		ESTs, Weakly similar to T32554 hypotheti	4.2
		AA355607		ESTs, Weakly similar to putative WHSC1 p	4.3
	303563	AA367699	Hs.10082	potassium intermediate/small conductance	3.3
	303642	AW299459		gb:xs50d08.x1 NCI_CGAP_Kid11 Homo sapien	4.2
	303780	Al424014	Hs.18995	KIAA1304 protein	3.6
10		AW629759		gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens	4.9
10		R53434	Hs.90207	hypothetical protein MGC11138	3.7
				• • • • • • • • • • • • • • • • • • • •	
		AA149951	Hs.62112	zinc finger protein 207	3
		AA582081		gb:nn32h08.s1 NCl_CGAP_Gas1 Homo sapiens	4.1
	305913	AA876109		gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens	3
15	305917	AA876469		gb:oe48b04.s1 NCI_CGAP_Pr25 Homo sapiens	3.1
		Al140014		gb:qa68f09.x1 Soares_fetal_heart_NbHH19W	3.5
		Al144243		gb:qb85b12.x1 Soares_fetal_heart_NbHH19W	3.9
					4.3
		Al476803	11- 470000	gb:tj77e12.x1 Soares_NSF_F8_9W_OT_PA_P_S	
20		Al581398		collagen, type I, alpha 1	4.6
20	308615	AK000142		hypothetical protein FLJ23045	4.4
	309177	Al951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	17.3
	309328	AW024348	Hs.233191	EST, Weakly similar to A27217 glucose tr	3.2
		AW168083		gb:xg59g04.x1 NCI_CGAP_Ut4 Homo sapiens	3.1
		AW170035	He 226726	Homo sapiens breast cancer antigen NY-BR	57,6
25					
23		Al199712		ESTs, Weakly similar to 1917210A Pro/Arg	4.6
		Al685841	Hs.161354		3.6
	310438	AW022192	Hs.200197	ESTs	4.6
	310683	Al939456	Hs.160870	ESTs	3.2
	310727	AK000703	Hs.323822	Homo sapiens mRNA for KIAA1551 protein,	3.6
30		Al380797	Hs.158992		10.2
50		Al955121		N-acetylgalactosamine-4-O-sulfotransfera	3.4
		AI476732	Hs.263912		10.9
		Al671439		Homo sapiens mRNA for KIAA1657 protein,	3.1
	311166	AI821005	Hs.118599		10.8
35	311237	AA641098	Hs.208809	ESTs, Moderately similar to ALU1_HUMAN A	4.3
		Al758660	Hs.206132		4.4
		Al828254		ESTs, Weakly similar to A47582 B-cell gr	5.1
		AW023595	Hs.232048		5.8
40		AA700870	Hs.14304	ESTs	3.3
40		A1056769	Hs.133512		3.9
	311872	R12375	Hs.194600	ESTs	3.3
	311889	AA767342	Hs.122483	ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
	311913	Al358522	Hs.270188	ESTs	3
	311923		Hs.189679		5.6
45		AA216387	110.100010	gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
75			11- 400750		
		AA373630	Hs.188750	to the second se	3
		AA759263	Hs.14041	ESTs	3.4
	312067	T78968	Hs.14411	ESTs	3.5
	312090	T80177	Hs.118064	similar to rat nuclear ubiquitous casein	3.8
50	312147	Al633744		ESTs, Weakly similar to 138022 hypotheti	4.4
20		BE261944		hexokinase 1	5.2
	312168	T04044	Hs.198882		3.3
		T94344	Hs.326263		3.3
		AA700439	Hs.188490	ESTs	3.4
55	312199	AW438602	Hs.191179	ESTs	3.9
	312219	H73505	Hs.117874	ESTs	4
		AA315703		ESTs, Weakly similar to ALUB_HUMAN !!!!	4.9
		AA972712	Hs.269737		5.7
<b>C</b> O		AA516420		ESTs, Weakly similar to 138022 hypotheti	6.3
60		AW439195		ESTs, Weakly similar to S65657 alpha-1C-	4.9
	312826	AW291545	Hs.185018	ESTs	4.9
	312837	AW292286	Hs.255058	ESTs	4.4
		AA497043	Hs.115685		3.1
		AI422023	Hs.161338		4.3
65		N76497		proteolipid protein 1 (Pelizaeus-Merzbac	3.3
UJ	040000	14/U49/	Hs.1787		
		AF026944	Hs.293797		5.8
	313096	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	4.5

	313126	AA746503	Hs.283313	ESTs	10
	313166	Al801098	Hs.151500	ESTs	3.5
	313197	AW979008	Hs.222487	ESTs	3.3
		AW960454	Hs.222830		4.7
5		Al420611	Hs.127832		3.4
5					
		AW449211		GDNF family receptor alpha 1	12.4
		AW150945	Hs.144758		4.1
	313385	AI032087	Hs.269819	ESTs	3
	313393	Al674685	Hs.200141	ESTs	5.2
10	313417	AA741151	Hs.137323	ESTs	3.5
		W92070		gb:zh48g05.r1 Soares_fetal_liver_spleen_	3.7
		Al273419	Uc 1251/6	hypothetical protein FLJ13984	.3
			ПS. 133140		
		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	5.6
1.5		AI540978	Hs.301997	hypothetical protein FLJ13033	3.2
15	313915	C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
	313975	AW175896	Hs.65114	keratin 18	3
		A1535895	Hs.221024	ESTs	4.9
		AV657317		hypothetical protein MGC3077	3.9
		AA827082	Hs.291872		3.1
20					
20		AW129357	Hs.329700		8.3
		AA648744	Hs.269493		6.6
	314121	A1732083	Hs.187619	ESTs	6.2
	314129	AA228366	Hs.115122	ESTs	4
	314138	AA740616		gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	5.9
25	•	AA743396	Hs.189023		3.1
20		AL036450	Hs.103238		4
-					8
		Al280112		Homo sapiens cDNA FLJ13266 fis, clone OV	
		Al697901	Hs.192425		3.7
	314322	AA907153	Hs.190060		3.3
30	314394	AW961597	Hs.130816	ESTs, Moderately similar to I38022 hypot	4.2
	314401	Al660412	Hs.234557		3.3
		AA602917	Hs.156974		4.7
		AA833655		Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
					4
25		A1204418	Hs.190080		
35		AW007211	Hs.16131		3.4
	314547	AA399272	Hs.144341	ESTs	6.7
	314558	AI873274	Hs.190721	ESTs	27.4
	314627	AA425310	Hs.155766	ESTs, Weakly similar to A47582 B-cell gr	4.4
		AW979268		gb:EST391378 MAGE resequences, MAGP Homo	4.6
40		AW207206	Hs.136319		20.7
-10		AA457367	Hs.191638		3.6
		AW026761	Hs.134374		3.6
		BE350122		ESTs, Weakly similar to I78885 serine/th	4.9
	314864	AW971198	Hs.294068		4.3
45	314881	A1095087	Hs.152299	ESTs, Moderately similar to S65657 alpha	3.7
	314882	AA828032	Hs.189076		3.1
		AW972359	Hs.293334	FSTs	3
		AI538613		Transmembrane protease, serine 3	10.9
		AA533447	Hs.312989		5.3
50					
50		AW292425	Hs.163484		12.9
		AA551104	Hs.189048	ESTs, Moderately similar to ALUC_HUMAN!	5.8
	315073	AW452948	Hs.257631	ESTs	4.2
	315080	AA744550	Hs.136345	ESTs	3.7
		A1025842	Hs.152530		6
55		AW136134	Hs.220277		3.9
55					
	315193	AI241331		ESTs, Moderately similar to I38937 DNA/R	4.4
	315196	Al367347	Hs.44898		8.2
		AI741506		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.6
		R38772	Hs.172619	myelin transcription factor 1-like	3.4
60		AW510994	Hs.220740		3.4
~ ~		Al222165	Hs.144923		4.9
		AA876905	Hs.125286		4
		AB037745		KIAA1324 protein	4.7
~ ==		AA218940		fidgetin-like 1	3.1
65		Al378817	Hs.191847	ESIS	3.1
		AA628539		ESTs, Moderately similar to ALU1_HUMAN A	3.2
	315526	AI193043		ESTs, Weakly similar to T17226 hypotheti	4.1
				**	

	315530	AW015415	Hs.127780	ESTs	8.9
		AA737415	Hs.152826		5.5
	315634	AA837085	Hs.220585	ESTs	6.3
~		AA648983	Hs.212911		3.6
5		Al418055	Hs.161160		5.1
		AW515373		Homo sapiens cDNA FLJ13580 fis, clone PL	3.1
		AW270550	Hs.116957		3.8
		AA737345 AA683336	Hs.294041 Hs.189046		5 3.1
10		AW865916	Hs.151206		4.7
10		AA830893	Hs.119769		4.1
		Al217477	Hs.194591		4.1
		AA764950	Hs.119898		7
		Al469960	Hs.170698		4.9
15	316052	A1962796	Hs.136754	ESTs	4.1
	316072	AW517524	Hs.135201	NOD2 protein	3.2
	316074	AW975114	Hs.293273		3.8
		AW203986	Hs.213003		3.2
20		AI187742	Hs.125562		3.7
20		A1904982	HS.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7 3.1
		Al433540 Al640761	Hs.224988	gb:ti69g05.x1 NCI_CGAP_Kid11 Homo sapien	3.5
		AA740994	Hs.209609		3.8
		AA741300		ESTs, Weakly similar to I38022 hypotheti	4.4
25		AA747807	Hs.149500		3.2
		AA938198		poly(A) polymerase gamma	9.4
		AW293174	Hs.252627		4.4
	316715	A1440266	Hs.170673	ESTs, Weakly similar to T24832 hypotheti	3
20		Al660898	Hs.195602		3.2
30		AI954880	Hs.134604		3.2
		AA836331	Hs.134981		4.4
		AA838114	Hs.221612		3.7 4.6
		AW014875 Al732892	Hs.137007 Hs.190489		5.9
35		AW445167	Hs.126036		4.1
55		Al125252	Hs.126419		3.5
		AI806867	Hs.126594		5.1
		AA972965	Hs.135568		6.9
	317501	AI822034	Hs.137097	ESTs	4.6
40		AW294909	Hs.132208		4.3
		AW664964	Hs.128899		6.1
		X56348		ret proto-oncogene (multiple endocrine n	3.1
		AI681545		hypothetical protein FLJ13117	3.4
45		A1827248	Hs.224398 Hs.211265	Homo sapiens cDNA FLJ11469 fis, clone HE	9.6 4.1
45		AW102941 Al565071	Hs.159983		10.3
		AW294522	Hs.149991		3.1
		Al077540	Hs.134090		3.9
		AW294013	Hs.200942		3
50		AI093930	Hs.163440	Homo sapiens cDNA: FLJ21000 fis, clone C	4.4
	318418	AF107493	Hs.118498	Homo sapiens LUCA-15 protein mRNA, splic	5.4
		AW402677		RNA binding motif protein, X chromosome	4.4
		AA526235		Homo sapiens cDNA FLJ11983 fis, clone HE	5.9
55		T49598	Hs.156832		4
55		NM_002543	Hs.77729	oxidised low density lipoprotein (lectin	7.3 17.8
		AI793124	Hs.144479 Hs.6818	ESTs	3
		F11802 NM_012391	Hs.79414	prostate epithelium-specific Ets transcr	3.6
		AI524124	Hs.270307		4.6
60		W88532	Hs.254562		3.3
		AA761668		gb:nz24c08.s1 NCI_CGAP_GCB1 Homo sapiens	3.2
		T79366	Hs.108258	actin binding protein; macrophin (microf	3.3
		AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
<i></i>		C19035	Hs.164259		3.3
65		AA534222	11- 070000	gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.3
		AA321166	Hs.278233		3.4
	320167	AA984373	Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	4.1

	320187	T99949	Hs.303428	Homo sapiens cDNA FLJ14832 fis, clone OV	5.3
		AL039402		DEME-6 protein	9.2
		Al026984	Hs.293662		3.1
5		U78082		RNA polymerase II transcriptional regula	3.1
3		N50617 . AI160015	Hs.80506 Hs.118112	small nuclear ribónucleoprotein polypept	6.1 3.5
		A160015 A1601188	Hs.120910	=	3.5
		AA214584	Hs.290167		3.7
		Al359144		Homo sapiens cDNA: FLJ23031 fis, clone L	3.1
10		BE144167	Hs.49994	hypothetical protein similar to RNA-bind	3.3
	321107	Al732643	Hs.144151		12.3
		AI769410	Hs.221461		3.3
		AA610649	Hs.333239		3
15		AB033041		vang (van gogh, Drosophila)-like 2	3.9
13		Al432199 AW975944	Hs.247084 Hs.237396		3 11.7
		AVV975544 Al471598	Hs.197531		3.8
		U29112	Hs.196151		4.4
		D80630		gb:HUM091D02B Human fetal brain (TFujiwa	3.2
20		R59890	Hs.83623	nuclear receptor subfamily 1, group I, m	3.1
	321910	H67065		ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
		AL049351		Homo sapiens mRNA; cDNA DKFZp566C093 (fr	3.5
		N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
25		AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19 3.6
25		AF075083 BE265745	He 10/350	gb:Homo sapiens full length insert cDNA ESTs, Weakly similar to ALUC_HUMAN !!!!	3
		W76326	113.134333	gb:zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
		Al357412	Hs.157601		11.5
		AW963372	Hs.46677	PRO2000 protein	3
30		T55958		gb:yb35f05.r1 Stratagene fetal spleen (9	3
		AF147347	11 050400	gb:Homo sapiens full length insert cDNA	4.2
		AF155108		Homo sapiens, Similar to RIKEN cDNA 2810	4
		W92147 AA017656	Hs.118394	gb:ze39h01.r1 Soares retina N2b4HR Homo	5.4 3.1
35		AW068805	Hs 288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
55		AW043782	Hs.293616		7.6
		AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
		C16391		gb:C16391 Clontech human aorta polyA mRN	16.5
40		AJ902456		ESTs, Weakly similar to 138022 hypotheti	4
40		AK002088		Homo sapiens cDNA FLJ11226 fis, clone PL.	3.3 6.3
		AL120862 AW675572	Hs.193620	programmed cell death 9 (PDCD9)	4.6
		AL133990	Hs.190642		10.5
		A1829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
45		AV651680	Hs.208558		4.3
		Al655499	Hs.161712		9.2
		AW445014	Hs.197746		3.1
		BE081058	Hs.243023		4 3
50		AA317962		ESTs, Moderately similar to PC4259 ferri	3.2
50		AW961560 AA410943	Hs.97600	ESTs BMP-R1B	8.4
		AL043683	Hs.8173	hypothetical protein FLJ10803	3,3
		AI825204	Hs.211408		4.5
		AL044949	Hs.116298		4.5
55		AI472078	Hs.303662		8.4
		BE069341	11 4000=4	gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
		AA431159	Hs.122954		3
	324296	Al524039 AA642007	Hs.192524 Hs.116369		3 3.3
60		AA464510	Hs.152812		3.3 16.5
00		Al823969	Hs.132678		3.3
	324598	AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	5
	324603	AW993522	Hs.292934		10.4
	324631	AA937116		ESTs, Weakly similar to I54374 gene NF2	3.3
65	324716	BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.2
	324748	AW974941		ESTs, Weakly similar to 178885 serine/th	3
	324771	AA631739	Hs.335440	201	3

	324774	AI031771	Hs.132586	ESTs	4.2	
	324823	AW516704	Hs.208726	ESTs	3.4	
	324824	Al826999	Hs.224624	ESTs	3.1	
_		AA704806	Hs.143842	ESTs, Weakly similar to 2004399A chromos	4.4	
5		AA613792		gb:no97h03.s1 NCI_CGAP_Pr2 Homo sapiens	3.9	
		Al375572	Hs.172634		18.8	
		AI805416	Hs.213897		3.3	
		Al064690	Hs.171176		4.2	
10	325372			Phase 2 & 3 Exons	4.4	
10	325544			Phase 2 & 3 Exons Phase 2 & 3 Exons	5.7 3.8	
	327075 332798			C22000007;gil12314195lemblCAB99338.1I (A	4.3	
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2	
	334447		~	NM 012429*:Homo sapiens SEC14 (S. cerevi	3.9	
15	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	
13	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL	20	
	338255			NM_014323*:Homo sapiens zinc finger prot	9	
		R21945	Hs 166975	splicing factor, arginine/serine-rich 5	4	
		AW812795		ESTs, Moderately similar to I38022 hypot	4.6	
20		R97268	Hs.177269		3.2	
		AA731602	Hs.120266		3.9	
		BE382657		signal transducer and activator of trans	4.1	
		AW836724		Homo sapiens mRNA expressed only in plac	3.7	
		M97935		AFFX control: STAT1	3.2	
25		M97935		AFFX control: STAT1	3	
		M55150		fumarylacetoacetate	3	
		M13755		interferon stimulated protein; 15 kDa	4.5	
		A1052047		ESTs	6.7	
		AA252033		ESTs; Weakly similar to !!!! ALU SUBFAMILY J	3.2	
30		AA401739		ESTs	3.3	
		H18459		hepatocellular carcinoma associated protein;	3	
		R48744		ESTs	4.2	
		M31682		inhibin; beta B (activin AB beta polypeptide)	3	
~ =		AA416873		ESTs	3	
35		D80240		HUM5G11A Human fetal brain (TFujiwara) Homo	4	
		R49590		ESTs	3.2	
				CH22_FGENES.678_5	16.8	
				CH22_FGENES.619_7	12.9	
40				CH22_FGENES.619_12	11.3	
40				CH22_EM:AC005500.GENSCAN.127 9	9.2	
				CH22_EM:AC005500.GENSCAN.304 2	8.5	
				CH22_FGENES.271_8	8.4 8	
				CH22_FGENES.619_13	7.3	
45				CH22_FGENES.271_7 CH22_FGENES.617_7	7.2	
73				CH.07_hs gi 6004473	7.1	
		1		CH22_FGENES.264_1	6.8	
		X03363		HER2 receptor tyrosine kinase (c erbB 2; ERBB2; n		
		7,00000		CH22_FGENES.617_9	6.5	
50				CH.07_hs gi 5868264	5.8	
• •				CH.19_hs gi 5867439	5.7	
				CH22_FGENES.63	5.3	
				CH.17_hs gi 5867230	5.1	
				CH.20_hs gi[6552458	5.1	
55				CH22_EM:AC005500.GENSCAN.148 22	4.7	
				CH22_FGENES.669_10	4.6	
		AA034918		KIAA1028 protein	4.6	
				CH22_FGENES.48_12	4.5	
				CH22_FGENES.118_2	4.5	
60		AF049569		ESTs	4.4	
		M13955		multiple UniGene matches	4.3	
				CH22_FGENES.619_8	4.3	
		110440011=::	000	CH22_FGENES.13 7	4.3	4.0
65		HG4126 HT43	396	O1100 FOENES 260 2	Zinc Finger Protein Hzf4	4.3
65				CH22_FGENES.360_3	4.3	
				CH22_FGENES.706_9	4.3 4.2	
				CH.21_hs gi 6531965	7.2	

CH22_FGENES.669_8  HG2614 HT2710  CH22_FGENES.48_18  matrix metalloproteinase 14 (membrane inserted) CH22_FGENES.271_6 CH22_FGENES.271_6 CH22_FGENES.271_6 CH22_FGENES.290_8  HG4716 HT5158  CH22_FGENES.13 5 CH22_FGENES.13 2 CH.14_hs gij6682474 CH.02_hs gij5867750 CH22_FGENES.617_8  AA714311  EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.49 9  CH22_EM:AC005500.GENSCAN.421 5  3.4  CH22_FGENES.313 4  CH22_FGENES.313 4  CH22_FGENES.313 4  CH22_FGENES.313 4  CH22_FGENES.360_1  HG2465 HT4871
5       X83535       matrix metalloproteinase 14 (membrane inserted)       4         CH22_FGENES.271_6       3.9         CH22_FGENES.617_3       3.9         CH22_FGENES.290_8       3.8         Guanosine 5' Monophosphate Synthase       3.8         CH22_FGENES.13 5       3.8         CH22_FGENES.13 2       3.8         CH.14_hs gil6682474       3.8         CH.02_hs gil5867750       3.8         CH22_FGENES.617_8       3.7         CH22_FGENES.617_8       0ncogene Ret/Ptc2, Fusion Activated       3.7         CH22_FGENES.543_20       3.7         CH22_FGENES.643_20       3.7         CH22_FGENES.619_4       3.5         CH22_FGENES.619_4       3.5         CH.16_hs gil5867087       3.5         AA714311       EST cluster (not in UniGene)       3.4         CH22_EM:AC005500.GENSCAN.149 9       3.4         CH22_EM:AC005500.GENSCAN.421 5       3.4         CH22_FGENES.13 4       3.3         CH22_FGENES.360_1       3.3
CH22_FGENES.271_6 CH22_FGENES.617_3 CH22_FGENES.290_8  HG4716 HT5158  CH22_FGENES.290_8  CH22_FGENES.290_8  CH22_FGENES.290_8  CH22_FGENES.33 5 CH22_FGENES.33 5 CH22_FGENES.33 2 CH.14_hs gij6682474 3.8 CH.20_hs gij6867750 3.8 CH22_FGENES.617_8  CH22_FGENES.204_2 3.5 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.6 CH22_FGENES.619_4 3.7 CH22
CH22_FGENES.617_3 CH22_FGENES.290_8 3.8  HG4716 HT5158  CH22_FGENES.290_8 3.8  CH22_FGENES.13 5 CH22_FGENES.13 2 3.8  CH.14_hs gi 6682474 CH.02_hs gi 5867750 CH22_FGENES.617_8  CH22_FGENES.617_8  CH22_DJ32!10.GENSCAN.23 39 CH22_FGENES.543_20 CH22_FGENES.543_20 CH22_FGENES.204_2 CH22_FGENES.204_2 3.5  CH22_FGENES.619_4 CH22_FGENES.619_4 CH.16_hs gi 5867087 3.5  AA714311  EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_FGENES.13 4 3.3 CH22_FGENES.13 4 3.3 CH22_FGENES.300_1 3.3 CH22_FGENES.360_1
CH22_FGENES.290_8  10  CH22_FGENES.13 5 CH22_FGENES.13 5 CH22_FGENES.13 2 CH.14_lns gij6682474 CH.02_lns gij5867750 CH22_FGENES.617_8 CH22_FGENES.617_8  15  HG4677 HT5102  CH22_DJ32!10.GENSCAN.23 39 CH22_FGENES.543_20 CH22_FGENES.543_20 CH22_FGENES.204_2 3.5 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.304_3 CH22_FGENES.306_1 3.3 CH22_FGENES.306_1
10
CH22_FGENES.13 5 CH22_FGENES.13 5 CH22_FGENES.13 2 CH.14_hs gi 6682474 CH.02_hs gi 5867750 3.8 CH22_FGENES.617_8 CH22_FGENES.617_8  Oncogene Ret/Ptc2, Fusion Activated 3.7  CH22_DJ32I10.GENSCAN.23 39 CH22_FGENES.543_20 CH22_FGENES.543_20 CH22_FGENES.204_2 CH22_FGENES.204_2 3.5 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs gi 5867087 3.5 AA714311 EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1
CH22_FGENES.13 2 CH.14_hs gi 6682474 3.8 CH.02_hs gi 5867750 3.8 CH22_FGENES.617_8 3.7 CH22_DJ32110.GENSCAN.23 39 CH22_FGENES.543_20 CH22_FGENES.543_20 CH22_FGENES.204_2 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 CH.16_hs gi 5867087 3.5 AA714311 EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.421 5 CH22_EM:AC005500.GENSCAN.421 5 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3
CH.14_hs gi 6682474 CH.02_hs gi 5867750 CH22_FGENES.617_8 3.7  CH22_FGENES.617_8 CH22_DJ32 10.GENSCAN.23 39 CH22_FGENES.543_20 CH22_EM:AC005500.GENSCAN.96 1 CH22_FGENES.204_2 CH22_FGENES.619_4 CH.16_hs gi 5867087 AA714311 EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.421 5 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3
CH.02_hs gij5867750 CH22_FGENES.617_8 3.7 CH22_FGENES.617_8  CH22_DJ32l10.GENSCAN.23 39 CH22_FGENES.543_20 CH22_EM:AC005500.GENSCAN.96 1 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 CH.16_hs gij5867087 AA714311 EST cluster (not in UniGene) CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.149 9 CH22_EM:AC005500.GENSCAN.421 5 CH22_FGENES.13 4 CH22_FGENES.13 4 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1
15 HG4677 HT5102 CH22_DJ32I10.GENSCAN.23 39 3.7 CH22_FGENES.543_20 3.7 CH22_FGENES.543_20 3.7 CH22_FGENES.204_2 3.5 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs giJ5867087 3.5 AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC0005500.GENSCAN.149 9 3.4 CH22_EM:AC0005500.GENSCAN.149 9 3.4 CH22_FGENES.13 4 3.3 CH22_FGENES.13 4 3.3 CH22_FGENES.13 4 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1
CH22_DJ32I10.GENSCAN.23 39 3.7 CH22_FGENES.543_20 3.7 CH22_EM:AC005500.GENSCAN.96 1 3.7 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs giJ5867087 3.5 AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 CH22_FGENES.13 4 3.3 CH.07_hs giJ6004478 3.3 CH22_FGENES.360_1 3.3
CH22_FGENES.543_20 3.7 CH22_EM:AC005500.GENSCAN.96 1 3.7 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs gi 5867087 3.5 AA714311 EST cluster (not in Unidene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 CH22_FGENES.13 4 3.3 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
CH22_EM:AC005500.GENSCAN.96 1 3.7 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs gi 5867087 3.5 AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
20 CH22_FGENES.204_2 3.5 CH22_FGENES.619_4 3.5 CH.16_hs gi 5867087 3.5 AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
20 CH22_FGENES.619_4 3.5 CH.16_hs giJ5867087 3.5 AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 CH22_FGENES.13 4 3.3 CH.07_hs giJ6004478 3.3 CH22_FGENES.360_1 3.3 CH22_FGENES.360_1 3.3
CH.16_hs gi 5867087 3.5  AA714311 EST cluster (not in UniGene) 3.4  CH22_EM:AC005500.GENSCAN.149 9 3.4  CH22_EM:AC005500.GENSCAN.421 5 3.4  CH22_FGENES.13 4 3.3  CH.07_hs gi 6004478 3.3  CH22_FGENES.360_1 3.3
AA714311 EST cluster (not in UniGene) 3.4 CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 25 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
CH22_EM:AC005500.GENSCAN.149 9 3.4 CH22_EM:AC005500.GENSCAN.421 5 3.4 25 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
25 CH22_FGENES.13 4 3.3 CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
CH.07_hs gi 6004478 3.3 CH22_FGENES.360_1 3.3
CH22_FGENES.360_1 3.3
HG2465 H148/1 Disa Binding Protein An Z Ali, Schice 5 5 5
11021001111011
CH22_FGENES.6_2 3.3 30 CH22_C20H12.GENSCAN.16 2 3.2
CH22_C65E1.GENSCAN.8 1 3.2
AA707750 ESTs; Weakly similar to cis Golgi matrix 3.1
CH22_FGENES.307_4 3.1
CH22_EM:AC005500.GENSCAN.248 14 3.1
35 CH.06_hs gi 5902482 3.1
CH22_FGENES.669_5 3.1
CH22_DJ32I10.GENSCAN.19 8 3.1
CH22_FGENES.527_6 3.1 CH22_FGENES.330_10 3.1
CH22_FGENES.330_10 3.1 40 CH22_FGENES.14 2 3.1
***
CONTROL CONTRO
CH22_EGENES.226.7 3
CH22_FGENES.226 7 3 CH22_FGENES.13 3 3
AA976074 ESTs 3 CH22_FGENES.226 7 3 CH22_FGENES.13 3 CH22_EM:AC005500.GENSCAN.209 12 3 CH22_FGENES.271_3 3

#### **TABLE 17A**

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

#### Pkey CAT number Accession

```
116845 393481_1
                            AA649530 AA659316 H64973
20
        103207 30635_-4
                            X72790
                            N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
        126257
               182217. 1
                            AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 Al636743 AW614951 BE467547 Al680833
        102791 37186_1
                            AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574
                            N25695 AW665466 Al818326 AA126128 Al480345 AW013827 AA248638 Al214968 AA204735 AA207155 AA206262 AA204833
25
                            AW003247 AW496808 Al080480 Al631703 Al651023 Al867418 AW818140 AA502500 Al206199 Al671282 Al352545 BE501030
                            Al652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048
                            AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 Al624817 BE466611 Al206344 AA574397
                            AA348354 Al493192
                            AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
        126872 142696_1
30
                            BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
        112631 1746257_1
                            R82040 R70934
        120742 176835_1
                            AA225084 AA302713
        106864 324239_1
                            Al311928 AA936030 T51931 AA609816 AA487195 AA664207
        109700 genbank_F09609
                                      F09609
35
        111532 genbank_R08440
                                      R08440
        113938 genbank_W81598
                                      W81598
               genbank_W84768
                                      W84768
        113947
               genbank_N22401
        124357
                                      N22401
                            AA121022 AA126422
        108733 504187_1
40
        112303 genbank_R54797
                                      R54797
                            AF075083 H52291 H52528
        322136 46802 1
                            W76326 AF086341 W72300
        322296 47334_1
        321811 1527481_1
                            D80630 D80896 D80895
                            AW979268 AA878419 AA431342 AA431628
        314648 293660_1
45
        322520 38916 1
                            T55958 T57205 AF147346
                            AF147347 T55426 T55503
        322521
               38917 1
                            AA017656 AA017374 AA019761
        322675 86787_1
                            Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
        323332 179142_1
        316186 425440_1
                            Al433540 AA728984 AA804981
50
        322975 1510563_1
                            C16391 C16413
                            BE069341 AW748403 AL044891 Al908240 AA393080
        324261 273265_1
        323817 233566_1
                            AA410943 AW948953 AA334202 AA332882
        301976 128835 1
                            T97905 AA101672
                            AA613792 AW182329 T05304 AW858385
        324961 376239_1
55
        303642 284260_1
                            AW299459 AA417112
                            AW629759 AW749955 AA633408 Al651005
               386364_1
        303797
        319551 357371 1
                            AA761668 AA573621 R92814 R09670
                            AA216387 T63548 AA228676
        311935 174129_1
                            AA071267 T65940 T64515 AA071334
        319834
               112523_1
60
        319977 345248_1
                            AA534222 AA632632 T81234
        314138 179960_1
                            AA740616 AA654854 AA229923
```

AA046309 AI263500 AA046397

313591 103087\_1

308106 Al476803
338255 CH22\_6856FG\_\_LINK\_EM:AC00
335809 CH22\_3181FG\_617\_6\_LINK\_EM
335824 CH22\_3197FG\_619\_11\_LINK\_E

5 307010 Al140014
307041 Al144243
305913 AA876109
305917 AA876469
309574 AW168083

10 325372 c12\_hs
325544 c12\_hs
332798 CH22\_14FG\_6\_5\_LINK\_C4G1.G
334223 CH22\_1507FG\_360\_4\_LINK\_EM
327075 c21\_hs
327075 c21\_hs
334447 CH22\_1746FG\_387\_7\_LINK\_EM
304782 AA582081
313434 441798\_1 W92070 AW019952 W92053

### **TABLE 17B**

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

	Pkev:	Unique number corresponding to an Eos probeset
10	Ref:	Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
		entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.

15				
13	Pkey	Ref	Strand	Nt_position
	334447	Dunham, I. et.al.	Plus	14308764-14308824
	335809	Dunham, I. et.al.	Plus	26310772-26310909
20	335824	Dunham, I. et.al.	Plus	26376860-26376942
	332798	Dunham, I. et.al.	Minus	232147-231974
	334223	Dunham, I. et.al.	Minus	12734365-12734269
	338255	Dunham, I. et.al.	Minus	15242294-15242231
	325372	5866920	Minus	1117061-1117304
25	325544	6682452	Plus	171228-171286
	327075	6531965	Plus	4041318-4041431

# TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is expressed in normal body tissues. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number

Pkey: ExAccn: UnigenelD: Unigene Title: R1: 10

Unigene gene title Ratio of tumor to normal body tissue

15	Pkey	ExAccn	UnigenelD	Unigene Title	R1
		BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9 12
20		M81057 M97815	Hs.180884 Hs.183650	carboxypeptidase B1 (tissue) cellular retinoic acid-binding protein 2	6.5
20		X52509	Hs.161640	tyrosine aminotransferase	12.4
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
		AA035613	Hs.141883	ESTs	6.9
		AW963419		stanniocalcin 2	5.3
25		AA011449	Hs.271627	ESTs	6.1
		AB033064	Hs.334806	KIAA1238 protein	7.3
		Al791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	8.2
	112637	R82331	Hs.164599	ESTs	5.4
	113206	BE262470	Hs.241471	RNB6	6.2
30	113970	W27249	Hs.8109	hypothetical protein FLJ21080	6,9
		A1733881	Hs.72472	BMP-R1B	10.1
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
		AW449064		collagen, type III, alpha 1 (Ehlers-Danl	8.4
25	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35		AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	6.2
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2 5.8
		D89377 AW183618	Hs.89404	msh (Drosophila) homeo box homolog 2 solute carrier family 30 (zinc transport	9.9
		AA312082	Hs.105445	GDNF family receptor alpha 1	5.7
40		AB020711	Hs.278346	KIAA0904 protein	7.7
40		BE542706		CEGP1 protein	7.3
		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	5.4
		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (	
		AL117406	Hs.200102	ATP-binding cassette transporter MRP8	6.7
45		AJ224172	Hs.204096	lipophilin B (uteroglobin family member)	13.8
		Al951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	17.3
	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
		Al380797	Hs.158992	ESTs	10.2
	311166	Al821005	Hs.118599	ESTs	10.8
50		AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		BE261944	Hs.118625	hexokinase 1	5.2
			Hs.105445	GDNF family receptor alpha 1	12.4
		C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
55		AA648744	Hs.269493	ESTS	6.6
33		AA740616 AA833655	Hs.206868	gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
		Al873274	Hs.190721	ESTs	27.4
			Hs.136319	ESTs	20.7
		AI538613	Hs.298241	Transmembrane protease, serine 3	10.9
60			Hs.312989	ESTs	5.3
50			Hs.163484	ESTs	12.9
			Hs.189048	ESTs, Moderately similar to ALUC_HUMAN !	5.8
	3				

	315196	AI367347	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA sequ	18.2
	315530	AW015415	Hs.127780	ESTs	8.9
	315634	AA837085	Hs.220585	ESTs	6.3
	316012	AA764950	Hs.119898	ESTs	7
5	316177	A1904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7
	316580	AA938198	Hs.146123	poly(A) polymerase gamma	9.4
	317803	AW664964	Hs.128899	ESTs	6.1
	317881	A1827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	9.6
	318740	NM_002543	3Hs.77729	oxidised low density lipoprotein (lectin	7.3
10		A1793124	Hs.144479	ESTs	17.8
	320211	AL039402	Hs.125783	DEME-6 protein	9.2
	321107	AI732643	Hs.144151	ESTs	12.3
	321644	AW975944	Hs.237396	ESTs	11.7
	321978	N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
15	322035	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19
	322766	AW068805	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
		AW043782		ESTs	7.6
		C16391		gb:C16391 Clontech human aorta polyA mRN	16.5
	323262	AL133990	Hs.190642	ESTs	10.5
20	323332	AI829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
	323817	AA410943		BMP-R1B	8.4
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49,4
	324432	AA464510	Hs.152812	ESTs	16.5
	324598	AW972227	Hs.163986	Homo sapiens cDNA: FLJ22765 fis, clone K	5
25	324603	AW993522	Hs.292934	ESTs	10.4
	324987	AI375572	Hs.172634	ESTs	18.8
	325544			Phase 2 & 3 Exons	5.7
	330388		Hs.46	HER2 receptor tyrosine kinase (c-erb-b2,	6.6
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2
30	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL	20
		AI052047		ESTs; Weakly similar to CYTOCHROME P450	6.7
		R72427			5.5
				CH22_FGENES.619_13	9.2
35					8
					6.5
					7.3
					12.9
					8.4
40					11.3
		•			8.5
					7.1
					7.2
					16.8

#### TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Gene cluster number Accession: Genbank accession numbers

15

	Pkey	CAT number	Accession
20	322975 324261 323817 311935	179142_1 1510563_1 273265_1 233566_1 174129_1	Al829520 Al791832 AA228414 Al791823 AA229211 AA229315 C16391 C16413 BE069341 AW748403 AL044891 Al908240 AA393080 AA410943 AW948953 AA334202 AA332882 AA216387 T63548 AA228676
25	335809 335824 325544	179960_1 CH22_3181FG_6 CH22_3197FG_6 c12_hs CH22_1507FG_3	19_11_LINK_E

# **TABLE 18B**

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic 5 sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 15	Pkey: Ref: Strand: Nt_posit	Sequen er Indicate	ce source. The C s DNA stran	per corresponding to an Eos probeset urce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.  A strand from which exons were predicted. eleotide positions of predicted exons.				
	Pkey	Ref	Strand	Nt_position				
20	335824 334223	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. 6682452	Plus	26310772-26310909 26376860-26376942 12734365-12734269 171228-171286				

# TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90<sup>th</sup> percentile value. The "average" normal adult tissue level was set to the 90<sup>th</sup> percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15<sup>th</sup> percentile value amongst the 144 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

1 =		
15	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

R1: Ratio of tumor to normal body tissue

20					
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	408591	AF015224	Hs.46452	mammaglobin 1	137.6
25	406964	M21305		gb:Human alpha satellite and satellite 3	71.0
	400291	AA401369	Hs.190721	ESTs	68.4
	407277	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	54.2
	449746	Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	46.4
	426878	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	
30	400292	AA250737	Hs.72472	BMP-R1B	37.4
	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	32.9
	408045	AW138959	Hs.245123		31.9
	407178	AA195651	Hs.104106		30.4
~ ~		C16391		gb:C16391 Clontech human aorta polyA mRN	27.7
35		U90304	Hs.25351	iroquois homeobox protein 5	24.8
		AA412108	Hs.269350	- · · ·	22.0
		NM_000230	Hs.194236	,,	21.9
	404561			trichorhinophalangeal syndrome I (TRPS1)	21.8
40		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
40		A1375572	Hs.172634		17.3
		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	16.6
		S73265	Hs.1473	gastrin-releasing peptide	16.5
		AW840171	Hs.265398		16.0
4.5		Al263307	Hs.239884	H2B histone family, member L	15.8
45		X51501	Hs.99949	prolactin-induced protein	15.8
		Al267700	Hs.317584		15.5
		AL120862		programmed cell death 9 (PDCD9)	14.8
		Al905687	Hs.2533	aldehyde dehydrogenase 9 family, member	14.5
50		C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	13.7
50		AJ224172	Hs.204096	lipophilin B (uteroglobin family member)	13.6
		AL133990	Hs.190642		13.5
		AB014544	Hs.21572	KIAA0644 gene product	13.0
		AA399272	Hs.144341		12.8
<i>E E</i>	402578			C1001134:gi 2117372 pir  165981 fatty ac	12.6
55		AA436989		H2A histone family, member A	12.2
		NM_003613	HS.15140/	cartilage intermediate layer protein, nu	12.0
		AA193450	11- 400007	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	11.9
		Al351010	Hs.102267	lysyl oxidase	11.9
	459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	11.5

		AW291168	Hs.41295	ESTs, Weakly similar to MUC2_HUMAN MUCIN	11.5
	429170	NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
	407276	Al951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	11.4
_	434377	AW137148	Hs.306593	Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
5	448390	AL035414	Hs.21068	hypothetical protein	11.1
	452401	NM_007115	Hs.29352	tumor necrosis factor, alpha-induced pro	11.0
	421037	A1684808	Hs.197653	programmed cell death 9 (PDCD9)	10.9
	452461	N78223	Hs.108106	transcription factor	10.7
	443348	AW873596	Hs.182278		10.6
10	421155	H87879	Hs.102267		10.5
	402606			NM_024626:Homo sapiens hypothetical prot	10.4
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.3
		Al357412	Hs.157601		10.2
15		W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1
10		NM_002497		NIMA (never in mitosis gene a)-related k	10.1
		AW292425	Hs.163484		9.9
		AI873274	Hs.190721		9.9
		H23789	Hs.144530		9.8
20		BE218705		metallothionein-like 5, testis-specific	9.7
20		D90041		N-acetyltransferase 1 (arylamine N-acety	9.7
		W20027	Hs.23439	ESTs	9.6
		AL360204		Homo sapiens mRNA full length insert cDN	9.6
		AI624342	Hs.170042		9.5
25			HS. 170042		9.3
25		A1907673	LI= 20E04	gb:lL-BT152-080399-004 BT152 Homo sapien Homo sapiens mRNA; cDNA DKFZp434E082 (fr	
		Al267652 AJ224741	Hs.30504		9.1
		AJ224741 AI127076	Hs.278461		9.1
			Hs.334473 Hs.57471	hypothetical protein DKFZp564O1278 ESTs	9.1
30		D60730	H5.5/4/1	gb;zt32h03.r1 Soares ovary tumor NbHOT H	9.1
50		AA410943		Target Exon	9.0
	406348	1124075	Ha 272400	short-chain alcohol dehydrogenase family	
		U31875			9.0 9.0
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	
35		AF026944	Hs.293797		8.8
33	405654		11- 00000	C12001521:gi 7513934 pir  T31081 cca3 pr	8.8
		AA279490	Hs.86368	calmegin	8.8
		A1955040		ESTs, Weakly similar to transformation-r	8.7
		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.5
40		AB033025	Hs.50081	KIAA1199 protein	8.4
40		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	8.3
		N52812	Hs.177403		8.2
		W67883		paternally expressed 10	8.2
		NM_007050		protein tyrosine phosphatase, receptor t	8.1
45		AL080207	HS. 134363	DKFZP434G232 protein	8.1
43	405095		11- 400705	Target Exon	8.1
		AA236115	Hs.120785		8.0
		AF026941	Hs.17518	Homo sapiens cig5 mRNA, partial sequence	0.8
		BE242870	Hs.75379	solute carrier family 1 (glial high affi	0.8
50		AW876523	Hs.15929	hypothetical protein FLJ12910	8.0
50		R17798	Hs.7535	COBW-like protein	7.9
		AI811202		Homo sapiens cDNA: FLJ23523 fis, clone L	7.9
		AF044197	HS.100431	small inducible cytokine B subfamily (Cy	7.9
		M31126	HS.272620	matrix metalloproteinase 11 (MMP11; stro	7.8
55	400285		11- 45000	Eos Control	7.7
33		T27503	Hs.15929	hypothetical protein FLJ12910	7.6
		AW880562	Hs.114574		7.5
		AW976987		ESTs, Weakly similar to 2109260A B cell	7.5
		H69125	Hs.133525		7.5
60		Al222020		CocoaCrisp	7.4
60		H59846		ESTs, Moderately similar to ALU7_HUMAN A	7.4
		Al380797	Hs.158992		7.3
		AA948033	Hs.130853		7.2
		AW602166	HS.ZZZ399	CEGP1 protein	7.2
65		AW368397	MS.150042	Homo sapiens cDNA FLJ14438 fis, clone HE	7.1
65		AW242243		peroxisomal farnesylated protein	7.0
		AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	6.9
	445885	AI734009	HS.12/699	KIAA1603 protein	6.9

	429432	AI678059	Hs.202676	synaptonemal complex protein 2	6.9
		Al375672	Hs.165028		6.9
	443788	Al732643	Hs.144151	ESTs	6.9
_	421373	AA808229	Hs.167771	ESTs	6.8
5	451398	Al793124	Hs.144479		6.8
	404253			<del>-</del>	6.8
		Al015591			6.7
		AW963419			6.6
10		AA321649	Hs.2248		6.6
10		BE545072	HS.122579		6.6
		AW818127 Al418055	Hs.161160	gb:CM1-ST0277-061299-059-b07 ST0277 Homo	6.6
		Al733682	Hs.130239	· ·	6.6
		A1970394	Hs.197075		6.6
15	408000		Hs.620		6.5
13	420757		Hs.99915		6.5
		BE041395			6.5
	400301		Hs.1657		6.5
		AW023482	Hs.97849		6.5
20	425704			Human clone 23948 mRNA sequence	6.4
	441134	W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
	424902	NM_003866	Hs.153687	inositol polyphosphate-4-phosphatase, ty	6.4
	448693	AW004854	Hs.228320	hypothetical protein FLJ23537	6.4
~ ~		AL137517		, , , , , , , , , , , , , , , , , , , ,	6.2
25		NM_014398	Hs.10887		6.1
		AA586894			6.1
		A1240665	Hs.8895		6.1
		M13509	Hs.83169		6.0
30	418092	AA972965	Hs.135568 Hs.106604		6.0 6.0
50		AA464510	Hs.152812		5.9
		AA310693			5.9
		AW975944	Hs.237396	•	5.9
	450701				5.9
35		AF115402	Hs.11713		5.9
		AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Homo	5.9
	425398	AL049689	Hs.156369		5.9
	414812		Hs.77367	monokine induced by gamma interferon	5.8
4.0	459371			0 10	5.8
40	411284				5.8
		AL031224	Hs.33102		5.8
		W52854	Hs.27099		5.7
		AW162916			5.7
45		A1733881	Hs.72472		5.6 5.6
45		AW016531 AW067903	Hs.122147 Hs.82772		5.5
		AA463893	Hs.220933		5.5
	439809				5.5
		AW299598	Hs.50895		5.4
50		AW748078		ESTs, Weakly similar to MUC2_HUMAN MUCIN	
-		Al742605	Hs.193696		5.4
	453931	AL121278	Hs.25144	ESTs	5.4
	444078	BE246919	Hs.10290	U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
	447102	BE167434	Hs.98471		5.4
55		Al879148	Hs.26770		5.4
		AW067800			5.3
		AA291553	Hs.190086		5.3
		AW970060	LI= 40000	gb:EST382140 MAGE resequences, MAGK Hom	
60		AA421081	Hs.12388	ESTs	5.3
00	452838		Hs.30743		5.3 5.3
		AB028945	Hs.12696 Hs.161640		5.3
	456938 422867		Hs.1584		5.2
	438167		Hs.24286	ESTs	5.2
65		AW207084			5.2
	449765		Hs.206832		5.2
	416276		Hs.79136	LIV-1 protein, estrogen regulated	5.2
				-	

	400300	X03363		HER2 receptor tyrosine kinase (c-erb-b2,	5.2
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
		AW449211		GDNF family receptor alpha 1	5.2
		AB028992		KIAA1069 protein	5.2
5		AW852530		gb:PM1-CT0243-071099-001-g06 CT0243 Homo	5.2
		AW851980	Hs.262346	ESTs, Weakly similar to S72482 hypotheti	5.2
		AI916269		ESTs, Weakly similar to ALU5_HUMAN ALU S	5.1
	400298	AA032279	Hs.61635		5.1
	431023	Al283133	Hs.297420		5.1
10	427666	Al791495	Hs.180142	calmodulin-like skin protein	5.1
	427718	A1798680	Hs.25933	ESTs	5.1
	434531	AA642007	Hs.116369	ESTs	5.1
	429220	AW207206	Hs.136319		5.1
	405494	NA		C2001837*:gi[12697903]dbj[BAB21770.1] (A	5.1
15		AW195285	Hs.194097	ESTs, Weakly similar to I38022 hypotheti	5.1
		Al201849		gb:qs76g04.x1 NCI_CGAP_Pr28 Homo sapiens	
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
		BE387335		ESTs, Weakly similar to S64054 hypotheti	5.0
20		R43646	Hs.12422	ESTs	5.0
20		W02414	Hs.38383	ESTs	5.0
		AW665281	Hs.224625		5.0
		AA236776	Hs.79078	MAD2 (mitotic arrest deficient, yeast, h	5.0
		AK000713		hypothetical protein FLJ20706	5.0 4.9
25		AW512260	Hs.87767	ESTs	4.9
43		X82125	Hs.25040	zinc finger protein 239	4.9
		AJ003029 M30703	Hs.65792	syntrophin, gamma 2 amphiregulin (schwannoma-derived growth	4.9
		Al655499	Hs.161712		4.8
		Al820662	Hs.129598		4.8
30		AF220050		uncharacterized hematopoletic stem/proge	4.8
50	400286		110.101000	C16000922:gi 7499103 pir  T20903 hypothe	4.8
		U71600		gb:Human zinc finger protein zfp31 (zf31	4.8
		Al831190	Hs.166676		4.8
		BE218239	Hs.202656		4.8
35		Al217477	Hs.194591	ESTs	4.8
	412785	AW997556	Hs.78521	KIAA1717 protein	4.8
	428368	BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	4.7
	436026	AI349764	Hs.217081	ESTs	4.7
4.0		AA191493	Hs.48778	niban protein	4.7
40	400284			estrogen receptor 1	4.7
		AW248508		Homo sapiens cDNA FLJ14035 fis, clone HE	4.7
		R42185	Hs.274803		4.7
		BE062109		chloride channel, calcium activated, fam	4.7 4.7
45		AW961489	Hs.154116		4.7
45		NM_003462 AF077345	Hs.33846 Hs.177936	dynein, axonemal, light intermediate pol	4.6
		AW813731		ESTs, Moderately similar to S65657 alpha	4.6
		R63503	Hs.28419	ESTs	4.6
	405718	1100000	110.20410	C4000799*:gij6330365 dbj BAA86508.1  (AB	4.6
50		AW207523	Hs.197628		4.6
•	429431	Z40313		Homo sapiens clone IMAGE:23371, mRNA seq	4.6
		M81057		carboxypeptidase B1 (tissue)	4.6
	447342	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	4.6
	430345	AK000282	Hs.239681	hypothetical protein FLJ20275	4.6
55	454307	AW855717		gb:RC1-CT0279-081299-013-b01 CT0279 Homo	
	400303	AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
		AA808189	Hs.272151	ESTs	4.6
		AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	
<b>CO</b>		AL036877	Hs.282878		4.6
60		AA514660	Hs.128443		4.6
		H15261	Hs.21948	ESTs	4.6
		AW246333	Hs.17901	Homo sapiens, clone IMAGE:3937015, mRNA,	4.6
		AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6)	4.5 4.5
65		AW966399	Hs.46821	hypothetical protein FLJ20086 Homo sapiens cDNA FLJ11346 fis, clone PL	4.5
05		W68815	L12'30 1002	gb:UI-HF-BN0-akx-e-02-0-UI.r1 NIH_MGC_50	4.5
		AW503329	He 247/02	annexin A2	4.5
	400/4/	AI925153	175.217493	CHITCANI AL	7.0

	112102	H56435		gb:yq98e09.r1 Soares fetal liver spleen	4.5
		D89053	He 268012	fatty-acid-Coenzyme A ligase, long-chain	4.5
		AW814902	113.200012	gb:MR1-ST0206-120400-022-f08 ST0206 Homo	
	401418			C14000338*:gi[7459502]pir] S74665 outer	4.5
5		AK001074	Hs 333435	Homo sapiens cDNA FLJ10212 fis, clone HE	4.5
-		AK001581		hypothetical protein FLJ10719; KIAA1794	4.4
		AA135257	Hs.47783		4.4
		AA335497		ESTs, Weakly similar to 138022 hypotheti	4.4
		AW419196		hypothetical protein FLJ13782	4.4
10		AW664964	Hs.128899		4.4
		BE463857	Hs.151258	hypothetical protein FLJ21062	4.4
		R31178		fibronectin 1	4.4
	410534	AW905138		gb:QV0-NN1071-280400-207-g07 NN1071 Homo	4.4
	405196	NA		C2000662*:gi 7512792 pir  T12482 hypothe	4.4
15	430217	N47863	Hs.336901	ribosomal protein S24	4.4
	401793			C17001545:gi 5360127 gb AAD42882.1 AF155	4.4
	415747	AA381209		gb:EST94257 Activated T-cells I Homo sap	4.4
		AB007975	Hs.131454	KIAA0506 protein	4.4
•	400238			C19000274*:gi 12741327 ref XP_008833.2	4.4
20		AF019612	Hs.297007	membrane-bound transcription factor prot	4.4
	400608			C10001899:gi[7508633 pir] T25392 hypothe	4.4
		AV657310	Hs.282898		4.3
		AL138272	Hs.62713	ESTs	4.3
25	405906			Target Exon	4.3
25	405925		U- 402070	Target Exon	4.3
		BE247684	Hs.103070		4.3 4.3
		H57646	Hs.42586	KIAA1560 protein zinc finger protein	4.3
		N63855 AA603305	115.142034	gb:np12d11.s1 NCI_CGAP_Pr3 Homo sapiens	4.3
30		N71277		gb:za36e03.s1 Soares fetal liver spleen	4.3
50		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	4.2
		Al266484	Hs.31570	ESTs, Weakly similar to KIAA1324 protein	4.2
		AA291377	Hs.50831	ESTs	4.2
		AA033714		hypothetical protein FLJ14260	4.2
35		NM_001898		cystatin SN	4.2
		BE158766		gb:IL2-HT0397-071299-024-F02 HT0397 Homo	4.2
		BE144884		gb:CM0-HT0182-041099-065-e11 HT0182 Homo	4.2
		BE538082	Hs.8172	ESTs, Moderately similar to A46010 X-lin	4.2
	408380	AF123050	Hs.44532	diubiquitin	4.2
40	406992	S82472		gb:beta -pol=DNA polymerase beta {exon a	4.2
	404285	NA		C6001909:gi 704441 dbj BAA18909.1  (D298	4.2
	425247	NM_005940		matrix metalloproteinase 11 (MMP11; stro	4.2
	428046	AW812795		ESTs, Moderately similar to I38022 hypot	4.2
4 6		AA026880	Hs.25252	prolactin receptor	4.2
45		AW592167	Hs.293299		4.2
		Al908165		GATA-binding protein 3 (T-cell receptor	4.2
		AW821113	Hs.72402	ESTs	4.2
		AA024538		Human DNA sequence from clone RP1-28H20	4.2
50		AW378065	Hs.8687	ESTS	4.2
30		AI085198	Hs.164226		4.2 4.1
		AB007948		KIAA0479 protein	4.1
	424687	AA894564	Hs.22242	matrix metalloproteinase 9 (gelatinase B ESTs	4.1
		AA634806	113.22242	gb:ab28c02.r1 Stratagene lung (937210) H	4.1
55		BE241831	Hs 172330	hypothetical protein MGC2705	4.1
55		R18717	Hs.8929	hypothetical protein FLJ11362	4.1
	455700	BE068115	110.0020	gb:CM1-BT0368-061299-060-g07 BT0368 Homo	
	431924	AK000850	Hs.272203	Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
		AI886558	Hs.184987		4.1
60	401451			NM_004496*:Homo sapiens hepatocyte nucle	4.1
		AI685464		gb:tt88f04.x1 NCI_CGAP_Pr28 Homo sapiens	4.1
		Al735283	Hs.172608		4.1
	429270	W60379	Hs.57773	ESTs	4.1
	443903	AI220547	Hs.135223		4.1
65	427122	AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	4.1
	410275	U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.1
	432912	BE007371	Hs.200313	E918	4.1

	403585			Target Exon	4.1
		Al394151	Hs.37932	ESTs	4.1
		AA640891	Hs.102406		4.1
~		BE264901		carbonic anhydrase VIII	4.1
5		NM_004354	Hs.79069	cyclin G2	4.1
		AA296520	Hs.89546	selectin E (endothelial adhesion molecul	4.1
	400555 410079	1104262	Hs.58589	Target Exon glycogenin 2	4.1 4.0
		NM_003528	Hs.2178	H2B histone family, member Q	4.0
10		AA448460		GE36 gene	4.0
		AL359055	Hs.67709	Homo sapiens mRNA full length insert cDN	4.0
		AL117406	Hs.200102	ATP-binding cassette transporter MRP8	4.0
		NM_002666	Hs.103253	· ·	4.0
1.5		AA228776	Hs.191721		4.0
15		AW954552 AW938484	MS.142034	zinc finger protein gb:CM0-DT0057-290200-253-d06 DT0057 Homo	4.0
	404142			Target Exon	4.0
		Al027604	Hs.159650		4.0
		Al693927	Hs.265165		4.0
20	415579	AA165232	Hs.222069	ESTs	4.0
	452891		Hs.212875	ESTs, Weakly similar to DYH9_HUMAN CILIA	4.0
		BE390440		gb:601283601F1 NIH_MGC_44 Homo sapiens c	
	452281		Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.0 4.0
25		AA417383 Al281848	Hs.82582	integrin, beta-like 1 (with EGF-like rep retinoic acid induced 3	4.0
	447377			transcription factor AP-2 alpha (activat	4.0
		AL119723		gb:DKFZp761A2124_r1 761 (synonym: hamy2)	4.0
		AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
20		AI591147	Hs.61232	ESTs	4.0
30	459574 458673	A1741122	MS.101810	Homo sapiens cDNA FLJ14232 fis, clone NT gb:za39d11.r1 Soares fetal liver spleen	4.0 4.0
		Al199738	Hs 208275	ESTs, Weakly similar to ALUA_HUMAN I!!!	4.0
		AI948607	Hs.264680		4.0
		AF153330	Hs.30246	solute carrier family 19 (thiamine trans	3.9
35	450192	AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554			Target Exon	3.9
		AA573006	Hs.19173	ESTs	3.9 3.9
	445813	AA442176	ms. 1000/6	alanine-glyoxylate aminotransferase 2-li gb:zw63b08.r1 Soares_total_fetus_Nb2HF8_	3.9
40		M86153	Hs.75618	RAB11A, member RAS oncogene family	3.9
	401781			Target Exon	3.9
	415296	F05086	Hs.328142	ESTs	3.9
		AA026777		gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
45		AI819068	Hs.209122		3.9 3.9
43	419759	Al472106	Hs.49303	actin related protein Homo sapiens cDNA FLJ11663 fis, clone HE	3.9
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.9
		AA419529	Hs.76391	myxovirus (influenza) resistance 1, homo	3.9
	452501	AB037791	Hs.29716	hypothetical protein FLJ10980	3.9
50		BE537217	Hs.30343	ESTs	3.9
		BE568414		Homo sapiens cDNA: FLJ22097 fis, clone H	3.9 3.9
		AI073512 BE152428	Hs.133916	gb:CM0-HT0323-151299-126-b04 HT0323 Homo	
	401785	DL 102420		NM 002275*:Homo sapiens keratin 15 (KRT1	3.9
55		M86699	Hs.169840	TTK protein kinase	3.9
		AI989885	Hs.231926	ESTS	3.9
	436033		Hs.255748		3.9
		BE172186	11- 00074	gb:MR0-HT0559-110300-005-h11 HT0559 Homo	
60		AA236645 AI184268	Hs.98274 Hs.339665	ESTs FSTe	3.8
00		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.8
	403593		5020	Target Exon	3.8
	442323	AW016669	Hs.29190	ESTs	3.8
<i>(</i> =		AW664873	Hs.87836	Homo sapiens PAC clone RP5-1087M19 from	3.8
65		W02410	Hs.205555		3.8
		AI217928 AA503020	Hs.144762 Hs.36563	hypothetical protein FLJ22418	3.8
	403042	MAGOODED	, 13.50505	in positional protein a cozzet to	٥.0

	443162		Hs.9029	DKFZP434G032 protein	3.8
	458194	AW383618	Hs.265459	ESTs, Moderately similar to ALU2_HUMAN A	3.8
	422475	AL359938	Hs.117313	Meis (mouse) homolog 3	3.8
		AA904244	Hs.153205		3.8
5		Al476732	Hs.263912		3.8
5		711470702	113.200312	Target Exon	3.8
	403426	A A 470450	11- 00000		
		AA470158	Hs.98202	ESTs	3.8
		BE222648		ESTs, Highly similar to c380A1.1b [H.sap	3.8
	443801	AW206942	Hs.253594	ESTs	3.8
10	410658	AW105231	Hs.192035	ESTs	3.8
		AW794600		gb:RC6-UM0014-170300-022-C05 UM0014 Hon	103.8
		NM_005756	He 184042	G protein-coupled receptor 64	3.8
		BE622641			3.8
				ESTs, Weakly similar to I38022 hypotheti	
1.5		Al742618	HS.181733	ESTs, Weakly similar to nitrilase homolo	3.7
15	401747			Homo sapiens keratin 17 (KRT17)	3.7
	420633	NM_014581	Hs.274480	odorant-binding protein 2A	3.7
	423545	AP000692	Hs.129781	chromosome 21 open reading frame 5	3.7
		AB029496	Hs.59729	semaphorin sem2	3.7
		BE005346	Hs.116410		3.7
20		AK001666		similar to SALL1 (sal (Drosophila)-like	3.7
20					3.7
		AA018534	Hs.103334		
	402696			C3002523:gi[6686211 sp Q27533 YH2M_CAEEI	
	446868	AV660737	Hs.135100	ESTs	3.7
	458154	AW816379	Hs.335018	ESTs .	3.7
25	422026	U80736	Hs.110826	trinucleotide repeat containing 9	3.7
		AB020689	Hs.90419		3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648	ESTs	3.7
			115.40040		3.7
20	401508			NM_024817:Homo sapiens hypothetical prot	
30		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7
	420362	U79734	Hs.97206	huntingtin interacting protein 1	3.7
	433384	AI021992	Hs.124244	ESTs	3.7
	434302	AA629065	Hs.116301	ESTs	3.7
		R55373	Hs.20864	ESTs	3.7
35		BE623004	110.20001	gb:601441282F1 NIH_MGC_72 Homo sapiens of	
55			Un 107070	hypothetical protein FLJ20761	3.7
		Al347502			
		T32982	Hs.102720		3.7
	405232			NM_015832:Homo sapiens methyl-CpG bindin	3.7
	430491	AL109791	Hs.241559	Homo sapiens mRNA full length insert cDN	3.7
40	455609	BE011668		gb:CM3-BN0223-100500-177-a04 BN0223 Hom	03.7
	450164	Al239923	Hs.30098	ESTs	3.7
		A1970797	Hs.64859	ESTs	3.7
		Al248584		Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
			113.130743		3.6
45	401049		11-00404	Target Exon	
43		D31771	Hs.89404	msh (Drosophila) homeo box homolog 2	3.6
		N74530	Hs.21168	ESTs	3.6
		AV658444	Hs.280776	tankyrase, TRF1-interacting ankyrin-rela	3.6
	437259	Al377755	Hs.120695		3.6
	428309	M97815	Hs.183650	cellular retinoic acid-binding protein 2	3.6
50	450522	Al698839		gb:wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	3.6
		AL120173	Hs.301663		3.6
		AW901456		gb:RC0-NN1012-270300-031-c07 NN1012 Home	13.6
				gb:EST60061 Activated T-cells XX Homo sa	3.6
		AA352111	11- 440070		
		Al142095	Hs.143273	ESIS	3.6
55		BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	
	414869	AA157291	Hs.21479	ubinuclein 1	3.6
	409064	AA062954	Hs.141883	ESTs	3.6
		Y12735	Hs.38018	dual-specificity tyrosine-(Y)-phosphoryl	3.6
		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091		110.12041	••	3.6
UU			U- 50445	Target Exon	
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6
	405153			Target Exon	3.6
		AA380177	Hs.125845	ribulose-5-phosphate-3-epimerase	3.6
	403639	NA		ENSP00000233023*:CDNA FLJ12662 fis, clon	3.6
65	404360			C7001385:gi 12082809 gb AAG48618.1 AF315	3.6
		AA766296	Hs.99200	ESTs	3.6
		AB007961		KIAA0492 protein	3.6
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				- /-

					• •
		BE350295	Hs.15032	RAN binding protein 17	3.6
		AA514986	Hs.283705		3.6
	439907	AA853978	Hs.124577	ESTs	3.6
_	453596	AA441838	Hs.62905	hypothetical protein FLJ14834	3.6
5	406446	NA		Target Exon	3.6
	418454	AA315308	Hs.195870	hypothetical protein FLJ14991	3.6
	434360	AW015415	Hs.127780		3.6
		W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.6
		Al697121		ESTs, Weakly similar to S65824 reverse t	3.6
10		AW291095	Hs.21814	interleukin 20 receptor, alpha	3.6
10					3.5
		AW297920	Hs.130054		
		AW860158		gb:RC0-CT0379-290100-032-b04 CT0379 Homo	
		AW968226	Hs.60798	ESTs	3.5
4 ~	402820			NM_017646*:Homo sapiens tRNA isopentenyl	3.5
15	417009	AA191719	Hs.314714	ESTs	3.5
	447048	AW393080	Hs.228320	hypothetical protein FLJ23537	3.5
	449978	Al806335	Hs.200829	ESTs, Weakly similar to T30171 ninein -	3.5
	428062	AA420683	Hs.98321	hypothetical protein FLJ14103	3.5
		NM_015368	Hs.30985	pannexin 1	3.5
20	400610	_		Target Exon	3.5
		W07361	Hs.22545	Homo sapiens cDNA FLJ12935 fis, clone NT	3.5
		AW960146		hypothetical protein FLJ12888	3.5
					3.5
		Al805416	Hs.213897		
25		NM_004272		Homer, neuronal immediate early gene, 1B	3.5
25		AW392342		centrosomal P4.1-associated protein; unc	3.5
		AW448937	Hs.197030		3.5
	423841	AW753967		gb:RC2-CT0304-080100-011-h12 CT0304 Homo	
	416806	NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.5
	422060	R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	3.5
30	433104	AL043002	Hs.128246	ESTs, Moderately similar to unnamed prot	3.5
	415778	H84847	Hs.49391	hypothetical protein LOC54149	3.5
	413054	AW316843	Hs.66309	hypothetical protein MGC11061	3.5
	416636	N32536	Hs.42645	solute carrier family 16 (monocarboxylic	3.5
		AI917494	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	3.5
35		A1057094	Hs.96867	Homo sapiens cDNA: FLJ23155 fis, clone L	3.5
		Al370876	Hs.79090	exportin 1 (CRM1, yeast, homolog)	3.5
		AW850178	113.73000		3.5
		AA314337	Un 2015/7		3.5
				ribosomal protein S7	
40		AA877124	Hs.172844		3.5
40	431291		Hs.25275	Kruppel-type zinc finger protein	3.5
		Al935016	Hs.216639		3.5
		BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	3.5
	458771	AW295151	Hs.163612	ESTs	3.5
	442942	AW167087	Hs.131562	ESTs	3.5
45	436550	Z50158	Hs.270235	ESTs, Weakly similar to MMHUB1 laminin b	3.5
	418849	AW474547	Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	3.5
·	424420	BE614743	Hs.146688	prostaglandin E synthase	3.5
		AW505021	Hs.88414	BTB and CNC homology 1, basic leucine zi	3.5
		Al908400	Hs.143789		3.5
50		AF086224	Hs.55238	ESTs	3.5
50			113.00200	C17000675:gij7290703 gb AAF46150.1  (AE0	3.5
	405917		He 470000		
		AW993582	Hs.176220		3.5
		W47595		transforming growth factor, beta 2	3.4
~ ~		AA283185	Hs.19327	ESTs	3.4
55		AW904466		PDZ domain protein (Drosophila inaD-like	3.4
		BE252383	Hs.184668	SBBI31 protein	3.4
		BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	3.4
	410555	U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.4
	447754	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	3.4
60		AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	3.4
	404097			C5000242*:gi[9369379]gb]AAF87128.1[AC006	3.4
		AF119861	Hs.283032	hypothetical protein PRO2015	3.4
		Al215069	Hs.89113	ESTs	3.4
	402421			C1001578*:gi[6759903]gb]AAF28099.1] (AF1	3.4
65	405248			Target Exon	3.4
<del>5</del> 5		AJ404672	He 334482	hypothetical protein FLJ23571	3.4
		BE247275		U5 snRNP-specific protein, 116 kD	3.4
	400000	DEC-11 61 0	110.101707	oo on are opcome protein, 1 to no	J.7

	432239 458747	BE618395	Hs.98074 Hs.2936 Hs.257391	itchy (mouse homolog) E3 ubiquitin prote matrix metalloproteinase 13 (collagenase hypothetical protein DKFZp761J1523	3.4 3.4 3.4
5	442082	R41823 AA210765	Hs.7413	ESTs; calsyntenin-2 gb:zr90c06.r1 NCI_CGAP_GCB1 Homo sapiens	3.4
3		AI346468	Hs.145789		3.4
		Al613276	Hs.5662 Hs.232168	guanine nucleotide binding protein (G pr	3.4
		Al247716 AA164366		hypothetical protein FLJ23511	3.4 3.4
10	435202	Al971313	Hs.170204	KIAA0551 protein	3.4
	410467	AF102546 NA	Hs.63931	dachshund (Drosophila) homolog Target Exon	3.3
	441826	AW503603	Hs.129915	phosphotriesterase related	3.3
15		AL037925 AW885727	Hs.301570	gb:DKFZp564M037_r1 564 (synonym: hfbr2)	3.3 3.3
13	441690		Hs.33106	ESTs	3.3
		AA814043	Hs.88045	ESTs	3.3
	418478 408908	U38945 BE296227	Hs.1174	cyclin-dependent kinase inhibitor 2A (me serine/threonine kinase 15	3.3 3.3
20		AI160386	Hs.125087	ESTs	3.3
		AF055575	Hs.23838	calcium channel, voltage-dependent, L ty	3.3
		NM_000685 AA160079	Hs.89472 Hs 172932	angiotensin receptor 1 Homo sapiens mRNA for partial 3'UTR, seg	3.3 3.3
		AW503857	Hs.4007	Sarcolemmal-associated protein	3.3
25		NM_005982	Hs.54416	sine oculis homeobox (Drosophila) homolo	3.3
		AW138872 AA280627	Hs.135288 Hs.57846	ESTS	3.3
		AA296961		gb:EST112514 Adrenal gland tumor Homo sa	3.3
30		AI936450	Hs.147482		3.3
30	402892 426681	NA AA994896	Hs.22514	Target Exon ESTs	3.3
		AA741545	Hs.282832	ESTs, Weakly similar to T24961 hypotheti	3.3
	409430			splicing factor, arginine/serine-rich 5	3.3
35		AI954968 AV653771	115.27 3003	matrix Gla protein gb:AV653771 GLC Homo sapiens cDNA clone	3.3
		AA121686	Hs.10592	ESTs	3.3
	406151	NA AW511956	Hs.293261	Target Exon	3.3
		AW820260	113.200201	gb:QV2-ST0296-150200-040-c10 ST0296 Homo	3.3
40	432415			ESTs, Weakly similar to A43932 mucin 2 p	3.3
	439310	AF086120 NA	Hs.102793	Target Exon	3.3
		AL045633	Hs.44269	ESTs	3.3
45		A1344166	Hs.155743		3.3 3.3
43		AW369771 AW204610	Hs.52620 Hs.22270	integrin, beta 8 ESTs	3.3
	442118	AA976718	Hs.202242	ESTs	3.3
		AA206186 AW043921	Hs.79889 Hs.130526	monocyte to macrophage differentiation-a	3.3
50	451474		Hs.207636		3.2
	442559	T10213		gycosyltransferase	3.2
	453921 420036	A1824009	Hs.44577 Hs.52792	ESTs Homo sapiens mRNA; cDNA DKFZp586l1823 (f	3.2
	435627	W88774	Hs.118370	ESTs	3.2
55		BE336654	Hs.70937	H3 histone family, member A	3.2
		AA863360 BE311926	Hs.26040 Hs.15830	ESTs, Weakly similar to fatty acid omega hypothetical protein FLJ12691	3.2 3.2
	403637			C3001106*:gij10047201jdbjjBAB13394.1j (A	3.2
60	405547	C0E766	Un 101022	NM_018833*:Homo sapiens transporter 2, A CGI-07 protein	3.2 3.2
00	427878 451871	Al821005	Hs.118599		3.2
	410313	R10305	Hs.185683	ESTs	3.2
	416856	N27833 Al652777	Hs.269028 Hs.197069	ESTs, Weakly similar to I38022 hypotheti	3.2 3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
	440684	AI253123	Hs.127356	ESTs, Highly similar to S21424 nestin [H	3.2
	459055	N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	3.2

		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	3.2
	430965	AA489732	Hs.154918	ESTs	3.2
	405394			Target Exon	3.2
	424693	BE169810	Hs.47557	ESTs	3.2
5	454265	H03556	Hs.300949	ESTs, Weakly similar to thyroid hormone	3.2
		AA765917	Hs.122840		3.2
		AK000684		hypothetical protein FLJ22104	3.2
		AL121282	Hs.257786		3.2
		AW856552		gb:RC1-CT0294-080100-012-a04 CT0294 Homo	
10		NM_005429	Hs.79141	vascular endothelial growth factor C	3.2
10		AA758239	Hs.180330		3.2
		AI249368	Hs.98558	ESTs	3.2
		H38857		Homo sapiens cDNA FLJ20738 fis, clone HE	3.2
		Ai904743		hypothetical protein FLJ10292	3.2
15		AI016377	Hs.131693		3.2
13				KIAA1226 protein	3.2
		AB033052	Hs.22151	· · · · · · · · · · · · · · · · · · ·	3.2
		AI198719	Hs.176376		
	404580	A A 2 D C 4 D 7	11- 47470	NM_014112*:Homo sapiens trichorhinophala	3.2
20		AA326187	Hs.17170	G protein-coupled receptor 4	3.2
20		AW974903	Hs.291231		3.1
		AW904907	Hs.30732	hypothetical protein FLJ13409; KIAA1711	3.1
		Al204995		gb:an03c03.x1 Stratagene schizo brain S1	3.1
	400195			NM_007057*:Homo sapiens ZW10 interactor	3.1
0.5		AW408557	Hs.235498	hypothetical protein FLJ14075	3.1
25		AW974175		ESTs, Weakly similar to MAPB_HUMAN MICRO	
		AA312735	Hs.30512	Homo sapiens mRNA for KIAA0556 protein,	3.1
		AA701327	Hs.17949	ESTs	3.1
	440801	AA906366	Hs.190535	ESTs	3.1
• •	426274	D38122	Hs.2007	tumor necrosis factor (ligand) superfami	3.1
30	423728	AW891294		solute carrier family 4, sodium bicarbon	3.1
	439677	R82331	Hs.164599	ESTs	3.1
	452834	A1638627			3.1
	431349	AA503653	Hs.156942	ESTs, Moderately similar to ALU2_HUMAN A	3.1
	417576	AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	3.1
35	430264	AA470519		gb:nc71f10.s1 NCI_CGAP_Pr1 Homo sapiens	3.1
	418827	BE327311	Hs.47166	HT021	3.1
	410835	AW806906		gb:QV4-ST0023-160400-172-d12 ST0023 Homo	3.1
		H15302	Hs.168950	Homo sapiens mRNA; cDNA DKFZp566A1046 (f	
	405336			Target Exon	3.1
40		AI683150	Hs.201550		3.1
		AI583052	Hs.270058		3.1
		BE160636		gb:PM1-HT0422-291299-002-c08 HT0422 Homo	
		Al768801	Hs.169943		3.1
	405848			Target Exon	3.1
45		BE066976		gb:PM0-BT0340-211299-003-c12 BT0340 Homo	
		M29994		<b>▼</b>	3.1
		W26713	Hs.256972		3.1
	423518				3.1
		AI065104			3.1
50		BE165753		•	3.1
50		AA706910	Hs.112742		3.1
		AL050027	113.112142	gb:Homo sapiens mRNA; cDNA DKFZp566C0324	
		AL030027 Al541305	Hs.48778		3.1
		AW407181		11. 11. 11. 11. 11. 11. 11. 11. 11. 11.	3.1
55			115.2 10377		3.1
55		AF026942 AW807227		gb:MR4-ST0062-180200-001-e10 ST0062 Homo	
			He 120226	·	
		NM_002914			3.1
	416790		Hs.7043		3.1
60		BE295866	Hs.94382		3.1
60		W94997	Hs.189917		3.1
•	426968		Ho 440465	amphiphysin (Stiff-Mann syndrome with br	3.1
		AL117431		Homo sapiens cDNA FLJ12198 fis, clone MA	3.1
		BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.1
65		AW138413	⊓S.739336		3.1
65		AA382814	11- 400500	, , , , , , , , , , , , , , , , , ,	3.1
		A1248013			3.1
	40/993	AW135274	Hs.12433	ESTs	3.1

	446466	H38026	Hs.308	arrestin 3, retinal (X-arrestin)	3.1
		BE219794	Hs.293471	ESTs	3.1
		AK001423	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	3.0
5		AB033035	Hs.51965	KIAA1209 protein	3.0
3		BE153855	Hs.61460	lg superfamily receptor LNIR	3.0 3.0
		AA232658 Al830417	Hs.44143	UDP-glucose:glycoprotein glucosyltransfe polybromo 1	3.0
	429826	N93266	Hs.40747	ESTs	3.0
		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	
10		NM_005357	Hs.95351	lipase, hormone-sensitive	3.0
	405609	NA _		ENSP00000241065*:CDNA	3.0
	404274			NM_002944*:Homo sapiens v-ros avian UR2	3.0
		AI971362	Hs.231945		3.0
15		H07118 N59650	Hs.6099	ESTs · ESTs	3.0
13	406291		Hs.27252	Target Exon	3.0
		BE383592		gb:601297871F1 NIH_MGC_19 Homo sapiens c	
		AW972359	Hs.293334	<u> </u>	3.0
		AI791988	Hs.129115		3.0
20	451353	N21043	Hs.42932	ESTs	3.0
		AI969716	Hs.13034	ESTs	3.0
		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326		11- 40504	C10000447*:gi[1168375]sp[P43467]AGA1_PED	3.0
25		BE169746 Al926047	Hs.12504 Hs.162859	likely ortholog of mouse Arkadia	3.0
23		AF245505	Hs.72157	DKFZP564I1922 protein	3.0
	401045	/ (( Z 10000		C11001883*:gi]6753278 ref NP_033938.1  c	3.0
	432162	AA584062	Hs.272798	hypothetical protein FLJ20413	3.0
		Al221894	Hs.39311	ESTs	3.0
30		BE077155		hypothetical protein DKFZp761B1514	3.0
		AW958879	Hs.270535		3.0
		H91882		Dvl-binding protein IDAX (inhibition of	3.0
		NM_014711 R13474		KIAA0419 gene product ESTs, Weakly similar to I38022 hypotheti	3.0
35		R52782	113.230203	gb:yg99d09.r1 Soares infant brain 1NIB H	3.0
		AB014528	Hs.43133	KIAA0628 gene product	3.0
	453913	AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
		Al754212	Hs.21951	Homo sapiens Xq pseudoautosomal region;	3.0
40		AW021173	Hs.18612	Homo sapiens cDNA: FLJ21909 fis, clone H	3.0
40		AW901879	Hs.314453		3.0
		D31118	Hs.191735 Hs.198529	hypothetical protein MGC10520	3.0
		AW294795 AA878939	Hs.125406		3.0
		Al375957		F-box only protein 22	3.0
45		AA281279	Hs.23317	hypothetical protein FLJ14681	3.0
		NM_014400	Hs.11950	GPI-anchored metastasis-associated prote	3.0
		AA701259	Hs.189299		3.0
		AI041793	Hs.42502	ESTS	3.0
50		BE175605	H- 055470	gb:RC5-HT0580-100500-022-H07 HT0580 Homo	3.0
50		AW295923 M31659		KIAA1843 protein solute carrier family 25 (mitochondrial	3.0
		AA397658	Hs.60257		3.0
		W01938		ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
				lymphoid nuclear protein (LAF-4) mRNA	2.9
55	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.9
		BE246743	Hs.288529	hypothetical protein FLJ22635	2.9
	403677			C4001462:gi 4887715 gb AAA79329.2  (L088	2.9
		BE067650	Un 100015	gb:MR4-BT0358-090300-003-e01 BT0358 Homo ESTs, Moderately similar to ALU1_HUMAN A	2.9
60	433233	W87434 BE568102	Hs 180312	mitochondrial ribosomal protein S16	2.9
00		Al674818	Hs.316433	Homo sapiens cDNA FLJ11375 fis, clone HE	2.9
		AA179949	Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N0763 (	
		AW365665	Hs.120388	ESTs	2.9
~ ~		Al633559	Hs.310359		2.9
65		N34128	Hs.145268		2.9
	402109		He anego	Target Exon Homo sapiens cDNA FLJ13010 fis, clone NT	2.9
	429029	BE501732	Hs.30622	HOMO Sapiens CDIVA FLU 150 TO 115, CIONE NT	2.9

		Al827248 AA249573		ESTs, Moderately similar to ZN91_HUMAN Z	2.9 2.9
	404721 445107	AJ208121	Hs.147313		2.9 2.9
5	401987 430566	AA481282	Hs.190149	· · · · · · · · · · · · · · · · · · ·	2.9 2.9
		Al939339	Hs.146883		2.9
		AW873606	Hs.149006		2.9
		AW194426	Hs.20726		2.9
10		AI868634			2.9
10	401458	A1000034	115.240330		2.9
		NIM 002470	Ha 404200		2.9
		NM_003478	Hs.101299		
		BE514127	11 450054	gb:601315974F1 NIH_MGC_8 Homo sapiens cD	
1.5		NM_012288			2.9
15		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	
	416931		Hs.80485		2.9
		BE161151	=0440	gb:PM0-HT0425-141299-001-F08 HT0425 Homo	
		NM_016122	Hs.56148		2.9
00		AA743991		gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	
20		A(193043			2.9
	454529		Hs.270425		2.9
	421379				2.9
		AF015592	Hs.28853		2.9
	457402	AW452648			2.9
25	449051	AW961400	Hs.333526		2.9
	408761	AA057264	Hs.238936		2.9
	401093				2.9
	435061	A1651474	Hs.163944		2.9
	447985	Al681475	Hs.200949	ESTs	2.9
30	449340	AW235786	Hs.195359	hypothetical protein MGC10954	2.9
	426384	Al472078	Hs.303662		2.9
	411905	BE265067		gb:601193893F1 NIH_MGC_7 Homo sapiens cD	2.9
	405953	NA		Target Exon	2.8
	420854	AW296927		gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	2.8
35	434265	AA846811	Hs.130554	Homo sapiens cDNA: FLJ23089 fis, clone L	2.8
	428365	AA295331	Hs.183861	Homo sapiens cDNA FLJ20042 fis, clone CO	2.8
	442861	AA243837	Hs.57787	ESTs	2.8
	448337	AW206453	Hs.3782	ESTs	2.8
	452554	AW452434	Hs.58006		2.8
40	412248	BE176480		gb:RC3-HT0585-160300-022-c02 HT0585 Homo	2.8
	449450	AL039852	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.8
	434757	A1038997	Hs.132921	ESTs	2.8
	409038	T97490	Hs.50002		2.8
	454545	AW806899		gb:QV4-ST0023-160400-172-c12 ST0023 Homo	2.8
45	439842	AI910896	Hs.132413	ESTs	2.8
	428479	Y00272	Hs.184572		2.8
	424800	AL035588	Hs.153203		2.8
	411086	BE070800		gb:RC3-BT0502-251199-011-c07 BT0502 Homo	
	400250	NA		Eos Control	2.8
50	449168	NM_016206	Hs.23142		2.8
	456482	AA485224		gb:aa41b12.s1 NCI_CGAP_GCB1 Homo sapiens	2.8
	426044	AA502490	Hs.336695		2.8
	431854	AA383550	Hs.271699	polymerase (DNA directed) iota	2.8
	405873	NA			2.8
55	440400	AA994364			2.8
	458265	Al075375	Hs.128193	ESTs, Weakly similar to IRX2_HUMAN IROQU	2.8
	413708	BE158791		gb:IL2-HT0397-091299-025-D02 HT0397 Homo	2.8
	423739	AA398155	Hs.97600		2.8
	424408	Al754813	Hs.146428		2.8
60	453096	AW294631	Hs.11325		2.8
	421825	AA298758	Hs.183747	ESTs, Moderately similar to CALB_HUMAN C	2.8
	417742	R64719		gb:EST22d11 WATM1 Homo sapiens cDNA clon	
	402765				2.8
	444378	R41339	Hs.12569		2.8
65	419172	AW338625	Hs.22120		2.8
	401497				2.8
	402376			C19000763*:gi[1363912 pir] JC4296 ring f	2.8
				•••	

	405041	NA		C3001706*:gi 1345652 sp P15989 CA36_CHIC	2.8
	408758	NM_003686	Hs.47504	exonuclease 1	2.8
	431917		Hs.2868	peripheral myelin protein 2	2.8
5		AA761190	Hs.244627		2.8
3		AA744862 AF086325	MS.194293	ESTs, Weakly similar to I54374 gene NF2 gb:Homo sapiens full length insert cDNA	2.8 2.8
	401283			Target Exon	2.8
		AW803201		gb:IL2-UM0077-070500-080-E06 UM0077 Homo	
		NM_014735	Hs.82292	KIAA0215 gene product	2.8
10		AW994005	Hs.337534		2.8
		AW291488	Hs.117305	Homo sapiens, clone IMAGE:3682908, mRNA	2.8
		AW815098	N= 00050	gb:QV4-ST0212-091199-023-f10 ST0212 Homo	
		BE247550 Al651930	Hs.86859 Hs.135684	growth factor receptor-bound protein 7	2.8 2.8
15		AK000375	Hs.88820	HDCMC28P protein	2.8
	414661		Hs.21929	ESTs	2.8
	425589	Al650633		Homo sapiens cDNA: FLJ23031 fis, clone L	2.8
		Al916662		kinectin 1 (kinesin receptor)	2.7
20		W23624	Hs.173059		2.7
20		NM_000399 BE386870	Hs.1395	early growth response 2 (Krox-20 (Drosop gb:601275271F1 NIH_MGC_20 Homo sapiens c	2.7
		R79707	Hs.263339	ESTs, Moderately similar to 138022 hypot	2.7
		BE247449	Hs.31082	hypothetical protein FLJ10525	2.7
	443772	AV646449	Hs.282872	ESTs	2.7
25		A1378562	Hs.159585		2.7
		AW371048	Hs.93758	H4 histone family, member H	2.7
	406504	NA AW959861	Hs.290943	C5000558:gi 4504675 ref NP_002175.1  int	2.7 2.7
		NM_004525		low density lipoprotein-related protein	2.7
30		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, comp	2.7
	423961	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	2.7
		N34524		gb:yy56d10.s1 Soares_multiple_sclerosis_	2.7
		BE314524	Hs.78776	putative transmembrane protein	2.7
35	419987	NM_005014	Hs.94070	osteomodulin Target Exon	2.7 2.7
33		X69970	Hs.79350	RYK receptor-like tyrosine kinase	2.7
		Al916512	Hs.198394		2.7
	408171	AA301228	Hs.43299	hypothetical protein FLJ12890	2.7
40		AW968128	Hs.336679		2.7
40		AA128978		hypothetical protein FLJ14917	2.7
		M31158 BE563085	Hs.77439 Hs.833	protein kinase, cAMP-dependent, regulato interferon-stimulated protein, 15 kDa	2.7 2.7
		AB026264	Hs.284245		2.7
		AA742577	Hs.303781	**_ '	2.7
45	439031	AF075079		gb:Homo sapiens full length insert cDNA	2.7
		W74653	Hs.271593	ESTs, Moderately similar to A47582 B-cel	2.7
	406153 406625	V42647	Un 110507	Target Exon stearoyl-CoA desaturase (delta-9-desatur	2.7 2.7
		Al188139	Hs.147050		2.7
50		Al572739		6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
		H09604	Hs.13268	ESTS	2.7
		AA255920	Hs.88095	ESTs	2.7
		AA495925	Hs.9394	ESTs	2.7
55		BE379623 AI050073	Hs.27693 Hs.135338	peptidylprolyl isomerase (cyclophilin)-l	2.7 2.7
55		Al741320	Hs 114121	Homo sapiens cDNA: FLJ23228 fis, clone C	2.7
		AA054726	Hs.285574		2.7
	416515	N91716	Hs.194140	ESTs, Weakly similar to I38022 hypotheti	2.7
<b>CO</b>		Z97630		H1 histone family, member 0	2.7
60		X54942	Hs.83758	CDC28 protein kinase 2	2.7
		AF086332	Hs.58314	ESTs ENSP00000245238*:CDNA FLJ10922 fis, clon	2.7 2.7
	402184 450496	AW449251	Hs.257131		2.7
		A1825440	Hs.224952		2.7
65	457938	Al373638	Hs.133900	ESTs	2.7
	441541	AA938663	Hs.199828		2.7
	441111	Al806867	Hs.126594	ESIS	2.7

	400000				
		AA383092	Hs.1608	replication protein A3 (14kD)	2.7
		AV653485	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	
	427961	AW293165	Hs.143134	ESTs	2.7
_	410889	X91662	Hs.66744	twist (Drosophila) homolog (acrocephalos	2.7
5	445234	AW137636	Hs.146059	ESTs	2.7
	413903	AA496493	Hs.23136	ESTs	2.7
	406069	NA		Target Exon	2.7
	447410	A1470235	Hs.172698	EST	2.7
	401256			NM_024089*:Homo sapiens hypothetical pro	2.7
10		AW975942	Hs.48524	ESTs	2.7
		AW958037	Hs.286	ribosomal protein L4	2.7
		BE144762	110.200	gb:CM0-HT0180-041099-065-b04 HT0180 Homo	
		BE327427	Hs.79953	ESTs	2.6
		AA045857	Hs.54943	fracture callus 1 (rat) homolog	2.6
15					
13		AL121053	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	2.6
		AF160477	Hs.61460	lg superfamily receptor LNIR	2.6
		AK001122	Hs.105859	• •	2.6
		AW893940	Hs.59698	ESTs	2.6
20		Z30201		gb:HHEA22G Atrium cDNA library Human hea	2.6
20		D38299	Hs.170917		2.6
	433068	NM_006456	Hs.288215	sialyltransferase	2.6
	421952	AA300900	Hs.98849	ESTs, Moderately similar to AF161511 1 H	2.6
	429208	AA447990	Hs.190478	ESTs	2.6
	430733	AW975920	Hs.283361	ESTs	2.6
25	441720	A1346487	Hs.28739	ESTs	2.6
	418986	AI123555	Hs.81796	ESTs	2.6
	432481	AW451645	Hs.151504	Homo sapiens cDNA FLJ11973 fis, clone HE	2.6
	434338	AW754311		gb:CM1-CT0337-141299-068-f07 CT0337 Homo	2.6
		AI675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	2.6
30		M25809	Hs.64173	ATPase, H transporting, lysosomal (vacuo	2.6
		AK002016		Homo sapiens, clone MGC:16327, mRNA, com	2.6
	425071			deiodinase, iodothyronine, type II	2.6
		AW292286	Hs.255058		2.6
		AA018311	Hs.114762		2.6
35	405822	70.010011	115.114102	Target Exon	2.6
55		AW976201	Hs.53913	hypothetical protein FLJ10252	2.6
		A1080042		ribosomal protein S24	2.6
		AA643687		Homo sapiens cDNA FLJ11980 fis, clone HE	2.6
				Homo sapiens cDNA FL311300 lis, clone NT	2.6
40		AW205878	Hs.29643		
40	405638	A14040000		Target Exon	2.6
		AW812256		gb:RC0-ST0174-191099-031-a07 ST0174 Homo	2.6
	403943				
		<b>707001</b>	11 404400	C5000355:gi 4503225 ref NP_000765.1  cyt	
		Z25884	Hs.121483	chloride channel 1 , skeletal muscle (Th	2.6
45	402800	NA		chloride channel 1 , skeletal muscle (Th Target Exon	2.6 2.6
45	402800 449144	NA A1989503	Hs.233405	chloride channel 1 , skeletal muscle (Th Target Exon ESTs	2.6 2.6 2.6
45	402800 449144 454934	NA A1989503 AW846080	Hs.233405 Hs.314324	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs	2.6 2.6 2.6 2.6
45	402800 449144 454934 424717	NA A1989503 AW846080 H03754	Hs.233405 Hs.314324 Hs.152213	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami	2.6 2.6 2.6 2.6 2.6
45	402800 449144 454934 424717 428303	NA Al989503 AW846080 H03754 AW974476	Hs.233405 Hs.314324 Hs.152213 Hs.183601	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16	2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970	NA A1989503 AW846080 H03754 AW974476 AA418187	Hs.233405 Hs.314324 Hs.152213	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16	2.6 2.6 2.6 2.6 2.6 2.6 2.6
45 50	402800 449144 454934 424717 428303 427970	NA Al989503 AW846080 H03754 AW974476	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970 450638 453034	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein,	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970 450638 453034	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein,	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970 450638 453034 455097	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo saplens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317 408875	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317 408875 427510	NA A1989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317 408875 427510 423201	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs Wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50	402800 449144 454934 424717 428303 427970 450638 455097 427317 408875 427510 423201 406271	NA A1989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.175312 Hs.125180	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs Wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50	402800 449144 454934 424717 428303 453034 455097 427317 408875 427310 423201 406271 442696	NA AI989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein SMZI nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50 55	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317 408875 427510 423201 406271 442696 454018	NA Al989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50	402800 449144 454934 422717 428303 427970 450638 453034 455097 427317 408875 427510 423201 406271 442696 454018 435420	NA A1989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 A1928513	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs	2.6
50 55	402800 449144 454934 424717 428303 427970 450638 453034 455097 427317 408875 427510 423201 406271 44269 454018 435420 434398	NA A1989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 A1928513 AA121098	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs ESTs Hypothetical protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs Serum-inducible kinase	2.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6
50 55	402800 449144 454934 424717 428303 45097 450638 453034 455097 427317 408875 427510 423201 406271 442696 454018 435420 434398 455708	NA A1989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 AI928513 AA121098 BE069326	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203 Hs.3838	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs serum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo	2.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6
50 55	402800 449144 454934 428303 427970 450638 453034 455097 427317 408875 427510 423201 406271 442696 454018 435420 434398 455708 439347	NA AI989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 AI928513 AA121098 BE069326 W24320	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203 Hs.3838	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs ESTs ESTs esrum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo Homo sapiens cDNA: FLJ21531 fis, clone C	2.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6
50 55 60	402800 449144 454934 424717 428303 453034 455097 427317 408875 427510 423201 406271 442696 454018 435420 434398 455708 455708 455708 455708 455708 455708 455708 455708	NA AI989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 AI928513 AA121098 BE069326 W24320 X64984	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203 Hs.3838 Hs.102941	chloride channel 1, skeletal muscle (Th Target Exon ESTs ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50 55	402800 449144 454934 424717 428303 450638 453034 455097 427317 408875 427310 406271 442696 454018 435420 434398 455404 434398 455404 434398 455404 434398 455404 434398 455404 434398 455404 434398 455404 434398 455404 434398 455404 434398 435404 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 43541 4	NA AI989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 AI928513 AA121098 BE069326 W24320 X64984 AA830431	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203 Hs.3838 Hs.102941 Hs.180811	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs serum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo Homo sapiens cDNA: FLJ21531 fis, clone C gb:H.sapiens mRNA HTPCRX10 for olfactory ESTs	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
50 55 60	402800 449144 454934 424717 428303 427970 450638 453034 457317 4027317 4027317 442696 454018 435420 434398 455708 439347 407523 407523 425101 435153	NA AI989503 AW846080 H03754 AW974476 AA418187 AK001826 BE246010 AW855802 AB028955 NM_015434 Z47542 NM_000163 BE566962 AW016892 AI928513 AA121098 BE069326 W24320 X64984	Hs.233405 Hs.314324 Hs.152213 Hs.183601 Hs.330515 Hs.25245 Hs.271468 Hs.175780 Hs.48604 Hs.179312 Hs.125180 Hs.7063 Hs.100855 Hs.59203 Hs.3838 Hs.102941	chloride channel 1 , skeletal muscle (Th Target Exon ESTs ESTs wingless-type MMTV integration site fami regulator of G-protein signalling 16 ESTs hypothetical protein FLJ11269 Homo sapiens mRNA for FLJ00038 protein, gb:RC1-CT0279-170200-023-d08 CT0279 Homo KIAA1032 protein DKFZP434B168 protein small nuclear RNA activating complex, po growth hormone receptor Target Exon Homo sapiens cDNA: FLJ20913 fis, clone A ESTs ESTs serum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo Homo sapiens cDNA: FLJ21531 fis, clone C gb:H.sapiens mRNA HTPCRX10 for olfactory ESTs	2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6

		BE160198		gb:QV1-HT0413-010200-059-h03 HT0413 Homo	
		BE274552	Hs.76578	P	2.6
		A1732892 AA831267	Hs.190489 Hs.12244		2.6 2.6
5		AA825686			2.6
	404440			NM_021048:Homo sapiens melanoma antigen,	2.6
	403388			01 12 11	2.6
	403775 405037			Target Exon NM_021628*:Homo sapiens arachidonate lip	2.6 2.6
10		AF290544			2.6
10		AA282067	Hs.88972		2.6
		AI872932		J	2.6
		AW516211		ring finger protein 21, interferon-respo	2.6
15		AI702885 BE391727	Hs.145568		2.6 2.6
1.5		N72264		J	2.6
		AW085961	Hs.130093		2.6
		Y08565	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6
20	404443	NNA 002542	Ua 20777	C8001428*:gi 6572242 emb CAB62951.1  (Z9	2.6 2.6
20		NM_003512 Al073913	Hs.28777	H2A histone family, member L ESTs, Weakly similar to JE0350 Anterior	2.6
		Al192105	Hs.147170		2.6
		AW963372	Hs.46677	PRO2000 protein	2.6
25		F13036	Hs.27373	Homo sapiens mRNA; cDNA DKFZp564O1763 (f	
25		R36075 AW081681	He senned	gb:yh88b01.s1 Soares placenta Nb2HP Homo ESTs, Weakly similar to T42689 hypotheti	2.6 2.6
		NM_000169	Hs.69089	galactosidase, alpha	2.6
		S70284	11010000	gb:stearoyl-CoA desaturase [human, adipo	2.6
20		H62943	Hs.154188		2.6
30		BE065837	U= 404007	gb:RC2-BT0318-110100-012-g12 BT0318 Homo	
		NM_012247 Al538613		SELENOPHOSPHATE SYNTHETASE; Human s Transmembrane protease, serine 3	2.5
		AF012023		integrin cytoplasmic domain-associated p	2.5
		AK001058	Hs.12680	Homo sapiens cDNA FLJ10196 fis, clone HE	2.5
35		BE245652		zinc finger protein 266	2.5
		L22524 AB020641	Hs.2256 Hs.57856	matrix metalloproteinase 7 (MMP7; uterin PFTAIRE protein kinase 1	2.5 2.5
		NM_000909		neuropeptide Y receptor Y1	2.5
		AW973708		Homo sapiens cDNA FLJ13446 fis, clone PL	2.5
40		AA767881	Hs.122897		2.5
		AK001741	Hs.8739	hypothetical protein FLJ10879	2.5 2.5
		AL042306 AW628666	Hs.97689 Hs.98440	VASA protein ESTs, Weakly similar to I38022 hypotheti	2.5
		AK002032		Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45		BE080908		gb:QV1-BT0631-280200-084-h07 BT0631 Homo	
		Al362790		KIAA1684 protein; likely homolog of mous	2.5
		BE394723 NM_002318	Hs.275243 Hs.83354	S100 calcium-binding protein A6 (calcycl lysyl oxidase-like 2	2.5 2.5
		AW375610		hypothetical protein FLJ13046 similar to	2.5
50		Al424899	Hs.188211	ESTs	2.5
		BE091089	11.00504	gb:PM4-BT0724-130400-006-c07 BT0724 Homo	
	410804	U64820 AW972565	Hs.66521 Hs.32399	Machado-Joseph disease (spinocerebellar ESTs, Weakly similar to S51797 vasodilat	2.5 2.5
		AW089705		ESTs, Weakly similar to S64329 probable	2.5
55		AI471598	Hs.197531		2.5
		AA065081		gb:zm13a03.s1 Stratagene pancreas (93720	2.5
		BE178536	Hs.11090	membrane-spanning 4-domains, subfamily A	2.5
		AF109298 AW247529	Hs.118258 Hs.6793	prostate cancer associated protein 1 platelet-activating factor acetylhydrola	2.5 2.5
60		BE158687	. 10.01 00	gb:CM0-HT0395-280100-169-b09 HT0395 Homo	
	425025	AW953168	Hs.12407	ESTs	2.5
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	2.5
	404826	NM_001809	Hs.1594	Target Exon centromere protein A (17kD)	2.5 2.5
65		NM_014918		KIAA0990 protein	2.5
	417404	NM_007350	Hs.82101	pleckstrin homology-like domain, family	2.5
	448516	AW898595		gb:RC1-NN0073-260400-011-g09 NN0073 Homo	02.5

	403356	NA		ENSP00000251525*:Hypothetical protein KI	2.5
	404983	4.4045505	11-00400	ENSP00000252242*:Keratin, type II cytosk	2.5
		AA215535	Hs.98133	ESTs	2.5
5		AW467143		actin related protein	2.5
5		AF186114	Hs.215937	tumor necrosis factor (ligand) superfami	2.5 2.5
		AW071349 AW582962		CGI-47 protein	2.5
		AF086041	Hs.42975	ESTs	2.5
	400925	AF000041	115.42575	Target Exon	2.5
10	404552	NΙΔ		ENSP00000220888*:ZINC FINGER TRANSCRIP	
10	_	AL133117	Hs.81376	Homo sapiens mRNA; cDNA DKFZp586L1121 (f	
	_	NM_002332	Hs.89137	low density lipoprotein-related protein	2.5
	426853		Hs.172777	baculoviral IAP repeat-containing 4	2.5
		NM_000318		peroxisomal membrane protein 3 (35kD, Ze	2.5
15		AA501760	Hs.15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (f	
	447128	AI271898	Hs.164866	cyclin K	2.5
	454693	AW813428		gb:MR3-ST0192-010200-210-c05 ST0192 Homo	2.5
	434657	AA641876	Hs.191840		2.5
• •	402077	NA		Target Exon	2.5
20	400289	X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	2.5
		AW885757	Hs.257862		2.5
		T27308	Hs.16986	hypothetical protein FLJ11046	2.5
		Al807894	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr	
25		A1024353		hypothetical protein FLJ14298	2.5
25		AA059013	Hs.22607	ESTs	2.5
		AA122393	Hs.70811	hypothetical protein FLJ20516	2.5 2.5
		AW162919 AI126772	Hs.40479	RAB2, member RAS oncogene family-like ESTs	2.5
		AI580090	Hs.48295	RNA helicase family	2.5
30		N80077	Hs.24792	chromosome 12 open reading frame 5	2.5
50		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	2.5
		AW297921	Hs.255703		2.5
		AA256769	Hs.94949	methylmalonyl-CoA epimerase	2.5
	428943	AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein	2.5
35	425320	U29344	Hs.83190	fatty acid synthase	2.5
		AA356923		nuclear cap binding protein subunit 2, 2	2.5
		AL039402		DEME-6 protein	2.5
		N52639	Hs.32683	ESTs	2.5
40		A1743977	Hs.205144	ESIS	2.5
40		AA740875	Hs.44307	ESTs, Moderately similar to I38022 hypot	2.5 2.5
		AW500507 AI920783	Hs.191435	KIAA1600 protein	2.5
		AA479033		ESTs, Weakly similar to A47582 B-cell gr	2.5
		Al446747		olfactory receptor, family 7, subfamily	2.5
45		AA116021	Hs.38260	ubiquitin specific protease 18	2.5
		NM_007069	Hs.37189	similar to rat HREV107	2.5
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	2.5
		AA236255	Hs.298419		2.5
	429118	H20669	Hs.35406	ESTs, Highly similar to unnamed protein	2.5
50	440331	AL046412	Hs.202151		2.5
		A1640355	Hs.312691		2.5
		AW298631			2.5
		A1937547	Hs.124915	hypothetical protein MGC2601	2.5
55		AW837349	11. 400044	gb:QV2-LT0038-270300-108-d12 LT0038 Homo	
55		AA843719	Hs.122341		2.5 2.5
	406414	V DU33U43	Un 140277	C5000506*:gi[124941 sp[P18614 ITA1_RAT I hypothetical protein DKFZp761L0424	2.5
		AB033043 BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	
		AA347746	Hs.9521	ESTs, Weakly similar to ZN43_HUMAN ZINC	2.5
60		BE159984	Hs.125395		2.5
00		AA635062	Hs.50094	Homo sapiens mRNA; cDNA DKFZp434O0515 (i	
		D86983		Melanoma associated gene	2.5
		AL135623		KIAA0575 gene product	2.5
		AA442324	Hs.795	H2A histone family, member O	2.5
65		D13752		cytochrome P450, subfamily XIB (steroid	2.5
		AA081395	Hs.42173	Homo sapiens cDNA FLJ10366 fis, clone NT	2.5
	403133			Target Exon	2.5

	413189	BE070231		gb:QV4-BT0407-260100-087-f12 BT0407 Homo	2.5
	400346	AB041269	Hs.272263	Homo sapiens mRNA for keratin 19, partia	2.5
	435509	Al458679	Hs.181915	ESTs	2.5
	458145	A1239457	Hs.130794	ESTs	2.5
5					

## TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ	
1		

5

Pkey:	Unique Eos probeset identifier number
	criidae ree breseet lacitation riamset
CAT number:	Gene cluster number

\_ Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	407647 407980 408254	1007366_1 103087_1 1049346_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656 AA046309 Al263500 AA046397 AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801
	400234	1043340_1	AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424 AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390 AW807395 AW845789 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098
25			AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807166 AW807501 AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807518 AW845800
			AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141 AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211 AW807498 AW807086 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807087 AW845784
30			AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160 AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103 AW845870 AW177109 AW177101 AW807528 AW807336 AW807038 AW177100 AW807411 AW807088 AW845865
			AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521 AW807488 AW807385 AW807355 AW807223 AW807155
35	409163	110418_1	AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457 AA064704 AA082878 AA075742 AA069162
	409695	114876_1	AA296961 AA296889 AA076945 AA077528 AA077497
	410534	1207247_1	AW905138 AW753008 R13818 Z43519
40	410672	1214882_1	AW794600 AW794730
40	410784	1221005_1	AW803201 BE079700 BE062940
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
	410835	1223785_1	AW806906 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604
	411050	1230330_1	AW814902 BE156656 BE156667 BE156590 BE156441 BE156447
15	411086	1231500_1	BE070800 AW875226 BE149115
45	411093	1231970_1	BE067650 AW817053
	411111	1232669_1	AW818127 AW818161 R09719
	411171	1234393_1	AW820260 AW820332 R94406
	411337	1239217_1	AW837349 AW857355 AW882717
50	411514 411670	1248638_1 1253680_1	AW850178 AW850233 AW850445 AW850446 AW856552 AW861101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562
50	411905	1265181_1	BE265067 BE264978 AW875420
	412102	1277395_1	H56435 H56572 AW892929
	412209	1283610_1	AW901456 AW901450 AW901441
	412248	1285000 1	BE176480 AW903298 AW903313
55	413043	1346556_1	BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678
55	413111	1349546 1	BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065792
	413189	1352723 1	BE070231 BE070229 BE070255
	413221	1353887 1	BE161151 BE162495 BE161002 BE072205 BE160989 BE162482
	413499	1373910_1	BE144884 H97942
60	413708	1384140 1	BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685
	414210	1426051_1	BE383592 BE261671
	414596	1465004_1	BE386870 Z41986 H08501
		_	

```
BE390440
        414605
                  1465790_-1
        415747
                  155189_1
                               AA381209 AA381245 AA167683
                  1574973 1
                               R52782 R17313 H24192 R19876
        416173
                  1696282_1
                               R64719 Z44680 R12451
        417742
 5
        417974
                  171237_1
                               AA210765 T95700 H94407
        418636
                  177402_1
                               AW749855 AA225995 AW750208 AW750206
                  185688_1
                               AA603305 AA244095 AA244183
        419536
        420854
                               AW296927 Al684514 Al263168 AA281079
                  197072_1
                               N34524 AA305071 AW954803 AA502335 Al433430 Al203597 AW026670 AW265323 AW850787 AA317554 AW993643
        422156
                  212379_1
10
                               AW835572 AW385512 Al334966 W32951 H62656 H53902 R88904 AW835732
        422996
                  223666_1
                               BE091089 BE091123 AA319959
                               AW503329 N46610 AA331571
        423833
                  232451_1
        423841
                  232507_1
                               AW753967 AA370795 AA331630 AW962550
        423945
                  233566 1
                               AA410943 AW948953 AA334202 AA332882
15
        425201
                  247933_1
                               AA352111 AW962247 AA429695
        426650
                               AA382814 AA402411 AA412355
                  270283_1
        426878
                  273265_1
                               BE069341 AW748403 AL044891 Al908240 AA393080
                               AA470519 BE303010 BE302954 BE384120
        430264
                  315008 1
        430785
                  323486_1
                               Z30201 AA486132 T72025
20
                               Al685464 AW971336 AA513587 AA525142
                  336411_1
        431676
        433687
                  373061_1
                               AA743991 AA604852 AW272737
        434338
                  383982_1
                               AW754311 AA630185 AW803285
        434469
                  387447 1
                               AA634806 C18732 AA729161 AA729860
                               Al872932 AA682306 BE220163 W88695 T81307 H91447
        435447
                  406400_1
25
        437152
                  43386_1
                               AL050027 BE089051
                  44418_1
                               AL119723 AL119874 Al909018 U50537
        437854
                               AF075079 H48601 H48795
                  46798_1
        439031
                               BE164500 AA832198 BE164502
        439255
                  470321_1
        444910
                  624951_1
                               Al201849 BE069007 AW946544
30
                               AV653771 BE089370
        445432
                  63943_1
                  69865_1
                               BE175605 Z43529 F06610 BE175602 AV661027
        446922
        447197
                  711623_1
                               R36075 Al366546 R36167
        448420
                  76273_1
                               BE623004 AA380669 BE263627 BE246433
                               AW898595 AW898588 AW898590 AW898663 AW898592 Al525093
        448516
                  766241 1
35
                  837264_1
                               Al698839 Al909260 Al909259
        450522
                               AW970060 AI732366 AI792313 AW839644
        450736
                  844652_1
        451024
                  85565_1
                               AA442176 AA259181
        451067
                  85759_1
                               BE172186 AA059279 AA020815 AA013437
        451340
                  86640_1
                               AW936273 AW340350 AA017208
40
        452542
                  921410_1
                               AW812256 AW812257 Al906423 Al906422
        452564
                  92227_1
                               AA026777 N50065 R09961 N54721
                  968371_1
        453472
                               AL037925 AL037931 AL037957
                               AW855717 AW362452 AW362443
        454307
                  1106070_1
        454359
                  1130674_1
                               N71277 AW390764
45
                               AW806899 AW866451 AW866393 AW866297 AW817869
        454545
                  1223779_1
        454693
                  1229132_1
                               AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
                               AW815098 BE154843 BE154831
                  1230493_1
        454714
        455047
                  1250536_1
                               AW852530 AW852527 AW852526
        455092
                  1252971 1
                               BE152428 AW855572 AW855607
50
                  1253130_1
                               AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
        455097
                               BE160198 AW935898 T11520 AW935930 AW856073 AW861034
        455100
                  1253334_1
                               AW938484 BE001245 BE001190
        455431
                  1289854_1
                               BE144762 AW979091
        455511
                  1321229 1
                               BE011668 BE011689 BE011627 BE011679 BE011699 BE011678 BE011696 BE011675 BE011622 BE011635
        455609
                  1337548_1
                               BE064952 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
55
                  1348732_1
        455651
                               BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
                               BE066976 BE066928 BE066927
        455685
                  1350393_1
                  1351264_1
                               BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198
        455700
                               BE069326 BE069290 BE069352
BE080908 BE072258 BE072190 BE072236
        455708
                  1352232_1
60
        455732
                  1353874_1
        455838
                  1374605_1
                               BE145808 BE145807 BE181883
        455935
                               BE158687 BE158688
                  1384144 1
        455945
                               BE160636 BE160606 BE160703
                  1385588_1
        456207
                  165078_-1
                               AA193450
65
                  192289_1
                               AA485224 AA287308 AA258121
        456482
                               AF086325 W72956 W73221 AA219112
        458094
                  47311_1
                               N99626 Al302701
        458673
                  679507_1
```

## TABLE 19B

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Sequence so	e number corresponding to an Eos probeset burce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication d "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
15	Strand: Nt_position:	Indica	tes DNA strand from which exons were predicted. tes nucleotide positions of predicted exons.
	Pkey Ref	Strand	Nt_position
20	400555 9801 400608 98876 400610 98876 400925 76519 401045 81176	66 Minus 71 Minus 21 Plus	134694-134817 96755-97558 117606-117928,124040-124147 38183-38391,43900-44086 90044-90184,91111-91345
25	401049 7232' 401093 8516' 401256 9796' 401283 9800' 401326 9212	77 Plus 37 Minus 73 Minus 93 Minus	149157-150692 22335-23166 45482-45620 47256-47456 226246-227505
30	401418 74528 401451 66348 401458 91878 401497 73813 401508 7534	68 Minus 86 Plus 70 Plus	124865-125075 119926-121272 76485-77597 92607-92813 110779-110983
35	401575 72298 401747 97898 401781 7249	04 Minus 72 Minus	76253-76364 118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097- 131258,131866-131932,132451-132575,133580-134011 83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
40	401785 7249 401793 7263 401987 4406 402077 8117 402109 81316 402184 8576	90 Minus 88 Minus 29 Minus 14 Plus 78 Minus	165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942 102945-103083 72893-73021,76938-77049 65014-65195 171722-171859,173197-173303 112844-112986,113505-113636
45	402376 9625 402421 9796 402578 9884 402606 9909 402696 7328	29 Minus 41 Minus 28 Plus 29 Minus	21753-22385 46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924 66350-66496 81747-82094 23600-23731
50	402765 9367 402800 6010 402820 6456 402892 8086	57 Plus 75 Plus 53 Minus 44 Minus	109588-109726 43921-44049,46181-46273 82274-82443 194384-194645 38314-38634
55	403133 73314 403356 85699 403388 94389 403426 97199 403585 81013	30 Plus 31 Plus 29 Minus 08 Minus	92839-93036 112733-113001,114599-114735 157156-158183 131266-131769
60	403593 68624 403637 86719 403639 86719 403677 73319 403775 77700 403943 77110	36 Minus 48 Plus 17 Minus 80 Minus	62554-62712,69449-69602 142647-142771,145531-145762 113234-113326,115186-115287,119649-119786 55008-55083,62860-63051 102247-102326,103095-103148 100742-100904,101322-101503

```
404091 7684554
                           Minus
                                     82121-83229
        404097 7770701
                                     55512-55781
                           Plus
        404142 9856692
                                     80316-80459
                           Minus
        404253 9367202
                           Minus
                                     55675-56055
 5
         404274 9885189
                           Plus
                                     104127-104318
        404285 2326514
                           Plus
                                     32282-32416
         404360 9858450
                                     122873-122966,151324-151469,153093-153253
                           Minus
         404440 7528051
                                     80430-81581
                           Plus
         404443 7579073
                                     87198-87441
                           Minus
                                     19854-20010
10
         404552 7243881
                           Plus
         404561 9795980
                                     69039-70100
                           Minus
         404580 6539738
                           Minus
                                     240588-241589
         404721 9856648
                                     173763-174294
                           Minus
         404826 6572184
                                     47726-48046
                           Plus
15
         404983 4432779
                                     51178-51374,52000-52173
                           Minus
         405037 7543748
                           Minus
                                     127374-127578
         405041 7547195
                                     121230-121714
                           Plus
                                     138877-139066
         405095 8072599
                           Plus
                                     175317-175500
         405153 9965565
                           Minus
20
         405196 7230083
                           Minus
                                     135716-135851
         405232 7249042
                           Plus
                                     125904-126063
        405248 7259728
405336 6094635
                                     637-777
                           Plus
                                     33267-33563
                           Plus
         405394 6624123
                           Minus
                                     31900-32373
25
         405460 7684569
                           Minus
                                     52223-52389
         405494 8050952
                                     70284-70518
                           Minus
                                     124361-124520,124914-125050
         405547 1054740
                           Plus
         405609 5757553
                           Minus
                                     42814-43010,43583-43783,44863-45033,46429-46554,47815-48018,49961-50153,51624-51727,51823-51959,52702-
                                     52918,55469-55601,57111-57307,58169-58296,60215-60332,61482-61727
                                     199260-199372,199826-199929
30
         405638 6289229
                           Plus
         405654 4895155
                           Minus
                                     53624-53759
         405718 9795467
                                     113080-113266
                           Plus
                                     154660-154974,155203-155379
         405822 6273498
                           Minus
                                     28135-28244
         405848 7651809
                           Minus
35
         405873 6758747
                           Minus
                                     32129-32764
         405906 7705124
                                     10835-11059
                           Minus
         405917 7712162
                           Minus
                                     106829-107213
         405925 6758795
                                     129935-130282
                           Plus
                                     65101-65574
         405953 7960374
                           Minus
40
         406069 9117732
                                     68880-69374
                           Plus
                                     94087-94285
         406151 7144806
                           Minus
         406153 9929734
                                     12902-13069
                           Minus
         406182 5923650
                           Minus
                                     28256-28935
         406271 7534217
                           Plus
                                     36179-36692
45
         406291 5686274
                                     9562-9867
                           Plus
                                     71754-71944
         406348 9255985
                           Minus
                                     49593-49850
         406414 9256407
                           Plus
         406446 9454509
                                     116424-116527,118721-118859,121187-121364
                           Minus
         406504 7711360
                                     107068-107277
                           Minus
50
                                     106956-107121
         406554 7711566
                           Plus
```

# TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85<sup>th</sup> percentile value amongst 144 non-malignant tissues, and the 96<sup>th</sup> percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

10

5

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigeneID: Unigene number

20 Pred.Prot.Domains: Predicted Protein Domains

Unigene Title: Unigene gene title

R1: Ratio of 93rd percentile of tumor to 85th percentile of normal body tissue

25	Pkey	ExAccn	UnigenelD	Pred.Prot.Domains	UnigeneTitle	R1
		AF015224		SS,Uteroglobin,SS,Uteroglobin	mammaglobin 1	168.6
		AA401369		TM	ESTs ESTs, Weakly similar to CP4Y_HUMAN CYTOC	73.2 65.7
30		Al668594 AW170035		,SS,p450 TM	Homo sapiens breast cancer antigen NY-BR	57.6
30		AA250737		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	57.0 55.9
		U31875	Hs.272499	,SS,TM	short-chain alcohol dehydrogenase family	53.8
		BE069341	113.272433	TM	gb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
		NM 000230	He 194236	SS,Leptin,SS,Leptin,	leptin (murine obesity homolog)	40.8
35		AA195651		,SS,Dihydroorotase,	ESTs	39.3
55		L11690	Hs.620	Plectin_repeat,SH3,spectrin,SS,Plectin_r	bullous pemphigoid antigen 1 (230/240kD)	37.3
		D31152	Hs.179729	SS,C1q,Collagen,SS,C1q,Collagen,	collagen, type X, alpha 1 (Schmid metaph	35.2
		AJ224172		,SS,Uteroglobin,	lipophilin B (uteroglobin family member)	30.0
		AA009647		,SS,TM,disintegrin,Pep_M12B_propep,Repro		25.7
40	420931	AF044197	Hs.100431	SS,IL8,SS	small inducible cytokine B subfamily (Cy	25.2
	422109	S73265	Hs.1473	SS,Bombesin,SS	gastrin-releasing peptide	24.8
	445730	Al624342	Hs.170042	,SS,TM,Cation_efflux	ESTs	24.1
	451110	AI955040	Hs.265398	SS	ESTs, Weakly similar to transformation-r	24.0
		Al127076	Hs.334473	TM	hypothetical protein DKFZp564O1278	23.8
45		X51501	Hs.99949	SS,SS	prolactin-induced protein	22.8
		A1267652		,SS,TM,GNS1_SUR4,cNMP_binding,Rlla	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
		NM_003613		ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
<b>~</b> 0		AI905687		SS	aldehyde dehydrogenase 9 family, member	20.3
50		AI375572	Hs.172634	,pkinase,	ESTs	19.2
		AA193450		,SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
			Hs.334473	TM	hypothetical protein DKFZp564O1278	18.2
		AA399272		SS	ESTs	18.2 18.1
55		X52509	Hs.161640	,SS,TM,aminotran_1_2,Cadherin_C_term,cad		17.9
55		AW840171	HS.265398	SS -450 00 TM -450	ESTs, Weakly similar to transformation-r	17.8
	402578	A1063307	U- 020004	SS,p450,SS,TM,p450	C1001134:gi 2117372 pir   65981 fatty ac	17.8
		Al263307 AL120862	Hs.239884	SS SS	H2B histone family, member L programmed cell death 9 (PDCD9)	17.0
		NM_014398		Lamp,SS,TM,Lamp,	similar to lysosome-associated membrane	17.5
	444342	1414[014996	10001	Lamp, 33, TW, Lamp,	ominatio 170000 me abboolated membrano	17.0

	449765	N92293 Hs.206832	SS	ESTs, Moderately similar to ALU8_HUMAN A	17.3
		AA321649 Hs.2248	SS,IL8,	small inducible cytokine subfamily B (CX	17.0
					16.7
			,SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	
_		W67883 Hs.137476	,pkinase,	paternally expressed 10	16.5
5		AB014544 Hs.21572	LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.3
	449448	D60730 Hs.57471	SS	ESTs	16.2
	418007	M13509 Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_	_matrix metalloproteinase 1 (MMP1; inters	15.7
	418994	AA296520 Hs.89546	SS,lectin_c,sushl,EGF,SS,EGF,lectin_c,su	selectin E (endothelial adhesion molecul	15.5
		AA441838 Hs.62905	SS	hypothetical protein FLJ14834	15.5
10		NM_007115Hs.29352	,SS,CUB,Xlink,	tumor necrosis factor, alpha-induced pro	15.0
10				PDZ domain containing 1	14.9
	446591		PDZ,SS		
		AA236115 Hs.120785	SS	ESTs	14.8
	452838		SS,SS	preferentially expressed antigen in mela	14.7
	422805	AA436989 Hs.121017	histone, SS, histone, histone	H2A histone family, member A	14.3
15	448390	AL035414 Hs.21068	SS	hypothetical protein -	14.2
	447342	Al199268 Hs.19322	,SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
		W20027 Hs.23439	,SS,Peptidase_M1,	ESTs	13.9
		Al082692 Hs.134662	,SS,TM,SNF	ESTs	13.7
					13.7
20		AA031956	,SS,LIM,	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	
20		Al733682 Hs.130239	SS	ESTs	13.5
	400289	X07820 Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
	411598	BE336654 Hs.70937	histone, SS, histone, histone	H3 histone family, member A	13.3
		AA948033 Hs.130853	,SS,histone,histone,linker_histone	ESTs	13.2
		AA706910 Hs.112742	,SS,Ribosomal_L7Ae,	ESTs	13.1
25		Al951118 Hs.326736	TM	Homo sapiens breast cancer antigen NY-BR	13.1
23					13.0
		AW873596 Hs.182278	,SS,DENN	calmodulin 2 (phosphorylase kinase, delt	
		Al684808 Hs.197653	SS	programmed cell death 9 (PDCD9)	12.9
		Al351010 Hs.102267	,SS,Lysyl_oxidase	lysyl oxidase	12.8
	400295	W72838 Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
30	452461	N78223 Hs.108106	,SS,G9a,PHD,	transcription factor	12.5 ·
	427365	Al873274 Hs.190721	TM	ESTs	12.4
		AF026944 Hs.293797	,SS,TPR	ESTs	12.3
		AA576953 Hs.22972	SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	12.0
				matrilin 3	11.9
25		AJ224741 Hs.278461	SS,EGF,vwa,SS,TM,vwa,		
35	408771	AW732573 Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
	432912	BE007371 Hs.200313	,SS,TM,Folate_carrier	ESTs	11.9
	447033	Al357412 Hs.157601	SS	ESTs	11.8
	421155	H87879 Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
		NM_002497Hs.153704	pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40		AL049689 Hs.156369	SS	hypothetical protein similar to tenascin	11.6
-10		R28363 Hs.24286	,SS,TM,7tm_1,p450,rrm	ESTs	11.5
				gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
		Al907673	,pkinase,		11.4
		AA410943	death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	
		AL360204 Hs.283853	SS	Homo sapiens mRNA full length insert cDN	11.4
45	402606		SS	NM_024626:Homo sapiens hypothetical prot	11.3
	445263	H57646 Hs.42586	,SS,Acyltransferase,	KIAA1560 protein	11.2
	430217	N47863 Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24	1e,ribosomal protein S24	11.1
	447164	AF026941 Hs.17518	,TM,IBR	Homo sapiens cig5 mRNA, partial sequence	11.1
		BE178536 Hs.11090	,SS,TM	membrane-spanning 4-domains, subfamily A	11.1
50		AL080207 Hs.134585	,SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
50				COBW-like protein	10.9
		R17798 Hs.7535	,SS,Fork_head,		
		U79293 Hs.159264	SS	Human clone 23948 mRNA sequence	10.7
		NM_007050Hs.225952	,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
	425523	AB007948 Hs.158244	,SS,laminin_B,laminin_EGF,laminin_Nterm	KIAA0479 protein	10.3
55	428368	BE440042 Hs.83326	SS,Peptidase_M10,hemopexin,SS,Peptidase	_matrix metalloproteinase 3 (stromelysin	10.3
	418912	NM_000685Hs.89472	SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
		U80736 Hs.110826	SS	trinucleotide repeat containing 9	10.3
		AL120173 Hs.301663	,SS,pkinase,	ESTs	10.3
				ESTs	10.2
60		AW016531 Hs.122147	,SS,ArfGap,		
60	400608	BEG 10070 11	SS,TM,SS,TM	C10001899:gi 7508633 pir  T25392 hypothe	10.1
		BE242870 Hs.75379	SS	solute carrier family 1 (glial high affi	10.0
		W68815 Hs.301885	SS	Homo sapiens cDNA FLJ11346 fis, clone PL	9.9
	402408	NA	,SS,carb_anhydrase	NM_030920*:Homo sapiens hypothetical pro	9.8
		AJ245671 Hs.12844	,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65		Al879148 Hs.26770	SS,lipocalin,lipocalin,	fatty acid binding protein 7, brain	9.6
00	405654		BTB,SS	C12001521:gi 7513934 pir  T31081 cca3 pr	9.6
		Al418055 Hs.161160	SS	ESTs	9.6
	434500	VIT 10000 US.101100	00	2010	0.0

	416220	N49776	Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
			Hs.270833	SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
		AW368397		,SS,UDPGT	Homo sapiens cDNA FLJ14438 fis, clone HE	9.4
		AA032279		TM	six transmembrane epithelial antigen of	9.4
5		AA279490		SS,TM,calreticulin,SS,TM,calreticulin,	calmegin	9.4
3					BMP-R1B	9.4
		Al733881		death,ZU5,TM,Activin_recp,pkinase,		
		AA291377		TM	ESTs	9.3
			Hs.202676	SS	synaptonemal complex protein 2	9.3
4.0		Al820662	Hs.129598	SS	ESTs	9.1
10			Hs.169849	,SS,TM,fn3,ig,	myosin-binding protein C, slow-type	9.1
	406687	M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase_	_matrix metalloproteinase 11 (MMP11; stro	9.1
	448693	AW004854	Hs.228320	SS	hypothetical protein FLJ23537	9.1
		AB041035		Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (	9.1
			Hs.128355	SS	ESTs, Moderately similar to ALU7_HUMAN A	9.0
15			Hs.25933	,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
13			Hs.77367	SS,IL8,SS,IL8	monokine induced by gamma interferon	8.8
			115.77307		Eos Control	8.8
	400285		U- 445000	,TM,ABC_tran,ABC_membrane,		8.8
			Hs.115263	SS,TM,EGF,SS,TM	epiregulin	
20		NM_004354		cyclin,SS	cyclin G2	8.8
20		AW512260		SS	ESTs	8.7
	452281		Hs.28792	,SS,TGF-beta,TGFb_propeptide,	Homo sapiens cDNA FLJ11041 fis, clone PL	8.7
	434531	AA642007	Hs.116369	SS	ESTs	8.6
	408380	AF123050	Hs.44532	,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6
	443788	AI732643	Hs.144151	TM	ESTs	8.6
25		A1222020		SS,SS	CocoaCrisp	8.5
		BE622641		SS.SS.ENTH.I LWEQ.ENTH.I LWEQ.DNA r	mis_reESTs, Weakly similar to I38022 hypotheti	8.5
			Hs.133525	,SS,TM	ESTs	8.5
		NM_004525		SS,EGF,ldl_recept_a,ldl_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
		AW963419		SS side_iecep(_a,idi_iecep(_b,oo,imi,c	stanniocalcin 2	8.4
30						8.4
50		AA635062		TM	Homo sapiens mRNA; cDNA DKFZp434O0515 (f	8.3
		Al831297		TM	ESTs	
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
~ =			Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
35	418092	R45154	Hs.106604	,death,ZU5,pkinase,Activin_recp,	ESTs	8.3
	439840	AW449211	Hs.105445	SS	GDNF family receptor alpha 1	8.2
	427811	M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_M	114carboxypeptidase B1 (tissue)	8.2
	420807	AA280627	Hs.57846	SS,cpn10	ESTs	8.2
	426320	W47595	Hs.169300	SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		,SS,kazal,	ESTs	8.1
		AW419196		SS	hypothetical protein FLJ13782	8.1
		AW248508		SS	Homo sapiens cDNA FLJ14035 fis, clone HE	8.0
	404347	A11240300	113.213121	SS	Target Exon	8.0
		A A 7 4 2 0 0 4		TM	gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	8.0
45		AA743991	11- 407774			8.0
43		AA808229		,SS,IMPDH_C,IMPDH_N,CBS	ESTs	
		NM_016010		SS	CGI-62 protein	7.9
		X70697	Hs.553	TM,SNF,SS,TM,SNF,	solute carrier family 6 (neurotransmitte	7.9
		N39015	Hs.190368	,SS,TM	ESTs	7.8
		AL138272		,TM,cpn60_TCP1,Sema,	ESTs	7.8
50	443646	Al085198		,TSPN,vwc,tsp_1,EGF,thiored,	ESTs	7.8
	446142	AI754693	Hs.145968	,TM,cadherin,Cadherin_C_term,	ESTs	7.7
	444649	AW207523	Hs.197628	,SS,rrm,	ESTs	7.6
	435147	AL133731	Hs.4774	,TM,SDF,UPAR_LY6,	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	7.6
		AI742605		TM	ESTs	7.6
55		AW207206		SS	ESTs	7.6
		AK000713		,SS,UDPGT	hypothetical protein FLJ20706	7.5
		AL031224		SS,SS	transcription factor AP-2 beta (activati	7.5
		R41396			hypothetical protein FLJ23045	7.5
			Hs.101774	SS SS	ubinuclein 1	7.5
60	414009	AA157291		SS SC TALTA		
60		U41060	Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065		,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
		Al742170	Hs.31297	,SS,TM	duodenal cytochrome b	7.4
		Al240665	Hs.8895	,SS,TM,disintegrin,Pep_M12B_propep,Repro		7.3
		U22376	Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65		R43646	Hs.12422	SS	ESTs	7.2
	422867		Hs.1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
	418004	U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2
					•	

	426451	AI908165	Hs.169946	SS,GATA,	GATA-binding protein 3 (T-cell receptor	7.1
	450701	H39960	Hs.288467	,SS,LRR	Homo sapiens cDNA FLJ12280 fis, clone MA	7.1
		Al198719		SS	ESTs	7.1
				The disintensis Deprehasia		
_			Hs.64311	,TM,disintegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
5	433138	AB029496	Hs.59729	SS,ig,Sema,SS,Sema,efhand	semaphorin sem2	7.0
	411558	AA102670	Hs.70725	SS,TM,SS,TM	gamma-aminobutyric acid (GABA) A recepto	7.0
		W87707	Hs.82065		interleukin 6 signal transducer (gp130,	7.0
		X63578				7.0
			Hs.295449	SS,efhand,SS,efhand,ras	parvalbumin	
	432731	R31178	Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10	442818	AK001741	Hs.8739	WD40,SS	hypothetical protein FLJ10879	6.9
		AF026942			gb:Homo sapiens cig33 mRNA, partial sequ	6.8
			No 477026			
		AF077345	HS.177936	SS,lectin_c,SS	ESTs	6.8
	410785	AW803341			gb:IL2-UM0079-090300-050-D03 UM0079 Homo	6.7
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_	_D .	
15	•	C11001883	*:ail67532781ref	fNP_033938.1] c	6.7	
10	419000				ESTs	6.7
		A1123555		,SS,Reprolysin,tsp_1,		
	442082	R41823	Hs.7413	,TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
	442861	AA243837	Hs.57787	SS	ESTs	6.6
			Hs.161712	,TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
20					ESTs, Moderately similar to ALU5_HUMAN A	6.6
20		R20893	Hs.325823			
	444381	BE387335	Hs.283713		ESTs, Weakly similar to S64054 hypotheti	6.6
	404091	NA		,TM,7tm_3,ANF_receptor,	Target Exon	6.6
		AW067903	Hs 82772	SS, Collagen, COLFI, TSPN, SS, TSPN	collagen, type XI, alpha 1	6.6
		AL135623		00,001129011,00211,10111,00,10111	MANGETE gang product	6.5
25					KIAA0575 gene product	
25	410275	U85658	Hs.61796		transcription factor AP-2 gamma (activat	6.4
	425236	AW067800	Hs.155223	SS	stanniocalcin 2	6.2
		NM_005025		,SS,serpin,	serine (or cysteine) proteinase inhibito	6.2
		AI815601			CD83 antigen (activated B lymphocytes, i	6.2
• •	412140	AA219691	Hs.73625		RAB6 interacting, kinesin-like (rabkines	6.2
30	442942	AW167087	Hs.131562	,SS,ig,Sema,pkinase,	ESTs	6.2
		AA026880			prolactin receptor	6.1
					DKFZP434G032 protein	6.1
			Hs.9029	filament, SS, filament, filament	•	
		W26713	Hs.256972	,SS,TM,DAGKa,DAGKc,	ESTs	6.1
	428479	Y00272	Hs.184572	,SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	6.1
35		X03363		,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
55			U- 400700			6.1
			Hs.102720	SS	ESTs	
	410079	U94362	Hs.58589		glycogenin 2	6.1
	401781			,SS,filament,Pribosyltran,filament,Armad	Target Exon	6.1
		NM_012093	RHs 18268		adenylate kinase 5	6.1
40			77 10. 10200			6.1
40	402230				Target Exon	
		NM_003528		histone, SS, histone,	H2B histone family, member Q	6.1
	428398	Al249368	Hs.98558	,SS,TM	ESTs ·	6.0
	458098	BE550224	Hs 74170		metallothionein 1E (functional)	6.0
						6.0
15			Hs.93913	SS,IL6,IL6,	interleukin 6 (interferon, beta 2)	
45		N32536	Hs.42645	,SS,TM	solute carrier family 16 (monocarboxylic	6.0
	419703	Al793257	Hs.128151	,SS,zf-C2H2,	ESTs	5.8
	424687		Hs.151738	SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe	omatrix metalloproteinase 9 (gelatinase B	5.8
		AI823951			tolloid-like 1	5.8
				SS		
	421296	NM_002666	SHS.103253	SS	perilipin	5.8
50	442117	AW664964	Hs.128899	,SS,TM	ESTs	5.7
		AA242758		,SS,TM	LIV-1 protein, estrogen regulated	5.7
				SS	KIAA0882 protein	5.7
		AB020689		33	FOT MANUEL CONTRACT ALLES ALLES ALLES	
		AI199738			ESTs, Weakly similar to ALUA_HUMAN !!!!	5.7
	432239	X81334	Hs.2936	SS,Peptidase_M10,hemopexin,SS,Peptidase_	_matrix metalloproteinase 13 (collagenase	5.6
55		AA904244		TM	ESTs	5.6
00	400286			SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gi 7499103 pir  T20903 hypothe	5.6
			11 000			
		H38026	Hs.308	arrestin,SS	arrestin 3, retinal (X-arrestin)	5.5
	423201	NM_000163	3Hs.125180	SS,TM,fn3,SS	growth hormone receptor	5.5
		W57554	Hs.125019	SS	lymphoid nuclear protein (LAF-4) mRNA	5.5
60		AF086332		,SS,TM,Syntaxin	ESTs	5.4
00						
		NM_005940		SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
	409757	NM_001898	3Hs.123114	,SS,cystatin,	cystatin SN	5.4
	425292	NM_005824	Hs.155545	SS	37 kDa leucine-rich repeat (LRR) protein	5.4
		AJ297436		,SS,TM	prostate stem cell antigen	5.4
65				OO TM		
65		AF153330			solute carrier family 19 (thiamine trans	5.3
		AL355715		SS	programmed cell death 9	5.3
	439310	AF086120	Hs.102793	,SS,TM,UDPGT,casein_kappa	ESTs	5.2
				· · · · - · ·		

	441111	A1806867	Hs.126594	,SS,TM,Phosphodiest,	ESTs	5.2
	452355	N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
	427711	M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
		AW749855		,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5		AL117406	Hs.200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
•	441690	R81733	Hs.33106	,SS,HECT,zf-UBR1,PABP,14-3-3,	ESTs	5.1
		W17064	Hs.332848	SS	SWI/SNF related, matrix associated, acti	5.1
		A1685086	Hs.26339	,SS,ras,	ESTs, Weakly similar to S21348 probable	5.1
	425325		Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_	TENT OTAD	J. 1
10	420020					•
10	100000		nolamine N-met		5.1	F 4
		Al633559	Hs.310359	SS	ESTs	5.1
		AI160386	Hs.12508/	SS	ESTs	5.1
	403593			,CIDE-N,pkinase	Target Exon	5.1
	407758	D50915	Hs.38365	SS,SS	KIAA0125 gene product	5.0
15		AW137636		,SS,TM	ESTs	5.0
	411165	NM_000169	9Hs.69089	SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo	galactosidase, alpha	4.9
	420633	NM_01458	1Hs.274480	SS,lipocalin,SS,lipocalin	odorant-binding protein 2A	4.9
	414117	W88559	Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	416783	AA206186	Hs.79889	SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093			TM,LRRCT,TM,LRRCT,	C12000586*:gij6330167 dbj BAA86477.1  (A	4.9
	411096	U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs	4.9
		Al247716		,SS,adh_zinc,	ESTs	4.9
		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		4.9
25		AA641836		,SS,trypsin	hypothetical protein FLJ23186	4.9
23						4.8
		AI215069		SS SS AA 3 3	ESTs	
		AF012023		,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
		M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
20	403199			SS,TM,Folate_carrier,SS,TM,Folate_carrie	NM_025243*:Homo sapiens solute carrier f	4.8
30		AW057736		,SS,TM,pkinase,Recep_L_domain,SH2,PH,F	urHER2 receptor tyrosine kinase (c-erb-b2,	4.8
		AF070526		,SS,Ca_channel_B,	Homo sapiens clone 24787 mRNA sequence	4.7
		M93221	Hs.75182	SS,TM,lectin_c,fn2,Ricin_B_lectin,SS,TM	mannose receptor, C type 1	4.7
	419563	AA526235	Hs.193162	SS	Homo sapiens cDNA FLJ11983 fis, clone HE	4.7
		BE093589		SS	hypothetical protein FLJ23468	4.6
35	452093	AA447453	Hs.27860	,SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
	442323	AW016669	Hs.29190	,SS,TM,CBS,voltage_CLC	ESTs	4.6
	450606	AI668605	Hs.60380	,TM,Glyco_hydro_1	ESTs, Moderately similar to ALU6_HUMAN A	4.6
		AA687376		,SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
		AA339449		AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	r phosphoribosylglycinamide formyltransfer	4.6
40		AI860021		pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
		AA151342		SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
		BE614743		,SS,TM,MAPEG,	prostaglandin E synthase	4.5
			Hs.146133	,SS,TM,UDPGT	ESTs	4.5
		H26735	Hs.91668	,SS,TM,PH,SH2,Furin-like,pkinase,Recep_L	<del></del>	4.5
45		AA831879		,SS,Hist_deacetyl,	ESTs	4.5
73		AI345455				4.5
				pkinase,OPR,	GA-binding protein transcription factor,	
		Al910275		SS,trefoil,SS,TM,Idl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
		BE391804		SS,TM,GBP,TM,GBP	guanylate binding protein 1, interferon-	4.5
50	426327	W03242	Hs.44898	SS	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5 °
50		M97711		SS,SS,ig,	gb:Human T-cell receptor (V beta 18.1, J	4.5
		AI638627		,SS,DEAD,Fork_head	KIAA1688 protein	4.5
	427315	AA179949	Hs.175563	SS	Homo sapiens mRNA; cDNA DKFZp564N0763 (f	4.4
		AA863360		,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
	442118	AA976718	Hs.202242	,ig,Sema,	ESTs	4.4
55	421524	AA312082	Hs.105445	SS	GDNF family receptor alpha 1	4.4
	453060	AW294092	Hs.21594	,SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
	453403	BE466639	Hs.61779	,SS,HMG_box,filament,	Homo sapiens cDNA FLJ13591 fis, clone PL	4.4
		AK000136		SS,LRR,SS	asporin (LRR class 1)	4.4
	453619		Hs.33922	SS	Homo sapiens, clone MGC:9084, mRNA, comp	4.3
60		NM_000246		SS,LRR,	MHC class II transactivator	4.3
		Al472078		,SS,ArfGap,	ESTs	4.3
		AW935490		,SS,BIR	Human chromosome 5q13.1 clone 5G8 mRNA	4.3
	416931		Hs.80485	SS,C1q,Collagen,SS,C1q,	adipose most abundant gene transcript 1	4.3
		AW296927	13.00700	,SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
65			Hs.89404	SS,homeobox,homeobox,		
05	418867			•	msh (Drosophila) homeo box homolog 2	4.3
		BE464288		,SS,TM,MIP, ,SS,TM,cadherin,cadherin	ESTs	4.3
	447499	AW262580	1 15. 14/ 0/4	,oo, i w,caunenn,caunenn	protocadherin beta 16	4.3

	441560	F13386 Hs.7888	,pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	409064	AA062954 Hs.141883	,SS,CUB,	ESTs	4.3
	422667	H25642 Hs.133471	,SS,TM,FMO-like	ESTs	4.3
_	454032	W31790 Hs.194293	,SS,TM	ESTs, Weakly similar to I54374 gene NF2	4.3
5	432663	Al984317 Hs.122589	TM	ESTs	4.3
	401747		,SS,filament,filament	Homo sapiens keratin 17 (KRT17)	4.3
		NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
		Al571514 Hs.133022	,SS,TM	ESTs	4.2
10		AW073310 Hs.163533	,pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
10		Al954968 Hs.279009	,SS,TM	matrix Gla protein	4.2
		Al821005 Hs.118599	,SS,GDNF,	ESTs	4.2 4.2
		AW972565 Hs.32399	WH1,WH1	ESTs, Weakly similar to S51797 vasodilat	4.2 4.2
		NM_000399Hs.1395 Al345227 Hs.105448	zf-C2H2,SS	early growth response 2 (Krox-20 (Drosop ESTs, Weakly similar to B34087 hypotheti	4.1
15		AA829286 Hs.332053	<pre>,SS,TM,pkinase ,SS,SAA_proteins,ABC_membrane,ABC_tran</pre>		4.1
15		Al192105 Hs.147170	SS	ESTs	4.1
		Al827248 Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fis, clone HE	4.1
		Al683487 Hs.152213	wnt,	wingless-type MMTV integration site fami	4.1
		Al150491 Hs.90756	,TM,Glyco_hydro_1	ESTs	4.1
20		NM_001809Hs.1594	,SS,TM,thiolase,	centromere protein A (17kD)	4.1
	406922	S70284	SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
		AL133916 Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
		AL035588 Hs.153203	HLH,SS	MyoD family inhibitor	4.1
	429922	Z97630 Hs.226117	,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
25		AW594641 Hs.192417	,SS,TM	ESTs	4.0
	409038		SS,IL8,SS,IL8	small inducible cytokine subfamily A (Cy	4.0
		BE153855 Hs.61460	,SS,HLH	lg superfamily receptor LNIR	4.0
		NM_005357Hs.95351	,SS,TM,p450,	lipase, hormone-sensitive	4.0
20		AA479033 Hs.130315	,SS,TM	ESTs, Weakly similar to A47582 B-cell gr	4.0 4.0
30	403329		SS,SS	Target Exon	4.0
		AW014875 Hs.137007	SS SS	ESTs Weakly similar to 150250 Aptorior	4.0
		Al073913 Hs.100686	,SS,Collagen,COLFI,TSPN,	ESTs, Weakly similar to JE0350 Anterior Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
		AW451645 Hs.151504 AL133619 Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35		NM_001949Hs.1189	SS	E2F transcription factor 3	4.0
55	431958		SS,TM,Cadherin_C_term,cadherin,SS,TM,cad		4.0
		NM_013989Hs.154424	SS,T4_deiodinase,T4_deiodinase,	deiodinase, iodothyronine, type II	4.0
	447197		,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
	428722		,SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
40	428330	L22524 Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo	pematrix metalloproteinase 7 (MMP7; uterin	3.9
	423242	AL039402 Hs.125783	SS	DEME-6 protein	3.9
•	449048		SS,SS,TM	similar to S68401 (cattle) glucose induc	3.9
		M31158 Hs.77439	,SS,cNMP_binding,RIIa,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
15		AW452631 Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
45		NM_015434Hs.48604	SS	DKFZP434B168 protein	3.8
		BE247550 Hs.86859 AB006190 Hs.25475	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8 3.8
			SS,TM,MIP,SS,TM,MIP, SS	aquaporin 7 KIAA1204 protein	3.8
		N72264 Hs.300670 Al935962 Hs.26289	SS	ESTs	3.8
50		NM_007069Hs.37189	TM,TM	similar to rat HREV107	3.8
50		AA371307 Hs.125056	,SS,DENN	ESTs	3.8
		BE170651 Hs.8700	,SS,START,	deleted in liver cancer 1	3.8
		AW293165 Hs.143134	SS	ESTs	3.8
		AW873606 Hs.149006	,SS,WH1,WH1	ESTs	3.8
55	403943	•	p450,SS,p450	C5000355:gi[4503225]ref[NP_000765.1] cyt	3.8
	408761	AA057264 Hs.238936	,SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
	423279	AW959861 Hs.290943	SS	ESTs	3.8
		NM_002407Hs.97644	,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
60		Al208121 Hs.147313	,SS,TM	ESTs, Weakly similar to 138022 hypotheti	3.7
60		AW974476 Hs.183601	SS,RGS,RGS,RGS	regulator of G-protein signalling 16	3.7
		BE160198	TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
		M26380 Hs.180878	,SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7 3.7
	418203		CKS,SS,CKS, SS	CDC28 protein kinase 2 chromosome 1 open reading frame 21	3.7 3.7
65		AW292053 Hs.12532 Al878918 Hs.10526	SS	cysteine and glycine-rich protein 2	3.7
00		AW373784 Hs.71	SS,ig,MHC_I,connexin,SCAN,SS,TM	alpha-2-glycoprotein 1, zinc	3.7
		Al916662 Hs.211577	SS,TM,SS	kinectin 1 (kinesin receptor)	3.7
	,20000	,	,, -, -, -, -, -, -, -, -, -, -,		

	454071	AI041793	Hs.42502	,TM,7tm_1,	ESTs	3.7
		H44491	Hs.252938	,SS,TM,EGF,ldl_recept_a,ldl_recept_b,EGF	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
				,SS,AAA,	ESTs	3.7
-		AW194426		,SS,Glycos_transf_2,	ESTs	3.7
5		W23624	Hs.173059	SS	ESTs	3.7
		Y08565	Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
		BE379727		lipocalin,SS,lipocalin,lipocalin,ferriti	fatty acid binding protein 4, adipocyte	3.7
		AW301344		,SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
10		NM_01473		PHD,pkinase,SS	KIAA0215 gene product	3.7
10		AI126271		SS CO TM 6-2 CO TM 6-2	ESTs, Weakly similar to YZ28_HUMAN HYPOT prolactin receptor	3.7 3.7
		AA890023 AU076643		SS,TM,fn3,SS,TM,fn3,		3.7 3.7
		AA676939		,SS,TM,efhand,ion_trans SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CUI	secreted phosphoprotein 1 (osteopontin,	3.6
		Y13647	Hs.119597	SS,TM,COB,F5_F6_type_C,MAM,SS,TM,COI	stearoyi-CoA desaturase (delta-9-desatur	3.6
15		AL049176		SS	chordin-like	3.6
13		AW207175		,SS,7tm_1,SPRY,	ESTs	3.6
		T97307	110.100771	,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal liver spleen	3.6
	401866	107007		,SS,filament,	Target Exon	3.6
		U10492	Hs.438	SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20		AA502490		SS	ESTs	3.6
		NM_000909		SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
		AW089705		SS	ESTs, Weakly similar to S64329 probable	3.6
		AA284775		,SS,TM,PMP22_Claudin,	ESTs	3.6
	431830	Y16645	Hs.271387	,SS,TM,IL8	small inducible cytokine subfamily A (Cy	3.6
25	444781	NM_014400	OHs.11950	,SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
	431493	A1791493	Hs.129873	,SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
	414175	Al308876	Hs.103849	,TM,hemopexin,Peptidase_M10,hemopexin,P	ehypothetical protein DKFZp761D112	3.6
		AF245505		ig,LRRCT,	DKFZP564I1922 protein	3.6
•		Al417828		,SS,TM	ESTs	3.5
30		AA847843		,SS,HMG_box,	Homo sapiens, clone IMAGE:3351295, mRNA	3.5
		S57296	Hs.323910	,SS,TM,SH2,PH,pkinase,Recep_L_domain,Ft		3.5
		AW961400		SS DOLLAR DOLLAR	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098		pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
35		H22570	Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5 3.5
33		AA808940		,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
		NM_002543		,SS,TM	oxidised low density lipoprotein (lectin ubiquitin specific protease 18	3.5
		AA116021 Al651930		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept SS	ESTs	3.5
		BE280074		cyclin,SS,TM,cyclin,	cyclin B1	3.5
40		AW452434		SS	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
-10		NM_014918		SS	KIAA0990 protein	3.4
		AK001423		SS	Homo sapiens cDNA FLJ10561 fis, clone NT	3.4
		U25128	Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
		AA426202		,TM,ABC_membrane,ABC_tran,Ribosomal_S		3.4
45		L34041	Hs.9739		Eglycerol-3-phosphate dehydrogenase 1 (so	3.4
		AA250970		,SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-I	3.4
	418054	NM_002318	3Hs.83354	,SS,rrm,PABP,pkinase,14-3-3,rrm ,SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	3.4
	414921	BE390551	Hs.77628	SS,START,SS,START,NNMT_PNMT_TEMT,	steroidogenic acute regulatory protein r	3.4
	452268	NM_003512	2Hs.28777	SS,histone,Calc_CGRP_IAPP,ig,MHC_I,SPR	Y,H2A histone family, member L	3.4
50	428862	NM_000346	3Hs.2316	SS,HMG_box,	SRY (sex determining region Y)-box 9 (ca	3.4
		AA442324		histone,SS,histone,BolA	H2A histone family, member O	3.4
		M25809	Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	401780			filament,SS,filament,filament	NM_005557*:Homo sapiens keratin 16 (foca	3.4
		NM_004585		TM	retinoic acid receptor responder (tazaro	3.4
55		AA319233		,SS,TM,Ribosomal_L27e,	ESTs	3.4
		C18356	Hs.295944	,Kunitz_BPTI,	tissue factor pathway inhibitor 2	3.4
		AF182277		SS,p450,SS	cytochrome P450, subfamily IIB (phenobar ESTs, Weakly similar to S65824 reverse t	3.4
		AA825686		SS SS U.S		3.4
60		Y15221	Hs.103982	SS,IL8, SH2,STAT,SS,STAT	small inducible cytokine subfamily B (Cy signal transducer and activator of trans	3.4 3.4
UU		NM_005419		,pkinase,	CDC2-related protein kinase 7	3.4 3.4
	405366	AW968504	110, 120010	RhoGEF,PH,SS,RhoGEF,PH,	NM_003371*:Homo sapiens vav 2 oncogene (	3.4
		BE274552	He 76579	SAP,SS,FG-GAP,vwa	protein inhibitor of activated STAT3	3.4
		AW797437		SS,sushi,trypsin,vwa,rrm,fibrinogen C,fn	B-factor, properdin	3.3
65		H73505	Hs.117874	,SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
0.5			Hs.79299	,SS,TM	lipoma HMGIC fusion partner-like 2	3.3
		NM_006456		,SS,Pribosyltran,	sialyltransferase	3.3
				•	-	

	115162	A A 279776	Hs.288649	SS,SS	hypothetical protein MGC3077	3.3
		AA918317		SS,SS	B-cell CLL/lymphoma 11B (zinc finger pro	3.3
		AF109302		SS	prostate cancer associated protein 7	3.3
		AK000725		SS	hypothetical protein FLJ20718	3.3
5		Al141031		SS	ESTs	3.3
_		U46258	Hs.339665	SS	ESTs	3.3
			Hs.172914	,SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-cis and 9-ci	3.3
		BE327427		,SS,TM,histone,ANF_receptor,guanylate_cy	ESTs	3.3
	414575	H11257	Hs.22968	,SS,pkinase,ig,	Homo sapiens clone IMAGE:451939, mRNA se	3.3
10		AL079905		SS,TGFb_propeptide,TGF-beta,SS	transforming growth factor, beta 1	3.3
		AW881145		SS	gb:QV0-OT0033-010400-182-a07 OT0033 Homo	3.3
			Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
			Hs.164680	,SS,T-box,UDPGT	ESTs	3.3 3.3
15			Hs.280380	SS,SS,Peptidase_M1,EGF,ig,tectin_c,sushi	aminopeptidase ESTs	3.3
13			Hs.134981 Hs.159412	,pkinase,	Homo sapiens clone 24628 mRNA sequence	3.3
			Hs.293616	SS	ESTs	3.3
			Hs.123469	SS	ESTs, Weakly similar to AF208855 1 BM-01	3.3
	434228		Hs.283978	,SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
20		BE314524		TM	putative transmembrane protein	3.3
		AF084545		,SS,Peptidase_M1,	Target	3.3
	439750	AL359053	Hs.57664 .	,TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
			Hs.133483	,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	3.3
05			Hs.193139	,SS,START,NNMT_PNMT_TEMT,	ESTs	3.3
25			Hs.334838	SS	KIAA1866 protein	3.3
		Y09763	Hs.22785	SS,TM,TM	gamma-aminobutyric acid (GABA) A recepto	3.3 3.3
		N62937 BE270266	Hs.269109	,Sema,ig, SS,TM,LRRCT,LRRNT,LRR,TM,LRRCT,	ESTs 5T4 oncofetal trophoblast glycoprotein	3.3
			Hs.332649	,SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
30		N48373	Hs.10247	,SS,ig,	activated leucocyte cell adhesion molecu	3.2
20			Hs.161723	,SS,CUB,	ESTs	3.2
			Hs.334882	SS,TM,SS,TM,G-patch	hypothetical protein FLJ14251	3.2
	421458	NM_003654	4Hs.104576	SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
			Hs.313503	,Sema,ig,	ESTs	3.2
35		BE562136		,SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
			Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
	415447		Hs.78454	SS,OLF,OLF,Ribosomal_L4	myocilin, trabecular meshwork inducible	3.2
		BE548446	HS.5767	SS,TM,SSF,SS,TM	Homo sapiens mRNA; cDNA DKFZp434F152 (fr gb:EST29171 Cerebellum II Homo sapiens c	3.2 3.2
40		AA326062 BE563085	He 833	,SS,p450,p450 ,SS,TM,ubiquitin,laminin_G,laminin_EGF,k	interferon-stimulated protein, 15 kDa	3.2
<del>1</del> 0			Hs.195922	,SS,Ribosomal_L14	ESTs	3.2
			Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
		U17760	Hs.75517	SS,laminin_EGF,laminin_Nterm,adh_short,S	laminin, beta 3 (nicein (125kD), kalinin	3.2
		AF160477	Hs.61460	,SS,HLH	lg superfamily receptor LNIR	3.2
45	435575	AF213457	Hs.44234	SS,ig,SS,TM	triggering receptor expressed on myeloid	3.2
		R21651	Hs.324725	,SS,TM,Ribosomal_S3Ae,G-gamma	ESTs, Moderately similar to A47582 B-cel	3.2
		AV658411		SS	KIAA1681 protein	3.2
		NM_00315		,SS,homeobox,	stanniocalcin 1	3.2
50			Hs.270149	,SS,fn3,	ESTs, Weakly similar to 2109260A B cell	3.2 3.2
30		T47667	Hs.28005	,SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL platelet-activating factor acetylhydrola	3.2
	402837	AW247529	HS.0183	,TM,p450,Ets SS	ENSP0000241312*:DJ947L8.1.8 (novel Sush	3.2
	439451	AF086270	Hs.278554	,SS,Chromo_shadow,chromo,	heterochromatin-like protein 1	3.1
	406664		Hs.9739		Eglycerol-3-phosphate dehydrogenase 1 (so	3.1
55			Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24		3.1
		AW068115		SS,LRR,LRRNT,SS,LRRNT,LRR,	biglycan	3.1
			Hs.294022	,SS,connexin,hormone_rec,zf-C4,connexin	hypothetical protein FLJ14950	3.1
	429197	H24471	Hs.26930	,SS,Gelsolin,	ESTs, Weakly similar to T20272 hypotheti	3.1
(0)		N30714	Hs.325960	,SS,TM	membrane-spanning 4-domains, subfamily A	3.1
60		AW191962		,SS,TM,C1q,	collagen, type VIII, alpha 2	3.1
	419092		Hs.89603	SS,TM,SEA,	mucin 1, transmembrane	3.1
			Hs.114727	,SS,PK,PK SS TM 7tm 1 rrm SS	Homo sapiens, clone MGC:16327, mRNA, com TONDU	3.1 3.1
		BE281128 AK000933		SS,TM,7tm_1,rrm,SS ,TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
65		Al538613	Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
		AJ245210	0.2002	SS	gb:Homo sapiens mRNA for immunoglobulin	3.1
	400903			SS	Target Exon	3.1
		•				

			Hs.132586	,SS,Glyco_hydro_2	ESTs	3.1
		AW962597		SS,WD40,SS,WD40,	KIAA1547 protein	3.1
		Al347487		fn3,SS,TM,EF1BD	class I cytokine receptor	3.1
5		AW383226		SS	ESTs, Weakly similar to G01763 atrophin-	3.1
5		Al936442		UBACT_repeat,SS,UBACT_repeat,ThiF_fami		3.1
	419150		Hs.89640	,TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		AA587773		,SS,SRCR,	Homo sapiens, Similar to RIKEN cDNA 5830	3.1
			Hs.104211	,Sema,ig,	ESTs	3.1
4.0		BE568452		,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10		N40449	Hs.201619	SS	ESTs, Weakly similar to S38383 SEB4B pro	3.1
	412519	AA196241	Hs.73980	SS,Troponin,Hemagglutinin,SS,TM,C2,Tropo	troponin T1, skeletal, slow	3.1
	450223	AA418204	Hs.241493	,SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
	422790	AA809875	Hs.25933	,TM,histone,Sec1,histone,sugar_tr	ESTs	3.1
	424269	AW137691	Hs.199754	,SS,TM,7tm_2,GPS	ESTs	3.1
15	435854	AJ278120	Hs.4996	.SS.WD40	putative ankyrin-repeat containing prote	3.1
		AW630534		,SS,TM,rrm,oxidored_q6,oxidored_q6	Homo sapiens, clone MGC:9381, mRNA, comp	3.1
	451631			SS	gb:ye79c02.s1 Soares fetal liver spleen	3.0
		AW591433	Hs.298241	,SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
			Hs.126730	,TM,PH,	ESTs, Weakly similar to KIAA1214 protein	3.0
20			Hs.325823	,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
	456592				gb:yq10c02.r1 Soares fetal liver spleen	3.0
			Hs.162209	SS,TM,SS,TM,PMP22_Claudin,PMP22_Claudin		3.0
		H58373	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
	401197	,1000.0	110.002000	arf,arf,	ENSP00000229263*:HSPC213.	3.0
25		AW204256	Hs 291887	,wnt,	ESTs	3.0
			Hs.336432	,SS,rrm,zf-RanBP,pkinase,C2,pkinase_C,DA		3.0
		AA381807		SS,SS	hypoxia-inducible protein 2	3.0
		W27249	Hs.8109	SS	hypothetical protein FLJ21080	3.0
	404826	VVZ1 Z-13		,SS,TM	Target Exon	3.0
30	458389	U70204	Hs.160152	,SS,RA	ESTs, Weakly similar to FPHU alpha-fetop	3.0
50		AL034548		HMG_box,pkinase,zf-CCHC,SS,TM,HMG_box		3.0
		AW977653			ribonucleotide reductase M2 polypeptide	3.0
		Al820961			ESTs	3.0
				,death,ZU5,pkinase,Activin_recp,		3.0
35				SS,Cu-oxidase,SS,Cu-oxidase,Cu-oxidase	hypothetical protein FLJ22704	3.0
55		C05837	Hs.145807	,SS,TM	hypothetical protein FLJ13593	
		AA688021		SS SO TOP I A	ESTS	3.0
		AW103364		SS,TGF-beta,TGFb_propeptide,SS,TGF-beta,		3.0
		AU077005			a disintegrin and metalloproteinase doma	3.0
40		AA374569		SS	ESTs, Moderately similar to 2109260A B c	3.0
40		AB032417		Frizzled,Fz,SS,TM,Frizzled,Fz,	frizzled (Drosophila) homolog 4	3.0
		U20325		SS,SS	cocaine- and amphetamine-regulated trans	3.0
		AW385224		,SS,TM,Phosphodiest,	ectonucleotide pyrophosphatase/phosphodi	3.0
		AW300118		,SS,TM,G-gamma	ESTs	3.0
	432284	AA532807	Hs.105822	,SS,TM,pkinase,	ESTs	3.0

#### TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	.0

5

Pkey:	Unique Eos probeset identifier number
·	<b>a</b> 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	410785 411667 418636	1221055_1 1253334_1 177402_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750206
25	420854	197072_1	AW296927 AI684514 AI263168 AA281079
	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 AI908240 AA393080
30	433687	373061_1	AA743991 AA604852 AW272737
	447197	711623_1	R36075 Al366546 R36167
	451631	878098_1	R00866 R01523 Al806815
	456207	1650781	AA193450
	456592	202684_1	R91600 T87079 AA291455

# TABLE 20B

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

	15				
		Pkey	Ref	Strand	Nt_position
		400608	9887666	Minus	96756-97558
		400903	2911732	Plus	59112-59228
1	20	401045	8117619	Plus	90044-90184,91111-91345
		401093	8516137	Minus	22335-23166
		401197	9719705	Plus	176341-176452
		401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-
					131932,132451-132575,133580-134011
1	25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573
		401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
		401866	8018106	Plus	73126-73623
		402230	9966312	Minus	29782-29932
		402408	9796239	Minus	110326-110491
	30	402578	9884928	Plus	66350-66496
		402606	9909429	Minus	81747-82094
		402837	9369121	Minus	2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320
		403199	9958183	Minus	58895-59036,66618-66789
		403329	8516120	Plus	96450-96598
	3 <i>5</i>	403593	6862650	Minus	62554-62712,69449-69602
		403943	7711864	Plus	100742-100904,101322-101503
		404091	7684554	Minus	82121-83229
		404347	9838195	Plus	74493-74829
		404826	6572184	Plus	47726-48046
4	40	405366	2182280	Plus	22478-22632
		405654	4895155	Minus	53624-53759

# TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small 10 molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85<sup>th</sup> percentile value amongst 144 non-malignant tissues, and the 96<sup>th</sup> percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, 15 peptidase, phosphatase, ATPase, or ion transporter domains). The predicted protein domains are noted.

• •	i noy.
20	ExAccn:

25

5

Unique Eos probeset identifier number

UnigenelD:

Exemplar Accession number, Genbank accession number

Unigene Title:

Unigene number Unigene gene title

Dkov

Ratio of 93rd percentile tumor to 85th percentile of normal body tissue

	25						
		Pkey	ExAcen	UnigenelD	Predicted Protein Domains	UnigeneTitle	R1
				Hs.176588	SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
	• •		AA250737		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
	30	424735		Hs.272499	ŞS,TM	short-chain alcohol dehydrogenase family	53.8
			AA195651		SS,Dihydroorotase,	ESTs	39.3
			AW138959		Phosphodiest,Somatomedin_B,	ESTs	34.9
		450375	AA009647	Hs.8850	SS,TM,disintegrin,Pep_M12B_propep,Reprol	a disintegrin and metalloproteinase doma	25.7
			NM_001394		DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
	35	445730	A1624342	Hs.170042	SS,TM,Cation_efflux	ESTs	24.1
		424634	NM_003613	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		420757	X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
		424399	AI905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	20.3
		447350	Al375572	Hs.172634	pkinase,	ESTs	19.2
4	40	456207	AA193450		SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
		456938	X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cadl	ntyrosine aminotransferase	18.1
		402578			SS,p450,SS,TM,p450	C1001134:gì 2117372 pir  I65981 fatty ac	17.8
		425692	D90041	Hs.155956	SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
		424001	W67883	Hs.137476	pkinase,	paternally expressed 10	16.5
4	45	418007	M13509	Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_	_matrix metalloproteinase 1 (MMP1; inters	15.7
		421727	Y13153	Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
		411869	W20027	Hs.23439	SS,Peptidase_M1,	ESTs	13.9
		400289	X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
		443348	AW873596	Hs.182278	SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
	50	424086	Al351010	Hs.102267	SS,Lysyl_oxidase	lysyl oxidase	12.8
		400295	W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
		408771	AW732573	Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		421155	H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
		424905	NM_002497	'Hs.153704	pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
4	55	438167	R28363	Hs.24286	SS,TM,7tm_1,p450,rrm	ESTs	11.5
		459583	Al907673		pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
		423945	AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
		445263	H57646	Hs.42586	SS,Acyltransferase,	KIAA1560 protein	11.2
						•	

	423887	AL080207	Hs.134585	SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
	429859	NM_007050			protein tyrosine phosphatase, receptor t	10.4
		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase_		10.3
_		NM_000685			angiotensin receptor 1	10.3
5		AL120173		SS,pkinase,	ESTs	10.3
	402408				NM_030920*:Homo sapiens hypothetical pro	9.8
				death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4 9.1
		M31126 AB041035		SS,Peptidase_M10,hemopexin,SS,Peptidase_	NM_016931:Homo sapiens NADPH oxidase 4 (	9.1
10	400285				Eos Control	8.8
10		AF123050		TM,ABC_tran,ABC_membrane, SS,TM,ubiquitin,7tm_3,ANF_receptor,sushi	diubiquitin	8.6
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866			inositol polyphosphate-4-phosphatase, ty	8.3
	431725			SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
15	418092				ESTs	8.3
	427811			SS,Zn_carbOpept,Propep_M14,SS,Propep_M		8.2
	423554	M90516			glutamine-fructose-6-phosphate transamin	8.1
		AW242243		SS,TM,WD40,ubiquitin,E1-E2_ATPase,Cation	peroxisomal famesylated protein	7.8
•		NM_001034		SS	ribonucleotide reductase M2 polypeptide	7.6
20		NM_004482			UDP-N-acetyl-alpha-D-galactosamine:polyp	7.6
	456986			SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
					ESTs	7.3
	407721			pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2
25	418004				aldehyde dehydrogenase 3 family, member a disintegrin and metalloproteinase doma	7.2 7.1
25	410555	AW204099		TM,disintegrin,Reprolysin,	ESTs, Weakly similar to AF126780 1 retin	6.9
		AP000692		GAF,PDEase	chromosome 21 open reading frame 5	6.8
	401045	AF000032		ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		0.0
	401040	C11001883		NP_033938.1  c	-P 6.7	
30	442082				ESTs; calsyntenin-2	6.7
				TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
	404091			TM,7tm_3,ANF_receptor,	Target Exon	6.6
	450865	Al248013		zf-C2H2	ESTs, Weakly similar to I38588 reverse t	6.5
		NM_002914			replication factor C (activator 1) 2 (40	6.5
35		AF055575			calcium channel, voltage-dependent, L ty	6.4
		AA932186			ESTs	6.2
		NM_005025			serine (or cysteine) proteinase inhibito	6.2
		AW167087			ESTs	6.2
40	428795				ESTs, Highly similar to A39769 N-acetyll	6.1
40	428479				cell division cycle 2, G1 to S and G2 to	6.1 6.1
	400300	NM_012093		SS,TM,pkinase,Recep_L_domain,SH2,PH,Fut SS,adenylatekinase,	adenylate kinase 5	6.1
	402230				Target Exon	6.1
	424687			SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pep		5.8
45				6PF2K,PGAM,	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
	432239			SS.Peptidase_M10,hemopexin,SS.Peptidase_		5.6
	400286				C16000922:gi 7499103 pir  T20903 hypothe	5.6
	425247	NM_005940	Hs.155324	SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
	434737	AA828246	Hs.291884	UCH-1,pkinase,OPR,Rhodanese,AMP-binding	,ESTs	5.4
50		AF086120			ESTs	5.2
		AI806867			ESTs	5.2
	452355				G protein-coupled receptor 34	5.2
	427711				solute carrier family 25 (mitochondrial	5.2
55		AL117406			ATP-binding cassette transporter MRP8	5.1
55	425325			SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_T		
	449706	AW291095	iolamine N-meth		5.1 interleukin 20 receptor, alpha	5.1
	403593				Target Exon	5.1
		AA564991			ESTs	5.0
60		Al281848		_ <u>_</u> •	retinoic acid induced 3	4.9
		NM_000169		SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo		4.9
				TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	411096				mitochondrial intermediate peptidase	4.9
	450506	NM_004460	Hs.418	SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_	N_fibroblast activation protein, alpha	4.9
65		AA641836	Hs.30085	SS,trypsin	hypothetical protein FLJ23186	4.9
	447752	M73700	Hs.105938		lactotransferrin	4.8
	427122	AW057736	Hs.323910	SS,TM,pkinase,Recep_L_domain,SH2,PH,Fur	nHER2 receptor tyrosine kinase (c-erb-b2,	4.8
				316		
				310		

	400181		•	SS,TM,3Beta_HSD,	ENSP00000171555:CDNA FLJ10727 fis, clone	4.6
	452093	AA447453	Hs.27860	SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
•	435542	AA687376	Hs.269533	SS.pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
	417576	AA339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
5			Hs.270651	pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
-			Hs.146688	SS,TM,MAPEG,	prostaglandin E synthase	4.5
		H26735	Hs.91668		Homo sapiens clone PP1498 unknown mRNA	4.5
		Al345455			GA-binding protein transcription factor,	4.5
				pkinase,OPR,		4.5
10		AI910275		SS,trefoil,SS,TM,ldl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	
10		AA863360		SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AW294092	HS.21594	SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
	400205				NM_006265*:Homo sapiens RAD21 (S. pombe)	4.4
		AW296927		SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
			Hs.278627	SS,pyr_redox,SS,Ribosomal_L39	prenylcysteine lyase	4.3
15	441560	F13386	Hs.7888	pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	416445	AL043004	Hs.79337	SS,pkinase,	KIAA0135 protein	4.3
	439024	R96696	Hs.35598	SS,TM,trypsin,vwd,ig	ESTs	4.3
			7Hs.279696	pkinase,pkinase_C,	serum/glucocorticold regulated kinase-li	4.2
			Hs.163533	pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
20	453775	NM_00291	6He 35120	SS,AAA,PI3_PI4_kinase,PI3Ka,PI3K_rbd,PI3		4.2
20			Hs.105448	SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
				SS,SAA_proteins,ABC_membrane,ABC_tran,		4.1
			Hs.332053			4.1
		NM_00180		SS,TM,thiolase,	centromere protein A (17kD)	
25		U38945	Hs.1174	ank,ank	cyclin-dependent kinase inhibitor 2A (me	4.1
25	406922			SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
			Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
	429922		Hs.226117	SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
	420139	NM_00535	7Hs.95351	SS,TM,p450,	lipase, hormone-sensitive	4.0
	425071	NM_013989	9Hs.154424	SS,T4_deiodinase,T4_deiodinase,	deiodinase, iodothyronine, type II	4.0
30	424511	BE300512	Hs.193557	SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
		U76456	Hs.190787	SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
	428330		Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo		3.9
		M31158	Hs.77439	SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
			Hs.313803	SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
35		BE247550		SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
55					ESTs	3.8
		AA 129040	Hs.128065	SS,Peptidase_C1,gpdh		3.8
	403943	41/050705	22. 470004	p450,SS,p450	C5000355:gi 4503225 ref NP_000765.1  cyt	
			Hs.173334	00 714 71 4	ELL-RELATED RNA POLYMERASE II, ELONGATIO	3.8
40			Hs.238936	SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
40		M26380	Hs.180878	SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
		X54942	Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7
		Al041793		TM,7tm_1,	ESTs	3.7
	424676	Y08565	Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
	457465	AW301344	Hs.122908	SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
45	417601	NM_01473	5Hs.82292	PHD,pkinase,SS	KIAA0215 gene product	3.7
	446619	AU076643	Hs.313	SS,TM,efnand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	406625	Y13647	Hs.119597	SS,TM,Desaturase,SS	stearoyl-CoA desaturase (delta-9-desatur	3.6
			Hs.106771	SS,7tm_1,SPRY,	ESTs	3.6
			9Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
50		NM_00315		SS,pkinase,vwa,vwa,Glyco_transf_8	serine/threonine kinase 2	3.6
50		NM_014400		SS,PH,lactamase B	GPI-anchored metastasis-associated prote	3.6
	494/01	VINTO 14400	Uns. 1 1330	· · · —	ESTs, Weakly similar to A36036 cytochrom	3.6
			Hs.129873	SS,p450,p450		
			Hs.194687	7111 1 7 11 1401 1 7	cholesterol 25-hydroxylase	3.6
ے ہے		Al308876	Hs.103849	TM,hemopexin,Peptidase_M10,hemopexin,Pe	epnypotnetical protein DKFZp761D112	3.6
55		AW895719		TM,ion_trans,K_tetra,	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
		NM_00381			a disintegrin and metalloproteinase doma	3.6
	425320		Hs.83190	Acyl_transf,adh_zinc,ketoacyl-synt,pp-bi	fatty acid synthase	3.5
			Hs.271699	IMS,SS	polymerase (DNA directed) iota	3.5
	407104	S57296	Hs.323910	SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
60	449051	AW961400	Hs.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098		pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
	454042		Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
		AA116021		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
		AF039241		Peptidase_M24,	histone deacetylase 5	3.5
65	412070	VII 0005741	Hs.177534	DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
05	412049		Hs.18268	SS,adenylatekinase,	adenylate kinase 5	3.5
	425776		Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
	723110	023120	113.100700	00,177,1 BIL_2,00,117,7 BIL_2	Asserting total of the second	0.7

	407040	4.4.400000 11.40400	71400	24 Ob at 000 tata a disaster a financia	0.4
		AA426202 Hs.40403		54eCbp/p300-interacting transactivator, wit	3.4
		L34041 Hs.9739		PE-glycerol-3-phosphate dehydrogenase 1 (so	3.4
		AA250970 Hs.25194		poly(A)-binding protein, cytoplasmic 1-l	3.4
_		NM_002318Hs.83354		lysyl oxidase-like 2	. 3.4
5		AA833930 Hs.28803		tRNA isopentenylpyrophosphate transferas	3.4
	410530	M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	407021	U52077	• = • • • •	gb:Human mariner1 transposase gene, comp	3.4
	421168	AF182277 Hs.33078	0 SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
		AA825686 Hs.32117		ESTs, Weakly similar to S65824 reverse t	3.4
10		AW968504 Hs.12307		CDC2-related protein kinase 7	3.4
- 0		NM_001141Hs.11125		arachidonate 15-lipoxygenase, second typ	3.3
		AW797437 Hs.69771		B-factor, properdin	3.3
		H73505 Hs.11787		ESTs	3.3
		NM_006456Hs.28821		sialyltransferase	3.3
15					3.3
13		AF037062 Hs.17291		retinol dehydrogenase 5 (11-cis and 9-ci	
		H11257 Hs.22968		Homo sapiens clone IMAGE:451939, mRNA se	3.3
		Al267371 Hs.17263		ESTs	3.3
		Al161293 Hs.28038		aminopeptidase	3.3
•		AF052152 Hs.15941		Homo sapiens clone 24628 mRNA sequence	3.3
20		Z42047 Hs.28397	8 SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
	433264	D85782 Hs.3229		cysteine dioxygenase, type I	3.3
		AF084545	SS,Peptidase_M1,	Target	3.3
	439750	AL359053 Hs.57664	TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
		R19897 Hs.10660		ESTs	3.3
25	452194	Al694413 Hs.33264	9 SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
		NM_003654Hs.10457		carbohydrate (keratan sulfate Gal-6) sul	3.2
		BE562136 Hs.9736	SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
		D86983 Hs.11889		Melanoma associated gene	3.2
		AA326062	SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	3.2
30		Al768235	SS,Trehalase	gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S	3.2
50		T47667 Hs.28005		Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
		AW247529 Hs.6793	TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
		U39817 Hs.36820		Bloom syndrome	3.1
					glycerol-3-
35		L34041 Hs.9739	SS,TM,transport_prot,SWIB,RhoGAP,DAG_	PE	glycerol-3-
33		te dehydrogenase 1 (s		FOT-	2.4
		R31770 Hs.23540		ESTs	3.1
		U77413 Hs.10029		O-linked N-acetylglucosamine (GlcNAc) tr	3.1
		BE281128 Hs.9030	SS,TM,7tm_1,rrm,SS	TONDU	3.1
4.0		AK000933 Hs.28661		Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
40		Al538613 Hs.29824		Transmembrane protease, serine 3	3.1
		T29618 Hs.89640		TEK tyrosine kinase, endothelial (venous	3.1
	444443	Al149286 Hs.55099	SS	rab6 GTPase activating protein (GAP and	3.1
	426283	NM_003937Hs.16913	9	kynureninase (L-kynurenine hydrolase)	3.1
		BE568452 Hs.5101	SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
45	450223	AA418204 Hs.24149		natural killer-tumor recognition sequenc	3.1
-		AW137691 Hs.19975		ESTs	3.1
		AW591433 Hs.29824		Transmembrane protease, serine 3	3.0
		BE077084 Hs.33643			3.0
	.020			· <del>-</del>	

#### TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

	4 1
1	11
•	v

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	420854	197072_1	AW296927 Al684514 Al263168 AA281079
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	451264	863988_1	Al768235 R31400 H29082 H23107
	455325	1279475_1	AW895719 N31451 N41451
	456207	1650781	AA193450

## TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
20	402230 402408 402578 403593	9796239 9884928	Plus Minus Minus Plus Minus Plus Minus	90044-90184,91111-91345 29782-29932 110326-110491 66350-66496 62554-62712,69449-69602 100742-100904,101322-101503 82121-83229

# TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 22 shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85<sup>th</sup> percentile value for 12 non-malignant breast specimens, and the 96<sup>th</sup> percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10	

5

Unique Eos probeset identifier number

ExAccn: UnigeneiD: Exemplar Accession number, Genbank accession number

15 Unigene Title:

Pkey:

Unigene number Unigene gene title

Ratio of 90th percentile tumor to 85th percentile normal breast tissue

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	400292	AA250737	Hs.72472	BMP-R1B	51.5
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	38.3
		Al127076	Hs.334473	hypothetical protein DKFZp564O1278	29.9
	431448	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	26.9
25	451110	Al955040	Hs.265398	ESTs, Weakly similar to transformation-r	25.8
	431211	M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	23.2
	418203	X54942	Hs.83758	CDC28 protein kinase 2	22.6
	407980	AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
	414646	AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
	409041	AB033025	Hs.50081	KIAA1199 protein	17.6
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	17.6
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	17.1
0.5		A1263307	Hs.239884	H2B histone family, member L	17.0
35		T97307		gb:ye53h05.s1 Soares fetal liver spleen	16.1
		D90041		N-acetyltransferase 1 (arylamine N-acety	16.1
		Al440266	Hs.170673		16.0
		AA321649	Hs.2248	small inducible cytokine subfamily B (CX	15.5
40		NM_01439		similar to lysosome-associated membrane	15.1
40		AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.9
		AA746503	Hs.283313		14.7
		H60720	Hs.81892	KIAA0101 gene product	14.4
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082	
15		Al768015	Hs.92127	ESTs	14.2 14.1
45		A1733881	Hs.72472	BMP-R1B	13.8
		AW840171 AL120659	Hs.265398		13.8
	400205		Hs.6111	aryl-hydrocarbon receptor nuclear transl NM_006265*:Homo sapiens RAD21 (S. pomb	
		AA489732	Hs.154918		13.4
50		AA948033	Hs.130853		13.3
50		AL120173	Hs.301663		13.2
	449722		Hs.23960	cyclin B1	13.2
		M18728	113.20000	gb:Human nonspecific crossreacting antig	13.0
	406690		Hs.220529		12.8
55	429925		6Hs.226213	cytochrome P450, 51 (lanosterol 14-alpha	12.8
		U33632	Hs.79351	potassium channel, subfamily K, member 1	12.7
		Al493046	Hs.146133		12.5
	441377		Hs.202656		12.5
		AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sa	
60		AA436989	Hs.121017	H2A histone family, member A	12.2
	407811	AW190902		cysteine knot superfamily 1, BMP antagon	12.2
	407178	AA195651	Hs.104106		12.2

	420931			small inducible cytokine B subfamily (Cy	12.1
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	12.0 12.0
		Al031771 H44186	Hs.132586 Hs.15456	PDZ domain containing 1	11.9
5		BE178536		membrane-spanning 4-domains, subfamily A	11.8
•		AW873596			11.7
		NM_006159		nel (chicken)-like 2	11.7
		AF026944		ESTs	11.6
10		AA156781		metallothionein 1E (functional)	11.5
10		AW975398			11.4
		H15261 AW600291	Hs.21948	ESTs hypothetical protein FLJ10430	11.3 11.3
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	11.3
		BE336654		H3 histone family, member A	11.2
15		Al633559	Hs.310359		11.2
	430770	AA765694			11.0
		Al684808		programmed cell death 9 (PDCD9)	10.9
	452461			transcription factor	10.7
20		AA576953		hypothetical protein FLJ13352	10.6 10.6
20		AW965339 Al370413		hypothetical protein FLJ22418	10.4
		W67883		paternally expressed 10	10.4
		Al199268		Homo sapiens, Similar to RIKEN cDNA 2010	
				NIMA (never in mitosis gene a)-related k	10.1
25		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, com	
		AW167087			10.1
				Homo sapiens cDNA FLJ11382 fis, clone HE	
		AA399272 Al624342	Hs.170042		10.1 10.0
30		A1926047	Hs.162859		10.0
50		AL355715		programmed cell death 9	9.9
		AW966399		hypothetical protein FLJ20086	9.9
	432169	Y00971	Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
2.5		H23789	Hs.144530	EST	9.9
35		Al655499	Hs.161712		9.8
				CGI-49 protein	9.8 9.7
		BE613126 C16391	ns.47703	B aggressive lymphoma gene gb:C16391 Clontech human aorta polyA mRN	
		AA151342	Hs 12677	CGI-147 protein	9.7
40		AI064690	Hs.171176		9.7
		AI022650	Hs.8117	erbb2-interacting protein ERBIN	9.7
	435570	AF212222		uncharacterized bone marrow protein BM04	9.7
		AL360204		Homo sapiens mRNA full length insert cDN	9.6
15				cholesterol 25-hydroxylase	9.6
45		D60730	Hs.57471	ESTs	9.6
		Al375499 R31178	Hs.27379	ESTs fibronectin 1	9.5 9.3
				leucine-rich repeat-containing 2	9.3
		R17798	Hs.7535	COBW-like protein	9.3
50		U80736		trinucleotide repeat containing 9	9.2
	432596	AJ224741			9.2
	439451	AF086270	Hs.278554	heterochromatin-like protein 1	9.2
		AA410943	11 00470	gb:zt32h03.r1 Soares ovary tumor NbHOT H	9.1
55	442432		Hs.38178	hypothetical protein FLJ23468 ESTs, Moderately similar to ZN91_HUMAN Z	9.1
55	446715	AW732573	Hs.173919 Hs 47584	potassium voltage-gated channel, delayed	9.0
	437021	AI076089	Hs.292239		9.0
	428479		Hs.184572	cell division cycle 2, G1 to S and G2 to	8.9
		Al767756	Hs.82302	Homo sapiens cDNA FLJ14814 fis, clone NT	8.9
60	402408			NM_030920*:Homo sapiens hypothetical pro	8.9
	418601			calmegin	8.8
	426327		Hs.44898	Homo sapiens clone TCCCTA00151 mRNA se	8.8 8.8
	419519	Al198719 AW296024	Hs.176376 Hs.150434		8.8
65		AI754693	Hs.145968		8.8
		Al745649	Hs.26549	KIAA1708 protein	8.7
		AW594641			8.7

	427585	D31152 Hs.17	79729	collagen, type X, alpha 1 (Schmid metaph	8.6
	415857	AA866115 Hs.12	27797	Homo sapiens cDNA FLJ11381 fis, clone HE	8.6
			53944		8.6
	431374	BE258532 Hs.25	51871	CTP synthase	8.4
5		AW067903 Hs.82		collagen, type XI, alpha 1	8.4
	437211	AA382207 Hs.55	509	ecotropic viral integration site 2B	8.3
		AA767373 Hs.35		ESTs, Moderately similar to ALU1_HUMAN A	8.3
	423887	AL080207 Hs.13	34585	DKFZP434G232 protein	8.2
		BE268362 Hs.75	535	COBW-like protein	8.2
10	429859	NM_007050Hs.22	25952	protein tyrosine phosphatase, receptor t	8.2
		AJ132592 Hs.59		zinc finger protein 281	8.2
	431725	X65724 Hs.28		Norrie disease (pseudoglioma)	8.1
	446258	AI283476 Hs.26	3478	ESTs	8.1
	416747	AW876523 Hs.15	5929	hypothetical protein FLJ12910	8.1
15	434424	Al811202 Hs.32	25335	Homo sapiens cDNA: FLJ23523 fis, clone L	8.1
	421650	AA781795 Hs.12	22587	ESTs	8.0
	429534	AW976987 Hs.16	33327	ESTs, Weakly similar to 2109260A B cell	8.0
				DNA replication factor	8.0
		AW293165 Hs.14			8.0
20	436481	AA379597 Hs.51	199	HSPC150 protein similar to ubiquitin-con	8.0
	418216	AA662240 Hs.28		AF15q14 protein	8.0
	418250	U29926 Hs.83	3918	adenosine monophosphate deaminase (isofo	7.9
	400285	NA		Eos Control	7.9
	401464	AF039241 Hs.90	028	histone deacetylase 5	7.9
25	407242	M18728		gb:Human nonspecific crossreacting antig	7.8
	422232			transcription factor EC	7.8
				hypothetical protein FLJ23403	7.8
				aminopeptidase	7.8
•				wingless-type MMTV integration site fami	7.7
30				ESTs, Weakly similar to I55214 salivary	7.6
	408805			vaccinia related kinase 1	7.6
	437207			hypothetical protein FLJ12910	7.6
		AK001741 Hs.87		hypothetical protein FLJ10879	7.6
25				kynureninase (L-kynurenine hydrolase)	7.5
35	424687			matrix metalloproteinase 9 (gelatinase B	7.5
		NM_016293Hs.14		bridging integrator 2	7.5 7.5
	433426 406639		33525	gb:Human T-cell receptor (V beta 18.1, J	7.5 7.5
		AW512260 Hs.87		ESTs	7.4
40				kinesin protein 9 gene	7.4
10		NM_001809Hs.15		centromere protein A (17kD)	7.4
				Homo sapiens, clone MGC:12318, mRNA, cor	
				ELL-RELATED RNA POLYMERASE II, ELON	
		BE391804 Hs.62		guanylate binding protein 1, interferon-	7.3
45	400268			NM_003292:Homo sapiens translocated prom	7.3
	439509	AF086332 Hs.58	3314	ESTs	7.3
	407771	AL138272 Hs.62	2713	ESTs	7.3
	407202	N58172 Hs.10	09370	ESTs	7.3
	433096	AU076803 Hs.28	32975	carboxylesterase 2 (intestine, liver)	7.2
50	422094			F-box only protein 5	7.1
				ESTs, Weakly similar to JE0350 Anterior	7.1
		AW182459 Hs.12		ESTs, Weakly similar to LEU5_HUMAN LEUK	
		AA398155 Hs.97	7600	ESTs	7.0
<i></i>		Al475858		gb:tc87d07.x1 NCI_CGAP_CLL1 Homo sapier	
55					7.0
		BE062906 Hs.28		KIAA1546 protein	7.0
		AK001468 Hs.62		anillin (Drosophila Scraps homolog), act	7.0
		AA808229 Hs.16		ESTS	6.9
60		AW241821 Hs.30			6.9
60		Al263293 Hs.15 AW500106 Hs.23		cytochrome P450, subfamily IIJ (arachido serine/threonine protein kinase MASK	6.8 6.8
		AW449211 Hs.10		GDNF family receptor alpha 1	6.8
		AA135257 Hs.47		B aggressive lymphoma gene	6.8
			93002		6.7
65		AF123050 Hs.44		diubiquitin	6.7
00	422956	BE545072 Hs.12	22579	hypothetical protein FLJ10461	6.7
	446651	AA393907 Hs.97		ESTs	6.7

		U24577	Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
		AA810265	Hs.122915	ESTs	6.7
		Al910275 AW023482	Hs.1406	trefoil factor 1 (pS2) ESTs	6.7 6.6
5	429597			a disintegrin and metalloproteinase doma	6.6
	422634		Hs.118821	CGI-62 protein	6.6
	421072	Al215069	Hs.89113	ESTs	6.5
		Al798680	Hs.25933	ESTs	6.5
10		N40449	Hs.201619	ESTs, Weakly similar to S38383 SEB4B pro	6.5
10	449343	Al151418 NM 001898	Hs.272458	protein phosphatase 3 (formerly 2B), cat cystatin SN	6.4 6.4
	447164	AF026941	Hs.17518	Homo sapiens cig5 mRNA, partial sequence	6.4
	456938		Hs.161640	tyrosine aminotransferase	6.4
		Al820961	Hs.193465	ÉSTs	6.4
15		NM_003866			6.4
		U65011	Hs.30743	preferentially expressed antigen in mela	6.4
		AA918317 AJ235664	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro gb:Homo sapiens mRNA for immunoglobulin	6.4 6.3
		A1222020	Hs.182364		6.3
20		AF217513		clone HQ0310 PRO0310p1	6.3
	434340	Al193043	Hs.128685	ESTs, Weakly similar to T17226 hypotheti ,	6.2
		AA394183	Hs.26873	ESTs	6.2
	402578	4141404004	1)- 700	C1001134:gi 2117372 pir  165981 fatty ac	6.2
25	409646	AW161391 W17064	Hs.332848	deoxycytidine kinase SWI/SNF related, matrix associated, acti	6.1 6.1
23	432415	T16971	Hs.289014		6.1
		Al082692	Hs.134662		6.1
	420929	Al694143	Hs.296251		6.1
20		BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	6.1
30		Al126772	Hs.40479	ESTs	6.0 6.0
		BE463721 U23752	Hs.97101 Hs.32964	putative G protein-coupled receptor SRY (sex determining region Y)-box 11	6.0
	425397	J04088		topoisomerase (DNA) II alpha (170kD)	6.0
	418007		Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
35	428585	AB007863		KIAA0403 protein	6.0
		AA761605		ESTs, Weakly similar to ALU1_HUMAN ALU	
		AA583206	Hs.2156	RAR-related orphan receptor A	6.0 6.0
		M31126 R45154	Hs.272620 Hs.106604	•	6.0
40	447051			ESTs, Weakly similar to Con1 [H.sapiens]	6.0
		AA972965	Hs.135568		6.0
		X81334	Hs.2936	matrix metalloproteinase 13 (collagenase	6.0
		AA100847		ESTs, Highly similar to AF174600 1 F-box	5.9
45		Al831297 AW972512	Hs.123310	sin3-associated polypeptide, 30kD	5.9 5.9
40		AW803341	115.20505	gb:IL2-UM0079-090300-050-D03 UM0079 Ho	
		BE548555	Hs.118554	CGI-83 protein	5.9
	451398	Al793124	Hs.144479		5.9
50	441881			hypothetical protein FLJ22624	5.8
50		AI005043	Hs.24143	Wiskott-Aldrich syndrome protein interac	5.8 5.8
	416636	N32536 Al375572	Hs.42645 Hs.172634	solute carrier family 16 (monocarboxylic	5.8
		AA305599		hypothetical protein PRO2013	5.8
	409151	AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	5.8
55		Al571940	Hs.7549	ESTs	5.8
	452281	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.8
		Al299139 Al033965	Hs.17517	ESTs sterol-C4-methyl oxidase-like	5.8 5.8
	430361	X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	5.7
60		AV657117		ESTs, Moderately similar to \$65657 alpha	5.7
~ ~		AA831879	Hs.136985	ESTs	5.7
		W47595	Hs.169300	transforming growth factor, beta 2	5.7
	452401	NM_00711	5Hs.29352	tumor necrosis factor, alpha-induced pro	5.7 5.7
65	448663	BE614599 AW016531	MS.106823	hypothetical protein MGC14797	5.7 5.7
05		Z47553	Hs.14286	flavin containing monooxygenase 5	5.7
	428336	AA503115	Hs.183752	microseminoprotein, beta-	5.6
				•	

	430379	AF134149	Hs.240395	potassium channel, subfamily K, member 6	5.6
				metallothionein-like 5, testis-specific	5.6
	444758	AL044878	Hs.11899		5.6
_		AF098158	Hs.9329	chromosome 20 open reading frame 1	5.6
5		X03635	Hs.1657	estrogen receptor 1	5.6
			Hs.301570		5.6
		AL157504		Homo sapiens mRNA; cDNA DKFZp586O072	
			Hs.212184		5.5
10		R41396	Hs.101774	hypothetical protein FLJ23045	5.5
10				hypothetical protein FLJ13782	5.5
		BE247706	ns.69/51	membrane-spanning 4-domains, subfamily A	
	401645	BE277414	He 5047	C16001440*:gi]12330704]gb]AAG52890.1]AF	
		AI734009		mel transforming oncogene (derived from KIAA1603 protein	5.5 5.4
15		Al742605	Hs.193696		5.4
10		NM_01598		cytokine receptor-like molecule 9	5.4
		X91221	Hs.144465		5.4
		R28363	Hs.24286	ESTs	5.4
		BE392914		Homo sapiens cDNA FLJ11344 fis, clone PL	
20		H59846		ESTs, Moderately similar to ALU7_HUMAN A	
	413554	AA319146		secretogranin II (chromogranin C)	5.4
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648	ESTs	5.4
~ =			Hs.150823		5.4
25		AF025441		Opa-interacting protein 5	5.3
		AA576635		CGI-48 protein	5.3
		AA814100		ESTs	5.3
		U91616	Hs.91640	nuclear factor of kappa light polypeptid	5.3
30		H39960		Homo sapiens cDNA FLJ12280 fis, clone MA	
30		AF070526		Homo sapiens clone 24787 mRNA sequence	
	449001	AW901400	He 172012	HER2 receptor tyrosine kinase (c-erb-b2, hypothetical protein DKFZp434J037	5.2
	431070	AVV909311	He 2/018/	transcription factor 19 (SC1)	5.2 5.2
		U65590	Hs.81134	interleukin 1 receptor antagonist	5.2
35				polyadenylate binding protein-interactin	5.2
	428804	AK000713	Hs.193736	hypothetical protein FLJ20706	5.2
		AF077345			5.2
	403485			C3001813*:gi 12737279 ref XP_012163.1  k	5.2
4.0	422168	AA586894		S100 calcium-binding protein A7 (psorias	5.1
40	421937	A1878857	Hs.109706	hematological and neurological expressed	5.1
	426752	X69490	Hs.172004	titin	5.1
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.1
		M81933	Hs.1634	cell division cycle 25A	5.1
45		Al810054	Hs.14119	ESTs	5.1
43				ESTs, Moderately similar to ALU7_HUMAN A	
		AL121278	Hs.25144	ESTs	5.1
	404347	M30703	Lia 070000	Target Exon	5.1
		D28235		amphiregulin (schwannoma-derived growth prostaglandin-endoperoxide synthase 2 (p	5.1
50		BE568452	Hs.5101	protein regulator of cytokinesis 1	5.1 5.1
50		R43646	Hs.12422	ESTs	5.1
		AK000796	Hs.4104	hypothetical protein	5.0
		H74319	Hs.188620		5.0
		AA993138			5.0
55		AA305688		UDP-Gal:betaGlcNAc beta 1,3-galactosyltr	5.0
	405348	NA		C7001664:gi 12698061 dbj BAB21849.1  (AB	
	436196	AK001084	Hs.333498	Homo sapiens cDNA FLJ10222 fis, clone HE	5.0
	437065	AL036450	Hs.103238	ESTs	5.0
	410196	Al936442	Hs.59838	hypothetical protein FLJ10808	5.0
60		NM_006235		POU domain, class 2, associating factor	5.0
		AU076643	Hs.313		4.9
	403329		11 0000-	Target Exon	4.9
		BE623003		Homo sapiens clone TCCCTA00142 mRNA se	
65		AI820662	Hs.129598		4.9
65		AW371048 AW966163	US:33/20	H4 histone family, member H	4.9
		AW966163 AL046017	He 192270	gb:EST378236 MAGE resequences, MAGI Ho calmodulin 2 (phosphorylase kinase, delt	
	700013	ALV40017	113.1022/0	camodami z (phosphorylase kinase, delt	4.9

		AA650274		fibronectin leucine rich transmembrane p	4.9
		NM_002104	4Hs.3066	granzyme K (serine protease, granzyme 3;	4.9
		R10799	Hs.191990		4.8
	452020	AA722012	Hs.255757	ESTs, Weakly similar to AT2A_HUMAN POTE	N4.8
5	449048	Z45051	Hs.22920	similar to S68401 (cattle) glucose induc	4.8
	408369	R38438	Hs.182575	solute carrier family 15 (H??? transport	4.8
	431645	AF078849		dynein light chain-A	4.8
	423575	C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	4.8
	444246	H93281	Hs.10710	hypothetical protein FLJ20417	4.8
10	421524	AA312082	Hs.105445	GDNF family receptor alpha 1	4.8
	452827	Al571835	Hs.55468	ESTs	4.8
	414222	AL135173	Hs.878	sorbitol dehydrogenase	4.8
	456086	AL161999	Hs.77324	eukaryotic translation termination facto	4.8
	419078	M93119	Hs.89584	insulinoma-associated 1	4.8
15	418973	AA233056	Hs.191518	ESTs	4.8
	447033	Al357412	Hs.157601	ESTs	4.8
	451621	AI879148	Hs.26770	fatty acid binding protein 7, brain	4.7
	419968	X04430	Hs.93913	interleukin 6 (interferon, beta 2)	4.7
	424326	NM_014479	9Hs.145296	disintegrin protease	4.7
20	431585	BE242803	Hs.262823	hypothetical protein FLJ10326	4.7
	429294	AA095971	Hs.198793	Homo sapiens cDNA: FLJ22463 fis, clone H	4.7
	416814	AW192307	Hs.80042	dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl	4.7
	439897	NM_015310	0Hs.6763	KIAA0942 protein	4.7
	429687	A1675749	Hs.211608	nucleoporin 153kD	4.7
25	422880	AF228704	Hs.121524	glutathione reductase	4.7
	405801			NM_000390:Homo sapiens choroideremia (Ra	4.6
		BE218886	Hs.282070	ESTs	4.6
	439544	W26354	Hs.28891	hypothetical protein FLJ11360; artemis p	4.6
20		U62027		complement component 3a receptor 1	4.6
30		AI864053	Hs.39972	ESTs, Weakly similar to l38588 reverse t	4.6
			Hs.337404		4.6
	403366	NA		Target Exon	4.6
	402542	11040074	11 45007	Target Exon	4.6
35		Al916071	Hs.15607	Homo sapiens Fanconì anemia complementat	
33		Al907114	Hs.71465	squalene epoxidase	4.6 4.6
		Al264155 Al459306	Hs.24908	CDP-diacylglycerol synthase (phosphatida ESTs	4.5
			Hs.245123		4.5
		Al472209	Hs.323117		4.5
40		AW630534		Homo sapiens, clone MGC:9381, mRNA, com	
		AF146761		BCM-like membrane protein precursor	4.5
		Al692181	Hs.49169	KIAA1634 protein	4.5
		AW962128	.10.10.100	gb:EST374201 MAGE resequences, MAGG H	
			Hs.254881		4.5
45		Al815395		fatty acid desaturase 2	4.5
				ESTs, Weakly similar to 2109260A B cell	4.4
		Al377755	Hs.120695		4.4
	400409	AF153341	Hs.283954	Homo sapiens winged helix/forkhead trans	4.4
		AA121673		zinc finger protein 281	4.4
50	426989	AI815206	Hs.99395	ESTs	4.4
	401866			Target Exon	4.4
	418819	AA228776	Hs.191721	ESTs	4.4
	406348			Target Exon	4.4
		AW895387		gb:QV4-NN0038-300300-157-c10 NN0038 Ho	
55		AW297880	Hs.98661	ESTs	4.4
		AW862214		gb:QV4-CT0361-301299-074-b05 CT0361 Ho	
				HSPC039 protein	4.4
				guanylate cyclase 1, soluble, beta 2	4.4
60				DKFZP586D0824 protein	4.4
60		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	
				low density lipoprotein-related protein	4.3
		AA706003		ESTs	4.3
	429922			H1 histone family, member 0	4.3
65	421379		HS. 103982	small inducible cytokine subfamily B (Cy HER2 receptor tyrosine kinase (c-erb-b2,	4.3 4.3
00	400300	AL041243	Hs.174104		4.3
	446595		Hs.15467	hypothetical protein FLJ20725	4.3
	440000	101740	110, 10701		

	403011	NA		ENSP00000215330*:Probable serine/threoni	4.3
	419055	Al365384	Hs.11571	Homo sapiens cDNA FLJ11570 fis, clone HE	4.3
		NM_001949		E2F transcription factor 3	4.3
~		AA687538		tetraspan 1	4.3
5				KIAA0704 protein	4.3
		AW188551		hypothetical protein FLJ14007	4.3
	441029		Hs.179246		4.3
			Hs.77424	olfactory receptor, family 2, subfamily	4.3 4.2
10				Fc fragment of IgG, high affinity Ia, re Homo sapiens cDNA FLJ14035 fis, clone HE	
10	452110		Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.2
				nucleolar phosphoprotein Nopp34	4.2
		AW953937		ESTs	4.2
	431818	AW510444 I	Hs.191705	ESTs, Weakly similar to T47184 hypotheti	4.2
15			Hs.164226		4.2
				ESTs, Weakly similar to S72482 hypotheti	4.2
		BE091926 I		mitotic spindle coiled-coil related prot	4.2
				DEME-6 protein	4.2
20		AA902953 I			4.2
20			Hs.50002	small inducible cytokine subfamily A (Cy	4.2
	495025	Δ\λ/G3ΩΛRR I	He 325820	hypothetical protein FLJ22635 protease, serine, 23	4.2 4.2
		BE247676		E-1 enzyme	4.2
		AK001376		hypothetical protein FLJ10514	4.1
25		AW779318 I		ESTs	4.1
				chloride channel, calcium activated, fam	4.1
		AW294909 I		ESTs	4.1
		BE244074 I		regulator of Fas-induced apoptosis	4.1
20		AW973352 I			4.1
30	425247	NM_0059401	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.1
		AF041163 I	HS./464/	Human T-cell receptor active alpha-chain	4.1
		BE562826 AK000136 F	Un 10760	gb:601336534F1 NIH_MGC_44 Homo sapien	
		AA383471 H		asporin (LRR class 1) conserved gene amplified in osteosarcoma	4.1 4.1
35	405850		113.100003	Target Exon	4.1
			Hs.190489		4.0
		AW292425 H			4.0
	400284			estrogen receptor 1	4.0
4.0			Hs.102987	ESTs	4.0
40			Hs.2488	lymphocyte cytosolic protein 2 (SH2 doma	4.0
		AW797437 F		B-factor, properdin	4.0
				Human clone 23948 mRNA sequence	4.0
		AA013051 H		topoisomerase (DNA) II binding protein	4.0
45	419092		Hs.89603 Hs.19030	mucin 1, transmembrane ESTs	4.0 4.0
73		AW963372 H		PRO2000 protein	4.0
	433404		Hs.102720		4.0
				thymidine kinase 1, soluble	4.0
		BE250127 H		CDC20 (cell division cycle 20, S. cerevi	3.9
50	414602	AW630088 H		Homo sapiens mRNA; cDNA DKFZp564B1264	f (f3.9
		AW411479 H	Hs.848	FK506-binding protein 4 (59kD)	3.9
	404580			NM_014112*:Homo sapiens trichorhinophala	
		AB018345 H	HS.2/65/	KIAA0802 protein	3.9
55	416658	AA031956	Ja 70422	gb:zk15e04.s1 Soares_pregnant_uterus_NbH fibrillin 2 (congenital contractural ara	
55				pre-B-cell leukemia transcription factor	3.9 3.9
				ATP-binding cassette transporter MRP8	3.9
		AW134924 F			3.9
	418918				3.9
60			Hs.110165		3.9
		AI201183 F	4s.130251	ESTs	3.9
			ls.330780	cytochrome P450, subfamily IIB (phenobar	3.9
		AW935490 F	ls.14658	Human chromosome 5q13.1 clone 5G8 mRNA	
<b>65</b>		BE019020 F			3.9
65		NM_002543H			3.9
		AA809875 H NM_007019H			3.9
	413/41	141A[_001.0.18L	13.33002	andami camer brotem Ex-O	3.9

		AA263172 Hs.35	protein tyrosine phosphatase, non-recept	3.9	
		Al498957 Hs.17086 AW236861 Hs.19313		3.8 3.8	
		NM_002267Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.8	
5		U40462 Hs.54452		3.8	
_		BE565647 Hs.74899		3.8	
	424028	AF055084 Hs.15369	2 Homo sapiens cDNA FLJ14354 fis, clone Y7	3.8	
	400021		AFFX control - HUMISGF3A/M97935_MA	3.8	
1.0		BE466639 Hs.61779		3.8	
10		Al267371 Hs.17263		3.8	
		AA631739 Hs.33544 AW207206 Hs.13631		3.8 3.8	
			4 ESTs, Weakly similar to B28096 line-1 pr	3.8	
	401045	A140444 115.15055	C11001883*:gi[6753278]ref[NP_033938.1] c	3.8	
15		AW449612 Hs.15247		3.8	
		NM_001838Hs.1652	chemokine (C-C motif) receptor 7	3.8	
	447630	Al660149 Hs.44865		3.8	
		AJ227892 Hs.14627		3.8	
20		AW068115 Hs.821	biglycan	3.8	
20		Al767949 Hs.17983		3.8	
		NM_003512Hs.28777		3.8 3.8	
		M81057 Hs.18088 AA165232 Hs.22206	4 carboxypeptidase B1 (tissue)	3.8	
		AL353944 Hs.50115			3.8
25			0 HER2 receptor tyrosine kinase (c-erb-b2,	3.7	0.0
	400286	NA	C16000922:gi[7499103[pir]]T20903 hypothe	3.7	
		Al623693 Hs.19153		3.7	
		AW900992 Hs.93796		3.7	
20			0 hypothetical protein FLJ22439	3.7	
30		AA371307 Hs.12505 Al916662 Hs.21157	6 ESTS 7 kinectin 1 (kinesin receptor)	3.7 3.7	
	457001		vitamin D (1,25- dihydroxyvitamin D3) re	3.7	
		AW406878	gb:UI-HF-BL0-adg-g-06-0-UI.r1 NIH_MGC_3		
		NM_014737Hs.80905		3.7	
35	436222	Al208737 Hs.12281	0 Homo sapiens cDNA FLJ11489 fis, clone HE	3.7	
		Al633553 Hs.13303		3.7	
			2 hypothetical protein FLJ20285	3.7	
		N49813 Hs.75615 NM_014141Hs.10655		3.7 3.7	
40		AW958544 Hs.11224		3.7	
			6 ESTs, Weakly similar to (defline not ava	3.7	
	406153		Target Exon	3.7	
	445563	AW873606 Hs.14900		3.7	
4.5		Al884911 Hs.32989		3.7	
45		AB011152 Hs.22572		3.7	
		AF113676 Hs.29768		3.6 3.6	
		U76248 Hs.20191 BE005771 Hs.15374	seven in absentia (Drosophila) homolog 2 6 hypothetical protein FLJ22490	3.6	
			9 ESTs, Weakly similar to I38022 hypotheti	3.6	
50		X98654 Hs.93837		3.6	
		AF188625 Hs.18950		3.6	
		Z29572 Hs.2556	tumor necrosis factor receptor superfami	3.6	
		Al800470 Hs.17194		3.6	
55			3 transcription factor 2, hepatic; LF-B3;	3.6	
55			6 ESTs, Weakly similar to I38022 hypotheti gb:QV3-BT0381-270100-073-c08 BT0381 Ho	3.6	
		BE069341 AW024973 Hs.28367		3.6	
		AV653264 Hs.13982			
	452101				
60		NM_014788Hs.17970		3.6	
		AW961434 Hs.31539		3.6	
		NM_000402Hs.80206		3.6	
		W26187 Hs.3327 S42303 Hs.161	Homo sapiens cDNA: FLJ22219 fis, clone H	3.6	
65	440516	AW015415 Hs.12778	cadherin 2, type 1, N-cadherin (neuronal 0 ESTs	3.6 3.6	
00		BE276891 Hs.19469		3.6	
		R43179 Hs.22895		3.6	
	•				

430044   AA464510   Hs.196242   ESTs   3.6		409619	AK001015	Hs.55220	BCL2-associated athanogene 2	3.6	
5 439247 AR980731 Hs.84 interleukin 2 receptor, gamma (severe co 3.6 kg 431542 Hs3010 Hs.5740 EST 3.5 kg 431542 Hs3010 Hs.5740 EST 3.5 kg 431542 Hs3010 Hs.5740 EST 3.5 kg 431748 AR234882 Hs.58141 EST 3.5 kg 437748 AR234882 Hs.58141 EST 3.5 kg 437748 AR234882 Hs.58141 EST 3.5 kg 437748 AR234882 Hs.5814 kg 43989 AW0602166 Hs.2422399 CEGPT protein 5.5 kg 43989 AW0602166 Hs.2422399 CEGPT protein 5.5 kg 43989 AW0602168 Hs.24213 kg 49899 AW0602168 Hs.24213 kg 49899 AW000725 Hs.50579 hypothetical protein FLJ20184 kg 42289 Z43734 Hs.242398 Hs.58241 Homo sapiens, clone IMAGE:3351295, mRNA3.5 kg 42289 Z43734 Hs.242398 Hs.2524398 Homo sapiens, clone IMAGE:3351295, mRNA3.5 kg 42289 Z43734 Hs.242398 Hs.242398 Homo sapiens clone IMAGE:3351295, mRNA3.5 kg 42289 Z43734 Hs.242398 Homo sapiens clone IMAGE:3351295, mRNA3.5 kg 42289 Z43734 Hs.242398 Homo sapiens clone IMAGE:3351295, mRNA3.5 kg 42289 AW014379 Hs.37907 EST 3.5 kg 43992 AW014379 Hs.37907 EST 3 kg 43992 AW014379 Hs.37907 EST 3 kg 441134 W23992 Hs.7678 kg 441134 W23993 Hs.13701 EST 3 kg 442214 AW875237 Hs.14721 kg 442214 AW875237 Hs.14721 kg 442214 AW875237 Hs.14721 kg 442214 AW875237 Hs.14721 kg 442214 kg 442414 AW875237 Hs.14721 kg 442214 kg 442414 kg 4444 kg 444							
5 439247 AP088020 Hs.46767 EST 431542 Hs3010 Hs.5740 EST5 437713 AA351647 Hs.2642 eukaryotic translation elongation factor 43784 AH10055 Hs. 161160 EST5 3.5 43788 AP123482 Hs.5814 43989 AW602768 Hs.5814 43989 AW600768 Hs.22399 CEGP1 protein 49999 AK000726 Hs.50579 409999 AK000726 Hs.50579 409999 AK000726 Hs.50579 409999 AK000726 Hs.50579 409990 AK000725 Hs.50579 409990 AK000726 Hs.50579 409990 AK000727 Hs.50579 409990 AK000726 Hs.50579 409990 AK000726 Hs.50579 409990 AK000726 Hs.50579 409990 AK000726 Hs.50579 409990 AK000727 Hs.50579 409990 AK000726 Hs.50579 409990							
431542 Hs3010 Hs.5740 ESTs 430713 AA351647 Hs.2642 eukaryofic translation elongation factor 434988 All 18055 Hs. 161160 ESTs 437749 AP234882 Hs.5814 suppression of tumorigenicity 7 3.5 439859 AW602166 Hs.222399 CEGP1 protein 439859 AW602166 Hs.222399 CEGP1 protein 439859 AW602166 Hs.222399 CEGP1 protein 439859 AW6021673 409299 AK600725 Hs.50579 40999 AK600725 Hs.50579 40989 AK600725 Hs.5	5						
434988 Al418055 Hs.161160 ESTs 3.5 437748 AF234882 Hs.5814 cyclin-dependent kinase inhibitor 3 (CDK 3.5 438569 AW002166 Hs.22399 CEGP1 protein Full 1812 Av0899 AW002169 Hs.22399 CEGP1 protein Full 1812 Av0899 AW002169 Hs.50579 hypothetical protein Full 1818 Av08216 Av08216 Hs.1614 Av08216 Av08		431542	H63010	Hs.5740		3.5	
10							
418322							
439569 AW602166 Hs.222399 (EGP1 protein 459583 Al907673 ypb:1L-BT152-080399-004 BT152 Homo sapiens.5 NM_019995Homo sapiens intersectin 2 (IT 3.5 NM_019959Homo sapiens intersectin 2 (IT 3.5 NM_01995Homo sapiens intersectin 2 (IT 3.5 NM_019959Homo sapiens intersectin 2 (IT 3.5 NM_01995Homo sapiens clone intersection 2 3 NM_01995Homo sapiens clone intersection 2 3 NM_01995Homo sapiens clone intersection 2 3 NM_01995Homo sapiens clo	10				cyclin-dependent kinase inhibitor 3 (CDK		
Month							
A09099   AK000725   Ns.50579   Nypothetical protein Fi.J.20718   3.5			Al907673				
459868 AA847843			A1/00070E	11- 50570			
43638   W92147	15						
442295 Al827248 Hs.224388 Horno saplens CDNA FLJ11469 fis, clone HE 3.5 417975 AA641836 Hs.30085 hypothetical protein FLJ123186 3.5 439326 AW014875 Hs.137007 ESTs 3.5 445873 AA250970 Hs.251946 poly(A)-binding protein, cytoplasmic 1-1 3.4 410153 BE311926 Hs.15830 depth 410153 BE311926 Hs.15830 depth 41821 BE390551 Hs.7628 441134 W29092 Hs.7678 444564 Al167877 Hs.143716 ESTs 3.4 44564 Al167877 Hs.143716 ESTs 3.4 422414 AW875237 Hs.132714 ESTs 3.4 422414 AW875237 Hs.132714 ESTs 3.4 422554 M90516 Hs.51833 depth 422554 M90516 Hs.1674 423554 M90516 Hs.1674 422359 NA 439398 AA284267 Hs.20163 Hs	10						
17975 AA641836 Hs.30085   hypothetical protein FLJ23186   3.5   hypothetical protein FLJ2186   3.5   hypothetical protein FLJ2186   3.5   hypothetical protein FLJ112773   3.5   hypothetical protein FLJ112773   3.5   hypothetical protein FLJ12691   3.4   hypothetical protein FLJ13117   3.4   hypothetical protein hypothetical protein FLJ13117   3.4   hypothetical protein hypothetical protein FLJ13117   3.4   hypothetical protein FLJ13117   3.4   hypothetical protein FLJ13117   3.4   hypothetical protein hypothetical protei							
A33730							
439926 AW014875 Hs.137007   ESTs   3.5   445873 AA250970 Hs.251946   5019(A)-binding protein, cytoplasmic 1-1   3.4   410153 BE311926 Hs.15830   422128 AW081145   50200-071033-010400-182-a07 OT0033 Homo   3.4   41134   W29092 Hs.7678   444564 Al167877   Hs.143716   ESTs   3.4   402470 NA   402470 NA   402470 NA   433345 Al681545 Hs.152982   409213 U01412   409213 U01412   402211   AA158177 Hs.18722   422611   AA158177 Hs.118722   422611   AA158177 Hs.118722   422611   AA158177 Hs.118722   422613   AA447492   Hs.20183   433398 AA284287   Hs.20183   433398   AA284287   Hs.20183   433398   AA284287   Hs.20183   43280   442115   Ak001763   Hs.22880   41215   Ak001763   Hs.22880   41215   Ak001763   Hs.22880   41215   Ak001763   Hs.28480   41216   AA682528   Hs.319825   Hs.33806   A42869   AA642258   Hs.319825   Hs.33806   A4280   A428428   Hs.228262   Hs.319825   A42869   AA03735   Hs.5338   A43378   AW392550   Hs.5338   A43378   AW392550   Hs.28428   Hs.32981   A42856   A400375   Hs.43843   A43378   AW392550   Hs.28480   A428597   AW016812   Hs.20266   A42850   A44967   AW016812   Hs.20266   A42850   A44967   AW016812   Hs.20266   A42859   AW016812   Hs.20266   A42850   AW016812   Hs.20266   A42859   AW016812   Hs.20266   A42850   A4361077   AA61071   Hs.34868   A43378   AW392550   Hs.231982   A42856   A4361071   Hs.32880   A42850   A44967   AW016812   Hs.20266   ESTs   A436107   A3361258   Hs.232880   A42859   AW51305   Hs.332881   ESTs   A3361258   Hs.232880   A4361258   Hs.232880   A4361258   Hs.232880   A42619   AW016812   Hs.20266   A42629   AW160375   Hs.32980   A42636   A42639   AW016818   Hs.20266   ESTs   A42669	20						
445873   AA250970   Hs.251946   poly(A)-binding protein, cytoplasmic 1-1   3.4	20						
422128 AW881145   Hs.77628					poly(A)-binding protein, cytoplasmic 1-l	3.4	
25         414921         BE390551         Hs.77628         steroidogenic acute regulatory protein r eliular retinoic acid-binding protein 1         3.4           444564         Al167877         Hs.16787         deliular retinoic acid-binding protein 1         3.4           402470         NA         Target Exon         3.4           418120         AA213437         Hs.192249         ESTS         3.4           402471         AW875237         Hs.13701         ESTS         3.4           403345         Al681545         Hs.152982         PTK6 protein tyrosine kinase 6         3.4           402471         AA158177         Hs.1818722         Hs.51333         PTK6 protein tyrosine kinase 6         3.4           422611         AA158177         Hs.1674         glubarine-fructose-6-phosphate transamin 3.4         ESTS           422611         AA47492         Hs.20183         Hs.272004         ESTS         3.4           415208         F01020         Hs.172004				Hs.15830			
441134   W29092   Hs.7678   cellular retinoic acid-binding protein 1   3.4     402470   NA	25			He 77628			3.4
444564	23						
418120 AA213437 Hs.192249 ESTs 3.4 422414 AW875237 Hs.13701 ESTs 3.4 43345 Al681545 Hs.152982 hypothetical protein FLJ13117 3.4 409213 U61412 Hs.51133 PTK6 protein tyrosine kinase 6 3.4 422611 AA158177 Hs.118722 (ucosyltransferase 8 (alpha (1,6) fucosy 3.4 423554 M90516 Hs.1674 glutamine-fructose-6-phosphate transamin 3.4 422619 AA447492 Hs.20183 ESTs, Weakly similar to AF164793 prote 3.4 402359 NA 439398 AA284267 415208 Hs.172004 titin 3.4 452853 AA812633 Hs.10845 ESTs Weakly similar to AF1647931 prote 3.4 452853 AA812633 Hs.10845 ESTs 3.4 415208 F01020 Hs.172004 titin 3.4 452853 AA812633 Hs.10845 ESTs 3.4 412115 AK001763 Hs.278228 RuvB (E coli homolog)-like 1 3.4 412115 AK001763 Hs.278229 RuvB (E coli homolog)-like 1 3.4 428977 AK001404 Hs.194698 cyclin B2 438280 AA622528 Hs.319825 Homo sapiens, clone IMAGE:3616574, mRNA,3.4 438689 AF037335 Hs.55338 carbonic anhydrase XII (tumor antigen H 3.4 428450 NM_014791Hs.184339 KlAA0175 gene product 3.3 412777 Al335773 Hs.270123 ESTs 3.3 412774 AW16812 Hs.200266 ESTs 3.3 412775 AW160375 Hs.74565 Hs.34398 KlAA0175 gene product 3.3 420542 NM_000505Hs.1321 coaquiation factor XII (Hageman factor) 3.3 425999 AW513051 Hs.34398 Hs.237868 Hs.237868 Hs.238988 ESTs, Weakly similar to I38022 hypothetici 3.3 425999 AW513051 Hs.74565 Hs.34498 Hs.32998 Hs.258998 ESTs, Weakly similar to I38022 hypotheti 3.3 426642 Kr3114 Hs.169849 Hs.25252 prolactin receptor 3.3 427080 AW068287 Hs.173465 squalene epoxidase 42869 Ns.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173465 rs-related C3 botulinum toxin substrate 3.3 427680 AW068280 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427680 AW068280 Hs.120910 ESTs 3.3							
30         422414 AW875237 Hs.13701 ESTs         3.4 433345 Al681545 Hs.152982 hypothetical protein FLJ13117 Js.4 409213 U61412 Hs.51133 PTK6 protein tyrosine kinase 6 Js.4 422611 AA158177 Hs.118722 fucosyltransferase 8 (alpha (1,6) fucosy 3.4 422619 AA447492 Hs.20183 ESTs, Weakly similar to AF164793 1 prote 3.4 402359 NA 439398 AA284267 Hs.20183 ESTs, Weakly similar to AF164793 1 prote 3.4 415208 F01020 Hs.172004 titin Js.4 49027 AJ271216 Hs.22880 Hs.172004 titin Js.4 449027 AJ271216 Hs.22880 Hypothetical protein Js.4 422807 AK001763 Hs.73239 hypothetical protein Js.4 422807 AK001404 Hs.194698 Cyclin B2 Hs.22822 Hs.319825 Homo saplens, clone IMAGE:3616574, mRNA,3.4 436895 AF037335 Hs.5338 carbonic anhydrase XII (tumor antigen H Js.5338 A43280 NM_014791Hs.184339 KIAA0175 gene product Js.5338 A43280 NM_000505Hs.1321 Coagulation factor XII (Hageman factor) Js.22809 AW513051 Hs.322918 ESTs, Weakly similar to Infly mobility gr Js.3 449065 Al627393 Hs.258998 ESTs, Weakly similar to Infly mobility gr Js.3 42599 AW513051 Hs.327808 Hs.258998 ESTs, Weakly similar to Infly mobility gr Js.3 42599 AW513051 Hs.327868 Hs.170197 glutamine-fructose-6-phosphate transamin Js.4 428450 Nm.014791Hs.184339 KlAA0175 gene product Js.4 428450 Nm.014791Hs.184339 KlAA0175 gene product Js.4 428450 Nm.014791Hs.184339 KlAA0175 gene product Js.5338 Carbonic anhydrase XII (tumor antigen H Js.74056 Settle Ms.74067) Hs.27402 Nm.000505Hs.1321 Coagulation factor XII (Hageman factor) Js.74050 A49065 Al627393 Hs.258998 ESTs, Weakly similar to Infly mobility gr Js.3 420540 AW068287 Hs.173466 Settle Normeodomain transcription fa Js.274080 AW068287 Hs.173466 Settle Normeodomain transcrip							
433345   Al681545   Hs.152982   hypothetical protein FLJ13117   3.4     409213	30						
409213 U61412 Hs.51133 PTK6 protein tyrosine kinase 6 3.4 422611 AA158177 Hs.118722 fucosyltransferase 8 (alpha (1,6) fucosy 3.4 422614 M90516 Hs.1674 glutamine-fructose-6-phosphate transamin 3.4 422619 AA447492 Hs.20183 ESTs, Weakly similar to AF164793 1 prote 3.4 C19001991*:gi 12656111 gb AAK00751.1 AF23.4 439398 AA284267 Hs.221504 ESTs 3.4 415208 F01020 Hs.172004 titin 3.4 452853 AA812633 Hs.10845 ESTs 3.4 449027 AJ271216 Hs.22880 dipeptidylpeptidase III 3.4 449027 AJ271216 Hs.22880 dipeptidylpeptidase III 3.4 42816 Y18418 Hs.272822 RuvB (E coli homolog)-like 1 3.4 42897 AK001404 Hs.194698 Hs.27822 RuvB (E coli homolog)-like 1 3.4 43368 A6822528 Hs.319825 Hs.079335 Hs.5338 443378 AW392550 Hs.9280 Hs.9280 at 284378 AW392550 Hs.9280 at 284378 AW392550 Hs.9280 at 284378 AW392550 Hs.9280 at 284378 AW392550 Hs.9280 at 28549 AW513051 Hs.32211 at 28549 AW513051 Hs.32321 at 28549 AW513051 Hs.32321 at 330280 AA361258 Hs.2200266 ESTs 3.3 at 28599 AW513051 Hs.323291 Hs.233881 AW30280 AA361258 Hs.233881 AW30280 A	50						
35         423554 M90516 Hs.2018 Hs.20183 ESTs, Weakly similar to AF164793 1 prote 3.4 402359 NA 402359 NA 439398 AA284267 Hs.221504 ESTs 3.4 415208 F01020 Hs.172004 ESTs 3.4 452853 AA812633 Hs.10845 ESTs 3.4 440027 AJ271216 Hs.22880 Hs.22880 Y18418 Hs.22880 Y18418 Hs.272822 RvyB (E coli homolog)-like 1 3.4 428977 AK001404 Hs.194695 ky.20in B2 3.4 431611 U58766 Hs.264428 tissue specific transplantation antigen 3.4 43286 AA622528 Hs.319825 Homos sapiens, clone IMAGE:3616574, mRNA,3.4 428450 NM_014791Hs.184339 KIAA0175 gene product 3.3 449571 AW016812 Hs.200266 Hs.26428 NM_000505Hs.1321 42277 AJ35773 Hs.270123 ESTs 3.3 420542 NM_000505Hs.1321 422754 AW160375 Hs.74565 A18327 U70370 Hs.84136 Hs.200266 Hs.26469 X73114 Hs.204044 ESTs 3.3 425999 AW513051 Hs.32398 Hs.273388 Hs.273388 Hs.273389 Hs.273339 Hs.273333 Hs.273333 Hs.273333 Hs.273333 Hs.273339 Hs.273333 Hs.273333 Hs.273333 Hs.273333 Hs.2733							
A42619							
402359 NA 439398 AA284267 Hs.221504 ESTs 3.4 415208 F01020 Hs.172004 titin 3.4 415208 AA812633 Hs.10845 ESTs 3.4 429345 R11141 Hs.199595 hypothetical protein 3.4 429027 AJ271216 Hs.22880 dipeptidylpeptidase III 3.4 428977 AK001763 Hs.73239 hypothetical protein FLJ10901 3.4 432180 Y18418 Hs.272822 RuvB (E coli homolog)-like 1 3.4 432181 U58766 Hs.264428 tissue specific transplantation antigen 3.4 43885 AF037335 Hs.5338 carbonic anhydrase XII (tumor antigen H 3.4 43378 AW392550 Hs.9280 Hs.9280 days arbonic anhydrase XII (tumor antigen H 3.4 428450 NM_014791Hs.184339 KIAA0175 gene product 3.3 449571 AW016812 Hs.200266 ESTs 3.3 412777 AI335773 Hs.270123 ESTs 3.3 420542 NM_000505Hs.1321 cagulation factor XII (Hageman factor) 3.3 412777 AI335773 Hs.270123 ESTs 3.3 420542 NM_000505Hs.1321 cagulation factor XII (Hageman factor) 3.3 412777 AI335773 Hs.271455 apaired-like homeodomain transcription fa 3.9 425999 AW513051 Hs.332981 ESTs, Weakly similar to high mobility gr 3.3 425999 AW513051 Hs.323981 ESTs, Weakly similar to high mobility gr 3.3 426516 BE262660 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 436523 Al601188 Hs.120910 ESTs	35						
439398 AA284267 Hs.221504 ESTs	55			HS.20103	C19001991*:ail12656111lablAAK00751.1lAF		
40 452853 AA812633 Hs.10845 ESTs				Hs.221504	ESTs		
40         429345         R11141         Hs.199695         hypothetical protein         3.4           449027         AJ271216         Hs.22880         dipeptidylpeptidase III         3.4           412115         AK001763         Hs.73239         hypothetical protein FLJ10901         3.4           432180         Y18418         Hs.272822         RuvB (E coli homolog)-like 1         3.4           428977         AK001404         Hs.194698         RuvB (E coli homolog)-like 1         3.4           431611         US8766         Hs.264428         tissue specific transplantation antigen         3.4           418286         AA622528         Hs.319825         Homo sapiens, clone IMAGE:3616574, mRNA,3.4           436895         AF037335         Hs.5338         carbonic anhydrase XII (tumor antigen H         3.4           436895         AW016812         Hs.200266         ESTs         3.3           429571         AW016812         Hs.200266         ESTs         3.3           412774         AW160375         Hs.74565         Hs.74565         Hs.744565         Hs.74565         Algenal file homeodomain transcription fa         3.3           45         449065         Al627393         Hs.258998         ESTs, Weakly similar to high mobility gr         3.3							
A49027 AJ271216	40						
A12115	40						
428977 AK001404 Hs.194698 cyclin B2 3.4 431611 U58766 Hs.264428 tissue specific transplantation antigen 3.4 418286 AA622528 Hs.319825 Homo sapiens, clone IMAGE:3616574, mRNA,3.4 438895 AF037335 Hs.5338 carbonic anhydrase XII (tumor antigen H 3.4 428450 NM_014791Hs.184339 KIAA0175 gene product 3.3 428450 NM_014791Hs.184339 Hs.270123 ESTs 3.3 412777 AI335773 Hs.270123 ESTs 3.3 420542 NM_000505Hs.1321 coagulation factor XII (Hageman factor) 3.3 412754 AW160375 Hs.74565 Hs.34136 Hs.284136 Hs.284136 Hs.237868 Interleukin 7 receptor 3.3 425999 AW513051 Hs.332981 ESTs, Weakly similar to high mobility gr 3.3 425999 AW513051 Hs.332981 ESTs, Weakly similar to high mobility gr 3.3 427080 AA361258 Hs.237868 Interleukin 7 receptor 3.3 427080 AW068287 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173466 Hs.120910 ESTs 428566 U41763 Hs.169849 Hs.120910 ESTs 438629 AI601188 Hs.20910 ESTs 3.3							
431611 U58766 Hs.264428 tissue specific transplantation antigen 3.4 418286 AA622528 Hs.319825 Hs.319825 Hs.5338 Hs.270123 Hs.34136 Hs.270123							
418286	15						
436895 AF037335 Hs.5338 carbonic anhydrase XII (tumor antigen H 43378 AW392550 Hs.9280 proteasome (prosome, macropain) subunit, 3.4 KIAA0175 gene product 3.3 KIAA0175 gene product 3.3 A49571 AW016812 Hs.200266 ESTs 3.3 A12777 AI335773 Hs.270123 ESTs 3.3 A20542 NM_000505Hs.1321 coagulation factor XII (Hageman factor) 3.3 A12754 AW160375 Hs.74565 A18277 U70370 Hs.84136 ESTs, Weakly similar to high mobility gr 3.3 A25999 AW513051 Hs.332981 ESTs, Weakly similar to high mobility gr 3.3 A30280 AA361258 Hs.237868 Hs.237868 A07777 AA161071 Hs.71465 A26516 BE262660 Hs.170197 Gulden epoxidase 3.3 A26516 BE262660 Hs.170197 Gulden epoxidase 3.3 A26429 X73114 Hs.169849 Hs.204044 Hs.169849 A26566 AA026680 Hs.25252 Prolactin receptor 3.3 A26566 U41763 Hs.265252 Prolactin receptor 3.3 A30265 A4026680 Hs.265252 Prolactin receptor 3.3 A30265 A4026880 Hs.265252 Prolactin receptor 3.3 A30265 A402680 Hs.26526 Hs.265252 Prolactin receptor 3.3 A30265 A402680 Hs.265252 Prolactin receptor 3.3 A30265 A402680 Hs.26526 Hs.26526 Prolactin receptor 3.3 A30265 Hs.26526 Prolactin receptor 3.3 A30	72						
428450       NM_014791Hs.184339       KIAA0175 gene product       3.3         449571       AW016812       Hs.200266       ESTs       3.3         412777       Al335773       Hs.270123       ESTs       3.3         420542       NM_000505Hs.1321       coagulation factor XII (Hageman factor)       3.3         412754       AW160375       Hs.74665       amyloid beta (A4) precursor-like protein       3.3         418327       U70370       Hs.84136       ESTs, Weakly similar to high mobility gr       3.3         449065       Al627393       Hs.258998       ESTs, Weakly similar to l38022 hypotheti       3.3         430280       AA361258       Hs.237868       Interleukin 7 receptor       3.3         407777       AA161071       Hs.71465       squalene epoxidase       3.3         426516       BE262660       Hs.170197       glutamic-oxaloacetic transaminase 2, mit       3.3         427080       AW068287       Hs.173466       ESTs       3.3         426429       X73114       Hs.169849       myosin-binding protein C, slow-type       3.3         428566       U41763       Hs.184916       clathrin, heavy polypeptide-like 1       3.3         418641       BE243136       Hs.86947       a disintegrin and me							
50       449571       AW016812       Hs.200266       ESTs       3.3         412777       Al335773       Hs.270123       ESTs       3.3         420542       NM_000505Hs.1321       coagulation factor XII (Hageman factor)       3.3         412754       AW160375       Hs.74565       amyloid beta (A4) precursor-like protein       3.3         418327       U70370       Hs.84136       ESTs, Weakly similar to high mobility gr       3.3         425999       AW513051       Hs.332981       ESTs, Weakly similar to 138022 hypotheti       3.3         430280       AA361258       Hs.237868       Interleukin 7 receptor       3.3         407777       AA161071       Hs.71465       squalene epoxidase       3.3         426516       BE262660       Hs.170197       glutamic-oxaloacetic transaminase 2, mit       3.3         427080       AW068287       Hs.173466       ESTs       3.3         426429       X73114       Hs.169849       myosin-binding protein C, slow-type       3.3         428566       U41763       Hs.184916       clathrin, heavy polypeptide-like 1       3.3         418641       BE243136       Hs.86947       a disintegrin and metalloproteinase doma       3.3         436293       Al601188					proteasome (prosome, macropain) subunit,		
412777 Al335773 Hs.270123 ESTs coagulation factor XII (Hageman factor) 3.3 amyloid beta (A4) precursor-like protein 3.3 paired-like homeodomain transcription fa 3.3 ESTs, Weakly similar to ligh mobility gr 3.3 amyloid beta (A4) precursor-like protein 3.3 amyloid beta (A5) precursor-like protein 3.3 amyloid beta (A5) precursor-like protein 3.3 amyloid beta (A5) precursor-like protein 6 3.3 amyloid beta (A5) precursor-like protein 4.3 amyloid beta (A5) precursor-like p	50						
420542 NM_000505Hs.1321 coagulation factor XII (Hageman factor) 3.3 412754 AW160375 Hs.74565 amyloid beta (A4) precursor-like protein 3.3 418327 U70370 Hs.84136 paired-like homeodomain transcription fa 3.3 425999 AW513051 Hs.3258998 ESTs, Weakly similar to high mobility gr 3.3 430280 AA361258 Hs.237868 interleukin 7 receptor 3.3 407777 AA161071 Hs.71465 putalene epoxidase 3.3 426516 BE262660 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 436293 Al601188 Hs.120910 ESTs	50						
55         418327         U70370         Hs.84136         paired-like homeodomain transcription fa ESTs, Weakly similar to high mobility gr 3.3 and ESTs, Weakly similar to high mobility gr 3.3 and 430280         AA361258         Hs.258998         ESTs, Weakly similar to l38022 hypotheti 3.3 and interleukin 7 receptor 3.3 and sequence epoxidase 3.3 and sequence epox					coagulation factor XII (Hageman factor)	3.3	
55       449065       Al627393       Hs.258998       ESTs, Weakly similar to high mobility gr and the state of the state							
425999 AW513051 Hs.332981 ESTs, Weakly similar to 138022 hypotheti 3.3 430280 AA361258 Hs.237868 interleukin 7 receptor 3.3 407777 AA161071 Hs.71465 squalene epoxidase 3.3 426516 BE262660 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173466 ESTs 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 446163 AA026880 Hs.25252 prolactin receptor 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 436293 Al601188 Hs.120910 ESTs 3.3	55						
430280 AA361258 Hs.237868 interleukin 7 receptor 3.3 407777 AA161071 Hs.71465 squalene epoxidase 3.3 426516 BE262660 Hs.170197 glutamic-oxaloacetic transaminase 2, mit 3.3 427080 AW068287 Hs.173466 ESTs 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 446163 AA026880 Hs.25252 prolactin receptor 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 3.3 436293 Al601188 Hs.120910 ESTs 3.3	55						
60       426516       BE262660       Hs.170197       glutamic-oxaloacetic transaminase 2, mit       3.3         414361       Al086138       Hs.204044       ESTs       3.3         427080       AW068287       Hs.173466       ras-related C3 botulinum toxin substrate       3.3         426429       X73114       Hs.169849       myosin-binding protein C, slow-type       3.3         446163       AA026880       Hs.25252       protactin receptor       3.3         428566       U41763       Hs.184916       clathrin, heavy polypeptide-like 1       3.3         418641       BE243136       Hs.86947       a disintegrin and metalloproteinase doma       3.3         436293       Al601188       Hs.120910       ESTs       3.3		430280	AA361258	Hs.237868	interleukin 7 receptor	3.3	
60 414361 Al086138 Hs.204044 ESTs 3.3 427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 446163 AA026880 Hs.25252 prolactin receptor 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 436293 Al601188 Hs.120910 ESTs 3.3							
427080 AW068287 Hs.173466 ras-related C3 botulinum toxin substrate 3.3 426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 446163 AA026880 Hs.25252 prolactin receptor 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 436293 Al601188 Hs.120910 ESTs 3.3	60						
426429 X73114 Hs.169849 myosin-binding protein C, slow-type 3.3 446163 AA026880 Hs.25252 prolactin receptor 3.3 428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 3.3 436293 Al601188 Hs.120910 ESTs 3.3	50						
428566 U41763 Hs.184916 clathrin, heavy polypeptide-like 1 3.3 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 3.3 436293 Al601188 Hs.120910 ESTs 3.3		426429	X73114	Hs.169849	myosin-binding protein C, slow-type	3.3	
65 418641 BE243136 Hs.86947 a disintegrin and metalloproteinase doma 3.3 436293 Al601188 Hs.120910 ESTs 3.3							
436293 Al601188 Hs.120910 ESTs 3,3	65	428566	U41/63				
	55						
		411257	AA628967			3.3	

	430253	AK001514	Hs.236844	hypothetical protein FLJ10652	3.3
		Al929659		signal recognition particle 72kD	3.3
		AK001455	Hs.5198	Down syndrome critical region gene 2	3.3
_		BE142681		polymerase (DNA directed), eta	3.3
5		H09048	Hs.23606	ESTs	3.3
		H91882 AA496078		Dvl-binding protein IDAX (inhibition of Human DNA sequence from clone RP11-2180	3.3
		AA446932	Hs.151428	ret finger protein 2	3.3
		AW270655			3.3
10		R43409	Hs.6829	Homo sapiens mRNA for KIAA1644 protein,	3.3
		AW978484		Homo sapiens cDNA: FLJ22554 fis, clone H	3.3
		Al015709	Hs.172089		
		AW408158 BE300330			3.3 3.3
15		BE614387		selenophosphate synthetase 2 c-Myc target JPO1	3.3
13		U24683		immunoglobulin heavy constant mu	3.3
		AA907734	Hs.124895		3.3
	408877	AA479033	Hs.130315	ESTs, Weakly similar to A47582 B-cell gr	3.3
20		C01765	Hs.38750	hypothetical protein FLJ11526	3.3
20		AA912183	Hs.47447	ESTs	3.3 3.3
	404755	U46258	Hs.339665	Target Exon	3.3
		Al821005	Hs.118599		3.2
		AW406289		hypothetical protein	3.2
25	430580	AA806105	Hs.300697		
	400202			NM_002795*:Homo sapiens proteasome (pro	
	400222		Un 074454	NM_002082*:Homo sapiens G protein-couple	3.2
		BE045897 BE550224	Hs.74170	ESTs, Weakly similar to I38022 hypotheti metallothionein 1E (functional)	3.2
30		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	3.2
•		Al027643	Hs.120912	ESTs	3.2
	442353	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	
		U79745		solute carrier family 16 (monocarboxylic	3.2
35		A1793257	Hs.128151		3.2 3.2
33		AA640891 H04588	Hs.102406 Hs.30469	ESTs	3.2
		Al244459		trinucleotide repeat containing 9	3.2
		Al821926		gb:nt78f05.x5 NCI_CGAP_Pr3 Homo sapiens	
	422032	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.2
40		NM_015156		KIAA0071 protein	3.2
		Al472078	Hs.303662		3.2 3.2
		N30714 AA310964	Hs.325960	membrane-spanning 4-domains, subfamily A SHP2 interacting transmembrane adaptor	3.2
		R35343	Hs.24968	Human DNA sequence from clone RP1-233G	
45		AA837085		ESTs	3.2
		AW292593		Homo sapiens, clone MGC:17333, mRNA, co	
		AW503785		complement component (3d/Epstein Barr vi	3.2
		AA025386		ESTs, Weakly similar to S10590 cysteine	3.2 3.2
50		AW408337 D50915	Hs.38365	CD7 antigen (p41) KIAA0125 gene product	3.2
50		AL047586		RNA binding motif protein 8B	3.2
	430015	AW768399			3.2
	433313	W20128	Hs.296039	ESTs	3.2
<i>5 5</i>		AA319233	Hs.5521	ESTs	3.2
55		AA418204 AW966728	Hs.241493	natural killer-tumor recognition sequenc	3.2 3.2
		AL118668	HS.34042	methionine adenosyltransferase II, beta gb:DKFZp761I0310_r1 761 (synonym: hamy2	
		AW405434	Hs.82575	small nuclear ribonucleoprotein polypept	3.2
	428027	U22029	Hs.334345	cytochrome P450, subfamily IIA (phenobar	3.2
60	441197	BE244638	Hs.166	sterol regulatory element binding transc	3.2
		NM_003613		cartilage intermediate layer protein, nu	3.2
	419986	AI345455 AF283770	Hs.78915 Hs 79630	GA-binding protein transcription factor, CD79A antigen (immunoglobulin-associated	3.2 3.2
	449465	NM_004380	)Hs.23598	CREB binding protein (Rubinstein-Taybi s	3.2
65	422166	W72424	Hs.112405	S100 calcium-binding protein A9 (calgran	3.2
	409079	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.2
	423551	AA327598	Hs.233785	ESTs	3.2

		AA036849	Hs.61829	Homo sapiens cDNA FLJ12763 fis, clone NT	
		AI733682	Hs.130239	ESTs	3.2
		Al796870	Hs.54277	DNA segment on chromosome X (unique) 992	
5		AF076292		forkhead box H1	3.2
3	417124	BE122762	Hs.25338	ESTs v-erb-b2 avian erythroblastic leukemia v	3.2
		Al703172		ESTs, Weakly similar to 2109260A B cell	3.2 3.1
	430271	T06199		DnaJ (Hsp40) homolog, subfamily B, membe	3.1
				interleukin 21 receptor	3.1
10		AI278023	Hs.89986	ESTs	3.1
		BE388898		hypothetical protein FLJ11307	3.1
		AL137589	Hs.152149		3.1
			Hs.211594		3.1
	432715	AA247152	Hs.200483		3.1
15	431574	AW572659	Hs.261373		3.1
	436876	AI124756	Hs.5337	isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	405017			Target Exon	3.1
		AA706910	Hs.112742		3.1
20		AL353957		hypothetical protein DKFZp434P0531	3.1
20	430105		Hs.2540	cholinergic receptor, nicotinic, alpha p	3.1
		NM_001141		arachidonate 15-lipoxygenase, second typ	3.1 3.1
		BE145360 Al267700	Hs.190064 Hs.317584	ESTs, Weakly similar to I38022 hypotheti ESTs	3.1
		Al879263	Hs.6986	Human glucose transporter pseudogene	3.1
25		AA890023	Hs.1906	prolactin receptor	3.1
		BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1
		AW247529		platelet-activating factor acetylhydrola	3.1
		Al638516	Hs.22630	cofactor required for Sp1 transcriptiona	3.1
	458021	AI885190	Hs.156089	ESTs, Weakly similar to repressor protei	3.1
30		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
	400814	NA		Target Exon	3.1
	402327			Target Exon	3.1
		AA190712	L)- 400075	gb:zp87f09.r1 Stratagene HeLa cell s3 93	3.1
35		AL355722		Homo sapiens EST from clone 35214, full	3.1
33		Al571514 NM_000579	Hs.133022	chemokine (C-C motif) receptor 5	3.1 3.1
		AJ245210	71 15.04440	gb:Homo sapiens mRNA for immunoglobulin	3.1
		AF052762		gb:Homo sapiens clone csneg8-1 immunoglo	3.1
		BE514514	Hs.109606	coronin, actin-binding protein, 1A	3.1
40	414523	AU076633	Hs.76353	serine (or cysteine) proteinase inhibito	3.1
	416379	N38857	Hs.203933	ESTs	3.1
		D89974	Hs.121102		3.1
		Al399956	Hs.208956		3.1
15		BE143533		hypothetical protein FLJ20035	3.1
45		AW899713			3.1
		AW963838 AB012124		Homo sapiens cDNA FLJ12136 fis, clone MA	3.1
	405381		Hs.30696	transcription factor-like 5 (basic helix Target Exon	3.1
		AW503820	He 192861	Spi-B transcription factor (Spi-1/PU.1 r	3.1
50		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C171	
•		U66468	Hs.159525	cell growth regulatory with EF-hand doma	3.1
	423306	W88562	Hs.108198	ESTs	3.1
		AA234276	Hs.88253	ESTs	3.1
			Hs.292133	ESTs, Moderately similar to 178885 serin	3.1
55		X60992	Hs.81226	CD6 antigen	3.0
		NM_01590		transcriptional intermediary factor 1	3.0
		BE241595	Hs.82848	selectin L (lymphocyte adhesion molecule	3.0
	402606			NM_024626:Homo sapiens hypothetical prot	3.0
60	401451	A A 2000CE0	11- 444400	NM_004496*:Homo sapiens hepatocyte nucle	2.0
60		AA299652	Hs.111496		
		BE384836 BE561850	Hs.3454 Hs.80506	KIAA1821 protein small nuclear ribonucleoprotein polypept	3.0 3.0
		Y14768	Hs.890	lymphotoxin beta (TNF superfamily, membe	3.0
	425081	X74794	Hs.154443	minichromosome maintenance deficient (S.	3.0
65	401519	• •	. 10. 10-1-1-10	C15000476*:gi 12737279 ref XP_012163.1	3.0
J-0		Al499220	Hs.71573	hypothetical protein FLJ10074	3.0
		AL135623		KIAA0575 gene product	3.0
				-	

	428423	AU076517	Hs.184276	solute carrier family 9 (sodium/hydrogen	3,0	
	413835	AI272727	Hs.249163	fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo sapiens clone 25218 mRNA sequence	3.0	
5	433658	L03678	Hs.156110	immunoglobulin kappa constant	3.0	
	427666	AI791495	Hs.180142	calmodulin-like skin protein	3.0	
	452514	AI904898		gb:RC-BT068-130399-085 BT068 Homo sapid	en3.0	
	429500	X78565	Hs.289114	hexabrachion (tenascin C, cytotactin)	3.0	
	432485	N90866	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Weakly similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 Hc		3.0
	453216	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G032	21 (f	3.0
	400929			ENSP00000252232*:Sterol regulatory eleme		
15	445145	A1961702	Hs.147434	ESTs	3.0	
	432615	AA557191	Hs.55028	ESTs, Weakly similar to 154374 gene NF2	3.0	
	423279	AW959861	Hs.290943	ESTs	3.0	
	429392	AL109712	Hs.296506	Homo sapiens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Weakly similar to ALUC_HUMAN !!!!	3.0	
20	451346	NM_006338	3Hs.26312	glioma amplified on chromosome 1 protein	3.0	
	413109	AW389845	Hs.110855	ESTs	3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C		3.0
	421462	AF016495	Hs.104624	aquaporin 9	3.0	
~ -	421750	AK000768		hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
	438930	AW843633	Hs.306163	hypothetical protein AL110115	3.0	

## TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers

15 Pkey CAT number Accessions 407980 103087\_1 AA046309 Al263500 AA046397 AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 410785 1221055\_1 20 411743 1256098\_1 AW862214 AW859811 AW862215 AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538 412138 1279172\_1 413269 1356961\_1 BE167526 BE167651 BE076401 R24654 416935 163179\_1 AA190712 AA190665 AA252564 AW881145 AA490718 M85637 AA304575 T06067 AA331991 422128 211994\_1 25 423945 233566\_1 AA410943 AW948953 AA334202 AA332882 424109 235506\_1 AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537 424128 235728 1 AW966163 AA335983 AA336011 AA335668 AA335973 AW962128 AA355353 AA427363 425331 250199\_1 426878 273265\_1 BE069341 AW748403 AL044891 Al908240 AA393080 30 432745 353673 1 Al821926 AA658826 AA564492 AA635129 Al791191 441153 51084\_2 BE562826 BE378727 448212 755099\_1 AI475858 AW969013 451128 859865\_1 AL118668 D78823 Al762176 452514 920172\_1 Al904898 Al904849 Al904899 35 456207 165078\_-1 AA193450

## TABLE 22B

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic 5 sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

	Pkey:	Unique number corresponding to an Eos probeset
10	Ref:	Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers

rs to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons. Strand:

Nt\_position:

15	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
	401645	7657839	Minus	34986-35133
	401714	6715702	Plus	96484-96681
25	401866	8018106	Plus	73126-73623
	402327	7656695	Minus	108675-108770,109801-109910
	402359	9211204	Minus	40403-41961
			Minus	110326-110491
20		9797107	Plus	195129-195776
30	402542		Minus	67076-67594 ·
	402578		Plus	66350-66496
		9909429	Minus	81747-82094
	403011		Minus	3468-3623
2.5	403212	7630897	Minus	156037-156210
35	403329	8516120	Plus	96450-96598
	403366	8783692	Minus	49323-49652
		9966528	Plus	2888-3001,3198-3532,3655-4117
	404347		Plus	74493-74829
40	404580	6539738	Minus	240588-241589
40	404755	7706327	Minus	53729-53846
	405017		Plus	35551-35690
	405348	2914717	Minus	43310-43462
	405381	6006920	Minus	7636-8054
4 ~	405801	2924321	Plus	63469-63694
45		6164995	Plus	13871-14110
	406153		Minus	12902-13069
	406348	9255985	Minus	71754-71944

# TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90<sup>th</sup> percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0 (i.e. 4-fold down-regulated in tumor vs. normal breast).

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

15 Unigene ID: Unigene number Unigene Title: Unigene gene title

R1: Ratio of 50th percentile normal body tissue to 75th percentile tumor

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	Ratio
•	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	22.4
	428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
		H57646	Hs.42586	KIAA1560 protein	15.4
25		T28499	Hs.89485	carbonic anhydrase IV	15.0
		M25079	Hs.155376	hemoglobin, beta	14.6
		AL049176	Hs.82223	chordin-like	14.6
		AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
20		A1983730	Hs.26530	serum deprivation response (phosphatidyl	13.6
30		A1446543	Hs.95511	ESTs	12.6
		AA934589	Hs.49696	ESTs	12.2
		H25642	Hs.133471	ESTs	12.0
		L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
25		NM_000163	Hs.125180	growth hormone receptor	11.7
35		AF027208	Hs.112360	prominin (mouse)-like 1	10.8
		AW207175	Hs.106771	ESTs	10.6
		X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
		AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
40		N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40		Al220684	Hs.272572	hemoglobin, alpha 2	9.5
		AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
		NM_004657	Hs.26530	serum deprivation response (phosphatidyl	9.4
		AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
45		Al365585	Hs.146246	ESTs	9.0
45		T53088	Hs.155376	hemoglobin, beta	8.9
		AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
		X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
		D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
50		AA779958	Hs.185932	ESTs	8.5
50		AU076442	Hs.117938	collagen, type XVII, alpha 1	8.4
		AB029496	Hs.59729	semaphorin sem2	8.3
	402195		11 404007	NM_004497*:Homo sapiens hepatocyte nucle	8.1
		AI754634	Hs.131987	ESTs	8.1
<i></i>		Al208121	Hs.147313	ESTs, Weakly similar to I38022 hypotheti	8.1
55		N77976	Hs.272572	hemoglobin, alpha 2	8.0
		AW377424	Hs.205126	Homo sapiens cDNA: FLJ22667 fis, clone H	8.0
		AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
		AA760849	Hs.294052	ESTs	7.5
60		AK000027	Hs.98633	ESTs	7.5
60	425078		Hs.154437	phosphodiesterase 2A, cGMP-stimulated ESTs	7.5
	430327	AW973636	Hs.55931	E018	7.4

	447577	Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Al150491	Hs.90756	ESTs	7.2
		R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	7.2
	424455	AA452006	Hs.333199	ESTs	7.1
5		AW956360	Hs.4748	adenylate cyclase activating polypeptide	7.1
		AI352340	Hs.131194	ESTs	7.0
		Al219304	Hs.283108	hemoglobin, gamma G	6.9
		A1446183 AA346839	Hs.9572 Hs.209100	ESTs, Highly similar to CYA5_HUMAN ADENY DKFZP434C171 protein	6.8 6.7
10		AI478427	Hs.43125	esophageal cancer related gene 4 protein	6.7
10		AB002058	Hs.113275	purinergic receptor P2X-like 1, orphan r	6.7
		AA256395	Hs.88156	ESTs	6.6
	404368	NA		ENSP00000241075*:TRRAP PROTEIN.	6.6
4 m		NM_006691	Hs.17917	extracellular link domain-containing 1	6.5
15		AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
		AL119796 AW963085	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		S72043	Hs.73133	gb:EST375158 MAGE resequences, MAGH Hon metallothionein 3 (growth inhibitory fac	6.4
20		BE250659	Hs.15463	Homo sapiens, clone IMAGE:2959994, mRNA	6.4
		AA701483	Hs.36341	ESTs	6.3
	402779			Target Exon	6.3
	418138	AA213626	Hs.136204	ESŤ	6.3
~~		AA742697	Hs.62492	ESTs, Weakly similar to B39066 proline-r	6.3
25		AA001732	Hs.173233	hypothetical protein FLJ10970	6.2
		BE143068		gb:MR0-HT0158-030200-003-b09 HT0158 Home	
		BE004783 NM_012093	Hs.18268	gb:MR2-BN0114-270400-004-e11 BN0114 Home adenylate kinase 5	6.1
		NM_014759	Hs.334688	KIAA0273 gene product	6.1
30		H15968	Hs.293845	Homo sapiens, clone IMAGE:3502329, mRNA,	6.1
		F08212	Hs.234898	ESTs, Weakly similar to 2109260A B cell	6.0
	400089	NA		Eos Control	6.0
	433614	W07475	Hs.277101	cytochrome c oxidase subunit IV isoform	5.9
25		N92818	Hs.64754	ESTs, Weakly similar to potential CDS [H	5.9
35		BE067414	11- 440050	gb:MR4-BT0355-200100-201-e05 BT0355 Homo	
		AA062610	Hs.148050	EST .	5.9
	406563	AW451023	Hs.65848	Target Exon hypothetical protein DKFZp761O132	5.9 5.9
		AA843387	Hs.87279	ESTs	5.9
40		NM_001874	Hs.334873	carboxypeptidase M	5.8
		AW809163		gb:MR4-ST0118-261099-012-a03 ST0118 Homo	
	453469	AB014533	Hs.33010	KIAA0633 protein	5.8
		Al372588	Hs.8022	TU3A protein	5.8
15		AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
45		BE063555	11- 2240	gb:CM1-BT0283-081199-033-d09 BT0283 Homo	
		AW876813 AW014486	Hs.3343 Hs.22509	phosphoglycerate dehydrogenase	5.7 5.7
		AW452355	Hs.256037	ESTs ESTs	5.7
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5.7
50		AI695473	Hs.298006	ESTs	5.7
	428553	AA181641	Hs.184907	G protein-coupled receptor 1	5.6
	404689			Target Exon	5.6
		R68857	Hs.265499	ESTs	5.6
55		\$47833	Hs.82927	adenosine monophosphate deaminase 2 (iso	5.6
55		H23963	Hs.32043	ESTs	5.6
		R50253 C15819	Hs.249129	cell death-inducing DFFA-like effector a gb:C15819 Clontech human aorta polyA mRN	5.5 5.5
		AW444613	Hs.288809	hypothetical protein FLJ20159	5.5
		AB020629	Hs.38095	ATP-binding cassette, sub-family A (ABC1	5.5
60		AI668605	Hs.60380	ESTs, Moderately similar to ALU6_HUMAN A	5.5
		AA345824	Hs.76688	carboxylesterase 1 (monocyte/macrophage	5.5
	401665	700070	11 4044= 1	C11000703:gi[10048448]ref[NP_065258.1] g	5.5
		T99079	Hs.191194	ESTs	5.5
65		AI161428	Hs.75916	splicing factor 3b, subunit 2, 145kD	5.5
UJ		BE005346 BE617015	Hs.116410 Hs.11006	ESTs ESTs, Moderately similar to T17372 plasm	5.5 5.5
	408122	AI432652	Hs.42824	hypothetical protein FLJ10718	5.5 5.5
	100122				5.0
				. 336	

	454016	AW016806	Hs.233108	ESTs	5.5
	414913	R25621		gb:yh45f06.r1 Soares placenta Nb2HP Homo	5.4
	459033	AA017590	Hs.129907	ESTs	5.4
		BE172240	Hs.126379	ESTs, Weakly similar to 138022 hypotheti	5.4
5		N49826	Hs.18602	ESTs	5.4
•		AA994520	110110002	gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	
	403612			Target Exon	5.3
		AA007629	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	5.3
				multimerin	5.3
10		R66634	Hs.268107		5.3
10		BE272452	Hs.183109	monoamine oxidase A	
		AA620814	Hs.144959	ESTs	5.3
		R99530	Hs.272572	hemoglobin, alpha 2	5.3
	427032	AF012023	Hs.173274	integrin cytoplasmic domain-associated p	5.3
	406305	BE261320	Hs.158196	transcriptional adaptor 3 (ADA3, yeast h	5.3
15	437411	AW613948	Hs.194915	ESTs	5.3
	442800	AI809481	Hs.131227	ESTs	5.3
	402054	NA		Target Exon	5.3
		AF212829	Hs.272406	potassium channel, subfamily K, member 9	5.3
		R59638	Hs.6181	ESTs	5.2
20		Al904646	110.0101	gb:QV-BT065-020399-103 BT065 Homo sapien	5.2
20		AB037721	Hs.173871	KIAA1300 protein	5.2
					5.2
		BE467930	Hs.170381	ESTs	5.2
		Al285901	Hs.181297	ESTs	
0.5	402698			ENSP00000251335*:DJ1003J2.1 (sodium and	5.2
25	401810			Target Exon	5.2
		AA827674	Hs.189073	ESTs	5.2
		AA424074	Hs.76780	protein phosphatase 1, regulatory (inhib	5.2
	427809	M26380	Hs.180878	lipoprotein lipase	5.1
	456063	NM_006744	Hs.76461	retinol-binding protein 4, interstitial	5.1
30	451186	AW023469	Hs.65256	ESTs, Weakly similar to leucine-rich gli	5.1
	451882	AI821324	Hs.100445	ESTs	5.1
	402583			NM 021620:Homo sapiens PR domain contain	.5.1
		NM 006103	Hs.2719	HE4; WFDC2; putative ovarian carcinoma m	5.1
		Al435179	Hs.126820	ESTs	5.1
35		R53467	Hs.269122	ESTs, Weakly similar to ALU1_HUMAN ALU S	5.1
55		BE143867	110.200 122	gb:MR0-HT0164-070100-013-h02 HT0164 Homo	
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5.1
		BE244537	Hs.167382	natriuretic peptide receptor A/guanylate	5.1
		AA486620		endomucin-2	5.0
40			Hs.41135		5.0
40		AW026692	Hs.224829	ESTs	
		D59597	Hs.118821	CGI-62 protein	5.0
		Al524307	Hs.162870	ESTs	5.0
		AI076012	Hs.121388	ESTs, Weakly similar to MDHC_HUMAN MALAT	5.0
4		BE160229		gb:QV1-HT0413-090200-062-a12 HT0413 Homo	
45		AF012626	Hs.54472	fragile X mental retardation 2	5.0
	409853	AW502327		gb:UI-HF-BR0p-aka-a-07-0-UI.r1 NIH_MGC_5	5.0
	405062			Target Exon	5.0
	446490	AK000706	Hs.15125	hypothetical protein FLJ20699	5.0
	417622	AW298163	Hs.82318	WAS protein family, member 3	5.0
50		AJ243662	Hs.110196	NICE-1 protein	5.0
		R62431	Hs.12758	ESTs	5.0
		R35009	Hs.24903	ESTs	5.0
	A1757A	R00348	110.121000	gb:ye69e06.r1 Soares fetal liver spleen	5.0
		AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55		AI768289		ESTs	4.9
55			Hs.304389		4.9
		BE550889	Hs.158491	ESTs	4.9
	443074	AW341470	Hs.144907	ESTs	
		A1783600	Hs.208052	ESTs	4.9
<b>CO</b>		AW014734	Hs.157969	ESTs	4.9
60		Al989812	Hs.199850	ESTs	4.9
		N94587	Hs.55063	ESTs	4.9
		AW973716	Hs.13913	KIAA1577 protein	4.9
	433200	AA682722	Hs.192725	ESTs	4.9
	430782	AF026263	Hs.247920	cholinergic receptor, muscarinic 5	4.8
65		AW137094	Hs.97990	ESTs	4.8
		AA868510	Hs.112496	ESTs	4.8
		AI349351	Hs.118944	hypothetical protein FLJ22477	4.8
				••	

	404707			· · · · · · · · · · · · · · · · · ·	
	421795		Hs.283822	Rhesus blood group, D antigen	4.8
		N77624	Hs.173717	phosphatidic acid phosphatase type 2B	4.8
		BE063965		gb:QV3-BT0296-140200-085-h01 BT0296 Homo	
_	443721	AW450451	Hs.266355	ESTs	4.8
5	408053	AW139474	Hs.246862	ESTs	4.8
		AA843716	Hs.177927	ESTs	4.7
	442969	Al025499	Hs.132238	ESTs	4.7
	426220	Al383475	Hs.171697	ESTs, Weakly similar to T13924 sdk prote	4.7
	414593	BE386764		gb:601273249F1 NIH_MGC_20 Homo sapiens c	4.7
10	426893	AA398716	Hs.97418	ESTs	4.7
		AW292618	Hs.113011	ESTs	4.7
	401590	NA		Target Exon	4.7
		AW134679	Hs.242849	ESTs	4.7
		AK000123	Hs.180479	hypothetical protein FLJ20116	4.6
15		AA045290	Hs.25930	ESTs, Weakly similar to 2109260A B cell	4.6
		R49187	Hs.6659	ESTs	4.6
		AA972327	Hs.142903	ESTs	4.6
		AW298235	Hs.101689	ESTs	4.6
		Al382726	Hs.182434	ESTs	4.6
20	403017	AIGOZIZO	110.102-10-1	Target Exon	4.6
20		N40087	Hs.15248	ESTs	4.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	4.6
		M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	4.6
					4.6
25		NM_001546	Hs.34853	inhibitor of DNA binding 4, dominant neg	4.6
23		Al 127000	Hs.146650	ESTS	
		AL137698	Hs.46531	Homo sapiens mRNA; cDNA DKFZp434C1915 (i	
		AW204277	Hs.250723	hypothetical protein MGC2747	4.6
		AF134707	Hs.278679	a disintegrin and metalloproteinase doma	4.6
20		Al375984	Hs.167216	ESTS	4.6
30		F00312	11 447400	gb:HSBB0D101 STRATAGENE Human skeletal	
		Al348455		Homo sapiens cDNA FLJ11777 fis, clone HE	4.6
		Al290653	Hs.124758	ESTS	4.6
		NM_014861	Hs.6168	KIAA0703 gene product	4.6
25		AW015933	Hs.112654	Homo sapiens, clone MGC:9764, mRNA, comp	4.5
35	423301		Hs.1645	cytochrome P450, subfamily IVA, polypept	4.5
		H86385	Hs.81737	palmitoyl-protein thioesterase 2	4.5
		AL389981	Hs.149219	Homo sapiens mRNA full length insert cDN	4.5
		AA335769	Hs.16262	ESTs	4.5
40	449338	H73444	Hs.394	adrenomedullin	4.5
40	434744	N94835	Hs.283828	Homo sapiens genomic DNA, chromosome 21q	4.5
	407402	AF035303		gb:Homo sapiens clone 23943 mRNA sequenc	4.5
	443510	NM_012190	Hs.9520	formyltetrahydrofolate dehydrogenase	4.5
		AA169114	Hs.12247	hypothetical protein FLJ11413	4.5
	415986	Z43619		gb:HSC1GE121 normalized infant brain cDN	4.5
45	457416	BE142052	Hs.62654	kringle-containing transmembrane protein	4.5
	418064	BE387287	Hs.83384	S100 calcium-binding protein, beta (neur	4.4
	437120	Al356125	Hs.157767	ESTs, Weakly similar to HXA2_HUMAN HOMEO	14.4
	453950	AA156998	Hs.211568	eukaryotic translation initiation factor	4.4
	401093			C12000586*:gi 6330167 dbj BAA86477.1  (A	4.4
50	436935	AW206494	Hs.253560	ESTs	4.4
	457974	AW842353	Hs.321717	ESTs, Weakly similar to S22765 heterogen	4.4
	428222	AL133112	Hs.183085	Homo sapiens mRNA; cDNA DKFZp434K098 (fr	4.4
	442705	Al264634	Hs.131127	ESTs	4.4
	437409	AL359599	Hs.283850	Homo sapiens mRNA; cDNA DKFZp547C126 (fr	4.4
55	458494	Al380906	Hs.158436	ESTs	4.4
	410490	H03589		gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
	416069		Hs.20982	ESTs	4.4
		AA807958	Hs.314232	ESTs	4.4
		AI499723	Hs.135089	ESTs	4.4
60		H87407	Hs.172944	chorionic gonadotropin, beta polypeptide	4.4
• • •		AF147401	Hs.23917	ESTs	4.3
	400870			C11000905:gi 11692565 gb AAG39879.1 AF28	4.3
		AA933590	Hs.28937	homeobox protein from AL590526	4.3
		H45384		gb:yn99c10.r1 Soares adult brain N2b5HB5	4.3
65		M12873		gb:Human lg rearranged H-chain mRNA VDJ4	4.3
00		AV654020	Hs.184261	ESTs, Weakly similar to T26686 hypotheti	4.3
	403263		0. 10 120 1	Target Exon	4.3
	700200				

	410034	BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Hom	0 4.3
		Al421645	Hs.139851	caveolin 2	4.3
	448427	BE395260	Hs.309438	EST	4.3
~		D45371	Hs.80485	adipose most abundant gene transcript 1	4.3
5		NM_002666	Hs.103253	perilipin	4.3
	400973		11. 55000	ENSP00000236667*:Mucin 5B (Fragment).	4.3
		AW366194	Hs.55962	ESTs	4.3
	405016	NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3
10		AI475671	Hs.88607	CY000171*:gi 9280405 gb AAF86402.1 AF245 ESTs, Highly similar to F-box protein FB	4.3 4.3
10	406118		113.00001	ENSP0000246632:CDNA FLJ20261 fis, clone	4.3
		T02850		gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818	Hs.221736	ESTs	4.3
	433088	AW451206	Hs.115899	ESTs	4.3
15	444445	AA342329	Hs.115920	Homo sapiens cDNA: FLJ22816 fis, clone K	4.3
		AI803166	Hs.28462	ESTs, Weakly similar to 138022 hypotheti	4.3
		A1377221	Hs.40528	ESTs	4.2
		BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
20		AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921	NA Al798425	Hs.42710	C5000212*:gi[10047237[dbj]BAB13407.1] (A ESTs	4.2 4.2
	406344	A17 30423	115.427 10	C5001660:gi[11611537 dbj]BAB18935.1] (AB	4.2
		AA191201	Hs.35861	DKFZP586E1621 protein	4.2
		BE155866	Hs.25522	KIAA1808 protein	4.2
25	458504	AW070634	Hs.144794	ESTs	4.2
	404682	NA		C9001188*:gi 12738842 ref NP_073725.1  p	4.2
		N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433			NM_001622:Homo sapiens alpha-2-HS-glycop	4.2
20		AW975460	Hs.143563	ESTS	4.2
30		Al309298 Al871247	Hs.279898	Homo sapiens cDNA: FLJ23165 fis, clone L	4.2
		AW973708	Hs.6262 Hs.201925	hypothetical protein MGC8407 Homo sapiens cDNA FLJ13446 fis, clone PL	4.2 4.2
		AA397789	Hs.161803	ESTs	4.2
		AF193807	Hs.131835	Rhesus blood group, B glycoprotein	4.2
35		Y09763	Hs.22785	gamma-aminobutyric acid (GABA) A recepto	4.2
	440610	AI733098	Hs.130800	ESTs	4.2
		AF086410		gb:Homo sapiens full length insert cDNA	4.2
		AA399975	Hs.274151	ligatin	4.2
40		AW594172	Hs.278513	TP53TG3 protein	4.2
40		T77545	Hs.187559	ESTS	4.2
		AI144152 AA318060	Hs.58246 Hs.135121	ESTs	4.2
		NM_015977	Hs.285681	hypothetical protein FLJ22415 Williams-Beuren syndrome chromosome regi	4.2 4.2
		R57171	Hs.57975	calsequestrin 2 (cardiac muscle)	4.1
45	400545		110.07 07 0	Target Exon	4.1
	403051			Target Exon	4.1
	420139	NM_005357	Hs.95351	lipase, hormone-sensitive	4.1
		AA007534	Hs.125062	ESTs	4.1
50		AA034116	Hs.118494	ESTs	4.1
50		W52010	Hs.191379	ESTs	4.1
		Al307802 Al150595	Hs.135560	ESTs, Weakly similar to T43458 hypotheti	4.1
		AA082947	Hs.122226	ESTs gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
		BE270758	Hs.69428	hypothetical protein MGC3020	4.1 4.1
55		Al306150	Hs.153450	ESTs, Weakly similar to 1909123A Na gluc	4.1
-		AK000708	Hs.169764	hypothetical protein FLJ20701	4.1
	453692	AL110416		gb:DKFZp434K0431_r1 434 (synonym: htes3)	4.1
	448640	AW817177	Hs.102558	Homo sapiens, clone MGC:5352, mRNA, comp	4.1
<b>CO</b>		AA203281	Hs.21798	ESTs	4.1
60		AW118878	Hs.110835	ESTS	4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	4.1
		AW631296 R06285	Hs.191215	gb:hh83c09.y1 NCI_CGAP_GU1 Homo sapiens ESTs	
	417629		110.101210	gb:yc92c07.r1 Soares infant brain 1NIB H	4.1
65	403593			Target Exon	4.1 4.0
	402690			Target Exon	4.0
	418190	R49591	Hs.270425	ESTs	4.0

	408641	AW245207	Hs.5555	hypothetical protein MGC5347	4.0
		AA829286	Hs.332053	serum amyloid A1	4.0
		AI811536	Hs.145734	ESTs	4.0
	438831	BE263273	Hs.6439	synapsin II	4.0
5	455578	BE006350	Hs.14355	Homo sapiens cDNA FLJ13207 fis, clone NT	4.0
	401840	NA		Target Exon	4.0
	413753	U17760	Hs.75517	laminin, beta 3 (nicein (125kD), kalinin	4.0
	445030	Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873	AW156913	Hs.150478	ESTs, Weakly similar to A Chain A, Cryst	4.0
10	456736	AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
	450112	BE047734	Hs.5473	ESTs, Moderately similar to ALU5_HUMAN A	4.0
	448906	AI589567	Hs.309719	ESTs	4.0

#### TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

#### Pkey CAT number Accessions

```
AW502327 AW502488 AW501829 AW502625 AW502687
       409853 1156226 1
20
                          BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
       410034 1170594_1
       410233 118656_1
                          AA082947 AA083036
       410490 1205347_1
                          H03589 AW750687 AW750688
                          AW809163 AW809247 AW809177 AW809190 AW809225
       410882 1225686 1
                          BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005
       411478 1247073_1
25
                          BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322
       413065 1347960_1
       413072 1348163 1
                          BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884
       414593 1464909_1
                          BE386764 BE387560
                          R25621 C03959 C04010
       414913 1506721_1
                          AW963085 AA159005 AW963073
       415011 151328_1
30
                          Z43619 R61274 H12206 R12883
       415986
              1564410_1
              1583547 1
                          H45384 H49125 H41699
       416267
                          R00348 R09593
       417574 1687770_1
       417629 1690392_1
                          T76945 R20210 R05755
       418556 1767866_-1
                          T02850
35
       419583 186198_1
                          F00312 AA247490 F31427 AA383663 F22045
       426328 264901_1
                          AW631296 AA375484
       439590 47413_1
                          AF086410 W94386 W74609
       442398 541271_1
                          AA994520 AW393574
                          C15819 AA024741 AA024742
       452205 90415_1
40
       452654 925931_1
                          BE004783 BE004947 AI911790
       453692 977825_1
                          AL110416 AW876759
                          AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807068 BE141561
       454183 1049636 1
                          BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345
                          AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399
                          AW807064 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216
45
                          AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308
                          AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433
                          AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019
                          AW807238 AW807201 BE141590 AW807302 AW807323 AW807380 AW807109 BE141588 AW845877 AW807418 AW807407
50
                          AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350
                          AW80728 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198
                          AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131
                          AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921
                          BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353
55
       454404 1170594_1
                          BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
                          BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911
       454775 1234106_1
       455282 1273020_1
                          BE143867 AW935060 AW886684
       459159 919998_1
                          Al904646 BE179494 BE179421
```

## TABLE 23B

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic 5 sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Dkov	Ref	Strand	Né position
	Pkey	Rei	Suanu	Nt_position
	400545	9800107	Minus	124618-124881
	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
4 ~	406118	9143818	Plus	53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

## **TABLE 24:**

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAccn
for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10	Pkey: ExAccn: Unigene Unigene Pred.Ce Seq.ID.N	elD: U Title: U	xemplar Access Inigene number Inigene gene title redicted Cellular			
15	Pkey	ExAccn	UnigenelD	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.
20	407276 415539 400297 450375	Al668594 Al951118 Al733881 Al127076 AA009647	Hs.8850	ESTs, Weakly similar to CP4Y_HUMAN CYTO Homo sapiens breast cancer antigen NY-BR BMP-R1B hypothetical protein DKFZp564O1278 a disintegrin and metalloproteinase doma	nuclear	Seq ID 1 & 2 Seq ID 3 & 4 Seq ID 5 & 6 Seq ID 7 & 8 Seq ID 9 & 10
25	429170 424399 422505 449765	NM_00139 NM_00139 AI905687 AL120862 N92293 D90041		dual specificity phosphatase 4 dual specificity phosphatase 4 aldehyde dehydrogenase 9 family, member ESTs ESTs, Moderately similar to ALU8_HUMAN A N-acetyltransferase 1 (arylamine N-acety	nuclear cytoplasm	Seq ID 11 & 12 Seq ID 11 & 12 Seq ID 13 & 14 Seq ID 15 & 16 Seq ID 17 & 18 Seq ID 19 & 20
30	439840 410102 429220	AW449211 AW248508 AW207208	Hs.155223 Hs.105445 Hs.279727 Hs.136319	stanniocalcin 2 GDNF family receptor alpha 1 Homo sapiens cDNA FLJ14035 fis, clone HE ESTs		Seq ID 21 & 22 Seq ID 23 & 24 Seq ID 25 & 26 Seq ID 27 & 28
35	409079 442818 442082 444381		Hs.7413 Hs.283713	LIV-1 protein, estrogen regulated interleukin 6 signal transducer (gp130, hypothetical protein FLJ10879 ESTs ESTs, Weakly similar to S64054 hypotheti		Seq ID 29 & 30 Seq ID 31 & 32 Seq ID 33 & 34 Seq ID 35 & 36 Seq ID 37 & 38
40	416636 442117 433043 429353	W57554	Hs.25252 Hs.42645 Hs.128899 Hs.125019 Hs.200102 Hs.91668	Homo sapiens cDNA FLJ13603 fis, clone PL solute carrier family 16 (monocarboxylic ESTs lymphoid nuclear protein (LAF-4) mRNA ATP-binding cassette transporter MRP8 Homo sapiens clone PP1498 unknown mRNA		Seq ID 39 & 40 Seq ID 41 & 42 Seq ID 43 & 44 Seq ID 45 & 46 Seq ID 47 & 48 Sea ID 49 & 50
45	446733 452747 423242 417433	AA863360 BE153855 AL039402 BE270266	Hs.26040 Hs.61460 Hs.125783	ESTs, Weakly similar to fatty acid omega lg superfamily receptor LNIR DEME-6 protein 5T4 oncofetal trophoblast glycoprotein Transmembrane protease, serine 3		Seq ID 51 & 52 Seq ID 53 & 54 Seq ID 55 & 56 Seq ID 57 & 58 Seq ID 59 & 60
50	439569 114480 404561 325372	BE066778 NA	Hs.136348 6 Hs.222399 Hs.151678	osteoblast specific factor 2 (fasciclin CEGP1 protein UDP-N-acetyl-alpha-D-galactosamine:polyp NM_014112*:Homo sapiens trichorhinophala Phase 2 & 3 Exons	mitochodria nuclear	Seq ID 61 & 62 Seq ID 63 & 64 Seq ID 65 & 66 Seq ID 67 & 68 Seq ID 69 & 70
55	335824 424735 400289 427585	NA U31875 X07820 D31152	Hs.334806 Hs.272499 Hs.2258 Hs.179729	KIAA1238 protein ENSP00000249072*:DJ222E13.1 (N-TERMIN short-chain alcohol dehydrogenase family matrix metalloproteinase 10 (stromelysin collagen, type X, alpha 1 (Schmid metaph		Seq ID 71 & 72 Seq ID 73 & 74 Seq ID 75 & 76 Seq ID 77 & 78 Seq ID 79 & 80
60	429441 421155 420931 420813	AJ224172 H87879 AF044197	6Hs.226213 Hs.204096 Hs.102267 Hs.100431 Hs.99949 Hs.30504	cytochrome P450, 51 (lanosterol 14-alpha lipophilin B (uteroglobin family member) lysyl oxidase small inducible cytokine B subfamily (Cy prolactin-induced protein Homo sapiens mRNA; cDNA DKFZp434E082	extracellular nuclear (fr	Seq ID 81 & 82 Seq ID 83 & 84 Seq ID 85 & 86 Seq ID 87 & 88 Seq ID 89 & 90 Seq ID 91 & 92

	420757	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	cytoplasm	Seq ID 93 & 94
	424905	NM_00249	7Hs.153704	NIMA (never in mitosis gene a)-related k	nuclear	Seq ID 95 & 96
	429859	NM_007050	DHs.225952	protein tyrosine phosphatase, receptor t		Seq ID 97 & 98
_	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	extracellular	Seg ID 99 & 100
5	445537	AJ245671	Hs.12844	EGF-like-domain, multiple 6		Sea ID 101 & 102
	428227	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 103 & 104
	424001	W67883	Hs.137476	paternally expressed 10		Seg ID 105 & 106
	421727	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3		Seq ID 107 & 108
	452838	U65011	Hs.30743	preferentially expressed antigen in mela	nuclear	Seq ID 109 & 110
10	419667	AU077005	Hs.92208	a disintegrin and metalloproteinase doma		Seg ID 111 & 112
	414812	X72755	Hs.77367	monokine induced by gamma interferon	extracellular	Seg ID 113 & 114
	426320	W47595	Hs.169300	transforming growth factor, beta 2		Seg ID 115 & 116
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	extracellular	Sea ID 117 & 118
	411558	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto		Seq ID 119 & 120
15	417866	AW067903	Hs.82772	collagen, type XI, alpha 1		Seq ID 121 & 122
	428398	A1249368	Hs.98558	ESTs		Seq ID 123 & 124
	431958	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	plasma membrane	Seq ID 125 & 126
	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	•	Seq ID 127 & 128
	412970	AB026436	Hs.177534	dual specificity phosphatase 10		Seq ID 129 & 130
20	421379	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy		Seq ID 131 & 132
	415752	BE314524	Hs.78776	putative transmembrane protein		Seq ID 133 & 134
	444051	N48373	Hs.10247	activated leucocyte cell adhesion molecu		Seq ID 135 & 136
	451110	Al955040	Hs.265398	ESTs. Weakly similar to transformation-r		Seg ID 137 & 138

#### TABLE 24A

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey: Unique Eos probeset identifier number

5

CAT number: Gene cluster number
Accession: Genbank accession numbers

15 Pkey CAT number Accession

335824 CH22\_3197FG\_619\_11\_LINK\_E 325372 c12\_hs

## **TABLE 24B**

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Ref:

Unique number corresponding to an Eos probeset

Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand:

Indicates DNA strand from which exons were predicted.

Nt\_position:

Indicates nucleotide positions of predicted exons.

15

10

5

Pkey Ref Strand Nt position 404561 9795980 Minus 69039-70100

20

#### Table 25

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (nr and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522)



	AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAATGCAA ATGCGAATGC AGTTAATAAG 540
	TATAAATGCA CAGCCCTCAT GCTTGCTGTA TGTCATGGAT CATCAGAGAT AGTTGGCATG 600
	CTTCTTCAGC AAAATGTTGA CGTCTTTGCT GCAGATATAT GTGGAGTAAC TGCAGAACAT 660
	TATGCTGTTA CTTGTGGATT TCATCACATT CATGAACAAA TTATGGAATA TATACGAAAA 720
5	TTATCTAAAA ATCATCAAAA TACCAATCCA GAAGGAACAT CTGCAGGAAC ACCTGATGAG 780
_	GCTGCACCCT TGGCGGAAAG AACACCTGAC ACAGCTGAAA GCTTGGTGGA AAAAACACCT 840
	GATGAGGCTG CACCCTTGGT GGAAAGAACA CCTGACACGG CTGAAAGCTT GGTGGAAAAA 900
	ACACCTGATG AGGCTGCATC CTTGGTGGAG GGAACATCTG ACAAAATTCA ATGTTTGGAG 960
	AAAGCGACAT CTGGAAAGTT CGAACAGTCA GCAGAAGAAA CACCTAGGGA AATTACGAGT 1020
10	CCTGCAAAAG AAACATCTGA GAAATTTACG TGGCCAGCAA AAGGAAGACC TAGGAAGATC 1080
10	GCATGGGAGA AAAAAGAAGA CACACCTAGG GAAATTATGA GTCCCGCAAA AGAAACATCT 1140
	GAGAAATTTA CGTGGGCAGC AAAAGGAAGA CCTAGGAAGA TCGCATGGGA GAAAAAAGAA 1200
	ACACCTGTAA AGACTGGATG CGTGGCAAGA GTAACATCTA ATAAAACTAA AGTTTTGGAA 1260
	AAAGGAAGAT CTAAGATGAT TGCATGTCCT ACAAAAGAAT CATCTACAAA AGCAAGTGCC 1320
15	AAAGGAAGAT CTAAGATGAT TICATGTCCT ACAAAAGAAT CATCTACAAA AGCAAGTGCC 1320  AATGATCAGA GGTTCCCATC AGAATCCAAA CAAGAGGAAG ATGAAGAATA TTCTTGTGAT 1380
13	TCTCGGAGTC TCTTTGAGAG TTCTGCAAAG ATTCAAGTGT GTATACCTGA GTCTATATAT 1440
	CAAAAAGTAA TGGAGATAAA TAGAGAAGTA GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC 1500
	AAGCCTGCCA TTGAAATGCA AAACTCTGTT CCAAATAAAG CCTTTGAATT GAAGAATGAA 1560
20	CAAACATTGA GAGCAGATCC GATGTTCCCA CCAGAATCCA AACAAAAGGA CTATGAAGAA 1620
20	AATTCTTGGG ATTCTGAGAG TCTCTGTGAG ACTGTTTCAC AGAAGGATGT GTGTTTACCC 1680
	AAGGCTACAC ATCAAAAAGA AATAGATAAA ATAAATGGAA AATTAGAAGA GTCTCCTAAT 1740
	AAAGATGGTC TTCTGAAGGC TACCTGCGGA ATGAAAGTTT CTATTCCAAC TAAAGCCTTA 1800
	GAATTGAAGG ACATGCAAAC TTTCAAAGCG GAGCCTCCGG GGAAGCCATC TGCCTTCGAG 1860
25	CCTGCCACTG AAATGCAAAA GTCTGTCCCA AATAAAGCCT TGGAATTGAA AAATGAACAA 1920
25	ACATGGAGAG CAGATGAGAT ACTCCCATCA GAATCCAAAC AAAAGGACTA TGAAGAAAAT 1980
	TCTTGGGATA CTGAGAGTCT CTGTGAGACT GTTTCACAGA AGGATGTGTG TTTACCCAAG 2040
	GCTGCGCATC AAAAAGAAAT AGATAAAATA AATGGAAAAT TAGAAGGGTC TCCTGTTAAA 2100
	GATGGTCTTC TGAAGGCTAA CTGCGGAATG AAAGTTTCTA TTCCAACTAA AGCCTTAGAA 2160
20	TTGATGGACA TGCAAACTTT CAAAGCAGAG CCTCCCGAGA AGCCATCTGC CTTCGAGCCT 2220
30	GCCATTGAAA TGCAAAAGTC TGTTCCAAAT AAAGCCTTGG AATTGAAGAA TGAACAAACA 2280
	TTGAGAGCAG ATGAGATACT CCCATCAGAA TCCAAACAAA AGGACTATGA AGAAAGTTCT 2340
	TGGGATTCTG AGAGTCTCTG TGAGACTGTT TCACAGAAGG ATGTGTGTTT ACCCAAGGCT 2400
	ACACATCAAA AAGAAATAGA TAAAATAAAT GGAAAATTAG AAGAGTCTCC TGATAATGAT 2460
25	GGTTTTCTGA AGGCTCCCTG CAGAATGAAA GTTTCTATTC CAACTAAAGC CTTAGAATTG 2520
35	ATGGACATGC AAACTTTCAA AGCAGAGCCT CCCGAGAAGC CATCTGCCTT CGAGCCTGCC 2580
	ATTGAAATGC AAAAGTCTGT TCCAAATAAA GCCTTGGAAT TGAAGAATGA ACAAACATTG 2640
	AGAGCAGATC AGATGTTCCC TTCAGAATCA AAACAAAAGA AGGTTGAAGA AAATTCTTGG 2700
	GATTCTGAGA GTCTCCGTGA GACTGTTTCA CAGAAGGATG TGTGTGTACC CAAGGCTACA 2760
40	CATCAAAAAG AAATGGATAA AATAAGTGGA AAATTAGAAG ATTCAACTAG CCTATCAAAA 2820
40	ATCTTGGATA CAGTTCATTC TTGTGAAAGA GCAAGGGAAC TTCAAAAAGA TCACTGTGAA 2880
*	CAACGTACAG GAAAAATGGA ACAAATGAAA AAGAAGTTTT GTGTACTGAA AAAGAAACTG 2940
	TCAGAAGCAA AAGAAATAAA ATCACAGTTA GAGAACCAAA AAGTTAAATG GGAACAAGAG 3000
	CTCTGCAGTG TGAGATTGAC TTTAAACCAA GAAGAAGAA AGAGAAGAAA TGCCGATATA 3060
	TTAAATGAAA AAATTAGGGA AGAATTAGGA AGAATCGAAG AGCAGCATAG GAAAGAGTTA 3120
45	GAAGTGAAAC AACAACTTGA ACAGGCTCTC AGAATACAAG ATATAGAATT GAAGAGTGTA 3180
	GAAAGTAATT TGAATCAGGT TTCTCACACT CATGAAAATG AAAATTATCT CTTACATGAA 3240
	AATTGCATGT TGAAAAAGGA AATTGCCATG CTAAAACTGG AAATAGCCAC ACTGAAACAC 3300
	CAATACCAGG AAAAGGAAAA TAAATACTTT GAGGACATTA AGATTTTAAA AGAAAAGAAT 3360
	GCTGAACTTC AGATGACCCT AAAACTGAAA GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420
50	TATAGTGGGC AGCTTAAAGT TCTGATAGCT GAGAACACAA TGCTCACTTC TAAATTGAAG 3480
	GAAAAACAAG ACAAAGAAAT ACTAGAGGCA GAAATTGAAT CACACCATCC TAGACTGGCT 3540
	TCTGCTGTAC AAGACCATGA TCAAATTGTG ACATCAAGAA AAAGTCAAGA ACCTGCTTTC 3600
	CACATTGCAG GAGATGCTTG TTTGCAAAGA AAAATGAATG TTGATGTGAG TAGTACGATA 3660
	TATAACAATG AGGTGCTCCA TCAACCACTT TCTGAAGCTC AAAGGAAATC CAAAAGCCTA 3720
55	AAAATTAATC TCAATTATGC AGGAGATGCT CTAAGAGAAA ATACATTGGT TTCAGAACAT 3780
-	GCACAAAGAG ACCAACGTGA AACACAGTGT CAAATGAAGG AAGCTGAACA CATGTATCAA 3840
	AACGAACAAG ATAATGTGAA CAAACACACT GAACAGCAGG AGTCTCTAGA TCAGAAATTA 3900
	TTTCAACTAC AAAGCAAAAA TATGTGGCTT CAACAGCAAT TAGTTCATGC ACATAAGAAA 3960
	GCTGACAACA AAAGCAAGAT AACAATTGAT ATTCATTTTC TTGAGAGGAA AATGCAACAT 4020
60	CATCTCCTAA AAGAGAAAAA TGAGGAGATA TTTAATTACA ATAACCATTT AAAAAACCGT 4080
00	ATATATCAAT ATGAAAAAGA GAAAGCAGAA ACAGAAAACT CA <u>TGA</u> GAGAC AAGCAGTAAG 4140
	AAACTTCTTT TGGAGAAACA ACAGACCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200
	GTCCTAGCAT CACCTTATGT TGAAAATCTT ACCAATAGTC TGTGTCAACA GAATACTTAT 4260
	TTTAGAAGAA AAATTCATGA TTTCTTCCTG AAGCCTACAG ACATAAAATA ACAGTGTGAA 4320
65	GAATTACTTG TTCACGAATT GCATAAAGCT GCACAGGATT CCCATCTACC CTGATGATGC 4380
05	AGCAGACATC ATTCAATCCA ACCAGAATCT CGCTCTGCAC TCCAGCCTAG GTGACAGAGT 4440
	GAGACTCCAC CTCGGAAA
	UNUNCTOCKO CTCUURAA
70	Seq ID NO: 4 Protein sequence:
, .	ond to vice a serious and account

70 Seq ID NO: 4 <u>Protein sequence:</u> Protein Accession #: NP\_443723.1

1 11 21 31 41 51

| | | | | | | | | | | | |

MTKRKKTINL NIQDAQKRTA LHWACVNGHE EVVTFLVDRK CQLDVLDGEH RTPLMKALQC 60
HQEACANILI DSGADINLVD VYGNMALHYA VYSEILSVVA KLLSHGAVIE VHNKASLTPL 120
LLSITKRSEQ IVEFLLIKNA NANAVNKYKC TALMLAVCHG SSEIVGMLLQ QNVDVFAADI 180

CGVTAEHYAV TCGFHHIHEQ IMEYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240 SLVEKTPDEA APLVERTPDT AESLVEKTPD EAASLVEGTS DKIQCLEKAT SGKFEQSAEE 300 TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360 IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420 5 DEEYSCDSRS LFESSAKIQV CIPESIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480 AFELKNEQTL RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540 KLEESPNKDG LLKATCGMKV SIPTKALELK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA 660 LELKNEQTWR ADEILPSESK QKDYEENSWD TESLCETVSQ KDVCLPKAAH QKEIDKINGK 660 LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIE MQKSVPNKAL 720 10 ELKNEOTLRA DEILPSESKO KDYEESSWDS ESLCETVSOK DVCLPKATHO KEIDKINGKL 780 EESPDNDGFL KAPCRMKVSI PTKALELMDM QTFKAEPPEK PSAFEPAIEM QKSVPNKALE 840 LKNEQTLRAD QMFPSESKQK KVEENSWDSE ŠLRETVSQKD VCVPKATHQK EMDKISGKLE 900 DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960 KVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020 DIELKSVESN LNQVSHTHEN ENYLLHENCM LKKEIAMLKL EIATLKHQYQ EKENKYFEDI 1080 KILKEKNAEL QMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILEAEIE 1140 15 SHIPPLASAV ODHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTIYNN EVLHQPLSEA 1200 QRKSKSLKIN LNYAGDALRE NTLVSEHAQR DQRETQCQMK EAEHMYQNEQ DNVNKHTEQQ 1260 ESLDQKLFQL QSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320 20 NNHLKNRIYQ YEKEKAETEN S Seq ID NO: 5 DNA sequence none found Nucleic Acid Accession #: 273-1785 (underlined sequences correspond to start and stop codons) Coding sequence: 25 51 CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGCC AGTGCGGAGA CCGCGGCGCT 60 GAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 30 GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCG TCCAAAGGTC 360 35 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420 GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480
GGTTGCCTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540
AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA 600 CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660 40 ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG 720 TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780 ATTCCTCCTG GAGAAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGGTC AGGAAGTGGA 840
TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900
ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960
GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG 1020 45 ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080 GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140 TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260
CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320
GACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380
ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 50 AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500 GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560
CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620
CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGAT GGGAAAACTC 1680
ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740
ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG 1800 55

Seq ID NO: 6 Protein sequence:
Protein Accession #: none found

60

TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860

TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920 CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAG TTGATCCGTG 1980


EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS  $\,$  480 RLTALRVKKT LAKMSESQDI KL

none found

Seq ID NO: 7 DNA sequence

Nucleic Acid Accession #:

5



PPQNPRKLIL AGNIIHSLMK SDLVEYFTLE MLHLGNNRIE VLEEGSFMNL TRLQKLYLNG 420
NHLTKLSKGM FLGLINLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPPHIFS 480
GVPLTKVNLK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540
TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600
LTDAVPLSVL ILGLLIMFIT IVFCAAGIVV LVLHRRRYK KKQVDEQMRD NSPVHLQYSM 660
YGHKTTHHTT ERPSASLYEQ HMVSPMVHVY RSPSFGPKHL EEEEERNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL EKERELQQLG ITEYLRKNIA 780
QLQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840

Seq ID NO: 9 DNA sequence

5

15

70

75

Nucleic Acid Accession #: NM\_003474

Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons)

51 41 CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACGCA CGCACACAC CGGGGGGAAA 120 20 CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT 180 CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC 240 GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300 GCGACGATGG CAGCGCCCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCCT GCTCGCCCTG 360 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 25 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600 TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660 TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 30 TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780 AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAAGCGT CCGGGGATCA 840 TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900 CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG 960 GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020 35 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140 CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 TCCCATGACA ATGCGCAGCT TGTCAGTGGG GTTTATTTCC AAGGGACCAC CATCGGCATG 1260 GCCCCAATCA TGAGCATGTG CACGGCAGAC CAGTCTGGGG GAATTGTCAT GGACCATTCA 1320 40 GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380 AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440 ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 45 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800 AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860 GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 50 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980
TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040
AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100
GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 55 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460
TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520
TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGT TGCGCCCTTC CCGGCCACCC 2580 60 CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640 CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CTTCCTCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CCTGCCAGCC 2820 AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCTCA GAAGCCTCTG 2880 CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940 65

CAATGGGAGA CTGGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACCAA 3000 GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060 TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTTA CCAACTTTTA 3120 GGATTTTTT TAATGTTTAA AACATCATTA CTATAAGAAC TTTGAGCTAC TGCCGTCAGT 3180 GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240 GCAGAAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300 CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTTAGTG AACTTGAAAT ATCCTGCTTG 3360

ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420

CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480 CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540 TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600

ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGATCTGA ACACTAGACA AGCCAGAACT 3720
TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780 GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840 5 CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 10 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4880 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 AATGCCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 15 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 20 AAACACACA AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 ACCAAAAAA AAAAAAAAAA AA Seq ID NO: 10 Protein sequence: NP\_003465.2 Protein Accession #: 30 51 11 21 31 41 MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD 60

35 SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY 120
YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180
SHHNTPNLAA KNVFPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240
LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300
DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360

DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420 SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480 ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG 540 AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600 IETNIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC 660 AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720

45 LAAGFVVYLK RKTLIRLIFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRKPP 780
DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840
ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP 900
RSTHTAYIK


Seq ID NO; 11 DNA sequence
Nucleic Acid Accession #: NM\_001394
Coding sequence: 400-1584(underlined sequences correspond to start and stop codons)

51

40

55

GTCTCCTCGG ACTGCCCAAA CCACTTTGAA GGACACTATC AGTACAAGTG CATCCCAGTG 1140
GAAGATAACC ACAAGGCCGA CATCAGCTCC TGGTTCATGG AAGCCATAGA GTACATCGAT 1200
GCCGTGAAGG ACTGCCGTGG GCGCGTGCTG GTGCACTGCC AGGCGGGCAT CTCGCGGTCG 1260
GCCACCATCT GCCTGGCCTA CCTGATGATG AAGAAACGGG TGAGGCTGGA GGAGGCCTTC 1320



AGAGCGAGGT CATATCTTTG CCCTTCCTGG ATCAGCTGGT GTCAACCCTC GTGGGCCTCC 600 TCAGCCCACA CAACCCGGCC CTGGCCGCTCGA TTATAGATGC CCAGTTCATT 660
TTTACTGGGT GCGTGGTGAA GAAATTATTC CTCGTGGTCA TCGAAGAGGT CGAATTGATG 720 ACTTGCGATA CCAGATAGAT GATAAACCAA ACAACCAGAT TCGAATATCC AAGCAACTCG 780 5 CAGAGTTTGT GCCATTGGAT TATTCTGTTC CTATAGAAAT CCCCACTATA AAATGTAAAC 840 CAGACAAACT TCCATTATTC AAACGGCAGT ATGAAAACCA CATATTTGTT GGCTCAAAAA 900 CTGCAGATCC TTGCTGTTAC GGTCACACCC AGTTTCATCT GTTACCTGAC AAATTAAGAA 960 GGGAAAGGCT TTTGAGACAA AACTGTGCTG ATCAGATAGA AGTTGTTTTT AGAGCTAATG 1020 CTATTGCAAG CCTTTTTGCT TGGACTGGAG CACAAGCTAT GTATCAAGGA TTCTGGAGTG 1080 10 AAGCAGATGT TACTCGACCT TTTGTCTCCC AGGCTGTGAT CACAGATGGA AAATACTTTT 1140 CCTTTTTCTG CTACCAGCTA AATACTTTGG CACTGACTAC ACAAGCTGAT CAAAATAACC 1200 CTCGTAAAAA TATATGTTGG GGTACACAAA GTAAGCCTCT TTATGAAACA ATTGAGGATA 1260 ATGATGTGAA AGGTTTTAAT GATGATGTTC TACTTCAGAT AGTTCACTTT CTACTGAATA 1320 GACCAAAAGA AGAAAAATCA CAGCTGTTGG AAAAC<u>TGA</u>AA AAGCATATTT GATTGAGAAC 1380 TGTGGGAATA TTTAAATTTT ACTGAAGGAA CAATAATGAT GAGATTTGTA ACTGTCAACT 1440 ATTAAATACA TTGATTTTTG AGACAAATAT TTCTTATGTC AACCTGTTAT TAGATCTCTT 1500 15 ACTCTGCTCA AATTCATCAC TGAAAGATTT AATTTTAGTT ACCTTTTGTT GATTTAAAAA 1560 TAATTGCATT TGTATATTGC TAACTGATAA GACAAATTGA GTTATTGAGC TATTAAATGC 1620 ACATTTTAAT ATAAATGCAG AAATCCCAAA TAAAATGCTA ACATACTGAA TTCAGTAATT 1680 20 AAAAGAACCC ACTGC Seq ID NO: 16 Protein sequence: NP 057724.1 Protein Accession #: 25

41 31

MAAARCWRPL LRGPRLSLHT AANAAATATE TTSQDVAATP VARYPPIVAS MTADSKAARL 60 RRIERWQATV HAAESVDEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120
PPAEPEPEP PEPEPALDLA ALRAVACDCL LQEHFYLRRR RRVHRYEESE VISLPFLDQL 180 30 VSTLVGLLSP HNPALAAAAL DYRCPVHFYW VRGEEIIPRG HRRGRIDDLR YQIDDKPNNQ 240 IRISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300 LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFVSQAV 360 ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420 35 IVHFLLNRPK EEKSOLLEN

Seg ID NO: 17 DNA sequence Nucleic Acid Accession #: NM\_025059.1

3-2150 (underlined sequences correspond to start and stop codons) Coding sequence:

51 11 21 31 41 GCATGAGCCT GGACTGCACC AGCCATATCG CGCTGGGTGC CGCTTCGCCA GCGCCCGAGG 60

40

70

75

45 AAACTTACGA TCATCTTTCG GAAGTCCCGG TCACGCGGGA GCAGTTAAAC CACTATCGGA ATGTGGCTCA AAATGCTCGA AGTGAACTTG CAGCAACTTT GGTCAAATTT GAATGTGCTC 180 AGTCTGAGCT TCAAGACCTC CGATCCAAGA TGCTTCTAA AGAAGTCTCC TGTCAAGAAC 240
TGAAAGCTGA AATTGGAGAGC TACAAGGAAA ACAATGCCAG AAAATCATCT CTCCTTACCT 300
CTTTGAGAGA CAGAGTTCAG GAACTAGAAG AAGAATCAGC AGCACTTTCC ACTTCTAAAA 360
TCAGAACAGA AATCACAGCT CACGCTGCAA TCAAGGAGAA CCAGGAATTA AAGAAGAAAG 420 50 TTGTAGAGTT AAATGAAAAA TTACAAAAGT GTTCAAAAGA AAATGAGGAG AATAAGAAAC 480 AAGTTTCAAA GAATTGCAGG AAACATGAGG AATTTCTGAC TCAACTGCGT GACTGCTTGG 540 ATCCAGATGA GAGGAATGAC AAGGCATCAG ATGAAGATTT AATTTTAAAG CTTAGAGACC 600 TGCGCAAAGA AAATGAATTC GTGAAAGGAC AAATTGTTAT TCTTGAAGAG ACTATAAATG 660 TCCATGAGAT GAAACAAAA GCTAGCAGAG AAACGATCAT GAGGCTGGCT TCAGAAGTCA 720
ACAGAGAGCA GAAAAAAGCT GCCTCCTGTA CTGAAAGAGAA AGAGAAGCTG AACCAGGACC 780
TGCTCAGTGC TGTAGAAGCA AAAGAAGCTC TTGAAAGGGA AGTTAAGATC TTCCAAGAAA 840
GGCTGCTTGC TGGCCAGCAG GTCTGGGATG CCTCAAAGCA GGAAGTGAGC CTCCTGAAGA 900 55 780 AAAGCTCTTC TGAGTTGGAG AAGAGTTTGA AGGCCAGTCA GGATGCAGTC ACAACCTCAC 960 AAAGCCAGTA CTCCTCATTT AGGGAGAAAA TCGCAGCCCT CCTTAGGGGC AGATTGAGCA 1020 60 TGACTGGGTC CACTGAGGAC ACCATTTTGG AGAAGATTCG AGAAATGGAC AGCCGGGAAG 1080
AAAGCAGGA CCGGATGGTC TCCCAGCTTG AAGCCCAAAT ATCTGAGCTT GTTGAACAGT 1140
TGGGAAAGGA GTCTGGGTTT CACCAGAAAG CTCTCCAGAG GGCCCAGAAA GCAGAGAATA 1200
TGTTGGAGAC TCTTCAGGGT CAGCTGACAC ACCTGGAGGC AGAGCTGGTT TCTGGAGGTG 1260 65 TTTTGCGAGA CAACTTGAAT TTTGAGAAAC AAAAATATCT TAAATTTCTG GATCAGCTTT 1320 CTCAGAAAAT GAAGTTGGAC CAGATGGCTG CCGAACTTGG CTTTGACACG CGGCTGGACG 1380

TGGTTTTAGC TCGAACAGAG CAGCTGGTTC GTCTTGAGAG CAATGCAGTC ATTGAGAACA 1440 AGACCATTGC CCACAATTTG CAGAGAAAGC TAAAGACACA GAAAGAGAG CTGGAGAGCA 1500 AAGAATTACA CATGAGCCTC CTCCGGCAGA AAATAGCCCA GCTGGAGGAG GAGAAGCAGG 1560 CACGCACGGC CTTGGTGGTT GAGAGGGACA ACGCGCATCT TACCATCAGG AACTTGCAGA 1620 AGAAGGTGGA GAGGCTGCAG AAAGAGCTGA ACACGTGTCG AGACTTGCAC ACCGAGCTCA 1680 AAGCCAAACT GGCCGACACC AATGAACTGA AGATTAAAAC TTTGGAACAG ACTAAAGCCA 1740 TTGAAGATCT AAACAAATCC AGAGACCAAC TGGAGAAGAT GAAGGAGAAA GCTGAGAAAA 1800 AGCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860
AAAGGGCCAG AAACATGATA GAAGTGGTAA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860
AAAGGGCCAG AAACATGATA GAAGTGGTAA CCAGTGAAAT GAAGACACTA AAAAAATCTC 1920
TGGAAGAAGC AGAAAAGAGA GAAAAGCAGC TGGCAGACTT CAGGGAGGTG GTGTCGCAGA 1980
TGCTAGGCTT GAACGTGACC AGCCTTGCTC TTCCTGATTA TGAAATCATC AAGTGTCTTG 2040

	AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100
	CTACTGGGCA AGAGAGGCAC CCACAAGGCC ATTTACAGCT TCTTCATTGA ACACTGTATC 2160
	TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220
	TCTTTGAGAT TTGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280
5	CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340
_	CAAAAAAAA AAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400
	AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460
	TACTAGCCGA TTTAGTTCTC ACAATAACCA TGTGGAGAAG CTGTGACATT TTTAATTTAC 2520
	AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAGG TTGCAGTTGG GTAGTGGTGG 2580
10	GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATGC 2640
	AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGAA TTGTTTGCAT AGAGGAAGGA 2700
	CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760
	CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820
	CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880
15	GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGGAGG 2940
	CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000
	CTCAGAAAA AAAAAAAAA AAAAAAAAA AAGTTAATGT CCAAAAATGA CAGATTTACA 3060
	AGTGTAAGCT ATATGATTTC TTCAAAAAGC AAAAGCAATA TACCTAATTC ATTTGGATCA 3120
	AACTTACATA GGTCTCAGGT CCTGTAAGAA ACTTGCCTGT TCTAACTGTT GCTACCAGAT 3180
20	TATATCTGGT GGTAATTGTT AATGTTTCAG CAGGGCTGGT CTCAGTCCTT TAAAATGGAA 3240
	AGCTTTATTT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTCT TATTCACCAA 3300
	TATATCCAAT ACACCCACAG CAATGGTACC TTTTTAAGAT CAGGATTTTA TTATGAATTC 3360
	CTGTCACTTT CTGTTTTCCA TTTAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420
	CTTAACTTCA CTGAGAAAAA TGTGTTACTC TTTTGGACAA TTTATCTTAT TTCTATCATA 3480
25	TAAGATGTAT TTTTTTATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540
	AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATATAC AACCAACCGT 3600
	TCGTGAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAACAT GGCAAAACTC CGTCTCTGCA 3660
	AAAAATACAA AAATGAGCCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720
	GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780
30	CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAAACA ACAACAACAA 3840
	AAAGTCAAAG TCATAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAATTAA 3900
	AGAGATGAAA CAATCAATTG CAAGGGTCAA AACTAGATTG GATCTTGGTT TGAATGAAAA 3960
	AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020
	ATATTAAAAT ATTTTTAATT TTTTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080
35	AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140
	AAAAAAAA A
4.0	Seq ID NO: 18 Protein sequence:
40	Protein Accession #: NP_079335.1
	<del>-</del>
	1 11 21 31 41 51
4.5	MSLDCTSHIA LGAASPAPEE TYDHLSEVPV TREQLNHYRN VAQNARSELA ATLVKFECAQ 60
45	SELQDLRSKM LSKEVSCQEL KAEMESYKEN NARKSSLLTS LRDRVQELEE ESAALSTSKI 120
	RTEITAHAAI KENQELKKKV VELNEKLQKC SKENEENKKQ VSKNCRKHEE FLTQLRDCLD 180
	PDERNDKASD EDLILKLRDL RKENEFVKGQ IVILEETINV HEMEAKASRE TIMRLASEVN 240
	REOKKAASCT EEKEKLNODL LSAVEAKEAL EREVKIFOER LLAGOOVWDA SKOEVSLLKK 300
	SSSELEKSLK ASQDAVTTSQ SQYSSFREKI AALLRGRLSM TGSTEDTILE KIREMDSREE 360
50	SRDRMVSQLE AQISELVEQL GKESGFHQKA LQRAQKAENM LETLQGQLTH LEAELVSGGV 420
	LRDNLNFEKQ KYLKFLDQLS QKMKLDQMAA ELGFDTRLDV VLARTEQLVR LESNAVIENK 480
	TIAHNLQRKL KTQKERLESK ELHMSLLRQK IAQLEEEKQA RTALVVERDN AHLTIRNLQK 540
	KVERLQKELN TCRDLHTELK AKLADTNELK IKTLEQTKAI EDLNKSRDQL EKMKEKAEKK 600
~ ~	LMSVKSELDT TEHEAKENKE RARNMIEVVT SEMKTLKKSL EEAEKREKQL ADFREVVSQM 660
55	I.GLNVTSLAL PDYEIIKCLE RLVHSHOHHF VTCACLKDVT TGOERHPOGH LOLLH

Seq ID NO: 19 DNA sequence
Nucleic Acid Accession #: AF071552, NM\_000662
Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons)

LGLNVTSLAL PDYEIIKCLE RLVHSHQHHF VTCACLKDVT TGQERHPQGH LQLLH

55

1 11 21 31 41 51

CTTTGTATAA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60
ACTCTATTGC ATGATTCTCC TGCCTACATC AGAAGACGTT TATAAGCCTA TTTTAAAGGA 120
TACCAGTTGG AATCTCTCTT TTATTAATCA CCAAGAGAAC CATGAACAAG CTGTTTATCA 180
TTTGACTCAT CATTTAATCT TGATTTCCAG CTTCTCACAC TTGAAAGAAG ACATAATACA 240
TTTCTCACAG GATTCTGGGA CTATTAACTG AACTTATGTG TGTAAAAGGA ATTCATACAA 300
TGAAAGCACT AGAAATAATT ATTATACTTA TAACCATTGT ATTTTTACAT GTTTAAAATA 360
TAGCCATAAT TAGCCTACTC AAATCCAAGT GTAAAAGTAA AATGATTTGC TTTCGTTTTG 420
TTTTCCTTGC TTAGGGGATC ATGGACATTG AAGCATATCT TGAAAGATT GGCTATAAGA 480
AGTCTAGGAA CAAATTGGAC TTGGAAACAT TAACTGACAT TCTTCAACAC CAGATCCGAG 540
CTGTTCCCTT TGAGAACCTT AACATCCATT GTGGGGATGC CATGGACTTA GGCTAAGAG 600
CCATTTTTGA TCAAGTTGTG AGAAGAAATC GGGGTGGATG GTGTCTCCAG GTCAATCATC 660
TTCTGTACTG GGCTCTGACC ACTATTGGTT TTGAGACCAC GATGTTGGGA GGGTATGTTT 720
ACAGCACTCC AGCCAAAAAA TACAGCACTG GCATGATTCA CCTTCTCCTG CAGGTGACCA 780

TTGATGGCAG GAACTACATT GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CTCTGGAGTT AATTTCTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900
AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960
AATTTCTTCA TTCTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020
TTAAGCCTCG AACAATTGAA GATTTTGAGT CTATGAATAC ATACCTGCAG ACATCTCCAT 1080 5 CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC CCCAGATGGG GTTCACTGTT 1140 TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATA'A GGACAATACA GATCTAATAG 1200 AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260 CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTTACTATT TAGAATAAAGG 1320
AGTAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380
TGTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440
TATAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACAAACCTT 1500
TTCAAATAAT AATAATAATA ATAATAATAA ATGTATTTTA AAGATGGCCT GTGGTTATCT 1560 10 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 <u>Protein sequence:</u> Protein Accession #: NP\_000653.1 20 11 31 41 21 MDIEAYLERI GYKKSRNKLD LETLTDILQH QIRAVPFENL NIHCGDAMDL GLEAIFDQVV 60 VEDSKYRKIY SFTLKPRTIE DESKYRKLY EBIEKVLKNI FNISLQRKLV PKHGDRAMDL GLEARPQVV 60

VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL 180

LEDSKYRKIY SFTLKPRTIE DFESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT 240

HRRFNYKDNT DLIEFKTLSE EBIEKVLKNI FNISLQRKLV PKHGDRFFTI 25 Seq ID NO: 21 DNA sequence Nucleic Acid Accession #: NM\_003714
Coding sequence: 123-1031(underlined sequences correspond to start and stop codons) 30 35 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60 GAGGAGGAAG AGGGGAGCAC AAAGGATCCA GGTCTCCCGA CGGGAGGTTA ATACCAAGAA 120 CCATGTGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTTG GCCACCTTTG 180
ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240
AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300
CTGGCGATGT GGGGTGTGGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360 40 GCTTACATGG GATTTGCATG ACTTTTCTGC ACAACGCTGG AAAATTTGAT GCCCAGGGCA 420 AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480 GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540 ACCTCAAGCA CGACCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGA 600 TCCATTTCAA GGACTTGCTG CTGCACGAAC CCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660 CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCACAGCGT GCAGGTTCAG TGTGAGCAGA 720 45 ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780 CGGCGCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900 50 GTGAGCGAGG TAGCAAGAGC CACCCAAACG CCCATGCCCG AGGCAGAGTC GGGGGCCTTG 960 GGGCTCAGGG ACCTTCCGG AGCAGCGAGT GGGAAGACG ACAGTCTGAG TATTCTGATA 1020
TCCGGAGGTG AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080
ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGGG GATGTCACAC GCAGGATTCT 1140
GTGGGGACTG TGGACTTCAT CGAGGTGTGT GTTCGCGGAA CGGACAGGTG AGATGGAGAC 1200 55 CCCTGGGGCC GTGGGGTCTC AGGGGTGCCT GGTGAATTCT GCACTTACAC GTACTCAAGG 1260 GAGCGCCCC GCGTTATCCT CGTACCTTTG TCTTCTTTCC ATCTGTGGAG TCAGTGGGTG 1320 TCGGCCGCTC TGTTGTGGG GAGGTGAACC AGGGAGGGGC AGGGCCAAGGC AGGGCCCCA 1380
GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440
GGTGCTGTCT CCGCGGAAGT CAGGGCGGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500
AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGCCCGAG GGGGTGCTTG 1560 60 GTGCCAAACT GAAATTCAGT TTCTTGTGTG GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680 GGGGGACACT GTCCAAGGGA GTGGCCCCTA TGAGTTTATA TTTTAACCAC TGCTTCAAAT 1740 CTCGATTTCA CTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 GCTTTCAAAC AAAAAAAAAA AAAAAAAAAA AAAAAAA Seq ID NO: 22 Protein sequence: Protein Accession #: NP 003705 70 21 31 41 51 11

MCAERLGOFM TLALVLATFO PARGTDATNP PEGPODRSSQ QKGRLSLONT AEIQHCLVNA 60 GDVGCGVFEC FENNSCEIRG LHGICMTFLH NAGKFDAQGK SFIKDALKCK AHALRHRFGC 120 ISRKCPAIRE MVSQLQRECY LKHDLCAAAQ ENTRVIVEMI HFKDLLLHEP YVDLVNLLLT 180

CGEEVKEAIT HSVQVQCEQN WGSLCSILSF CTSAIQKPPT APPERQPQVD RTKLSRAHHG 240 EAGHHLPEPS SRETGRGAKG ERGSKSHPNA HARGRVGGLG AQGPSGSSEW EDEQSEYSDI 300

75


356

RR

5

Seq ID NO: 23 DNA sequence

Nucleic Acid Accession #:



NM\_005264.1

CAGGGCGGC GAGGACGGG GAGGTGGGGG GGCCGCCC CCCGCGCAGC CGACAGCCCC 240 CGCTCTCTAC AAAGAGGCCG AGCTGCGCCT GAAGGGCAGC AGCAACACCA CGGAGTGTGT 420 5 TCCCGTGCCC ACCTCCGAGC ACGTGGCCGA GATCGTGGGC AGGCAAGGCT GCAAGATTAA 480 GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT 540 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TTCTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660
GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG 720
GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACATA 780
CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840 10 CGTGGAGCGT GCGCGCGAGG AGATCGAGAC GCACATCGCG GTGCGCACTG GCAAGATCCT 900 CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCG 960 CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA 1020 GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCCACGCCT 1080 GGGTGAGCAG GGCGGGACT TTGGCTACGG CGGGTACCTC TTTCCGGGCT ATGGCGTGGG 1140 CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGCCAGGA 1200 15 GAACGCCACG CCCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCCTCCT CCTCTTCCGC 1260 CAAGGCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCCT GCCACTTCCG CGGGACCGA 1320 20 GCTGGCCGGA CTCCCGAGGC GCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTAAACTTGG 1380 TGGGGGCGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440 AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25 Seq ID NO: 26 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 30 51 11 21 31 41 FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP 60 RAGEDGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV 180 FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240 LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL 300 EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360 GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSS 420 35 KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLOGFSKLG GGGLRSPGGG RDCMVCFESE 480 40 VTAALVPCGH NLFCMECAVR ICERTDPECP VCHITATQAI RIFS Sea ID NO: 27 DNA sequence FGENESH predicted Nucleic Acid Accession #: 1-2070 (underlined sequences correspond to start and stop codons) Coding sequence: 45 ATGAGCGGTG CGGGGGTGGC GGCTGGGACG CGGCCCCCA GCTCGCCGAC CCCGGGCTCT 60 CGGCGCCGGC GCCAGCGCC CTCTGTGGGC GTCCAGTCCT TGAGGCCGCA GAGCCCGCAG 120
CTCAGGCAGA GCGACCCGCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTT 180
CAGCAGCAGC ACTCGGAGAT GCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240
GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGCCC TGCCTCCCCA GGCACACTCA 300 50 ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360 GGGGGAACAC AGGACGGGA GCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGCC 420 55 CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480 60 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840
GCACTTCCCC ATCCTGACAG CGGCCCCAC CCAGCCCAGG ATCCTGGGCT GTGGTCTCAA 900
GCTCACTTCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGA 960
TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTGCCTA GGGCTCTCCC TTCCCAGGGA 1020
GACATGGAGA AGGGGGTTGA GGGAGGGCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 65 CTGTTCTGGG CAAAGTGTGG CCCAAGTCGG CAGCCCCAGC CCTGCAGTGC TGGGGACGCT 1140 GACAGGACAC GGGAAGAGGC CATGCTTTCC CTCGGGACCT GCTGTTCCAT GTGTCCCAAG 1200 70 TCCTTCAACA AGCAAGATTC AAAAGCTGAC GTCTCCCAGA AGGCGGACCT GGAAGAGGAG 1560
CCCCTACTTC ACAACAGCAA GCTGGACAAA GTTCCTGGGG TACAAGGGCA GGCCAGAAAG 1620 GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTGTATGG GGAACAGCCA GCACCAGGGC 1680 AGGCAGATGG GGGCGGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740 75 ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800

ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGGCGCC TGCATCGCTC AGTGCTT<u>TGA</u>

Seq ID NO: 28 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted

LKOTPKNNFA EROKRLQAMQ KRRLHRSVL

10

15

20

25

30

5

Seq ID NO: 29 DNA sequence
Nucleic Acid Accession #: NM\_012319.2
Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons)

31 41 11 21 CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA 60 CCAGTGGGCC CGTGTGGAAC CAAACCTGCG CGCGTGGCCG GGCCGTGGGA CAACGAGGCC 120 GCGGAGACGA AGGCGCAATG GCGAGGAAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC 180 TCTCTGTCAC AAATCCCCTT CATGAACTAA AAGCAGCTGC TTTCCCCCAG ACCACTGAGA 240 35 AAATTAGTCC GAATTGGGAA TCTGGCATTA ATGTTGACTT GGCAATTTCC ACACGGCAAT 300 ATCATCTACA ACAGCTTTTC TACCGCTATG GAGAAAATAA TTCTTTGTCA GTTGAAGGGT 360 TCAGAAAATT ACTTCAAAAT ATAGGCATAG ATAAGATTAA AAGAATCCAT ATACACCATG 420 40 ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCA TGAGCGTCAC TCAGACCATG 480 AGCATCACTC AGACCACGAG CATCACTCTG ACCATGATCA TCACTCTCAC CATAATCATG 540 CTGCTTCTGG TAAAAATAAG CGAAAAGCTC TTTGCCCAGA CCATGACTCA GATAGTTCAG 600 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720 45 TCTCTGAAGG AACTCACTTT CTAGAGACAA TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA 900 GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTAATCTCTGT CCAGCCATCA 1020
TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080
CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140 50 TCAGTTTCCT GTCTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200 AATTTCTCCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTTT 1260 TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320
CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAAA 1380
GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440
TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 55 AGAAGAAACC TGAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620 60 GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680 65 GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTGTC 2040 ATGAGCTIT TACIGNAGGE TIATCANGIG GITTANGIAC TICIGITGGE GIGTLETIC 2040
ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100
AGCAGGCTGT CCTTTATTAAT GCATTGTCAG CCATGCTGGC GTATCTTGGA ATGGCAACAG 2160
GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTG GATATTTGCA CTTACTGCTG 2220
GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC AATGATGCTA 2280 70 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 GTTTTGGAAT TATGTTACTT ATTTCCATAT TTGAACATAA AATCGTGTTT CGTATAAATT 2400 TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT 2460 AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAAA GTTAGTGGGT TTTGTGATTT 2520 TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTA ATATTTAAGT 2580 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAATGT CTTTAATGCT 2700 75

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760 TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820 AGCAAAGAAA TAAAGGAGAA AAGAGAAGAA TCTGAGAATT GGGGAGGCAT AGATTCTTAT 2880 AAAAATCACA AAATTTGTTG TAAATTAGAG GGGAGAAATT TAGAATTAAG TATAAAAAGG 2940 5 CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3000 GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060 AAATATATTT AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TTTCAAAATG 3120 TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180 TATTGCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240 10 CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300 TCATTTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360 GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 GATGTTTCTT TTTTACACAA TAAATTCCTT ATATCAGCTT G

Seq ID NO: 30 <u>Protein sequence:</u>
Protein Accession #: NP\_036451.2 15

70

41 51

20 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL 60 FYRYGENNSL SVEGFRKLLO NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240

NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300 25 RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360 LVALAVGTLS GDAFLHLLPH SHASHHISHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420 TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480 EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540

HSHFHDTLGQ SDDLIHHHHD YHHLLHHHHH QNHIPPHSHSQ RYSREELKDA GVATLAWMVI 600 MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660 30 NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720 RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF

Seg ID NO: 31 DNA sequence 35 Nucleic Acid Accession #: NM 002184.1 256-3012(underlined sequences correspond to start and stop codons) Coding sequence:

40 GAGCAGCAA AAGGCCCGCG GAGTCGCGCT GGGCCGCCCC GGCGCAGCTG AACCGGGGGC 60 CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCGC AAGGGGTTCG TGCGCTGTGG 120 AGACGCGGAG GGTCGAGGCG GCGCGGCCTG AGTGAAACCC AATGGAAAAA GCATGACATT 180 TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTGG 240

AAATATCCGC GCAAGATGTT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300 45 CTCACCACTG AATCTACAGG TGAACTTCTA GATCCATGTG GTTATATCAG TCCTGAATCT 360 CCAGTTGTAC AACTTCATTC TAATTTCACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420
GATTATTTC ATGTAAATGC TAATTACATT GTCTGGAAAA CAAACCATTT TACTATTCCT 480
AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540
TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600

50 TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAC CTAAAAATTT GAGTTGCATT 660 GTGAACGAGG GGAAGAAAT GAGGTGTGAG TGGGATGGTG GAAGGGAAAC ACACTTGGAG 720 ACAAACTTCA CTTTAAAATC TGAATGGGCA ACACACAAGT TTGCTGATTG CAAAGCAAAA 780 CGTGACACCC CCACCTCATG CACTGTTGAT TATTCTACTG TGTATTTTGT CAACATTGAA 840

GTCTGGGTAG AAGCAGAGAA TGCCCTTGGG AAGGTTACAT CAGATCATAT CAATTTTGAT 900 CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960 CTGTCTAGTA TCTTAAAATT GACATGGACC AACCCAAGTA TTAAGAGTGT TATAATACTA 1020 55 AAATATAACA TTCAATATAG GACCAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCCTGAA 1080 GACACAGCAT CCACCCGATC TTCATTCACT GTCCAAGACC TTAAACCTTT TACAGAATAT 1140

GTGTTTAGGA TTCGCTGTAT GAAGGAAGAT GGTAAGGGAT ACTGGAGTGA CTGGAGTGAA 1200 60 GAAGCAAGTG GGATCACCTA TGAAGATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260 ATAGATCCAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320 CCTTTTGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380 CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440

TATCTAGCAA CCCTAACAGT AAGAAATCTT GTTGGCAAAT CAGATGCAGC TGTTTTAACT 1500 65 ATCCCTGCCT GTGACTTTCA AGCTACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560 GATAACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAGAA ATATATACTT 1620 GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGATGGT 1680 ACCGTGCATC GCACCTATTT AAGAGGGAAC TTAGCAGAGA GCAAATGCTA TTTGATAACA 1740 GTTACTCCAG TATATGCTGA TGGACCAGGA AGCCCTGAAT CCATAAAGGC ATACCTTAAA 1800

CAAGCTCCAC CTTCCAAAGG ACCTACTGTT CGGACAAAAA AAGTAGGGAA AAACGAAGCT 1860 GTCTTAGAGT GGGACCAACT TCCTGTTGAT GTTCAGAATG GATTTATCAG AAATTATACT 1920 ATATTTTATA GAACCATCAT TGGAAATGAA ACTGCTGTGA ATGTGGATTC TTCCCACACA 1980 GAATATACAT TGTCCTCTTT GACTAGTGAC ACATTGTACA TGGTACGAAT GGCAGCATAC 2040

ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100
GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160
GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGTT 2220
CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTC AAGGCACAAT 2280 75

ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTCAAA 2400
AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460
TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CTTCACAAAA CACTTCGAGC 2520
ACTGTCCAGT ATTCTACCGT GGTACACAGT GGCTACAGAC ACCAAGTTCC GTCAGTCCAA 2580 5 GTCTTCTCAA GATCCGAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640 CTACAATTAG TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA AAGGTCAAAG 2760 CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820 10 ATTTCACAAT CCTGTGGATC TGGGCAAATG AAAATGTTTC AGGAAGTTTC TGCAGCAGAT 2880 GCTTTTGGTC CAGGTACTGA GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT 2940 GCGACTGATG AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 3000 CTAAAATGAT TTTATCTGTG AATTC 15 Seq ID NO: 32 <u>Protein sequence:</u>
Protein Accession #: NP\_002175.1 21 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV 60 NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL 240 25 KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR 300 CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360 GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD 420 FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480 VLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540
QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600
KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK 660
SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN 720 30 TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS 780 ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV 840 35 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900 MPKSYLPQTV RQGGYMPQ Seq ID NO: 33 DNA sequence NM 018255.1 Nucleic Acid Accession #: 40 Coding sequence: 11-2491 (underlined sequences correspond to start and stop codons) AGTTGGCGAC ATGGTGGCAC CCGTGCTGGA GACTTCTCAC GTGTTTTGCT GCCCAAACCG 60 GGTGCGGGGA GTCCTGAACT GGAGCTCTGG GCCCAGAGGA CTTCTGGCCT TTGGCACGTC 120 CTGCTCCGTG GTGCTCTATG ACCCCCTGAA AAGGGTTGTT GTTACCAACT TGAATGGTCA 180 45 CACCGCCCGA GTCAATTGCA TACAGTGGAT TTGTAAACAG GATGGCTCCC CTTCTACTGA 240 ATTAGTTTCT GGAGGATCTG ATAATCAAGT GATTCACTGG GAAATAGAGG ATAATCAGCT 300 TTTAAAAGCA GTGCATCTTC AAGGCCATGA AGGACCTGTT TATGCGGTGC ATGCTGTTTA 360 50 CCAGAGGAGG ACATCAGATC CTGCATTATG TACACTGATC GTTTCTGCAG CTGCAGATTC 420 55 CTTTGGTAGA GATCTTTTCC TAGCAAGCTG TTCACAAGAT TGCCTGATAA GAATATGGAA 720 GCTGTATATA AAGTCAACAT CTTTAGAAAC TCAGGATGAC GATAACATAA GACTGAAAGA 780 AAATACTTTT ACCATAGAAA ATGAAAGTGT TAAAATAGCA TTTGCTGTTA CTCTGGAGAC 840 AGTGCTAGCC GGTCATGAAA ACTGGGTAAA TGCAGTTCAC TGGCAACCTG TGTTTTACAA 900 AGATGGTGTC CTACAGCAGC CAGTGAGATT ATTATCTGCT TCCATGGATA AAACCATGAT 960 TCTCTGGGCT CCAGATGAAG AGTCAGGAGT TTGGCTAGAA CAGGTTCGAG TAGGTGAAGT 1020 60 AGGTGGGAAT ACTTTGGGAT TTTATGATTG CCAGTTCAAT GAAGATGGCT CCATGATCAT 1080 TGCTCATGCT TTCCACGGAG CGTTGCACCT TTGGAAACAG AATACAGTTA ACCCAAGAGA 1140 GTGGACTCCA GAGATTGTCA TTTCAGGACA CTTTGATGGT GTCCAAGACC TAGTCTGGGA 1200 TCCAGAAGGA GAATTTATTA TCACTGTTGG TACTGATCAG ACAACTAGAC TTTTTGCTCC 1260 ATGGAAGAG AAAGACCAAT CACAGGTGAC TTGGCATGAA ATTGCAAGGC CTCAGATACA 1320
TGGGTATGAC CTGAAATGTT TGGCAATGAT TAATCGGTTT CAGTTTGTAT CTGGAGCAGA 1380
TGAAAAAGTT CTTCGGGTTT TTTCTGCACC TCGGAATTTT GTGGAAAATT TTTGTGCCAT 1440
TACAGGACAA TCACTGAATC ATGTGCTCTG TAATCAAGAT AGTGATCTTC CAGAAGGAGC 1500 65 CACTGTCCCT GCATTGGGAT TATCAAATAA AGCTGTCTTT CAGGGAGATA TAGCTTCTCA 1560 70 GCCTTCTGAT GAAGAGGAGC TGTTAACTAG TACTGGTTTT GAGTATCAGC AGGTGGCCTT 1620 TCAGCCCTCC ATACTTACTG AGCCTCCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1680
GCCTGAAGTT CAAAAACTAT ATGGGCACG TTATGAAATA TTTTGTGTTA CTTGTAACAG 1740
TTCAAAGACT CTGCTTGCCT CAGCTTGTAA GGCAGCTAAG AAAGAGCATG CAGCTATCAT 1800
TCTTTGGAAC ACTACATCTT GGAAACAGGT GCAGAATTTA GTTTTCCACA GTTTGACAGT 1860
CACGCAGATG GCCTTCTCAC CTAATGAGAA GTTCTTACTA GCTGTTTCCA GAGATCGAAC 1920 75 CTGGTCATTG TGGAAAAAGC AGGATACAAT CTCACCTGAG TTCGAGCCAG TTTTTAGTCT 1980 TTTTGCCTTC ACCAACAAA TTACTTCTGT GCACAGTAGA ATTATTTGGT CTTGTGATTG 2040

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGGTGG TTGTCTGGGG 2100
TGAGTGCGAC TCCACTGATG ACTGTATTGA GCACAACATT GGCCCCTGCT CCTCAGTCCT 2160
GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCCA GTGCTCACC CTTCTCAACG 2220
ATACGTGGTT GCAGTAGGAT TGGAGTGTGG AAAGATTTGC TTATATACCT GGAAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2340
TCATACACTG GCTATCAGAA AATTATGCTG GAAGAATTGC AGTGGAAAAA CTGAACAGAA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAGATC ACACTGTGAA 2460
GATACACAGA GTCAATAAAT GTGCACTG<u>TAA</u>TGG

Seq ID NO: 34 <u>Protein sequence:</u>
Protein Accession #: NP\_060725.1

60

65

70

75

FHGALHLWKQ NTVNPREWTP EIVISGHFDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420 KDQSQVTWHE IARPQIHGYD LKCLAMINRF QFVSGADEKV LRVFSAPRNF VENFCAITGQ 480 SLNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540 ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600 TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVPSLFAF 660

25 TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660
TNKITSVHSR IWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720
GAVTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PEINDWTHCV ETSQSQSHTL 780
AIRKLCWKNC SGKTEQKEAE GAEWLHFASC GEDHTVKIHR VNKCAL

30 Seq ID NO: 35 DNA sequence
Nucleic Acid Accession #: NM\_022131
Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)

41 51 11 21 31 35 TGCTGCGAGG ATGCTGCCTG GGCGGCTGTG CTGGGTGCCG CTCCTGCTGG CGCTGGGCGT 60 GGGGAGCGGC AGCGGCGGTG GCGGGGACAG CCGCCAGCGC CGCCTCCTCG CGGCTAAAGT 120 CAATAAGCAC AAGCCATGGA TCGAGACTTC ATATCATGGA GTCATAACTG AGAACAATGA 180 CACAGTCATT TTGGACCCAC CACTGGTAGC CCTGGATAAA GATGCACCGG TTCCTTTTGC 240
AGGGGAAATC TGTGCGTTCA AGATCCATGG CCAGGAGCTG CCCTTTGAGG CTGTGGTGCT 300
CAACAAGACA TCAGGAGAGG GCCGGCTCCG TGCCAAGAGC CCCATTGACT GTGAGTTGCA 360 40 GAAGGAGTAC ACATTCATCA TCCAGGCCTA TGACTGTGGT GCTGGGCCCC ACGAGACAGC 420 CTGGAAAAG TCACACAGG CCGTGGTCCA TATACAGGTG AAGGATGTCA ACGAGTTTGC TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540 45 CATTCTGCAG GTGGAGGCCA TTGACGAGGA CTGCTCCCCA CAGTACAGCC AGATCTGCAA 600 CTATGAAATC GTCACCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 660 CACTGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACGA 720 CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTGA AGCCAGTTTG 780 720

50 CAAGCCTGGC TGGCAAGACT GGACCAAGAG GATTGAGTAC CAGCCTGGCT CCGGGAGCAT 840
GCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTCTT CCCTCCAGAT 900
CGTCACAGAG CTGCAGACTA ATTACATTGG GAAGGGTTGT GACCGGGAGAC CCTACTCTGA 960
GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCCC 1020
TAGCGCTGCC ACCAACTGGA CTGCAGGACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1080
GTTTGACGGC AGGCAGGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1140
TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200

TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCAGG CTGACACCTT 1320
TCGCCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA 1380
TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440
ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCATGC AACTCACAGT 1500
CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAAACCACAG TTTGCTCAGT TCTTTCATGG 1560
AAGCCTGGCC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCCTG 1620
CCTGCAGGCC TGCAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680

GGAAACCATC CTCTGCAACT CAGACAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA 1260

CCTGCAGGCC TGCAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680
AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGCTTAG GCCAAGGAA 1740
CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGGG 1800
TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGCTTT GGGGAAGACG TATGCATCAG 1860
TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATCGAGCCCC GGATCACCCT 1920
CCGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980

CCGGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTCCA GGGGGACC 1880
CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040
GAAAACCACA GACCCCAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100
TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAGGCAG GAGTGCTTGG AGCTCAACCA 2160
CAGTGAGGCT CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220
CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340
CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAGA 2400

TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460
TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520



Seq ID NO: 38 <u>Protein sequence:</u> Protein Accession #: none found

15

50

55

1 11 21 31 41 51

MRPQGPAASP QRLRGLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA 60
GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL 120
GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ 180
GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240
1 PK

25 Seq ID NO: 39 DNA sequence
Nucleic Acid Accession #: NM\_000949
Coding sequence: 285-2153(underlined sequences correspond to start and stop codons)

CATCTGCAAC CGTTTTCACT CTGCTACTTT TTCTCAACAC CTGCCTTCTG AATGGACAGT 360
TACCTCCTGG AAAACCTGAG ATCTTTAAAT GTCGTTCTCC CAATAAGGAA ACATTCACCT 420
GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480
GGGAAGGAG AGCACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540
GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600
CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660

AGCCAGACCC TCCTTTGGAG CTGGCTGTGG AAGTAAAACA GCCAGAAGAC AGAAAAACCCT 720
ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780
TCCTGTATGA AATTCGAATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840
GGCAGCAAAC AGAGTTTAAG ATTCTCAGCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900
TTCGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGCGACC TTCATTCAGA 960
TACCTAGTGA CTTCACCATG AATGATACAA CCGTGTGGAT CTCTGTGGCT GTCCTTTCTG 1020
CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080

CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080 GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140 AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200 ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAGATGA TAGTGAGGAC CAGCATCTAA 1260 TGTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGGTATGAA ACCCAACATAC CTGGATCCTG 1320 ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380 AACCCCAGGC CAATCCCTC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCAGAGAATC 1440

CTGAAACAC CCACACCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCTATT 1500
TTCATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACC 1560
CCAGATCCTC TTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620
CACCGGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTCT CAAACCATTA 1680
AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740
CTGACCAGGA TACGCCCTGG CTGCTCCCC AGGAGAAAAC CCCCTTTGGC TCCGCTAAAC 1800


60 CTGACAGGA TACGCCCTGG CTGCTGCCCC AGGAGAAAAC CCCTTGGC TGCACAAC 1860
CCTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860
AACAGAGAG GAACAGCGGC AAGCCCAAGA AGCCCGGGAC TCCTGAGAAC AATAAGGAGT 1920
ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980
CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCAAAGAGGC CCCACATCA CTTGAACAGA 2040

ATCAAGCTGA GAAAGCCCTG GCCAACTTCA CTGCAACATC AAGCAAGTGC AGGCTCCAGC 2100
TGGGTGGTTT GGATTACCTG GATCCCGCAT GTTTTACACA CTCCTTTCAC TGATAGCTTG 2160
ACTAATGGAA TGATTGGTTA AAATGTGATT TTTCTTCAGG TAACACTACA GAGTACGTGA 2220
AATGCTCAAG AATGTAGTCA GACTGACACT ACTAAAGCTC CCAGCTCCTT TCATGCTCCA 2280
TTTTTAACCA CTTGCCTCTT TCTCCAGCAG CTGATTCCAG AACAAATCAT TATGTTTCCT 2340
AACTGTGATT TGTAGATTTA CTTTTTGCTG TTAGTTATAA AACTATGTGT TCAATGAAAT 2400
AAAAGCACAC TGCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460

70 AAAAGCACAC TGCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460 GCTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTG TCAAAATTGT TTACCATAGA 2520 AAGATGACAA AAGAAAATTT TCCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580 AACTGCATAA CCTTTACACT TCCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640 AAAGAAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TCCTATACCT TACTGACACA 2700

75 TTGCTGATAT GCAAGTAAGA AAT







QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EESRSGETNS 300 CVEEIIREMT WLPPLSAIQA PGKVEPTKFF FPNKDSQLVS SGHNNFKKGD AEPESPDNGT 360 SNTSMLEDDL KLSSDEEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSSG 420 TSSSSSDSES SSGSDSETES SSSESEGSKP PHFSSPEAEP ASSNKWQLDK WLNKVNPHKP 480 5 PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540 GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600 NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660 KSKEFIETES SSSSSSSDSD LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGPR 720 APVGSINART TSDIAKELEE OFYTLVPFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780 HLPQEPGVLS APATKDSESA PPSHTSDTPA EKALPKSKRK RKCDNEDDYR EIKKSQGEKD 840 SSSRLATSTS NTLSANHCNM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900 10 RPNGNSLFTS ASSSKKPKAD SOLOPHGGDL TKAAHNNSEN IPLHKSRPOT KPWSPGSNGH 960 RDCKROKLVF DDMPRSADYF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FIECGNAMEQ 1020 GPMESKSPYY LMYSETVELI RYAMRLKTHS GPNATPEDKQ LAALCYRCLA LLYWRMFRLK 1080 15 RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTPSP ISPNPFPGSS VGSQGSLSNA 1140 SALSPSTIVS IPQRIHQMAA NHVSITNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200 TLHSSMEHLV QYSQQGLHWL RNSAHLS

Seq ID NO: 47 DNA sequence
Nucleic Acid Accession #: NM\_033151
Coding sequence: 351-4499(underlined sequences correspond to start and stop codons)


51 21 25 ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC ACTAAGTGAT TTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGGC 180 TAAGGAGAG AAAGAGCAGG CACCCAAACC TCTGCATGGC CCCAATATGC TCCCTGCAGG 240 30 GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300 CTTTTCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA ATGACTAGGA 360 AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC ATCGACATAG 420 GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT GGCCCCTGGA 480 GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 540 35 ATGATGCTGC CTTGAGAACC ATGATTCCCT TCCGTCCCAA GCCGAGGTTT CCTGCCCCCC 600 AGCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC ACCCCGCTCA 660 TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720 ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 780 GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840 40 TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900 TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960 GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020 GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTG 1080 AGAAGCTCAT CCAACTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140
TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200
CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA TACACTGCAT 1260
TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320 45 CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT GTGACCAGTG 1380 AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA TTTGCAAAAA 1440 50 TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500
GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCA 1560
TCCACACATC CTTAAAGCTG AAACTCACAG CGTCAATGGC CTTCAGCATG CTGGCCTCCT 1620
TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680
CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCCA GGAGAGCCCT GTTTTCTATG 1740 55 TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTGA GGAGGCCACC TTGTCATGGC 1800 AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGGAAC GGGCATGCTT 1860 CTGAGGGGAT GACCAGGCCT AGAGATGCCC TCGGGCCAGA GGAAGAAGGG AACAGCCTGG 1920 GCCCAGAGTT GCACAAGATC AACCTGGTGG TGTCCAAGGG GATGATGTTA GGGGTCTGCG 1980 GCACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAGCCAT CCTGGAGGAG ATGCACTTGC 2040
TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCCAGCAG GCCTGGATCG 2100
TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGCGC ATATGACAAG GCCCGATACC 2160 60 TCCAGGTGCT CCACTGCTGC TCCCTGAATC GGGACCTGGA ACTTCTGCCC TTTGGAGACA 2220 TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280
TGGCCGCGC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCCC CTGTCTGCTG 2340
TGGACGCCCA CGTGGGGAAG CACATTTTTG AGGAGTGCAT TAAGAAGACA CTCAGGGGGA 2400
AGACGGTCGT CCTGGTGACC CACCAGCTGC AGTACTTAGA ATTTTTGTGGC CAGATCATTT 2460
TGTTGGAAAA TGGGAAAAATC TGTGAAAATG GAACTCACAG TGAGTTAATG CAGAAAAAAGG 2520 65 GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATGTTGCAGG 2580 GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTICGGAC AIGTIGCAGG 2580
ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGTCA GGCTCCTGGCC ACCTCCCTGG 2640
AAGAGGTCTCT CAACGGAAAT GCTGTGCCGG AGCATCAGCT CACACAGGAG GAGGAGATGG 2700
AAGAAGGCTC CTTGAGTTGG AGGGTCTACC ACCACTACAT CCAGGCAGCT GGAGGTTACA 2760
TGGTCTCTTG CATAATTTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG GCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880
ATGGAACCAT GGCAGACCTG GGCAACATTG CAGACAATCC TCAACTGTCC TCTTACCAGC 2940 70 75 TGGTGTACGG GCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAGGGATTT 3000 TCACCAAAGT CACGAGGAAG GCATCCACGG CCCTGCACAA CAAGCTCTTC AACAAGGTTT 3060


TCCGCTGCCC CATGAGTTTC TTTGACACCA TCCCAATAGG CCGGCTTTTG AACTGCTTCG 3120

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180 TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240 TAATGGGAGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3300 TCGGTGTGTT CAAGAGACTG GAGAACTATA GCCGGTCTCC TTTATTCTCC CACATCCTCA 3360 5 ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420 AGTTTAAGAG GCTGACTGAT GCGCAGAATA ACTACCTGCT GTTGTTTCTA TCTTCCACAC 3480 GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540 TCGTGGCTTT TGGCATTTCC TCCACCCCT ACTCCTTTAA AGTCATGGCT GTCAACATCG 3600 TGCTGCAGCT GGCGTCCAGC TTCCAGGCCA CTGCCCGGAT TGGCTTGGAG ACAGAGGCAC 3660 AGTTCACGGC TGTAGAGAGG ATACTGCAGT ACATGAAGAT GTGTGTCTCG GAAGCTCCTT 3720 10 TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATATTTC 3780 AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCACGGC ATCAACCTGA 3840 CCATCCGCGG CCACGAAGTG GTGGGCATCG TGGGAAGGAC GGGCTCTGGG AAGTCCTCCT 3900 TGGGCATGGC TCTCTTCCGC CTGGTGGAGC CCATGGCAGG CCGGATTCTC ATTGACGGCG 3960 TGGACATTTG CAGCATCGGC CTGGAGGACT TGCGGTCCAA GCTCTCAGTG ATCCCTCAAG 4020 ATCCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTTGAC CGTCACACTG 4080 15 ACCAGCAGAT CTGGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAGTTCC 4140 CCAAAAAGCT GCATACAGAT GTGGTGGAAA ACGGTGGAAA CTTCTCTGTG GGGGAGAGGC 4200 AGCTGCTCTG CATTGCCAGG GCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAG 4260 20 CCACAGCCTC CATTGACATG GAGACAGACA CCCTGATCCA GCGCACAATC CGTGAAGCCT 4320 TCCAGGGCTG CACCGTGCTC GTCATTGCCC ACCGTGTCAC CACTGTGCTG AACTGTGACC 4380 ACATCCTGGT TATGGGCAAT GGGAAGGTGG TAGAATTTGA TCGGCCGGAG GTACTGCGGA 4440 AGAAGCCTGG GTCATTGTTC GCAGCCCTCA TGGCCACAGC CACTTCTTCA CTGAGA<u>TAA</u>G 4500 GAGATGTGGA GACTTCATGG AGGCTGGCAG CTGAGCTCAG AGGTTCACAC AGGTGCAGCT 4560 25 TCGAGGCCCA CAGTCTGCGA CCTTCTTGTT TGGAGATGAG AACTTCTCCT GGAAGCAGGG 4620 GTAAATGTAG GGGGGGTGGG GATTGCTGGA TGGAAACCCT GGAATAGGCT ACTTGATGGC 4680 TCTCAAGACC TTAGAACCCC AGAACCATCT AAGACATGGG ATTCAGTGAT CATGTGGTTC 4740 TCCTTTTAAC TTACATGCTG AATAATTTTA TAATAAGGTA AAAGCTTATA GTTTTCTGAT 4800 CTGTGTTAGA AGTGTTGCAA ATGCTGTACT GACTTTGTAA AATATAAAAC TAAGGAAAAC 4860 30 Seq ID NO: 48 <u>Protein sequence:</u> Protein Accession #: NP\_149163.2 35 MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPEAPGRAAVPPWGKYDAALRTMIPFRYPRFPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPLSVHDASDKNVQRLHRLWEEE VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEEQLGNVVHGVGLCFALF LSECVKSLSFSSSWIINORTAIRFRAAVSSFAFEKLIOFKSVIHITSGEAISFFTGDVNYLFEGVCYGPL VLITCASLVICSISSYFIIGYTAFIAILCYLLVFPLAVFMTRMAVKAQHHTSEVSDQRIRVTSEVLTCIK 40 LIKMYTWEKPFAKIIEDLRRKERKLLEKCGLVQSLTSITLFIIPTVATAVWVLIHTSLKLKLTASMAFSM LASINLIRLSVFFVPIAVKGLTNSKSAVMRFKKFFLQESPVFYVQTLQDPSKALVFEEATLSWQQTCPGI VNGALELERNGHASEGMTRPRDALGPEEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE MHLLEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLELLPFGDMTEIGER GLNLSGGQKQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHIFEECIKKTLRGKTVVLVTHQLQYLEFCG 45 OIILLENGKICENGTHSELMOKKGKYAQLIOKMHKEATSDMLQDTAKIAEKPKVESQALATSLEESLNGN AVPEHOLTOEEEMEEGSLSWRVYHHYIQAAGGYMVSCIIFFFVVLIVFLTIFSFWWLSYWLEQGSGTNSS RESNGTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF RESIGNMADDISHADINGLEF TQLY TQLINALLELIC VOVCSSQIFT TO TREAT TREATMENT AND THE STRUCK TO STRUCK THE 50 SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL VIAHRVTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR 55 Seq ID NO: 49 DNA sequence Nucleic Acid Accession #: NM 033419 18-980 (underlined sequences correspond to start and stop codons) Coding sequence: 60 41 11 31 CGAGCCAGGG AGAAAGG<u>ATG</u> GCCGGCCTGG CGGCGCGGTT GGTCCTGCTA GCTGGGGCAG 60 CGGCGCTGGC GAGCGCTCC CAGGGCGACC GTGAGCCGGT GTACCGCGAC TGCGTACTGC 120
AGTGCGAAGA GCAGAACTGC TCTGGGGGCG CTCTGAATCA CTTCCGCTCC CGCCAGCCAA 180
TCTACATGAG TCTAGCAGGC TGGACCTGTC GGGACGACTG TAAGTATGAG TGTATGTGGG 240
TCACCGTTGG GCTCTACCTC CAGGAAGGTC ACAAAGTGCC TCAGTTCCAT GGCAAGTGGC 300 65 CCTTCTCCCG GTTCCTGTTC TTTCAAGAGC CGGCATCGGC CGTGGCCTCG TTTCTCAATG 360 GCCTGGCCAG CCTGGTGATG CTCTGCCGCT ACCGCACCTT CGTGCCAGCC TCCTCCCCCA TGTACCACAC CTGTGTGGCC TTCGCCTGGG TGTCCCTCAA TGCATGGTTC TGGTCCACAG 480
TTTTCCACAC CAGGGACACT GACCTCACAG AGAAAATGGA CTACTTCTGT GCCTCCACTG 540
TCATCCTACA CTCAATCTAC CTGTGCTGCG TCAGGACCGT GGGGCTGCAG CACCCAGCTG 600
TGGTCAGTGC CTTCCGGGCT CTCCTGCTGC TCATGCTGAC CGTGCACGTC TCCTACCTGA 660 70 GCCTCATCCG CTTCGACTAT GGCTACAACC TGGTGGCCAA CGTGGCTATT GGCCTGGTCA 720 ACGTGGTGTG GTGGCTGGCC TGGTGCCTGT GGAACCAGCG GCGGCTGCCT CACGTGCGCA


AGTGCGTGGT GGTGGTCTTG CTGCTGCAGG GGCTGTCCCT GCTCGAGCTG CTTGACTTCC 840 CACCGCTCTT CTGGGTCCTG GATGCCCATG CCATCTGGCA CATCAGCACC ATCCCTGTCC 900 ACGTCCTCTT TTTCAGCTTT CTGGAAGATG ACAGCCTGTA CCTGCTGAAG GAATCAGAGG 960

75






Seq ID NO: 53 DNA sequence




Coding sequence: 1-1362(underlined sequences correspond to start and stop codons) 51

31



TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800 AAAATCTTTC TGAAAGAAGT AAATGATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA 1860 TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920 GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980 5 CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT 2040 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC 2160 AGACTGATTA AAGAAGGTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220 AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280 10 GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340 ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400 GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460
ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520
GAAGGTCGTT CTCAG<u>TGA</u>AA ATCCAAAAAC CAGAAAAAAA TGTTTATACA ACCCTAAGTC 2580
AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880 CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAATGCA CGCAAGCCAT 2940
TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000
TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060
CAACTAATTT TGTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA 3120 20 TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 25 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA Seq ID NO: 62 <u>Protein sequence:</u>
Protein Accession #: NP\_006466 30 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60 KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGLGIVGA TTTQRYSDAS 120 KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVNVE LLNALHSHMI NKRMLTKDLK 180 NGMIIPSMYN NLGLFINHYP NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF 240 IEAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300 35 MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360 IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420 VQRLLKLILQ NHILKVKVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480 40 RNGAIHIFRE IIKPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA 540 FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND 600 TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST 660 FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIIKTEGPTL TKVKIEGEPE FRLIKEGETI 720 TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL 780 45 QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ Seq ID NO: 63 DNA sequence Nucleic Acid Accession #: NM 020974 Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 11 31 GGCGTCCGCG CACACCTCCC CGCCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 CCGCAACCGC TGAGCCATCC <u>ATG</u>GGGGTCG CGGGCCGCAA CCGTCCCGGG GCGCCCTGGG 120 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGGCGGGG GCCGTCCCGC 180 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 55 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360 TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420 60 TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480 AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 GCAAGGAGGG GTTTTTCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 65 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780 GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGGAGG AGCTGCCTTG 840 AGCGAGAGGA CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900 ATAAACGGGT GAAACGCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960 ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020 TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080 70 GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140 AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200 GTGACCACAG CTGCATCAAC CACCCTGGCA CATTGCTTG TGCTTGCAAC CGAGGGTACA 1260
CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGCT 1320
GTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380 75 AGCTCCACTG GAATAAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500






AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840 CTTCTAGCAG TAAGAAGGAC TTGAAAAGCG CAGTTCTGAG TGAGAAGGCT GGCTTCAATT ATGAAAGCCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA GAAATATGTT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020 5 CGCAAAGAGC AGAGGCAGAT GACCTCAAG ATATGGCCTG CACCCCCTCA GGGGACTCAC 1080
TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140
AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200
AAGTGCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260
ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320 10 GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440 ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500 CTGGTGTGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 15 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 ACACTCCTGT TGGGTACTCA GTGCCCATAA AGCCCCTCGA TTCCTCTAGA CAAAATGGTA 1920 20 CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980
CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACGGAGC AGTGCAGTCA GGCGGCCTTA 2040
ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100
AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAAGA 2160 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 25 GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTTCTCC 2280 GTCATTATCA ACAGCTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGTC 2340 CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400
GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460
GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520
TACTCCTCTT TCACTATGAA AGTGTGCATG AGTCCCAAGC ATCGGATGTC AAACAAGAAG 2580 30 CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTGTCAA GGAAAGCAAA GAACACTCAT 2640 GTACCAAATG TGATTTTATT ACCCAAGTGG AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 CACACAGCTG CTACAAATGC CGTCAGTGCA GTTTTACAGC TGCCGATACT CAGTCACTAC 2760 TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820 35 AGGACGGTCA TGCCATATCC ACCATCAAAG AGGAGCCCAA AATTGACTTC AGGGTCTACA 2880 ATCTGCTAAC TCCAGACTCT AAAATGGGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940 AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGAGT TCCAGTGATG 3000 ACCTTCGCAA TGTGACTTGG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060 AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120 40 GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGACC TATTTATGGC TTGGCTGTGG 3180 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240
AGCAGTATCC TGCATCGGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300
GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360
GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420 45 CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480 GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAGA 3540 GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660
GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720
TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780
ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAG AGCAGTCCTA 3840 50 TAGAAAAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900 AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960 CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020 55 TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080 ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140
TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200
CACCAAATGT AAAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAA GTTGATAGAA 4260 GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320 60 TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380 GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440 GGAACAATGC ACAAGTGGAA AAAAATGGAA AACC<u>TAA</u>AGA GTAAAACCTT AGCACTTAGC 4500 GAACAATIC ACAAGIGGAA AAAAATIGGAA AACAATIAAAA GIAAAACEI AGCAATIAAA AAAAATAAGGT TTTCTTGATG GGAATTCAAT AGCITGATAT GTCTTATGAA 4560 GACTATTAA AAAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCCTTCTTTT 4620 GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680 65 AGAAAGATG GAAGATGGTA AACAATCACT TTTTAAAACC TGTTAAGTCA AAACCATCTT 4740 70 AGAAAAATGG CGCCCTCTCA ATTTAGTCTT CTCTCATTGG CCATGTTTCA GATTTTGACC 5040 TAGAAATGCG AGCTGTGGTT AGGCTTGGTT AGAGTGCAGC AAGCAACATG ACAGATGGTG 5100 GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160 TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGTTTAGA TTCATTTGT 5220
CCACACATGT ACCCATTTTA AAAAACAATG TCCTCGATGC TTCTGTAGTG ATTTCATTTTGT 5220
AGCCAGGTAT TTCTTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340
TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400 75

CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTGGTT AAATATAATT TCCAAACTTT 5520 GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580 CAATCCCTTC ATTAAATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCTTAGAA 5640 5 GTATGTCCTC ATAGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700 GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760 TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820 TTTAATAATT TGCATTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAGATGTAG 5880 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 10 AGAACAAATA GGAAAAAAA AACTTATTTT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000 ATAATGGTGC CTGACATATT GAATAATTAT TTTCTACAGT GTACGTATGC AACAAAGATA 6060 TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATTT GCAAAAGATA 6000
CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGTAGATA ATCCTTTTGT GTGTGTGTGT 6180
GTGCATTAAA GTTGTAAACG GTAACATGAA ACAAATGAAA GTTCTTGCTA TAATGGTATG 6240
GAAAACAAGA AGGAAATGAA AATATTTTTA TGCCTACTTA GGAAAAAAAG GGTAGCACTT 6300 15 ATTCATTCCA AGTACTTTTT TTTTTTTAAT TTTTAAGCTC TTAACTCACA TTGTTATGCT 6360 TAAGATGATA AACATATATC CTCTTTTTAT TGCTTTGTCT ATGTTTCATA TGAAACATTT 6420 CAGAAATTAT TTTGATAAGT GTTGCTGGAA TCTGCAACGC TGATTTTTTT TTGCATTCTG 6480 TAGTCGCATT TGCACTCCAT TTTTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 TTGGGTTTTG TTTCTTTTTC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600 AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660 20 TTGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAGAG 6720 AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTGCTTCA GTTTCATTGT TAACGGGCCT 6780 TATTCTGATC TCACCTGTCG CGTAGCTCTA ATATTCACAT AAACTGAAAT AAAGAAGTGG 6840 25 AATGAGGAGC TTTGACATTC AAATTATGTG ATGTAATTTA TCTTCCTTAG GAATTTTGAT 6900 GGATGCATCT CAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAT CTAAAAAAAGA 6960 GAGGAGATTC CCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAGAATA ACAGAATGCA 7020 TCGTGGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCAGA 7080 AGTTTGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAACT ACTCATTAAG 7140 30 CAATTTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7200 ATTTTCATTC AATTTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 AATACATATC ACTATTCTTG GAATATTTAT GGTCAGTCTA CTTTTTAGTA AAATATTTTT 7320 GATATTTTTGC TITCATTATT ATACATATTT TGGTGGAGAA GAGGTTGGGC TTTTTTGAAA 7440
GAGACAAAAA TTTATTATAAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500
CATCTCTCAA GATATATTAT AAAATTTATT TTTTTAATTT AAGATTTCTG AATTATTTA 7560
TCTTAAATTG TGATTTTAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 35 CATGATGATT TAGGAATTTT CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TTGTGTGCCA TTTAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800
TTTTCTCACT CTTTCTCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAAA 7860
AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920
CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAAGA 7880 40 GTATGCCCAA TTCTCTCTAC ATGACATATT GAGATTTTTT TTAATCAACT TTTAAGATAG 8040 45 TGATGTTCTG TTCTAAACTG TTCTGTTTTA GTGAAGGTAG ATTTTTATAA AACAAGCATG 8100 GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTATCTTTA ACAGCTCTTT 8160 GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220 ATCCAATGCA AATACAGCTC CAAAAATATT AAATGTATAT ATATTTTAAA ATGCCTGAGG 8280 AAATACATTT TTCTTAATAA ACTGAAGAGT CTCAGTATGG CTATTAAAAT AATTATTAGC 8340 50 CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400 GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460 TGGAAATGTG GAGTAAAGAA GCTGGTGGTC TGCTTCTGTG CTGTATGCCA GCCTTTTGCC 8520 TTAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTGGT TTGAGAGCCA TGGCAAAAAA 8580 AAAAAAGAA AAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640
TGTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAAATGCAA CCTGAGTATC AAACTAAATA 8700
TTCTAATCAA AGGTAGGTAC TGTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760
AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTCC CAAAGAAAGA 8820 55 CGGCCAAGGG CAGAGGCATG GATTCTTTGC AGAGCACTTC CTTTTGGTTT TTCAGTACTG 8880 TTTCATAGAC AGTGGGCTCA CATGTTCCTG ATAGTGCTGC AGTTGCTTAG AAAGCATCCC 8940 AGTTAATTGC AGTAATTAGA ACTTCTGGAA TATGCTAGGG CAGAAGTATG TCAAGTATGT 9000
CACATGAAGA AAATGTGAAA TTCAAGAGTA ATCCACACGT GAGAAACTAG CCAAGTATGT 9060
TTCATGTGTT CTCTTGAAAG GAAAGGGAGA GCTGTAAGCT TCACTCTGTC CTACACCGGA 9120
GAAAAGCAGG AATAACTTTA CCGTGGAAAT AATGTTTAGC TTTTATCAGA GAAAATTGTC 9180
CTTCTAGAGC ATAGAGTCCC AAAACTCAAT TCTGGTTTTC CCCTGTTTTT TTTTTTTTT 9240 60 65 TTTTTCCCAA CATATGAACT GCAGCATATC ACTTTTTCTT TTTGTGCCTC AGGTTCCTCA 9300 CCTGTAAAAT TGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360 GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGT 9420
ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480
GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATA GTGTTGACTA 9540
TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAGT TTCTTAATGG CTACCAATAA 9600 70 GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9660 GAAAACTTTG GGGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720 TACAGCAATA TTCACCAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGCTAAGA 9780 AAAAGAATTC AATTTGTAGT CCTGATTTGA ATACTAGAAT GTTGGCTATA ATAGTTCTGT 9840
TCTTACAACA CATGAAATTT TTTCGTTTTA TTTTATTTTG TTTTCATAGT GCATGTTCAT 9900
TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 75 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460



	CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200
	GGTGTTCCTC TGCCGGATAC TTTCTCTTAT GGTGGCCACG AAAATTTTGC TAAAATGATT 1260
	GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAGA ATACGCGGGG TCACAGAGGT 1320
	AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCCA TCTTATTCGC 1380
5	CATGAAGCGC CATACCTGTT CCAGAAGTAT GTTAAAGAGT CTCATGGACG GGATGTACGT 1440
9	
	GTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTTCAAC AGATGGGAGA 1500
	ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1560
	AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
10	CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680
10	GCCTTTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740
	CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800
	AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1860
	GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920
	CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980
15	
13	GAC <u>TGA</u> CTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTTCT 2040
	ATTTTTAAAA CCAACTTGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAT 2100
	TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160
	TTCATTTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATAGAA AAATGTCAGG 2220
	CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGTAT GCTCATAGGC CATGAGGAAC 2280
20	AAATACTTTT TTTTTTCAT GGTCCCTTGC TTTTGTTTTT GTACAAAAA AAATGGTTTT 2340
20	
	GCTACAAATA TCCAAGTAGC ATAACTTCAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400
	AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460
	TCCTTATTAA CTAGCAGCTT TAGTTTGTAG TTTATGAAAT CTTGAGGGGC TCTTTTACTG 2520
0.5	GGATTTCTTA TTTTTTGTT TTTTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
25	CCCAATAAAG GCTTCTTAAT GACAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640
	AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGTAGATAAA ATTACACTAG 2700
	TTTAAAATAT GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTG AAAGATGTGC 2760
	TCTGTTAATG TTGCTTTTTT TTTTTTTTT TAATACATGC TAGTCTAACA TTTCCTGCTC 2820
	TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880
30	
50	ACACTGACTT GAAACATGTA CATTTAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940
	TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000
	TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060
	TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120
	TTGTTTCCAT CAACTAATCA AAAAGGATAA TTTAGAAAAT GGAGCATGAT GGGAAACAGA 3180
35	GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240
	TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300
	GTTGTTTGTT TTTTTCCTTT TGTTTCTAGC CTGTTCAGTG TACAGTTTAT TCAAGGCTAC 3360
	ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
	TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480
40	
40	CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540
	AAAAGCCCCC AAACTGCATA TAATATGAGC CTTTAAAACA TGGGTAAAAC TAATCCCATT 3600
	GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCAACG TAATTTTTTA 3660
	AACAGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TTTACCCAAG CCCTTTCTTG 3720
4.5	CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATTTCTTGG ACACTACTAG 3780
45	AGAGACTTCG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTGATCA 3840
	TGCTTACTTG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900
	CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960
	CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020
	TAATTTATCT TAGGATATTC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080
50	
50	GGGGACTCAC ATACATATAT TAATACCTCT GACTCATTAA CAGAAAGAAA TACTTGGTAC 4140
	TTCTTTCGCT GAATGACCAT ACTGTGGAGG ATGCATACTA TTTGGTATAG AGAAATAAAT 4200
	GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACCATCTGG 4260
	TTGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320
55	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGGAGGAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740 GTTAAAATTT TAACTATAAT TGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT TGTGTATATT ATAAAACTTGAAATT TTTGTATATT 4740 GTTAAAATTG TAAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
60	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAAATCTGAA TTGTAAAATT TTTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT TGTGTATATT ATAAAACTTGAAATT TTTGTATATT 4740 GTTAAAATTG TAAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATATGCAT TCACATGATA TATAGGAAAT AGTGGAAATT AGTTCATTAG CTTTATTCAC 44500 GTTATCTTAG ATTTTAAAAA CATGGATAT CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAAATT TTTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATAT TTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
60 65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATAT ATACAAATAT GTGTAAATGAT AAAACTGAA TTGTAAAATT TTTGTATAATT 4740 GTTAAAATTG TAAATTGTAAAT TGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAATT TTTGTATATT 4740 GTTAAAATTG TAAATTCTAAA TTGTATTTCA AAAATCATAT TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATAT ATACAAATAT GTGTAAATGAT AAAACTGAA TTGTAAAATT TTTGTATAATT 4740 GTTAAAATTG TAAATTGTAAAT TGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAAATGAT AAAAATCTGAA TTGTAAATT TTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATATTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATAT TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TCTTGAATT CCTCCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATAGAGA 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAAATT TTTGTATATT 4740 GTTAAAATTG TAAATTGTATATTCA AAAATGATAT TTCTTGATAT TGTTTTATA 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CTTCAAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATA TATCAAATAT GTGTAAATGAT AAAACTGAA TTGTAAAATT TTTGTATAATT 4740 GTTAAAATTG TAAATCTTCAAA TTGTATTTCA AAAATTGATTATTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAATT TTTGTATATT 4740 GTTAAAATTG TAAATCTGAA TTGTATATTATT TTCTTAATT 4740 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAATT TTTGTATATT 4740 GTTAAAATTG TAAATCTGAA TTGTATATTATT TTCTTAATT 4740 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CTTCAAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGATA TATCAAATAT GTGTAAATGAT AAAACTGAA TTGTAAAATT TTTGTATAATT 4740 GTTAAAATTG TAAATCTTCAAA TTGTATTTCA AAAATTGATTATTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CATACTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CATTATTCAC 4440 TATATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTCCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAAATT TTTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATAT TTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATCTTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATGGCT ATTATGAGAG 4680 AGAATGATA TATCAAAATAT GTGTAAATGAT AAAATCTGAA TTGTAAAATT TTTGTATAAT 4740 GTTAAAATTG TAATCAAATAT TGTGTATATTCAA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CATACTAT 4380 ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CATTATTCAC 4440 TATATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTCCAAGAT TGAGGTAGAG 4560 AATAAGAGCA AATCATCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAAATT TTTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATAT TTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAAACATA CAAGTATGAA CTATTCTATT

ELAGHGVPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHEAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 5 LSEQGKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NVGFIAFDKA CNLDVAGIIA 300 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 ELLTKLPGGL FNMNQLLANE IKLLVD Seq ID NO: 73 DNA sequence 10 Nucleic Acid Accession #: XM\_040080.2 Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons) 21 31 15 CTGAGTGGGG GCGGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120 GTGAGGGAGT GACAGCAGCG CATTCGCGGG ACGAGAGCG<u>A TG</u>AGTGAGAA CGCCGCACCA 180 GGTCTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCGCAGC CAAAGCCTGG 240 GGCTCCCTGC AGGGCCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGGCTCC 300
TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360
GGTCATGGGC TCTCGTCCCA TTACAGCCCA GGTGTCCCAT ATTACCTCCA GACTTTTGTG 420 20 AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480 AGCTTCGGTG GCGTCGTGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540 CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600 25 ACCTACAAGC GGAGAGCCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660 CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA AGAGCAATAG CCACTTGAGT 720
GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGAACCACGA AGGTGGCCAC AGGTCTGGTT 780
CTGAACAGAG ACCAGAGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840
CTGTGTGCGC ATTCCATCAG GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900 30 GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960 ACGATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATCACTGT 1020 GTCCACATGA GCGAACCCCA GCACGTGGCC AGTATCATCA GCTCCTTCTT ACAGTGCACA 1080 CACATGCTCC CAGCCCAGCT GTAGCTCTGG GCCTGGAACT ATGAAGACCT AGTGCTCCCA 1140 GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200 AGGCCTCACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260 AACTTCAACA TCTGTGACCT CAAGGGGGAG ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320 35 CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380 CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A Seq ID NO: 74 <u>Protein sequence:</u> Protein Accession #: XP\_040080.1 40 41 31 11 45 MSENAAPGLI SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPLLPQDFY 60 YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSFG GVVGGMFFCT 120 FPEMVDKLIL LDTPLFLLES DEMENLLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRLL 180 KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISRELCA HSIRKLQAHV 240 LLIKAVHGYF DSRQNYSEKE SLSFMIDTMK STLKEQFQFV EVPGNHCVHM SEPQHVASII 300 50 SSFLQCTHML PAQL Seq ID NO: 75 DNA sequence Nucleic Acid Accession #: NM 005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons) 55 21 31 GGTTCCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 60 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 CACCATCTTT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240
GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300
TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360
CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAGG AAGCATCTCA 420 65 GACACCAACC ACTATGCTGT CAGCAGTTGC CCGGGGCTAC CAGGGCTGGT TTCATCCCTG 480 TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGCG TCCTGGCTAA 540 CCGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACGTCT 600 GGCCCGGGAC GGGCCCACG TGGTCATCAG CAGCCGGAAG CAGCAGAACG TGGACCGGGC 660 CATGGCCAAG CTGCAGGGGG AGGGGCTGAG TGTGGCGGGC ATTGTGTGCC ACGTGGGGAA 720 GGCTGAGGAC CGGGAGCAGC TGGTGGCCAA GGCCCTGGAG CACTGTGGGG GCGTCGACTT 780 70 CCTGGTGTGC AGCGCAGGGG TCAACCCTCT GGTAGGGAGC ACTCTGGGGA CCAGTGAGCA 840 GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900 GCTGCCCTAC ATGGAGAACA GGAGGGGTGC TGTCATCCTG GTCTCTTCCA TTGCAGCTTA 960 TAATCCAGTA GTGGCGCTGG GTGTCTACAA TGTCAGCAAG ACAGCGCTGC TGGGTCTCAC 1020 75 TAGAACACTG GCATTGGAGC TGGCCCCCAA GGACATCCGG GTAAACTGCG TGGTTCCAGG 1080 AATTATAAAA ACTGACTTCA GCAAAGTGTT TCATGGGAAT GAGTCTCTCT GGAAGAACTT 1140 CAAGGAACAT CATCAGCTGC AGAGGATTGG GGAGTCAGAG GACTGTGCAG GAATCGTGTC 1200

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60 RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120


CTCCACTCGG CTCTGAGAGG AGTGGGGGGG GCTGCGTAGC TGTGGTCCCA GCCCAGGAGC 1320 CTGAGGGGGT GTCTAGGTGA TCATTTGGAT CTGGAGCAGA GTCTGCCATT CTGCCAGACT 1380 AGCAATTTGG GGGCTTACTC ATGCTAGGCT TGAGGAAGAA GAAAAACGCT TCGGCATTCT 1440 5 Seq ID NO: 76 Protein sequence: Protein Accession #: NP\_005785 10 31 MLSAVARGYQ GWFHPCARLS VRMSSTGIDR KGVLANRVAV VTGSTSGIGF AIARRLARDG 60 AHVVISSRKQ QNVDRAMAKL QGEGLSVAGI VCHVGKAEDR EQLVAKALEH CGGVDFLVCS 120 AGVNPLVGST LGTSEQIWDK ILSVNVKSPA LLLSQLLPYM ENRRGAVILV SSIAAYNPVV 180 15 ALGVYNVSKT ALLGLTRTLA LELAPKDIRV NCVVPGIIKT DFSKVFHGNE SLWKNFKEHH 240 QLQRIGESED CAGIVSFLCS PDASYVNGEN IAVAGYSTRL Seq ID NO: 77 DNA sequence 20 Nucleic Acid Accession #: NM\_002425 Coding sequence: 26-1453 (underlined sequences correspond to start and stop codons) 31 21 25 AAAGAAGGTA AGGGCAGTGA GAATGATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180 AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAGGAATG CAGAAGTTCC TTGGGTTGGA 240 GGTGACAGGG AAGCTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300 TCCTGACGTT GGTCACTTCA GCTCCTTTCC TGGCATGCCG AAGTGGAGGA AAACCCACCT 360 TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420 30 TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGTATGA 480 AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAGAA CATGGAGACT TTTACTCTTT TGATGGCCCA GGACACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TTTATGGAGA 600 35 TATTCACTTT GATGATGATG AAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT 660 CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGGCTCTTT CACTCAGCCA ACACTGAAGC 720
TTTGATGTAC CACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780
TGATGTGAAT GGCATTCAGT CTCTCTACGG ACCTCCCCCT GCCTCTACTG AGGAACCCCT 840
GGTGCCCACA AAATCTGTTC CTTCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900 40 GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 960 TTGGCGAAGA TCCCACTGGA ACCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 CTCTCTTCCA TCATATTTGG ATGCTGCATA TGAAGTTAAC AGCAGGGACA CCGTTTTTAT 1080 TTTTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140
AGGCATCCAT ACCCTGGGTT TTCCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200
CAAGGAAAAG AAGAAAACAT ACTTCTTTGC AGCGGACAAA TACTGGAGAT TTGATGAAAA 1260
TAGCCAGTCC ATGGAGCAAG GCTTCCCTAG ACTAATAGCT GATGACTTTC CAGGAGTTGA 1320 45 GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTTTC TACTTCTTCA GTGGATCATC 1380 ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440 GTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500 50 ATTATTCATC TAATGTATTA TGAGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTGACT 1560 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTTC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740 CTT 55 Seq ID NO: 78 Protein sequence: Protein Accession #: NP\_002416 31 60 MHLAFLVLLC LPVCSAYPLS GAAKEEDSNK DLAQQYLEKY YNLEKDVKQF RRKDSNLIVK 60 KIQGMQKFLG LEVTGKLDTD TLEVMRKPRC GVPDVGHFSS FPGMPKWRKT HLTYRIVNYT 120 PDLPRDAVDS AIEKALKVWE EVTPLTFSRL YEGEADIMIS FAVKEHGDFY SFDGPGHSLA 180 HAYPPGPGLY GDIHFDDDEK WTEDASGTNL FLVAAHELGH SLGLFHSANT EALMYPLYNS 240 FTELAQFRLS QDDVNGIQSL YGPPPASTEE PLVPTKSVPS GSEMPAKCDP ALSFDAISTL 300 65 RGEYLFFKDR YFWRRSHWNP EPEFHLISAF WPSLPSYLDA AYEVNSRDTV FIFKGNEFWA 360 IRGNEVQAGY PRGIHTLGFP PTIRKIDAAV SDKEKKKTYF FAADKYWRFD ENSQSMEQGF 420 PRLIADDFPG VEPKVDAVLQ AFGFFYFFSG SSQFEFDPNA RMVTHILKSN SWLHC 70 Seq ID NO: 79 DNA sequence NM\_000493.1 Nucleic Acid Accession #: Coding sequence: 1-2043 (underlined sequences correspond to start and stop codons) 75 ATGCTGCCAC AAATACCCTT TTTGCTGCTA GTATCCTTGA ACTTGGTTCA TGGAGTGTTT 60 TACGCTGAAC GATACCAAAC GCCCACAGGC ATAAAAGGCC CACTACCCAA CACCAAGACA 120


CTTCCTGTGC TCTCCAGATG CCAGCTACGT CAACGGGGAG AACATTGCGG TGGCAGGCTA 1260

	CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240 GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300
5	GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAGA 360 GGACCATATG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420 CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACAA 480 CAGGGACCAC CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAGGG TGCACCAGGA 540 GTCCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600
10	GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660 AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAGGTGATAG AGGTTTTCCG 720
	GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780 GAAGGCATTG GAAAGCCAGG AGCTGCTGGA GCCCCAGGCC AGCCAGGGAT TCCAGGAACA 840 AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900
15	CCAGGCTTGC CAGGCCTGAA GGGAGAAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960 GCCAAAGGGG AACAAGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020 GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCT 1080 AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAGGG TGAAAGGGGT 1140 TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200
20	GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260 CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320 CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCTA TTGGGCCACC AGGCATTCCA 1380 GGATTCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGGCATA 1440 GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AAGAGGCCCC 1500
25	TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 ATGCCTGAGG GTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAAA TTTTGTATAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTTCA 1800
30	TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860 GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920 ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAATGC CGAGTCAAAT 1980 GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCTCAG GATTCCTAGT GGCTCCAATG 2040 TGAGTACACC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100
35	CCCCACCCTA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATTTT TATTTTCTGA 2160 AATACAGATT TGAGCTATCA GACCAACAAA CCTTCCCCCT GAAAAGTGAG CAGCAACGTA 2220 AAAACGTATG TGAAGCCTCT CTTGAATTTC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280 TTCTCCAATA TTAAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAA 2340 AAACAAAGCA ACAAAAAAAA AAATTAAAAAA AAAAAACAGA AATAGAGCTC TAAGTTATGT 2400
40	GAAATTTGAT TTGAGAAACT CGGCATTTCC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAAA CTTTGTAGAA CITAAATACT 2520 TGAATATTCA AATTTAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 TGAGGCCTGT ATGGCCCCTT TCATCAATAT CTATTCAAAT ATACAGGTGC ATATATACTT 2640 GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700
45	TTTCATCAAT GAACCTTTTC AAAACTTTTC TATGATTGCA GAGAAGCTTT TTATATACCC 2760 AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTA GTTAACACAA GTGTGATTAA 2820 TTTGATTTCT TTAATTCCTT ATTGAATCTT ATGTGATATG ATTTTCTTGGA TTTACAGAAC 2880 ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940 CAAAATTCGA CTAGAAGTGG AGATATATTA TTTATTTATG CACTGTACTG TATTTTTATA 3000
50	TTGCTGTTTA AAACTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3060 TCCTTATTTA CGACACAATA AAATAACATC AATAGATTT TAGGCTGAAT TAATTTGAAA 3120 GCAGCAATTT GCTGTTCTCA ACCATTCTTT CAAGGCTTTT CATTCGACAC AATAAAATAA
55	Seq ID NO: 80 Protein sequence: Protein Accession #: NP_000484.1
60	1 11 21 31 41 51
,	TPGPPGPAGP RGHPGPSGPP GKPGYGSPGL QGEPGLPGPP GPSAVGKPGV PGLPGKPGER 120 GPYGPKGDVG PAGLPGPRGP PGPPGIPGPA GISVPGKPGQ QGPTGAPGPR GFPGEKGAPG 180 VPGMNGQKGE MGYGAPGRPG ERGLPGPQGP TGPSGPPGVG KRGENGVPGQ PGIKGDRGFP 240
65 ,	GEMGPIGPPG PQGPPGERGP EGIGKPGAAG APGQPGIPGT KGLPGAPGIA GPPGPPGFGK 300 PGLPGLKGER GPAGLPGGPG AKGEQGPAGL PGKPGLTGPP GNMGPQGPKG IPGSHGLPGP 360 KGETGPAGPA GYPGAKGERG SPGSDGKPGY PGKPGLDGPK GNPGLPGPKG DPGVGGPPGL 420 PGPVGPAGAK GMPGHNGEAG PRGAPGIPGT RGPIGPPGIP GFPGSKGDPG SPGPPGPAGI 480 ATKGLNGPTG PPGPPGPRGP SGEPGLPGPP GPPGPPGQAV MPEGFIKAGQ RPSLSGTPLV 540
70	SANQGVTGMP VSAFTVILSK AYPAIGTPIP FDKILYNRQQ HYDPRTGIFT CQIPGIYYFS 600 YHVHVKGTHV WVGLYKNGTP VMYTYDEYTK GYLDQASGSA IIDLTENDQV WLQLPNAESN 660 GLYSSEYVHS SFSGFLVAPM
	O TO MO OF DATA

Seq ID NO: 81 DNA sequence NM\_000786 Nucleic Acid Accession #: Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)

75





GCTCAAGTCT GAACTCTACC TCCAGACAGA <u>ATG</u>AAGTTCA TCTCGACATC TCTGCTTCTC 120 ATGCTGCTGG TCAGCAGCCT CTCTCCAGTC CAAGGTGTTC TGGAGGTCTA TTACACAAGC 180 TTGAGGTGTA GATGTGTCCA AGAGAGCTCA GTCTTTATCC CTAGACGCTT CATTGATCGA 240 ATTCAAATCT TGCCCCGTGG GAATGGTTGT CCAAGAAAAG AAATCATAGT CTGGAAGAAG 300 5 AACAAGTCAA TTGTGTGTGT GGACCCTCAA GCTGAATGGA TACAAAGAAT GATGGAAGTA 360 TTGAGAAAAA GAAGTTCTTC AACTCTACCA GTTCCAGTGT TTAAGAGAAA GATTCCC<u>TGA</u> 420 TGCTGATATT TCCACTAAGA ACACCTGCAT TCTTCCCTTA TCCCTGCTCT GGATTTTAGT 480 TTTGTGCTTA GTTAAATCTT TTCCAGGGAG AAAGAACTTC CCCATACAAA TAAGGCATGA 540 GGACTATGTG AAAAATAACC TTGCAGGAGC TGATGGGGCA AACTCAAGCT TCTTCACTCA 600 10 CAGCACCCTA TATACACTTG GAGTTTGCAT TCTTATTCAT CAGGGAGGAA AGTTTCTTTG 660 AAAATAGTTA TICAGTTATA AGTAATACAG GATTATTTTG ATTATATACT TGTTGTTTAA 720
TGTTTAAAAT TTCTTAGAAA ACAATGGAAT GAGAATTTAA GCCTCAAATT TGAACATGTG 780
GCTTGAATTA AGAAGAAAAT TATGGCATAT ATTAAAAGCA GGCTTCTATG AAAGACTCAA 840
AAAGCTGCCT GGGAGGCAGA TGGAACTTGA GCCTGCAAG AGGCAAAGGA ATCCATGTAG 900 15 TAGATATCCT CTGCTTAAAA ACTCACTACG GAGGAGAATT AAGTCCTACT TTTAAAGAAT 960 TTCTTTATAA AATTTACTGT CTAAGATTAA TAGCATTCGA AGATCCCCAG ACTTCATAGA 1020 ATACTCAGGG AAAGCATTTA AAGGGTGATG TACACATGTA TCCTTTCACA CATTTGCCTT 1080 GACAAACTTC TTTCACTCAC ATCTTTTTCA CTGACTTTTT TTGTGGGGGC GGGGCCGGGG 1140 GGACTCTGGT ATCTAATTCT TTAATGATTC CTATAAATCT AATGACATTC AATAAAGTTG 1200 20 AGCAAACATT TTACTT Seq ID NO: 88 Protein sequence: NP\_006410.1 Protein Accession #: 25 MKFISTSLLL MLLVSSLSPV QGVLEVYYTS LRCRCVQESS VFIPRRFIDR IQILPRGNGC 60 PRKEIIVWKK NKSIVCVDPQ AEWIQRMMEV LRKRSSSTLP VPVFKRKIP 30 Seq ID NO: 89 DNA sequence Nucleic Acid Accession #: NM\_002652 Coding sequence: 37-477 (underlined sequences correspond to start and stop codons) 21 31 41 35 CTTCTCTGGG ACACATTGCC TTCTGTTTTC TCCAGC<u>ATG</u>C GCTTGCTCCA GCTCCTGTTC 60 AGGGCCAGCC CTGCCACCCT GCTCCTGGTT CTCTGCCTGC AGTTGGGGGC CAACAAAGCT 120 CAGGACAACA CTCGGAAGAT CATAATAAAG AATTTTGACA TTCCCAAGTC AGTACGTCCA 180 AATGACGAAG TCACTGCAGT GCTTGCAGTT CAAACAGAAT TGAAAGAAATG CATGGTGGTT 240

AAAACTTACC TCATTAGCAG CATCCCTCTA CAAAGGTGCAT TTAACTATAA GTATACTGCC 300

TGCCTATGTG ACGACAATCC AAAAACCTTC TACTGGGACT TTTACACCAA CAGAACTGTG 360

CAAATTGCAG CCGTCGTTGA TGTTATTCGG GAATTAGGCA TCTGCCCTGA TGATGCTGCT 420 40 GTAATCCCCA TCAAAAACAA CCGGTTTTAT ACTATTGAAA TCCTAAAGGT AGAATAATGG 480 AAGCCCTGTC TGTTTGCCAC ACCCAGGTGA TTTCCTCTAA AGAAACTTGG CTGGAATTTC 540 45 TGCTGTGGTC TATAAAATAA ACTTCTTAAC ATGCTT Seq ID NO: 90 Protein sequence:
Protein Accession #: NP\_002643.1 50 31 MRLLQLLFRA SPATLLLVLC LQLGANKAQD NTRKIIIKNF DIPKSVRPND EVTAVLAVQT 60 ELKECMVVKT YLISSIPLQG AFNYKYTACL CDDNPKTFYW DFYTNRTVQI AAVVDVIREL 120 GICPDDAAVI PIKNNRFYTI EILKV 55 Seq ID NO: 91 DNA sequence AK000341 Nucleic Acid Accession #: Coding sequence: 85-975 (underlined sequences correspond to start and stop codons) 60 GATAGCGCCG GGCAGAGGGA CCCGGCTACC CTGGACAGCG CATCGCCGCC CGCCCGGGTC 60 GCCGCGCCAC AGCCGCTGCG GATC<u>ATG</u>GAA CATCTAAAGG CCTTTGATGA TGAAATCAAT 120 GCTTTTTTGG ACAATATGTT TGGACCGCGA GATTCTCGAG TCAGAGGGTG GTTCACGTTG 180 65 GACTCTTACC TTCCTACCTT TTTTCTTACT GTCATGTATC TGCTCTCAAT ATGGCTGGGT 240 AACAAGTATA TGAAGAACAG ACCTGCTCTT TCTCTCAGGG GTATCCTCAC CTTGTATAAT 300 CTTGGAATCA CACTTCTCTC CGCGTACATG CTGGCAGAGC TCATTCTCTC CACTTGGGAA 360 GGAGGCTACA ACTTACAGTG TCAAGATCTT ACCAGCGCAG GGGAAGCTGA CATCCGGGTA 420 GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCCTGGA CACAATTTTC 480 70 TTCGTTTTGC GGAAAAAAC GAGTCAGATT ACTTTTCTTC ATGTATATCA TCATGCTTCT 540 ATGTTTAACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTTCTTTGGA 600 CCAACACTGA ACAGTTTTGT CCACATTCTT ATGTACTCCT ACTATGGACT TTCTGTGTTT 660 CCATCTATGC ACAAGTATCT TTGGTGGAAG AAATATCTCA CACAGGCTCA GCTGGTGCAG 720
TTCGTGCTCA CCATCACGCA CACCATGAGC GCCGTCGTGA AACCGTGTGG CTTCCCCTTC 780
GGTTGTCTCA TCTTCCAGTC ATCTTATATG CTAACGTTAG TCATCCTCTT CTTAAATTTT 840 75 TATGTTCAGA CATACCGAAA AAAGCCAATG AAGAAAGATA TGCAAGAGCC ACCTGCAGGG 900
AAAGAAGTGA AGAATGGTTT TTCCAAAGCC TACTTCACTG CAGCAAATGG AGTGATGAAC 960

AAGAAAGCAC AA<u>TAA</u>AAATG AGTAACAGAA AAAGCACATA TACTAGCCTA ACAGATTGGC 1020 TTGTTTTAAA GCAAAGACTG AATTGAAGGT TACATGTTTT AGGATAAACT AATTTCTTTT 1080 GAGTTCATAA ATCATTTGTA CCCAGAATGT ATTAATATAT TGCTATTAGG TTAATCTGTT 1140 AACTGAATGC TTTGATCAGC ATTGAGGTGA TGCTCACCTC CGAGGACCTC AGAACTGGTG 1200 5 CAGCTTCTCT CTCCCTCCCT CCCACAGACT GAACCTTTCG CCAGAAGCTG TCCTTATAAC 1260 GCCTTATACG CATACACAGC CAGGAAACGT GGAGCATTGT TTCTCACAGA GAGTCTCCAA 1320 ATAAAAAGGG TTTTGTTCAG ATTAAAATGT TTACAACAAA ATGTTAATTA TATTCTAAAT 1380 ACAGGGTATG TTCTAATCTA TATTAAGCAA TAATGCCAGT GCATAATCAT TCCATTTGTT 1440 CCTTTAGCAA TCAACCCCAG AAAATATTAA AATGGGATCA TACACAGAAG ATAGAAAAAT 1500 CTAGCAAAAC TTCTCTTTCT GTAAGCCAGA GTCTTGTCTA TCAGATTCCC ACAACCACTC 1560 CTGATTCTAA ATTTAGTGAT ATGGTAATGA AATTGGTATT TATTTTAAAT ATTAGTTATT 1620 10 CTAAGGAGAA AAAAATGCTT CTGCAAGATT TTCATAATTC AGGGGCTGTG GATAGGATTG 1680 TTCCTCTGTT TCCCTAATCA TTCATCTGTT CATGTCTCCC TCTTGTGCCA GTCAGCCTAG 1740 GTTATACAGA TGCCATGCTC CACACCACGA GCAGTGTACA AATCTGGCTG CCCGTTTACT 1800 TTCTGAGCAA GCACTGGAGT CCACTCCGAC CTTTTTCTTT GAACATGCAT GCTGCTGGAA 1860 TATGTATAAA TCAGAACTAG CAGAAGTAGC AGAGTGATGG GAGCAAAATA GGCACTGAAT 1920 15 TCGTCAACTC TTTTTTGTGA GCCTACTTGT GAATATTACC TCAGATACCT GTTGTCACTC 1980 TTCACAGGTT ATTTAAGTTC TTGAAGCTGG GAGGAAAAAG ATGGAGTAGC TTGGAAAGAT 2040 TCCAGCACTG AGCCGTGAGC CGGTCATGAG CCACGATAAA AAATGCCAGT TTGGCAAACT 2100 20 CAGCACTCCT GTTCCCTGCT CAGGTATATG CGATCTCTAC TGAGAAGCAA GCACAAAAGT 2160 AGACCAAAGT ATTAATGAGT ATTTCCTTTC TCCATAAGTG CAGGACTGTT ACTCACTACT 2220 AAACTCTACC AAGAATGGAA ACCAAGAATA TTTTCTGAAG ATTTTTTTGA AGATTAATTT 2280 ATACCCTATA AAATAAAACT TGTTAGCTTC GATGAAGTCA AAAAAAAAA AAAAAAAAA 25 Seq ID NO: 92 Protein sequence: BAA91096.1 Protein Accession #: 30 MEHLKAFDDE INAFLDNMFG PRDSRVRGWF TLDSYLPTFF LTVMYLLSIW LGNKYMKNRP 60 ALSLRGILTL YNLGITLLSA YMLAELILST WEGGYNLQCQ DLTSAGEADI RVAKVLWWYY 120 FSKSVEFLDT IFFVLRKKTS QITFLHVYHH ASMFNIWWCV LNWIPCGQSF FGPTLNSFVH 180 ILMYSYYGLS VFPSMHKYLW WKKYLTQAQL VQFVLTITHT MSAVVKPCGF PFGCLIFQSS 240 YMLTLVILFL NFYVQTYRKK PMKKDMQEPP AGKEVKNGFS KAYFTAANGV MNKKAQ 35 Seq ID NO: 93 DNA sequence Nucleic Acid Accession #: NM 000044 Coding sequence: 1115-3874 (underlined sequences correspond to start and stop codons) 40 CGAGATCCCG GGGAGCCAGC TTGCTGGGAG AGCGGGACGG TCCGGAGCAA GCCCACAGGC 60 AGAGGAGGCG ACAGAGGGAA AAAGGGCCGA GCTAGCCGCT CCAGTGCTGT ACAGGAGCCG 120 AAGGGACGCA CCACGCCAGC CCCAGCCCGG CTCCAGCGAC AGCCAACGCC TCTTGCAGCG 180 45 CGGCGGCTTC GAAGCCGCCG CCCGGAGCTG CCCTTTCCTC TTCGGTGAAG TTTTTAAAAG 240 CTGCTAAAGA CTCGGAGGAA GCAAGGAAAG TGCCTGGTAG GACTGACGGC TGCCTTTGTC 300 CTCCTCCTCT CCACCCGCC TCCCCCACC CTGCCTTCCC CCCCTCCCCC GTCTTCTCTC 360 CCGCAGCTGC CTCAGTCGGC TACTCTCAGC CAACCCCCCT CACCACCCTT CTCCCCACCC 420 GCCCCCCGC CCCCGTCGGC CCAGCGCTGC CAGCCCGAGT TTGCAGAGAG GTAACTCCCT 480
TTGGCTGCAG GCGGCGAGC TAGCTGCACA TTGCAAAGAA GGCTCTTAGG AGCCAGGCGA 540
CTGGGGAGCG GCTTCAGCAC TGCAGCCACG ACCCGCCTGG TTAGAATTCC GGCGGAGAGA 600 50 ACCCTCTGTT TTCCCCCACT CTCTCTCCAC CTCCTCCTGC CTTCCCCACC CCGAGTGCGG 660 AGCAGAGATC AAAAGATGAA AAGGCAGTCA GGTCTTCAGT AGCCAAAAAA CAAAACAAAC 720 AAAAACAAAA AAGCCGAAAT AAAAGAAAAA GATAATAACT CAGTTCTTAT TTGCACCTAC 780 TTCAGTGGAC ACTGAATTTG GAAGGTGGAG GATTTTGTTT TTTTCTTTTA AGATCTGGGC 840
ATCTTTTGAA TCTACCCTTC AAGTATTAAG AGACAGACTG TGAGCCTAGC AGGGCAGATC 900
TTGTCCACCG TGTGTCTTCT TCTGCACGAG ACTTTGAGGC TGTCAGAGCG CTTTTTGCGT 960
GGTTGCTCCC GCAAGTTTCC TTCTCTGGAG CTTCCCGCAG GTGGGCAGCT AGCTGCAGCG 1020 55 ACTACCGCAT CATCACAGCC TGTTGAACTC TTCTGAGCAA GAGAAGGGGA GGCGGGGTAA 1080 60 GGGAAGTAGG TGGAAGATTC AGCCAAGCTC AAGG<u>ATG</u>GAA GTGCAGTTAG GGCTGGGAAG 1140 65 GGGTGAGGAT GGTTCTCCCC AAGCCCATCG TAGAGGCCCC ACAGGCTACC TGGTCCTGGA 1440 TGAGGAACAG CAACCTTCAC AGCCGCAGTC GGCCCTGGAG TGCCACCCCG AGAGAGGTTG 1500 CGTCCCAGAG CCTGGAGCCG CCGTGGCCGC CAGCAAGGGG CTGCCGCAGC AGCTGCCAGC 1560 ACTCCGGAC GAGGATGACCG CCGTGGCCC ATCCACGTTG TCCCTGCTGG GCCCCACTTT 1620
CCCCGGCTTA AGCAGCTGCTC CCGCTGACCT TAAAGACATC CTGAGCGAGG CCAGCACCAT 1680
GCAACTCCTT CAGCAACAGC AGCAGGAAGC AGTATCCGAA GGCAGCAGCA GCGGGAGAGC 1740
GAGGGAGGCC TCGGGGGCTC CCACTTCCTC CAAGGACAAT TACTTAGGGG GCACTTCGAC 1800 70 CATTTCTGAC AACGCCAAGG AGTTGTGTAA GGCAGTGTCG GTGTCCATGG GCCTGGGTGT 1860 GGAGGCGTTG GAGCATCTGA GTCCAGGGGA ACAGCTTCGG GGGGATTGCA TGTACGCCCC 1920 ACTTTTGGGA GTTCCACCG CTGTGCGTCC CACTCCTTGT GCCCCATTGG CCGAATGCAA 1980 75 AGGTTCTCTG CTAGACGACA GCGCAGGCAA GAGCACTGAA GATACTGCTG AGTATTCCCC 2040 TTTCAAGGGA GGTTACACCA AAGGGCTAGA AGGCGAGAGC CTAGGCTGCT CTGGCAGCGC 2100 TGCAGCAGGG AGCTCCGGGA CACTTGAACT GCCGTCTACC CTGTCTCTCT ACAAGTCCGG 2160




TTGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA 720 THOUGH ACCITATIAC AROTECETO AGARAGAA TO AGARAGAA 720
AATCAGATAT CTGGTCATTG GGCTGCTTGC TGTATGAGTT ATGTGCATTA ATGCCTCCAT 780
TTACAGCTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGGCAAA TTCAGGCGAA 840
TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG 900
ATTACCATCG ACCTTCTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG 960 5 CAGACGAGCA AAGAAGAAAT CTTGAGAGAA GAGGGCGACA ATTAGGAGAG CCAGAAAAAT 1020 CGCAGGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC 1080 GAGAGCGAGC TCTCAAAGCA AGAGAAGAAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG 1140 TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA 1200 10 GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC 1260 CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA 1320 GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA 1380 GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC 1440 TGAAAAGCAG ACAGATCCTG GGCATGCGC<u>T AG</u>CCAGGTAG AGAGACACAG AGCTGTGTAC 1500 AGGATGTAAT ACTACCAACC TTTAAAGACT GATATTCAAA TGCTGTAGTG TTGAATACTT 1560
GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG 1620
TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC 1680
ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG 1740 15 GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAATATT 1800 20 TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT 1860 TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTTAAA TGTTTTTGAG CTTAGAAAAC 1920 CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC 1980 TCTGTAGTTC AAATCTGTTA GCTTTGTGAA AATTCATCAC TGTGATGTTT GTATTCTTTT 2040 TTTTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA 2100 25 TAAAAGAATT CTTCAGTTA Seq ID NO: 96 Protein sequence:
Protein Accession #: NP\_002488 30 51 GIREFNPNIM ANEVERINMI TOSISGENEA RELATEDKIN ASEHOMOSAP IENSMPSRAE 60 DYEVLYTIGT GSYGRCOKIR RKSDGKILVW KELDYGSMTE AEKOMLVSEV NLLRELKHPN 120 IVRYYDRIID RTNTTLYIVM EYCEGGDLAS VITKGTKERQ YLDEEFVLRV MTQLTLALKE 180 35 CHRRSDGGHT VLHRDLKPAN VFLDGKQNVK LGDFGLARIL NHDTSFAKTF VGTPYYMSPE 240 QMNRMSYNEK SDIWSLGCLL YELCALMPPF TAFSQKELAG KIREGKFRRI PYRYSDELNE 300 IITRMLNIKD YHRPSVEEIL ENPLIADLVA DEQRRNLERR GRQLGEPEKS QDSSPVLSEL 360 KLKEIQLQER ERALKAREER LEQKEQELCV RERLAEDKLA RAENLLKNYS LLKERKFLSL 420 ASNPELLNLP SSVIKKKVHF SGESKENIMR SENSESQLTS KSKCKDLKKR LHAAQLRAQA 480 40 LSDIEKNYQL KSRQILGMR Seq ID NO: 97 DNA sequence Nucleic Acid Accession #: NM\_007050.2 Coding sequence: 185-4576 (underlined sequences correspond to start and stop codons) 45 41 CCTCCCGCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60 CCCGAGCGGA GCCAGCCGC CGCACAGCCA GCGGCCGCCC CGGCGATGCG GGGCCACCCC 120 GCGCCGCCC CAGTCCCGGC CCCGGCCCC GCGGGAAGGG GCTGAGCTGC GGGCCCCCC 180
CCGGATGGCG AGCCTCGCCC CCGGCCCCC CTGAGGCTGC CCGCCGCCCC 180
CCGGATGGCG AGCCTCGCCC CAGCTGCCCT CAGCCTGCTC CTGAGGCTGC AGCTGCCCC 240
ACTGCCCGGC GCCCGGGCTC AGAGCGCCCC AGGTGGCTGT TCCTTTGATG AGCACTACAG 300
CAACTGTGGT TATAGTGTGG CTCTAGGGAC CAATGGGTTC ACCTGGGAGC AGATTAACAC 360 50 AACGGAGAAA CCAATGCTGG ACCAGGCAGT GCCCACAGGA TCTTTCATGA TGGTGAACAG 420 55 CTCTGGGAGA GCCTCTGGCC AGAAGGCCCA CCTTCTCCTG CCAACCCTGA AGGAGAATGA 480 CACCCACTGC ATCGACTTCC ATTACTACTT CTCCAGCCGT GACAGGTCCA GCCCAGGGGC 540 CTTGAACGTC TACGTGAAGG TGAATGGTGG CCCCCAAGGG AACCCTGTGT GGAATGTGTC 600 CGGGGTCGTC ACTGAGGGCT GGGTGAAGGC AGAGCTCGCC ATCAGCACTT TCTGGCCACA 660
TTTCTATCAG GTGATATTTG AATCCGTCTC ATTGAAGGGT CATCCTGGCT ACATCGCCGT 720
GGACGAGGTC CGGGTCCTTG CTCATCCATG CAGAAAAGCA CCTCATTTTC TGCGACTCCA 780 60 AAACGTGGAG GTGAATGTGG GGCAGAATGC CACATTTCAG TGCATTGCTG GTGGGAAGTG 840 GTCTCAGCAT GACAAGCTTT GGCTCCAGCA ATGGAATGGC AGGGACACGG CCCTGATGGT 900 CACCCGTGTG GTCAACCACA GGCGCTTCTC AGCCACAGTC AGTGTGGCAG ACACTGCCCA 960
GCGGAGCGTC AGCAAGTACC GCTGTGTGAT CCGCTCTGAT GGTGGGTCTG GTGTGTCCAA 1020
CTACGCGGAG CTGATCGTGA AAGAGCCTCC CACGCCCATT GCTCCCCCAG AGCTGCTGGC 1080
TGTGGGGGCC ACATACCTGT GGATCAAGCC AAATGCCAAC TCCATCATCG GGGATGGCCC 1140
CATCATCCTG AAGGAAGTGG AATATCGCAC CACCACAGGC ACGTGGGCAG AGACCCCACAT 1200 65 AGTCGACTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260 AGTGCTCCTC ACACGACCAG GTGAGGGGGG TACGGGACCG CCAGGGGCTC CCCTCACCAC 1320 AGIGACEAG ACACGACAG GIGAGGGGG TACACAGACC CCAGGAATCG TAGACATCAG 1380
AGCCCGGCAG CTGACCCTGC AGTGGGAGCC CTTCCGCTAC GCGGTGACCC GCTGCCATAG 1440
CTACAACCTC ACCGTGCAGT ACCAGTATGT GTTCAACCAG CAGCAGTACG AGGCCGAGGA 1500
GGTCATCCAG ACCTCCTCCC ACTACACCCT GCGAGGCCTG CGCCCCTTCA TGACCATCCG 1560
GCTGCGACTC TTGCTGTCTA ACCCCGAGGG CCGAATGGAG AGCGAGGAGC TGGTGGTGCA 1620 70 75 GACTGAGGAA GACGTTCCAG GAGCTGTTCC TCTAGAATCC ATCCAAGGGG GGCCCTTTGA 1680 GGAGAAGATC TACATCCAGT GGAAACCTCC CAATGAGACC AATGGGGTCA TCACGCTCTA 1740 CGAGATCAAC TACAAGGCTG TCGGCTCGCT GGACCCAAGT GCTGACCTCT CGAGCCAGAG 1800

GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860 GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920
CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980 ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040 5 TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100 AGCTGACATT ATTGAGTGCT TTTCGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160 TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220
TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTC TCCCCCTGAA 2280
AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340
TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400 10 CTGCCTCCTC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460 GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520 TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAAT GCTTATTCCT ACTCCTATTA 2580 CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640
GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700
TGAAGGCTTC TCTTCTAGTT CTCAGGACGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760
GCTTTCCCAG CCCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820 15 GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880 CATCACGCAG ATGAAGAGAG GCCAGGGCTA CGGGTTCAAG GAGGAATACG AGGCCTTACC 2940 20 AGAGGGCAG ACAGCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000
ATATGGGAAC ATCATATCCT ACGACCATTC CCGGGTGAGG CTGCTGGTGC TGGATGGAGA 3060
CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120
CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTGGAGAA TGATCTGGCA 3180
GGAGAACTCC GCCAGCATCG TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAATG 3240 25 TGTGCGATAC TGGCCAGATG ACACGGAGGT CTACGGAGAC ATTAAAGTCA CCCTGATTGA 3300 AACAGAGCCC CTGGCAGAAT ACGTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTTCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TGGGCCCATA GTGGTCCACT GCAGTGCTGG GGCTGGGCGG ACTGGCTGCT TCATTGCCAT 3540 TGACACCATG CTTGACATGG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600 30 TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660 CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTGT GTGAGTTCCG 3720 TTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780 TGAATTTCAG ACCCTCAACA TTGTGACACC CCGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 35 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA ATCCAGCAAT TACATCAACG CAGCACTGAT 3960 GGATAGCCAC AAGCAGCCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCGT 4020 GGCAGACTTC TGGAGGCTGG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080 GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCG GGTGCTATGG 4140 40 GCCCATCCAG GTGGAGTTCG TCTCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200 CCGCATCTGT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260
CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCTCTCTGC TCAAAGTGGT 4320
CCGACGACTG GAGAAGTGGC AGGAGCAGTA TGACGGGAGG GAGGGACGTA CTGTGGTCCA 4380
CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440
GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500 45 ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTGTA TACGAGGTGG CACTGGAATA 4560 TTTAAGCTCC TTT<u>TAG</u>CTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620 CAAGCCCCT TTTGTGTGAA TGGCAGTAAC TGGGCTCAGG AGCTCTGAGG TGGCACCCTG 4680 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740 50 GGGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAGGC CCAGGCTTCC TTTTCAACCT 4800 AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCCAC AAGCAAGGCC TTGGATTTCT 4860 GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920 AGGTGCTGGG GAGTGGGAGG CTCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980 TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040 55 CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 CCTTACGATG TTCCCTAGGC CACAAGAGAG GCCCCCCATC CTCACACCTA ACCTGCATGG 5160 GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT 5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTGT 5280 GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCCTT GTCTTTGTAA 5340 60 AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA 5460 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA 5520 AGAAGGGGC GGGGGAGTTT GAGTATGTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT 5580 TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640 AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700 65 TGCATAATTT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820 GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940
CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTTATCAT CTCCATTTGA TCATCTCCTC 6000
CAATGAGGAA ACCCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060
AATGGCAATG AGACTTCTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120 70 TATGGAGGGA AAATAAGGCC AGAAACTTCT GAGCAGATAA CTCCACAAAT GGAAATTTAG 6180 TACTTTCTTC CTGATGCCAG TTCTTCTGGG AAGCGCAGAA TTTCAGATAT ATTTTAGTAA 6240 75 CACATTCCCA GCTCCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300 TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360 CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420


TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600 AGAAGGGAC GTCCATTCCT GCTGGGTCTT AACAAGCATA AAAAGGAAAA AAAGGAAACT 6660 5 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 GTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTCCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GCCCAAGACT CCTTCTGGGC 6900
CAATGGGGCT GCCTCTTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960
CTTTTTAATA TCACATCTAT TTGTCTGTCT GCTCATTGTT TTGTTGCTGG AACTAAATAT 7020
GCAATGGATC ATGAGACTCA GATTCTATGA GAAACCCAGG GTCTCTGCTT TACCACGGAG 7080 10 CAGGGTCACC AACCCAGATC TCCAGGCCCA TGAGGATGGA ACATGAAAGG AGCCGACAAA 7140 AGTTGCTTCC ATTGGCATGG GCTCTGGAGC TGTCCAGAAG TCCAGGACA CCAGACTTGA 7200 TCAAGGAAGG GCTGTCACTT TAGAGGTTCA AAAGGAAGTG CCTCAAAGCA AAGGCAAGCA 7260 15 AAGGAACCC ACGATGAACT TGCTCTTTTC CTTTGATGAG CCTCTCCCCA GGTGTATTTC 7320
AGCAGACCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380
GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440 ATGCTATTTT CTTAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTTT TTTCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560 20 AGACAGTGGC TTTTATCATT TTAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620 AAACTTGCAA AAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680 GATTICCCC AGCTCATCCC CTTATTITCC CACAACCCAA CCATCTCTA AAGCAGGACA 7740
GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAAATTGA GGCTTATGGA TGGGGATGAC 7800
TTCCCTAAGA TCCCATGGGA CAAGGATGTG GCAAGGCTTG GATGAGATGG GGCACCAGTG 7860
CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCC 7920 25 CAGGGGGTCT CCCCACCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980 AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8040 CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT 8100 TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160 GGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 30 TTCCAGCATT CTAAAGGAGG GTTTGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 35 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520 40 TATGACGGAC CCTAGGTCAG CTGGTCTTCA GCTTGACCCT AGAATTGACT CTAGGAGCAG 8820 TGACCCTGCT GCCTCCCAGA GCCAGTTATA GGCTCAAGAT CAAGACCAAC TGACCTTCTC 8880 CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000 ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAGAAGC 9060 TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120 45 CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 50 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 55 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720 ACCCCTTAGA GTACATAGAG GTATCAGTCC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780 GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9840 CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9900 ATGAAGAAAG CCACCCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960 CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020 60 AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 AGGGAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 CTTCTTAGCC TGTGACCAGC TTCAAATCAC AGCCAAGTAA AACAAGGAAA TAGGAAAAGT 10260
AAATCCAACT AGAAGAGACA AGCTGAGATT CAGATTTGTT TACTCCTCCC ATGCAAAGTT 10320
TCCCTGTTGG AGGTTTTCCA TGTATACATG TCTAGAAGTG ATAGAATGCA AGGCCTTGGC 10380
TTTGTCTTGC AGGGATCTGC CTTTGAGGTC ATAGACTGAA CAGCAGGGAG AGAGGTTAGT 10440 65 GGTGGAGTGT GGGGGGAGCT GTTCTAGCTC CAGTTTCTTC TGACACATTT TTCAGGATCA 10500 GGIGAGIGI GGGGGAGCI GTICTAGCIC CAGTITCTIC IGACACHTI ITAGGAICA 10500
TGGATCTGAT CCTCCGAAGC ACAGCAGAGA TATCTAAGCC ATATTTTGTGC ACATGAGCAG 10560
ACTCTTCTAG TTTTTTAGTA ACCAGGGATG GGCTTTTGCA TGGCACTGAC TATAGAGATG 10620
TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680
AAAGGTCATC AAAGGGCATT CACCAACTGA AATCCACTCA TGAATGTTAG GTCTCTAAAA 10740
GGAGGCATCA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800 70 CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860 75 CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATGGGGCT TCCTTCTATA TCTGAGAACT 10920 GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980 TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040

TAGGAAGTAA ACCACCAAAA TTACAAAATT GAGTCTCTGT ACAATTACTT CAGTGCCTTT 11160 GGGCTTATGA ATACAAATCA GTGGGCCTTC TCTATGATGG TCCAACAAAC TCTCAGTGTC 11220 CACCCTGTCC CTGTATCTCC CATGGAAGAT GAATAATGTC AGGTGTTCTT TGGGTCAAAG 11280 GCCCCAGGGC AGTCTGGAGG CTTAGAGGGC AGAGTGGTGT CATTCCATGT AAAGTTAGGC 11340
TTCTGAGGGG TCAGGCAGAA TATGGTGTCC ATATCTTCCA TAGCTCTGCA GATTCTTGGA 11400
TGAAGTCAAG CACAGTTTGC TAGACCCAGG TCACTCCTCT GAGTATAACT AGGACCCATG 11460
AGTGAAACTT AATAGCTGTA AGGAAGAACC TGCTGCTCTGC CAGAGAGGAT AAGCTGCCCA 11520 5 TCTCAGCAGC TGTCTAAAAG AAGGCAGGTG TCTCTTTAAA GGGAAGAGAA GCATTGGTGA 11580 10 AATGGATTTC AGGTCACTTC CATTCCAGAT GGGTGAGATC TTGTGGAGCT GGGATCATGT 11640 TTGAACTCAT TCATACCTGT AGAGCACGAA TCCAAGTAGA TTGTGTTTGG TCTGTACAGG 11700 CTGAAGCCCC CTGCTCTCCC ACCCAAGTGC CCCCACTGAG CAGGCCAACA TGCTGTTGTG 11760 GCCACATATA CTGGGCTGAT CCAGGCTGGT TATCACCAAA CAGCAAACCA TAGGGAACAG 11820 CTGCTTTGCC ATAGACCCAA TACCCATGTA GATCTCTCAT GAGAGCAGCC ATAACTCAGA 11880 15 CCCACTGACC AACAGGGCCA TGAGTGACAG CCAGAACCAG TGAAGGTCCA AGTAGGACAC 11940 AGAGCAGGGC TTTTCTTACC ATACACATTA TCTCCAGAGG TTATTTCTAC CCCACTCCCT 12000 ATTCAAGGCC TGTTGGAGCA CACTGCAAAA GCAAAAGCAC AGTAACTCAA TTTACACATG 12060 ATTATAATCA TTTCCAGTGC ACACATTCAAAA CAAAAGCAA AGTAACCAA TTTACACATG 1200
AAATCAGGCT TACCCATGT ACACATTCA TCACCAGGTG GATCCTGAGC TAGCCCATGT 12120
AAATCCGGGT TAACCCATAT TGGTAATCAT ACTCAAAAGC ACTTTTCACC CTACATTCTA 12180
CTAGCCAATC AAAGACAAAG AGTTGTGGCC TCTACCATTG CCTTGGCTTC TGGACACCCT 12240
CACAAGCTAT CCCAAGGTTC CCGCTCAACT CCAGGGAGGC TGACATCTTC ACATCCACTG 12300
GGCATATAAT ATTGCATGAG ACCAAAGTCT CCACACTCTT TGCAGCCTCC TCCATGAATC 12360 20 CCAATGGCCT GCACTTGTAC AGTTTGGGTG TTTGATAGAT AAAGCACGTA TGAGAAGAGA 12420 AAACAAAATA AATCAACTTT TTAAAAAAGC CAGCACTGTG CTGTCAATGT TTTTTTTTC 12480 25 TTTTCAATTC TAGCTCAGAA AAGCAGAAGG TAAATAATGT CAGGTCAATG AATATCAGAT 12540 ATATTTTTTG ACTGTACATT ACAGTGAAGT GTAATCTTTT TACACCTGCA AGTCCATCTT 12600 ATTTATTCTT GTAAATGTTC CCTGACAATG TTTGTAATAT GGCTGTGTTA AAAAATCTAT 12660 ACAATAAAGC TGTGACCCTG 30 Seq ID NO: 98 Protein sequence: NP\_008981.1 Protein Accession #: 35 GIREFNPPRO TEINTYROSI NEPHOSPHAT ASERECEPTO RTYPETHOMO SAPIENSMAS 60 LAALALSLLL RLOLPPLPGA RAOSAPGGCS FDEHYSNCGY SVALGTNGFT WEQINTTEKP 120 MLDQAVPTGS FMMVNSSGRA SGQKAHLLLP TLKENDTHCI DFHYYFSSRD RSSPGALNVY 180 VKVNGGPQGN PVWNVSGVVT EGWVKAELAI STFWPHFYQV IFESVSLKGH PGYIAVDEVR 240 VLAHPCRKAP HFLRLQNVEV NVGQNATFQC IAGGKWSQHD KLWLQQWNGR DTALMVTRVV
NHRRFSATVS VADTAQRSVS KYRCVIRSDG GSGVSNYAEL IVKEPPTPIA PPELLAVGAT 360
YLWIKPNANS IIGDGPIILK EVEYRTTTGT WAETHIVDSP NYKLWHLDPD VEYEIRVLLT 420
RPGEGGTGPP GAPLTTRTKC ADPVHGPQNV EIVDIRARQL TLQWEPFGYA VTRCHSYNLT 480 40 VQYQYVFNQQ QYEAEEVIQT SSHYTLRGLR PFMTIRLRLL LSNPEGRMES EELVVQTEED 540 VPGAVPLESI QGGPFEEKIY IQWKPPNETN GVITLYEINY KAVGSLDPSA DLSSQRGKVF 600 45 KLRNETHHLF VGLYPGTTYS FTIKASTAKG FGPPVTTRIA TKISAPSMPE YDTDTPLNET 660 DTTITVMLKP AQSRGAPVSV YQLVVKEERL QKSRRAADII ECFSVPVSYR NASSLDSLHY 720 FAAELKPANL PYTQPFTVGD NKTYNGYWNP PLSPLKSYSI YFQALSKANG ETKINCVRLA 780 TKAPMGSAQV TPGTPLCLLT TGASTQNSNT VEPEKQVDNT VKMAGVIAGL LMFIIILLGV 840 MLTIKRRRNA YSYSYYLSQR KLAKKQKETQ SGAQREMGPV ASADKPTTKL SASRNDEGFS 900 50 SSSQDVNGFT DGSRGELSOP TLTIOTHPYR TCDPVEMSYP RDQFQLAIRV ADLLQHITQM 960 KRGQGYGFKE EYEALPEGQT ASWDTAKEDE NRNKNRYGNI ISYDHSRVRL LVLDGDPHSD 1020 YINANYIDGY HRPRHYIATQ GPMQETVKDF WRMIWQENSA SIVMVTNLVE VGRVKCVRYW 1080 PDDTEVYGDI KVTLIETEPL AEYVIRTFTV QKKGYHEIRE LRLFHFTSWP DHGVPCYATG 1140 LIGFVRQVKF LNPPEAGPIV VHCSAGAGRT GCFIAIDTHL DMAENGVVD IFNCVRELRA 1200 QRVNLVQTEE QYVFVHDAIL EACLCGNTAI PVCEFRSLYY NISRLDPQTN SSQIKDEFQT 1260 LNIVTPRVRP EDCSIGLLPR NHDKNRSMDV LPLDRCLPFL ISVDGESSNY INAALMDSHK 1320 55 OPAAFVVTOH PLPNTVADFW RLVFDYNCSS VVMLNEMDTA QFCMQYWPEK TSGCYGPIQV 1380 EFVSADIDED IIHRIFRICN MARPQDGYRI VQHLQYIGWP AYRDTPPSKR SLLKVVRRLE 1440 KWQEQYDGRE GRTVVHCLNG GGRSGTFCAI CSVCEMIQQQ NIIDVFHIVK TLRNNKSNMV 1500 60 ETLEQYKFVY EVALEYLSSF Seq ID NO: 99 DNA sequence Nucleic Acid Accession #: NM 002988.1 Coding sequence: 71-340 (underlined sequences correspond to start and stop codons) 65 CCGGCACGAG AGGAGTTGTG AGTTTCCAAG CCCCAGCTCA CTCTGACCAC TTCTCTGCCT 60 GCCCAGCATC ATGAAGGGCC TTGCAGCTGC CCTCCTTGTC CTCGTCTGCA CCATGGCCCT 120
CTGCTCCTGT GCACAAGTTG GTACCAACAA AGAGCTCTGC TGCCTCGTCT ATACCTCCTG 180 70 GCAGATTCCA CAAAAGTTCA TAGTTGACTA TTCTGAAACC AGCCCCCAGT GCCCCAAGCC 240 AGGTGTCATC CTCCTAACCA AGAGAGGCCG GCAGATCTGT GCTGACCCCA ATAAGAAGTG 300 AGGITCAGAAA TACATCAGCG ACCTGAAGCT GAATGCTIGA GGGGCCTGA AGCTGCAGG 360
GCCCAGTGAA CTTGGTGGGC CCAGGAGGG ACAGGAGCT GAGCCAGGGC AATGGCCTG 420
CCACCCTGGA GGCCACCTCT TCTAAGAGTC CCATCTGCTA TGCCCAGCCA CATTAACTAA 480
CTTTAATCTT AGTTTATGCA TCATATTTCA TTTTGAAATT GATTTCTATT GTTGAGCTGC 540 75 ATTATGAAAT TAGTATTTTC TCTGACATCT CATGACATTG TCTTTATCAT CCTTTCCCCT 600

TTAATGTAGT TCATGGTTCC TTAGTGAGCA GGACTCTTGG ATGTGGAGGA GAAAGGGTCA 11100




Seq ID NO: 103 DNA sequence



NM\_001565.1

Nucleic Acid Accession #:



LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

NM 003679.1


Seq ID NO: 107 DNA sequence

Nucleic Acid Accession #:

5

Coding sequence: 47-1507(underlined sequences correspond to start and stop codons) 10 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTT<u>ATG</u>G ACTCATCTGT 60 CATTCAAAGG AAAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG 120
CTTTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT 180
GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240
CTTGAAAGCT GTTGGCCTGG AAGATCAGAT TGTATCCCAA GGTATTCCCA TGAGAGCAAG 300 15 AATGATCCAC TCTCTTTCAG GAAAAAAGTC TGCAATTCCC TATGGGACAA AGTCTCAGTA 360 TATTCTTTCT GTAAGCAGAG AAAATCTAAA CAAGGATCTA TTGACTGCTG CTGAGAAATA 420 CCCCAATGTG AAAATGCACT TTAACCACAG GCTGTTGAAA TGTAATCCAG AGGAAGGAAT 480 GATCACAGTG CTTGGATCTG ACAAAGTTCC CAAAGATGTC ACTTGTGACC TCATTGTAGG 540
ATGTGATGGA GCCTATTCAA CTGCAGATC TCACCTGATG AAGAAACCTC GCTTTGATTA 600
CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660
TTATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720
ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780 20 AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCCAG AAATACTTTC CGGATGCCAT CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900 25 GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020 GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTGTC TTCCTGTGTT 1080 CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200 30 TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260 AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 ACTCTTTTTC TTGGGATCAC TGATAGCCAT CAGCAGTACC TACCTACTTA TACACTACAT 1380 GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCTC ACTTCCGGAA 1440 TACAACATGT TTCCCCGCAA AGGCCGTGGA CTCCCTAGAA CAAATTTCCA ATCTCATTAG 1500 CAGG<u>TGA</u>TAG AAAGGTTTTG TGGTAGCAAA TGCATGATTT CTCTGTGACC AAAATTAAGC 1560 35 ATGAAAAAA TGTTTCCATT GCCATATTTG ATTCACTAGT GGAAGATAGT GTTCTGCTTA 1620 TAATTAAACT GAATGTAGAG TATCTCTGTA TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 ATTTTAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740 AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800 TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860
TGACTCAACA CCTAGGACTA AAAATCACAA CTTAACTAGC ATGTTAACTG CACTTTTCAT 1920
TACGTGAATG GAACTTACCT AACCACAGGG CTCAGACTTA CTAGATAAAA CCAGAAATGG 1980 40 AAATAAGGAA TTCAGGGGAG TTCCAGAGAC TTACAAAATG AACTCATTTT ATTTTCCCAC 2040 CTTCAAATAT AAGTATTATC ATCTATCTGT TTATCGTCTA TCTATCTATC ATCTATCTAT 2100 45 TCTATTTATT TATGTATTTA GAGATCAGGT CTCACTCTGT TGACCAGGCT GGAGTGCAGT 2220 GGTGAGATCT GGGTTCACTG CAACCTCTGC CTCCTGGGCT CAAGCAATCC TCCCACTTCA 2280 GCCTCCCAAA TAGCTGGGGC TACCATGGTA TTTTTCAGTA GAGACCGGGT CTTGCCATGC 2340 TGCCCAGGCC AGTCTCAAAC TCCTGGCCTC ATGTGATCTG CCCACCTCAG CCTCCCAAAG 2400 50 TACAGGGATT AGAGTTGTGA GCCACCGCTG CCAGCCCAGA GTTACCCTCT AAAGATAAGA 2460 AAAAGGCTAT TAATATCATA CTAAGTGAAG GACAGGAAAG GGTTTTATTC ATAAATTAAA 2520 TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTTATA GAAATACAAA 2580 GCCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640 CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700 TCTTTGGTTC ATCCTTCTTT AACAGGCTGC TGAGTCACTC AGAAATCCTT CAAACATGAT 2760 55 ATGATTCAGT GTTTCTTTC TATATTGTCA ATGAAAACCT TGAGTTCTAA TAATCCATGT 2880 TCAGTTTGTA GGGAAAGAAA AAATAATTTT TCCTTCTACC CACTTTAGGT TCCTTGGCTG 2940 GGGCCCTAT AACAAAAGAC AGATTGACAA GAGAAAAACA AACATAAATT TATTAGCGGG 3000 TATATGTAAT ATATATGTGG GAAATACAGG GGAATGAGCA AATCTCAAAG AGCTGGCGTC 3060
TTAGAACTCC CTGGCTTATA TAGCATCGAC AAAGAACAGT AAATTTTAG AGAAACAACA 3120
AAACAAAGAA AAAGAGCTTT GAGTCTGTAG GGGCAGCAAT TTGGGGGAAG CAAATATATG 3180
GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240 60 TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTTT CCAACAAGAG 3300 65 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420 TACGCGACAG TTATTTTTAC AGTAAGGTAT TTTCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATTTAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGTTAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600 70 ATTAAAAGAA TTTGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCAATTC 3660 GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720 CTTCTTATGA TGAAAGTCCA AAAGTGGCAT CCAATTTAAG GCCCCATCTT TCGTTGCCAT 3780 TCTTCATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTGGACCCAT TGGTTTTGTC 3840 GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3900 GAAAGTCACT TTTTTCTTTG GCCTGTCCCC ATCTTTCTGT GACATCACAA TGGGTCTGAT 3960 CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020 75 GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAAT AAAGTGGAAT 4080

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TTTGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TTTATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ATGTAGGACC ATTTCAATAC CTTGTAATCC TCCAAGCTTC AATCTGCACA CACTTTCTAT 4320 5 GAGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCCACAA ATATTCAGTG 4380
GGCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTTTTTACTA TAAGCATCAA 4440 AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500 AATTAGGTGA AGAATTTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560 TATAGCAGAC AGCACTAATG TCATCAACAA ACATTGTTCT TCTCCGTGTC CTGGGTACAA 4620 CATCGAATAA TATTTCTTGG CCTCCTTTCC GCTTCTCCTC TCTGCTGTTC CTCTCTACAA 4680 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740 10 AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800 GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 15 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 TAAAAATATA ATAAATAGCT Seq ID NO: 108 <u>Protein sequence:</u> Protein Accession #: NP\_003670.1 20 31 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT 120 AAEKYPNVKM HFNHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180 25 PRFDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP 240 FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV 300 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 420 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 30 SNLISR Seq ID NO: 109 DNA sequence Nucleic Acid Accession #: NM\_006115.1 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) 11 21 31 41 51 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC 60 40 CGGGACACCC CACCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAAATGGA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 45 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 50 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAGT TCATTCCAGTA GAGGTGCTCG TAGACCTGTT 780
CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840
GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900
TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTTGG AAGTGACTTG 960
TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 55 GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 60 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500 CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620
TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGCT 1680
TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740 65 GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 70 GTTCAGTGAG GAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100 TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAA AAAAAAA 75



AAFCGNMFVE PGEQCDCGFL DDCVDPCCDS LTCQLRPGAQ CASDGPCCQN CQLRPSGWQC 480 RPTRGDCDLP EFCPGDSSQC PPDVSLGDGE PCAGGQAVCM HGRCASYAQQ CQSLWGPGAQ 540 5 PAAPLCLQTA NTRGNAFGSC GRNPSGSYVS CTPRDAICGQ LQCQTGRTQP LLGSIRDLLW 600 ETIDVNGTEL NCSWVHLDLG SDVAQPLLTL PGTACGPGLV CIDHRCQRVD LLGAQECRSK 660 CHGHGVCDSN RHCYCEEGWA PPDCTTQLKA TSSLTTGLLL SLLVLLVLVM LGAGYWYRAR 720 LHQRLCQLKG PTCQYRAAQS GPSERPGPPQ RALLARGTKS QGPAKPPPPR KPLPADPQGR 780 CPSGDLPGPG AGIPPLVVPS RPAPPPPTVS SLYL 10 Sea ID NO: 113 DNA sequence Nucleic Acid Accession #: NM\_002416 Coding sequence: 40-417 (underlined sequences correspond to start and stop codons) 15 41 51 21 31 ATCCAATACA GGAGTGACTT GGAACTCCAT TCTATCACTA TGAAGAAAAG TGGTGTTCTT 60 TTCCTCTTGG GCATCATCTT GCTGGTTCTG ATTGGAGTGC AAGGAACCCC AGTAGTGAGA 120 AAGGGTCGCT GTTCCTGCAT CAGCACCAAC CAAGGGACTA TCCACCTACA ATCCTTGAAA 180 20 GACCTTAAAC AATTTGCCCC AAGCCCTTCC TGCGAGAAAA TTGAAATCAT TGCTACACTG 240 AAGAATGGAG TTCAAACATG TCTAAACCCA GATTCAGCAG ATGTGAAGGA ACTGATTAAA 300 AAGTGGGAGA AACAGGTCAG CCAAAAGAAA AAGCAAAAGA ATGGGAAAAA ACATCAAAAA 360 AAGAAAGTTC TGAAAGTTCG AAAATCTCAA CGTTCTCGTC AAAAGAAGAC TACA<u>TAA</u>GAG 420 ACCACTTCAC CAATAAGTAT TCTGTGTTAA AAATGTTCTA TTTTAATTAT ACCGCTATCA 480 25 TTCCAAAGGA GGATGGCATA TAATACAAAG GCTTATTAAT TTGACTAGAA AATTTAAAAC 540 ATTACTCTGA AATTGTAACT AAAGTTAGAA AGTTGATTTT AAGAATCCAA ACGTTAAGAA 600
TTGTTAAAGG CTATGATTGT CTTTGTTCTT CTACCACCCA CCAGTTGAAT TTCATCATGC 660
TTAAAGGCCAT GATTTTAGCA ATACCCATGT CTACCACAGAT GTTCACCAA CCACATCCCA 720
CTCACAACAG CTGCCTGGAA GAGCAGCCCT AGGCTTCCAC GTACTGCAGC CTCCAGAGAG 780 30 TATCTGAGGC ACATGTCAGC AAGTCCTAAG CCTGTTAGCA TGCTGGTGAG CCAAGCAGTT 840 TGAAATTGAG CTGGACCTCA CCAAGCTGCT GTGGCCATCA ACCTCTGTAT TTGAATCAGC 900 CTACAGGCCT CACACACAAT GTGTCTGAGA GATTCATGCT GATTGTTATT GGGTATCACC 960 ACTGGAGATC ACCACACAT INTETTAGA GCTTCTTC TGGTTTTTTTGGA AGCCATGTGA 1020
TTCCATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATTC 1080
AAGTCAGCTC TTCTCCATCC TACCACAATG CAGTGCCTTT CTTCTCTCCA GTGCACCTGT 1140
CATATGCTCT GATTTATCTG AGTCAACTCC TTTCTCATCT TGTCCCCAAC ACCCCACAGA 1200
AGTGCTTTCT TCTCCCAATT CATCCTCACT CAGTCCAGCT TAGTTCAAGT CCTGCCTCTT 1260 35 AAATAAACCT TTTTGGACAC ACAAATTATC TTAAAACTCC TGTTTCACTT GGTTCAGTAC 1320 CACATGGGTG AACACTCAAT GGTTAACTAA TTCTTGGGTG TTTATCCTAT CTCTCCAACC 1380 40 AGATTGTCAG CTCCTTGAGG GCAAGAGCCA CAGTATATTT CCCTGTTTCT TCCACAGTGC 1440 CTAATAATAC TGTGGAACTA GGTTTTAATA ATTTTTTAAT TGATGTTGTT ATGGGCAGGA 1500 TGGCAACCAG ACCATTGTCT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 CTAGCCTCTG GTAACCTCTT ACTTATTATC TTCAGGACAC TCACTACAGG GACCAGGGAT 1620 GATGCAACAT CCTTGTCTTT TTATGACAGG ATGTTTGCTC AGCTTCTCCA ACAATAAGAA 1680 45 GCACGTGGTA AAACACTTGC GGATATTCTG GACTGTTTTT AAAAAATATA CAGTTTACCG 1740 AAAATCATAT AATCTTACAA TGAAAAGGAC TTTATAGATC AGCCAGTGAC CAACCTTTTC 1800 CCAACCATAC AAAAATTCCT TTTCCCGAAG GAAAAGGGCT TTCTCAATAA GCCTCAGCTT 1860 TCTAAGATCT AACAAGATAG CCACCGAGAT CCTTATCGAA ACTCATTTTA GGCAAATATG 1920
AGTTTTATTG TCCGTTTACT TGTTTCAGAG TTTGTATTGT GATTATCAAT TACCACACCA 1980
TCTCCCATGA AGAAAGGGAA CGGTGAAGTA CTAAGCGCTA GAGGAAGCAG CCAAGTCGGT 2040
TAGTGGAAGC ATGATTGGTG CCCAGTTAGC CTCTGCAGGA TGTGGAAACC TCCTTCCAGG 2100 50 GGAGGTTCAG TGAATTGTGT AGGAGAGGTT GTCTGTGGCC AGAATTTAAA CCTATACTCA 2160 CTTTCCCAAA TTGAATCACT GCTCACACTG CTGATGATTT AGAGTGCTGT CCGGTGGAGA 2220 TCCCACCCGA ACGTCTTATC TAATCATGAA ACTCCCTAGT TCCTTCATGT AACTTCCCTG 2280 55 AAAAATCTAA GTGTTTCATA AATTTGAGAG TCTGTGACCC ACTTACCTTG CATCTCACAG 2340 GTAGACAGTA TATAACTAAC AACCAAAGAC TACATATTGT CACTGACACA CACGTTATAA 2400 TCATTTATCA TATATATACA TACATGCATA CACTCTCAAA GCAAATAATT TTTCACTTCA 2460 AAACAGTATT GACTTGTATA CCTTGTAATT TGAAATATTT TCTTTGTTAA AATAGAATGG 2520 TATCAATAAA TAGACCATTA ATCAG 60 Seq ID NO: 114 Protein sequence: Protein Accession #: NP 002407 51 31 65 MKKSGVLFLL GIILLVLIGV QGTPVVRKGR CSCISTNQGT IHLQSLKDLK QFAPSPSCEK 60 IEIIATLKNG VQTCLNPDSA DVKELIKKWE KQVSQKKKQK NGKKHQKKKV LKVRKSQRSR 120 70 Seg ID NO: 115 DNA sequence NM\_003238.1 Nucleic Acid Accession #: Coding sequence: 182-1426 (underlined sequences correspond to start and stop codons) 51 75 CAAGCAGGAT ACGTTTTTCT GTTGGGCATT GACTAGATTG TTTGCAAAAG TTTCGCATCA 60 AAAACAAACA ACAACAACAA AAAACCAAAC AACTCTCCTT GATCTATACT TTGAGAATTG 120 399

AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360 PGNSCPCPGP APAKTCIMEA STDFLPGLNF SNCSRRALEK ALLDGMGSCL FERLPSLPPM 420

AATGCACTAC TGTGTGCTGA GCGCTTTTCT GATCCTGCAT CTGGTCACGG TCGCGCTCAG 240 CCTGTCTACC TGCAGCACAC TCGATATGGA CCAGTTCATG CGCAAGAGGA TCGAGGCGAT 300 CCGCGGGCAG ATCCTGAGCA AGCTGAAGCT CACCAGTCCC CCAGAAGACT ATCCTGAGCC 360 5 CGAGGAAGTC CCCCGGAGG TGATTTCCAT CTACAACAGC ACCAGGGACT TGCTCCAGGA 420 GAAGGCGAGC CGGAGGGCGG CCGCCTGCGA GCGCGAGAGG AGCGACGAAG AGTACTACGC 480 CAAGGAGGTT TACAAAATAG ACATGCCGCC CTTCTTCCCC TCCGAAAATG CCATCCCGCC 540 CACTTTCTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600
TGCTTCCAAT TTGGTGAAAG CAGAAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660
AGTGCCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAGATT TAACATCTCC 720
AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780 10 CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840 TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900 AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCACCT CCACATATAC 960 15 CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAAA AACAGTGGGA AGACCCCACA 1020 TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080 GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTTTAC ATTGATTTCA AGAGGGATCT AGGGTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATTTA TGGAGTTCAG ACACTCAGCA 1260 20 CAGCAGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320 CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380 TGAACAGCTT TCTAATATGA TTGTAAAGTC TTGCAAATGC AGC<u>TAA</u>AATT CTTGGAAAAG 1440 TGGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG ACGACGACAA CGATGATGCT 1500 TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAAATTT TTGAAAAGGC 1560 GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTGTTTG TTAAAACTGG CATCTGACAC 1620 25 AAAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTTTT TTAAA Seq ID NO: 116 Protein sequence: 30 NP\_003229.1 Protein Accession #: MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 35 EEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TEYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180
TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240
NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300
KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 40 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS Seq ID NO: 117 DNA sequence NM\_000095.1 Nucleic Acid Accession #: Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons) 45 CAGCACCCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCGCGT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120 50 GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT 180 GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240 CGGGATGCAG CAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGCGC 300 GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGCGG 360 CCCCTGCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420 55 CGCCCACCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480 GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGC GTGGGGCTGG CTTTCGCCAA 540 GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCAAC ATAACTGCGT 600 CCCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660 CTTCGTGGGC GACCAGGCGT CCGGCTGCCA GCGCGCGCA CAGCGCTTCT GCCCCGACGG 720 60 CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC 780 GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840 AGACGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG 900 CGTGACTGTG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960 CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAG GACAACTGCC CGCTGGTGCG 1020 GAACCCAGAC CAGCGCAACA CGGACGAGGA CAAGTGGGGC GATGCGTGCG ACAACTGCCG 1080 GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA 1140 65 CGACGACATC GACGGCGACC GGATCCGCAA CCAGGCCGAC AACTGCCCTA GGGTACCCAA 1200 CTCAGACCAG AAGGACAGTG ATGGCGATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA 1260 GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GTGGGAGATG CTTGTGACAG 1320 70 CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC 1380 TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA 1440 CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500 GGAGGACGCG GACAGGGACG GCGTGGGCGA CGTGTGCCAG GACGACTTTG ATGCAGACAA 1560 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620 75 GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGCG CAGATTGACC CCAACTGGGT 1680 GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 GGGTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC 1800

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860 CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA 1920 GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGAAC AGCTGCGGAA 1980 CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG 2040 5 AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100 GGGCTACATC AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT 2160 CTTGGACACA ACCATGCGGG GTGGCCGCCT GGGGGTCTTC TGCTTCTCCC AGGAGAACAT 2220 CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCCA 2280 TCAGCTGCGG CAAGCC<u>TAG</u>G GACCAGGGTG AGGACCCGCC GGATGACAGC CACCCTCACC 2340 GCGGCTGGAT GGGGGCTCTG CACCCAGCCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG 2400 10 AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG Seq ID NO: 118 Protein sequence: Protein Accession #: NP\_000086.1 15

35

65

MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT 60 FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGGR CGPCPAGFTG 120 20 NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180 INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH 240
ADCVLERDGS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSGQ 300
EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK 360
DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420
VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS 480 25 RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD 540 PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI 600 FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660 ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG 720 30

Seq ID NO: 119 DNA sequence Nucleic Acid Accession #: NM\_014211 Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons)

RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA

51 GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60 GTCCTGCCTG TAGGCCTGAA GGACTTGCCC TAACAGAGCC TCAACAACTA CCTGGTGATT 120 40 CCTACTTCAG CCCCTTGGTG TGAGCAGCTT CTCAACATGA ACTACAGCCT CCACTTGGCC 180 TTCGTGTGTC TGAGTCTCTT CACTGAGAGG ATGTGCATCC AGGGGAGTCA GTTCAACGTC 240 GAGGTCGGCA GAAGTGACAA GCTTTCCCTG CCTGGCTTTG AGAACCTCAC AGCAGGATAT 300
AACAAATTTC TCAGGCCCAA TTTTGGTGGA GAACCCGTAC AGATAGCGCT GACTCTGGAC 360
ATTGCAAGTA TCTCTAGCAT TTCAGAGAGT AACATGGACT ACACAGCCAC CATATACCTC 420
CGACAGCGCT GGATGGACCA GCGGCTGGTG TTTGAAGGCA ACAAGAGCTT CACTCTGGAT 480 45 GCCCGCCTCG TGGAGTTCCT CTGGGTGCCA GATACTTACA TTGTGGAGTC CAAGAAGTCC 540 TTCCTCCATG AAGTCACTGT GGGAAACAGG CTCATCCGCC TCTTCTCCAA TGGCACGGTC CTGTATGCCC TCAGAATCAC GACAACTGTT GCATGTAACA TGGATCTGTC TAAATACCCC 660 ATGGACACAC AGACATGCAG GACAGCTG GAAAGCTGGG GCTATGATGG AAATGATGTG 720
GAGTTCACCT GGCTGAGAGG GAACGACTCT GTGCGTGGAC TGGAACACCT GCGGCTTGCT 780
CAGTACACCA TAGAGCGGTA TTTCACCTTA GTCACCAGAT CGCAGCAGGA GACAGGAAAT 840
TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900 50 ACCTACGTTC CTTCCACTTT CCTGGTGGTG TTGTCCTGGG TTTCATTTTG GATCTCTCTC 960 GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGACGACCG TGTTATCAAT GACCACACTG 1020 55 ATGATCGGGT CCCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGGC CATCGATGTG 1080 TACCTGGGGA TCTGCTTTAG CTTTGTGTTT GGGGCCTTGC TAGAATATGC AGTTGCTCAC 1140
TACAGTTCCT TACAGCAGAT GGCAGCCAAA GATAGGGGGA CAACAAAGGA AGTAGAAGAA 1200
GTCAGTATTA CTAATATCAT CAACAGCTCC ATCTCCAGCT TTAAACGGAA GATCAGCTTT 1260
GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320 60 GACAAGTTCA AGTTTGTCTT CCGAGAAAAG ATGGGCAGGA TTGTTGATTA TTTCACAATT 1380 CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTTGAT TTTTATGCTA 1440 GCCAATGTAT TTTACTGGGC ATACTACATG TATTTT<u>TGA</u>G TCAATGTTAA ATTTCTTGCA 1500 TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTTTAGG CCAAGTGTGC 1500
ACCCACATC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAAGA 1620
ATGAAGCTCC AACCATTGTT CTAAGCTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680
TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740

TTACAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800 AAGAATGGGA AGGAGACCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CTAAAGTAAC 1860 TATACATGTT TTTTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920 GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TACATTGT CCTATTACA 1980
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAAATATGA ATATATTTA 2040
ATACCACAAC AGAATTATCC CCAATTCCA ATAAGTCCTA TCATTGAAAA TTCAAATATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TTTATTCCCC CACCTATTCCAT ACCATTACAT 2220 70 75 TTTATTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280 GGAAATGGAA GATTTTTTTG TAACTTGTTC TAGAAGTCTT AATATGGGCT GTTGCCATGA 2340 AGGCTTGCAG AATTGAGTCC ATTTTCTAGC TGCCTTTATT CACATAGTGA TGGGGTACTA 2400

AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460 GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520 TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAAC TGCTTGACCC AGGAACAAGT 2580 GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640 5 TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGTGTGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TTTAGACAAT CTCGCCATCT 2880 TTAATTTCTT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940 10 ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000 CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTA 3060 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120 -TATGAGCCAA TCATATTTGT GATTTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180 AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAAA CTGTGAAATA 3240 15 AATATACCAT ATTAGCTACC CACC Seq ID NO: 120 Protein sequence: Protein Accession #: NP 055026.1 20 41 21 31 MNYSLHLAFV CLSLFTERMC IOGSOFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60 VQIALTLDIA SISSISESNM DYTATIYLRQ RWMDQRLVFE GNKSFTLDAR LVEFLWVPDT 120 YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITTTVAC NMDLSKYPMD TQTCKLQLES 180 25 WGYDGNDVEF TWLRGNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240 NVLYFILETY VPSTFLVVLS WVSFWISLDS VPARTCIGVT TVLSMTTLMI GSRTSLPNTN 300 CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNIINSSIS 360 SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 LFPLIFMLAN VFYWAYYMYF 30 Seg ID NO: 121 DNA sequence Nucleic Acid Accession #: NM\_001854 Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons) 35 AACCATCAAA TTTAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TGTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120 TTCGTGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180 40 GGTGGAAAAC GAAACGGTGG CTCTGGGATT TCACCGTAAC AACCCTCGCA TTGACCTTCC 240 TCTTCCAAGC TAGAGAGGTC AGAGGAGCTG CTCCAGTTGA TGTACTAAAA GCACTAGATT TTCACAATTC TCCAGAGGGA ATATCAAAAA CAACGGGATT TTGCACAAAC AGAAAGAATT 360
CTAAAGGCTC AGATACTGCT TACAGAGTTT CAAAGCAAGC ACAACTCAGT GCCCCAACAA 420
AACAGTTATT TCCAGGTGGA ACTTTCCCAG AAGACTTTTC AATACTATTT ACAGTAAAAC 480
CAAAAAAAAGG AATTCAGTCT TTCCTTTTAT CTATATATAA TGAGCATGGT ATTCAGCAAA 540 45 TTGGTGTTGA GGTTGGGAGA TCACCTGTTT TTCTGTTTGA AGACCACACT GGAAAACCTG 600 CCCCAGAAGA CTATCCCCTC TTCAGAACTG TTAACATCGC TGACGGGAAG TGGCATCGGG 660 TAGCAATCAG CGTGGAGAAG AAAACTGTGA CAATGATTGT TGATTGTAAG AAGAAAACCA 720
CGAAACCACT TGATAGAAGT GAGAGAGCAA TTGTTGATAC CAATGGAATC ACGGTTTTTG 780
GAACAAGGAT TTTGGATGAA GAAGTTTTTG AGGGGGACAT TCAGCAGTTT TTGATCACAG 840
GTGATCCCAA GGCAGCATAT GACTACTGTG AGCATTATAG TCCAGACTGT GACTCTTCAG 900 50 CACCCAAGGC TGCTCAAGCT CAGGAACCTC AGATAGATGA GTATGCACCA GAGGATATAA 960 TCGAATATGA CTATGAGTAT GGGGAAGCAG AGTATAAAGA GGCTGAAAGT GTAACAGAGG 1020 GACCCACTGT AACTGAGGAG ACAATAGCAC AGACGGAGGC AAACATCGTT GATGATTTTC 1080 AAGAATACAA CTATGGAACA ATGGAAGATA ACCAGACAGA AGCTCCTAGG CATGTTTCTG 1140
GGACAAATGA GCCACAATCCA GTTGAAGAAA TATTTACTGA AGAATACTA ACGGGAGAGG 1200
ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAAACAAA GAAATAGACG 1260
GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTTAGGCGA ATATGATTTT TATGAATATA 1320 55 AAGAATATGA AGATAAACCA ACAAGCCCCC CTAATGAAGA ATTTGGTCCA GGTGTACCAG 1380 60 CAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATGG TGCATATGGA GAGAAAGGAC 1440 AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500 CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACAAAGG CCCCACTGGA CCCCCTGGTG 1560
ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACCA AGGGCCTGAT GGTCTACCTG 1620
GTCCTCCTGG TACTATGTTG ATGTTACCGT TCCGTTATGG TGGTGATGGT TCCAAAAGGAC 1680
CAACCATCTC TGCTCAGGAA GCTCAGGCTC AAGCTATTCT TCAGCAGGCT CGGATTGCTC 1740 65 TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCTG 1800 GTTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTCC TCAGGGCCCT CGAGGCGTCC 1860 AGGGTCCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920
GAAGAGGAAT GCCAGGAGAA CCTGGGGCAA AGGGAGATCG AGGGTTTGAT GGACTTCCGG 1980
GTCTGCCAGG TGACAAAGGT CACAGGGGTG AACGAGGTCC TCAAGGTCCT CCAGGTCCTC 2040 70 CTGGTGATGA TGGAATGAGG GGAGAAGATG GAGAAATTGG ACCAAGAGGT CTTCCAGGTG 2100 AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGGAACTCC AGGAGCTCCA GGGCAGCCTG 2160 GTATGGCAGG TGTAGATGGC CCCCCAGGAC CAAAAGGGAA CATGGGTCCC CAAGGGGAGC 2220 CTGGGCCTCC AGGTCAACAA GGGAATCCAG GACCTCAGGG TCTTCCTGGT CCACAAGGTC 2280 CAATTGGTCC TCCTGGTGAA AAAGGACCAC AAGGAAAACC AGGACTTGCT GGACTTCCTG 2340 GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAGAAGGCCA GTCTGGAGAA AAGGGGGCTC 2400 75

CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGGT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAAGA TGGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640 CTTCAGGTCA AGCAGGAGAA AAGGGAAAAC TTGGAGTTCC AGGATTACCA GGATATCCAG 2700 5 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAGA 2760 AAGGTGCACG GGGAGTAGCT GGCAAACCAG GCCCTCGGGG TCAGCGTGGT CCAACGGGTC 2820 CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880 GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940 TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGGC TGCCCAGGAC 3000 ACCCTGGGCA ACGTGGGGAG ACTGGATTTC AAGGCAAGAC CGGCCCTCCT GGCCAGGGG 3060 GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 10 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240 GTTTCCCAGG GGAAAGAGGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 15 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGCC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480 AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 20 GCCCTCCGG TCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660 ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGGTG 3720 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780 GTGAAAAAGG TGAAAATGGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840 GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900 CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 25 GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140 GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 30 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACGAGGT CCTCCTGGAG 4260 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500 35 GCTCCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560 AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 40 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 45 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340 GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400 50 ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460 TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520 ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT 5580 AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640 TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700 55 TACCATTTAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760 ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 TTCTCAACTC TCCTTTTCCT ATTTGAATTT CTTTGGTGCT GTAGAAAACA AAAAAAGAAA 5880 AATATATAT CATAAAAAAT ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAACAG 5940 TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000 CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 60 GATGGCAATA ATATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 TTTCTTTGGT TAATGATGAA ATTCCTTTGT GTGTGTTT Seq ID NO: 122 <u>Protein sequence:</u>
Protein Accession #: NP\_001845

65


21


41

11 31 51 MEPWSSRWKT KRWLWDFTVT TLALTFLFQA REVRGAAPVD VLKALDFHNS PEGISKTTGF 60 70 CTNIKNISKGS DTAYRVSKQA QLSAPTKQLF PGGTFPEDFS ILFTVKPKKG IQSFLLSIYN 120 EHGIQQIGVE VGRSPVFLFE DHTGKPAPED YPLFRTVNIA DGKWHRVAIS VEKKTVTMIV 180 DCKKKTTKPL DRSERAIVDT NGITVFGTRI LDEEVFEGDI QOFLITGDPK AAYDYCEHYS 240 PDCDSSAPKA AQAQEPQIDE YAPEDIIEYD YEYGEAEYKE AESVTEGPTV TEETIAQTEA 300 75 NIVDDFQEYN YGTMESYQTE APRHVSGTNE PNPVEEIFTE EYLTGEDYDS QRKNSEDTLY 360 ENKEIDGRDS DLLVDGDLGE YDFYEYKEYE DKPTSPPNEE FGPGVPAETD ITETSINGHG 420 AYGEKGQKGE PAVVEPGMLV EGPPGPAGPA GIMGPPGLQG PTGPPGDPGD RGPPGRPGLP 480

GPVGGPGSSG AKGESGDPGP QGPRGVQGPP GPTGKPGKRG RPGADGGRGM PGEPGAKGDR 600
GFDGLPGLPG DKGHRGERGP QGPPGPPGDD GMRGEDGEIG PRGLPGEAGP RGLLGPRGTP 660
GAPGQPGMAG VDGPPGPKGN MGPQGEPGPP GQQGNPGPQG LPGPQGPIGP PGEKGPQGKP 720
GLAGLPGADG PPGHPGKEGQ SGEKGALGPP GPQGPIGXPG PRGVKGADGV RGLKGSKGEK 780 5 GEDGFPGFKG DMGLKGDRGE VGQIGPRGXD GPEGPKGRAG PTGDPGPSGQ AGEKGKLGVP 840 GLPGYPGRQG PKGSTGFPGF PGANGEKGAR GVAGKPGPRG QRGPTGPRGS RGARGPTGKP 900 GPKGTSGGDG PPGPPGERGP QGPQGPVGFP GPKGPPGPPG RMGCPGHPGQ RGETGFQGKT 960 GPPGPGGVVG PQGPTGETGP IGERGYPGPP GPPGEQGLPG AAGKEGAKGD PGPQGISGKD 1020 10 GPAGLRGFPG ERGLPGAQGA PGLKGGEGPQ GPPGPVGSPG ERGSAGTAGP IGLRGRPGPQ 1080 GPPGPAGEKG APGEKGPQGP AGRDGVQGPV GLPGPAGPAG SPGEDGDKGE IGEPGQKGSK 1140 GGKGENGPPG PPGLQGPVGA PGIAGGDGEP GPRGQQGMFG QKGDEGARGF PGPPGPIGLQ 1200 GLPGPPGEKG ENGDVGPWGP PGPPGPRGPQ GPNGADGPQG PPGSVGSVGG VGEKGEPGEA 1260 GNPGPPGEAG VGGPKGERGE KGEAGPPGAA GPPGAKGPPG DDGPKGNPGP VGFPGDPGPP 1320 15 GELGPAGQDG VGGDKGEDGD PGQPGPPGPS GEAGPPGPPG KRGPPGAAGA EGRQGEKGAK 1380 GEAGAEGPPG KTGPVGPQGP AGKPGPEGLR GIPGPVGEQG LPGAAGQDGP PGPMGPPGLP 1440 GLKGDPGSKG EKGHPGLIGL IGPPGEQGEK GDRGLPGTQG SPGAKGDGGI PGPAGPLGPP 1500 GPPGLPGPQG PKGNKGSTGP AGQKGDSGLP GPPGPPGPPG EVIQPLPILS SKKTRRHTEG 1560 MQADADDNIL DYSDGMEEIF GSLNSLKQDI EHMKFPMGTQ TNPARTCKDL QLSHPDFPDG 1620 20 EYWIDPNOGC SGDSFK-VYCN FTSGGETCIY PDKKSEGVRI SSWPKEKPGS WFSEFKRGKL 1680 LSYLDVEGNS INMVQMTFLK LLTASARQNF TYHCHQSAAW YDVSSGSYDK ALRFLGSNDE 1740 EMSYDNNPFI KTLYDGCTSR KGYEKTVIEI NTPKIDQVPI VDVMISDFGD QNQKFGFEVG 1800 **PVCFLG** 25 Seq ID NO: 123 DNA sequence NM 015886 Nucleic Acid Accession #: Coding sequence: 485-1261 (underlined sequences correspond to start and stop codons) 30 GAATTCCCCC CCCCCCCCC TCACTTGGTG TGTCTATATG TCTGGCAGAC ATTATCAGCA 60 CATTCTCTGT TGTTACCTGT GATTCATTTT TTCTTCACTC TCCAGGTGAA TTTCAATTGC 120 TGAAAATTTC CCACTGAAAA TATGCAGTAA TATATTTTGT GGTTCAGACA TTTGGGGCAA 180 ATGGTTCACA TTCATTTTAG GGTTAGTGGT CATGCTGTTT ATTTTTCTCT GCTATACAAA 240 35 GTTCCTCTTA GGGGTCTGCC TCATGACACT AAAAAATGAA TAGAGATTCT ACTGTAGGTT 300 ATCTCCTAGG CTTGAGTTCA ACATTTGTTT GGATTTTTGA AGAAAGTCAA ATCAAGCAAT 360 GCTCCCAAAT GATGTCTTTG TAAATTCATA CCCTCTGGCC CTATTTTTT TCATAGACCC 420 TAACTCTACC TTTCTGCTTT AAAGCAAAGT AAACTCGGTG GCCTCTTCTT CTCCACCCCT 480
CAAAATGATA GCAATCTCTG CCGTCAGCAG TGCACTCCTG TTCTCCCTTC TCTGTGAAGC 540
AAGTACCGTC GTCCTACTCA ATTCCACTGA CTCATCCCCG CCAACCAATA ATTTCACTGA 600
TATTGAAGCA GCTCTGAAAG CACAATTAGA TTCAGCGGAT ATCCCCAAAG CCAGGCGGAA 660 40 GCGCTACATT TCGCAGAATG ACATGATCGC CATTCTTGAT TATCATAATC AAGTTCGGGG 720 CAAAGTGTTC CCACCGGCAG CAAATATGGA ATATATGGTT TGGGATGAAA ATCTTGCAAA 780 ATCGCAGAG GCTTGGGCGC CTACTTGCAT TTGGGACCAT GGACCTTCTT ACTTACTGAG 840
ATTTTTTGGC CAAAATCTAT CTGTACGCAC TGGAAGATAT CGCTCTATTC TCCAGTTGGT 900
CAAGCCATGG TATGATGAAG TGAAAGATTA TGCTTTTCCA TATCCCCAGG ATTGCAACCC 960
CAGATGTCCT ATGAGATGTT TTGGTCCCAT GTGCACACAT TATACGCAGA TGGTTTGGGC 1020
CACTTCCAAT CGGATAGGAT GCGCAATTCA TGCTTGCCAA AACATGAATG TTTGGGGATC 1080 45 50 AGAAGCACCA TATAAAGTAG GGGTACCATG TTCATCTTGT CCTCCAAGTT ATGGGGGATC 1200 55 Seq ID NO: 124 Protein sequence: Protein Accession #: NP\_056970.1 11 21 31 41 51 60 MIAISAVSSA LLFSLLCEAS TVVLLNSTDS SPPTNNFTDI EAALKAQLDS ADIPKARRKR 60 YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF 120 LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT 180 SNRIGCAIHA CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC 240 65 TDNLCFPGVT SNYLYWFK Seq ID NO: 125 DNA sequence Nucleic Acid Accession #: NM 001793 70 Coding sequence: 54-2543 (underlined sequences correspond to start and stop codons) 31 41 GCGGAACACC GGCCGCCGT CGCGGCAGCT GCTTCACCCC TCTCTCTGCA GCCATGGGGC 60 75 TCCCTCGTGG ACCTCTCGCG TCTCTCCTCC TTCTCCAGGT TTGCTGGCTG CAGTGCGCGG 120 CCTCCGAGCC GTGCCGGGCG GTCTTCAGGG AGGCTGAAGT GACCTTGGAG GCGGGAGGCG 180 CGGAGCAGGA GCCCGGCCAG GCGCTGGGGA AAGTATTCAT GGGCTGCCCT GGGCAAGAGC 240

GADGLPGPPG TMLMLPFRYG GDGSKGPTIS AQEAQAQAIL QQARIALRGP PGPMGLTGRP 540





 $\underline{\mathbf{TG}}\mathbf{CCTGGGAG}\ \mathbf{CCTCGGCCC}\ \mathbf{GCGCCAAGCT}\ \mathbf{GGGTGCTGTT}\ \mathbf{GCTGCGGCTG}\ \mathbf{CTGGCGTTGC} \quad \mathbf{120}$ 

NEPSRVMPSO PLHIVLESLK REGKEPLVLK GGLSSFKQNH ENLCDNSLQL QECREVGGGA 300 SAASSLI-POP IPTTPDIENA ELTPILIFILF LGNEQDAQDL DTMQRLNIGY VINVTTHLPL 360 YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420 5 AYLMKHTRMT MTDAYKFVKG KRPIISPNLN FMGQLLEFEE DLNNGVTPRI LTPKLMGVET 480 Seq ID NO: 131 DNA sequence Nucleic Acid Accession #: NM\_005409.3 10 Coding sequence: 94-378 (underlined sequences correspond to start and stop codons) TTCCTTTCAT GTTCAGCATT TCTACTCCTT CCAAGAAGAG CAGCAAAGCT GAAGTAGCAG 60 CAACAGCACC AGCAGCAACA GCAAAAAACA AAC<u>ATG</u>AGTG TGAAGGGCAT GGCTATAGCC 120
TTGGCTGTGA TATTGTGTGC TACAGTTGTT CAAGGCTTCC CCATGTTCAA AAGAGGACGC 180 15 TGTCTTTGCA TAGGCCCTGG GGTAAAAGCA GTGAAAGTGG CAGATATTGA GAAAGCCTCC 240 ATAATGTACC CAAGTAACAA CTGTGACAAA ATAGAAGTGA TTAATTACCCT GAAAGAAAAT 300
AAAGGACAAC GATGCCTAAA TCCCAAATCG AAGCAAGCAA GGCTTATAAT CAAAAAAAGTT 360
GAAAGAAAGA ATTTT<u>TAA</u>AA ATATCAAAAC ATATGAAGTC CTGGAAAAGG GCATCTGAAA 420
AACCTAGAAC AAGTTTAACT GTGACTACTG AAATGACAAG AATTCTACAG TAGGAAACTG 480
AGACTTTTCT ATGGTTTTGT GACTTTCAAC TTTTGTACAG TTATGTGAAAG GATGAAAAGGT 540 20 GGGTGAAAGG ACCAAAAACA GAAATACAGT CTTCCTGAAT GAATGACAAT CAGAATTCCA 600 CTGCCCAAAG GAGTCCAGCA ATTAAATGGA TTTCTAGGAA AAGCTACCTT AAGAAAGGCT 660 25 GGTTACCATC GGAGTTTACA AAGTGCTTTC ACGTTCTTAC TTGTTGTATT ATACATTCAT 720 GCATTTCTAG GCTAGAGAAC CTTCTAGATT TGATGCTTAC AACTATTCTG TTGTGACTAT 780 GAGAACATTT CTGTCTCTAG AAGTTATCTG TCTGTATTGA TCTTTATGCT ATATTACTAT 840 CTGTGGTTAC AGTGGAGACA TTGACATTAT TACTGGAGTC AAGCCCTTAT AAGTCAAAAG 900 CATCTATGTG TCGTAAAGCA TTCCTCAAAC ATTTTTTCAT GCAAATACAC ACTTCTTTCC 960 30 CCAAATATCA TGTAGCACAT CAATATGTAG GGAAACATTC TTATGCATCA TTTGGTTTGT 1020 TTTATAACCA ATTCATTAAA TGTAATTCAT AAAATGTACT ATGAAAAAAA TTATACGCTA 1080 TGGGATACTG GCAACAGTGC ACATATTTCA TAACCAAATT AGCAGCACCG GTCTTAATTT 1140 GATGTTTTTC AACTTTTATT CATTGAGATG TTTTGAAGCA ATTAGGATAT GTGTGTTTAC 1200
TGTACTTTTT GTTTTGATCC GTTTGTATAA ATGATAGCAA TATCTTGGAC ACATTTGAAA 1260
TACAAAATGT TTTTGTCTAC CAAAGAAAAA TGTTGAAAAA TAAGCAAATG TATACCTAGC 1320
AATCACTTTT ACTTTTTGTA ATTCTGTCTC TTAGAAAAAT ACATAATCTA ATCAATTTCT 1380 35 TTGTTCATGC CTATATACTG TAAAATTTAG GTATACTCAA GACTAGTTTA AAGAATCAAA 1440 40 Seq ID NO: 132 Protein sequence: NP\_005400.1 Protein Accession #: 51 31 41 11 21 45 MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI 60 EVIITLKENK GQRCLNPKSK QARLIIKKVE RKNF Sea ID NO: 133 DNA sequence NM\_012342 Nucleic Acid Accession #: 50 Coding sequence: 373-1155 (underlined sequences correspond to start and stop codons) 21 CTGGCGCGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGAGACCC TACTCTCTTC 60 GCTGAGAACG GCCGCTAGCG GGGACTGAAG GCCGGGAGCC CACTCCCGAC CCGGGGCTAG 120 CGTGCGTCCC TAGAGTCGAG CGGGGCAAGG GAGCCAGTGG CCGCCGACGG GGGACCGGGA 180 55 AACTTTTCTG GGCTCCTGGA GAGCCCTGTA GCCGCGCTCC ATGCTCCGGC AGCGGCCCGA 240 AACCCAGCCC CGCCGCTGAC GGAGCCCGCC GCTCCGGGCA GGGCCCATGC CCTGCGCGCT 300 CCGGGGGTCG TAGCTGCCGC CGAGCCGGGG CTCCGGAAGC CGGCGGGGGC GCCGCGGCCG 360 TGCGGGGGT CA<u>ATG</u>GATCG CCACTCCAGC TACATCTTCA TCTGGCTGCA GCTGGAGCTC 420
TGCGCCATGG CCGTGCTGCT CACCAAAGGT GAAATTCGAT GCTACTGTGA TGCTGCCCAC 480
TGTGTAGCCA CTGGTTATAT GTGTAAATCT GAGCTCAGC CCTGCTTCTC TAGACTTCTT 540
GATCCTCAGA ACTCAAATTC CCCACTCACC CATGGCTGCC TGGACTCTCT TGCAAGCACG 600 60 ACAGACATCT GCCAAGCCAA ACAGGCCCGA AACCACTCTG GCACCACCAT ACCCACATTG 660 65 GAATGCTGTC ATGAAGACAT GTGCAATTAC AGAGGGCTGC ACGATGTTCT CTCTCCTCCC 720 AGGGGTGAGG CCTCAGGACA AGGAAACAGG TATCAGCATG ATGGTAGCAG AAACCTTATC 780 ACCAAGGTGC AGGAGCTGAC TTCTTCCAAA GAGTTGTGGT TCCGGGCAGC GGTCATTGCC 840 ACCAAGGIGC AGGAGCIGAC TICTICCAAA GAGTIGIGGI ICCGGGCAGC GGICATTGCC 840
GTGCCCATTG CTGGAGGGCT GATTTTAGTG TTGCTTATTA TGTTGGCCCT GAGGATGCTT 900
CGAAGTGAAA ATAAGAGGCT GCAGGATCAG CGGCAACAGA TGCTCTCCCG TTTGCACTAC 960
AGCTTTCACG GACACCATTC CAAAAAGGGG CAGGTTGCAA AGTTAGACTT GGAATGCATG 1020
GTGCCGGTCA GTGGGCACGA GAACTGCTGT CTGACCTGTG ATAAAATGAG ACAAGCAGAC 1080 70

CTCAGCAACG ATAAGATCCT CTCGCTTGTT CACTGGGGCA TGTACAGTGG GCACGGGAAG 1140

75

MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240

AAATATATAT ATTTTGTCTG A Seq ID NO: 134 Protein sequence: NP\_036474.1 Protein Accession #: 41 21 31 MDRHSSYIFI WLQLELCAMA VLLTKGEIRC YCDAAHCVAT GYMCKSELSA CFSRLLDPQN 60 SNSPLTHGCL DSLASTTDIC QAKQARNHSG TTIPTLECCH EDMCNYRGLH DVLSPPRGEA 120 SGQGNRYQHD GSRNLITKVQ ELTSSKELWF RAAVIAVPIA GGLILVLLIM LALRMLRSEN 180 KRLQDQRQQM LSRLHYSFHG HHSKKGQVAK LDLECMVPVS GHENCCLTCD KMRQADLSND 240 KILSLVHWGM YSGHGKLEFV Seq ID NO: 135 DNA sequence NM\_001627.1 Nucleic Acid Accession #: Coding sequence: 64-1815 (underlined sequences correspond to start and stop codons) CGGGACGACG CCCCTCCTG CGGCGTGGAC TCCGTCAGTG GCCCACCAAG AAGGAGGAGG 60 AAT<u>ATG</u>GAAT CCAAGGGGGC CAGTTCCTGC CGTCTGCTCT TCTGCCTCTT GATCTCCGCC 120 ACCGTCTTCA GGCCAGGCCT TGGATGGTAT ACTGTAAATT CAGCATATGG AGATACCATT 180 ATCATACCTT GCCGACTTGA CGTACCTCAG AATCTCATGT TTGGCAAATG GAAATATGAA AAGCCCGATG GCTCCCCAGT ATTTATTGCC TTCAGATCCT CTACAAAGAA AAGTGTGCAG

TACGACGATG TACCAGAATA CAAAGACAGA TTGAACCTCT CAGAAAACTA CACTTTGTCT

360
ATCAGTAATG CAAGGATCAG TGATGAAAAG AGATTTGTGT GCATGCTAGT AACTGAGGAC

420 AACGTGTTTG AGGCACCTAC AATAGTCAAG GTGTTCAAGC AACCATCTAA ACCTGAAATT 480 GTAAGCAAAG CACTGTTTCT CGAAACAGAG CAGCTAAAAA AGTTGGGTGA CTGCATTTCA 540 GAAGACAGTT ATCCAGATGG CAATATCACA TGGTACAGGA ATGGAAAAGT GCTACATCCC 600 CTTGAAGGAG CGGTGGTCAT AATTTTTAAA AAGGAAATGG ACCAGTGAC TCAGCTCTAT 660 ACCATGACTT CCACCCTGGA GTACAAGACA ACCAAGGCTG ACATACAAAT GCCATTCACC 720 TGCTCGGTGA CATATTATGG ACCATCTGGC CAGAAAACAA TTCATTCTGA ACAGGCAGTA 780 TTTGATATTT ACTATCCTAC AGAGCAGGTG ACAATACAAG TGCTGCCACC AAAAAATGCC ATCAAAGAAG GGGATAACAT CACTCTTAAA TGCTTAGGGA ATGGCAACCC TCCCCCAGAG 900 GAATTTTTGT TTTACTTACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960 CTGATGGATG TGAGGCGCAA TGCAACAGGA GACTACAAGT GTTCCCTGAT AGACAAAAA 1020 AGCATGATTG CTTCAACAGC CATCACAGTT CACTATTTGG ATTTGTCCTT AAACCCAAGT 1080 GGAGAAGTGA CTAGACAGAT TGGTGATGCC CTACCCGTGT CATGCACAAT ATCTGCTAGC 1140
AGGAATGCAA CTGTGGTATG GATGAAAGAT AACATCAGGC TTCGATCTAG CCCGTCATTT 1200
TCTAGTCTTC ATTATCAGGA TGCTGGAAAC TATGTCTGCG AAACTGCTCT GCAGGAGGTT 1260 GAAGGACTAA AGAAAAGAGA GTCATTGACT CTCATTGTAG AAGGCAAACC TCAAATAAAA 1320 ATGACAAAGA AAACTGATCC CAGTGGACTA TCTAAAACAA TAATCTGCCA TGTGGAAGGT 1380 TTTCCAAAGC CAGCCATTCA GTGGACAATT ACTGGCAGTG GAAGCGTCAT AAACCAAACA 1440 GAGGAATCTC CTTATATTAA TGGCAGGTAT TATAGTAAAA TTATCATTTC CCCTGAAGAG 1500 AATGTTACAT TAACTTGCAC AGCAGAAAAC CAACTGGAGA GAACAGTAAA CTCCTTGAAT 1560 GTCTCTGCTA TAAGTATTCC AGAACACGAT GAGGCAGACG AGATAAGTGA TGAAAACAGA 1620 GAAAAGGTGA ATGACCAGGC AAAACTAATT GTGGGAATCG TTGTTGGTCT CCTCCTTGCT 1680 GCCCTTGTTG CTGGTGTCGT CTACTGGCTG TACATGAAGA AGTCAAAGAC TGCATCAAAA 1740 CATGTAAACA AGGACCTCGG TAATATGGAA GAAAACAAAA AGTTAGAAGA AAACAATCAC 1800 AAAACTGAAG CCTAAGAGAG AAACTGTCCT AGTTGTCCAG AGATAAAAAT CATATAGACC 1860

TAAACAAAAA TGTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500

AATTGAAGCA TGAACGTGGA TTGTATTTAA GACATAAACA AAGACATTGA CAGCAATTCA 1920 TGGTTCAAGT ATTAAGCAGT TCATTCTACC AAGCTGTCAC AGGTTTTCAG AGAATTATCT 1980 CAAGTAAAAC AAATGAAATT TAATTACAAA CAATAAGAAC AAGTTTTGGC AGCCATGATA 2040 ATAGGTCATA TGTTGTGTTT GGTTCAATTT TTTTTCCGTA AATGTCTGCA CTGAGGATTT 2100

CTTTTTGGTT TGCCTTTTAT GTAAATTTTT TACGTAGCTA TTTTTATACA CTGTAAGCTT 2160

Seq ID NO: 136 Protein sequence:
Protein Accession #: NP\_001618.1

5

10

15

20

25

30

35

40

45

50

55


1 11 21 31 41 51

| | | | | | | | | | | |

MESKGASSCR LLFCLLISAT VFRPGLGWYT VNSAYGDTII IPCRLDVPQN LMFGKWKYEK 60
PDGSPVFIAF RSSTKKSVQY DDVPEYKDRL NLSENYTLSI SNARISDEKR FVCMLVTEDN 120
VFEAPTIVKV FKQPSKPEIV SKALFLETEQ LKKLGDCISE DSYPDGNITW YRNGKVLHPL 180
EGAVVIIFKK EMDPVTQLYT MTSTLEYKTT KADIQMPFTC SVTYYGPSGQ KTIHSEQAVF 240
DIYYPTEQVT IQVLPPKNAI KEGDNITLKC LGNGNPPPEE FLFYLPGQPE GIRSSNTYTL 300
MDVRNATGD YKCSLIDKKS MIASTAITVH YLDLSLNPSG EVTRQIGDAL PVSCTISASR 360

MDVRRNATGD YKCSLIDKKS MIASTAITVH YLDLSLNPSG EVTRQIGDAL PVSCTISASR 360 NATVVWMKDN IRLRSSPSFS SLHYQDAGNY VCETALQEVE GLKKRESLTL IVEGKPQIKM 420 TKKTDPSGLS KTIICHVEGF PKPAIQWTIT GSGSVINQTE ESPYINGRYY SKIIISPEEN 480

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADEISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA



It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

## WHAT IS CLAIMED IS:

- 1 1. A method of detecting a breast cancer-associated transcript in a cell 2 from a patient, the method comprising contacting a biological sample from the patient with a 3 polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence
- 4 as shown in Tables 1-25.
- 1 2. The method of claim 1, wherein the biological sample comprises 2 isolated nucleic acids.
- 1 3. The method of claim 2, wherein the nucleic acids are mRNA.
- 1 4. The method of claim 2, further comprising the step of amplifying
- 2 nucleic acids before the step of contacting the biological sample with the polynucleotide.
- 1 5. The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Tables 1-25.
- 1 6. The method of claim 1, wherein the polynucleotide is immobilized on 2 a solid surface.
- The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat breast cancer.
- 1 8. The method of claim 1, wherein the patient is suspected of having 2 breast cancer.
- 9. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.
- 1 10. The nucleic acid molecule of claim 9, which is labeled.
- 1 11. An expression vector comprising the nucleic acid of claim 9.
- 1 12. A host cell comprising the expression vector of claim 11.

1		13.	An isolated polypeptide which is encoded by a nucleic acid molecule
2	having polynucleotide sequence as shown in Tables 1-25.		
1		14.	An antibody that specifically binds a polypeptide of claim 13.
1		15.	The antibody of claim 14, further conjugated to an effector component.
1 2	fluorescent lab	16. pel	The antibody of claim 15, wherein the effector component is a
_	iiuoiobooiii tuo	,01.	
1		17.	The antibody of claim 15, wherein the effector component is a
2	radioisotope or a cytotoxic chemical.		
1		18.	The antibody of claim 15, which is an antibody fragment.
1		19.	The antibody of claim 15, which is a humanized antibody
1		20.	A method of detecting a breast cancer cell in a biological sample from
2	a patient, the method comprising contacting the biological sample with an antibody of claim		
3	14.		
1		21.	The method of claim 20, wherein the antibody is further conjugated to
2	an effector component.		
1		22.	The method of claim 21, wherein the effector component is a
2	fluorescent lab	el.	
1		23.	A method for identifying a compound that modulates a breast cancer-
2	associated polypeptide, the method comprising the steps of:		
3		(i) con	tacting the compound with a breast cancer-associated polypeptide, the
4	polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least		
5	80% identical to a sequence as shown in Tables 1-25; and		
6	(ii) determining the functional effect of the compound upon the polypeptide.		
1		24	A drug screening assay comprising the steps of

(i) administering a test compound to a mammal having breast cancer or a cell isolated therefrom;

(ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.